{
   "Study": {
      "row": [
         {
            "NCTdataId": "NCT00001137",
            "SecondaryId": "1U01AI068636",
            "BriefTitle": "Long-Term Data Collection From Participants in Adult AIDS Clinical Trials",
            "OfficialTitle": "Adult AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) Protocol",
            "LeadSponsorClass": "AIDS Clinical Trials Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "AIDS Clinical Trials Group",
            "BriefSummary": "The purpose of this study is to determine what combinations of anti-HIV drugs work best in\r\n\r\n      patients treated over several years. The study will also assess the occurrence of side\r\n\r\n      effects and opportunistic infections in patients",
            "Description": "A compilation of outcomes of various antiretroviral therapies would be beneficial when\r\n\r\n      evaluating which strategies are most effective in long-term treatment of HIV-1. Using data\r\n\r\n      from present and recently completed studies, this",
            "OverallStatus": "Completed",
            "StartDate": "January 2000",
            "CompletionDate": "November 2013",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "AIDS Clinical Trials Group",
            "StudyCondition": "HIV Infections",
            "studyLocation": "Univ of Alabama at Birmingham",
            "Enrollment": "5982",
            "NctKeyword": "Treatment Experienced, Treatment Naive, Virus Replication, AIDS-Related Opportunistic Infections, HIV-1, Risk Factors, Incidence, RNA, Viral, Anti-HIV Agents, Viral Load, Lipodystrophy, Nervous System, Cardiovascular System, Neurologic Symptoms,",
            "MeshKeyword": "HIV Infections,",
            "Eligibility": "Inclusion Criteria\r\n\r\n\r\n\r\n          -  HIV-1 infected\r\n\r\n\r\n\r\n          -  Enrolled in an AIDS Clinical Trial Group (ACTG) parent study and has enrolled in this\r\n\r\n             study on or before the Week 16 visit of the parent study, including",
            "EligibleGender": "All",
            "MinAge": "13 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "December 2013",
            "LastChanged": "December 5, 2013",
            "FirstReceived": "January 28, 2000",
            "OverallOfficial": "Constance A. Benson, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Division of Infectious Disease, Antiviral Research Center, University of California, San Diego",
            "LocationName": "Univ of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00001137",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20000013 - NIAID- Fischl",
            "FileProcessContentId": "440",
            "Division": "Medicine",
            "StdyDivision": "7803",
            "EprostNbr": "20000013",
            "StudyNumber": "20000013 - NIAID- Fischl",
            "StudyTitle": "AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL",
            "PIID": "825",
            "PicNum": "C00454409",
            "PILastName": "Fischl",
            "PIFirstName": "Margaret",
            "CoodCNbr": "C00454409",
            "CoordLastName": "Fischl",
            "CoordFirstName": "Margaret",
            "CoordEmail": "mfischl@med.miami.edu",
            "CoordPhone": "3052433847",
            "EnteredByCNbr": "C00454409",
            "EnteredByLastName": "Fischl",
            "EnteredByFirstName": "Margaret",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "02/02/2000",
            "IRBApprovedFrom": "02/02/2000",
            "IRBApprovedTo": "05/16/2014",
            "InfoEdNbr": "54792",
            "WIrb": "20052120",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "National Institute of Allergy and Infectious Diseases",
            "SiteSampleSize": "UMMG:200",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "200",
            "EprostState": "Approved",
            "StudyCoordinator": "Leslie Thompson",
            "StudyObjective": "Primary Objective:\r\nTo determine therapeutic strategies or regimens that are effective in achieving long-term (durable) suppression of HIV-1 replication to levels below the limit of detection with the least associated toxicity. The strategies and regimens to be compared will be determined by the future antiretroviral studies in which subjects co-enroll.",
            "NationalSampleSize": "6100",
            "NCTNbr": "NCT00001137",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00028145",
            "SecondaryId": "U01AI068632",
            "BriefTitle": "Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission",
            "OfficialTitle": "Perinatal Core Protocol",
            "LeadSponsorClass": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to collect and study clinical and laboratory information about\r\n\r\n      a pregnant or new mother and her medical care that will increase our knowledge of the best\r\n\r\n      care for HIV-infected pregnant women and the",
            "Description": "The current low rate of vertical transmission of HIV in the U.S. limits the number and types\r\n\r\n      of questions concerning transmission risk and pathogenesis that can be addressed by a single\r\n\r\n      clinical trial. Specific U.S. Public Heal",
            "OverallStatus": "Completed",
            "StartDate": "October 2002",
            "CompletionDate": "June 2013",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
            "StudyCondition": "HIV Infections",
            "studyLocation": "Univ. of Alabama Birmingham NICHD CRS (5096)",
            "Enrollment": "3090",
            "NctKeyword": "Women's Health, Disease Transmission, Vertical, Preventive Medicine, Treatment Experienced,",
            "MeshKeyword": "HIV Infections, Pregnancy Complications, Pregnancy Complications, Infectious,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  HIV infected\r\n\r\n\r\n\r\n          -  At least 14 weeks pregnant OR have delivered a liveborn or stillborn infant and are\r\n\r\n             within 14 days of the delivery\r\n\r\n\r\n\r\n          -  Currently receiving",
            "EligibleGender": "Female",
            "MinAge": "14 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "October 2014",
            "LastChanged": "October 8, 2014",
            "FirstReceived": "December 13, 2001",
            "OverallOfficial": "Ruth Tuomala, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Director of Obstetrics and Gynecology, Brigham and Women's Hospital",
            "LocationName": "Univ. of Alabama Birmingham NICHD CRS (5096)",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00028145",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20020620 - NIAID - Scott",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20020620",
            "StudyNumber": "20020620 - NIAID - Scott",
            "StudyTitle": "ACTG P1025 Perinatal Core Protocol - A Multicenter Trial of the Pediatric AIDS Clinical Trials Group, version 4.0",
            "PIID": "1243",
            "PicNum": "C00795461",
            "PILastName": "Scott",
            "PIFirstName": "Gwendolyn",
            "CoodCNbr": "C00057173",
            "CoordLastName": "Bryan",
            "CoordFirstName": "Patricia",
            "CoordEmail": "pbryan@med.miami.edu",
            "CoordPhone": "3052434447",
            "EnteredByCNbr": "C00482361",
            "EnteredByLastName": "Falk",
            "EnteredByFirstName": "Alan",
            "ActiveEnrollingDate": "10/07/2002",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/07/2002",
            "IRBApprovedFrom": "10/07/2002",
            "IRBApprovedTo": "01/22/2014",
            "InfoEdNbr": "54944",
            "Expr1": "N/A",
            "Tarea": "Immunology/Infectious Disease",
            "TareaCode": "13340",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "National Institute of Allergy and Infectious Diseases",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "82",
            "Totalaccrued": "79",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "25",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "82",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:245,UMHC:5",
            "AccrualPercentageMet": "31.6",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "250",
            "EprostState": "Approved",
            "StudyCoordinator": "Patricia Bryan,Sady Dominguez",
            "StudyObjective": "Primary Objectives:\r\n1. To assess maternal and infant safety of new and existing interventions prescribed for prevention of mother-to-child transmission (MTCT) of HIV and/or womens health\r\na. To address hypotheses pertaining to current and emerging safety issues\r\nb. To identify areas for focused clinical trials/Data Analysis Concept Sheets (DACS)\r\nc. To provide safety data to National Institutes of Health (NIH) and Food and Drug Administration (FDA) as requested\r\n\r\n2. To assess the effectiveness of interventions prescribed for prevention of mother-to-child transmission (MTCT) and/or for womens health with regard to immune and viral parameters.\r\n3. To provide a framework and specimen repository for intensive substudies (such as P1026s, pharmacokinetics in pregnancy), New Works Concept Sheets (NWCS), and DACS that aim to further elucidate mechanisms of MTCT of HIV, as well as factors that affect maternal and infant outcomes.\r\n\r\n\r\nSECONDARY OBJECTIVES:\r\n1. To identify genotypic/phenotypic resistance mutations in HIV-infected mothers according to antiretroviral (ARV) history and to compare resistance genotypes in any mother-infant pairs where transmission occurred.\r\n\r\n2. To describe HIV-infected pregnant women and their infants receiving care at IMPAACT sites in terms of clinical, immunological, and virological characteristics; receipt of ARVs; mode of delivery; and MTCT rates.\r\n\r\n3. To facilitate the conduct of other relevant trials:\r\na. Provide estimates of women with particular characteristics for development of clinical trials to further the MTCT/maternal health research agenda\r\nb. Referral of infants to available long term follow-up and/or early therapy protocols\r\nc. Referral of women into appropriate ACTG, IMPAACT, and other trials\r\n\r\n4. To further assess adherence to ARVs among HIV-infected pregnant women during pregnancy and postpartum as follows:\r\na. Assess the association between rates of adherence and reported clinical toxicities.\r\nb. Describe rates of new resistance mutations to ARVs received among subjects with high versus low adherence, and determine rates of MTCT of such mutations.\r\nc. Assess the association of ARV adherence with womens health, mode of delivery and pregnancy outcomes",
            "NationalSampleSize": "5000",
            "NCTNbr": "NCT00028145",
            "StudyKeywords": "ORIM: Kanchan Sakhrani (QA: 10/11/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00029198",
            "SecondaryId": "R01AT000370-01",
            "BriefTitle": "Preterm Infants' Weight Gain Following Massage Therapy",
            "OfficialTitle": "Preterm Infants' Weight Gain Following Massage Therapy",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "The specific aims of this study are: 1) to replicate the data that following ten days of\r\n\r\n      massage therapy, preterm infants show greater daily weight gain and are discharged from the\r\n\r\n      hospital earlier than the controls, thus demon",
            "Description": "A number of studies have documented an average of 47% greater weight gain in preterm\r\n\r\n      neonates following massage therapy. Our currently funded study suggests that massage therapy\r\n\r\n      increases vagal activity, oxytocin, and IGF-1. In",
            "OverallStatus": "Completed",
            "StartDate": "April 2003",
            "CompletionDate": "March 2008",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "University of Miami",
            "StudyCondition": "Premature Birth",
            "studyLocation": "University of Miami School of Medicine",
            "Enrollment": "139",
            "NctKeyword": "Massage Therapy, Preterm Infants, Weight Gain, Vagal Tone, IGF-1, Oxytocin, Brazelton,",
            "MeshKeyword": "Weight Gain, Premature Birth,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Gestational age between 28 and 32 weeks\r\n\r\n\r\n\r\n          -  Birthweight between 800 and 1,400 grams\r\n\r\n\r\n\r\n          -  Birthweight, length, and head circumference appropriate for gestational age",
            "EligibleGender": "All",
            "MinAge": "28 Weeks",
            "MaxAge": "32 Weeks",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "April 2014",
            "LastChanged": "April 9, 2014",
            "FirstReceived": "January 9, 2002",
            "OverallOfficial": "Tiffany M Field, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "University of Miami School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00029198",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20000123 - NATL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICI - Field",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20000123",
            "StudyNumber": "20000123 - NATL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICI - Field",
            "StudyTitle": "Preterm Infants' Weight Gain Following Massage Therapy",
            "PIID": "344",
            "PicNum": "C00654765",
            "PILastName": "Field",
            "PIFirstName": "Tiffany",
            "CoodCNbr": "C00009581",
            "CoordLastName": "Diego",
            "CoordFirstName": "Miguel",
            "CoordEmail": "m.diego@miami.edu",
            "CoordPhone": "3052436781",
            "EnteredByCNbr": "C00654765",
            "EnteredByLastName": "Field",
            "EnteredByFirstName": "Tiffany",
            "ActiveEnrollingDate": "06/22/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/22/2012",
            "IRBApprovedFrom": "03/15/2000",
            "IRBApprovedTo": "09/29/2016",
            "InfoEdNbr": "63506",
            "WIrb": "20051550",
            "Expr1": "N/A",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "33",
            "Totalaccrued": "33",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "33",
            "FirstNinety": "3",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Gladys Gonzalez,Miguel Diego",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00029198",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00038727",
            "BriefTitle": "Diabetes Prevention Program Outcomes Study",
            "OfficialTitle": "Diabetes Prevention Program Outcomes Study",
            "LeadSponsorClass": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
            "OversightAuthority": "Yes",
            "BriefSummary": "The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an\r\n\r\n      intensive lifestyle or metformin to prevent or delay the development of diabetes in a high\r\n\r\n      risk population due to the presence of impair",
            "Description": "The current DPPOS Executive Summary and protocol, as well as DPP protocol and lifestyle\r\n\r\n      manuals and publications are available at: http://www.bsc.gwu.edu/dpp/index.htmlvdoc",
            "OverallStatus": "Unknown status",
            "StartDate": "September 2002",
            "CompletionDate": "January 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
            "StudyCondition": "Diabetes Mellitus",
            "studyLocation": "George Washington University",
            "Enrollment": "2776",
            "NctKeyword": "DPP, IGT, Prediabetes, Type 2 diabetes, Macrovascular disease, Microvascular disease,",
            "MeshKeyword": "Diabetes Mellitus,",
            "InterventionKeyword": "Metformin,",
            "Eligibility": "Participation as a volunteer in the DPP.",
            "EligibleGender": "All",
            "MinAge": "25 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Rockville",
            "State": "Maryland",
            "Zip": "20852",
            "Country": "United States",
            "VerificationDate": "June 2014",
            "LastChanged": "June 16, 2014",
            "FirstReceived": "June 4, 2002",
            "OverallOfficial": "David M. Nathan, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Massachusetts General Hospital",
            "LocationName": "George Washington University",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00038727",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20020457 - NIH/NIDDK - Goldberg",
            "FileProcessContentId": "440",
            "Division": "Endocrinology",
            "StdyDivision": "10241",
            "EprostNbr": "20020457",
            "StudyNumber": "20020457 - NIH/NIDDK - Goldberg",
            "StudyTitle": "Diabetes Prevention Program Outcomes Study or DPPOS",
            "PIID": "725",
            "PicNum": "C00032088",
            "PILastName": "Goldberg",
            "PIFirstName": "Ronald",
            "CoodCNbr": "C00032088",
            "CoordLastName": "Goldberg",
            "CoordFirstName": "Ronald",
            "CoordEmail": "r.goldberg1@miami.edu",
            "CoordPhone": "3052436505",
            "EnteredByCNbr": "C00032088",
            "EnteredByLastName": "Goldberg",
            "EnteredByFirstName": "Ronald",
            "ActiveEnrollingDate": "06/22/2009",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/22/2009",
            "IRBApprovedFrom": "08/19/2002",
            "IRBApprovedTo": "04/24/2017",
            "AccountNbr": "660394",
            "InfoEdNbr": "30659 / 33233",
            "WIrb": "20051317",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "NIDDK",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "99",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "99",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A,Clinical Research Center (CRC):N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "AgentDevices": "Agent: Glucophage",
            "StudyObjective": "Primary Objective\r\nTo compare, after short-term (24 weeks) oral administration of double-blind treatment, the change from baseline in HbA1c achieved with each dose of BMS-477118 plus metformin versus placebo plus metformin in subjects with type 2 diabetes who have inadequate glycemic control defined as HbA1c > 7.0% and < 10.0% and currently treated with 15000 mg but not more than 2550 mg of stable dose of metformin per day.\r\n\r\nSecondary Objectives\r\nTo comapre eahc dose of BMS-477118 plus metformin versus placebo plus metformin after 24 weeks of oral administration of double-blind therapy for the following:\r\n1) the change from basline in the area under the curve (AUC) from 0 to 180 minutes for postprandial glucose (PPG) response to an oral glucose tolerance test (OGTT)\r\n2. the change from basline in fasing plasma glucose (FPG)\r\n3. the proportion of subjects achieving a terapeutic glycemic response defined as HbA1c <7.0%",
            "NationalSampleSize": "137",
            "NCTNbr": "NCT00038727",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00042289",
            "SecondaryId": "10040",
            "BriefTitle": "Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy",
            "OfficialTitle": "Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum",
            "LeadSponsorClass": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "BriefSummary": "The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV)\r\n\r\n      and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are\r\n\r\n      the various interactions between a drug an",
            "Description": "Pregnant women experience unique physiological changes that may result in clinically\r\n\r\n      significant alterations in drug PKs. Unfortunately, there have been few clinical trials to\r\n\r\n      study the PKs of ARV, TB, and hormonal contraceptiv",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2003",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "StudyCondition": "HIV Infections",
            "studyLocation": "UAB Pediatric Infectious Diseases CRS",
            "Enrollment": "1786",
            "NctKeyword": "Pregnancy, Pharmacokinetics, Treatment Experienced,",
            "MeshKeyword": "HIV Infections,",
            "InterventionKeyword": "Ritonavir, Lopinavir, Atazanavir Sulfate, Darunavir, Cobicistat, Tenofovir, Nevirapine, Dolutegravir, Moxifloxacin, Efavirenz, Bedaquiline, Etravirine, Rifampin, Isoniazid, Kanamycin, Ethionamide, Prothionamide, Capreomycin, Pyrazinamide, Linezolid, Cyclo",
            "Eligibility": "Maternal Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Participant must belong to one of the following 5 groups:\r\n\r\n\r\n\r\n               1. HIV-infected pregnant women greater than or equal to 20 weeks gestation NOT on\r\n\r\n                  TB treatmen",
            "EligibleGender": "Female",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 29, 2016",
            "FirstReceived": "July 26, 2002",
            "OverallOfficial": "Mark Mirochnick, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Boston Medical Center",
            "ContactName": "Emily F. Demske",
            "ContactPhone": "301-628-3322",
            "LocationStatus": "Completed",
            "LocationName": "UAB Pediatric Infectious Diseases CRS",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00042289",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20030106 - NIAID - Scott",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20030106",
            "StudyNumber": "20030106 - NIAID - Scott",
            "StudyTitle": "IMPAACT P1026s\nPharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and\nPostpartum\nVersion 9.0, Dated 22 September 2014",
            "PIID": "1243",
            "PicNum": "C00795461",
            "PILastName": "Scott",
            "PIFirstName": "Gwendolyn",
            "CoodCNbr": "C00482361",
            "CoordLastName": "Falk",
            "CoordFirstName": "Alan",
            "EnteredByCNbr": "C00795461",
            "EnteredByLastName": "Scott",
            "EnteredByFirstName": "Gwendolyn",
            "ActiveEnrollingDate": "08/02/2004",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/16/2005",
            "IRBApprovedFrom": "03/10/2003",
            "IRBApprovedTo": "03/29/2017",
            "InfoEdNbr": "54679 / 54944",
            "WIrb": "20021617",
            "Expr1": "Phase IV",
            "Tarea": "Immunology/Infectious Disease",
            "TareaCode": "13340",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "National Institute of Allergy and Infectious Diseases",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "43",
            "Totalaccrued": "42",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "11",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "43",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:100",
            "AccrualPercentageMet": "42",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "100",
            "EprostState": "Approved",
            "StudyCoordinator": "Sady Dominguez",
            "AgentDevices": "Agents: Viread, Lexiva, Isentress, Prezista, Kaletra, Intelence, Crixivan, Viracept, Norvir, Sustiva",
            "StudyObjective": "PRIMARY OBJECTIVE:\r\nTo describe the pharmacokinetic (PK) parameters during pregnancy of selected antiretroviral (ARV) drugs currently used in the clinical care of pregnant HIV infected women, and to determine if therapeutic dosing regimens of these antiretroviral drugs produce adequate drug exposure during pregnancy compared to a) historical data from non-pregnant adults and b) the same women in the study cohorts during the postpartum period.\r\n\r\nSECONDARY OBJECTIVES:\r\n1. To compare antiretroviral drug concentrations in plasma from cord blood with those in maternal plasma at the time of delivery.\r\n2. To indirectly assess the induction of cytochrome P450 3A4 by determining the ratio in urine of 6&#61538;-hydroxycortisol to cortisol.\r\n3. To determine plasma protein binding of atazanavir, fosamprenavir, lopinavir, nelfinavir and tipranavir during pregnancy and postpartum.",
            "NationalSampleSize": "60",
            "NCTNbr": "NCT00042289",
            "StudyKeywords": "Protocol at External IRB\r\nORIM QA: Kanchan Sakhrani (10/11/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00132691",
            "SecondaryId": "U10EY014660",
            "BriefTitle": "Multicenter Uveitis Steroid Treatment (MUST) Trial",
            "OfficialTitle": "Multicenter Uveitis Steroid Treatment (MUST) Trial",
            "LeadSponsorClass": "JHSPH Center for Clinical Trials",
            "SponsorAgency": "Other",
            "LeadSponsor": "JHSPH Center for Clinical Trials",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to compare the effectiveness of standardized systemic therapy\r\n\r\n      versus fluocinolone acetonide implant therapy for the treatment of severe cases of\r\n\r\n      non-infectious intermediate uveitis, posterior uveiti",
            "Description": "The MUST trial is a randomized controlled clinical trial comparing two treatments for\r\n\r\n      patients with vision-threatening non-infectious intermediate uveitis, posterior uveitis, or\r\n\r\n      panuveitis:\r\n\r\n\r\n\r\n        -  local therapy with",
            "OverallStatus": "Completed",
            "StartDate": "September 2005",
            "CompletionDate": "December 2010",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "JHSPH Center for Clinical Trials",
            "StudyCondition": "Uveitis",
            "studyLocation": "Jacobs Retina Center, UCSD",
            "Enrollment": "255",
            "NctKeyword": "uveitis, non-infectious intermediate uveitis, non-infectious posterior uveitis, non-infectious panuveitis,",
            "MeshKeyword": "Uveitis,",
            "InterventionKeyword": "Cyclophosphamide, Mycophenolate mofetil, Immunosuppressive Agents, Azathioprine, Chlorambucil, Alkylating Agents, Fluocinolone Acetonide,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Age 13 years or older\r\n\r\n\r\n\r\n          -  Best-corrected visual acuity of hand motions or better in at least one eye with\r\n\r\n             uveitis\r\n\r\n\r\n\r\n          -  Intraocular pressure 24 mm Hg or less",
            "EligibleGender": "All",
            "MinAge": "13 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "La Jolla",
            "State": "California",
            "Zip": "92037",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 13, 2016",
            "FirstReceived": "August 19, 2005",
            "OverallOfficial": "Douglas Jabs, MD, MBA",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Icahn School of Medicine at Mount Sinai",
            "LocationName": "Jacobs Retina Center, UCSD",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00132691",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20053309 - NEI - Davis",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20053309",
            "StudyNumber": "20053309 - NEI - Davis",
            "StudyTitle": "Longterm Followup of Patients Who Participated in the Multicenter Uveitis Steroid Treatment Trial (MUST Trial Followup Study)Previous phase Titled:Multicenter Uveitis Steroid Treatment (MUST) Trial Protocol",
            "PIID": "861",
            "PicNum": "C00771718",
            "PILastName": "Davis",
            "PIFirstName": "Janet",
            "CoodCNbr": "C00371467",
            "CoordLastName": "Chin",
            "CoordFirstName": "Marie",
            "CoordEmail": "mchin@med.miami.edu",
            "CoordPhone": "305-326-6348",
            "EnteredByCNbr": "C05023820",
            "EnteredByLastName": "Stepien",
            "EnteredByFirstName": "Kimberly",
            "ActiveEnrollingDate": "01/01/2007",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/11/2013",
            "IRBApprovedFrom": "09/06/2005",
            "IRBApprovedTo": "05/22/2017",
            "AccountNbr": "66817R",
            "InfoEdNbr": "52219,69007",
            "WIrb": "20051637",
            "Expr1": "Phase IV",
            "Tarea": "Retina",
            "TareaCode": "12038",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "National Eye Institute",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "14",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "14",
            "FirstNinety": "0",
            "SiteSampleSize": "ABLEH:20",
            "AccrualPercentageMet": "10",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "20",
            "EprostState": "Approved",
            "StudyCoordinator": "Carmen Huerta",
            "AgentDevices": "Agent: Retisert, Sandimmune, Cytoxan, Imuran, Leukeran, Deltasone, Cellcept",
            "StudyObjective": "PURPOSE:\r\nThe primary objective of the Multicenter Uveitis Steroid Treatment (MUST) Trial is to compare the efficacy of standardized systemic therapy versus fluocinolone acetonide implant therapy for the treatment of severe cases of non-infectious intermediate uveitis, posterior uveitis or panuveitis. Patients with active uveitis will be randomized, with a 1:1 allocation ratio, to treatment with either the fluocinolone acetonide implant or standardized systemic therapy consisting of oral corticosteroids and supplementary immunosuppressive drugs when indicated, according to standardized guidelines. The design outcome variable for the study is visual acuity; other outcomes include other aspects of visual function, success in controlling uveitis, retinal morphologic outcomes, quality of life, costeffectiveness, and occurrence of potential ocular and systemic complications of uveitis and of therapy. \r\n\r\nSPECIFIC AIMS:\r\nObjectives and Study Hypotheses 2.1 Specific aims of the MUST Trial: 1) To compare the visual outcomes of patients with uveitis treated with the sustainedrelease intraocular fluocinolone acetonide implant therapy to those treated with systemic therapy using oral corticosteroids supplemented by corticosteroid-sparing immunosuppressive drugs when indicated; 2) To compare the efficacy of the alternative treatment strategies for controlling uveitis and ameliorating/preventing structural complications of uveitis over time; 3) To compare the rates of local ocular corticosteroid-induced complications and the rates of systemic complications between the treatment groups; 4) To compare the self-reported quality of life of the treatment groups. \r\n\r\n2.2 HYPOTHESES: 1) Patients randomized to implant therapy will have better visual outcomes. 2) Patients randomized to implant therapy will have improved control of uveitis, a decreased rate of posterior segment structural complications of the uveitis (such as cystoid macular edema and epiretinal membranes), and an increased rate of corticosteroid-induced ocular complications, such as cataracts, ocular hypertension, and glaucoma. 3) Patients randomized to systemic therapy will have a higher rate of systemic complications, such as diabetes, hypertension, and osteoporosis. 4) Improved visual outcomes and the absence of systemic corticosteroid complications (and the additional treatments needed to combat them) will result in a better quality of life for patients randomized to implant therapy.",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT00132691",
            "StudyKeywords": "ORIM: Kanchan Sakhrani (QA: 11/9/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00178724",
            "SecondaryId": "W81XH-13-2-0040",
            "BriefTitle": "North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury - Registry",
            "OfficialTitle": "North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury",
            "LeadSponsorClass": "Robert G. Grossman, MD",
            "SponsorAgency": "Other",
            "LeadSponsor": "Robert G. Grossman, MD",
            "OversightAuthority": "No",
            "BriefSummary": "The NACTN Spinal Cord Injury Registry is a network of clinical centers collecting\r\n\r\n      de-identified data from patients admitted through the Emergency Department of a NACTN center\r\n\r\n      at the time of injury with an initial (first time) s",
            "Description": "The participating centers include:\r\n\r\n\r\n\r\n      Houston Methodist Hospital, Houston; University of Texas Health Science Center, Houston;\r\n\r\n      University of Toronto, Toronto; University of Virginia, Charlottesville; University of\r\n\r\n      Lou",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2005",
            "CompletionDate": "July 2023",
            "Phase": "Phase 1",
            "StudyType": "Observational",
            "StudyPhase": "Phase 1",
            "StudySource": "The Methodist Hospital System",
            "StudyCondition": "Spinal Cord Injury",
            "studyLocation": "Stanford University",
            "Enrollment": "1500",
            "NctKeyword": "spinal cord injury, SCI, traumatic spinal cord injury, acute spinal cord injury, paralysis,",
            "MeshKeyword": "Wounds and Injuries, Spinal Cord Injuries,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Any patient male or female > or equal to 18 years of age with first time spinal cord\r\n\r\n             injury caused by trauma and has neurological deficit (paralysis/weakness or loss of\r\n\r\n             se",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Stanford",
            "State": "California",
            "Zip": "94305",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 29, 2016",
            "FirstReceived": "September 13, 2005",
            "OverallOfficial": "Robert G Grossman, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Houston Methodist Hospital, Houston",
            "ContactName": "Elizabeth G Toups, MS, RN, CCRP",
            "ContactPhone": "713-441-3897",
            "ContactEmail": "etoups@houstonmethodist.org",
            "LocationStatus": "Recruiting",
            "LocationName": "Stanford University",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00178724",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20080701 - CRF - Guest",
            "FileProcessContentId": "440",
            "Division": "Neurosurgery",
            "StdyDivision": "9636",
            "EprostNbr": "20080701",
            "StudyNumber": "20080701 - CRF - Guest",
            "StudyTitle": "North American Clinical Trials Network (NACTN) for Treatment of Spinal Cord Injury",
            "PIID": "1287",
            "PicNum": "C00054757",
            "PILastName": "Guest",
            "PIFirstName": "James",
            "CoodCNbr": "C09918326",
            "CoordLastName": "Jimsheleishvili",
            "CoordFirstName": "George",
            "CoordEmail": "gxj150@med.miami.edu",
            "EnteredByCNbr": "C09918326",
            "EnteredByLastName": "Jimsheleishvili",
            "EnteredByFirstName": "George",
            "ActiveEnrollingDate": "02/26/2009",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/26/2009",
            "IRBApprovedFrom": "01/30/2009",
            "IRBApprovedTo": "07/04/2017",
            "InfoEdNbr": "35192",
            "Expr1": "N/A",
            "Tarea": "Spine",
            "TareaCode": "9641",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "SponsorGroup": "Foundation",
            "Sponsor": "The Christopher Reeve Foundation",
            "Prescreened": "42",
            "Screenedfailed": "0",
            "SignedICF": "97",
            "Totalaccrued": "69",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "69",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "117",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:700,UMH:300",
            "AccrualPercentageMet": "6.9",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "1000",
            "EprostState": "Approved",
            "StudyObjective": "The primary goal of this study is to collect information on the natural course of traumatic spinal cord injury (SCI) in order to contribute to a multi-center database containing information about etiology, level, severity, demographic characteristics of health delivering services and outcomes for persons who incur a SCI. An SCI database will serve as a baseline to plan for clinical trials of therapies that show promising results in the laboratory.",
            "NationalSampleSize": "800",
            "NCTNbr": "NCT00178724",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT00306098",
            "SecondaryId": "NIH #1U42 RR016603-01",
            "BriefTitle": "Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression",
            "OfficialTitle": "Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression",
            "LeadSponsorClass": "Rodolfo Alejandro",
            "SponsorAgency": "Other",
            "LeadSponsor": "Rodolfo Alejandro",
            "OversightAuthority": "Yes",
            "BriefSummary": "SPECIFIC AIMS:\r\n\r\n\r\n\r\n        1. To reverse hyperglycemia and insulin dependency in patients with Type 1 Diabetes\r\n\r\n           Mellitus by islet cell transplantation;\r\n\r\n\r\n\r\n        2. To eliminate the incidence of hypoglycemia coma and unaware",
            "Description": "This Phase II trial will have 3 groups: Group A will receive islets from 2 donors and will\r\n\r\n      not receive infliximab. Group B will receive, in addition to Daclizumab, Sirolimus, and\r\n\r\n      Tacrolimus, a dose of infliximab and islets from",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "December 2000",
            "CompletionDate": "May 2019",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Diabetes Mellitus, Type I",
            "studyLocation": "University of Miami, Diabetes Research Institute",
            "Enrollment": "40",
            "NctKeyword": "Transplantation, Islets of Langerhans,",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Patients between 18 and 65 years of age\r\n\r\n\r\n\r\n          2. Patients with type 1 diabetes mellitus for more than 5 years duration\r\n\r\n\r\n\r\n          3. One or more of the following:\r\n\r\n\r\n\r\n               -",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 9, 2016",
            "FirstReceived": "March 17, 2006",
            "OverallOfficial": "Rodolfo Alejandro, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami, Diabetes Research Institute",
            "LocationName": "University of Miami, Diabetes Research Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00306098",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20000196 - NIH/JDRFI - Alejandro",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20000196",
            "StudyNumber": "20000196 - NIH/JDRFI - Alejandro",
            "StudyTitle": "Islet Cell Transplantation Alone in Patients with Type 1 Diabetes Mellitus: Steroid Free Immunosuppression.",
            "PIID": "473",
            "PicNum": "C00309269",
            "PILastName": "Alejandro",
            "PIFirstName": "Rodolfo",
            "CoodCNbr": "C09431526",
            "CoordLastName": "Moraes Leao Peixoto",
            "CoordFirstName": "Eduardo",
            "CoordEmail": "epeixoto@med.miami.edu",
            "CoordPhone": "3052433389",
            "EnteredByCNbr": "C02023715",
            "EnteredByLastName": "Froud",
            "EnteredByFirstName": "Tatiana",
            "ActiveEnrollingDate": "08/28/2000",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/28/2000",
            "IRBApprovedFrom": "06/05/2000",
            "IRBApprovedTo": "03/06/2017",
            "AccountNbr": "66469E",
            "InfoEdNbr": "40163/29143/32627",
            "Expr1": "N/A",
            "Tarea": "Islet Transplant",
            "TareaCode": "12545",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "National Insitute Health, Juvenile Research Foundation International",
            "Prescreened": "4",
            "Screenedfailed": "0",
            "SignedICF": "21",
            "Totalaccrued": "21",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "21",
            "FirstNinety": "2",
            "SiteSampleSize": "JMH:500,Clinical Research Center (CRC):N/A,UMMG:500",
            "AccrualPercentageMet": "2.1",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "1000",
            "EprostState": "Approved",
            "StudyCoordinator": "David Baidal,Ana Alvarez,Luz Arazo,Carlos Blaschke,Della Matheson,Elina Linetsky",
            "AgentDevices": "Agent: Enbrel,Islet Cells,Zenapax,Campath,Myfortic,Prograf,Byetta,Remicade,CellCept,Thymoglobulin,",
            "StudyObjective": "Part A: Trial of Islet Transplantation in Brittle Type 1 Diabetic Patients Using Edmonton Protocol of Steroid-Free Immunosuppression \r\nPart B: Single-Donor Islet Transplantation in Brittle Type 1 Diabetic Patients Using Edmonton Protocol of Steroid-Free Immunosuppression and Anti-TNF-&#61537; chimeric monoclonal antibody (infliximab) \r\nPart C: Single-Donor Islet Transplantation in Brittle Type 1 Diabetic Patients Using Edmonton Protocol of Steroid-Free Immunosuppression and a TNF-&#61537; inhibitor (etanercept) \r\n\r\nSPECIFIC AIMS:\r\na) To reverse hyperglycemia and insulin dependency in patients with Type 1 Diabetes Mellitus by islet cell transplantation;\r\nb) To eliminate the incidence of hypoglycemia coma and unawareness in patients with Type 1 Diabetes Mellitus by islet cell transplantation;\r\nc) To assess long-term safety and function of successful islet cell transplants in patients with Type 1 Diabetes Mellitus;\r\nd) To determine whether the natural history of the microvascular, macrovascular and neuropathic complications of Diabetes Mellitus are altered following successful transplantation of islet cells; and \r\ne) To assess the effect of infliximab in preventing early islet destruction, and thereby eliminating the need for a second donors islet cells.\r\nf) To assess the effect of etanercept in preventing early islet destruction. \r\ng) To assess the effect of exenatide or sitagliptin to improve islet graft function and survival in subjects who have returned to using exogenous insulin.\r\nh) To assess the ability of exenatide or sitagliptin to improve islet survival at time of transplantation.\r\ni) To assess the impact of acute and chronic use of exenatide or sitagliptin on gastric emptying in islet allograft recipients.\r\nj) To assess the impact of physical exercise on metabolic outcomes of islet transplant recipients.",
            "NationalSampleSize": "156",
            "NCTNbr": "NCT00306098",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00310375",
            "SecondaryId": "RTG115098",
            "BriefTitle": "Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial",
            "OfficialTitle": "A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301)",
            "LeadSponsorClass": "GlaxoSmithKline",
            "SponsorAgency": "Industry",
            "LeadSponsor": "GlaxoSmithKline",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to evaluate the safety and tolerability of long-term therapy\r\n\r\n      with retigabine administered as adjunctive therapy in adult epilepsy patients with\r\n\r\n      partial-onset seizures, who completed the VRX-RET-E22-",
            "Description": "This Phase 3 trial is an open-label extension study of the placebo-controlled, double-blind\r\n\r\n      VRX-RET-E22-301 trial. Patients who have completed the VRX-RET-E22-301 trial and who meet\r\n\r\n      inclusion and exclusion criteria will be trea",
            "OverallStatus": "Completed",
            "StartDate": "May 2006",
            "CompletionDate": "November 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "GlaxoSmithKline",
            "StudyCondition": "Epilepsy",
            "studyLocation": "University of Alabama -- Department of Neurology/Epilepsy Center",
            "Enrollment": "181",
            "NctKeyword": "Epilepsy, Partial Seizures, Potassium Channels, Anticonvulsant, Complex Partial Seizures, Epilepsies, Partial, RTG115098,",
            "MeshKeyword": "Epilepsy,",
            "InterventionKeyword": "Ezogabine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patient has successfully completed the Maintenance and Transition phases of Study\r\n\r\n             VRX-RET-E22-301 for the treatment of partial-onset seizures\r\n\r\n\r\n\r\n          -  Patient is expected to be",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "October 4, 2016",
            "FirstReceived": "March 30, 2006",
            "OverallOfficial": "GSK Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "GlaxoSmithKline",
            "LocationName": "University of Alabama -- Department of Neurology/Epilepsy Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00310375",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20060435 - Valeant - Serrano",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20060435",
            "StudyNumber": "20060435 - Valeant - Serrano",
            "StudyTitle": "A multicenter, open-label, long term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of STudy VRX-RET-E22-301)  VRX-RET-E22-303",
            "PIID": "2238",
            "PicNum": "C09412656",
            "PILastName": "Serrano",
            "PIFirstName": "Enrique",
            "CoodCNbr": "C06981767",
            "CoordLastName": "Frost",
            "CoordFirstName": "Haydee",
            "CoordEmail": "hfrost@med.miami.edu",
            "CoordPhone": "3052438829",
            "EnteredByCNbr": "C06981767",
            "EnteredByLastName": "Frost",
            "EnteredByFirstName": "Haydee",
            "ActiveEnrollingDate": "12/20/2007",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/20/2007",
            "IRBApprovedFrom": "06/15/2006",
            "IRBApprovedTo": "04/15/2014",
            "AccountNbr": "66292N",
            "InfoEdNbr": "27433",
            "WIrb": "20060588",
            "Expr1": "Phase III",
            "Tarea": "Epilepsy",
            "TareaCode": "8936",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Valeant",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:2",
            "AccrualPercentageMet": "100",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "2",
            "EprostState": "Protocol at External IRB",
            "StudyCoordinator": "Pedro Figueredo",
            "AgentDevices": "Agent",
            "StudyObjective": "",
            "NationalSampleSize": "280",
            "NCTNbr": "NCT00310375",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00315627",
            "BriefTitle": "Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation",
            "OfficialTitle": "Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation",
            "LeadSponsorClass": "Rodolfo Alejandro",
            "SponsorAgency": "Other",
            "LeadSponsor": "Rodolfo Alejandro",
            "OversightAuthority": "No",
            "BriefSummary": "The purposes of this study are:\r\n\r\n\r\n\r\n        1. To reverse hyperglycemia and insulin dependency in patients with type 1 diabetes\r\n\r\n           mellitus through islet transplantation utilizing steroid free, calcineurin-inhibitor\r\n\r\n           f",
            "Description": "STUDY DESIGN:\r\n\r\n\r\n\r\n      The initial proposal submitted to the JDRFI was to compare 3 different groups of patients\r\n\r\n      receiving islet cell transplants utilizing steroid-free, calcineurin-free protocols. The 3\r\n\r\n      groups were as foll",
            "OverallStatus": "Completed",
            "StartDate": "July 2005",
            "CompletionDate": "January 2014",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Type 1 Diabetes Mellitus",
            "studyLocation": "Diabetes Research Institute",
            "Enrollment": "3",
            "NctKeyword": "Islet Transplantation,",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        Potential candidates must have type 1 diabetes mellitus and fulfill one or more of the\r\n\r\n        following:\r\n\r\n\r\n\r\n          1. Manifest signs and symptoms that are severe enough to be incapacitating.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 9, 2016",
            "FirstReceived": "April 14, 2006",
            "OverallOfficial": "Rodolfo Alejandro, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Diabetes Research Institute - University of Miami",
            "LocationName": "Diabetes Research Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00315627",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20040205 - JDRI - Alejandro",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20040205",
            "StudyNumber": "20040205 - JDRI - Alejandro",
            "StudyTitle": "Steroid-free and Long-term Calcineurin-Free Trial in Islet Cell Transplantation",
            "PIID": "473",
            "PicNum": "C00309269",
            "PILastName": "Alejandro",
            "PIFirstName": "Rodolfo",
            "CoodCNbr": "C00051652",
            "CoordLastName": "Wilkes",
            "CoordFirstName": "John",
            "EnteredByCNbr": "C00641215",
            "EnteredByLastName": "Messinger",
            "EnteredByFirstName": "Shari",
            "ActiveEnrollingDate": "05/10/2004",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/10/2004",
            "IRBApprovedFrom": "05/10/2004",
            "IRBApprovedTo": "05/19/2014",
            "AccountNbr": "66938L",
            "InfoEdNbr": "30118",
            "Expr1": "N/A",
            "Tarea": "Islet Transplant",
            "TareaCode": "12545",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "Juvenile Diabetes Research Institute Foundation",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:12,Clinical Research Center (CRC):N/A,JMH:12",
            "AccrualPercentageMet": "12.5",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "24",
            "EprostState": "Approved",
            "StudyCoordinator": "Eduardo Moraes Leao Peixoto,Mohammad Alajarmeh,Ryosuke Misawa,Luz Arazo,Carlos Blaschke,Della Matheson,Elina Linetsky",
            "AgentDevices": "Drug: Campath,CellCept,Enbrel,Prograf,Rapamune",
            "StudyObjective": "",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT00315627",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00392327",
            "SecondaryId": "NCI-2009-00336",
            "BriefTitle": "Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma",
            "OfficialTitle": "Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients",
            "LeadSponsorClass": "Children's Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Oncology Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase III trial studies different chemotherapy and radiation therapy\r\n\r\n      regimens to compare how well they work in treating young patients with newly diagnosed,\r\n\r\n      previously untreated, high-risk medulloblastoma. Drugs",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To determine whether carboplatin radiosensitization increases long term event-free\r\n\r\n      survival for high risk medulloblastoma/primitive neuroectodermal tumor (PNET) patients.\r\n\r\n\r\n\r\n      II. To determine",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2007",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Children's Oncology Group",
            "StudyCondition": "Untreated Childhood Medulloblastoma",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "400",
            "MeshKeyword": "Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Medulloblastoma, Pinealoma,",
            "InterventionKeyword": "Cisplatin, Cyclophosphamide, Carboplatin, Vincristine, Lenograstim, Isotretinoin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Newly diagnosed, previously untreated: (1) M0 medulloblastoma with > 1.5 cm^2\r\n\r\n             residual; (2) M+ medulloblastoma; patients with diffusely anaplastic medulloblastoma\r\n\r\n             are elig",
            "EligibleGender": "All",
            "MinAge": "3 Years",
            "MaxAge": "21 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 19, 2016",
            "FirstReceived": "October 25, 2006",
            "OverallOfficial": "James Olson, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Active, not recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00392327",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20070437 - COG - BARREDO",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20070437",
            "StudyNumber": "20070437 - COG - BARREDO",
            "StudyTitle": "ACNS0332:  Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as ProApoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients.",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C11973083",
            "CoordLastName": "Best",
            "CoordFirstName": "Wendy",
            "CoordEmail": "wtbest@med.miami.edu",
            "CoordPhone": "305-243-7130",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "03/28/2007",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/28/2007",
            "IRBApprovedFrom": "03/28/2007",
            "IRBApprovedTo": "06/08/2017",
            "InfoEdNbr": "50950",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "Phase III",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "Children Oncology Group",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:10",
            "AccrualPercentageMet": "20",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "10",
            "EprostState": "External IRB",
            "CancerCenterNbr": "2007035",
            "StudyCoordinator": "Myriam Zayas,Wendy Best",
            "AgentDevices": "Drug: Vincristine",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00392327",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00447798",
            "SecondaryId": "1R01DA017612",
            "BriefTitle": "Project Hope: Hospital Visit is an Opportunity for Prevention and Engagement With HIV-positive Crack Users",
            "OfficialTitle": "Project Hope: Hospital Visit is an Opportunity for Prevention and Engagement With HIV-positive Crack Users",
            "LeadSponsorClass": "Columbia University",
            "SponsorAgency": "Other",
            "LeadSponsor": "Columbia University",
            "OversightAuthority": "Yes",
            "BriefSummary": "The proposed study uses a two-arm randomized experimental design to evaluate the efficacy of\r\n\r\n      a brief, theoretically-guided, \"Prevention Care Advocate\" intervention with HIV-positive\r\n\r\n      crack users. Study participants will be recru",
            "Description": "The proposed study uses a two-arm randomized experimental design to evaluate the efficacy of\r\n\r\n      a brief, theoretically-guided, \"Prevention Care Advocate\" intervention with HIV-positive\r\n\r\n      crack users. Study participants will be recru",
            "OverallStatus": "Completed",
            "StartDate": "June 2005",
            "CompletionDate": "May 2011",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Columbia University",
            "StudyCondition": "HIV Infections",
            "studyLocation": "University of Miami Hospital & Clinics/ Jackson Memorial Hospital",
            "Enrollment": "413",
            "NctKeyword": "HIV positive, crack cocaine user, inpatient hospital setting, HIV knowledge, motivation, perceived self-efficacy, risky sexual behavior, HIV seronegativity,",
            "MeshKeyword": "HIV Infections, HIV Seropositivity,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  HIV positive\r\n\r\n\r\n\r\n          -  Sexually active\r\n\r\n\r\n\r\n          -  Recruited from inpatient/hospital setting\r\n\r\n\r\n\r\n          -  Crack user\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -  HIV ne",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "March 2015",
            "LastChanged": "March 31, 2015",
            "FirstReceived": "March 13, 2007",
            "OverallOfficial": "Lisa R Metsch, Ph.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "University of Miami Hospital & Clinics/ Jackson Memorial Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00447798",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20053072 - NIDA - Metsch",
            "FileProcessContentId": "440",
            "Division": "Epidemiology",
            "StdyDivision": "10636",
            "EprostNbr": "20053072",
            "StudyNumber": "20053072 - NIDA - Metsch",
            "StudyTitle": "Prevention among HIV Crack Users in the Hospital  Project HOPE (Hospital Opportunity for Prevention and Engagement)",
            "PIID": "217",
            "PicNum": "C00263516",
            "PILastName": "Rodriguez",
            "PIFirstName": "Allan E.",
            "CoodCNbr": "C00540059",
            "CoordLastName": "Metsch",
            "CoordFirstName": "Lisa",
            "EnteredByCNbr": "C00540059",
            "EnteredByLastName": "Metsch",
            "EnteredByFirstName": "Lisa",
            "ActiveEnrollingDate": "08/08/2006",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/08/2006",
            "IRBApprovedFrom": "02/17/2005",
            "IRBApprovedTo": "09/08/2016",
            "AccountNbr": "66159L",
            "InfoEdNbr": "36191",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "NIDA",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "181",
            "Totalaccrued": "181",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "181",
            "FirstNinety": "19",
            "SiteSampleSize": "UMMG:250",
            "AccrualPercentageMet": "72.4",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "250",
            "EprostState": "Approved",
            "StudyCoordinator": "Isabella Rosa-cunha,Gabriel Cardenas",
            "StudyObjective": "SPECIFIC AIMS AND HYPOTHESES:\r\nAim 1: To evaluate the efficacy of the intervention in reducing unprotected sexual intercourse (anal or vaginal sex without a condom), increasing the use of HIV primary outpatient care, and increasing readiness to enter drug treatment. Three hypotheses will be tested at each follow-up point (6 and 12 months).\r\nAim 2: To examine whether knowledge, motivation and perceived self-efficacy are mediating factors in behavioral change. Mediation exists if 1) the independent variable (in this case, group) is associated with the mediator variable, 2) the mediator is associated with the outcome variable; and 3) the independent variable and the outcome are correlated (Baron and Kenny, 1986). In addition to the hypotheses listed under Aim 1, several hypotheses will be tested to examine the role of mediating variables in changing each of the behavioral outcomes (unprotected sexual intercourse, use of HIV Primary outpatient care, and readiness to enter drug treatment) at each follow up point.\r\nAim 3: To determine to what extent changes in behavioral outcomes are maintained over time. Each of the hypotheses listed above will be posited separately for each of the follow up points. Hypotheses specific to the second follow up at 12 months will be used to satisfy Aim 3 by incorporating the 6-month measures using generalized estimating equations. The appropriate link function for the outcome variable will be used (e.g., logit for a binary outcome variable).",
            "NationalSampleSize": "260",
            "NCTNbr": "NCT00447798",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00456807",
            "BriefTitle": "Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years",
            "OfficialTitle": "Complementary Testing to Further Evaluate the Immunogenicity of a GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Aged Over 26 Years Enrolled in Study 104820.",
            "LeadSponsorClass": "GlaxoSmithKline",
            "SponsorAgency": "Industry",
            "LeadSponsor": "GlaxoSmithKline",
            "BriefSummary": "Infection with human papillomavirus (HPV) has been clearly established as the central cause\r\n\r\n      of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of\r\n\r\n      the uterus or womb). This infection may go aw",
            "OverallStatus": "Completed",
            "StartDate": "April 2007",
            "CompletionDate": "January 2008",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "GlaxoSmithKline",
            "StudyCondition": "Infections, Papillomavirus",
            "studyLocation": "GSK Investigational Site",
            "Enrollment": "100",
            "NctKeyword": "Human Papillomavirus,",
            "InterventionKeyword": "Vaccines,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  A female enrolled in study 104820 and who received three doses of study\r\n\r\n             vaccine/control.\r\n\r\n\r\n\r\n          -  Subjects who the investigator believes that they can and will comply with the",
            "EligibleGender": "Female",
            "MinAge": "26 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Amsterdam",
            "Zip": "1007 MB",
            "Country": "Netherlands",
            "VerificationDate": "November 2016",
            "LastChanged": "November 3, 2016",
            "FirstReceived": "April 4, 2007",
            "OverallOfficial": "GSK Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "GlaxoSmithKline",
            "LocationName": "GSK Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00456807",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20057595 - GSK - Chakhtoura",
            "FileProcessContentId": "440",
            "Division": "Obstetrics and  Gynecology",
            "StdyDivision": "10251",
            "EprostNbr": "20057595",
            "StudyNumber": "20057595 - GSK - Chakhtoura",
            "StudyTitle": "HPV 015:  A Phase III, Double-blind, Randomized, Controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline Biologicals’ HPV-16/18 L1/ASO4 Vaccine Administered Intramuscularly According to a Three-Dose Schedule (0, 1, 6 month) in Healthy Adult Female Subjects aged 26 years and above.",
            "PIID": "669",
            "PicNum": "C00765112",
            "PILastName": "Chakhtoura",
            "PIFirstName": "Nahida",
            "CoodCNbr": "C00315909",
            "CoordLastName": "Plummer",
            "CoordFirstName": "Yvette",
            "CoordEmail": "yplummer@med.miami.edu",
            "EnteredByCNbr": "C00765112",
            "EnteredByLastName": "Chakhtoura",
            "EnteredByFirstName": "Nahida",
            "ActiveEnrollingDate": "03/20/2006",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/20/2006",
            "IRBApprovedFrom": "01/10/2006",
            "IRBApprovedTo": "10/26/2014",
            "AccountNbr": "66220W",
            "InfoEdNbr": "26064",
            "WIrb": "20052539",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Glaxo Smith Kline",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "11",
            "Totalaccrued": "11",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "11",
            "FirstNinety": "11",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Sindy Jaramillo",
            "NationalSampleSize": "5400",
            "NCTNbr": "NCT00456807",
            "StudyKeywords": "ORIM QA: Kanchan Sakhrani (11/24/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT00468117",
            "BriefTitle": "Efficacy of Islet After Kidney Transplantation",
            "OfficialTitle": "Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients: Efficacy of Islet After Kidney Transplantation (CIT-06)",
            "LeadSponsorClass": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "OversightAuthority": "Yes",
            "BriefSummary": "Type 1 diabetes is an autoimmune disease in which the insulin-producing pancreatic beta\r\n\r\n      cells are destroyed, resulting in poor blood sugar control. The purpose of this study is to\r\n\r\n      assess the benefit of islet transplantation in",
            "Description": "Type 1 diabetes is commonly treated with the administration of insulin, either by multiple\r\n\r\n      insulin injections or by a continuous supply of insulin through a wearable pump. Insulin\r\n\r\n      therapy allows long-term survival in individual",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "January 2007",
            "CompletionDate": "September 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "StudyCondition": "Type 1 Diabetes Mellitus",
            "studyLocation": "University of California, San Francisco",
            "Enrollment": "24",
            "NctKeyword": "Hypoglycemia, Kidney Transplant, Insulin independence, Islet Transplantation, Intensive Insulin Therapy,",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1,",
            "InterventionKeyword": "Etanercept, Basiliximab, Antilymphocyte Serum, Daclizumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Mentally stable and able to comply with study procedures;\r\n\r\n\r\n\r\n          -  Clinical history compatible with type 1 diabetes with onset of disease at less than\r\n\r\n             40 years of age, insulin",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "68 Years",
            "Volunteers": "No",
            "City": "San Francisco",
            "State": "California",
            "Zip": "94143",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 7, 2016",
            "FirstReceived": "May 1, 2007",
            "OverallOfficial": "James F. Markmann, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Massachusetts General Hospital",
            "LocationName": "University of California, San Francisco",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00468117",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20060508 - NIDDKD - Ricordi",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20060508",
            "StudyNumber": "20060508 - NIDDKD - Ricordi",
            "StudyTitle": "Islet Transplantation in Type 1 Diabetic Kidney Allograft RecipientsEfficacy of Islet after Kidney Transplantation",
            "PIID": "1318",
            "PicNum": "C00064947",
            "PILastName": "Ricordi",
            "PIFirstName": "Camillo",
            "CoodCNbr": "C09431526",
            "CoordLastName": "Moraes Leao Peixoto",
            "CoordFirstName": "Eduardo",
            "CoordEmail": "epeixoto@med.miami.edu",
            "CoordPhone": "3052433389",
            "EnteredByCNbr": "C00064947",
            "EnteredByLastName": "Ricordi",
            "EnteredByFirstName": "Camillo",
            "ActiveEnrollingDate": "07/27/2007",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/27/2007",
            "IRBApprovedFrom": "01/25/2007",
            "IRBApprovedTo": "11/01/2017",
            "AccountNbr": "66642M",
            "InfoEdNbr": "29562 / 35891 / 32651",
            "WIrb": "20062404",
            "Expr1": "Phase III",
            "Tarea": "Islet Transplant",
            "TareaCode": "12545",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "NATL INST OF DIABETES & DIGESTIVE & KIDNEY DISEASE/NIH/NIAID/NIDDK",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Elina Linetsky,Ana Alvarez,Carlos Blaschke,Della Matheson",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00468117",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00475605",
            "SecondaryId": "FG506-06-37",
            "BriefTitle": "A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis",
            "OfficialTitle": "APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis",
            "LeadSponsorClass": "LEO Pharma",
            "SponsorAgency": "Industry",
            "LeadSponsor": "LEO Pharma",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is an observational study to assess the long-term safety of Protopic® Ointment for the\r\n\r\n      treatment of atopic dermatitis. Patients whose ages are/were < 16 years at the time of first\r\n\r\n      tacrolimus ointment exposure are eligible",
            "Description": "Data will be collected at enrollment and every 6 months thereafter either by interview,\r\n\r\n      Internet, or physician office visit. Each subject will be followed for 10 years in this\r\n\r\n      study.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "May 2005",
            "CompletionDate": "August 2022",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "LEO Pharma",
            "StudyCondition": "Atopic Dermatitis",
            "studyLocation": "Shelby Dermatology",
            "Enrollment": "8037",
            "NctKeyword": "atopic dermatitis, child, tacrolimus ointment, Protopic Ointment,",
            "MeshKeyword": "Dermatitis, Dermatitis, Atopic, Eczema,",
            "InterventionKeyword": "Tacrolimus,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subjects who first used Protopic® 0.03% or 0.1% before they were sixteen years of age\r\n\r\n             and were treated for at least 6 weeks for the treatment of Atopic dermatitis may\r\n\r\n             enro",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "16 Years",
            "Volunteers": "No",
            "City": "Albaster",
            "State": "Alabama",
            "Zip": "35007",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 7, 2016",
            "FirstReceived": "May 17, 2007",
            "OverallOfficial": "Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Astellas Pharma Global Development",
            "LocationName": "Shelby Dermatology",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00475605",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20057355 - Astellas - Schachner",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20057355",
            "StudyNumber": "20057355 - Astellas - Schachner",
            "StudyTitle": "APPLES: A prospective pediatric longitudinal evaluation to assess the longterm safety of Tacrolimus Ointment for the treatment of atopic dermatitis.",
            "PIID": "793",
            "PicNum": "C00433811",
            "PILastName": "Schachner",
            "PIFirstName": "Lawrence",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C00433811",
            "EnteredByLastName": "Schachner",
            "EnteredByFirstName": "Lawrence",
            "ActiveEnrollingDate": "09/30/2005",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/30/2005",
            "IRBApprovedFrom": "09/30/2005",
            "IRBApprovedTo": "03/13/2017",
            "AccountNbr": "66326X",
            "InfoEdNbr": "25908",
            "WIrb": "20051375",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "SponsorGroup": "Industry",
            "Sponsor": "Astellas Pharma Global Development",
            "SiteSampleSize": "UMMG:800,JMH:250",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "1050",
            "EprostState": "Approved",
            "StudyCoordinator": "Carol Kittles",
            "StudyObjective": "The APPLES Study is a large cohort study to assess the long-term safety of tacrolimus ointment 0.03% or 0.1% in the treatment of subjects with atopic dermatitis under actual use conditions, including the risk of developing cutaneous or systemic malignancies.",
            "NationalSampleSize": "1025",
            "NCTNbr": "NCT00475605",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "StudyInvINDNbr": "46,878",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT00505375",
            "BriefTitle": "Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus",
            "OfficialTitle": "Effects of CTLA-4 Ig (Abatacept) On The Progression of Type 1 Diabetes In New Onset Subjects",
            "LeadSponsorClass": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine whether treatment with CTLA4-Ig (Abatacept) in\r\n\r\n      individuals with new onset T1DM will improve insulin secretion (C-peptide production)\r\n\r\n      compared to placebo.",
            "Description": "Type 1 diabetes mellitus (T1DM) is a T-cell mediated autoimmune disease in which\r\n\r\n      insulin-producing beta cells are completely or near completely destroyed resulting in\r\n\r\n      life-long dependence on exogenous insulin.\r\n\r\n\r\n\r\n      CTLA",
            "OverallStatus": "Completed",
            "StartDate": "February 2008",
            "CompletionDate": "May 2012",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
            "StudyCondition": "Type 1 Diabetes Mellitus",
            "studyLocation": "Childrens Hospital Los Angeles",
            "Enrollment": "112",
            "NctKeyword": "CTLA4-Ig, Abatacept, Beta-cell function, T-cells, DPT-1, treatment, treatment of type 1 diabetes, new onset type 1 diabetes, juvenile diabetes, T1D, diabetes mellitus, Type 1 diabetes TrialNet, TrialNet,",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1,",
            "InterventionKeyword": "Abatacept,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age 6-45\r\n\r\n\r\n\r\n          2. Within 3 months (100 days) of diagnosis of T1DM based on ADA criteria\r\n\r\n\r\n\r\n          3. At least one diabetes-related autoantibody\r\n\r\n\r\n\r\n          4. Stimulated C-peptide",
            "EligibleGender": "All",
            "MinAge": "6 Years",
            "MaxAge": "45 Years",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90027",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 7, 2016",
            "FirstReceived": "July 20, 2007",
            "OverallOfficial": "Tihamer Orban, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Joslin Diabetes Center",
            "LocationName": "Childrens Hospital Los Angeles",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00505375",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20071180 - NIH & NIDDK - Marks",
            "FileProcessContentId": "440",
            "Division": "Endocrinology",
            "StdyDivision": "10241",
            "EprostNbr": "20071180",
            "StudyNumber": "20071180 - NIH & NIDDK - Marks",
            "StudyTitle": "Effects of CTLA4 Ig (Abatacept) On The Progression of Type 1 Diabetes In New Onset Subjects (Protocol TN09)VERSION 1.0IND 101,237",
            "PIID": "877",
            "PicNum": "C00763957",
            "PILastName": "Marks",
            "PIFirstName": "Jennifer",
            "CoodCNbr": "C00694387",
            "CoordLastName": "Matheson",
            "CoordFirstName": "Della",
            "CoordEmail": "dmatheso@miami.edu",
            "CoordPhone": "3052433781",
            "EnteredByCNbr": "C03886426",
            "EnteredByLastName": "Blaschke",
            "EnteredByFirstName": "Carlos",
            "ActiveEnrollingDate": "03/04/2008",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/04/2008",
            "IRBApprovedFrom": "03/04/2008",
            "IRBApprovedTo": "01/13/2014",
            "InfoEdNbr": "56933",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "NIH/NIDDK",
            "SiteSampleSize": "UMMG:15,Clinical Research Center (CRC):N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "15",
            "EprostState": "Approved",
            "StudyCoordinator": "Luz Arazo,Della Matheson",
            "AgentDevices": "Agent: Orencia",
            "StudyObjective": "",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00505375",
            "StudyInvIND": "0",
            "StudyInvINDNbr": "101,237",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00508547",
            "SecondaryId": "PSOLAR",
            "BriefTitle": "Psoriasis Longitudinal Assessment and Registry (PSOLAR)",
            "OfficialTitle": "A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics",
            "LeadSponsorClass": "Janssen Scientific Affairs, LLC",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Janssen Scientific Affairs, LLC",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to further evaluate the safety of infliximab and ustekinumab in\r\n\r\n      patients with plaque psoriasis, and other all forms of psoriasis (such as plaque psoriasis\r\n\r\n      and psoriatic arthritis occurring together)",
            "Description": "PSOLAR is an 8 year registry study. A registry is an observational study that evaluates the\r\n\r\n      status of a disease. This registry study will only include patients who volunteer to take\r\n\r\n      part. About 2000 infliximab-exposed patients",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "June 2007",
            "CompletionDate": "May 2021",
            "Phase": "Phase 4",
            "StudyType": "Observational",
            "StudyPhase": "Phase 4",
            "StudySource": "Janssen Scientific Affairs, LLC",
            "StudyCondition": "Psoriasis",
            "Enrollment": "12056",
            "NctKeyword": "Methotrexate, Acitretin, Cyclosporine, Systemic PUVA, Infliximab, Adalimumab, Alefacept, Efalizumab, Etanercept, Psoriasis, Psoriatic arthritis, Skin disease, Cosentyx,",
            "MeshKeyword": "Arthritis, Psoriasis, Arthritis, Psoriatic,",
            "InterventionKeyword": "Infliximab, Ustekinumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Have a diagnosis of psoriasis\r\n\r\n\r\n\r\n          -  Are candidates for, or are currently receiving conventional systemic agents (eg,\r\n\r\n             methotrexate, acitretin, cyclosporine or systemic psoral",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "99 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 29, 2016",
            "FirstReceived": "July 27, 2007",
            "OverallOfficial": "Janssen Scientific Affairs, LLC Clinical Trial",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Janssen Scientific Affairs, LLC",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00508547",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20080864 - CENTOCOR - ROMANELLI",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20080864",
            "StudyNumber": "20080864 - CENTOCOR - ROMANELLI",
            "StudyTitle": "PSOLAR A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Sysytemic Therapies Including Biologics",
            "PIID": "692",
            "PicNum": "C00325250",
            "PILastName": "Romanelli",
            "PIFirstName": "Paolo",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C00015559",
            "EnteredByLastName": "Doty",
            "EnteredByFirstName": "Martha",
            "ActiveEnrollingDate": "09/23/2009",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/23/2009",
            "IRBApprovedFrom": "11/24/2008",
            "IRBApprovedTo": "05/31/2016",
            "AccountNbr": "66630K",
            "InfoEdNbr": "33925",
            "Expr1": "Phase IV",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "SponsorGroup": "Industry",
            "Sponsor": "Centocor, Inc.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "23",
            "Totalaccrued": "23",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "20",
            "CurrentlyActiveTreatment": "3",
            "Totalpatients": "23",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:150,UMHC:50",
            "AccrualPercentageMet": "11.5",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "200",
            "EprostState": "Approved",
            "StudyCoordinator": "Carol Kittles",
            "StudyObjective": "The primary objective of the registry is to evaluate the safety of Remicade in patients with chronic severe psoriasis utilizing a disease-based approach that collects comparable informatiom from patients with psoriasis who are using systemic therapies other then Remicade.",
            "NationalSampleSize": "200",
            "NCTNbr": "NCT00508547",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00539162",
            "SecondaryId": "RP160145",
            "BriefTitle": "Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women",
            "OfficialTitle": "Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women",
            "LeadSponsorClass": "M.D. Anderson Cancer Center",
            "SponsorAgency": "Other",
            "LeadSponsor": "M.D. Anderson Cancer Center",
            "OversightAuthority": "No",
            "BriefSummary": "The goal of this clinical research study is to evaluate a method involving a blood test,\r\n\r\n      called CA-125, that may be helpful in the early detection of ovarian cancer in women who are\r\n\r\n      at low risk.",
            "Description": "Currently, there is no effective screening to detect ovarian cancer at its earliest stage in\r\n\r\n      low risk women. CA-125 is an FDA approved blood test that may show the presence of ovarian\r\n\r\n      cancer.\r\n\r\n\r\n\r\n      If you are eligible to",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2, 2001",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "M.D. Anderson Cancer Center",
            "StudyCondition": "Ovarian Cancer",
            "studyLocation": "Sylvester Comprehensive Cancer Center, Univ of Miami Miller School of Medicine",
            "Enrollment": "8000",
            "NctKeyword": "Ovarian Cancer, CA 125 Algorithm, Cancer Detection, Questionnaire, Survey,",
            "MeshKeyword": "Ovarian Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Female, >/= 50 years old or less than 75 years old.\r\n\r\n\r\n\r\n          2. Postmenopausal (>/= 12 months amenorrhea).\r\n\r\n\r\n\r\n          3. Have at least one ovary.\r\n\r\n\r\n\r\n          4. Cancer-free and have no",
            "EligibleGender": "Female",
            "MinAge": "50 Years",
            "MaxAge": "74 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "October 3, 2007",
            "OverallOfficial": "Karen H. Lu, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "M.D. Anderson Cancer Center",
            "ContactName": "Gwen H. Corrigan",
            "ContactPhone": "713-563-1790",
            "LocationStatus": "Recruiting",
            "LocationName": "Sylvester Comprehensive Cancer Center, Univ of Miami Miller School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00539162",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20150600 - Intramural - Slomovitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150600",
            "StudyNumber": "20150600 - Intramural - Slomovitz",
            "StudyTitle": "Use of CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women",
            "PIID": "22712",
            "PicNum": "C11916703",
            "PILastName": "Slomovitz",
            "PIFirstName": "Brian",
            "CoodCNbr": "C11916703",
            "CoordLastName": "Slomovitz",
            "CoordFirstName": "Brian",
            "EnteredByCNbr": "C11916703",
            "EnteredByLastName": "Slomovitz",
            "EnteredByFirstName": "Brian",
            "ActiveEnrollingDate": "12/21/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/21/2015",
            "IRBApprovedFrom": "09/04/2015",
            "IRBApprovedTo": "09/01/2017",
            "DiseaseSiteListDesc": "Ovary",
            "Expr1": "N/A",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Screening",
            "StudyType_Code": "6181",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "22",
            "Totalaccrued": "22",
            "InFollowUp": "5",
            "CurrentlyEnrolled": "17",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "22",
            "FirstNinety": "13",
            "SiteSampleSize": "Plantation:N/A,UMHC:N/A,UMD:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Lidia Sanchez Ortiz",
            "NationalSampleSize": "1250",
            "NCTNbr": "NCT00539162",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT00628498",
            "BriefTitle": "Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study",
            "OfficialTitle": "Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study",
            "LeadSponsorClass": "Jazz Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Jazz Pharmaceuticals",
            "OversightAuthority": "No",
            "BriefSummary": "Single arm, open-label study to provide Defibrotide to patients diagnosed with VOD.\r\n\r\n      Defibrotide is no longer available though the Emergency Use IND mechanism (also known as\r\n\r\n      compassionate use, or single patient named use). This",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "December 2007",
            "CompletionDate": "December 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Jazz Pharmaceuticals",
            "StudyCondition": "Hepatic Veno-Occlusive Disease",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "1206",
            "NctKeyword": "VOD,",
            "MeshKeyword": "Hepatic Veno-Occlusive Disease,",
            "InterventionKeyword": "Defibrotide,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        Entry criteria include the following:\r\n\r\n\r\n\r\n          1. Clinical diagnosis of VOD, made by Baltimore Criteria, Modified Seattle Criteria, or\r\n\r\n             biopsy proven:\r\n\r\n\r\n\r\n             1.1 Baltimore",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "October 31, 2016",
            "FirstReceived": "February 25, 2008",
            "OverallOfficial": "William Tappe, M.D.",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Jazz Pharmaceuticals",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00628498",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20101123 - Gentium - Andreansky",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20101123",
            "StudyNumber": "20101123 - Gentium - Andreansky",
            "StudyTitle": "Defibrotide 200605: DEFIBROTIDE FOR PATIENTS WITH HEPATIC VENOOCCLUSIVE DISEASE (VOD): A TREATMENT IND STUDY",
            "PIID": "590",
            "PicNum": "C06466265",
            "PILastName": "Andreansky",
            "PIFirstName": "Martin",
            "CoodCNbr": "C00046839",
            "CoordLastName": "Willumsen",
            "CoordFirstName": "Silvia",
            "CoordEmail": "swillums@med.miami.edu",
            "CoordPhone": "3055857359",
            "EnteredByCNbr": "C06466265",
            "EnteredByLastName": "Andreansky",
            "EnteredByFirstName": "Martin",
            "ActiveEnrollingDate": "12/30/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/30/2010",
            "IRBApprovedFrom": "12/30/2010",
            "IRBApprovedTo": "01/03/2017",
            "InfoEdNbr": "33122",
            "WIrb": "20080429",
            "Expr1": "Phase III",
            "Tarea": "Hematology/Oncology",
            "TareaCode": "13338",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Gentium",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "11",
            "Totalaccrued": "11",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "11",
            "FirstNinety": "1",
            "SiteSampleSize": "UMH:10,UMHC:10,JMH:10",
            "AccrualPercentageMet": "36.66666666666666666666666666666666666667",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "30",
            "EprostState": "Approved",
            "StudyCoordinator": "Silvia Willumsen,Gabriela D'Antonio",
            "AgentDevices": "Agent: Defibrotide",
            "StudyObjective": "",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT00628498",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00628745",
            "SecondaryId": "FX-R-001",
            "BriefTitle": "Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)",
            "OfficialTitle": "Transthyretin-associated Amyloidosis Outcomes Survey (Thaos): A Global, Multi-center, Longitudinal, Observational Survey Of Patients With Documented Transthyretin (Ttr) Mutations Or Wild-type Ttr Amyloidosis",
            "LeadSponsorClass": "Pfizer",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Pfizer",
            "OversightAuthority": "No",
            "BriefSummary": "THAOS is a global, multi-center, longitudinal observational survey open to all patients with\r\n\r\n      transthyretin-associated amyloidoses (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM\r\n\r\n      (cardiomyopathy) and wild-type ATTR-CM. It is",
            "Description": "n/a NA",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2007",
            "CompletionDate": "June 2021",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Pfizer",
            "StudyCondition": "Transthyretin Mutations",
            "studyLocation": "Mayo Clinic Arizona",
            "Enrollment": "1",
            "NctKeyword": "TRANSTHYRETIN, AMYLOIDOSIS, TRANSTHYRETIN AMYLOIDOSIS,",
            "MeshKeyword": "Amyloidosis, Amyloid Neuropathies, Familial,",
            "Eligibility": "Inclusion Criteria: Patients must meet all of the following inclusion criteria to be\r\n\r\n        eligible for enrollment into THAOS:\r\n\r\n\r\n\r\n          1. Evidence of a personally signed and dated informed consent document indicating that",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85054",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 3, 2017",
            "FirstReceived": "February 25, 2008",
            "OverallOfficial": "Pfizer CT.gov Call Center",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Pfizer",
            "ContactName": "Pfizer CT.gov Call Center",
            "ContactPhone": "1-800-718-1021",
            "LocationStatus": "Active, not recruiting",
            "LocationName": "Mayo Clinic Arizona",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00628745",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20141001 - Pfizer - Hoffman",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20141001",
            "StudyNumber": "20141001 - Pfizer - Hoffman",
            "StudyTitle": "Transthyretin- Associated Amyloidosis Outcomes Survey (Thaos): A Global, Multi-Center, Longitudinal, Observational Survey of Patients With Documented Transthyretin (TTR) Mutations or Wild Type TTR Amyloidosis",
            "PIID": "4418",
            "PicNum": "C11465246",
            "PILastName": "Hoffman",
            "PIFirstName": "James",
            "CoodCNbr": "C11908603",
            "CoordLastName": "Pallapati",
            "CoordFirstName": "Rachel",
            "CoordEmail": "rpallapati@med.miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "10/19/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/19/2015",
            "IRBApprovedFrom": "06/18/2015",
            "IRBApprovedTo": "04/11/2017",
            "AccountNbr": "665447",
            "DiseaseSiteListDesc": "Other Hematopoietic",
            "Expr1": "N/A",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Other",
            "SponsorGroup": "Industry",
            "Sponsor": "Pfizer",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMD:N/A,UMHC:N/A,Plantation:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Micaela Martinez,Vivin Mohan,Penny Eyer",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT00628745",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT00665561",
            "SecondaryId": "2007-006148-24",
            "BriefTitle": "Prospective Observational Epidemiologic Study of Maraviroc's Safety",
            "OfficialTitle": "An International, Multicenter, Prospective Observational Study Of The Safety Of Maraviroc Used With Optimized Background Therapy In Treatment-experienced Hiv-1 Infected Patients",
            "LeadSponsorClass": "ViiV Healthcare",
            "SponsorAgency": "Industry",
            "LeadSponsor": "ViiV Healthcare",
            "OversightAuthority": "No",
            "BriefSummary": "The study will assess if use of maraviroc along with an optimized background regimen of\r\n\r\n      antiretroviral drugs in usual clinical practice is as safe as using only an optimized\r\n\r\n      regimen of antiretroviral drugs.",
            "Description": "All patients meeting the study eligibility criteria at participating sites will be invited\r\n\r\n      to participate.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "March 2008",
            "CompletionDate": "October 2018",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "ViiV Healthcare",
            "StudyCondition": "Human Immunodeficiency Virus",
            "studyLocation": "Health Services Center",
            "Enrollment": "3000",
            "NctKeyword": "Maraviroc, HIV-1, Safety, Non-interventional,",
            "MeshKeyword": "Immunologic Deficiency Syndromes, Acquired Immunodeficiency Syndrome, HIV Infections,",
            "InterventionKeyword": "Maraviroc,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Treatment experienced, HIV-1 infected patients\r\n\r\n\r\n\r\n          -  18 years or older\r\n\r\n\r\n\r\n          -  Receive an approved assay for determination of HIV-1 tropism\r\n\r\n\r\n\r\n        Exclusion Criteria:",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Hobson City",
            "State": "Alabama",
            "Zip": "36201",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 5, 2016",
            "FirstReceived": "April 23, 2008",
            "OverallOfficial": "Pfizer CT.gov Call Center",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Pfizer",
            "LocationName": "Health Services Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00665561",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20080249 - Pfizer - Castro",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20080249",
            "StudyNumber": "20080249 - Pfizer - Castro",
            "StudyTitle": "Pfizer A4001067  An International, MultiCenter, Prospective Observational Study of the Safety of Maraviroc used with optimized Background Therapy in Treatment Experienced HIV1 Infected Patients.",
            "PIID": "233",
            "PicNum": "C00432804",
            "PILastName": "Castro",
            "PIFirstName": "Jose",
            "CoodCNbr": "C00243042",
            "CoordLastName": "Tanner",
            "CoordFirstName": "Tom",
            "CoordEmail": "ttanner@med.miami.edu",
            "EnteredByCNbr": "C00243042",
            "EnteredByLastName": "Tanner",
            "EnteredByFirstName": "Tom",
            "ActiveEnrollingDate": "10/17/2008",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/17/2008",
            "IRBApprovedFrom": "09/02/2008",
            "IRBApprovedTo": "07/28/2015",
            "AccountNbr": "66509N",
            "InfoEdNbr": "31961",
            "Expr1": "N/A",
            "Tarea": "HIV-related",
            "TareaCode": "233",
            "Blinding": "None",
            "Randomization": "Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Pfizer",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "12",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "5",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "12",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:50",
            "AccrualPercentageMet": "14",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "50",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Tom Tanner",
            "AgentDevices": "Agent: Maraviroc",
            "StudyObjective": "To estimate the incidence rates of:\r\n(a) centers for Disease Control and prevention category C AIDS-defining OI\r\n(b) viral encephalitis\r\n(c) liver failure\r\n(d) rhabdomyolysis in treatment -experienced HIV-1 infected subjects receiving maraviroc during time of use and for up to six months following discontinuation of maraviroc during time of use and for up to six months following discontinuation of maraviroc treatment, up to a total of five years since entry into the study.",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00665561",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00677768",
            "SecondaryId": "5RC1NS068179-02",
            "BriefTitle": "Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)",
            "OfficialTitle": "A Multicenter Study for the Validation of ALS Biomarkers",
            "LeadSponsorClass": "Massachusetts General Hospital",
            "SponsorAgency": "Other",
            "LeadSponsor": "Massachusetts General Hospital",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples\r\n\r\n      from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron\r\n\r\n      diseases, as well as other neurodegenerative dis",
            "Description": "Researchers tested what changes happen in volunteers with ALS that can be seen in the blood\r\n\r\n      and what changes are unique to ALS and are different from those found in healthy volunteers\r\n\r\n      and volunteers with neurological diseases o",
            "OverallStatus": "Completed",
            "StartDate": "April 2008",
            "CompletionDate": "November 2015",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Massachusetts General Hospital",
            "StudyCondition": "Amyotrophic Lateral Sclerosis",
            "studyLocation": "Phoenix Neurological Associates, Ltd.",
            "Enrollment": "475",
            "NctKeyword": "Biomarkers, Plasma, Cerebrospinal Fluid, DNA, Serum,",
            "MeshKeyword": "Sclerosis, Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Nervous System Diseases, Paraparesis, Paraparesis, Spastic,",
            "Eligibility": "1. ALS Volunteers\r\n\r\n\r\n\r\n             Inclusion Criteria:\r\n\r\n\r\n\r\n               -  Diagnosis of possible (excluding volunteers with UMN signs ONLY), probable,\r\n\r\n                  probable-laboratory supported, or definite ALS, either sporadic",
            "EligibleGender": "All",
            "MinAge": "30 Years",
            "MaxAge": "80 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85018",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "June 2, 2016",
            "FirstReceived": "May 9, 2008",
            "OverallOfficial": "James D. Berry, MD, MPH",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Massachusetts General Hospital",
            "LocationName": "Phoenix Neurological Associates, Ltd.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00677768",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20080181 - ALS - Sharma",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20080181",
            "StudyNumber": "20080181 - ALS - Sharma",
            "StudyTitle": "A Multicenter Study for the Validation of ALS BiomarkersProtocol BIOALS01Amendment 1, protocol version 2.0 dated May 12, 2009Amendment 2,version 3.0,dated 01December, 2009",
            "PIID": "198",
            "PicNum": "C00576419",
            "PILastName": "Sharma",
            "PIFirstName": "Khema",
            "CoodCNbr": "C00588473",
            "CoordLastName": "Koggan",
            "CoordFirstName": "Donald",
            "CoordEmail": "dkoggan@med.miami.edu",
            "CoordPhone": "3052437424",
            "EnteredByCNbr": "C00588473",
            "EnteredByLastName": "Koggan",
            "EnteredByFirstName": "Donald",
            "ActiveEnrollingDate": "09/12/2008",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/12/2008",
            "IRBApprovedFrom": "09/12/2008",
            "IRBApprovedTo": "06/24/2014",
            "AccountNbr": "66552L",
            "InfoEdNbr": "31238 / 52044",
            "Expr1": "N/A",
            "Tarea": "Neuro-Muscular Disorders",
            "TareaCode": "8938",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "ALS Association",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "19",
            "Totalaccrued": "18",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "10",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "19",
            "FirstNinety": "4",
            "SiteSampleSize": "UMMG:33",
            "AccrualPercentageMet": "54.54545454545454545454545454545454545455",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "33",
            "EprostState": "Approved",
            "StudyCoordinator": "Julie Steele,Monica Quesada",
            "StudyObjective": "The primary objective is to identify factors that contribute to the pathogenesis of amyotrophic lateral sclerosis (ALS). Development of disease biomarkers and diagnostic laboratory tests would facilitate earlier treatment intervention, help monitor treatment efficacy; and, ultimately, lead to the identification of targets that could be used in therapy development. \r\n\r\nSpecific aim 1 is to develop a laboratory test that can be used by primary care physicians, neurologists and other clinicians to provide guidance with regard to [something to worry about] (possible ALS). It would provide benefit in generating appropriate referrals to neurological specialists early in disease progression. False negatives could be tolerated but false positives cannot (i.e. high specificity required with acceptable sensitivity).\r\n\r\nThe test will identify people with ALS and distinguish ALS from disorders that present with similar symptoms (e.g. carpal tunnel, radiculopathies, myopathies). A test with high sensitivity for ALS can be very useful for specialty neurologist as well for early and accurate detection for inclusion in clinical trials. Blood (plasma and DNA) and CSF samples will be collected at multiple sites representing the four regions of the United States from age and gender matched healthy individuals, disease mimics, and ALS patients.\r\n\r\nSpecific aim 2 is to assess how biomarkers discovered in aim 1 change with disease course. Blood samples will be collected longitudinally from ALS and suspected ALS volunteers. Plasma and DNA samples will be collected at Screening/Baseline visit or at months 6, 12, or 18 visits for analysis and will be stored for future DNA research. For the neurological disease and healthy control volunteers who already had blood and or CSF collected for the study, they will be contacted and asked to participate in the DNA portion of the study. These volunteers will only be contacted if they gave permission to be contacted to provide additional clinical information or samples. This portion of the study is voluntary and all volunteers have the option to refuse participation.\r\n[plasma and DNA] terminology was added for clarification. The sponsor has increased the overall enrollment number and have included CSF collection for an additional 50 healthy control volunteers and serum collection for all volunteers fro the study.",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00677768",
            "StudyKeywords": "CRIS:Latevola; ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT00687882",
            "BriefTitle": "Evaluation of the Duration of Therapy for Thrombosis in Children",
            "OfficialTitle": "Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children",
            "LeadSponsorClass": "Johns Hopkins All Children's Hospital",
            "SponsorAgency": "Other",
            "LeadSponsor": "Johns Hopkins All Children's Hospital",
            "OversightAuthority": "Yes",
            "BriefSummary": "The Kids-DOTT trial is a randomized controlled clinical trial whose primary objective is to\r\n\r\n      evaluate non-inferiority of shortened-duration (6 weeks) versus conventional-duration (3\r\n\r\n      months) anticoagulation in children with first",
            "Description": "Children (birth to 21 years of age, inclusive) with first-episode venous thrombosis in\r\n\r\n      association with a reversible clinical trigger (key exclusions: history of cancer; severe\r\n\r\n      thrombophilia state disclosed) are enrolled and pr",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2008",
            "CompletionDate": "December 2020",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Johns Hopkins All Children's Hospital",
            "StudyCondition": "Venous Thrombosis",
            "studyLocation": "University of Alabama Birmingham",
            "Enrollment": "750",
            "NctKeyword": "Venous Thromboembolism, Postthrombotic Syndrome, Antithrombotic Therapy, Duration of Therapy, Children,",
            "MeshKeyword": "Thrombosis, Venous Thrombosis,",
            "InterventionKeyword": "Antibodies, Antibodies, Antiphospholipid, Anticoagulants,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Children (birth to <21 years of age) with radiologically-confirmed acute venous\r\n\r\n             thrombosis in the past 30 days\r\n\r\n\r\n\r\n          2. In the opinion of the investigator, the venous thrombosi",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "20 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 25, 2016",
            "FirstReceived": "May 6, 2008",
            "OverallOfficial": "Neil A Goldenberg, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Johns Hopkins All Children's Hospital",
            "ContactName": "Neil A Goldenberg, MD, PhD",
            "ContactPhone": "727-767-6886",
            "ContactEmail": "ngolden4@jhmi.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00687882",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20150032 - Intramural - Corrales-Medina",
            "FileProcessContentId": "440",
            "Division": "Pediatrics Oncology",
            "StdyDivision": "10646",
            "EprostNbr": "20150032",
            "StudyNumber": "20150032 - Intramural - Corrales-Medina",
            "StudyTitle": "Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children",
            "PIID": "23193",
            "PicNum": "C11918839",
            "PILastName": "Corrales Medina",
            "PIFirstName": "Fernando",
            "CoodCNbr": "C05045811",
            "CoordLastName": "Prado",
            "CoordFirstName": "Cecilia",
            "CoordEmail": "cprado@med.miami.edu",
            "CoordPhone": "3052436925",
            "EnteredByCNbr": "C11918839",
            "EnteredByLastName": "Corrales Medina",
            "EnteredByFirstName": "Fernando",
            "ActiveEnrollingDate": "10/28/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/28/2016",
            "IRBApprovedFrom": "04/06/2015",
            "IRBApprovedTo": "02/22/2017",
            "Expr1": "Approved Drug/Off-Label use",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Maria Santaella,Leandro Pisani,Myriam Zayas",
            "NationalSampleSize": "36",
            "NCTNbr": "NCT00687882",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00706147",
            "SecondaryId": "3517",
            "BriefTitle": "Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis",
            "OfficialTitle": "Phase II/III Randomized, Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (ALS)",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study will be to demonstrate the safety, tolerability, and efficacy of\r\n\r\n      arimoclomol in subjects with SOD1 positive familial Amyotrophic Lateral Sclerosis (ALS).\r\n\r\n      This type of ALS is HEREDITARY (runs in familie",
            "Description": "Using a seamless, adaptive, phase II/III design, the investigators will determine the safety\r\n\r\n      and efficacy of arimoclomol in patients with SOD1 positive familial ALS. Both stage-1 and\r\n\r\n      stage-2 are randomized, double-blind and pla",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "January 2009",
            "CompletionDate": "December 2016",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "University of Miami",
            "StudyCondition": "Amyotrophic Lateral Sclerosis 1",
            "studyLocation": "University of Miami Miller School of Medicine",
            "Enrollment": "39",
            "NctKeyword": "Hereditary ALS, Hereditary neurological disease, Lou Gehrig's Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis (ALS), Familial ALS, Neuromuscular disease, SOD1 mutation, Superoxide dismutase, SOD1 positive ALS, inherited ALS,",
            "MeshKeyword": "Sclerosis, Motor Neuron Disease, Amyotrophic Lateral Sclerosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Type of ALS that is hereditary (runs in families) only.\r\n\r\n\r\n\r\n          -  El Escorial criteria for familial ALS and a family history of a pathogenic mutation\r\n\r\n             in a gene known to be assoc",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "February 2015",
            "LastChanged": "February 18, 2015",
            "FirstReceived": "June 24, 2008",
            "OverallOfficial": "Michael Benatar, MBChB, DPhil",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "University of Miami Miller School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00706147",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20100758 - FOOD AND DRUG ADMINSTRATION,ALS ASSOC - Benatar",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20100758",
            "StudyNumber": "20100758 - FOOD AND DRUG ADMINSTRATION,ALS ASSOC - Benatar",
            "StudyTitle": "Phase II/III, Randomized, PlaceboControlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (ALS)",
            "PIID": "3255",
            "PicNum": "C09944978",
            "PILastName": "Benatar",
            "PIFirstName": "Michael",
            "CoodCNbr": "C09991678",
            "CoordLastName": "Gronka",
            "CoordFirstName": "Susan",
            "EnteredByCNbr": "C09952076",
            "EnteredByLastName": "Walker",
            "EnteredByFirstName": "Margaret",
            "ActiveEnrollingDate": "12/19/2008",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/19/2008",
            "IRBApprovedFrom": "11/01/2010",
            "IRBApprovedTo": "06/15/2016",
            "InfoEdNbr": "56850/55330",
            "Tarea": "Neuro-Muscular Disorders",
            "TareaCode": "8938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "SiteSampleSize": "Non University of Miami:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Julie Steele,Sara-Claude Michon,Eliana Reyes",
            "NationalSampleSize": "39",
            "NCTNbr": "NCT00706147",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00706940",
            "BriefTitle": "Tear Dynamics After Restasis Treatment in Dry Eye Patients",
            "OfficialTitle": "Tear Dynamics After Restasis Treatment in Dry Eye Patients Phase II Clinical Trial and Phase IIb 6-month Follow-up After Discontinuation of Study Treatment",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "Observe the changes of tear volume in dry eye patients after Restasis treatment of 3 months\r\n\r\n      and during 6-month follow-up after discontinuation of study treatment.",
            "Description": "Using an imaging device name optical coherence tomography to image the tear volume in dry\r\n\r\n      eye patients before and after Restasis treatment.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "August 2011",
            "CompletionDate": "December 2016",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Dry Eye",
            "studyLocation": "Bascom Palmer Eye Institute",
            "Enrollment": "60",
            "NctKeyword": "dry eye, Optical coherence tomography,",
            "MeshKeyword": "Keratoconjunctivitis Sicca, Dry Eye Syndromes,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        The participant will be eligible for entry in the study if s/he:\r\n\r\n\r\n\r\n          1. Is at least 18 years old and has full legal capacity to volunteer;\r\n\r\n\r\n\r\n          2. Has read and signed the IRB Informed",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "90 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "March 2016",
            "LastChanged": "March 8, 2016",
            "FirstReceived": "June 26, 2008",
            "OverallOfficial": "Jianhua Wang, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "Bascom Palmer Eye Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00706940",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20080340 - ALLERGAN - Wang",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20080340",
            "StudyNumber": "20080340 - ALLERGAN - Wang",
            "StudyTitle": "Tear dynamics after Restasis treatment in dry eye patients",
            "PIID": "884",
            "PicNum": "C05027803",
            "PILastName": "Wang",
            "PIFirstName": "Jianhua",
            "CoodCNbr": "C05027803",
            "CoordLastName": "Wang",
            "CoordFirstName": "Jianhua",
            "CoordEmail": "j.wang3@miami.edu",
            "CoordPhone": "3054825010",
            "EnteredByCNbr": "C05027803",
            "EnteredByLastName": "Wang",
            "EnteredByFirstName": "Jianhua",
            "ActiveEnrollingDate": "07/02/2008",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/02/2008",
            "IRBApprovedFrom": "06/23/2008",
            "IRBApprovedTo": "02/11/2016",
            "AccountNbr": "66472N",
            "InfoEdNbr": "31990 / 40316 / 51803",
            "Expr1": "N/A",
            "Tarea": "Neuro-Ophthalmology",
            "TareaCode": "13137",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "Allergan , Inc",
            "SiteSampleSize": "ABLEH:20",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "20",
            "EprostState": "Approved",
            "StudyCoordinator": "Mohamed Shousha,Carolina Betancurt,Sandra Pineda",
            "AgentDevices": "Device: Optical Coherence Tomography",
            "StudyObjective": "The purpose of this study is to determine tear dynamics changes after dry eye treatment with Restasis using newly developed ultra-high resolution optical coherence tomography (OCT). We will test the hypothesis that OCT measurements of tear film dynamics can determine the differences after the treatment. This project will advance our knowledge of tear film dynamics and its changes after dry eye treatments.",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00706940",
            "StudyKeywords": "ORIM: Kanchan Sakhrani (QA: 11/17/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT00708162",
            "SecondaryId": "2007-004225-26",
            "BriefTitle": "Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir",
            "OfficialTitle": "A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Expe",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to compare the safety, tolerability and efficacy of a regimen\r\n\r\n      containing once-daily elvitegravir (EVG) versus twice-daily raltegravir (RAL) added to a\r\n\r\n      background regimen (1 fully-active ritonavir (R",
            "Description": "The background regimen will be constructed by the investigator based on viral resistance\r\n\r\n      testing. The fully active PI will be defined by phenotypic resistance analysis. For\r\n\r\n      phenotypic susceptibility, fully active is defined as",
            "OverallStatus": "Completed",
            "StartDate": "July 2008",
            "CompletionDate": "April 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "HIV Infection",
            "studyLocation": "Southwest Center for HIV/AIDS",
            "Enrollment": "724",
            "NctKeyword": "HIV, HIV I, Treatment Experienced,",
            "MeshKeyword": "HIV Infections,",
            "InterventionKeyword": "Ritonavir, Raltegravir Potassium,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening\r\n\r\n\r\n\r\n          -  Documented resistance or at least six months experience prior to screening with two\r\n\r\n             or more different classes of",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85006",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 21, 2016",
            "FirstReceived": "June 30, 2008",
            "OverallOfficial": "Javier Szwarcberg, MD, MPH",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "Southwest Center for HIV/AIDS",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00708162",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20080538 - Gilead Sciences - Campo",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20080538",
            "StudyNumber": "20080538 - Gilead Sciences - Campo",
            "StudyTitle": "GSUS1830145 : A Multicenter, Randomized, DoubleBlind, DoubleDummy, Phase 3 Study of the Safety and Efficacy of RitonavirBoosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV1 Infected, Antiretroviral TreatmentExperienced Adults",
            "PIID": "235",
            "PicNum": "C00552940",
            "PILastName": "Campo",
            "PIFirstName": "Rafael E.",
            "CoodCNbr": "C01932899",
            "CoordLastName": "Mercado",
            "CoordFirstName": "Sandra",
            "CoordEmail": "smercado@med.miami.edu",
            "EnteredByCNbr": "C00552940",
            "EnteredByLastName": "Campo",
            "EnteredByFirstName": "Rafael E.",
            "ActiveEnrollingDate": "11/10/2008",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/05/2013",
            "IRBApprovedFrom": "09/02/2008",
            "IRBApprovedTo": "08/18/2015",
            "AccountNbr": "66513E",
            "InfoEdNbr": "32763",
            "Tarea": "HIV-related",
            "TareaCode": "233",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Gilead Sciences, Inc.",
            "Prescreened": "0",
            "Screenedfailed": "8",
            "SignedICF": "12",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "12",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:15",
            "AccrualPercentageMet": "26.66666666666666666666666666666666666667",
            "ActiveCal": "1",
            "PaymentRcvd": "3125",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "15",
            "EprostState": "Approved",
            "StudyCoordinator": "Tom Tanner,Kenia Moreno",
            "AgentDevices": "Agents: Ritonavir, Elvitegravir, Raltegravir",
            "StudyObjective": "The primary efficacy objective of this study is as follows:\r\n To assess non-inferiority of a regimen containing ritonavir-boosted elvitegravir versus raltegravir, each administered with a background regimen in HIV-1 infected, antiretroviral treatment-experienced adult subjects as determined by the proportion of subjects achieving and maintaining confirmed HIV-1 RNA < 50 copies/mL through Week 48\r\n\r\nThe secondary objective of this study is as follows:\r\n To evaluate the efficacy, safety and tolerability of the two treatment arms through 48 weeks of treatment",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00708162",
            "StudyKeywords": "Kanchan, Sean = ORIM",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT00745420",
            "SecondaryId": "U01HL069294",
            "BriefTitle": "Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)",
            "OfficialTitle": "Unrelated Donor Reduced Intensity Bone Marrow Transplant for Children With Severe Sickle Cell Disease (BMT CTN #0601)",
            "LeadSponsorClass": "Medical College of Wisconsin",
            "SponsorAgency": "Other",
            "LeadSponsor": "Medical College of Wisconsin",
            "OversightAuthority": "Yes",
            "BriefSummary": "Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease\r\n\r\n      that can cause organ damage, stroke, and intense pain episodes. A blood stem cell transplant\r\n\r\n      is a treatment option for someone with a se",
            "Description": "SCD is an inherited blood disorder. Symptoms include anemia, infections, organ damage, and\r\n\r\n      intense episodes of pain, also called \"sickle cell crises.\" SCD is caused by an abnormal\r\n\r\n      type of hemoglobin, which is a protein inside r",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "August 2008",
            "CompletionDate": "December 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Medical College of Wisconsin",
            "StudyCondition": "Sickle Cell Disease",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "39",
            "NctKeyword": "Sickle Cell Disease, Sickle Cell Anemia,",
            "MeshKeyword": "Anemia, Sickle Cell,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  SCD (genotype hemoglobin SS disease [Hb SS], genotype hemoglobin SC disease\r\n\r\n             [HbSC],sickle ß°[Sß°] thalassemia, or sickle ß^+[Sß^+]thalassemia) with one or more\r\n\r\n             of the foll",
            "EligibleGender": "All",
            "MinAge": "3 Years",
            "MaxAge": "19 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "May 2016",
            "LastChanged": "May 17, 2016",
            "FirstReceived": "August 29, 2008",
            "OverallOfficial": "Mary Horowitz, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Center for International Blood and Marrow Transplant Research",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00745420",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20080721 - NHLBI - Andreansky",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20080721",
            "StudyNumber": "20080721 - NHLBI - Andreansky",
            "StudyTitle": "NIH BMT CTN 0601. Unrelated Donor Reduced Intensity Bone Marrow Transplant for Children with Severe Sickle Cell Disease",
            "PIID": "590",
            "PicNum": "C06466265",
            "PILastName": "Andreansky",
            "PIFirstName": "Martin",
            "CoodCNbr": "C00046839",
            "CoordLastName": "Willumsen",
            "CoordFirstName": "Silvia",
            "CoordEmail": "swillums@med.miami.edu",
            "CoordPhone": "3055857359",
            "EnteredByCNbr": "C01997997",
            "EnteredByLastName": "Kleiner",
            "EnteredByFirstName": "Gary",
            "ActiveEnrollingDate": "10/06/2009",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/06/2009",
            "IRBApprovedFrom": "10/06/2008",
            "IRBApprovedTo": "06/29/2016",
            "AccountNbr": "66637L",
            "InfoEdNbr": "33818",
            "Tarea": "Immunology/Infectious Disease",
            "TareaCode": "13340",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "NIH",
            "Sponsor": "National Heart, Lung and Blood Institute",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:10",
            "AccrualPercentageMet": "20",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "10",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Gabriela D'Antonio",
            "AgentDevices": "Agent: campath 1H,cellcept,fludarbine,melphalan,methotrexate,neoral,neupogen,solumedrol,unrelated um",
            "StudyObjective": "Primary Objective: The primary objective is to determine event-free survival (EFS) at 1 year after unrelated donor (URD) hematopoietic stem cell transplantation (HCT) using bone marrow (BM) or umbilical cord blood (UCB) in patients with sickle cell disease (SCD). Death, disease recurrence or graft rejection by 1 year will be considered events for this endpoint.\r\nSecondary Objectives: \r\n\r\nSecondary objectives include determining the effect of HCT on clinical and laboratory manifestations of severe sickle cell disease including stroke and determining the incidence of other transplant-related outcomes. The latter include: overall survival; red blood cell, neutrophil, and platelet recovery; grades II-IV and grade III-IV acute graft-versus-host disease (GVHD); chronic GVHD; hepatic veno-occlusive disease (VOD); idiopathic pneumonia syndrome (IPS); central nervous system (CNS) toxicity (reversible posterior leukoencephalopathy syndrome [RPLS], hemorrhage, and seizures); neurocognitive dysfunction; cytomegalovirus (CMV) infection; adenovirus infection; Epstein Barr virus post-transplant lymphoproliferative disease (EBV PTLD); invasive fungal infection; donor chimerism; immune reconstitution; and, health-related quality of life (QOL).",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00745420",
            "StudyKeywords": "ORIM: Kanchan Sakhrani & Eric Ponce (QA: 11/1/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00768066",
            "BriefTitle": "The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)",
            "OfficialTitle": "A Phase I/II, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Bone Marrow or Mesenchymal) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Fai",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "The technique of transplanting progenitor cells into a region of damaged myocardium, termed\r\n\r\n      cellular cardiomyoplasty, is a potentially new therapeutic modality designed to replace or\r\n\r\n      repair necrotic, scarred, or dysfunctional m",
            "OverallStatus": "Completed",
            "StartDate": "August 2008",
            "CompletionDate": "September 2013",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Stem Cell Transplantation",
            "studyLocation": "University of Miami Miller School of Medicine",
            "Enrollment": "65",
            "NctKeyword": "Chronic Ischemic Left Ventricular Dysfunction,",
            "MeshKeyword": "Heart Failure, Ventricular Dysfunction, Ventricular Dysfunction, Left,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of chronic ischemic left ventricular dysfunction secondary to MI.\r\n\r\n\r\n\r\n          -  Be a candidate for cardiac catheterization.\r\n\r\n\r\n\r\n          -  Been treated with appropriate maximal medic",
            "EligibleGender": "All",
            "MinAge": "21 Years",
            "MaxAge": "90 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2015",
            "LastChanged": "November 9, 2015",
            "FirstReceived": "October 3, 2008",
            "OverallOfficial": "Joshua M Hare, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "University of Miami Miller School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00768066",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20070443 - Biocardia - Heldman",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20070443",
            "StudyNumber": "20070443 - Biocardia - Heldman",
            "StudyTitle": "A Phase I/II, Randomized, DoubleBlinded, PlaceboControlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Bone Marrow or Mesenchymal) in Patients with Chronic Ischemic Heart Failure Secondary to Myocardial Infarc",
            "PIID": "896",
            "PicNum": "C05065867",
            "PILastName": "Hare",
            "PIFirstName": "Joshua",
            "CoodCNbr": "C00130574",
            "CoordLastName": "Difede",
            "CoordFirstName": "Darcy",
            "CoordEmail": "ddifede@med.miami.edu",
            "CoordPhone": "3052439106",
            "EnteredByCNbr": "C00130574",
            "EnteredByLastName": "Difede",
            "EnteredByFirstName": "Darcy",
            "ActiveEnrollingDate": "09/10/2008",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/10/2008",
            "IRBApprovedFrom": "07/14/2008",
            "IRBApprovedTo": "05/18/2016",
            "AccountNbr": "66493R",
            "InfoEdNbr": "29717",
            "Expr1": "Phase I/II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Biocardia, Inc.",
            "Prescreened": "0",
            "Screenedfailed": "27",
            "SignedICF": "99",
            "Totalaccrued": "74",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "99",
            "FirstNinety": "3",
            "SiteSampleSize": "UMH:72",
            "AccrualPercentageMet": "102.777777777777777777777777777777777778",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "72",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Rafael Cires,Cindy Delgado,Marietsy Pujol,Darcy Difede",
            "AgentDevices": "Agent: Mesenchymal Stem Cells (MSCs); Device: Helical Infusion Catheter",
            "StudyObjective": "The specific aim of this clinical study is to evalaute the safety and efficacy of autologous whole mononuclear bone marrow cells (hBMC) or autologous bone marrow-derived MSCs as a therapy for chronic ischemic heart failure. MSCs have been chosen because they have been shown to be effective in small and large animal models, and offer the substantial advantage of already having approval from the FDA for use in humans.",
            "NationalSampleSize": "72",
            "NCTNbr": "NCT00768066",
            "StudyKeywords": "ORIM QA: Kanchan Sakhrani (5/3/10)\r\nTherapeutic Area: Stem Cell Transplantation; Ventricular Dysfunction (Left)\r\nStudy Type: Interventional",
            "StudyInvIND": "1",
            "StudyInvINDNbr": "13568",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00772200",
            "SecondaryId": "NCI-2009-00383",
            "BriefTitle": "Neuropsychological and Behavioral Testing in Younger Patients With Cancer",
            "OfficialTitle": "Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer",
            "LeadSponsorClass": "Children's Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Oncology Group",
            "OversightAuthority": "No",
            "BriefSummary": "This research trial studies neuropsychological (learning, remembering or thinking) and\r\n\r\n      behavioral testing in younger patients with cancer. Collecting information over time from a\r\n\r\n      series of tests may help doctors develop effecti",
            "Description": "OBJECTIVES:\r\n\r\n\r\n\r\n      I. To utilize a standardized battery of age-appropriate neuropsychological and behavioral\r\n\r\n      tests in conjunction with Children's Oncology Group (COG) Phase III clinical trials to\r\n\r\n      evaluate cognitive, socia",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2008",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Children's Oncology Group",
            "StudyCondition": "Chemotherapeutic Agent Toxicity",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "755",
            "MeshKeyword": "Neurotoxicity Syndromes,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  The patient must be currently be enrolled or plan to be enrolled on a COG therapeutic\r\n\r\n             study that aims to examine neuropsychological, social, emotional, and/or behavioral\r\n\r\n             f",
            "EligibleGender": "All",
            "MinAge": "1 Month",
            "MaxAge": "21 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 14, 2016",
            "FirstReceived": "October 14, 2008",
            "OverallOfficial": "Leanne Embry",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00772200",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20090351 - COG - Barredo",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20090351",
            "StudyNumber": "20090351 - COG - Barredo",
            "StudyTitle": "ALTE07C1 Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C11973083",
            "CoordLastName": "Best",
            "CoordFirstName": "Wendy",
            "CoordEmail": "wtbest@med.miami.edu",
            "CoordPhone": "305-243-7130",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "07/31/2009",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/31/2009",
            "IRBApprovedFrom": "07/31/2009",
            "IRBApprovedTo": "07/12/2017",
            "InfoEdNbr": "40725",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "N/A",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "SponsorGroup": "Foundation",
            "Sponsor": "Children Oncology Group",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "2",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:5",
            "AccrualPercentageMet": "20",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "5",
            "EprostState": "External IRB",
            "StudyCoordinator": "Jennifer Reichbach Douglas,Nuria Garantiva,Myriam Zayas",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00772200",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00790933",
            "SecondaryId": "2008-002784-14",
            "BriefTitle": "An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease",
            "OfficialTitle": "A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease",
            "LeadSponsorClass": "Takeda",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Takeda",
            "OversightAuthority": "Yes",
            "BriefSummary": "This multicenter, open-label study will collect data on the occurrence of important clinical\r\n\r\n      safety events resulting from chronic vedolizumab (MLN0002) administration.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "May 2009",
            "CompletionDate": "December 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Takeda",
            "StudyCondition": "Ulcerative Colitis",
            "Enrollment": "2200",
            "MeshKeyword": "Ulcer, Colitis, Ulcerative, Crohn Disease, Colitis,",
            "InterventionKeyword": "Vedolizumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. a. Previous treatment in Study C13004, Study C13006, Study C13007, or Study 13011\r\n\r\n             that, in the opinion of the investigator, was well tolerated OR b. Moderate to severe\r\n\r\n             Cro",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 13, 2017",
            "FirstReceived": "November 5, 2008",
            "OverallOfficial": "Medical Monitor",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Millennium Pharmaceuticals, Inc.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00790933",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20090211 - MILLENNIUM   - Abreu",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20090211",
            "StudyNumber": "20090211 - MILLENNIUM   - Abreu",
            "StudyTitle": "A Phase 3, Openlabel Study to Determine the LongTerm Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohns Disease",
            "PIID": "651",
            "PicNum": "C00510000",
            "PILastName": "Abreu",
            "PIFirstName": "Maria",
            "CoodCNbr": "C09950089",
            "CoordLastName": "Morillo",
            "CoordFirstName": "Diana",
            "CoordEmail": "dmorillo@med.miami.edu",
            "CoordPhone": "3052436405",
            "EnteredByCNbr": "C09950089",
            "EnteredByLastName": "Morillo",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "09/01/2009",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/10/2013",
            "IRBApprovedFrom": "05/11/2009",
            "IRBApprovedTo": "04/10/2017",
            "AccountNbr": "66628E",
            "InfoEdNbr": "35646/62785",
            "Expr1": "Phase III",
            "Tarea": "Gastrointestinal, Stomach, Esophageal",
            "TareaCode": "6187",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Millennium Pharmaceuticals, Inc.",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "23",
            "Totalaccrued": "20",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "23",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:10,Clinical Research Center (CRC):N/A",
            "AccrualPercentageMet": "200",
            "ActiveCal": "6",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "10",
            "EprostState": "Approved",
            "StudyCoordinator": "Diana Morillo,Francia Carabali",
            "AgentDevices": "Agent: MLN0002",
            "StudyObjective": "STUDY OBJECTIVES \r\nPrimary Objective \r\n To determine the safety profile of long-term MLN0002 treatment \r\n\r\nResource Utilization and Patient Reported Outcome Objectives \r\n To determine the effect of long-term MLN0002 treatment on time to major IBD-related events (hospitalizations, surgeries, and procedures) \r\n To examine the effect of long-term MLN0002 treatment on health-related quality of life (QOL) measurements \r\n\r\nExploratory Objective \r\n To obtain data regarding the effect of long-term MLN0002 treatment on maintaining clinical response and remission",
            "NationalSampleSize": "26",
            "NCTNbr": "NCT00790933",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00814099",
            "SecondaryId": "U01HL086622",
            "BriefTitle": "Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)",
            "OfficialTitle": "Sedation Management in Pediatric Patients With Acute Respiratory Failure",
            "LeadSponsorClass": "University of Pennsylvania",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Pennsylvania",
            "OversightAuthority": "Yes",
            "BriefSummary": "People with acute respiratory failure usually require the use of an artificial breathing\r\n\r\n      machine, known as a mechanical ventilator. Sedative medications, which help keep people calm\r\n\r\n      and reduce anxiety, are often prescribed for",
            "Description": "People who are hospitalized for acute respiratory failure are typically supported on\r\n\r\n      mechanical ventilation, which delivers oxygen and a continuous level of pressure to the\r\n\r\n      damaged lungs. Over 90% of infants and children suppor",
            "OverallStatus": "Completed",
            "StartDate": "January 2009",
            "CompletionDate": "December 2013",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "University of Pennsylvania",
            "StudyCondition": "Respiratory Insufficiency",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "2449",
            "NctKeyword": "Acute Respiratory Failure, Acute Lung Injury,",
            "MeshKeyword": "Lung Diseases, Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome, Adult, Respiratory Insufficiency, Pulmonary Valve Insufficiency,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  At least 2 weeks of age (and at least 42 weeks post-menstrual age) and less than 18\r\n\r\n             years of age\r\n\r\n\r\n\r\n          -  Intubated and mechanically ventilated for acute lung disease",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "18 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "July 2015",
            "LastChanged": "July 14, 2015",
            "FirstReceived": "December 19, 2008",
            "OverallOfficial": "Martha A.Q. Curley, RN, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Pennsylvania",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00814099",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20100564 - UPenn - McLaughlin",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20100564",
            "StudyNumber": "20100564 - UPenn - McLaughlin",
            "StudyTitle": "RESTORE Sedation Management in Pediatric Patients with Acute Respiratory FailureU01 HL086622 and U01 HL086649",
            "PIID": "1244",
            "PicNum": "C00097025",
            "PILastName": "Mclaughlin",
            "PIFirstName": "Gwenn",
            "CoodCNbr": "C00097025",
            "CoordLastName": "Mclaughlin",
            "CoordFirstName": "Gwenn",
            "CoordEmail": "gmclaugh@med.miami.edu",
            "CoordPhone": "3055856051",
            "EnteredByCNbr": "C00097025",
            "EnteredByLastName": "Mclaughlin",
            "EnteredByFirstName": "Gwenn",
            "ActiveEnrollingDate": "11/05/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/05/2010",
            "IRBApprovedFrom": "08/30/2010",
            "IRBApprovedTo": "11/12/2016",
            "InfoEdNbr": "54218",
            "Expr1": "N/A",
            "Tarea": "Intensive Care",
            "TareaCode": "13339",
            "Blinding": "None",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "SponsorGroup": "Federal Non-NIH",
            "Sponsor": "University of Pennsylvania (clinical coordinating Center)",
            "Prescreened": "6",
            "Screenedfailed": "0",
            "SignedICF": "29",
            "Totalaccrued": "26",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "12",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "29",
            "FirstNinety": "5",
            "SiteSampleSize": "JMH:240",
            "AccrualPercentageMet": "10.83333333333333333333333333333333333333",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "240",
            "EprostState": "Approved",
            "StudyObjective": "This cluster randomized clinical trial will test an innovative approach to sedation management that includes: [a] team education and consensus on the use of sedatives in pediatric patients supported on mechanical ventilation, [b] team identification of the patients trajectory of illness and daily prescription of a sedation goal, [c] a Nurse-Implemented Goal-Directed Comfort Algorithm that guides moment-to-moment titration of opioids and benzodiazepines, and [d] team feedback on sedation management performance. The intervention is an organizational change directed at all pediatric intensive care unit (PICU) clinicians. The unit of randomization is the PICU, the unit of inference is the patient, and we will control for center effects. Approximately 26 pediatric intensive care units (approximately half randomized to the pediatric sedation management intervention and the remainder to continue to provide usual care) will enroll 2900 critically-ill infants and children supported on mechanical ventilation. We believe that patients managed per sedation protocol will experience fewer days of mechanical ventilation, less sedative exposure, fewer iatrogenic withdrawal symptoms, a shorter intensive care length of stay, less costs, and experience a better post-discharge quality of life and emotional health.",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00814099",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00835770",
            "SecondaryId": "2008-004753-14",
            "BriefTitle": "BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)",
            "OfficialTitle": "A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis",
            "LeadSponsorClass": "Biogen",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Biogen",
            "OversightAuthority": "No",
            "BriefSummary": "The primary objective of this study is to evaluate the long-term safety profile of BG00012\r\n\r\n      (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term\r\n\r\n      efficacy of BG00012 using clinical endpoints and d",
            "Description": "The initial BG00012 dosage for the extension study (240 mg BID or 240 mg TID) was the same\r\n\r\n      as that used in the Phase 3 Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451).\r\n\r\n      Subsequent to the initiation of this study, BG000",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "February 2009",
            "CompletionDate": "February 2023",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Biogen",
            "StudyCondition": "Relapsing-Remitting Multiple Sclerosis",
            "studyLocation": "Research Site",
            "Enrollment": "1738",
            "NctKeyword": "relapsing, multiple sclerosis, remitting, oral,",
            "MeshKeyword": "Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting,",
            "InterventionKeyword": "Dimethyl Fumarate,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n        -Subjects who participated in and completed as per protocol previous BG00012 clinical\r\n\r\n        studies 109MS301 (NCT00420212) or 109MS302 (NCT00451451).\r\n\r\n\r\n\r\n        Key Exclusion Criteria:",
            "EligibleGender": "All",
            "MinAge": "19 Years",
            "MaxAge": "58 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 3, 2016",
            "FirstReceived": "February 2, 2009",
            "OverallOfficial": "Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Biogen",
            "LocationName": "Research Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00835770",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20100513 - Biogen - Sheremata",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20100513",
            "StudyNumber": "20100513 - Biogen - Sheremata",
            "StudyTitle": "(109MS303[Extension Study) A DoseBlind, Multicenter, Extension Study to Determine the LongTerm Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with RelapsingRemitting Multiple Sclerosis",
            "PIID": "121",
            "PicNum": "C00457629",
            "PILastName": "Sheremata",
            "PIFirstName": "William",
            "CoodCNbr": "C02523614",
            "CoordLastName": "Babcock",
            "CoordFirstName": "Yanet",
            "CoordEmail": "YBabcock@med.miami.edu",
            "CoordPhone": "3052431088",
            "EnteredByCNbr": "C00457629",
            "EnteredByLastName": "Sheremata",
            "EnteredByFirstName": "William",
            "ActiveEnrollingDate": "02/21/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/21/2011",
            "IRBApprovedFrom": "12/06/2010",
            "IRBApprovedTo": "12/04/2017",
            "AccountNbr": "66780R",
            "InfoEdNbr": "53777",
            "Expr1": "Phase III",
            "Tarea": "Multiple Sclerosis",
            "TareaCode": "9837",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Biogen Idec",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Gloria Rodriguez (Neurology),Yanet Babcock",
            "AgentDevices": "Agent: Dimethyl fumarate",
            "StudyObjective": "OBJECTIVES\r\n\r\n&#61607; Primary Objectives: \r\nThe primary objective of the study is to evaluate the long-term safety profile of BG00012.\r\n\r\n&#61607; Additional Objectives\r\nSecondary Objectives of this study are as follows:\r\n\r\n To evaluate the long-term efficacy of BG00012 using clinical endpoints (including relapse and ARR) and disability progression (Expanded Disability Status Scale [EDSS]).\r\n\r\n To evaluate further the long-term effects of BG00012 on Multiple Sclerosis (MS) brain lesions on MRI scans in participants who had MRI scans as part of Studies 109MS301 and 109MS302. The following MRI endpoints will be evaluated in the subset of participants who participated in the MRI scans: number and volume of Gd-enhancing lesions, number and volume of new or newly-enlarging T2 lesions, number and volume of T1 hypointense lesions, brain atrophy, and magnetization transfer ratio (MTR).\r\n\r\n To evaluate the long-term effects of BG00012 on health economics assessments and the visual function test. The endpoints are the SF-36 and EQ-5D quality of life questionnaire, and the visual function test scores.",
            "NationalSampleSize": "4",
            "NCTNbr": "NCT00835770",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00855335",
            "SecondaryId": "TMC114HIV3015",
            "BriefTitle": "A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women",
            "OfficialTitle": "A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women",
            "LeadSponsorClass": "Janssen Scientific Affairs, LLC",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Janssen Scientific Affairs, LLC",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to study how changes in the body during pregnancy influence the\r\n\r\n      blood levels of TMC114 (darunavir) and ritonavir taken together, darunavir and cobicistat\r\n\r\n      taken as a fixed-dose combination, TMC125 (e",
            "Description": "There are many biological changes that occur during pregnancy, some of which may affect the\r\n\r\n      way HIV medications are absorbed, distributed and removed within the body. Some medications\r\n\r\n      have been used for HIV treatment during pre",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2009",
            "CompletionDate": "June 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Janssen Scientific Affairs, LLC",
            "StudyCondition": "HIV",
            "Enrollment": "90",
            "NctKeyword": "HIV-1, HIV, Pregnancy, Postpartum, Human immunodeficiency virus, PREZISTA, INTELENCE, NORVIR, TMC114, TMC125, darunavir, ritonavir, etravirine, rilpivirine, TMC278, Cobicistat, treatment experienced,",
            "MeshKeyword": "HIV Infections,",
            "InterventionKeyword": "Ritonavir, Darunavir, Cobicistat, Rilpivirine, Etravirine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Pregnant females (18-26 weeks of gestation)\r\n\r\n\r\n\r\n          -  documented HIV-1 infection\r\n\r\n\r\n\r\n          -  Receiving darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine at",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Aurora",
            "State": "Colorado",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 11, 2017",
            "FirstReceived": "March 2, 2009",
            "OverallOfficial": "Janssen Scientific Affairs, LLC Clinical Trial",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Janssen Scientific Affairs, LLC",
            "ContactName": "Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:",
            "ContactEmail": "JNJ.CT@sylogent.com",
            "LocationStatus": "Withdrawn",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00855335",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20090145 - Tibotec  - Yasin",
            "FileProcessContentId": "440",
            "Division": "Obstetrics and  Gynecology",
            "StdyDivision": "10251",
            "EprostNbr": "20090145",
            "StudyNumber": "20090145 - Tibotec  - Yasin",
            "StudyTitle": "A single-arm, open-label study to assess the pharmacokinetics of darunavir and ritonavir, darunavir and cobicistat, etravirine, and rilpivirine in HIV-1 infected pregnant women",
            "PIID": "2996",
            "PicNum": "C00683800",
            "PILastName": "Yasin",
            "PIFirstName": "Salih",
            "CoodCNbr": "C00315909",
            "CoordLastName": "Plummer",
            "CoordFirstName": "Yvette",
            "CoordEmail": "yplummer@med.miami.edu",
            "EnteredByCNbr": "C00334550",
            "EnteredByLastName": "Fernandez",
            "EnteredByFirstName": "Diann",
            "ActiveEnrollingDate": "08/06/2009",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/06/2009",
            "IRBApprovedFrom": "05/05/2009",
            "IRBApprovedTo": "03/06/2017",
            "AccountNbr": "66585E",
            "InfoEdNbr": "35401",
            "Expr1": "Phase II/III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Tibotec Therapeutics Clinical Affairs",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "38",
            "Totalaccrued": "33",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "38",
            "FirstNinety": "3",
            "SiteSampleSize": "JMH:20,UMMG:5,Clinical Research Center (CRC):N/A",
            "AccrualPercentageMet": "132",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "25",
            "EprostState": "Approved",
            "StudyCoordinator": "Sindy Jaramillo,Sam-mosley Ayuk",
            "AgentDevices": "Agents: PREZISTA, INTELENCE, NORVIR",
            "StudyObjective": "Primary Objective\r\nThe primary objective of the study is to assess the influence of pregnancy on the pharmacokinetics of darunavir/ritonavir and/or etravirine during the second and third trimesters of pregnancy, as well as postpartum.\r\nSecondary Objective(s)\r\nThe secondary objectives are as follows:\r\n1. To document anti-viral activity during gestation and postpartum \r\n2. To document the safety and tolerability of darunavir/r and/or etravirine-based antiretroviral regimens during gestation and postpartum \r\n3. To compare darunavir/r and/or etravirine concentrations between serum and cord blood samples that may be collected at the time of delivery \r\n4. To assess outcomes for infants of women treated with darunavir/r and/or etravirine during pregnancy",
            "NationalSampleSize": "47",
            "NCTNbr": "NCT00855335",
            "StudyKeywords": "ORIM: Kanchan Sakhrani (QA: 11/24/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00867048",
            "SecondaryId": "U01AI068641",
            "BriefTitle": "Strategic Timing of Antiretroviral Treatment",
            "OfficialTitle": "Strategic Timing of AntiRetroviral Treatment",
            "LeadSponsorClass": "University of Minnesota - Clinical and Translational Science Institute",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Minnesota - Clinical and Translational Science Institute",
            "OversightAuthority": "Yes",
            "BriefSummary": "Objectives:\r\n\r\n\r\n\r\n        -  To find out if the chance of developing a serious illness or of getting AIDS is less if\r\n\r\n           patients start taking HIV medicines at a time when their cluster-of-differentiation-4\r\n\r\n           (CD4)+ cell c",
            "Description": "Background:\r\n\r\n\r\n\r\n        -  Most guidelines agree that if the number of your CD4+ cells (cells in your blood which\r\n\r\n           help fight infection) drops below 350 cells/mm3, or if you have symptoms of AIDS, you\r\n\r\n           should start t",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "March 2009",
            "CompletionDate": "December 2017",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "University of Minnesota - Clinical and Translational Science Institute",
            "StudyCondition": "HIV Infection",
            "studyLocation": "University of Southern California",
            "Enrollment": "4688",
            "NctKeyword": "highly active antiretroviral therapy (HAART), CD4 Count, Early Intervention, HIV, HIV Infection, HIV Infections, treatment naive,",
            "MeshKeyword": "Infection, HIV Infections, Acquired Immunodeficiency Syndrome,",
            "Eligibility": "INCLUSION CRITERIA:\r\n\r\n\r\n\r\n          -  Signed informed consent\r\n\r\n\r\n\r\n          -  HIV infection documented by a plasma HIV RNA viral load, rapid HIV test or any\r\n\r\n             licensed* ELISA test; and confirmed by another test using a diff",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Alhambra",
            "State": "California",
            "Zip": "91803",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 28, 2016",
            "FirstReceived": "March 20, 2009",
            "OverallOfficial": "James D Neaton, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Minnesota - Clinical and Translational Science Institute",
            "LocationName": "University of Southern California",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00867048",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20100994 - INSTITUTE FOR CLINICAL RESEARCH - Kolber",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20100994",
            "StudyNumber": "20100994 - INSTITUTE FOR CLINICAL RESEARCH - Kolber",
            "StudyTitle": "START  Strategic Timing of Antiretroviral Treatment.",
            "PIID": "207",
            "PicNum": "C00711703",
            "PILastName": "Kolber",
            "PIFirstName": "Michael",
            "CoodCNbr": "C00711703",
            "CoordLastName": "Kolber",
            "CoordFirstName": "Michael",
            "CoordEmail": "mkolber@med.miami.edu",
            "EnteredByCNbr": "C00711703",
            "EnteredByLastName": "Kolber",
            "EnteredByFirstName": "Michael",
            "ActiveEnrollingDate": "12/12/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/12/2011",
            "IRBApprovedFrom": "03/01/2011",
            "IRBApprovedTo": "12/14/2016",
            "AccountNbr": "66837C",
            "InfoEdNbr": "55820",
            "Expr1": "Phase IV",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "7",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Kenia Moreno,Tom Tanner",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT00867048",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00878254",
            "SecondaryId": "SCCC-2008043",
            "BriefTitle": "Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma",
            "OfficialTitle": "Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (R-MACLO/VAM) in Patients With Previously Untreated Mantle Cell Lymphoma",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "The investigator(s) hypothesize that Rituximab together with combination chemotherapy,\r\n\r\n      followed by Rituximab maintenance therapy, will provide better disease control with improved\r\n\r\n      response rates and overall survival in patients",
            "Description": "This is a phase 2 study of Rituximab in combination with Methotrexate, Doxorubicin,\r\n\r\n      Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna\r\n\r\n      (R-MACLO/IVAM) in subjects with previously untreated Man",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2009",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Mantle-Cell Lymphoma",
            "studyLocation": "University of Miami",
            "Enrollment": "22",
            "NctKeyword": "Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, MCL, NHL,",
            "MeshKeyword": "Lymphoma, Lymphoma, Mantle-Cell,",
            "InterventionKeyword": "Doxorubicin, Liposomal doxorubicin, Etoposide, Etoposide phosphate, Isophosphamide mustard, Cytarabine, Cyclophosphamide, Rituximab, Methotrexate, Vincristine, Ifosfamide, Mesna,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Previously untreated, histologically confirmed mantle cell lymphoma,\r\n\r\n\r\n\r\n          2. Measurable or evaluable disease (at least one site with >1.5 cm in diameter\r\n\r\n\r\n\r\n          3. All stages are eli",
            "EligibleGender": "All",
            "MinAge": "19 Years",
            "MaxAge": "72 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33186",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 20, 2016",
            "FirstReceived": "April 7, 2009",
            "OverallOfficial": "Izidore S. Lossos, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00878254",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20080803 - Intramural - LOSSOS",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20080803",
            "StudyNumber": "20080803 - Intramural - LOSSOS",
            "StudyTitle": "SCCC 2008043:  Phase II Study of Rituximab in Combination with Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and MESNA (RMACLO/IVAM) in Patients with Previously Untreated Mantle Cell Lymphoma",
            "PIID": "396",
            "PicNum": "C02540370",
            "PILastName": "Lossos",
            "PIFirstName": "Izidore",
            "CoodCNbr": "C11923689",
            "CoordLastName": "Mohan",
            "CoordFirstName": "Vivin",
            "CoordEmail": "vxm153@miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "03/12/2009",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/12/2009",
            "IRBApprovedFrom": "01/05/2009",
            "IRBApprovedTo": "02/14/2017",
            "InfoEdNbr": "33378",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma",
            "Expr1": "Phase II",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "4",
            "Screenedfailed": "2",
            "SignedICF": "19",
            "Totalaccrued": "17",
            "InFollowUp": "6",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "5",
            "Totalpatients": "19",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:25",
            "AccrualPercentageMet": "68",
            "ActiveCal": "2",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "25",
            "EprostState": "Approved",
            "CancerCenterNbr": "2008043",
            "StudyCoordinator": "Nathalie Luis,Rachel Pallapati",
            "AgentDevices": "Rituximab",
            "StudyObjective": "Primary objective: Progression-free survival\r\nSecondary objectives: Overall Survival, Response Rate, Toxicity",
            "NationalSampleSize": "22",
            "NCTNbr": "NCT00878254",
            "StudyKeywords": "CRIS:Granado",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00897325",
            "SecondaryId": "NCI-2009-00310",
            "BriefTitle": "Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma",
            "OfficialTitle": "A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens",
            "LeadSponsorClass": "Children's Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Oncology Group",
            "BriefSummary": "This research study is collecting and storing samples of bone marrow and blood from patients\r\n\r\n      with relapsed acute lymphoblastic leukemia or relapsed non-Hodgkin lymphoma. Collecting and\r\n\r\n      storing samples of bone marrow and blood f",
            "Description": "OBJECTIVES:\r\n\r\n\r\n\r\n      I. Establish a mechanism to bank specimens of tumor cells and host germline DNA from\r\n\r\n      patients with acute lymphoblastic leukemia (ALL) at first and subsequent relapse.\r\n\r\n\r\n\r\n      II. Make these specimens availa",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2006",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Children's Oncology Group",
            "StudyCondition": "Recurrent Adult Acute Lymphoblastic Leukemia",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "528",
            "MeshKeyword": "Lymphoma, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of acute lymphoblastic leukemia (ALL) or prior history of non-Hodgkin\r\n\r\n             lymphoma\r\n\r\n\r\n\r\n          -  In first or subsequent marrow relapse with ≥ 25% blasts in bone marrow and/or",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "30 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 14, 2016",
            "FirstReceived": "May 9, 2009",
            "OverallOfficial": "Stephen Hunger",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00897325",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20070561 - COG - BARREDO",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20070561",
            "StudyNumber": "20070561 - COG - BARREDO",
            "StudyTitle": "AALL05B1: A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens.",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C00722004",
            "CoordLastName": "Garantiva",
            "CoordFirstName": "Nuria",
            "CoordEmail": "nfc19@miami.edu",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "07/17/2007",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/17/2007",
            "IRBApprovedFrom": "11/21/2007",
            "IRBApprovedTo": "11/24/2016",
            "InfoEdNbr": "51718",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma,Lymphoid Leukemia",
            "Expr1": "N/A",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Randomization": "Non - Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "Children Oncology Group",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:10",
            "AccrualPercentageMet": "10",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "10",
            "EprostState": "External IRB",
            "CancerCenterNbr": "2007019",
            "StudyCoordinator": "Myriam Zayas,Wendy Best",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00897325",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00898365",
            "SecondaryId": "NCI-2009-00416",
            "BriefTitle": "Study of Kidney Tumors in Younger Patients",
            "OfficialTitle": "Renal Tumors Classification, Biology, and Banking Study",
            "LeadSponsorClass": "Children's Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Oncology Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "This research trial studies kidney tumors in younger patients. Collecting and storing\r\n\r\n      samples of tumor tissue, blood, and urine from patients with cancer to study in the\r\n\r\n      laboratory may help doctors learn more about changes that",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. Classify patients with renal tumors by histological categorization, surgico-pathological\r\n\r\n      stage, presence of metastases, age at diagnosis, tumor weight, and loss of heterozygosity\r\n\r\n      for chromoso",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2006",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Children's Oncology Group",
            "StudyCondition": "Clear Cell Sarcoma of the Kidney",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "5000",
            "MeshKeyword": "Neoplasms, Carcinoma, Renal Cell, Wilms Tumor, Sarcoma, Clear Cell, Rhabdoid Tumor, Kidney Neoplasms, Nephroma, Mesoblastic, Hyperplasia,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients with the first occurrence of any tumor of the kidney identified on CT scan\r\n\r\n             or MRI are eligible for this study; histologic diagnosis is not required prior to\r\n\r\n             enrol",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "29 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 18, 2016",
            "FirstReceived": "May 9, 2009",
            "OverallOfficial": "Elizabeth Mullen, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00898365",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20060374 - COG - BARREDO",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20060374",
            "StudyNumber": "20060374 - COG - BARREDO",
            "StudyTitle": "AREN03B2:  Renal Tumors Classification, Biology and Banking Study.",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C11973083",
            "CoordLastName": "Best",
            "CoordFirstName": "Wendy",
            "CoordEmail": "wtbest@med.miami.edu",
            "CoordPhone": "305-243-7130",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "05/22/2006",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/22/2006",
            "IRBApprovedFrom": "05/22/2006",
            "IRBApprovedTo": "11/30/2016",
            "InfoEdNbr": "40195",
            "WIrb": "20060872",
            "DiseaseSiteListDesc": "Kidney",
            "Expr1": "N/A",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Randomization": "Non - Randomized",
            "Expr2": "Correlative",
            "StudyType_Code": "140",
            "ResearchType": "Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "Children Oncology Group",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "6",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:20",
            "AccrualPercentageMet": "30",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "20",
            "EprostState": "External IRB",
            "CancerCenterNbr": "2006041",
            "StudyCoordinator": "Noeline Lewis,Nuria Garantiva,Myriam Zayas,Jessica Ardente",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00898365",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00899990",
            "SecondaryId": "NCI-2009-00370",
            "BriefTitle": "Collecting and Storing Biological Samples From Patients With Ewing Sarcoma",
            "OfficialTitle": "A COG Study for Collecting and Banking Ewing Sarcoma Specimens",
            "LeadSponsorClass": "Children's Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Oncology Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "This research study is collecting and storing samples of tumor tissue, bone marrow, and\r\n\r\n      blood from patients with Ewing sarcoma. Collecting and storing samples of tumor tissue, bone\r\n\r\n      marrow, and blood from patients with cancer to",
            "Description": "OBJECTIVES:\r\n\r\n\r\n\r\n      I. Collect biological specimens, including associated demographic and clinical data, from\r\n\r\n      patients with Ewing sarcoma.\r\n\r\n\r\n\r\n      II. Provide a repository for long-term storage of Ewing sarcoma-related biologi",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2008",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Children's Oncology Group",
            "StudyCondition": "Askin Tumor",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "900",
            "MeshKeyword": "Sarcoma, Sarcoma, Ewing, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of Ewing sarcoma, including peripheral primitive neuroectodermal tumor and\r\n\r\n             Askin tumor\r\n\r\n\r\n\r\n               -  Newly diagnosed or recurrent disease",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "21 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 21, 2016",
            "FirstReceived": "May 9, 2009",
            "OverallOfficial": "Stephen Lessnick, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00899990",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20100009 - COG - Barredo",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20100009",
            "StudyNumber": "20100009 - COG - Barredo",
            "StudyTitle": "AEWS07B1  A COG Study for Collecting and Banking Ewing Sarcoma Specimens",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C11973083",
            "CoordLastName": "Best",
            "CoordFirstName": "Wendy",
            "CoordEmail": "wtbest@med.miami.edu",
            "CoordPhone": "305-243-7130",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "02/14/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/14/2010",
            "IRBApprovedFrom": "02/14/2010",
            "IRBApprovedTo": "07/27/2017",
            "DiseaseSiteListDesc": "Bones and Joints",
            "Expr1": "N/A",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "SponsorGroup": "Foundation",
            "Sponsor": "COG",
            "SiteSampleSize": "JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Myriam Zayas,Nuria Garantiva",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00899990",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00904241",
            "SecondaryId": "NCI-2009-00397",
            "BriefTitle": "Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma",
            "OfficialTitle": "Neuroblastoma Biology Studies",
            "LeadSponsorClass": "Children's Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Oncology Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "This research trial studies biomarkers in tumor tissue samples from patients with newly\r\n\r\n      diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from\r\n\r\n      patients with cancer in the laboratory may help doct",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To prospectively analyze the factors that are currently used for risk-group assignment\r\n\r\n      (v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog [MYCN] copy\r\n\r\n      number by fluores",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2000",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Children's Oncology Group",
            "StudyCondition": "Disseminated Neuroblastoma",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "10000",
            "MeshKeyword": "Neuroblastoma, Ganglioneuroblastoma,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  All newly diagnosed patients with suspected neuroblastoma, suspected\r\n\r\n             ganglioneuroblastoma, or suspected ganglioneuroma/maturing subtype seen at Children's\r\n\r\n             Oncology Group (",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "30 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 21, 2016",
            "FirstReceived": "May 16, 2009",
            "OverallOfficial": "Michael Hogarty, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Active, not recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00904241",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20010127 - COG - BARREDO",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20010127",
            "StudyNumber": "20010127 - COG - BARREDO",
            "StudyTitle": "Neuroblastoma Biology Studies, COG ANBL00B1/SCCC 2001002",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C11973083",
            "CoordLastName": "Best",
            "CoordFirstName": "Wendy",
            "CoordEmail": "wtbest@med.miami.edu",
            "CoordPhone": "305-243-7130",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "06/16/2005",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/16/2005",
            "IRBApprovedFrom": "11/20/2001",
            "IRBApprovedTo": "03/31/2017",
            "InfoEdNbr": "50882",
            "WIrb": "20002018",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "N/A",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Randomization": "Non - Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "Children Oncology Group",
            "Prescreened": "5",
            "Screenedfailed": "0",
            "SignedICF": "13",
            "Totalaccrued": "15",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "15",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:40",
            "AccrualPercentageMet": "37.5",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "40",
            "EprostState": "External IRB",
            "CancerCenterNbr": "2005077",
            "StudyCoordinator": "Myriam Zayas,Nuria Garantiva",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00904241",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00919750",
            "SecondaryId": "NCI-2009-00334",
            "BriefTitle": "Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors",
            "OfficialTitle": "A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens",
            "LeadSponsorClass": "Children's Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Oncology Group",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to collect and store brain tissue samples and blood from\r\n\r\n      children with brain cancer that will be tested in the laboratory. Collecting and storing\r\n\r\n      samples of tumor tissue and blood from patients to t",
            "Description": "OBJECTIVES:\r\n\r\n\r\n\r\n      I. Collect brain tumor tissue and an accompanying blood sample from pediatric patients with\r\n\r\n      brain tumors treated at Children's Oncology Group institutions.\r\n\r\n\r\n\r\n      II. Provide a repository for long-term sto",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2005",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Children's Oncology Group",
            "StudyCondition": "Childhood Atypical Teratoid/Rhabdoid Tumor",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "5000",
            "MeshKeyword": "Neoplasms, Glioma, Brain Neoplasms, Neoplasms, Germ Cell and Embryonal, Astrocytoma, Ependymoma, Oligodendroglioma, Meningioma, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Medulloblastoma, Craniopharyngioma, Adamantinoma, Optic Nerve Glioma",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of brain tumor\r\n\r\n\r\n\r\n          -  Previously treated at a Children's Oncology Group (COG) institution\r\n\r\n\r\n\r\n               -  Patients are eligible at time of diagnosis, second-look surgery,",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "18 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 21, 2016",
            "FirstReceived": "June 11, 2009",
            "OverallOfficial": "Scott Pomeroy",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00919750",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20040900 - COG - BARREDO",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20040900",
            "StudyNumber": "20040900 - COG - BARREDO",
            "StudyTitle": "A children's Oncology Group Protocol for collecting and banking pediatric brain tumor research specimens SCCC2005032",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C11973083",
            "CoordLastName": "Best",
            "CoordFirstName": "Wendy",
            "CoordEmail": "wtbest@med.miami.edu",
            "CoordPhone": "305-243-7130",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "04/18/2005",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/18/2005",
            "IRBApprovedFrom": "04/18/2005",
            "IRBApprovedTo": "08/22/2017",
            "WIrb": "20040900",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "N/A",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Randomization": "Non - Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "Children Oncology Group",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "3",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:5,JMH:5",
            "AccrualPercentageMet": "30",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "10",
            "EprostState": "Approved",
            "CancerCenterNbr": "2005032",
            "StudyCoordinator": "Myriam Zayas,Nuria Garantiva",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT00919750",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00920972",
            "BriefTitle": "Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases",
            "OfficialTitle": "A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime",
            "LeadSponsorClass": "Washington University School of Medicine",
            "SponsorAgency": "Other",
            "LeadSponsor": "Washington University School of Medicine",
            "OversightAuthority": "Yes",
            "BriefSummary": "The hypothesis for this study is that a preparative regimen that maximizes host\r\n\r\n      immunosuppression without myeloablation will be well tolerated and sufficient for\r\n\r\n      engraftment of donor hematopoietic cells. It is also to determine",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2001",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Washington University School of Medicine",
            "StudyCondition": "Metabolic Disorders",
            "studyLocation": "Phoenix Children's Hospital",
            "Enrollment": "220",
            "NctKeyword": "Bone marrow, Transplant, Transplantation, Hematopoietic, Umbilical cord, Related, Unrelated, Reduced, Non-myeloablative, Nonmyeloablative, Non-malignant, Nonmalignant,",
            "MeshKeyword": "Disease, Metabolic Diseases, Hemoglobinopathies, Bone Marrow Diseases,",
            "InterventionKeyword": "Fludarabine, Fludarabine phosphate, Alemtuzumab, Melphalan, Hydroxyurea, Thiotepa, Vidarabine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        Stratum 1: Patient must have a hemoglobinopathy receiving a matched related transplant\r\n\r\n        with bone marrow or peripheral blood stem cells.\r\n\r\n\r\n\r\n        Stratum 2: Patient must have thalassemia recei",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "20 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85016",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 1, 2016",
            "FirstReceived": "June 15, 2009",
            "OverallOfficial": "Shalini Shenoy, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Washington University School of Medicine (in St. Louis)",
            "ContactName": "Lisa Murray, MA, CCRP",
            "ContactPhone": "3144544240",
            "ContactEmail": "Murray_L@kids.wustl.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Phoenix Children's Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00920972",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20070637 - PEDIATRICS - Andreansky",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20070637",
            "StudyNumber": "20070637 - PEDIATRICS - Andreansky",
            "StudyTitle": "A study of hematopoietic stem cell transplantation (HSCT) in pediatric non-maligant disease using a reduced intensity preparatory regime with campath 1H, fludaribine and melphalan.Washington Univ 01923",
            "PIID": "590",
            "PicNum": "C06466265",
            "PILastName": "Andreansky",
            "PIFirstName": "Martin",
            "CoodCNbr": "C00046839",
            "CoordLastName": "Willumsen",
            "CoordFirstName": "Silvia",
            "CoordEmail": "swillums@med.miami.edu",
            "CoordPhone": "3055857359",
            "EnteredByCNbr": "C01997997",
            "EnteredByLastName": "Kleiner",
            "EnteredByFirstName": "Gary",
            "ActiveEnrollingDate": "07/16/2007",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/16/2007",
            "IRBApprovedFrom": "07/16/2007",
            "IRBApprovedTo": "07/10/2017",
            "InfoEdNbr": "31043/55775",
            "Expr1": "Phase I/II",
            "Tarea": "Immunology/Infectious Disease",
            "TareaCode": "13340",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:10,JMH:10,UMMG:10",
            "AccrualPercentageMet": "10",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "30",
            "EprostState": "Approved",
            "StudyCoordinator": "Gabriela D'Antonio,Yamilet Delgado Vigoa",
            "AgentDevices": "Agent: campath,Fludarabine,melphalan,neoral,neupogen,solumedrol,trexall,umbilical cord blood",
            "StudyObjective": "Primary:\r\n\r\n1.1 To determine if treatment with alemtuzumab, fludarabine and melphalan followed by related/unrelated bone marrow (BM), peripheral blood (PB) stem cells or umbilical cord blood cells (UCB) will result in donor engraftment on day +100\r\n\r\n1.2 To determine major toxicities from this conditioning regimen, within the first 100 days after transplantation.\r\n\r\nSecondary: \r\n\r\n1.3 To determine the time to neutrophil engraftment (ANC>500/dl for the first of three consecutive days) and platelet engraftment (platelet count >50,000/dl for the first of seven days without platelet transfusions)\r\n\r\n1.4 To determine the incidence of acute GVHD within 100 days after transplantation.\r\n\r\n1.5 To determine the incidence and extent of chronic GVHD within the first 2 years after transplantation.\r\n\r\n1.6 To determine engraftment within the first two years after transplantation.",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT00920972",
            "StudyKeywords": "ORIM: Kanchan Sakhrani & Eric Ponce (QA: 10/24/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00955968",
            "SecondaryId": "U01AI068632",
            "BriefTitle": "IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women",
            "OfficialTitle": "IMPAACT 1077HS: HAART Standard Version of the Promoting Maternal and Infant Survival Everywhere (PROMISE) Study",
            "LeadSponsorClass": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study is a randomized strategy trial conducted among women who received highly active\r\n\r\n      antiretroviral therapy (HAART) during pregnancy for purposes of prevention of\r\n\r\n      mother-to-child transmission (PMTCT) of HIV but do not oth",
            "OverallStatus": "Completed",
            "StartDate": "January 2010",
            "CompletionDate": "August 2016",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
            "StudyCondition": "HIV Infection",
            "studyLocation": "University of Southern California MCA Center (5048)",
            "Enrollment": "1653",
            "NctKeyword": "HIV Infection, HAART, Maternal Health,",
            "MeshKeyword": "HIV Infections,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Women age > 18 years or who have attained the minimum age of independent consent, as\r\n\r\n             defined by the local IRB, and are willing and able to provide written informed\r\n\r\n             consent",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Alhambra",
            "State": "California",
            "Zip": "21287",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 1, 2016",
            "FirstReceived": "August 7, 2009",
            "OverallOfficial": "Judith S. Currier, MD, MS",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "University of California, Los Angeles",
            "LocationName": "University of Southern California MCA Center (5048)",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00955968",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20090724 - GSK/BMS/Abbott/Gilead - Scott",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20090724",
            "StudyNumber": "20090724 - GSK/BMS/Abbott/Gilead - Scott",
            "StudyTitle": "IMPAACT 1077HS HAART Standard Version of the PROMISE Study(Promoting Maternal and Infant Survival Everywhere)",
            "PIID": "1243",
            "PicNum": "C00795461",
            "PILastName": "Scott",
            "PIFirstName": "Gwendolyn",
            "CoodCNbr": "C00057173",
            "CoordLastName": "Bryan",
            "CoordFirstName": "Patricia",
            "CoordEmail": "pbryan@med.miami.edu",
            "CoordPhone": "3052434447",
            "EnteredByCNbr": "C00795461",
            "EnteredByLastName": "Scott",
            "EnteredByFirstName": "Gwendolyn",
            "ActiveEnrollingDate": "04/05/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/05/2010",
            "IRBApprovedFrom": "04/05/2010",
            "IRBApprovedTo": "02/14/2017",
            "AccountNbr": "66639C",
            "InfoEdNbr": "33398",
            "Expr1": "Phase III",
            "Tarea": "Immunology/Infectious Disease",
            "TareaCode": "13340",
            "Blinding": "None",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "GlaxoSmithKline; NIH; Bristol-Myers squibb; Abbott; Gilead Sciences",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "13",
            "Totalaccrued": "12",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "13",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:120,UMMG:N/A",
            "AccrualPercentageMet": "10",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "120",
            "EprostState": "Approved",
            "StudyCoordinator": "Grace Alvarez",
            "AgentDevices": "Agents: EPIVIR, Retrovir, COMBIVIR, Norvir, Kaletra, Videx, Viread, Reyataz, Truvada",
            "StudyObjective": "OBJECTIVES: Primary Objective and Endpoint\r\n\r\nTo determine whether continuation of HAART (Arm A) postpartum reduces morbidity and mortality among women receiving HAART for PMTCT when compared to HAART discontinuation and re-initiation according to current standards of care (SoC) (Arm B). The primary combined endpoint includes death, AIDS-defining illness, and serious non-AIDS-defining cardiovascular, renal, and hepatic events or death.\r\n\r\nSecondary Objectives\r\n\r\n1. To determine, characterize, and compare the rates of AIDS-defining and HIV-related illnesses, opportunistic infections, immune reconstitution inflammatory syndromes, and other targeted medical conditions (see Appendix II), with regard to outcomes and survival.\r\n2. To assess toxicity, both selected moderate (Grade 2) laboratory abnormalities (renal, hepatic, and hematologic) and severe (Grade 3 or Grade 4) laboratory values and signs and symptoms.\r\n3. To compare emergence of HIV-1 resistance to ART during the 1st, 2nd, and 3rd years following randomization and at end of study. \r\n4. To evaluate rates of self-reported adherence to HAART and its association with the primary endpoint and with CD4+ cell count, HIV-1 viral load, and HIV-1 resistance patterns at 1, 2, and 3 years following randomization.\r\n5. To compare quality of life measurements between the study arms at 1, 2, and 3 years following randomization.\r\n6. To investigate changes in plasma concentrations of inflammatory and thrombogenic markers between arms and to correlate these markers to clinical events.\r\n7. To evaluate cost effectiveness and feasibility of the trial strategies.",
            "NationalSampleSize": "40",
            "NCTNbr": "NCT00955968",
            "StudyKeywords": "ORIM: Kanchan Sakhrani (QA: 11/1/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT00980460",
            "SecondaryId": "NCI-2011-01975",
            "BriefTitle": "Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer",
            "OfficialTitle": "Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "BriefSummary": "This phase III trial studies the side effects and how well risk-based therapy works in\r\n\r\n      treating younger patients with newly diagnosed liver cancer. Surgery, chemotherapy drugs\r\n\r\n      (cancer fighting medicines), and when necessary, li",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To estimate the event-free survival (EFS) in children with stage I (non-pure fetal\r\n\r\n      histology [PFH], non-small cell undifferentiated [SCU]) and stage II (non-SCU)\r\n\r\n      hepatoblastoma treated with s",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2009",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "PRETEXT Stage 1 Hepatoblastoma",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "253",
            "MeshKeyword": "Hepatoblastoma,",
            "InterventionKeyword": "Liposomal doxorubicin, Irinotecan, Cisplatin, Doxorubicin, Fluorouracil, Vincristine, Everolimus, Sirolimus, Camptothecin, Liver Extracts, Succinylcholine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must be newly diagnosed with histologically-proven hepatoblastoma\r\n\r\n\r\n\r\n          -  In emergency situations when a patient meets all other eligibility criteria and has\r\n\r\n             had base",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "21 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "September 18, 2009",
            "OverallOfficial": "Howard Katzenstein",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT00980460",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20100550 - NCCF-COG - Barredo",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20100550",
            "StudyNumber": "20100550 - NCCF-COG - Barredo",
            "StudyTitle": "AHEP0731 Treatment of Children with All Stages of Hepatoblastoma",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C11973083",
            "CoordLastName": "Best",
            "CoordFirstName": "Wendy",
            "CoordEmail": "wtbest@med.miami.edu",
            "CoordPhone": "305-243-7130",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "08/02/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/02/2010",
            "IRBApprovedFrom": "02/22/2010",
            "IRBApprovedTo": "04/13/2017",
            "DiseaseSiteListDesc": "Liver",
            "Expr1": "Phase III",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "NCCF - COG",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:10",
            "AccrualPercentageMet": "20",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "10",
            "EprostState": "External IRB",
            "StudyCoordinator": "Myriam Zayas,Nuria Garantiva",
            "AgentDevices": "Agent: Irinotecan, Filgrastim, Vincristine, Doxorubicin, Cisplatin",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT00980460",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01000753",
            "SecondaryId": "COG-ANHL04B1",
            "BriefTitle": "Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma",
            "OfficialTitle": "Rare And Cutaneous Non-Hodgkin Lymphoma Registry",
            "LeadSponsorClass": "Children's Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Oncology Group",
            "OversightAuthority": "No",
            "BriefSummary": "RATIONALE: Collecting and storing samples of tissue from patients with cancer to test in the\r\n\r\n      laboratory may help the study of cancer in the future.\r\n\r\n\r\n\r\n      PURPOSE: This research study is collecting and storing tissue samples from",
            "Description": "OBJECTIVES:\r\n\r\n\r\n\r\n        -  To determine the clinical features, treatment, and outcome of patients with rare or\r\n\r\n           cutaneous pediatric non-Hodgkin lymphoma (NHL).\r\n\r\n\r\n\r\n        -  To determine the pathologic and biologic features o",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2005",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Children's Oncology Group",
            "StudyCondition": "Lymphoma",
            "studyLocation": "Children's Hospital of Alabama at University of Alabama at Birmingham",
            "Enrollment": "250",
            "NctKeyword": "adult diffuse small cleaved cell lymphoma, adult diffuse mixed cell lymphoma, grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3 follicular lymphoma, childhood immunoblastic large cell lymphoma, adult immunoblastic large cell lymphoma, mant",
            "MeshKeyword": "Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders,",
            "Eligibility": "DISEASE CHARACTERISTICS:\r\n\r\n\r\n\r\n          -  Diagnosis of non-Hodgkin lymphoma (NHL)\r\n\r\n\r\n\r\n               -  Any histology, except for Burkitt or Burkitt-like, diffuse large B-cell,\r\n\r\n                  anaplastic large cell, or lymphoblastic",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "21 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 18, 2016",
            "FirstReceived": "October 22, 2009",
            "OverallOfficial": "Amanda M. Termuhlen, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Nationwide Children's Hospital",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama at University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01000753",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20057090 - COG - BARREDO",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20057090",
            "StudyNumber": "20057090 - COG - BARREDO",
            "StudyTitle": "ANHL04B1: Rare and Cutaneous NonHodgkin's Lymphoma Registry",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C00722004",
            "CoordLastName": "Garantiva",
            "CoordFirstName": "Nuria",
            "CoordEmail": "nfc19@miami.edu",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "07/15/2005",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/15/2005",
            "IRBApprovedFrom": "07/15/2005",
            "IRBApprovedTo": "09/06/2017",
            "WIrb": "20051260",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma",
            "Expr1": "N/A",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Randomization": "Non - Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "Children Oncology Group",
            "SiteSampleSize": "JMH:5",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "5",
            "EprostState": "External IRB",
            "CancerCenterNbr": "2005095",
            "StudyCoordinator": "Myriam Zayas,Wendy Best",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01000753",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01003639",
            "SecondaryId": "1U10EY017281-01A1",
            "BriefTitle": "Idiopathic Intracranial Hypertension Treatment Trial",
            "OfficialTitle": "A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss",
            "LeadSponsorClass": "St. Luke's-Roosevelt Hospital Center",
            "SponsorAgency": "Other",
            "LeadSponsor": "St. Luke's-Roosevelt Hospital Center",
            "OversightAuthority": "Yes",
            "BriefSummary": "Idiopathic intracranial hypertension (IIH), also called pseudotumor cerebri, is a disorder\r\n\r\n      of elevated intracranial pressure of unknown cause [Corbett, et al., 1982; Wall, et al.,\r\n\r\n      1991]. Its incidence is 22.5 new cases each yea",
            "Description": "Clinical Phase: Phase II Investigators: NORDIC Network sites Study Centers: 38 study centers\r\n\r\n      Coordinating Center - University of Rochester Statistical Center - University of Rochester\r\n\r\n      Study Period Planned enrollment duration: 2",
            "OverallStatus": "Completed",
            "StartDate": "January 2010",
            "CompletionDate": "January 2014",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "St. Luke's-Roosevelt Hospital Center",
            "StudyCondition": "Idiopathic Intracranial Hypertension",
            "studyLocation": "University of Alabama Birmingham",
            "Enrollment": "166",
            "NctKeyword": "papilledema, vision loss, headache, obesity, women, diplopia, tinnitus,",
            "MeshKeyword": "Hypertension, Intracranial Hypertension, Pseudotumor Cerebri,",
            "InterventionKeyword": "Aspirin, Ibuprofen, Naproxen, Acetaminophen, Acetazolamide,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Diagnosis of IIH by modified Dandy criteria Signs and symptoms of increased\r\n\r\n             intracranial pressure Absence of localizing findings on neurologic examination\r\n\r\n             Absence of defor",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "60 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "January 2015",
            "LastChanged": "March 3, 2015",
            "FirstReceived": "October 28, 2009",
            "OverallOfficial": "Michael Wall, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "University of Iowa",
            "LocationName": "University of Alabama Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01003639",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20090988 - NEI - Lam",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20090988",
            "StudyNumber": "20090988 - NEI - Lam",
            "StudyTitle": "A Multicenter, Double-blind, Randomized,Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet plus Acetazolamide vs Diet plus Placebo in Subjects with Idiopathic Intracranial Hypertension with Mild Visual Loss",
            "PIID": "1115",
            "PicNum": "C00679155",
            "PILastName": "Lam",
            "PIFirstName": "Byron",
            "CoodCNbr": "C07458455",
            "CoordLastName": "Morante",
            "CoordFirstName": "Alexis",
            "CoordEmail": "amorante@med.miami.edu",
            "EnteredByCNbr": "C00679155",
            "EnteredByLastName": "Lam",
            "EnteredByFirstName": "Byron",
            "ActiveEnrollingDate": "02/17/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/17/2011",
            "IRBApprovedFrom": "02/08/2010",
            "IRBApprovedTo": "01/13/2014",
            "AccountNbr": "66694Y / 66695A",
            "InfoEdNbr": "50870 / 53219",
            "Expr1": "Phase IV",
            "Tarea": "Neuro-Ophthalmology",
            "TareaCode": "13137",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Federal Non-NIH",
            "Sponsor": "National Eye Institute",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "12",
            "Totalaccrued": "8",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "12",
            "FirstNinety": "0",
            "SiteSampleSize": "ABLEH:20",
            "AccrualPercentageMet": "40",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "20",
            "EprostState": "Approved",
            "StudyCoordinator": "Alexis Morante,Jennifer Verriotto,Ruth Vandenbroucke,Potyra Rosa",
            "AgentDevices": "Agent: Acetazolamide",
            "StudyObjective": "Purpose:\r\nThis trial will study subjects who have mild visual loss from Idiopathic Intracranial Hypertension (IIH) to (1) establish convincing, evidence-based treatment strategies for IIH to restore and protect vision, (2) follow subjects up to 4 years to observe the long-term treatment outcomes and (3) determine the\r\ncause of IIH. To meet those aims, the trial will be divided into a 12-month\r\nintervention phase and a 3-year observational phase. Subjects are not\r\nrequired to complete the observational phase of the study, but will be\r\nasked to do so and consented for the observational phase of the study at\r\nthe conclusion of the intervention phase (12 months). This study will test the effectiveness (usefulness) of two treatments in patients with mild visual loss. Specifically, it will compare treatment of IIH with a supervised dietary program and acetazolamide to a supervised dietary program and placebo (a tablet with no active ingredient).\r\n\r\n\r\nSpecific Aims::::There are two main objectives:\r\n\r\nThe primary objective is determining the efficacy of a weight reduction\r\nand/or low sodium diet plus acetazolamide vs diet plus placebo in reducing or reversing visual loss. Change in the average perimetric mean deviation (PMD) from baseline to Month 6 is the primary outcome variable.\r\n\r\nThe second objective is to determine the serum and CSF levels of potential mediators of IIH suggested by the genetic analysis. Subjects and control subjects will be genotyped at single nucleotide polymorphisms (SNPs) contained within genes encoding molecules likely to be involved in the etiology of IIH.Determine differences in Vitamin A and other factors related to its metabolism in subjects and controls. Study hormone levels related to obesity and to gender in subjects and controls using the results of the genetic testing.",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT01003639",
            "StudyKeywords": "ORIM: Kanchan Sakhrani (QA: 11/24/10)",
            "StudyInvIND": "1",
            "StudyInvINDNbr": "71,231",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01005576",
            "BriefTitle": "Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia",
            "OfficialTitle": "A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)",
            "LeadSponsorClass": "Washington University School of Medicine",
            "SponsorAgency": "Other",
            "LeadSponsor": "Washington University School of Medicine",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study is being done to determine if blood cell transplants, with either bone marrow or\r\n\r\n      cord blood from unrelated donors, are effective in children with severe thalassemia and if\r\n\r\n      this treatment approach has acceptable risks",
            "OverallStatus": "Unknown status",
            "StartDate": "January 2010",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Washington University School of Medicine",
            "StudyCondition": "Severe Thalassemia",
            "studyLocation": "Regents of University of California- UCLA",
            "Enrollment": "20",
            "NctKeyword": "Thalassemia, Alemtuzumab, Hematopoietic cell transplant, non-myeloablative,",
            "MeshKeyword": "Thalassemia,",
            "InterventionKeyword": "Fludarabine, Fludarabine phosphate, Alemtuzumab, Melphalan,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  1-16.00 years old\r\n\r\n\r\n\r\n          -  Have transfusion dependent thalassemia major\r\n\r\n\r\n\r\n          -  Shall not have an HLA-matched family donor\r\n\r\n\r\n\r\n          -  Must have a suitably matched unrelate",
            "EligibleGender": "All",
            "MinAge": "1 Year",
            "MaxAge": "16 Years",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90095",
            "Country": "United States",
            "VerificationDate": "April 2014",
            "LastChanged": "April 15, 2014",
            "FirstReceived": "October 29, 2009",
            "OverallOfficial": "Shalini Shenoy, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Washington University School of Medicine",
            "LocationName": "Regents of University of California- UCLA",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01005576",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20110280 - PBMTC - Andreansky",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20110280",
            "StudyNumber": "20110280 - PBMTC - Andreansky",
            "StudyTitle": "TCRNNMD 0901 A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)",
            "PIID": "590",
            "PicNum": "C06466265",
            "PILastName": "Andreansky",
            "PIFirstName": "Martin",
            "CoodCNbr": "C10711892",
            "CoordLastName": "D'Antonio",
            "CoordFirstName": "Gabriela",
            "CoordEmail": "Gabriela.Dantonio@jhsmiami.org",
            "CoordPhone": "3058560601",
            "EnteredByCNbr": "C01294252",
            "EnteredByLastName": "Hustace",
            "EnteredByFirstName": "Tally",
            "ActiveEnrollingDate": "09/29/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/29/2011",
            "IRBApprovedFrom": "08/08/2011",
            "IRBApprovedTo": "07/13/2017",
            "InfoEdNbr": "56720",
            "DiseaseSiteListDesc": "Multiple",
            "Expr1": "Pilot/Feasibility",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Transplant",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "Pediatric Blood and Marrow Transplant Consortium.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:8,JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "12.5",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "8",
            "EprostState": "Approved",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01005576",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01013649",
            "SecondaryId": "NCI-2011-01987",
            "BriefTitle": "Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery",
            "OfficialTitle": "A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase II-R/III trial studies gemcitabine hydrochloride with or without\r\n\r\n      erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation\r\n\r\n      therapy and capecitabine or fluorouracil in trea",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To determine whether the addition of erlotinib (erlotinib hydrochloride) to gemcitabine\r\n\r\n      (gemcitabine hydrochloride) adjuvant chemotherapy shows a signal for improved survival as\r\n\r\n      compared to g",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2009",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Pancreatic Acinar Cell Carcinoma",
            "studyLocation": "Providence Hospital",
            "Enrollment": "950",
            "MeshKeyword": "Adenocarcinoma, Pancreatic Neoplasms, Carcinoma, Acinar Cell,",
            "InterventionKeyword": "Gemcitabine, Fluorouracil, Capecitabine, Erlotinib Hydrochloride,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Histologic proof of primary head of pancreas invasive adenocarcinoma managed with a\r\n\r\n             potentially curative resection (i.e., removal of all gross tumor) involving a classic\r\n\r\n             p",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Mobile",
            "State": "Alabama",
            "Zip": "36608",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "November 13, 2009",
            "OverallOfficial": "Ross Abrams",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "NRG Oncology",
            "LocationStatus": "Suspended",
            "LocationName": "Providence Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01013649",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20110584 - RTOG - Portelance",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20110584",
            "StudyNumber": "20110584 - RTOG - Portelance",
            "StudyTitle": "RTOG 0848: A Phase III trial evaluating both Erlotinib and Chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma",
            "PIID": "2807",
            "PicNum": "C09960880",
            "PILastName": "Portelance",
            "PIFirstName": "Lorraine",
            "CoodCNbr": "C00294869",
            "CoordLastName": "Martin",
            "CoordFirstName": "Doris",
            "CoordEmail": "dmartin3@med.miami.edu",
            "CoordPhone": "3052435491",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "12/07/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/07/2011",
            "IRBApprovedFrom": "10/23/2011",
            "IRBApprovedTo": "11/16/2017",
            "InfoEdNbr": "61201",
            "DiseaseSiteListDesc": "Pancreas",
            "Expr1": "Phase III",
            "Tarea": "Pancreatic, Liver, and Related Cancers",
            "TareaCode": "12443",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "RTOG",
            "Prescreened": "1",
            "Screenedfailed": "1",
            "SignedICF": "10",
            "Totalaccrued": "9",
            "InFollowUp": "6",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "11",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,JMH:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Laura Freedman,Pavel Noa Hechavarria,Zaida Abreu,Fernando Vazquez Pascual,Lilibet Zamora Cabezas,Lilly Sanchez,Greeyt Hernandez,Maggie Chislom,Marinellie Vega",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01013649",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01038206",
            "BriefTitle": "Familias Unidas: Preventing Substance Abuse in Hispanic Youth",
            "OfficialTitle": "Familias Unidas Stage III Study: Preventing Substance Abuse in Hispanic Youth",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "The focus of this study will be to test the Familias Unidas Intervention program among\r\n\r\n      Hispanic 8th graders in the Miami-Dade County Public School System. This study will\r\n\r\n      contribute to the advancement of knowledge in both the s",
            "Description": "Substance use (including cigarette and illicit drug use) and HIV represent major public\r\n\r\n      health problems facing America's youth (CDC, 2007; Johnston, O'Malley, Bachman, &\r\n\r\n      Schulenberg, 2007). Hispanic adolescents report higher us",
            "OverallStatus": "Completed",
            "StartDate": "August 2010",
            "CompletionDate": "June 2014",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "University of Miami",
            "StudyCondition": "Prevention",
            "studyLocation": "Center for Family Studies and Miami-Dade County Public Schools",
            "Enrollment": "746",
            "NctKeyword": "prevention, HIV, drugs, smoking, Hispanic, Adolescent, Familias Unidas, Parent-Preadolescent Training, parent-centered, unsafe sexual behavior, efficacy, intervention,",
            "MeshKeyword": "Substance-Related Disorders,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Female and male adolescents of Hispanic immigrant origin, defined by the Primary\r\n\r\n             caregiver as Self-identified Hispanic.\r\n\r\n\r\n\r\n          -  Adolescents attending 8th grade at baseline",
            "EligibleGender": "All",
            "MinAge": "12 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "June 2015",
            "LastChanged": "June 2, 2015",
            "FirstReceived": "December 22, 2009",
            "OverallOfficial": "Guillermo Prado, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "Center for Family Studies and Miami-Dade County Public Schools",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01038206",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20080637 - NIH - Prado",
            "FileProcessContentId": "440",
            "Division": "Epidemiology",
            "StdyDivision": "10636",
            "EprostNbr": "20080637",
            "StudyNumber": "20080637 - NIH - Prado",
            "StudyTitle": "Familias Unidas Stage III Study: Preventing Substance Abuse in Hispanic Youth",
            "PIID": "1241",
            "PicNum": "C00339100",
            "PILastName": "Prado",
            "PIFirstName": "Guillermo (Willy)",
            "CoodCNbr": "C00467960",
            "CoordLastName": "Estrada",
            "CoordFirstName": "Yannine",
            "CoordEmail": "yestrada@med.miami.edu",
            "CoordPhone": "3052436614",
            "EnteredByCNbr": "C00339100",
            "EnteredByLastName": "Prado",
            "EnteredByFirstName": "Guillermo (Willy)",
            "ActiveEnrollingDate": "08/27/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/01/2011",
            "IRBApprovedFrom": "10/23/2008",
            "IRBApprovedTo": "03/09/2015",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Randomized",
            "Expr2": "Behavioral",
            "StudyType_Code": "156",
            "SponsorGroup": "NIH",
            "Prescreened": "2",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "493",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "493",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "494",
            "FirstNinety": "308",
            "SiteSampleSize": "MDCPMS:3000,CIT:N/A,SHE:N/A,JOS:N/A,WES:N/A,SOU:50,RIV:50,CAM:50,PON:50,KEY:50,HOW:50,CFS:N/A,HIA:N/A,MSP:N/A,KIN:50,WRT:50,ROC:50,PAU:50,MIA:50,LAW:50,DEV:50,FIE:50",
            "AccrualPercentageMet": "13.32432432432432432432432432432432432432",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "3700",
            "EprostState": "Approved",
            "StudyCoordinator": "Yannine Estrada,Alexa Rosen",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01038206",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT01047865",
            "BriefTitle": "Type 1 Diabetes Recurrence in Pancreas Transplants",
            "OfficialTitle": "Recurrence of T1D in Pancreas Transplantation",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The hypothesis is that humoral and cellular islet-specific responses are an early risk\r\n\r\n      factor for recurrence of autoimmunity and hyperglycemia in simultaneous pancreas-kidney\r\n\r\n      (SPK) recipients independent of alloimmunity. This s",
            "Description": "To identify the factors associated with recurrence of diabetes in subjects who received a\r\n\r\n      simultaneous pancreas-kidney (SPK) or pancreas transplant. The study will see if there are\r\n\r\n      changes in the participant's blood that will h",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2005",
            "CompletionDate": "May 2017",
            "Phase": "Phase 2",
            "StudyType": "Observational",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Diabetes Mellitus, Type 1",
            "studyLocation": "University of Miami Miller School of Medicine Transplant Clinic",
            "Enrollment": "295",
            "NctKeyword": "Type 1 Diabetes (T1D), Autoimmunity,",
            "MeshKeyword": "Diabetes Mellitus, Recurrence, Diabetes Mellitus, Type 1,",
            "InterventionKeyword": "Pancrelipase, Pancreatin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patient has been fully informed and has signed a dated IRB approval informed consent\r\n\r\n             form and is willing to follow study procedures for the extent of the study (24\r\n\r\n             months)",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 31, 2016",
            "FirstReceived": "January 12, 2010",
            "OverallOfficial": "George Burke, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "George Burke, M.D.",
            "ContactPhone": "305-355-5111",
            "ContactEmail": "gburke@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Miller School of Medicine Transplant Clinic",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01047865",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20053039 - NIDDK - Burke",
            "FileProcessContentId": "440",
            "Division": "Surgery Transplant",
            "StdyDivision": "13543",
            "EprostNbr": "20053039",
            "StudyNumber": "20053039 - NIDDK - Burke",
            "StudyTitle": "EVALUATION OF RECIPIENTS OF SPK OR PANCREAS TRANSPLANT FOR AUTOIMMUNITY",
            "PIID": "1228",
            "PicNum": "C00284385",
            "PILastName": "Burke",
            "PIFirstName": "George",
            "CoodCNbr": "C01323914",
            "CoordLastName": "Hanson",
            "CoordFirstName": "Lois",
            "CoordEmail": "lhanson2@med.miami.edu",
            "CoordPhone": "3053555315",
            "EnteredByCNbr": "C01323914",
            "EnteredByLastName": "Hanson",
            "EnteredByFirstName": "Lois",
            "ActiveEnrollingDate": "05/14/2008",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/14/2008",
            "IRBApprovedFrom": "05/14/2008",
            "IRBApprovedTo": "10/22/2017",
            "InfoEdNbr": "37164",
            "WIrb": "20050510",
            "Expr1": "N/A",
            "Tarea": "Kidney and Pancreas",
            "TareaCode": "13541",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "NATL INST OF DIABETES & DIGESTIVE & KIDNEY DISEASES",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "80",
            "Totalaccrued": "79",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "79",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "80",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:400,UMMG:400",
            "AccrualPercentageMet": "9.875",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "800",
            "EprostState": "Approved",
            "StudyCoordinator": "Lissett Tueros,Isabel Fernandez,Francesco Vendrame",
            "StudyObjective": "PURPOSE\r\n\r\nTo identify the factors associated with recurrence of diabetes in subjects who received a simultaneous pancreas-kidney (SPK) or pancreas transplant.\r\nThe purpose of the study is to look at the serum (blood) for markers that may help to identify recurrence of diabetes and compare this information with that obtained from a biopsy of the pancreas transplant.",
            "NationalSampleSize": "400",
            "NCTNbr": "NCT01047865",
            "StudyKeywords": "ORIM QA: Kanchan Sakhrani (9/9/10)\r\nTherapeutic Area: Kidney and Pancreas Transplantation",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01049919",
            "SecondaryId": "BBIO.CR.CT002",
            "BriefTitle": "Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)",
            "OfficialTitle": "MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia (CLI) in Subjects With Severe Peripheral Arterial Disease (PAD)",
            "LeadSponsorClass": "Biomet Biologics, LLC",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Biomet Biologics, LLC",
            "OversightAuthority": "Yes",
            "BriefSummary": "This trial will evaluate the safety and efficacy of concentrated bone marrow aspirate (cBMA)\r\n\r\n      to prevent or delay major amputation and/or death in subjects with critical limb ischemia\r\n\r\n      (CLI) due to severe peripheral arterial dise",
            "Description": "This is a prospective, randomized, double-blind, placebo controlled, multicenter trial\r\n\r\n      intended for subjects with critical limb ischemia (CLI) that are unsuitable for\r\n\r\n      revascularization. The investigational treatment utilizes au",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "June 2010",
            "CompletionDate": "May 2020",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Zimmer Biomet",
            "StudyCondition": "Critical Limb Ischemia",
            "studyLocation": "Central Arkansas Veterans Healthcare System",
            "Enrollment": "152",
            "NctKeyword": "Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease, CLI, PAD, PVD, Angiogenesis, Stem Cells, Cell Therapy, Limb Salvage, Amputation, Leg Pain,",
            "MeshKeyword": "Ischemia, Vascular Diseases, Peripheral Arterial Disease, Peripheral Vascular Diseases,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Unilateral or bilateral lower extremity ischemia due to advanced peripheral arterial\r\n\r\n             disease\r\n\r\n\r\n\r\n          -  Unsuitable for revascularization\r\n\r\n\r\n\r\n          -  Minor tissue loss (Ru",
            "EligibleGender": "All",
            "MinAge": "21 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Zip": "72205",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "December 14, 2016",
            "FirstReceived": "January 14, 2010",
            "OverallOfficial": "Michael P. Murphy, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Indiana University School of Medicine",
            "LocationName": "Central Arkansas Veterans Healthcare System",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01049919",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20100941 - BIOMET INC - Velazquez",
            "FileProcessContentId": "440",
            "Division": "Surgery",
            "StdyDivision": "7805",
            "EprostNbr": "20100941",
            "StudyNumber": "20100941 - BIOMET INC - Velazquez",
            "StudyTitle": "MarrOwStim PAD Kit for the Treatment of Critical LimB IschemIa (CLI) in Subjects with Severe Peripheral ArteriaL DiseasE (PAD) (MOBILE)",
            "PIID": "685",
            "PicNum": "C06065010",
            "PILastName": "Velazquez",
            "PIFirstName": "Omaida",
            "CoodCNbr": "C00792691",
            "CoordLastName": "Salinas",
            "CoordFirstName": "Kay",
            "CoordEmail": "ksalinas2@med.miami.edu",
            "CoordPhone": "3052431147",
            "EnteredByCNbr": "C00792691",
            "EnteredByLastName": "Salinas",
            "EnteredByFirstName": "Kay",
            "ActiveEnrollingDate": "04/11/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/24/2013",
            "IRBApprovedFrom": "04/11/2011",
            "IRBApprovedTo": "02/14/2017",
            "AccountNbr": "66788X",
            "InfoEdNbr": "52723/64833",
            "Expr1": "Phase III",
            "Tarea": "Vascular and Endovascular Surgery",
            "TareaCode": "16744",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "BIOMET INC",
            "Prescreened": "7",
            "Screenedfailed": "3",
            "SignedICF": "17",
            "Totalaccrued": "11",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "17",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Jean (Lynne) Sparling",
            "NationalSampleSize": "40",
            "NCTNbr": "NCT01049919",
            "StudyKeywords": "MarrowStim, PAD, Treatment,Critical, Limb, Ischemia, CLI, Severe, Peripheral, Arterial, Disease, PAD",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01054573",
            "SecondaryId": "VX-TiDP24-C219",
            "BriefTitle": "VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo",
            "OfficialTitle": "An Open-label, Single-arm, Roll-over Trial of Telaprevir in Combination With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) for Subjects From the Control Group of the VX- 950-TiDP24-C216 Trial Who Failed Therapy for Virologic Reasons",
            "LeadSponsorClass": "Janssen Infectious Diseases BVBA",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Janssen Infectious Diseases BVBA",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to provide access to telaprevir for patients from the control\r\n\r\n      group in the C216 study, who failed treatment for virologic reasons. Efficacy, safety and\r\n\r\n      tolerability of telaprevir in combination with",
            "Description": "This is an open-label (i.e all people involved know the identity of the intervention),\r\n\r\n      single-arm, roll-over trial of telaprevir in combination with pegylated interferon (Peg-IFN)\r\n\r\n      alfa-2a and ribavirin (RBV). The purpose of the",
            "OverallStatus": "Completed",
            "StartDate": "April 2010",
            "CompletionDate": "May 2012",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Janssen Infectious Diseases BVBA",
            "StudyCondition": "Hepatitis C, Chronic",
            "Enrollment": "90",
            "NctKeyword": "Hepatitis C, Chronic, Telaprevir, Roll-over study,",
            "MeshKeyword": "Hepatitis, Hepatitis C, Hepatitis C, Chronic,",
            "InterventionKeyword": "Interferons, Ribavirin, Peginterferon alfa-2a,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patient from the control group of the C216 study who failed therapy for virologic\r\n\r\n             reasons\r\n\r\n\r\n\r\n          -  Patient must have completed all assessments in the C216 trial",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "70 Years",
            "Volunteers": "No",
            "City": "Coronado",
            "State": "California",
            "Country": "United States",
            "VerificationDate": "May 2013",
            "LastChanged": "May 6, 2013",
            "FirstReceived": "January 21, 2010",
            "OverallOfficial": "Janssen Infectious Diseases BVBA Clinical Trial",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Janssen Infectious Diseases BVBA",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01054573",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20100218 - Tibotec - Schiff",
            "FileProcessContentId": "440",
            "Division": "Hepatology",
            "StdyDivision": "10246",
            "EprostNbr": "20100218",
            "StudyNumber": "20100218 - Tibotec - Schiff",
            "StudyTitle": "VX-950-TiDP24-C219\nAn open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) for subjects from the control group of the VX-950-TiDP24-C216 trial who failed therapy for virologic reasons",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C00272649",
            "CoordLastName": "Vega",
            "CoordFirstName": "Marinellie",
            "CoordEmail": "mvega@med.miami.edu",
            "CoordPhone": "3052436809",
            "EnteredByCNbr": "C00758491",
            "EnteredByLastName": "Schiff",
            "EnteredByFirstName": "Eugene",
            "ActiveEnrollingDate": "05/20/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/20/2010",
            "IRBApprovedFrom": "04/26/2010",
            "IRBApprovedTo": "03/12/2014",
            "InfoEdNbr": "52501, 56553",
            "Expr1": "Phase III",
            "Tarea": "Hepatitis C",
            "TareaCode": "12636",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Tibotec BVBA",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "1",
            "SiteSampleSize": "UMH:3,UMMG:3",
            "AccrualPercentageMet": "33.33333333333333333333333333333333333333",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "6",
            "EprostState": "Approved",
            "StudyCoordinator": "Lia Quezada,Sonia Carvalho,Odalys Rodriguez-Bravo",
            "AgentDevices": "Agents: Pegasys; Telaprevir; Copegus",
            "StudyObjective": "The purpose of the trial is to provide access to telaprevir for subjects who were randomized to the control group in the VX-950-TiDP24-C216 trial (referred to as C216 trial hereafter) and who failed therapy for virologic reasons. The efficacy, safety, and tolerability of telaprevir in combination with Peg-IFN alfa-2a and RBV will be evaluated. In addition, amino acid changes from baseline in the HCV NS3 protease domain will be evaluated.\r\n\r\nThe objectives are:\r\n- to provide access to telaprevir for subjects with chronic HCV genotype 1 infection who were randomized to the control group in the C216 trial and who failed therapy for virologic reasons;\r\n- to evaluate efficacy, safety, and tolerability of telaprevir in combination with Peg-IFN alfa-2a and RBV in these subjects;\r\n- to evaluate amino acid changes from baseline in the HCV NS3 protease domain.",
            "NationalSampleSize": "120",
            "NCTNbr": "NCT01054573",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT01061164",
            "SecondaryId": "U01AI068632",
            "BriefTitle": "IMPAACT P1074: Long-Term Outcomes in HIV-Infected Infants, Children, and Adolescents",
            "OfficialTitle": "A Prospective Surveillance Study of Long-Term Outcomes in HIV-Infected Infants, Children and Adolescents",
            "LeadSponsorClass": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will examine the long-term effects of HIV infection, highly active antiretroviral\r\n\r\n      therapy (HAART), and experimental treatments on children who participated in PACTG 219C or\r\n\r\n      select IMPAACT studies.",
            "Description": "The use of HAART has been important in extending the lives of people with HIV infection.\r\n\r\n      However, prolonged use of HAART may have long-term consequences. In addition, people\r\n\r\n      participating in clinical trials using experimental t",
            "OverallStatus": "Completed",
            "StartDate": "March 2009",
            "CompletionDate": "June 2014",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
            "StudyCondition": "HIV Infections",
            "studyLocation": "Univ. of Alabama Birmingham NICHD CRS (5096)",
            "Enrollment": "1207",
            "MeshKeyword": "HIV Infections,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Past or current documentation of a confirmed diagnosis of HIV-1 infection defined as\r\n\r\n             two separate peripheral blood specimens from different days, and each specimen must\r\n\r\n             be",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "October 2014",
            "LastChanged": "March 23, 2015",
            "FirstReceived": "February 1, 2010",
            "OverallOfficial": "Myron J. Levin, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "University of Colorado at Denver Health Sciences Center",
            "LocationName": "Univ. of Alabama Birmingham NICHD CRS (5096)",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01061164",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20090188 - NIAID - Scott",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20090188",
            "StudyNumber": "20090188 - NIAID - Scott",
            "StudyTitle": "P1074: A PROSPECTIVE SURVEILLANCE STUDY OF LONGTERM OUTCOMES IN HIVINFECTED INFANTS, CHILDREN AND ADOLESCENTS",
            "PIID": "1243",
            "PicNum": "C00795461",
            "PILastName": "Scott",
            "PIFirstName": "Gwendolyn",
            "CoodCNbr": "C00482361",
            "CoordLastName": "Falk",
            "CoordFirstName": "Alan",
            "EnteredByCNbr": "C00057173",
            "EnteredByLastName": "Bryan",
            "EnteredByFirstName": "Patricia",
            "ActiveEnrollingDate": "09/16/2009",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/16/2009",
            "IRBApprovedFrom": "05/18/2009",
            "IRBApprovedTo": "01/22/2014",
            "InfoEdNbr": "54944",
            "Expr1": "N/A",
            "Tarea": "Immunology/Infectious Disease",
            "TareaCode": "13340",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Chart Review",
            "StudyType_Code": "6164",
            "ResearchType": "Other",
            "SponsorGroup": "NIH",
            "Sponsor": "NIH/NIAID",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "42",
            "Totalaccrued": "42",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "42",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:120",
            "AccrualPercentageMet": "35",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "120",
            "EprostState": "Approved",
            "StudyObjective": "PRIMARY OBJECTIVE:\r\n1. To identify possible long-term adverse outcomes of HIV infection and complications of antiretroviral therapy (ART) or experimental interventions other than ARTs in HIV-infected infants, children and adolescents at IMPAACT sites in the United States.\r\n\r\nSECONDARY OBJECTIVES:\r\n\r\n1. To utilize this prospective surveillance study together with compatible cohorts to detect signals of complications of HIV infection and/or of current and future ARTs or other experimental interventions in HIV-infected infants, children and adolescents.\r\n\r\n2. To utilize this prospective surveillance study (separately or together with compatible cohorts) as a basis and/or population source for additional focused substudies to further investigate the incidence and prevalence of adverse outcomes related to HIV infection and complications of ART or other experimental interventions in HIV-infected infants, children and adolescents.",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01061164",
            "StudyKeywords": "ORIM QA: Kanchan Sakhrani (11/1/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT01085656",
            "BriefTitle": "A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS",
            "OfficialTitle": "A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)",
            "LeadSponsorClass": "University of Florida",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Florida",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503\r\n\r\n      (combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML\r\n\r\n      and MDS.",
            "Description": "Despite initial disease remissions with cytotoxic chemotherapies, patients with AML and MDS\r\n\r\n      often relapse and die of their disease. Novel strategies for targeting dependent pathways\r\n\r\n      are needed. AML and MDS depend on blood vesse",
            "OverallStatus": "Terminated",
            "StartDate": "February 2011",
            "CompletionDate": "January 2016",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Florida",
            "StudyCondition": "Leukemia, Myelogenous, Acute",
            "studyLocation": "UF Health Shands Cancer Hopsital",
            "Enrollment": "18",
            "MeshKeyword": "Leukemia, Syndrome, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute,",
            "InterventionKeyword": "Combretastatin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must be at least 18 years of age;\r\n\r\n\r\n\r\n          -  Patients must have either:\r\n\r\n\r\n\r\n               -  AML (de novo or secondary, and any WHO 2008 classification excluding acute",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Gainesville",
            "State": "Florida",
            "Zip": "32608",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 10, 2016",
            "FirstReceived": "March 11, 2010",
            "OverallOfficial": "Christopher R. Cogle, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Florida",
            "LocationName": "UF Health Shands Cancer Hopsital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01085656",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20150655 - Oxigene Inc - Watts",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150655",
            "StudyNumber": "20150655 - Oxigene Inc - Watts",
            "StudyTitle": "A Phase 1b Dose Escalation of OXi4503 as a Single Agent in Combination with Cytarabine with Subsequent Combination Phase 2 Cohorts for Subjects with Relapsed/Refractory Acute Myelogenous leukemia (AML) and Myelodysplastic Syndromes (MDS)",
            "PIID": "22711",
            "PicNum": "C11915545",
            "PILastName": "Watts",
            "PIFirstName": "Justin",
            "CoodCNbr": "C11954409",
            "CoordLastName": "Ogden",
            "CoordFirstName": "Jillian",
            "CoordEmail": "jbo25@miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "10/12/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/12/2015",
            "IRBApprovedFrom": "09/21/2015",
            "IRBApprovedTo": "08/28/2017",
            "AccountNbr": "665792",
            "DiseaseSiteListDesc": "Myeloid and Monocytic Leukemia,Other Hematopoietic",
            "Expr1": "Phase I",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Oxigene, Inc",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "9",
            "Totalaccrued": "8",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "9",
            "FirstNinety": "3",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yvonne Dinh,Randy Astaiza,Tamara Leon Aliz",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01085656",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01092767",
            "BriefTitle": "Study to Determine if the Valiant Stent Graft is Safe and Effective in Treating Patients Who Have a Blunt Thoracic Aortic Injury",
            "OfficialTitle": "Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System for the Endovascular Treatment of Blunt Thoracic Aortic Injuries (RESCUE)",
            "LeadSponsorClass": "Medtronic Endovascular",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Medtronic Endovascular",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine if the Valiant stent graft is safe and effective\r\n\r\n      in treating patients who have a blunt thoracic aortic injury (BTAI). BTAI is when the aorta\r\n\r\n      has been injured due to traumatic force to t",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "April 2010",
            "CompletionDate": "May 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Medtronic Endovascular",
            "StudyCondition": "Blunt Thoracic Aortic Injury",
            "studyLocation": "University of Alabama",
            "Enrollment": "50",
            "NctKeyword": "Thoracic Aneurysm, Thoracic Transection, Endovascular Aortic Repair,",
            "MeshKeyword": "Wounds and Injuries,",
            "Eligibility": "Inclusion Criteria\r\n\r\n\r\n\r\n          -  Subject had a blunt thoracic aortic injury which:\r\n\r\n\r\n\r\n          -  was confirmed, at a minimum, by diagnostic contrast-enhanced computerized tomography\r\n\r\n             angiogram (CTA) and/or contrast-e",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 5, 2017",
            "FirstReceived": "March 16, 2010",
            "OverallOfficial": "Rodney White, M.D., F.A.C.S.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Harbor UCLA",
            "LocationName": "University of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01092767",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20100375 - Medtronic - Velazquez",
            "FileProcessContentId": "440",
            "Division": "Surgery",
            "StdyDivision": "7805",
            "EprostNbr": "20100375",
            "StudyNumber": "20100375 - Medtronic - Velazquez",
            "StudyTitle": "Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft with the Captivia Delivery System for the Endovascular Treatment of Blunt Thoracic Aortic Injuries (RESCUE)",
            "PIID": "685",
            "PicNum": "C06065010",
            "PILastName": "Velazquez",
            "PIFirstName": "Omaida",
            "CoodCNbr": "C00792691",
            "CoordLastName": "Salinas",
            "CoordFirstName": "Kay",
            "CoordEmail": "ksalinas2@med.miami.edu",
            "CoordPhone": "3052431147",
            "EnteredByCNbr": "C00245987",
            "EnteredByLastName": "Sparling",
            "EnteredByFirstName": "Jean (Lynne)",
            "ActiveEnrollingDate": "09/07/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/24/2011",
            "IRBApprovedFrom": "09/07/2010",
            "IRBApprovedTo": "04/09/2017",
            "InfoEdNbr": "40460",
            "Expr1": "N/A",
            "Tarea": "Vascular and Endovascular Surgery",
            "TareaCode": "16744",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "Medtronic Vascular, Inc.",
            "Prescreened": "4",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "3",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:2,UMH:N/A,UMHC:N/A",
            "AccrualPercentageMet": "200",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "2",
            "EprostState": "Approved",
            "AgentDevices": "Device: Valiant Thoracic Stent Graft with the Captiva Delivery System",
            "StudyObjective": "The purpose of this clinical study is to evaluate the safety and effectiveness of the Valiant Captivia in the treatment of BTAI in the DTA.\r\n\r\nThe primary objective is to evaluate the safety and effectiveness of Valiant Captivia in the treatment of BTAI as determined by all cause mortality within 30 days of the index procedure.\r\nThe secondary objectives are to evaluate the acute and long term safety and effectiveness by reporting the following:\r\nAcute (to 30 days):\r\n Successful delivery and deployment of the stent graft\r\n Device, procedure and/or aortic related adverse events\r\n Aortic related mortality (defined as: death caused by the underlying thoracic aortic injury and/or from any procedure intended to treat the aortic injury)\r\nThe following will be reported at 6, 12, 24, 36, 48 and 60 months:\r\n Secondary procedures\r\n Device, procedure and/or aortic related serious adverse events\r\n All cause mortality",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01092767",
            "StudyKeywords": "Valiant, Thoracic, Stent, Graft,Captivia, Delivery,Endovascular, Treatment,Blunt, Thoracic Aortic Injuries, RESCUE",
            "StudyInvIND": "1",
            "StudyInvINDNbr": "G090201",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01096368",
            "SecondaryId": "NCI-2011-02029",
            "BriefTitle": "Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma",
            "OfficialTitle": "Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years",
            "LeadSponsorClass": "Children's Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Oncology Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase III trial is studying maintenance chemotherapy to see how well it\r\n\r\n      works compared to observation following induction chemotherapy and radiation therapy in\r\n\r\n      treating young patients with newly diagnosed ependy",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To determine the event-free survival (EFS) and overall survival (OS) of children with\r\n\r\n      completely resected ependymoma treated with maintenance chemotherapy comprising vincristine\r\n\r\n      sulfate, cisp",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2010",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Children's Oncology Group",
            "StudyCondition": "Childhood Infratentorial Ependymoma",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "400",
            "MeshKeyword": "Ependymoma,",
            "InterventionKeyword": "Etoposide phosphate, Cisplatin, Etoposide, Cyclophosphamide, Carboplatin, Vincristine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Histologically confirmed intracranial ependymoma meeting the following criteria:\r\n\r\n\r\n\r\n               -  Newly diagnosed disease\r\n\r\n\r\n\r\n               -  Classic ependymoma (WHO II) or anaplastic ependy",
            "EligibleGender": "All",
            "MinAge": "1 Year",
            "MaxAge": "21 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 30, 2016",
            "FirstReceived": "March 30, 2010",
            "OverallOfficial": "Amy A. Smith, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "ContactName": "Amy A. Smith, MD",
            "ContactPhone": "321-841-8560",
            "ContactEmail": "amy.smith@orlandohealth.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01096368",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20100658 - COG - Barredo",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20100658",
            "StudyNumber": "20100658 - COG - Barredo",
            "StudyTitle": "ACNS0831 Phase III Randomized Trial of PostRadiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years.",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C11973083",
            "CoordLastName": "Best",
            "CoordFirstName": "Wendy",
            "CoordEmail": "wtbest@med.miami.edu",
            "CoordPhone": "305-243-7130",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "02/08/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/08/2011",
            "IRBApprovedFrom": "02/08/2011",
            "IRBApprovedTo": "07/13/2017",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "Phase III",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Blinding": "None",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "COG",
            "SiteSampleSize": "UMHC:10,JMH:10",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "20",
            "EprostState": "External IRB",
            "StudyCoordinator": "Myriam Zayas,Nuria Garantiva",
            "AgentDevices": "Agent: cysplatin, Cyclophosphamide, Mesna, Filgrastim, Carboplatin, Etoposide, Vincristine",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01096368",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01117168",
            "SecondaryId": "10-C-0111",
            "BriefTitle": "Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group",
            "OfficialTitle": "Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN) Children s Oncology Group",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "BriefSummary": "Background:\r\n\r\n\r\n\r\n      - The Children s Oncology Group has established a research network, the Childhood Cancer\r\n\r\n      Research Network (CCRN), to collect information about children with cancer and other\r\n\r\n      conditions that are benign b",
            "Description": "Background:\r\n\r\n\r\n\r\n        -  Institutional membership in the Children s Oncology Group (COG) requires registration\r\n\r\n           of all pediatric cancer patients seen at their site. This registration process includes\r\n\r\n           all patients.",
            "OverallStatus": "Recruiting",
            "StartDate": "April 30, 2010",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "National Institutes of Health Clinical Center (CC)",
            "StudyCondition": "Pediatric Cancer",
            "studyLocation": "National Institutes of Health Clinical Center, 9000 Rockville Pike",
            "Enrollment": "80",
            "NctKeyword": "Children's Oncology Group, Pediatric Oncology, Pediatric Cancer, Registration, Leukemia, Brain Tumor, Sarcoma,",
            "MeshKeyword": "Sarcoma, Brain Neoplasms, Neoplasms,",
            "Eligibility": "-  INCLUSION CRITERIA:\r\n\r\n\r\n\r\n          -  Pre-CCRN Entry\r\n\r\n\r\n\r\n          -  All new patients seen in COG member institutions with any of the following diagnoses\r\n\r\n             are eligible:\r\n\r\n\r\n\r\n               -  All cancer cases with an",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "18 Years",
            "Volunteers": "No",
            "City": "Bethesda",
            "State": "Maryland",
            "Zip": "20892",
            "Country": "United States",
            "VerificationDate": "September 26, 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "May 4, 2010",
            "OverallOfficial": "Brigitte C Widemann, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "National Cancer Institute (NCI)",
            "ContactName": "Sharon Mavroukakis, R.N.",
            "ContactPhone": "(301) 496-4164",
            "ContactEmail": "mavroukakis@nih.gov",
            "LocationStatus": "Recruiting",
            "LocationName": "National Institutes of Health Clinical Center, 9000 Rockville Pike",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01117168",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20080165 - COG - BARREDO",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20080165",
            "StudyNumber": "20080165 - COG - BARREDO",
            "StudyTitle": "ACCRN07, Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network(CCRN)",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C00722004",
            "CoordLastName": "Garantiva",
            "CoordFirstName": "Nuria",
            "CoordEmail": "nfc19@miami.edu",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "09/20/2007",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/20/2007",
            "IRBApprovedFrom": "05/16/2008",
            "IRBApprovedTo": "05/02/2017",
            "DiseaseSiteListDesc": "Multiple",
            "Expr1": "N/A",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Randomization": "Non - Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Other",
            "SponsorGroup": "Foundation",
            "Sponsor": "Children Oncology Group",
            "Prescreened": "0",
            "Screenedfailed": "10",
            "SignedICF": "112",
            "Totalaccrued": "102",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "112",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "CancerCenterNbr": "2008018",
            "StudyCoordinator": "Myriam Zayas,Wendy Best",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01117168",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01142427",
            "SecondaryId": "NCI-2011-02235",
            "BriefTitle": "Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",
            "OfficialTitle": "Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)",
            "LeadSponsorClass": "Children's Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Oncology Group",
            "OversightAuthority": "No",
            "BriefSummary": "This research trial studies a risk-based classification system for patients with newly\r\n\r\n      diagnosed acute lymphoblastic leukemia. Gathering health information about patients with\r\n\r\n      acute lymphoblastic leukemia may help doctors learn",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To provide a risk classification scheme for all patients with newly diagnosed acute\r\n\r\n      lymphoblastic leukemia (ALL), which will be used to assign treatment on Children's Oncology\r\n\r\n      Group (COG) fro",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2010",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Children's Oncology Group",
            "StudyCondition": "Adult B Acute Lymphoblastic Leukemia",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "14250",
            "MeshKeyword": "Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patient has newly diagnosed acute leukemia:\r\n\r\n\r\n\r\n               -  > 25% blasts on a bone marrow (BM) aspirate or\r\n\r\n\r\n\r\n               -  If a BM aspirate is not obtained or is not diagnostic of acute",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "30 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 24, 2016",
            "FirstReceived": "June 10, 2010",
            "OverallOfficial": "Karen Rabin",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01142427",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20110036 - COG - Barredo",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20110036",
            "StudyNumber": "20110036 - COG - Barredo",
            "StudyTitle": "AALL08B1 Classification of Newly Diagnosed Acute Lymphoblastic Leukemia",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C00722004",
            "CoordLastName": "Garantiva",
            "CoordFirstName": "Nuria",
            "CoordEmail": "nfc19@miami.edu",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "02/10/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/10/2011",
            "IRBApprovedFrom": "01/13/2011",
            "IRBApprovedTo": "06/08/2017",
            "DiseaseSiteListDesc": "Lymphoid Leukemia",
            "Expr1": "N/A",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "COG",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "10",
            "Totalaccrued": "10",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "10",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Myriam Zayas,Wendy Best",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01142427",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01166009",
            "BriefTitle": "Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries",
            "OfficialTitle": "Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries",
            "LeadSponsorClass": "Center for International Blood and Marrow Transplant Research",
            "SponsorAgency": "Other",
            "LeadSponsor": "Center for International Blood and Marrow Transplant Research",
            "OversightAuthority": "No",
            "BriefSummary": "The primary purpose of the Research Database is to have a comprehensive source of\r\n\r\n      observational data that can be used to study HSC transplantation.\r\n\r\n\r\n\r\n      A secondary purpose of the Research Database is to have a comprehensive sou",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2002",
            "CompletionDate": "July 2020",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Center for International Blood and Marrow Transplant Research",
            "StudyCondition": "Autologous Stem Cell Transplantation",
            "studyLocation": "Center for International Blood and Marrow Transplant Research",
            "Enrollment": "99999999",
            "NctKeyword": "Data Collection, CIBMTR, NMDP, Stem Cell Transplantation,",
            "MeshKeyword": "Hematologic Neoplasms,",
            "Eligibility": "Eligibility to Participate in the Research Database\r\n\r\n\r\n\r\n        Recipient Eligibility Criteria:\r\n\r\n\r\n\r\n          -  Any recipient of an unrelated or related donor or autologous HSC transplant in a\r\n\r\n             CIBMTR center is eligible t",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Minneapolis",
            "State": "Minnesota",
            "Zip": "55413",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 24, 2016",
            "FirstReceived": "July 16, 2010",
            "OverallOfficial": "Douglas Rizzo, M.D.,M.S",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Center for International Blood and Marrow Transplant Research",
            "ContactName": "Marie Matlack",
            "ContactPhone": "612-627-5811",
            "ContactEmail": "mmatlack@nmdp.org",
            "LocationStatus": "Recruiting",
            "LocationName": "Center for International Blood and Marrow Transplant Research",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01166009",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20057012 - NMDP - Andreansky",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20057012",
            "StudyNumber": "20057012 - NMDP - Andreansky",
            "StudyTitle": "Transplant Registry Reporting",
            "PIID": "590",
            "PicNum": "C06466265",
            "PILastName": "Andreansky",
            "PIFirstName": "Martin",
            "CoodCNbr": "C06466265",
            "CoordLastName": "Andreansky",
            "CoordFirstName": "Martin",
            "CoordEmail": "m.andreansky@miami.edu",
            "CoordPhone": "3055855635",
            "EnteredByCNbr": "C06466265",
            "EnteredByLastName": "Andreansky",
            "EnteredByFirstName": "Martin",
            "ActiveEnrollingDate": "07/12/2005",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/20/2012",
            "IRBApprovedFrom": "10/15/2007",
            "IRBApprovedTo": "12/14/2017",
            "AccountNbr": "66425L",
            "InfoEdNbr": "31423 / 31652",
            "WIrb": "20051149",
            "DiseaseSiteListDesc": "Multiple",
            "Expr1": "N/A",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Randomization": "Non - Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "Sponsor": "National Bone Marrow Program",
            "Prescreened": "4",
            "Screenedfailed": "0",
            "SignedICF": "655",
            "Totalaccrued": "604",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "514",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "667",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:600,UMMG:N/A,JMH:N/A",
            "AccrualPercentageMet": "100.666666666666666666666666666666666667",
            "ActiveCal": "3",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "600",
            "EprostState": "Approved",
            "CancerCenterNbr": "2007068",
            "StudyCoordinator": "Patricia Gomez,Yamilet Delgado Vigoa,Gabriela D'Antonio,Idena Harrell",
            "StudyObjective": "To collect information on the reason patients have transplants, how the transplants are done, and how the patients do after transplant. \r\n\r\nThe purpose of this research is to collect information on stem cell transplantation patients. This includes patients receiving stem cells from bone marrow, peripheral blood, and cord blood. The Bone Marrow Program at the University of Miami collects information about transplants that we perform. This information will be shared with the Center for International blood and Marrow transplant research(CIBMTR) and the Pediatric Bone and Bone Marrow Transplant Consortium. Additionally, if donors are found through the National Marrow Donor Program, we would also like to share information with them. We share information because the registries enable doctors and other researchers to learn more about transplantation and outcomes.\r\n\r\nNational Marrow Donor Program (NMDP) collects blood samples on donors and their recipients. Specimens taken before the transplant and 100 days after the transplant can be used by researches to study the transplant and its outcome.",
            "NationalSampleSize": "2000",
            "NCTNbr": "NCT01166009",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01179048",
            "SecondaryId": "2009-012201-19",
            "BriefTitle": "Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results",
            "OfficialTitle": "A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events",
            "LeadSponsorClass": "Novo Nordisk A/S",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novo Nordisk A/S",
            "OversightAuthority": "Yes",
            "BriefSummary": "This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of\r\n\r\n      this trial is to determine the long term effect of liraglutide on cardiovascular events in\r\n\r\n      subjects with type 2 diabetes.",
            "OverallStatus": "Completed",
            "StartDate": "August 2010",
            "CompletionDate": "December 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Novo Nordisk A/S",
            "StudyCondition": "Diabetes",
            "studyLocation": "Novo Nordisk Investigational Site",
            "Enrollment": "9340",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 2,",
            "InterventionKeyword": "Liraglutide,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Type 2 diabetes\r\n\r\n\r\n\r\n          -  Age min. 50 years at screening and concomitant cardiovascular, cerebrovascular or\r\n\r\n             peripheral vascular disease or chronic renal failure or chronic heart",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Alabaster",
            "State": "Alabama",
            "Zip": "35007",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 15, 2016",
            "FirstReceived": "August 6, 2010",
            "OverallOfficial": "Global Clinical Registry (GCR, 1452)",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Novo Nordisk A/S",
            "LocationName": "Novo Nordisk Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01179048",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20100596 - Novo Nordisk - Miranda-Palma",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20100596",
            "StudyNumber": "20100596 - Novo Nordisk - Miranda-Palma",
            "StudyTitle": "LEADER Liraglutide Effect and Action in Diabetes:Evaluation of cardiovascular outcome Results A Longterm, Multicentre, International, Randomised Double blind, Placebo controlled Trial to Determine Liraglutide Effects on Cardiovascular Events Trial ID: EX2211-3748",
            "PIID": "1111",
            "PicNum": "C02129536",
            "PILastName": "Miranda-Palma",
            "PIFirstName": "Bresta",
            "CoodCNbr": "C00121533",
            "CoordLastName": "Masters",
            "CoordFirstName": "Burlett",
            "CoordEmail": "bmasters2@med.miami.edu",
            "CoordPhone": "305-243-5354",
            "EnteredByCNbr": "C02129536",
            "EnteredByLastName": "Miranda-Palma",
            "EnteredByFirstName": "Bresta",
            "ActiveEnrollingDate": "12/03/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/03/2010",
            "IRBApprovedFrom": "10/11/2010",
            "IRBApprovedTo": "07/26/2016",
            "AccountNbr": "66754T",
            "InfoEdNbr": "54068",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Novo Nordisk",
            "Prescreened": "0",
            "Screenedfailed": "6",
            "SignedICF": "24",
            "Totalaccrued": "18",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "24",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:150",
            "AccrualPercentageMet": "12",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "150",
            "EprostState": "Approved",
            "StudyCoordinator": "Burlett Masters,Luz Arazo,Ada Konwai",
            "AgentDevices": "Agent: Victoza",
            "StudyObjective": "The primary purpose of this trial is to determine the long-term effect of liraglutide on cardiovascular outcomes and other clinically important events.",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT01179048",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01190189",
            "BriefTitle": "Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study",
            "OfficialTitle": "Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study",
            "LeadSponsorClass": "GlaxoSmithKline",
            "SponsorAgency": "Industry",
            "LeadSponsor": "GlaxoSmithKline",
            "BriefSummary": "This extension study is designed to assess the safety of GSK Biological's human\r\n\r\n      papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study\r\n\r\n      NCT00294047 and received the control vaccine in countr",
            "Description": "This Protocol Posting has been updated following Protocol Amendment 1, December 2010,\r\n\r\n      leading to the update of 1 of the primary outcome measures and following Protocol Amendment\r\n\r\n      2, January 2011, leading to the removal of one of",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "April 2011",
            "CompletionDate": "November 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "GlaxoSmithKline",
            "StudyCondition": "Infections, Papillomavirus",
            "studyLocation": "GSK Investigational Site",
            "Enrollment": "600",
            "NctKeyword": "Serious adverse events (SAEs), HPV vaccine, Medically significant conditions, Cervical neoplasia,",
            "InterventionKeyword": "Vaccines,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subjects who the investigator believes can and will comply with the requirements of\r\n\r\n             the protocol\r\n\r\n\r\n\r\n          -  A subject previously enrolled in study NCT00294047, who received the c",
            "EligibleGender": "Female",
            "MinAge": "26 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Aurora",
            "State": "Colorado",
            "Zip": "80045",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 16, 2017",
            "FirstReceived": "August 26, 2010",
            "OverallOfficial": "GSK Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "GlaxoSmithKline",
            "LocationName": "GSK Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01190189",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20150861 - GlaxoSmithKline - Maguire",
            "FileProcessContentId": "440",
            "Division": "Obstetrics and  Gynecology",
            "StdyDivision": "10251",
            "EprostNbr": "20150861",
            "StudyNumber": "20150861 - GlaxoSmithKline - Maguire",
            "StudyTitle": "A phase IIIb, open-label, multi-centre immunization study to evaluate the safety of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine\nadministered intramuscularly according to a 0, 1, 6-month schedule in healthy female subjects who received the placebo control in the GSK HPV-015 study",
            "PIID": "4102",
            "PicNum": "C10569413",
            "PILastName": "Maguire",
            "PIFirstName": "Karla",
            "CoodCNbr": "C08168652",
            "CoordLastName": "Jaramillo",
            "CoordFirstName": "Sindy",
            "CoordEmail": "sjaramillo@med.miami.edu",
            "CoordPhone": "305-243-2150",
            "EnteredByCNbr": "C10569413",
            "EnteredByLastName": "Maguire",
            "EnteredByFirstName": "Karla",
            "ActiveEnrollingDate": "04/21/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/21/2016",
            "IRBApprovedFrom": "12/15/2015",
            "IRBApprovedTo": "12/14/2016",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "GlaxoSmithKline",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "3",
            "Totalpatients": "3",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Sindy Jaramillo",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT01190189",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01190930",
            "SecondaryId": "NCI-2011-02599",
            "BriefTitle": "Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma",
            "OfficialTitle": "Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)",
            "LeadSponsorClass": "Children's Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Oncology Group",
            "BriefSummary": "This partially randomized phase III trial studies different combinations of risk-adapted\r\n\r\n      chemotherapy regimens and their side effects and comparing how well they work in treating\r\n\r\n      younger patients with newly diagnosed standard-r",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      l. To determine if a maintenance regimen containing weekly oral methotrexate at 40\r\n\r\n      mg/m^2/week will result in an improved disease free survival (DFS) compared to that\r\n\r\n      containing weekly oral meth",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2010",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Children's Oncology Group",
            "StudyCondition": "Adult B Lymphoblastic Lymphoma",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "9022",
            "MeshKeyword": "Lymphoma, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Down Syndrome,",
            "InterventionKeyword": "Dexamethasone acetate, Dexamethasone, Dexamethasone 21-phosphate, Liposomal doxorubicin, Pegaspargase, Doxorubicin, Cytarabine, Cyclophosphamide, Methotrexate, Vincristine, Asparaginase, 6-Mercaptopurine, Thioguanine, BB 1101, 2-Aminopurine, Calcium, Diet",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  B-ALL patients must be enrolled on AALL08B1 prior to treatment and enrollment on\r\n\r\n             AALL0932\r\n\r\n\r\n\r\n               -  Note: B-LLy patients are not eligible for AALL08B1, and can enroll direc",
            "EligibleGender": "All",
            "MinAge": "1 Year",
            "MaxAge": "30 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 23, 2016",
            "FirstReceived": "August 27, 2010",
            "OverallOfficial": "Anne Angiolillo",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "ContactName": "Peter Adamson",
            "ContactPhone": "612-624-8651",
            "ContactEmail": "Adamson@email.chop.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01190930",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20110038 - COG - Barredo",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20110038",
            "StudyNumber": "20110038 - COG - Barredo",
            "StudyTitle": "AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk BPrecursor Acute Lymphoblastic Leukemia (ALL)",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C00722004",
            "CoordLastName": "Garantiva",
            "CoordFirstName": "Nuria",
            "CoordEmail": "nfc19@miami.edu",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "07/27/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/27/2010",
            "IRBApprovedFrom": "07/27/2010",
            "IRBApprovedTo": "08/10/2017",
            "DiseaseSiteListDesc": "Lymphoid Leukemia",
            "Expr1": "Phase III",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "5",
            "Totalaccrued": "4",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:30,JMH:30",
            "AccrualPercentageMet": "6.66666666666666666666666666666666666667",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "60",
            "EprostState": "External IRB",
            "StudyCoordinator": "Myriam Zayas,Wendy Best",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01190930",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01194570",
            "SecondaryId": "2010-020338-25",
            "BriefTitle": "A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis",
            "OfficialTitle": "A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis",
            "LeadSponsorClass": "Hoffmann-La Roche",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Hoffmann-La Roche",
            "BriefSummary": "This randomized, parallel group, double-blind, placebo controlled study will evaluate the\r\n\r\n      efficacy and safety of ocrelizumab in participants with primary progressive multiple\r\n\r\n      sclerosis. Eligible participants will be randomized",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "March 2011",
            "CompletionDate": "April 2021",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Hoffmann-La Roche",
            "StudyCondition": "Multiple Sclerosis, Primary Progressive",
            "Enrollment": "732",
            "MeshKeyword": "Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of primary progressive multiple sclerosis (according to revised McDonald\r\n\r\n             criteria)\r\n\r\n\r\n\r\n          -  EDSS at screening from 3 to 6.5 points\r\n\r\n\r\n\r\n          -  Disease duratio",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "55 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85006",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 6, 2017",
            "FirstReceived": "August 28, 2010",
            "OverallOfficial": "Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Hoffmann-La Roche",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01194570",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20110319 - GENENTECH INC - Sheremata",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20110319",
            "StudyNumber": "20110319 - GENENTECH INC - Sheremata",
            "StudyTitle": "ORATORIO Study: Phase III, multicentre, randomized, parallelgroup, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis.",
            "PIID": "121",
            "PicNum": "C00457629",
            "PILastName": "Sheremata",
            "PIFirstName": "William",
            "CoodCNbr": "C02523614",
            "CoordLastName": "Babcock",
            "CoordFirstName": "Yanet",
            "CoordEmail": "YBabcock@med.miami.edu",
            "CoordPhone": "3052431088",
            "EnteredByCNbr": "C06062326",
            "EnteredByLastName": "Rodriguez (Neurology)",
            "EnteredByFirstName": "Gloria",
            "ActiveEnrollingDate": "01/05/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/05/2012",
            "IRBApprovedFrom": "08/15/2011",
            "IRBApprovedTo": "06/19/2017",
            "AccountNbr": "66883K",
            "InfoEdNbr": "57550",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Gloria Rodriguez (Neurology),Ruta Sawant,Yanet Babcock",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01194570",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01202864",
            "SecondaryId": "R01NS069763-01",
            "BriefTitle": "Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH)",
            "OfficialTitle": "Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH)",
            "LeadSponsorClass": "University of Cincinnati",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Cincinnati",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to find risk factors for hemorrhagic stroke, specifically\r\n\r\n      intracerebral hemorrhage (ICH), among Caucasians, African Americans, and Hispanics.",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "August 2010",
            "CompletionDate": "June 2016",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Cincinnati",
            "StudyCondition": "Intracerebral Hemorrhage",
            "studyLocation": "University of Arizona",
            "Enrollment": "6000",
            "NctKeyword": "Intracerebral Hemorrhage, ICH, Stroke, Cerebrovascular accident,",
            "MeshKeyword": "Hemorrhage, Cerebral Hemorrhage,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        All cases must meet the following eligibility criteria:\r\n\r\n\r\n\r\n          1. Age 18 years or greater, fulfillment of the criteria for intracerebral hemorrhage\r\n\r\n\r\n\r\n          2. Resident for at least 6 months",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Tucson",
            "State": "Arizona",
            "Zip": "85724",
            "Country": "United States",
            "VerificationDate": "May 2015",
            "LastChanged": "May 27, 2015",
            "FirstReceived": "September 14, 2010",
            "OverallOfficial": "Daniel Woo, MD, MS",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Cincinnati",
            "LocationName": "University of Arizona",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01202864",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1030000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1030000",
            "StudyId": "20100173 - NINDS ERICH - Koch",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20100173",
            "StudyNumber": "20100173 - NINDS ERICH - Koch",
            "StudyTitle": "ETHNIC/RACIAL VARIATIONS OF INTRACEREBRAL HEMORRHAGE(ERICH)",
            "PIID": "171",
            "PicNum": "C00123749",
            "PILastName": "Koch",
            "PIFirstName": "Sebastian",
            "CoodCNbr": "C06976212",
            "CoordLastName": "Perez",
            "CoordFirstName": "Mario",
            "CoordEmail": "mperez20@med.miami.edu",
            "CoordPhone": "3052437043",
            "EnteredByCNbr": "C06976212",
            "EnteredByLastName": "Perez",
            "EnteredByFirstName": "Mario",
            "ActiveEnrollingDate": "10/30/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/30/2010",
            "IRBApprovedFrom": "10/13/2010",
            "IRBApprovedTo": "04/16/2016",
            "AccountNbr": "66676T",
            "InfoEdNbr": "36847",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "National Institute of Neurological Disorders & Stroke",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "228",
            "Totalaccrued": "228",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "228",
            "FirstNinety": "21",
            "SiteSampleSize": "JMH:200,UMMG:200,UMHC:N/A,UMH:N/A",
            "AccrualPercentageMet": "57",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "400",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Mario Perez,Jorge Bracho, II,Andrea Escobar",
            "StudyObjective": "The goals for the current proposal are to improve our understanding of the epidemiology of intracerebral hemorrhage (ICH) among minorities including the relative importance of potential candidate genes for ICH. Given the numerous risk factors to be examined and the potential for interactions, a large sample size is required and no single center would be able to efficiently recruit sufficient numbers of cases and controls. \r\n\r\nThus, we propose to perform a multi-center case-control study of ICH. All cases and controls will be recruited using identical interview processes and phenotype definitions, handling of biologic samples, centralized neuroimaging analysis and case and control identification using identical methods. This methodology would represent a critical advantage to performing a large genome-wide association study of ICH including minorities.\r\n\r\nOur specific aims are:\r\n\r\n1) In anticipation of a large, genome-wide association study of intracerebral hemorrhage (ICH) among minorities, we will collect 1000 cases of ICH among whites, 1000 cases among African Americans and 1000 cases among Hispanics and 3000 demographically matched controls. The cases will be identified using uniform case criteria, risk factor data definitions and data collection methods, centralized control identification through random digit dialing and with identical interviews, and biologic sample collection. One in every 5 ICH will undergo a study-required MRI with gradient echo imaging in addition to collection of routine clinical scans. One in every 5 ICH will also have samples processed for proteomics and transciptomics. While our long-term goal is to perform a major genome-wide association study for ICH among blacks and Hispanics, a critical next step is to collect cases and controls in a scientifically rigourous way. This will allow us to take into account important environmental, traditional and genetic factors in our design of a GWAS as well to better understand the epidemiology of ICH among minorities. \r\n\r\n2) Identify differences in risk factor distribution by race, ethnicity and location of intracerebral hemorrhage (ICH) using a case-control design. Preliminary data suggests that significant differences in risk factors exists by race and ethnicity. Our sample size will achieve sufficient power to account for multiple comparisons and to examine the importance of genetic risk factors such as apolipoprotein E alleles. Prior studies have lacked sufficient cases with DNA samples to determine the importance of this risk factor in minority populations. \r\n\r\n3) Determine differences in imaging characteristics among AAs and Hispanic ICH Cases compared to Whites using a case-only comparison. Most studies of microbleeds have been limited to non-Hispanic white ICH cases. While an existing effort to examine microbleeds among AA ICH cases is underway, at present, there has been no studies of microbleeds among Hispanics with ICH or sufficient collection of cases from all three groups for a comparison to be made. Through the proposal, we will gather available CT and MRI neuroimaging on every case (occuring within the first seven days of admission). To avoid biases in clinical practice of ordering MRI, one in every five cases in which an MRI can be safely performed will have a study-related MRI. Using a case-only comparison (as controls will not have neuroimaging performed as part of the study), and including covariates identified as significant risk factors for ICH through the case-control study, we will be able to characterize differences by race/ethnicity in volume of ICH, location of ICH, number and location/topography of microbleeds, and severity of underlying white matter disease (leukoaraiosis). \r\n\r\n4) Determine differences in outcomes of ICH based on race/ethnicity compared to non-Hispanic whites using a case-only comparison. Studies in ischemic stroke suggest variable outcome based on a number of factors including socioeconomic factors. ICH tends to affect AAs and Hispanics at a younger age than non-Hispanic whites (hereafter whites) and has a higher morbidity and mortality rate than ischemic stroke. However, no study has determined the risk factors for these differences in outcomes by race/ethnicity and for long-term outcome (1 year) or, in particular, examined differences based on location and treatment of risk factors.\r\n\r\n5) Determine level of population admixture between centers, ethnicity and race using a control-only analysis. Hispanic Americans may differ in their ancestry (Mexican, Cuban, Puerto Rican or other national background). Similarly, African Americans and whites may demonstrate admixture when comparing individuals from southern United States to Midwest or Northeastern regions. Determining the degree of population admixture will be an important factor for consideration in analysis of candidate genes as well as for a planned genome-wide association study. To accomplish this aim, we will genotype 176 ancestry informative markers as well as genotype approximately 250 candidate gene polymorphisms obtained from genome scans among whites and priority candidate genes and estimate the admixture porportions in the 3000 cases and 3000 controls. Using these markers, we can analyze controls from each racial/ethnic group and as a whole for significant clusters or subpopulations for consideration in designing a future GWAS.\r\n\r\nThus upon completion of the study, we will have sufficient power to examine all known risk factors for ICH among AAs and Hispanics including known genetic risk factors and those implicated by results of ongoing GWAS studies among whites, we will have created a neuroimaging repository and a biologic sample repository of ICH including DNA isolation with quality control measures, ancestry informative markers genotyped as well as samples processed for proteomics and transciptomics for future studies which have been gathered on cases undergoing case identification and classification using uniform definitions and risk factor data collection.",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01202864",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01204632",
            "BriefTitle": "Cardiometabolic Risk, Obesity and Cardiovascular Disease in People With Spinal Cord Injury",
            "OfficialTitle": "Cardiometabolic Risk, Obesity and Cardiovascular Disease in People With Spinal Cord Injury",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to develop and field-test new tools for diagnosis and hazard\r\n\r\n      assessment of cardiometabolic risk (CMR) in people with chronic spinal cord injury (SCI) and\r\n\r\n      to advance the evidence base with much neede",
            "Description": "Unlike current assessments utilizing lipid scores, the new system will be anchored in more\r\n\r\n      reliable measurements of cardiovascular disease (CVD) burden using contemporary surrogate\r\n\r\n      end points of coronary artery calcium (CAC) sc",
            "OverallStatus": "Completed",
            "StartDate": "March 2010",
            "CompletionDate": "December 2015",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Spinal Cord Injury",
            "studyLocation": "The Miami Project to Cure Paralysis",
            "Enrollment": "74",
            "MeshKeyword": "Wounds and Injuries, Cardiovascular Diseases, Spinal Cord Injuries,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  traumatic spinal cord injury between C4 and T12\r\n\r\n\r\n\r\n          -  have a motor complete injury as classified as American Spinal Injury Association\r\n\r\n             Impairment Scale (AIS) grade A or B",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "February 2016",
            "LastChanged": "February 17, 2016",
            "FirstReceived": "September 16, 2010",
            "OverallOfficial": "Mark S Nash, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami Miller School of Medicine, The Miami Project to Cure Paralysis",
            "LocationName": "The Miami Project to Cure Paralysis",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01204632",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20090977 - NIDRR RRTC - Nash",
            "FileProcessContentId": "440",
            "Division": "Neurosurgery",
            "StdyDivision": "9636",
            "EprostNbr": "20090977",
            "StudyNumber": "20090977 - NIDRR RRTC - Nash",
            "StudyTitle": "Cardiometabolic Risk, Obesity and Cardiovascular Disease in People with Spinal Cord Injury",
            "PIID": "840",
            "PicNum": "C00137246",
            "PILastName": "Nash",
            "PIFirstName": "Mark",
            "CoodCNbr": "C03121195",
            "CoordLastName": "Burns",
            "CoordFirstName": "Patricia",
            "CoordEmail": "pburns@med.miami.edu",
            "EnteredByCNbr": "C00137246",
            "EnteredByLastName": "Nash",
            "EnteredByFirstName": "Mark",
            "ActiveEnrollingDate": "03/15/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/15/2011",
            "IRBApprovedFrom": "03/16/2010",
            "IRBApprovedTo": "01/20/2015",
            "AccountNbr": "66675Y",
            "InfoEdNbr": "51906 / 55597",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Federal Non-NIH",
            "Sponsor": "NIDRR RRTC Grant H133B090002",
            "Prescreened": "81",
            "Screenedfailed": "3",
            "SignedICF": "72",
            "Totalaccrued": "69",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "103",
            "FirstNinety": "9",
            "SiteSampleSize": "UMMG:34,JMH:N/A",
            "AccrualPercentageMet": "202.941176470588235294117647058823529412",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "34",
            "EprostState": "Approved",
            "StudyCoordinator": "Patricia Burns",
            "StudyObjective": "The purpose of this study is to develop and field-test new tools for diagnosis and hazard assessment of cardiometabolic risk (CMR) in people with chronic spinal cord injury (SCI) and to advance the evidence base with much needed information on CMR and CVD burden in people with SCI. These data can be used to develop screening guidelines for early identification and prevention of CMR in SCI, as well as targeted approaches to primary disease management. \r\n\r\nSpecific Aims:\r\n1. Examine the relationships among surrogates of cardiovascular disease burden in persons with SCI and established cardiometabolic risks.\r\n2. Identify significant predictors of cardiometabolic risk (CMR) that are unique to persons with specific levels of SCI.\r\n3. Develop and validate SCI CMR assessment tool (RISK) based on cardiometabolic risk scores.\r\n4. Develop and validate an adjusted BMI table for SCI.",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01204632",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01206062",
            "SecondaryId": "268200900040C-1-0-1",
            "BriefTitle": "Systolic Blood Pressure Intervention Trial",
            "OfficialTitle": "Systolic Blood Pressure Intervention Trial",
            "LeadSponsorClass": "National Heart, Lung, and Blood Institute (NHLBI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
            "OversightAuthority": "Yes",
            "BriefSummary": "Elevated blood pressure (BP) is an important public health concern. It is highly prevalent,\r\n\r\n      the prevalence may be increasing, and it is a risk factor for several adverse health\r\n\r\n      outcomes, especially coronary heart disease, strok",
            "Description": "SPRINT will randomize about 9250 participants aged ≥ 50 years with SBP ≥130 mm Hg and at\r\n\r\n      least one additional CVD risk factor. The trial will compare the effects of randomization to\r\n\r\n      a treatment program of an intensive SBP goal",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "October 2010",
            "CompletionDate": "December 2016",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "National Heart, Lung, and Blood Institute (NHLBI)",
            "StudyCondition": "Hypertension",
            "studyLocation": "Wake Forest University School of Medicine",
            "Enrollment": "9361",
            "NctKeyword": "blood pressure, antihypertensive, systolic, diastolic, heart failure, myocardial infarction, stroke, chronic kidney disease, dementia, cognitive decline,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  At least 50 years old\r\n\r\n\r\n\r\n        Systolic blood pressure of\r\n\r\n\r\n\r\n          -  130 - 180 mm Hg on 0 or 1 medication\r\n\r\n\r\n\r\n          -  130 - 170 mm Hg on up to 2 medications\r\n\r\n\r\n\r\n          -  130",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Winston-Salem",
            "State": "North Carolina",
            "Zip": "27157",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 24, 2016",
            "FirstReceived": "September 20, 2010",
            "OverallOfficial": "David M. Reboussin, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Wake Forest University Health Sciences",
            "LocationName": "Wake Forest University School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01206062",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20100637 - NIH - Contreras",
            "FileProcessContentId": "440",
            "Division": "Nephrology",
            "StdyDivision": "10250",
            "EprostNbr": "20100637",
            "StudyNumber": "20100637 - NIH - Contreras",
            "StudyTitle": "Systolic Blood Pressure Intervention Trial (SPRINT)",
            "PIID": "522",
            "PicNum": "C00210471",
            "PILastName": "Contreras",
            "PIFirstName": "Gabriel",
            "CoodCNbr": "C00329755",
            "CoordLastName": "Vassallo",
            "CoordFirstName": "Jacqueline",
            "CoordEmail": "JVassall@med.miami.edu",
            "EnteredByCNbr": "C00210471",
            "EnteredByLastName": "Contreras",
            "EnteredByFirstName": "Gabriel",
            "ActiveEnrollingDate": "02/16/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/16/2011",
            "IRBApprovedFrom": "11/08/2010",
            "IRBApprovedTo": "08/10/2017",
            "AccountNbr": "66762W",
            "InfoEdNbr": "54375",
            "Expr1": "N/A",
            "Tarea": "Hypertension",
            "TareaCode": "13037",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "NIH,NHLBI, NIDDK, NINDS,NIA, Wake Forest University",
            "Prescreened": "1",
            "Screenedfailed": "25",
            "SignedICF": "146",
            "Totalaccrued": "122",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "88",
            "CurrentlyActiveTreatment": "24",
            "Totalpatients": "146",
            "FirstNinety": "10",
            "SiteSampleSize": "UMMG:200,Clinical Research Center (CRC):N/A,JMH:200,UMHC:200",
            "AccrualPercentageMet": "20.33333333333333333333333333333333333333",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "600",
            "EprostState": "Approved",
            "StudyCoordinator": "Jacqueline Vassallo",
            "StudyObjective": "Primary Hypothesis: In people aged &#8805; 55 years with SBP &#8805;130 mm Hg and either a history of CVD, eGFR between 25 and 60, or a Framingham Risk Score (FRS) indicating 10-year CVD risk of &#8805;15%, does a therapeutic strategy that targets a SBP of < 120 mm Hg reduce the rate of CVD events compared to a strategy that targets a SBP of < 140 mm Hg? This hypothesis will be tested using a composite outcome including: cardiovascular death, myocardial infarction, stroke, heart failure, and non-MI acute coronary syndrome ascertained over a follow-up period of up to 6 years. Interim monitoring for overall trial efficacy will be based on the accrued rate of this primary outcome. The anticipated event rate for this outcome is 2.2%/year. \r\n\r\nSubgroup Hypotheses:\r\nSPRINT will examine intervention effects in a number of subgroups; Two subgroups are of particular interest due their connection to possible biological mechanisms affecting the primary outcome: \r\n1. participants with and without CKD (eGFR <60 ml/min/1.73m2) at baseline, 2. participants < or &#8805; 75 years at baseline.\r\n\r\nConsistency of the effects for the intervention on the primary outcome will also be examined in subgroups defined by gender, race/ethnicity (black vs. non-black), presence of clinical CVD at baseline (i.e., primary and secondary prevention participants) and tertiles of baseline systolic BP.\r\n\r\nSubgroup analyses for secondary outcomes are described in Chapter 10 of the protocol. \r\n\r\nSecondary Hypotheses: \r\nSPRINT prespecifies two types of secondary hypotheses. The first type will address secondary outcomes in analyses designed to support and confirm the primary analysis. These will include components of the primary composite outcome, total mortality, and a composite of the primary composite with total mortality (CVD-free survival). The other type addresses two areas of non-cardiovascular clinical effects: renal and cognitive outcomes. \r\n\r\nObjectives for renal outcomes and the CKD subgroup:\r\n1. For the CKD subgroup, we will determine whether the intensive intervention arm experiences a lower rate of a composite of renal outcomes composed of: ESRD or A 50% decline from baseline eGFR \r\n2. For the non-CKD subgroup, we will determine whether the intensive intervention arm experiences a lower rate of progression to CKD, defined as  ESRD or  30% decrease from baseline eGFR and an end value of <60 ml/min/1.73M2 \r\n\r\nSPRINT MIND:\r\nSPRINT-MIND is an integral part of the overall SPRINT study and all SPRINT participants will participate in one or more components of SPRINT-MIND. There are three objectives of SPRINT-MIND. The primary objective is to determine whether a strategy of intensive blood pressure lowering to target systolic blood pressure (SBP) <120 mm Hg versus a standard treatment target of 140 mm Hg will produce a greater reduction in the incidence of all-cause dementia. The second objective is to determine whether global cognitive function measured in key specific domains of cognition will decline less in persons randomized to a SBP goal of <120 mm Hg versus a standard treatment goal of 140 mm Hg in a representative sub-sample of approximately 2800 SPRINT participants. The third objective is to assess whether MRI-derived changes in brain structure differ by treatment assignment in a subset (approximately 640) of the 2800 participants.\r\n\r\nSPRINT MIND Hypotheses:\r\n1. All-cause Dementia. The incidence of all-cause dementia will be lower in SPRINT participants assigned to the intensive SBP treatment arm compared to their counterparts assigned to the standard SBP treatment arm.\r\n2. Cognitive Decline. The combined rate of decline in all domains of cognition will be slower in the intensive SBP treatment arm compared to the standard SBP treatment arm. This hypothesis will be tested in a randomly selected subset of 2800 participants enrolled in SPRINT. \r\n3. MRI Brain Changes. The volume small vessel ischemic disease (SVID) will be lower in SPRINT participants assigned to the intensive SBP treatment arm compared to their counterparts assigned to the standard SBP treatment arm. A sub-hypothesis is that total brain volume will also be greater (thus less atrophy) in the intensively treated group. The MRI sub-study will be conducted in 640 participants chosen from the 2800 selected to receive regular extensive cognitive assessment.",
            "NationalSampleSize": "120",
            "NCTNbr": "NCT01206062",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01208974",
            "SecondaryId": "SCCC-2009004",
            "BriefTitle": "Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction",
            "OfficialTitle": "A Phase I Trial Assessing the Safety and Feasibility of Prophylactic Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Immediate Reconstruction in Patients With In-Situ or Invasive Breast Cancer",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "Overall rationale: Prophylactic NAC irradiation after nipple-areola sparing mastectomy and\r\n\r\n      immediate reconstruction for patient with ductal carcinoma in-situ or invasive breast cancer\r\n\r\n      will allow better cosmesis and patient's sa",
            "Description": "-  The use of NAC-sparing mastectomy followed by postoperative NAC (nipple-areola complex)\r\n\r\n           external beam radiotherapy for selected patient with early stage invasive or in-situ\r\n\r\n           breast cancers will be technically feasib",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2009",
            "CompletionDate": "October 2017",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Breast Cancer",
            "studyLocation": "University of Miami Sylvester Comprehensive Cancer Center",
            "Enrollment": "18",
            "NctKeyword": "Breast Cancer, Nipple Area Complex, Mastectomy, Radiation Therapy, Nipple-Sparing, Breast Reconstruction,",
            "MeshKeyword": "Breast Neoplasms, Carcinoma, Ductal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must have histologically confirmed in-situ or invasive breast carcinoma.\r\n\r\n\r\n\r\n          -  Tis, T1, T2 invasive or non-invasive carcinoma of the breast; lesion less than 4 cm.",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 26, 2016",
            "FirstReceived": "September 22, 2010",
            "OverallOfficial": "Cristiane Takita, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Sylvester Comprehensive Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01208974",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20090299 - Intramural - TAKITA",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20090299",
            "StudyNumber": "20090299 - Intramural - TAKITA",
            "StudyTitle": "SCCC 2009004:  A phase I trial assessing the safety and feasibility of prophylactic nippleareola complex (NAC) irradiation after nipplesparing mastectomy and immediate reconstruction in patients with insitu or invasive breast cancer",
            "PIID": "278",
            "PicNum": "C00550352",
            "PILastName": "Takita",
            "PIFirstName": "Cristiane",
            "CoodCNbr": "C00294869",
            "CoordLastName": "Martin",
            "CoordFirstName": "Doris",
            "CoordEmail": "dmartin3@med.miami.edu",
            "CoordPhone": "3052435491",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "10/26/2009",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/26/2009",
            "IRBApprovedFrom": "06/08/2009",
            "IRBApprovedTo": "03/06/2017",
            "InfoEdNbr": "35669",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase I",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Prescreened": "7",
            "Screenedfailed": "6",
            "SignedICF": "23",
            "Totalaccrued": "17",
            "InFollowUp": "14",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "27",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:18,JMH:N/A,UMD:0",
            "AccrualPercentageMet": "94.44444444444444444444444444444444444444",
            "ActiveCal": "4",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "18",
            "EprostState": "Approved",
            "CancerCenterNbr": "2009004",
            "StudyCoordinator": "Marinellie Vega,Lilibet Zamora Cabezas,Greeyt Hernandez,Fernando Vazquez Pascual,Maggie Chislom,Lilly Sanchez",
            "NationalSampleSize": "18",
            "NCTNbr": "NCT01208974",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01209000",
            "SecondaryId": "1U54DK083912",
            "BriefTitle": "Nephrotic Syndrome Study Network",
            "OfficialTitle": "Nephrotic Syndrome Study Network Under the Rare Diseases Clinical Research Network",
            "LeadSponsorClass": "University of Michigan",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Michigan",
            "OversightAuthority": "Yes",
            "BriefSummary": "Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous\r\n\r\n      nephropathy (MN), generate an enormous individual and societal financial burden, accounting\r\n\r\n      for approximately 12% of prevalent end stage re",
            "Description": "Idiopathic Nephrotic Syndrome (NS) is a rare disease syndrome responsible for approximately\r\n\r\n      12% of all causes of end-stage kidney disease (ESRD) and up to 20% of ESRD in children.\r\n\r\n      Treatment strategies for Focal and Segmental Gl",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2010",
            "CompletionDate": "June 2019",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Michigan",
            "StudyCondition": "Minimal Change Disease (MCD)",
            "studyLocation": "University of Southern California-Children's Hospital",
            "Enrollment": "600",
            "NctKeyword": "Focal and Segmental Glomerulosclerosis, Focal & Segmental Glomerulosclerosis, Focal Segmental Glomerulosclerosis, FSGS, Minimal change disease, MCD, Membranous Nephropathy, MN, Nephrotic Syndrome, Neph Syndrome, NEPTUNE, NephCure, Halpin,",
            "MeshKeyword": "Syndrome, Kidney Diseases, Nephrotic Syndrome, Nephrosis, Glomerulonephritis, Membranous, Nephrosis, Lipoid, Glomerulosclerosis, Focal Segmental,",
            "Eligibility": "Cohort A (biopsy cohort) Inclusion Criteria:\r\n\r\n\r\n\r\n        Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric\r\n\r\n        participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90227",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 10, 2016",
            "FirstReceived": "July 29, 2010",
            "OverallOfficial": "Matthias Kretzler, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Michigan",
            "ContactName": "Chrysta C. Lienczewski, BS",
            "ContactPhone": "1-877-9-NEPTUNE",
            "ContactEmail": "NEPTUNE-Study@umich.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Southern California-Children's Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01209000",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20090572 - NIH - Contreras",
            "FileProcessContentId": "440",
            "Division": "Nephrology",
            "StdyDivision": "10250",
            "EprostNbr": "20090572",
            "StudyNumber": "20090572 - NIH - Contreras",
            "StudyTitle": "The Nephrotic Syndrome Study Network (NEPTUNE) Rare Disease Clinical Research Consortium",
            "PIID": "639",
            "PicNum": "C00649227",
            "PILastName": "Fornoni",
            "PIFirstName": "Alessia",
            "CoodCNbr": "C00329755",
            "CoordLastName": "Vassallo",
            "CoordFirstName": "Jacqueline",
            "CoordEmail": "JVassall@med.miami.edu",
            "EnteredByCNbr": "C00210471",
            "EnteredByLastName": "Contreras",
            "EnteredByFirstName": "Gabriel",
            "ActiveEnrollingDate": "09/27/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/24/2012",
            "IRBApprovedFrom": "11/12/2009",
            "IRBApprovedTo": "09/11/2017",
            "InfoEdNbr": "50614",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "NIH, Office of Rare Diseases(NIDDK)/Univ.of Mich",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "43",
            "Totalaccrued": "38",
            "InFollowUp": "8",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "43",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:27,UMMG:27,UMHC:27",
            "AccrualPercentageMet": "46.91358024691358024691358024691358024691",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "81",
            "EprostState": "Approved",
            "StudyCoordinator": "Jacqueline Vassallo,Patricia Wahl",
            "StudyObjective": "The main aim of this study is to find markers of progressive Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), and Membranoproliferative Glomerulonephropathy (MN) in two cohorts of patients. This study will provide researchers with access to de-identified health information and laboratory samples from people with the above kidney disease.",
            "NationalSampleSize": "80",
            "NCTNbr": "NCT01209000",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01216176",
            "SecondaryId": "SCCC-2008002",
            "BriefTitle": "A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer",
            "OfficialTitle": "A Phase I Pharmacokinetic and Randomized Phase II Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer",
            "LeadSponsorClass": "Joyce Marie Slingerland",
            "SponsorAgency": "Other",
            "LeadSponsor": "Joyce Marie Slingerland",
            "OversightAuthority": "Yes",
            "BriefSummary": "The investigators propose to conduct a Phase I/randomized Phase II study design in order to\r\n\r\n      test the tolerability and efficacy of AZD0530 when used together with anastrozole in therapy\r\n\r\n      for ER+ and/or PR+, postmenopausal breast",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2008",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Breast Cancer",
            "studyLocation": "Stanford University",
            "Enrollment": "72",
            "NctKeyword": "Breast Cancer, Postmenopausal, Metastatic Phase I ONLY, AZD0530, Anastrozole, Phase I for metastatic disease, Phase II for newly diagnosed breast cancer, Pharmacokinetic, PK, Hormone Receptor, Estrogen Receptor, Progesterone Receptor, ER+, PR+, HER negati",
            "MeshKeyword": "Breast Neoplasms,",
            "InterventionKeyword": "Hormones, Saracatinib, Anastrozole,",
            "Eligibility": "Inclusion Criteria - Phase 1 (Cohort A):\r\n\r\n\r\n\r\n          -  Female patient ≥ 18 years\r\n\r\n\r\n\r\n          -  Patient must be postmenopausal, verified by 1 of the following:\r\n\r\n\r\n\r\n               -  Bilateral surgical oophorectomy",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Palo Alto",
            "State": "California",
            "Zip": "94304",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 18, 2016",
            "FirstReceived": "October 5, 2010",
            "OverallOfficial": "Joyce Slingerland, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami Sylvester Comprehensive Cancer Center",
            "ContactName": "University of Miami Sylvester Comprehensive Cancer Center",
            "ContactPhone": "866-574-5124",
            "ContactEmail": "sylvester@emergingmed.com",
            "LocationStatus": "Terminated",
            "LocationName": "Stanford University",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01216176",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20080325 - Intramural - SLINGERLAND",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20080325",
            "StudyNumber": "20080325 - Intramural - SLINGERLAND",
            "StudyTitle": "A PHASE I PHARMACOKINETIC AND RANDOMIZED PHASE II TRIAL OF NEOADJUVANT TREATMENT WITH ANASTROZOLE PLUS AZDO530 IN POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE BREAST CANCER  SCCC 2008002",
            "PIID": "272",
            "PicNum": "C02547977",
            "PILastName": "Slingerland",
            "PIFirstName": "Joyce",
            "CoodCNbr": "C03416430",
            "CoordLastName": "Torres",
            "CoordFirstName": "Onaidy",
            "CoordEmail": "otorres@med.miami.edu",
            "CoordPhone": "3052439503",
            "EnteredByCNbr": "C11972191",
            "EnteredByLastName": "Harris",
            "EnteredByFirstName": "Bretinsa",
            "ActiveEnrollingDate": "10/20/2008",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/20/2016",
            "IRBApprovedFrom": "09/08/2008",
            "IRBApprovedTo": "05/17/2017",
            "AccountNbr": "66500Y",
            "InfoEdNbr": "31822",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase I/II",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Blinding": "Double",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "Federal Flag in DMAS",
            "Prescreened": "14",
            "Screenedfailed": "11",
            "SignedICF": "82",
            "Totalaccrued": "71",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "4",
            "Totalpatients": "83",
            "FirstNinety": "3",
            "SiteSampleSize": "UMHC:72,Plantation:N/A,Stanford University:9,JMH:N/A,UMD:N/A",
            "AccrualPercentageMet": "87.65432098765432098765432098765432098765",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "81",
            "EprostState": "Approved",
            "CancerCenterNbr": "2008002",
            "StudyCoordinator": "Halyna Hailes,Deborah Conte,Mae Lyssa Bauduy-Roy,Sarah Raybin",
            "AgentDevices": "Drug: AZD0530",
            "NationalSampleSize": "60",
            "NCTNbr": "NCT01216176",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01220583",
            "SecondaryId": "CDR0000686072",
            "BriefTitle": "Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery",
            "OfficialTitle": "A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors",
            "LeadSponsorClass": "Radiation Therapy Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Radiation Therapy Oncology Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in\r\n\r\n      chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells,\r\n\r\n      either by killing the cells or by stopping them",
            "Description": "OBJECTIVES:\r\n\r\n\r\n\r\n      Primary\r\n\r\n\r\n\r\n        -  Determine the feasibility of conducting a cooperative group prospective clinical trial\r\n\r\n           in patients with resected malignant salivary gland tumors.\r\n\r\n\r\n\r\n        -  Acquire prelimin",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2011",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Radiation Therapy Oncology Group",
            "StudyCondition": "Head and Neck Cancer",
            "studyLocation": "City of Hope Comprehensive Cancer Center",
            "Enrollment": "120",
            "NctKeyword": "stage I salivary gland cancer, stage II salivary gland cancer, stage III salivary gland cancer, high-grade salivary gland mucoepidermoid carcinoma, salivary gland adenocarcinoma, stage IVA salivary gland cancer, stage IVB salivary gland cancer, stage IVC",
            "MeshKeyword": "Head and Neck Neoplasms, Salivary Gland Neoplasms,",
            "InterventionKeyword": "Cisplatin,",
            "Eligibility": "DISEASE CHARACTERISTICS:\r\n\r\n\r\n\r\n          -  Pathologically proven diagnosis of a malignant major salivary gland tumor of the\r\n\r\n             following histologic subtypes:\r\n\r\n\r\n\r\n               -  High-grade mucoepidermoid carcinoma",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Duarte",
            "State": "California",
            "Zip": "91010-3000",
            "Country": "United States",
            "VerificationDate": "March 2016",
            "LastChanged": "March 2, 2016",
            "FirstReceived": "October 12, 2010",
            "OverallOfficial": "Cristina P. Rodriguez, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "OHSU Knight Cancer Institute",
            "LocationStatus": "Recruiting",
            "LocationName": "City of Hope Comprehensive Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01220583",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130022 - RTOG - Samuels",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20130022",
            "StudyNumber": "20130022 - RTOG - Samuels",
            "StudyTitle": "RTOG 1008: A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors",
            "PIID": "3262",
            "PicNum": "C10007990",
            "PILastName": "Samuels",
            "PIFirstName": "Michael",
            "CoodCNbr": "C04035535",
            "CoordLastName": "Sanchez",
            "CoordFirstName": "Lilly",
            "CoordEmail": "lsanchez@med.miami.edu",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "05/14/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/14/2013",
            "IRBApprovedFrom": "03/18/2013",
            "IRBApprovedTo": "03/06/2017",
            "DiseaseSiteListDesc": "Lip, Oral Cavity and Pharynx",
            "Expr1": "Phase II",
            "Tarea": "Head and Neck Cancer",
            "TareaCode": "12440",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "RTOG",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Marinellie Vega,Pavel Noa Hechavarria,Zaida Abreu,Giovana R Thomas,Greeyt Hernandez,Lilibet Zamora Cabezas,Fernando Vazquez Pascual,Maggie Chislom,Doris Martin",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01220583",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01232361",
            "BriefTitle": "IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents",
            "OfficialTitle": "IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents",
            "LeadSponsorClass": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
            "OversightAuthority": "No",
            "BriefSummary": "The main purpose of this study is to find out how stimulant medications (methylphenidate or\r\n\r\n      amphetamine/ dextroamphetamine) for the treatment of Attention Deficit Hyperactivity\r\n\r\n      Disorder (ADHD)are processed in HIV-1 infected and",
            "Description": "P1080 is a pilot population pharmacokinetic study of HIV-1 infected and uninfected children\r\n\r\n      and adolescents who are taking methylphenidate or amphetamine/ dextroamphetamine for the\r\n\r\n      treatment of ADHD. Prescribing various psychia",
            "OverallStatus": "Completed",
            "StartDate": "September 2010",
            "CompletionDate": "July 2016",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group",
            "StudyCondition": "ADHD",
            "studyLocation": "Univ. of Alabama Birmingham NICHD CRS (5096)",
            "Enrollment": "127",
            "NctKeyword": "ADHD, HIV, Pharmacokinetics,",
            "InterventionKeyword": "Protease Inhibitors,",
            "Eligibility": "Inclusion Criteria for HIV-1 Infected Subjects\r\n\r\n\r\n\r\n          -  Children and adolescents age ≥6 to <25 years at entry.\r\n\r\n\r\n\r\n          -  Documented HIV-1 infection defined as positive test results obtained from 2 different",
            "EligibleGender": "All",
            "MinAge": "6 Years",
            "MaxAge": "25 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "October 29, 2010",
            "OverallOfficial": "Brookie Best, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "University of California, San Diego/IMPAACT",
            "LocationName": "Univ. of Alabama Birmingham NICHD CRS (5096)",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01232361",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20100566 - NICHD/NIAID - Scott",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20100566",
            "StudyNumber": "20100566 - NICHD/NIAID - Scott",
            "StudyTitle": "IMPAACT Protocol P1080, “A Pilot Study of Psychiatric and Antiretroviral Medication Concentrations in HIV-1 Infected and Uninfected Children and Adolescents.”",
            "PIID": "1243",
            "PicNum": "C00795461",
            "PILastName": "Scott",
            "PIFirstName": "Gwendolyn",
            "CoodCNbr": "C00057173",
            "CoordLastName": "Bryan",
            "CoordFirstName": "Patricia",
            "CoordEmail": "pbryan@med.miami.edu",
            "CoordPhone": "3052434447",
            "EnteredByCNbr": "C00795461",
            "EnteredByLastName": "Scott",
            "EnteredByFirstName": "Gwendolyn",
            "ActiveEnrollingDate": "10/08/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/08/2010",
            "IRBApprovedFrom": "09/07/2010",
            "IRBApprovedTo": "07/04/2017",
            "InfoEdNbr": "54944/55577",
            "Expr1": "Phase IV",
            "Tarea": "Immunology/Infectious Disease",
            "TareaCode": "13340",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "NICHD/NIAID",
            "Prescreened": "2",
            "Screenedfailed": "0",
            "SignedICF": "14",
            "Totalaccrued": "13",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "16",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:10",
            "AccrualPercentageMet": "130",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "10",
            "EprostState": "Approved",
            "StudyCoordinator": "Sady Dominguez",
            "StudyObjective": "PRIMARY OBJECTIVE:\r\nTo describe the pharmacokinetics of the selected psychiatric medications currently prescribed in HIV-1 infected and uninfected children and adolescents.\r\n\r\nSECONDARY OBJECTIVES:\r\n1. To compare psychiatric medication exposure in HIV-1 infected children and adolescents on selected antiretrovirals to that seen in uninfected children and adolescents.\r\n2. To compare ARV (PI and NNRTI) exposure in subjects taking selected psychiatric medications with published ARV (PI and NNRTI) pharmacokinetic values in children and adolescents.\r\n3. To compare psychiatric medication concentrations in HIV-1 infected subjects taking ritonavir versus HIV-1 infected subjects taking efavirenz versus HIV uninfected subjects (taking neither ritonavir nor efavirenz).\r\n4. To compare the frequency of psychiatric medication dose changes, dose requirement in mg/kg and tolerance between HIV-1 infected and HIV uninfected subjects with routine use of psychiatric medications over one year.",
            "NationalSampleSize": "40",
            "NCTNbr": "NCT01232361",
            "StudyKeywords": "ORIM: Kanchan Sakhrani (QA: 11/1/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01233609",
            "BriefTitle": "Trial of Oral Valproic Acid for Retinitis Pigmentosa",
            "OfficialTitle": "A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa",
            "LeadSponsorClass": "Foundation Fighting Blindness Clinical Research Institute",
            "SponsorAgency": "Other",
            "LeadSponsor": "Foundation Fighting Blindness Clinical Research Institute",
            "OversightAuthority": "Yes",
            "BriefSummary": "The objectives of this study are to evaluate the efficacy of Valproic Acid (VPA) to both\r\n\r\n      slow the progression of visual function loss and/or to restore visual function in patients\r\n\r\n      with Autosomal Dominant Retinitis Pigmentosa (R",
            "Description": "Retinitis Pigmentosa (RP) is an incurable and untreatable group of heterogeneous retinal\r\n\r\n      degenerative diseases that cause severe visual loss. There is currently no therapeutic that\r\n\r\n      substantially slows the progression of this di",
            "OverallStatus": "Completed",
            "StartDate": "November 2010",
            "CompletionDate": "December 2015",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Foundation Fighting Blindness Clinical Research Institute",
            "StudyCondition": "Retinitis Pigmentosa",
            "studyLocation": "University of Miami, Bascom Palmer Eye Institute",
            "Enrollment": "90",
            "NctKeyword": "retinitis pigmentosa, valproic acid, visual field,",
            "MeshKeyword": "Retinitis, Retinitis Pigmentosa,",
            "InterventionKeyword": "Valproic Acid,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Understand/sign the IRB-approved study informed consent document.\r\n\r\n\r\n\r\n          2. Age greater than or equal to 18 years, no upper age limit\r\n\r\n\r\n\r\n          3. Males and non-child bearing females mus",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "March 2016",
            "LastChanged": "March 21, 2016",
            "FirstReceived": "November 1, 2010",
            "OverallOfficial": "Patricia Zilliox, PhD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Foundation Fighting Blindness Clinical Research Institute",
            "LocationName": "University of Miami, Bascom Palmer Eye Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01233609",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110944 - NATL NEUROVISION RESEARCH INSTITUTE - Lam",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20110944",
            "StudyNumber": "20110944 - NATL NEUROVISION RESEARCH INSTITUTE - Lam",
            "StudyTitle": "A Phase II Multiple Site, Randomized, PlaceboControlled Trial of Oral Valproic Acid for Retinitis Pigmentosa Protocol H13371",
            "PIID": "1115",
            "PicNum": "C00679155",
            "PILastName": "Lam",
            "PIFirstName": "Byron",
            "CoodCNbr": "C07458455",
            "CoordLastName": "Morante",
            "CoordFirstName": "Alexis",
            "CoordEmail": "amorante@med.miami.edu",
            "EnteredByCNbr": "C07458455",
            "EnteredByLastName": "Morante",
            "EnteredByFirstName": "Alexis",
            "ActiveEnrollingDate": "09/07/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/07/2012",
            "IRBApprovedFrom": "01/23/2012",
            "IRBApprovedTo": "03/27/2017",
            "AccountNbr": "66917X",
            "InfoEdNbr": "59024",
            "Expr1": "Phase II",
            "Tarea": "Neuro-Ophthalmology",
            "TareaCode": "13137",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Federal Non-NIH",
            "Prescreened": "12",
            "Screenedfailed": "5",
            "SignedICF": "14",
            "Totalaccrued": "9",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "14",
            "FirstNinety": "1",
            "SiteSampleSize": "BPPB:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Potyra Rosa,Jennifer Verriotto",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01233609",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01240902",
            "BriefTitle": "Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement",
            "OfficialTitle": "Medtronic CoreValve® U.S. Pivotal Trial",
            "LeadSponsorClass": "Medtronic Cardiovascular",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Medtronic Cardiovascular",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of the study is to evaluate the safety and efficacy of the Medtronic CoreValve®\r\n\r\n      System in the treatment of symptomatic severe aortic stenosis in subjects who have a\r\n\r\n      predicted high risk for aortic valve surgery and/o",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "November 2010",
            "CompletionDate": "August 2020",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Medtronic Cardiovascular",
            "StudyCondition": "Severe Aortic Stenosis",
            "studyLocation": "Banner Good Samaritan",
            "Enrollment": "1453",
            "NctKeyword": "Valvular Heart Disease, Critical Aortic Stenosis, Severe Aortic Stenosis, High Risk, Aortic Valve Replacement,",
            "MeshKeyword": "Constriction, Pathologic, Aortic Valve Stenosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Extreme Risk Only: Subject must have comorbidities such that one cardiologist and two\r\n\r\n             cardiac surgeons agree that medical factors preclude operation, based on a conclusion",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85006",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 5, 2016",
            "FirstReceived": "November 10, 2010",
            "OverallOfficial": "David H Adams, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Icahn School of Medicine at Mount Sinai",
            "LocationName": "Banner Good Samaritan",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01240902",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20100706 - Pivotal - De Marchena",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20100706",
            "StudyNumber": "20100706 - Pivotal - De Marchena",
            "StudyTitle": "Medtronic CoreValve U.S. Pivotal Trial",
            "PIID": "1187",
            "PicNum": "C00491335",
            "PILastName": "De Marchena",
            "PIFirstName": "Eduardo",
            "CoodCNbr": "C04284337",
            "CoordLastName": "Marin y Kall",
            "CoordFirstName": "Christian",
            "CoordEmail": "cmarin@med.miami.edu",
            "CoordPhone": "3055856217",
            "EnteredByCNbr": "C00491335",
            "EnteredByLastName": "De Marchena",
            "EnteredByFirstName": "Eduardo",
            "ActiveEnrollingDate": "12/22/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/22/2010",
            "IRBApprovedFrom": "12/13/2010",
            "IRBApprovedTo": "12/07/2015",
            "AccountNbr": "66786N",
            "InfoEdNbr": "54640",
            "Expr1": "N/A",
            "Tarea": "Aortic valve stenosis",
            "TareaCode": "16636",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Medtronic, Inc",
            "Prescreened": "0",
            "Screenedfailed": "30",
            "SignedICF": "60",
            "Totalaccrued": "30",
            "InFollowUp": "4",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "60",
            "FirstNinety": "0",
            "SiteSampleSize": "UMH:40,JMH:20,UMHC:40",
            "AccrualPercentageMet": "30",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "100",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Maureen Lowery,Ximena Marincic-Sanchez,Carlos Alfonso,Suresh Atapattu,Christian Marin y Kall",
            "AgentDevices": "Device: CoreValve",
            "StudyObjective": "PURPOSE\r\nThe purpose of this protocol is to evaluate the safety and efficacy of the\r\nMedtronic CoreValve® System in the treatment of symptomatic severe aortic stenosis in subjects who have a predicted high risk for aortic valve surgery. High risk surgical subjects will be randomized to either transcatheter aortic valve implant (TAVI) with the Medtronic CoreValve® System (MCS) or SAVR in a 1:1 ratio.\r\n\r\nThe primary objective is to demonstrate that the safety and effectiveness of the Medtronic CoreValve® System (MCS), as measured by all cause mortality rates at 12 months, is non-inferior to surgical aortic valve replacement (SAVR) in the treatment of symptomatic severe aortic stenosis in subjects who have a predicted high risk for aortic valve surgery.",
            "NationalSampleSize": "70",
            "NCTNbr": "NCT01240902",
            "StudyInvIND": "1",
            "StudyInvINDNbr": "G100012",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01243424",
            "SecondaryId": "2009-013157-15",
            "BriefTitle": "CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes",
            "OfficialTitle": "A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.",
            "LeadSponsorClass": "Boehringer Ingelheim",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Boehringer Ingelheim",
            "BriefSummary": "The aim of the study is to investigate the longterm impact on cardiovascular morbidity and\r\n\r\n      mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g.,\r\n\r\n      weight and hypoglycaemia) of treatment with linag",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "October 2010",
            "CompletionDate": "March 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Boehringer Ingelheim",
            "StudyCondition": "Diabetes Mellitus, Type 2",
            "studyLocation": "1218.74.01113 Boehringer Ingelheim Investigational Site",
            "Enrollment": "6115",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 2,",
            "InterventionKeyword": "Glimepiride, Linagliptin,",
            "Eligibility": "Inclusion criteria:\r\n\r\n\r\n\r\n          1. Type 2 diabetes\r\n\r\n\r\n\r\n          2. Elevated glycosylated haemoglobin (HbA1c): 6.5 - 8.5%, inclusive, if treatment naïve\r\n\r\n             or mono-/dual therapy with metformin and/or an alpha-glucosidase i",
            "EligibleGender": "All",
            "MinAge": "40 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Athens",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 6, 2016",
            "FirstReceived": "November 17, 2010",
            "OverallOfficial": "Boehringer Ingelheim",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Boehringer Ingelheim",
            "LocationName": "1218.74.01113 Boehringer Ingelheim Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01243424",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110525 - BOEHRINGER INGELHEIM - Miranda-Palma",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20110525",
            "StudyNumber": "20110525 - BOEHRINGER INGELHEIM - Miranda-Palma",
            "StudyTitle": "A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patient with type 2 diabetes mellitus at high cardiovascular risk (The CAROLINA Trial)Protocol 1218.74",
            "PIID": "1111",
            "PicNum": "C02129536",
            "PILastName": "Miranda-Palma",
            "PIFirstName": "Bresta",
            "CoodCNbr": "C00121533",
            "CoordLastName": "Masters",
            "CoordFirstName": "Burlett",
            "CoordEmail": "bmasters2@med.miami.edu",
            "CoordPhone": "305-243-5354",
            "EnteredByCNbr": "C01987671",
            "EnteredByLastName": "Konwai",
            "EnteredByFirstName": "Ada",
            "ActiveEnrollingDate": "02/15/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/15/2012",
            "IRBApprovedFrom": "11/15/2011",
            "IRBApprovedTo": "08/15/2017",
            "InfoEdNbr": "58039",
            "Expr1": "Phase III",
            "Tarea": "Diabetes (Type II)",
            "TareaCode": "12544",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "BOEHRINGER INGELHEIM",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "6",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Burlett Masters",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT01243424",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01249443",
            "SecondaryId": "NCI-2011-02511",
            "BriefTitle": "Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection",
            "OfficialTitle": "A Phase 1 Study of Vorinostat in Combination With Paclitaxel and Carboplatin in Solid Tumors (With Focus on Upper Aerodigestive Cancers) in Persons With HIV Infection",
            "LeadSponsorClass": "AIDS Malignancy Consortium",
            "SponsorAgency": "Other",
            "LeadSponsor": "AIDS Malignancy Consortium",
            "OversightAuthority": "No",
            "BriefSummary": "This phase I clinical trial is studying the side effects and the best dose of vorinostat\r\n\r\n      when given together with paclitaxel and carboplatin in treating patients with metastatic or\r\n\r\n      recurrent solid tumors and human immunodeficie",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To determine the safety and tolerability of vorinostat in combination with paclitaxel and\r\n\r\n      carboplatin in solid tumor patients with HIV infection.\r\n\r\n\r\n\r\n      II. To determine the maximal tolerated do",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "November 2013",
            "CompletionDate": "January 2020",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "AIDS Malignancy Consortium",
            "StudyCondition": "HIV Infection",
            "studyLocation": "UC San Diego Moores Cancer Center",
            "Enrollment": "17",
            "MeshKeyword": "Infection, Communicable Diseases, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Breast Neoplasms, Carcinoma, Stomach Neoplasms, HIV Infections, Acquired Immunodeficiency Syndrome, Esophageal Neoplasms, Oropharyngeal Neoplasms,",
            "InterventionKeyword": "Paclitaxel, Vorinostat, Albumin-Bound Paclitaxel, Carboplatin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must have known HIV infection and histologically confirmed solid malignancy\r\n\r\n             that is metastatic or unresectable and is therefore incurable; although the focus of\r\n\r\n             t",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "LA Jolla",
            "State": "California",
            "Zip": "92093",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 11, 2016",
            "FirstReceived": "November 25, 2010",
            "OverallOfficial": "Missak Haigentz",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "AIDS Associated Malignancies Clinical Trials Consortium",
            "LocationName": "UC San Diego Moores Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01249443",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110391 - AIDS Malignancy - Ramos",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20110391",
            "StudyNumber": "20110391 - AIDS Malignancy - Ramos",
            "StudyTitle": "AMC PROTOCOL 078: A Phase 1 Study of Paclitaxel and Carboplatin in Solid Tumors (with Focus on Upper Aerodigestive Cancers) in Persons with HIV Infection.",
            "PIID": "433",
            "PicNum": "C03978871",
            "PILastName": "Ramos",
            "PIFirstName": "Juan Carlos",
            "CoodCNbr": "C11923689",
            "CoordLastName": "Mohan",
            "CoordFirstName": "Vivin",
            "CoordEmail": "vxm153@miami.edu",
            "EnteredByCNbr": "C11964150",
            "EnteredByLastName": "Smith",
            "EnteredByFirstName": "Nyesha",
            "ActiveEnrollingDate": "03/23/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/23/2012",
            "IRBApprovedFrom": "11/07/2011",
            "IRBApprovedTo": "11/06/2017",
            "DiseaseSiteListDesc": "Soft Tissue",
            "Expr1": "Phase I",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "AIDS Malignancy Consortium",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:2,UMMG:N/A",
            "AccrualPercentageMet": "50",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "2",
            "EprostState": "Approved",
            "AgentDevices": "Vorinostat, Paclitaxel, Carboplatin",
            "NationalSampleSize": "26",
            "NCTNbr": "NCT01249443",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01271790",
            "BriefTitle": "A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C",
            "OfficialTitle": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of a 4-drug\r\n\r\n      regimen with GS-9451 and Tegobuvir and 24 weeks of a 3-drug regimen of GS-9451 without\r\n\r\n      Tegobuvir, all with Peginterferon Alfa-2a (Pegasys®",
            "OverallStatus": "Completed",
            "StartDate": "October 2010",
            "CompletionDate": "September 2013",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "Hepatitis C, Chronic",
            "studyLocation": "Digestive Health Specialists of the Southeast",
            "Enrollment": "245",
            "NctKeyword": "Hepatitis C, HCV, Rapid Virologic Response, Sustained Virologic Response, Direct Acting Antiviral, Combination Therapy, HCV RNA, Polymerase inhibitor, Protease inhibitor, Treatment naïve, GS-9190, GS-9451,",
            "MeshKeyword": "Hepatitis, Hepatitis A, Hepatitis C, Hepatitis C, Chronic,",
            "InterventionKeyword": "Ribavirin, Peginterferon alfa-2a, Interferon-alpha,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Adult subjects 18 to 70 years of age\r\n\r\n\r\n\r\n          -  Chronic HCV infection for at least 6 months prior to Baseline (Day 1)\r\n\r\n\r\n\r\n          -  Liver biopsy results (performed no more than 2 years pri",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "70 Years",
            "Volunteers": "No",
            "City": "Dothan",
            "State": "Alabama",
            "Zip": "36305",
            "Country": "United States",
            "VerificationDate": "January 2014",
            "LastChanged": "January 8, 2014",
            "FirstReceived": "January 5, 2011",
            "OverallOfficial": "Bittoo Kanwar",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "Digestive Health Specialists of the Southeast",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01271790",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20100983 - Gilead - Schiff",
            "FileProcessContentId": "440",
            "Division": "Hepatology",
            "StdyDivision": "10246",
            "EprostNbr": "20100983",
            "StudyNumber": "20100983 - Gilead - Schiff",
            "StudyTitle": "(Protocol GS-US-196-0140)\nA Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C00272649",
            "CoordLastName": "Vega",
            "CoordFirstName": "Marinellie",
            "CoordEmail": "mvega@med.miami.edu",
            "CoordPhone": "3052436809",
            "EnteredByCNbr": "C00758491",
            "EnteredByLastName": "Schiff",
            "EnteredByFirstName": "Eugene",
            "ActiveEnrollingDate": "04/27/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/27/2011",
            "IRBApprovedFrom": "04/11/2011",
            "IRBApprovedTo": "03/10/2014",
            "AccountNbr": "66811A",
            "InfoEdNbr": "55850",
            "Expr1": "Phase II",
            "Tarea": "Hepatitis C",
            "TareaCode": "12636",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Gilead Sciences, Inc",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "7",
            "Totalaccrued": "4",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "4",
            "SiteSampleSize": "UMH:20,JMH:N/A,UMMG:20",
            "AccrualPercentageMet": "10",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "40",
            "EprostState": "Approved",
            "StudyCoordinator": "Lia Quezada,Eva Pavicic,Odalys Rodriguez-Bravo,Maria Onate-Silva,Sonia Carvalho",
            "AgentDevices": "Agents: Copegus, Pegasys, GS-9190, GS-9451",
            "StudyObjective": "Objectives: \r\nThe primary objective of this study is:\r\nTo evaluate the antiviral efficacy (sustained virologic response [SVR]; defined as undetectable HCV RNA 24 weeks following treatment cessation) of 16 and 24 weeks of a 4-drug regimen with tegobuvir and 24 weeks of a 3-drug regimen of GS-9451 without tegobuvir (GS-9190), all with peginterferon alfa 2a (PEG), and ribavirin (RBV) followed by response guided PEG/RBV with a control arm of PEG/RBV therapy for 48 weeks.\r\n\r\nThe secondary objectives of this study include the following:\r\n To evaluate the safety and tolerability of therapy in each treatment arm\r\n To evaluate the emergence of viral resistance following therapy\r\nwith GS-9451 when administered with PEG and RBV with and without tegobuvir\r\n To characterize viral dynamics and steady state pharmacokinetics of GS-9451 and tegobuvir when administered with PEG and RBV\r\n\r\nExploratory objectives of this study include the following:\r\n Assess genetic variation in the human IL28B gene as a predictor of virologic response in each treatment arm\r\n Through genetic discovery research (i.e. pharmacogenomics) in subjects who provide their additional and specific consent: to identify or validate genetic markers that may be predictive of the natural history of HCV disease, the virologic response to therapy, and the tolerability of drugs used in HCV therapeutics.\r\n\r\nResistance Registry Substudy objective:\r\n To evaluate HCV resistance profiles and the persistence of selected viral resistant mutations in subjects who do not achieve SVR \r\n\r\nLong-term SVR Registry Substudy objective:\r\n To evaluate the durability of response in subjects who achieve SVR\r\n\r\nOpen-label Retreatment Substudy objectives:\r\n To evaluate the antiviral efficacy of 24 weeks of therapy with GS-9451, tegobuvir, PEG and RBV followed by 24 additional weeks of PEG and RBV in subjects who fail to respond to PEG and RBV in the control arm of this study.",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT01271790",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "1",
            "StudyInvINDNbr": "76,031",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01310023",
            "SecondaryId": "PH100",
            "BriefTitle": "Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women",
            "OfficialTitle": "Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women",
            "LeadSponsorClass": "Harvard School of Public Health",
            "SponsorAgency": "Other",
            "LeadSponsor": "Harvard School of Public Health",
            "OversightAuthority": "No",
            "BriefSummary": "SMARTT will estimate the incidence of conditions and diagnoses potentially related to in\r\n\r\n      utero exposure to antiretroviral therapy and/or exposure in the first two months of life\r\n\r\n      among children born of HIV-infected mothers.",
            "Description": "Many antiretroviral therapy (ART) medications given to a pregnant woman cross the placenta\r\n\r\n      and can be detected in the amniotic fluid and cord blood resulting in substantial fetal\r\n\r\n      exposure. Therefore, there is concern about toxi",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2007",
            "CompletionDate": "July 2020",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Harvard School of Public Health",
            "StudyCondition": "Antiretroviral Toxicity",
            "studyLocation": "University of Alabama",
            "Enrollment": "3400",
            "NctKeyword": "Conditions and diagnoses potentially related to perinatal exposure to antiretroviral medications,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        Static Surveillance Cohort:\r\n\r\n\r\n\r\n          -  HIV-exposed but -uninfected infants and children; lack of infection must be\r\n\r\n             documented by medical or research record review. Children exposed an",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 10, 2017",
            "FirstReceived": "March 4, 2011",
            "OverallOfficial": "George R. Seage, ScD, MPH",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Harvard School of Public Health",
            "ContactName": "Julie K Alperen, DrPH",
            "ContactPhone": "617-432-6762",
            "ContactEmail": "jalperen@hsph.harvard.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01310023",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20061031 - NIH - Scott",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20061031",
            "StudyNumber": "20061031 - NIH - Scott",
            "StudyTitle": "PEDIATRIC HIV/AIDS COHORT STUDY (PHACS)\nSurveillance Monitoring for ART Toxicities Study in HIV-uninfected Children Born to HIV-infected Women (SMARTT Study)\nPROTOCOL PH100\nVersion 5.0\nAugust 16, 2016",
            "PIID": "1243",
            "PicNum": "C00795461",
            "PILastName": "Scott",
            "PIFirstName": "Gwendolyn",
            "CoodCNbr": "C00482361",
            "CoordLastName": "Falk",
            "CoordFirstName": "Alan",
            "EnteredByCNbr": "C00795461",
            "EnteredByLastName": "Scott",
            "EnteredByFirstName": "Gwendolyn",
            "ActiveEnrollingDate": "02/26/2007",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/26/2007",
            "IRBApprovedFrom": "02/26/2007",
            "IRBApprovedTo": "03/01/2017",
            "AccountNbr": "66735R",
            "InfoEdNbr": "36900/51137/51360/51693/53734/57923/58232/61328/63160/63647",
            "Expr1": "N/A",
            "Tarea": "Immunology/Infectious Disease",
            "TareaCode": "13340",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "371",
            "Totalaccrued": "368",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "274",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "373",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:320,UMMG:120,UMHC:120",
            "AccrualPercentageMet": "65.71428571428571428571428571428571428571",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "560",
            "EprostState": "Approved",
            "StudyCoordinator": "Gabriel Fernandez,Sady Dominguez",
            "StudyObjective": "The specific aims of SMARTT are:\r\n\r\nTo create a Static Surveillance Cohort to extend domain-specific data collection in children either 1) previously enrolled in any of the approved studies for enrollment into SMARTT; 2) previously enrolled in another pediatric HIV/AIDS cohort study with SMARTT Protocol Chair approval, or 3) \r\nnot previously enrolled in an approved study but with equivalent data available in the medical record.\r\n To create a Dynamic Surveillance Cohort to examine domain-specific data of children newly exposed to ART in utero and/or in the first two months of life; \r\n To identify a set of triggers for each domain that define a signal of possible ART toxicity and compare the occurrence of these signals with previously collected data and by ART exposure; and \r\n To encourage and facilitate the development of hypothesis-driven studies to evaluate whether a signal is the result of ART exposure in utero and/or in the first two months of life.",
            "NationalSampleSize": "760",
            "NCTNbr": "NCT01310023",
            "StudyKeywords": "ORIM QA: Kanchan Sakhrani (10/20/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01324180",
            "SecondaryId": "Sunshine Project 001",
            "BriefTitle": "Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)",
            "OfficialTitle": "A Phase I Window, Dose Escalating and Safety Trial of Metformin in Combination With Induction Chemotherapy in Relapsed Refractory Acute Lymphoblastic Leukemia: Metformin With Induction Chemotherapy of Vincristine, Dexamethasone, Doxorubicin, and PEG-aspar",
            "LeadSponsorClass": "H. Lee Moffitt Cancer Center and Research Institute",
            "SponsorAgency": "Other",
            "LeadSponsor": "H. Lee Moffitt Cancer Center and Research Institute",
            "OversightAuthority": "Yes",
            "BriefSummary": "H. Lee Moffitt Cancer Center and Research Institute will be the Sunshine Project\r\n\r\n      Coordinator, but will not be recruiting locally.\r\n\r\n\r\n\r\n      The purpose of the trial is to study the clinical and biological effects of metformin in",
            "Description": "This will be a phase I protocol of Vincristine, Dexamethasone, Doxorubicin, and\r\n\r\n      PEG-asparaginase (VPLD) and metformin conducted in the Sunshine Project sites for children\r\n\r\n      with recurrent ALL. All sites will be eligible to open t",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "March 2011",
            "CompletionDate": "July 2017",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "H. Lee Moffitt Cancer Center and Research Institute",
            "StudyCondition": "Acute Lymphoblastic Leukemia",
            "studyLocation": "Connecticut Children's Medical Center",
            "Enrollment": "14",
            "NctKeyword": "ALL, Relapsed, Refractory,",
            "MeshKeyword": "Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid,",
            "InterventionKeyword": "Metformin, Dexamethasone acetate, Dexamethasone, Dexamethasone 21-phosphate, Liposomal doxorubicin, Pegaspargase, Doxorubicin, Vincristine, Asparaginase, BB 1101,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  ALL or lymphoblastic lymphoma patients in first or higher relapse.\r\n\r\n\r\n\r\n          -  Male or Female age 1-30 years at initial diagnosis.\r\n\r\n\r\n\r\n          -  Signed informed consent.\r\n\r\n\r\n\r\n          -",
            "EligibleGender": "All",
            "MinAge": "1 Year",
            "MaxAge": "30 Years",
            "Volunteers": "No",
            "City": "Hartford",
            "State": "Connecticut",
            "Zip": "06106",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 23, 2016",
            "FirstReceived": "March 24, 2011",
            "OverallOfficial": "Julio M. Barredo, M.D.",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Holtz Children's Hospital University of Miami Miller School of Medicine",
            "LocationName": "Connecticut Children's Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01324180",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110140 - Pediatric CA Foundation - Goldberg",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20110140",
            "StudyNumber": "20110140 - Pediatric CA Foundation - Goldberg",
            "StudyTitle": "A Phase I Window, Dose Escalating and Safety Trial of Metformin in Combination with Induction Chemotherapy in Relapsed Refractory Acute Lymphoblastic Leukemia: Metformin with Induction Chemotherapy of Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD)",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C00110674",
            "CoordLastName": "Zayas",
            "CoordFirstName": "Myriam",
            "CoordEmail": "MZayas2@med.miami.edu",
            "EnteredByCNbr": "C00110674",
            "EnteredByLastName": "Zayas",
            "EnteredByFirstName": "Myriam",
            "ActiveEnrollingDate": "03/21/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/21/2011",
            "IRBApprovedFrom": "03/21/2011",
            "IRBApprovedTo": "03/13/2017",
            "AccountNbr": "66883X",
            "InfoEdNbr": "56810",
            "DiseaseSiteListDesc": "Lymphoid Leukemia",
            "Expr1": "Phase I",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "Pediatric Cancer Foundation",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "7",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "6",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:3,UMMG:N/A",
            "AccrualPercentageMet": "233.333333333333333333333333333333333333",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "3",
            "EprostState": "Approved",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT01324180",
            "StudyKeywords": "Leukemia",
            "StudyInvIND": "1",
            "StudyInvINDNbr": "111415",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01324570",
            "SecondaryId": "2010-021954-21",
            "BriefTitle": "Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children",
            "OfficialTitle": "An Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Buprenorphine Transdermal System (BTDS) in Children From 7 to 16 Years of Age, Inclusive, Who Require Continuous Opioid Analgesia for Moderate to Severe Pain",
            "LeadSponsorClass": "Purdue Pharma LP",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Purdue Pharma LP",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to characterize the safety, PK, and efficacy of BTDS in\r\n\r\n      patients of ages 7 to 16 years.",
            "Description": "A study of safety, PK, and efficacy of BTDS in patients of ages 7 to 16 years, inclusive,\r\n\r\n      who require continuous opioid analgesia for moderate to severe pain.",
            "OverallStatus": "Completed",
            "StartDate": "July 2011",
            "CompletionDate": "May 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Purdue Pharma LP",
            "StudyCondition": "Pain",
            "studyLocation": "Long Beach Memorial Medical Center",
            "Enrollment": "41",
            "NctKeyword": "Pain, Opioid, Analgesia, Moderate to severe pain,",
            "InterventionKeyword": "Buprenorphine,",
            "Eligibility": "Inclusion Criteria include:\r\n\r\n\r\n\r\n          -  Male and female patients, 7 to 16 years of age, inclusive, with malignant and/or\r\n\r\n             nonmalignant moderate to severe pain requiring or anticipated to require continuous,",
            "EligibleGender": "All",
            "MinAge": "7 Years",
            "MaxAge": "16 Years",
            "Volunteers": "No",
            "City": "Long Beach",
            "State": "California",
            "Zip": "90806",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 6, 2016",
            "FirstReceived": "March 24, 2011",
            "LocationName": "Long Beach Memorial Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01324570",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130186 - Purdue Pharma L.P. - Gebhard",
            "FileProcessContentId": "440",
            "Division": "Anesthesiology",
            "StdyDivision": "10236",
            "EprostNbr": "20130186",
            "StudyNumber": "20130186 - Purdue Pharma L.P. - Gebhard",
            "StudyTitle": "An Openlabel, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Buprenorphine Transdermal System (BTDS) in Children From 7 to 16 Years of Age, Inclusive, Who Require Continuous Opioid Analgesia for Moderate to Severe Pain",
            "PIID": "706",
            "PicNum": "C04976318",
            "PILastName": "Gebhard",
            "PIFirstName": "Ralf",
            "CoodCNbr": "C10565278",
            "CoordLastName": "Gutierrez",
            "CoordFirstName": "Juan",
            "CoordEmail": "JGutierrez4@med.miami.edu",
            "EnteredByCNbr": "C04976318",
            "EnteredByLastName": "Gebhard",
            "EnteredByFirstName": "Ralf",
            "ActiveEnrollingDate": "09/29/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/29/2014",
            "IRBApprovedFrom": "05/21/2013",
            "IRBApprovedTo": "02/23/2017",
            "Expr1": "Phase III",
            "Tarea": "Pain Management",
            "TareaCode": "16648",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "3",
            "Screenedfailed": "2",
            "SignedICF": "6",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Juan Gutierrez,Maria Antor",
            "NationalSampleSize": "40",
            "NCTNbr": "NCT01324570",
            "StudyKeywords": "Kids pain, child pain, skin patch, opioids, buprenorphine, BTDS system, pediatric pain, pain",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01337076",
            "BriefTitle": "Evaluation of a Revised Indication for Determining Adult Cochlear Implant Candidacy",
            "OfficialTitle": "Evaluation of a Revised Indication for Determining Adult Cochlear Implant Candidacy",
            "LeadSponsorClass": "Cochlear",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Cochlear",
            "OversightAuthority": "No",
            "BriefSummary": "The Sponsor values the progression of hearing healthcare practice and acknowledges a need\r\n\r\n      for re-evaluation of indications for determining adult cochlear implant candidacy. This need\r\n\r\n      arises from current research, peer reviewed",
            "Description": "Existing research, as discussed, supports the opinion that current candidacy criteria are\r\n\r\n      set conservatively. The Sponsor, in addition to the support of recent peer reviewed\r\n\r\n      literature illustrating a need for an appropriate cri",
            "OverallStatus": "Completed",
            "StartDate": "May 2012",
            "CompletionDate": "January 2014",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Cochlear",
            "StudyCondition": "Hearing Loss",
            "studyLocation": "Mayo Clinic",
            "Enrollment": "21",
            "MeshKeyword": "Hearing Loss,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Eighteen years of age or older at the time of the study.\r\n\r\n\r\n\r\n          -  Preoperative aided CNC word score in quiet of greater than or equal to 10% and less\r\n\r\n             than or equal to ¬¬40% in",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Rochester",
            "State": "Minnesota",
            "Zip": "55905",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 23, 2016",
            "FirstReceived": "April 14, 2011",
            "OverallOfficial": "Colin Driscoll, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Mayo Clinic",
            "LocationName": "Mayo Clinic",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01337076",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130365 - COCHLEAR AMERICAS - Telischi",
            "FileProcessContentId": "440",
            "Division": "Otolaryngology",
            "StdyDivision": "10136",
            "EprostNbr": "20130365",
            "StudyNumber": "20130365 - COCHLEAR AMERICAS - Telischi",
            "StudyTitle": "Safety and Efficacy of the Cochlear Nucleus CI422 Cochlear Implant in Adults",
            "PIID": "3160",
            "PicNum": "C00773714",
            "PILastName": "Telischi",
            "PIFirstName": "Fred",
            "CoodCNbr": "C00575387",
            "CoordLastName": "Goodwin",
            "CoordFirstName": "Leslie",
            "CoordEmail": "lgoodwin@med.miami.edu",
            "EnteredByCNbr": "C06931201",
            "EnteredByLastName": "Pelusso",
            "EnteredByFirstName": "Constanza",
            "ActiveEnrollingDate": "03/12/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/12/2015",
            "IRBApprovedFrom": "07/16/2013",
            "IRBApprovedTo": "05/04/2016",
            "InfoEdNbr": "66904",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device",
            "SponsorGroup": "Other",
            "Sponsor": "COCHLEAR AMERICAS",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "ABLEH:N/A,UMMG:N/A,UMHC:N/A,JMH:N/A,Non University of Miami:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Constanza Pelusso",
            "NationalSampleSize": "4",
            "NCTNbr": "NCT01337076",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01343043",
            "BriefTitle": "A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma",
            "OfficialTitle": "A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma",
            "LeadSponsorClass": "Adaptimmune",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Adaptimmune",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this early (pilot) clinical trial is to test the effects (both good and bad)\r\n\r\n      of chemotherapy and adoptive immunotherapy with T cells engineered to recognize NY-ESO-1\r\n\r\n      peptide in patients with unresectable, metasta",
            "Description": "Design\r\n\r\n\r\n\r\n      - Patients will undergo apheresis at the enrolling institution. Fresh PBMC will be shipped\r\n\r\n      to a central manufacturer for gene transduction, activation and expansion, then\r\n\r\n      cryopreserved and shipped back to th",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2011",
            "CompletionDate": "March 2028",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Adaptimmune",
            "StudyCondition": "Synovial Sarcoma",
            "studyLocation": "City of Hope",
            "Enrollment": "65",
            "NctKeyword": "Sarcoma, Cell Therapy, T Cell Therapy, NY-ESO-1, Immuno-oncology, Metastatic, Previously treated, T Cell Receptor,",
            "MeshKeyword": "Sarcoma, Sarcoma, Synovial,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Synovial sarcoma that has been treated with standard chemotherapy containing\r\n\r\n             ifosfamide and/or doxorubicin and remains: unresectable or metastatic or\r\n\r\n             progressive/persisten",
            "EligibleGender": "All",
            "MinAge": "4 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Duarte",
            "State": "California",
            "Zip": "91010",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 4, 2016",
            "FirstReceived": "April 26, 2011",
            "OverallOfficial": "Sandra D'Angelo, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Memorial Sloan Kettering Cancer Center",
            "ContactName": "Sandra D'Angelo, MD",
            "ContactPhone": "646-888-1394",
            "ContactEmail": "lees4@mskcc.org",
            "LocationStatus": "Recruiting",
            "LocationName": "City of Hope",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01343043",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150726 - Adaptimmune - Wilky",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150726",
            "StudyNumber": "20150726 - Adaptimmune - Wilky",
            "StudyTitle": "A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T cells in HLA-A2+Patients with Synovial Sarcoma",
            "PIID": "4630",
            "PicNum": "C11848802",
            "PILastName": "Wilky",
            "PIFirstName": "Breelyn",
            "CoodCNbr": "C12022610",
            "CoordLastName": "Solomon",
            "CoordFirstName": "Thankam",
            "CoordEmail": "thankam.solomon@med.miami.edu",
            "EnteredByCNbr": "C07181703",
            "EnteredByLastName": "Zhang",
            "EnteredByFirstName": "Lei",
            "ActiveEnrollingDate": "06/15/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/15/2016",
            "IRBApprovedFrom": "04/04/2016",
            "IRBApprovedTo": "04/03/2017",
            "AccountNbr": "667162",
            "DiseaseSiteListDesc": "Soft Tissue",
            "Expr1": "Pilot/Feasibility",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Adaptimmune Transforming",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Luis,Georges Tahhan",
            "NationalSampleSize": "2",
            "NCTNbr": "NCT01343043",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01345006",
            "BriefTitle": "Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy",
            "OfficialTitle": "A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dyst",
            "LeadSponsorClass": "Astellas Institute for Regenerative Medicine",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Astellas Institute for Regenerative Medicine",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a safety and tolerability trial to evaluate the effect of subretinal injection of\r\n\r\n      human embryonic stem cell derived retinal pigment epithelium cells in patients with\r\n\r\n      Stargardt's Macular Dystrophy (SMD).",
            "Description": "This study is a Phase I/II, open-label, non randomized, sequential, multi-center clinical\r\n\r\n      trial. There will be 5 cohorts, the 4 low vision cohorts will contain 3 patients, the better\r\n\r\n      vision cohort will contain 4 patients. The e",
            "OverallStatus": "Completed",
            "StartDate": "April 2011",
            "CompletionDate": "August 2015",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Astellas Pharma Inc",
            "StudyCondition": "Stargardt's Macular Dystrophy",
            "studyLocation": "Jules Stein Eye Institute, UCLA School of Medicine",
            "Enrollment": "13",
            "NctKeyword": "juvenile macular dystrophy, SMD, fundus flavimaculatus,",
            "MeshKeyword": "Macular Degeneration,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Adult male or female over 18 years of age.\r\n\r\n\r\n\r\n          -  Clinical diagnosis of advanced SMD.\r\n\r\n\r\n\r\n          -  If known, the patient's genotype will be recorded in the medical history, if unknown",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90095",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 9, 2016",
            "FirstReceived": "April 28, 2011",
            "OverallOfficial": "Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Astellas Institute for Regenerative Medicine",
            "LocationName": "Jules Stein Eye Institute, UCLA School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01345006",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140131 - Advanced Cell Technology - Lam",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20140131",
            "StudyNumber": "20140131 - Advanced Cell Technology - Lam",
            "StudyTitle": "Long Term Follow Up to a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients with Stargardt’s Macular Dystrophy (SMD)",
            "PIID": "1115",
            "PicNum": "C00679155",
            "PILastName": "Lam",
            "PIFirstName": "Byron",
            "CoodCNbr": "C07458455",
            "CoordLastName": "Morante",
            "CoordFirstName": "Alexis",
            "CoordEmail": "amorante@med.miami.edu",
            "EnteredByCNbr": "C00679155",
            "EnteredByLastName": "Lam",
            "EnteredByFirstName": "Byron",
            "ActiveEnrollingDate": "08/08/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/08/2014",
            "IRBApprovedFrom": "06/27/2014",
            "IRBApprovedTo": "04/04/2017",
            "InfoEdNbr": "70558",
            "ResearchType": "Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Advanced Cell Technology",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Alexis Morante,Jennifer Verriotto,Potyra Rosa",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT01345006",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01351545",
            "BriefTitle": "A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)",
            "OfficialTitle": "A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications",
            "LeadSponsorClass": "Center for International Blood and Marrow Transplant Research",
            "SponsorAgency": "Other",
            "LeadSponsor": "Center for International Blood and Marrow Transplant Research",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study is an access and distribution protocol for unlicensed cryopreserved cord blood\r\n\r\n      units (CBUs) in pediatric and adult patients with hematologic malignancies and other\r\n\r\n      indications.",
            "Description": "Principal Investigators:\r\n\r\n\r\n\r\n      The principal investigators (PIs) will be transplant physicians at all participating U.S.\r\n\r\n      transplant centers.\r\n\r\n\r\n\r\n      Study Design:\r\n\r\n\r\n\r\n      This study is an access and distribution protoco",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2011",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Center for International Blood and Marrow Transplant Research",
            "StudyCondition": "Hematologic Malignancies",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "99999",
            "MeshKeyword": "Disease, Neoplasms, Immunologic Deficiency Syndromes, Congenital Abnormalities, Thalassemia, beta-Thalassemia, Pancytopenia, Lymphoproliferative Disorders,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Disorders affecting the hematopoietic system that are inherited, acquired, or result\r\n\r\n             from myeloablative treatment\r\n\r\n\r\n\r\n          -  Signed informed consent (and signed assent, if applic",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 18, 2017",
            "FirstReceived": "May 9, 2011",
            "OverallOfficial": "John Miller, MD, PhD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "NMDP/CIBMTR",
            "ContactName": "Lexi Adams, MPH, CCRP",
            "ContactPhone": "612-884-8735",
            "ContactEmail": "aadams@nmdp.org",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01351545",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20111031 -NMDP- Komanduri",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20111031",
            "StudyNumber": "20111031 -NMDP- Komanduri",
            "StudyTitle": "A Multicenter Access And Distribution Protocol For Unlicensed Cryopreserved Cord Blood Units (CBUS) For Transplantation In Adult Patients With Hematologic Malignancies And Other Indications",
            "PIID": "1930",
            "PicNum": "C06948118",
            "PILastName": "Komanduri",
            "PIFirstName": "Krishna",
            "CoodCNbr": "C10180073",
            "CoordLastName": "Gonzalez",
            "CoordFirstName": "Nohelia",
            "CoordEmail": "ngonzalez5@med.miami.edu",
            "CoordPhone": "3052434903",
            "EnteredByCNbr": "C11964150",
            "EnteredByLastName": "Smith",
            "EnteredByFirstName": "Nyesha",
            "ActiveEnrollingDate": "02/29/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/29/2012",
            "IRBApprovedFrom": "02/20/2012",
            "IRBApprovedTo": "12/20/2016",
            "DiseaseSiteListDesc": "Leukemia, Other,Other Hematopoietic",
            "Expr1": "N/A",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Drug",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "NATIONAL MARROW DONOR PROGRAM",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "5",
            "Totalaccrued": "5",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Patricia Gomez",
            "NationalSampleSize": "200",
            "NCTNbr": "NCT01351545",
            "StudyKeywords": "Note: per Deborah email on 2/12/2016 this a therapeutic study.  PRC Form is incorrect.",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01351545",
            "BriefTitle": "A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)",
            "OfficialTitle": "A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications",
            "LeadSponsorClass": "Center for International Blood and Marrow Transplant Research",
            "SponsorAgency": "Other",
            "LeadSponsor": "Center for International Blood and Marrow Transplant Research",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study is an access and distribution protocol for unlicensed cryopreserved cord blood\r\n\r\n      units (CBUs) in pediatric and adult patients with hematologic malignancies and other\r\n\r\n      indications.",
            "Description": "Principal Investigators:\r\n\r\n\r\n\r\n      The principal investigators (PIs) will be transplant physicians at all participating U.S.\r\n\r\n      transplant centers.\r\n\r\n\r\n\r\n      Study Design:\r\n\r\n\r\n\r\n      This study is an access and distribution protoco",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2011",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Center for International Blood and Marrow Transplant Research",
            "StudyCondition": "Hematologic Malignancies",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "99999",
            "MeshKeyword": "Disease, Neoplasms, Immunologic Deficiency Syndromes, Congenital Abnormalities, Thalassemia, beta-Thalassemia, Pancytopenia, Lymphoproliferative Disorders,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Disorders affecting the hematopoietic system that are inherited, acquired, or result\r\n\r\n             from myeloablative treatment\r\n\r\n\r\n\r\n          -  Signed informed consent (and signed assent, if applic",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 18, 2017",
            "FirstReceived": "May 9, 2011",
            "OverallOfficial": "John Miller, MD, PhD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "NMDP/CIBMTR",
            "ContactName": "Lexi Adams, MPH, CCRP",
            "ContactPhone": "612-884-8735",
            "ContactEmail": "aadams@nmdp.org",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01351545",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110787 - NATL MARROW DONOR PROGRAM - Andreansky",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20110787",
            "StudyNumber": "20110787 - NATL MARROW DONOR PROGRAM - Andreansky",
            "StudyTitle": "A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications",
            "PIID": "590",
            "PicNum": "C06466265",
            "PILastName": "Andreansky",
            "PIFirstName": "Martin",
            "CoodCNbr": "C00046839",
            "CoordLastName": "Willumsen",
            "CoordFirstName": "Silvia",
            "CoordEmail": "swillums@med.miami.edu",
            "CoordPhone": "3055857359",
            "EnteredByCNbr": "C00046839",
            "EnteredByLastName": "Willumsen",
            "EnteredByFirstName": "Silvia",
            "ActiveEnrollingDate": "11/17/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/28/2013",
            "IRBApprovedFrom": "12/19/2011",
            "IRBApprovedTo": "10/16/2017",
            "InfoEdNbr": "58960, 68821",
            "DiseaseSiteListDesc": "Other Hematopoietic",
            "Expr1": "Phase IV",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Correlative",
            "StudyType_Code": "140",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "Externally Peer Re-review",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "6",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,JMH:100,UMMG:N/A",
            "AccrualPercentageMet": "6",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "100",
            "EprostState": "Approved",
            "StudyCoordinator": "Gabriela D'Antonio,Yamilet Delgado Vigoa",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT01351545",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01369082",
            "BriefTitle": "Extended Follow-Up After Islet Transplantation in T1D",
            "OfficialTitle": "Extended Follow-Up After Islet Transplantation in Type 1 Diabetes (CIT-08)",
            "LeadSponsorClass": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to provide patients who have received at least one islet\r\n\r\n      transplant as a previous participant in a Clinical Islet Transplantation Consortium (CIT)\r\n\r\n      clinical trial with maintenance immunosuppressive m",
            "Description": "After islet-cell transplantation in the CIT studies*, each subject receives maintenance\r\n\r\n      immunosuppressive medications.\r\n\r\n\r\n\r\n      The purpose of this protocol is to collect additional follow-up for safety and efficacy from\r\n\r\n      CI",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "May 2011",
            "CompletionDate": "July 2018",
            "Phase": "Phase 3",
            "StudyType": "Observational",
            "StudyPhase": "Phase 3",
            "StudySource": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "StudyCondition": "Type 1 Diabetes (T1D)",
            "studyLocation": "University of California, San Francisco",
            "Enrollment": "75",
            "NctKeyword": "islet allograft function, c-peptide production, maintenance immunosuppressive medications,",
            "MeshKeyword": "Diabetes Mellitus, Type 1,",
            "InterventionKeyword": "Tacrolimus, Mycophenolate mofetil, Cyclosporins, Cyclosporine, Sirolimus, Immunosuppressive Agents, Mycophenolic Acid,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subjects who have received an islet transplant during participation in the following\r\n\r\n             Clinical Islet Transplantation (CIT) parent studies: CIT02 (NCT00464555), CIT03\r\n\r\n             (NCT00",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "San Francisco",
            "State": "California",
            "Zip": "94143",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 14, 2016",
            "FirstReceived": "June 3, 2011",
            "OverallOfficial": "Bernhard Hering, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Minnesota - Clinical and Translational Science Institute",
            "LocationName": "University of California, San Francisco",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01369082",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120246 - NIH (NIAID and NIDDK are co-sponsoring study)/NIH  - Ricordi",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20120246",
            "StudyNumber": "20120246 - NIH (NIAID and NIDDK are co-sponsoring study)/NIH  - Ricordi",
            "StudyTitle": "CLINICAL ISLET TRANSPLANTATION (CIT)PROTOCOL CIT08Extended Follow Up after Islet Transplantation in Type 1 Diabetes",
            "PIID": "1318",
            "PicNum": "C00064947",
            "PILastName": "Ricordi",
            "PIFirstName": "Camillo",
            "CoodCNbr": "C09431526",
            "CoordLastName": "Moraes Leao Peixoto",
            "CoordFirstName": "Eduardo",
            "CoordEmail": "epeixoto@med.miami.edu",
            "CoordPhone": "3052433389",
            "EnteredByCNbr": "C00622014",
            "EnteredByLastName": "Pavicic",
            "EnteredByFirstName": "Eva",
            "ActiveEnrollingDate": "07/17/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/17/2012",
            "IRBApprovedFrom": "07/12/2012",
            "IRBApprovedTo": "05/15/2017",
            "InfoEdNbr": "68473",
            "Expr1": "N/A",
            "Tarea": "Islet Transplant",
            "TareaCode": "12545",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "2",
            "SiteSampleSize": "BPPB:N/A,JMH:N/A,UMMG:N/A,UMH:N/A,UMHC:N/A,Clinical Research Center (CRC):N/A,Non University of Miami:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Elina Linetsky,Ana Alvarez,Luz Arazo,Carlos Blaschke,Della Matheson",
            "NationalSampleSize": "4",
            "NCTNbr": "NCT01369082",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01371305",
            "SecondaryId": "STX-003",
            "BriefTitle": "STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)",
            "OfficialTitle": "Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)",
            "LeadSponsorClass": "Biogen",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Biogen",
            "OversightAuthority": "Yes",
            "BriefSummary": "The primary objective of this study is to evaluate the safety and tolerability of\r\n\r\n      subcutaneously (SC) administered multiple, escalating doses of BG00011 (a humanized\r\n\r\n      monoclonal antibody directed against the alpha v beta 6 (αvβ6",
            "Description": "This study was previously posted by Stromedix, Inc. In April, 2014, sponsorship of the trial\r\n\r\n      was transferred to Biogen. The study drug name was changed from STX-100 to BG00011 and the\r\n\r\n      study number was changed from STX-003 to 20",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2012",
            "CompletionDate": "August 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Biogen",
            "StudyCondition": "Idiopathic Pulmonary Fibrosis (IPF)",
            "studyLocation": "Research Site",
            "Enrollment": "40",
            "MeshKeyword": "Fibrosis, Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonias, Pulmonary Fibrosis,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Clinical features consistent with IPF prior to screening (based on the American\r\n\r\n             Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory\r\n\r\n             Society",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "84 Years",
            "Volunteers": "No",
            "City": "San Francisco",
            "State": "California",
            "Zip": "94143",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 6, 2017",
            "FirstReceived": "June 3, 2011",
            "OverallOfficial": "Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Biogen",
            "ContactName": "Biogen",
            "ContactEmail": "clinicaltrials@biogen.com",
            "LocationStatus": "Active, not recruiting",
            "LocationName": "Research Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01371305",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110339 - STROMEDIX INC - Glassberg",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20110339",
            "StudyNumber": "20110339 - STROMEDIX INC - Glassberg",
            "StudyTitle": "Randomized, DoubleBlind, PlaceboControlled, Multiple Dose, DoseEscalation Study of STX100 in Patients with Idiopathic Pulmonary Fibrosis (IPF)",
            "PIID": "839",
            "PicNum": "C00393339",
            "PILastName": "Glassberg Csete",
            "PIFirstName": "Marilyn",
            "CoodCNbr": "C00047281",
            "CoordLastName": "Simonet",
            "CoordFirstName": "Emmanuelle",
            "CoordEmail": "esimonet@med.miami.edu",
            "CoordPhone": "3052433728",
            "EnteredByCNbr": "C00047281",
            "EnteredByLastName": "Simonet",
            "EnteredByFirstName": "Emmanuelle",
            "ActiveEnrollingDate": "09/12/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/12/2011",
            "IRBApprovedFrom": "07/19/2011",
            "IRBApprovedTo": "07/04/2017",
            "AccountNbr": "66874G",
            "InfoEdNbr": "57316",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase II",
            "Tarea": "Idiopathic Pulmonary Fibrosis (IPF)",
            "TareaCode": "13536",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "STROMEDIX INC",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "5",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Emmanuelle Simonet,Esther Diaz,Lilian Cadet,Johana Arana,Eliana Mendes,Patricia Rebolledo",
            "AgentDevices": "STX001",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01371305",
            "StudyKeywords": "IPF, PULMONARY, FIBROSIS, STROMEDIX, STX",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01371981",
            "SecondaryId": "NCI-2011-02670",
            "BriefTitle": "Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",
            "OfficialTitle": "A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in\r\n\r\n      treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib\r\n\r\n      tosylate may stop the growth of cancer cells by",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To compare event-free survival (EFS) and overall survival (OS) in patients with de novo\r\n\r\n      acute myeloid leukemia (AML) without high allelic ratio fms-like tyrosine kinase\r\n\r\n      (FLT3)/internal tandem",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2011",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Leukemia Cutis",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "1750",
            "MeshKeyword": "Leukemia, Myeloid, Leukemia, Myeloid, Acute, Leukemia, Sarcoma, Myeloid,",
            "InterventionKeyword": "Sorafenib, Etoposide phosphate, Bortezomib, Etoposide, Cytarabine, Daunorubicin, Asparaginase, Podophyllotoxin, Mitoxantrone, Niacinamide,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must be newly diagnosed with de novo acute myelogenous leukemia\r\n\r\n\r\n\r\n          -  Patients with previously untreated primary AML who meet the customary criteria for\r\n\r\n             AML with >=",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "29 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "June 10, 2011",
            "OverallOfficial": "Richard Aplenc",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01371981",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20160853 - COG - Barredo",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160853",
            "StudyNumber": "20160853 - COG - Barredo",
            "StudyTitle": "AAML1031  A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND 58443, NSC 681239) and Sorafenib (BAY 439006, IND69896, NSC 724772) for Patients with High Allelic Ratio FLT3/ITD.",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C00722004",
            "CoordLastName": "Garantiva",
            "CoordFirstName": "Nuria",
            "CoordEmail": "nfc19@miami.edu",
            "EnteredByCNbr": "C00722004",
            "EnteredByLastName": "Garantiva",
            "EnteredByFirstName": "Nuria",
            "ActiveEnrollingDate": "07/16/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/16/2012",
            "IRBApprovedFrom": "07/16/2012",
            "IRBApprovedTo": "07/23/2017",
            "InfoEdNbr": "65076/65853",
            "DiseaseSiteListDesc": "Myeloid and Monocytic Leukemia",
            "Expr1": "Phase III",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "COG",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "10",
            "Totalaccrued": "9",
            "InFollowUp": "4",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "10",
            "FirstNinety": "4",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Myriam Zayas",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01371981",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01392625",
            "SecondaryId": "1R01HL110737-01",
            "BriefTitle": "PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)",
            "OfficialTitle": "A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Dilated Cardiomyopathy.",
            "LeadSponsorClass": "Joshua M Hare",
            "SponsorAgency": "Other",
            "LeadSponsor": "Joshua M Hare",
            "OversightAuthority": "Yes",
            "BriefSummary": "The technique of transplanting progenitor cells into a region of damaged myocardium, termed\r\n\r\n      cellular cardiomyoplasty1, is a potentially new therapeutic modality designed to replace or\r\n\r\n      repair necrotic, scarred, or dysfunctional",
            "Description": "This is a Pilot Study, intended as a safety assessment prior to a full comparator study. In\r\n\r\n      this Pilot Study, cells administered via the Biosense Webster MyoStar NOGA injection\r\n\r\n      catheter system will be tested in 36 patients in t",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "June 2011",
            "CompletionDate": "August 2017",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Non-ischemic Dilated Cardiomyopathy",
            "studyLocation": "University of Miami School of Medicine",
            "Enrollment": "36",
            "NctKeyword": "Non ischemic dilated cardiomyopathy, Dilated cardiomyopathy, Heart failure, Cardiac Stem Cell Transplantation, Stem Cells,",
            "MeshKeyword": "Cardiomyopathies, Cardiomyopathy, Dilated,",
            "Eligibility": "Major Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Be ≥ 18 and < 95 years of age.\r\n\r\n\r\n\r\n          -  Provide written informed consent.\r\n\r\n\r\n\r\n          -  Diagnosis of nonischemic dilated cardiomyopathy.\r\n\r\n\r\n\r\n          -  Be a candidate for card",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "95 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 21, 2016",
            "FirstReceived": "June 29, 2011",
            "OverallOfficial": "Joshua M Hare, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "University of Miami School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01392625",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20100968 - BW / SCF - Hare",
            "FileProcessContentId": "440",
            "Division": "Interdisciplinary Stem Cell Research",
            "StdyDivision": "16746",
            "EprostNbr": "20100968",
            "StudyNumber": "20100968 - BW / SCF - Hare",
            "StudyTitle": "A Phase I/II, Randomized Pilot Study of the Comparative Safety and Efficacy of Transendocardial Injection of Autologous  Mesenchymal Stem Cells Versus Allogeneic Mesenchymal Stem Cells in Patients With Nonischemic Dilated Cardiomyopathy.  The PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDONDCM Study)",
            "PIID": "896",
            "PicNum": "C05065867",
            "PILastName": "Hare",
            "PIFirstName": "Joshua",
            "CoodCNbr": "C00130574",
            "CoordLastName": "Difede",
            "CoordFirstName": "Darcy",
            "CoordEmail": "ddifede@med.miami.edu",
            "CoordPhone": "3052439106",
            "EnteredByCNbr": "C05065867",
            "EnteredByLastName": "Hare",
            "EnteredByFirstName": "Joshua",
            "ActiveEnrollingDate": "12/20/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/20/2010",
            "IRBApprovedFrom": "12/20/2010",
            "IRBApprovedTo": "08/04/2017",
            "AccountNbr": "66835L",
            "InfoEdNbr": "55122",
            "Expr1": "Phase I/II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Device/Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "Biosense Webster, Inc. / Sabrina Cohen Foundation",
            "Prescreened": "0",
            "Screenedfailed": "39",
            "SignedICF": "78",
            "Totalaccrued": "44",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "78",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:N/A,UMH:N/A,UMMG:45",
            "AccrualPercentageMet": "97.77777777777777777777777777777777777778",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "45",
            "EprostState": "Approved",
            "StudyCoordinator": "Darcy Difede,Lina Caceres Cardenas,Jairo Tovar,Mayra Vidro Casiano,Cindy Delgado,Marietsy Pujol",
            "AgentDevices": "Agent: Human Mesenchymal Stem Cells (hMSCs) / Device: MyoStar NOGA Injection Catheter System",
            "StudyObjective": "The primary objectibe of this study is to demonstrate the safety of allogeneic hMSCs administered by transendocardial injection in patients with nonischemic dilated cardiomyopathy.\r\n\r\nThe secondary objective of this study is to compare the safety of allogeneic hMSCs to autologous hMSCs administered by transendocardial injection in patients with nonischemic cardiomyopathy and to demonstrate the efficacy of autologous hMSCs and allogeneic hMSCs administered by transendocardial injection in patients with nonischemic cardiomyopathy.",
            "NationalSampleSize": "36",
            "NCTNbr": "NCT01392625",
            "StudyKeywords": "Dept: Institutional Stem Cell Institute\r\nORIM: Kanchan Sakhrani",
            "StudyInvIND": "1",
            "StudyInvINDNbr": "14419",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01400620",
            "BriefTitle": "Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer",
            "OfficialTitle": "Phase 2 Study to Evaluate the Safety and Efficacy of IZN-6N4 for the Prevention of Chemo-Radiation-Induced Oral Mucositis in Patients With Head and Neck Cancer",
            "LeadSponsorClass": "Izun Pharma Ltd",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Izun Pharma Ltd",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to determine whether an oral rinse composed of botanical\r\n\r\n      extracts is effective in the prevention of severe inflammation of the lining of the oral\r\n\r\n      cavity caused by chemotherapy and radiation therapy",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "March 2012",
            "CompletionDate": "January 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Izun Pharma Ltd",
            "StudyCondition": "Oral Mucositis",
            "studyLocation": "UF Health Cancer Center",
            "Enrollment": "110",
            "NctKeyword": "oral mucositis, chemoradiation, head and neck cancer,",
            "MeshKeyword": "Head and Neck Neoplasms, Mucositis, Stomatitis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  diagnosis of head and neck cancer\r\n\r\n\r\n\r\n          -  planned treatment course to include Cisplatin and radiation therapy, cumulative\r\n\r\n             prescription dose between 50-70 Gy\r\n\r\n\r\n\r\n          -",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Gainesville",
            "State": "Florida",
            "Zip": "32610",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 13, 2016",
            "FirstReceived": "July 20, 2011",
            "LocationName": "UF Health Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01400620",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140912 - Izun Pharmaceuticals - Samuels",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140912",
            "StudyNumber": "20140912 - Izun Pharmaceuticals - Samuels",
            "StudyTitle": "PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IZN-6N4 FOR THE PREVENTION OF CHEMO-RADIATION-INDUCED ORAL MUCOSITIS IN PATIENTS WITH HEAD AND NECK CANCER.",
            "PIID": "3262",
            "PicNum": "C10007990",
            "PILastName": "Samuels",
            "PIFirstName": "Michael",
            "CoodCNbr": "C04035535",
            "CoordLastName": "Sanchez",
            "CoordFirstName": "Lilly",
            "CoordEmail": "lsanchez@med.miami.edu",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "07/31/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/31/2015",
            "IRBApprovedFrom": "06/02/2015",
            "IRBApprovedTo": "05/16/2017",
            "AccountNbr": "665041",
            "DiseaseSiteListDesc": "Lip, Oral Cavity and Pharynx",
            "Expr1": "Phase II",
            "Tarea": "Head and Neck Cancer",
            "TareaCode": "12440",
            "Expr2": "Prevention",
            "StudyType_Code": "6163",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Izun Pharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "30",
            "Totalaccrued": "25",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "30",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMD:N/A,UM Kendall:N/A,Plantation:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Penny Eyer,Pavel Noa Hechavarria,Maggie Chislom,Zaida Abreu,Lilibet Zamora Cabezas,Greeyt Hernandez,Doris Martin,Marinellie Vega,Fernando Vazquez Pascual",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT01400620",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01404312",
            "SecondaryId": "10848",
            "BriefTitle": "Evaluating the Safety and Effectiveness of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection",
            "OfficialTitle": "Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection",
            "LeadSponsorClass": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "OversightAuthority": "Yes",
            "BriefSummary": "HIV-infected people have an increased risk of developing active tuberculosis (TB). The\r\n\r\n      standard course of treatment for TB is 6 to 9 months of isoniazid (INH). A shorter course of\r\n\r\n      treatment may be as effective and potentially i",
            "Description": "The World Health Organization (WHO) estimates that in 2009 there were 9.4 million new cases\r\n\r\n      of TB, and 1.68 million people died as a result of TB. Among new TB cases, 1.1 million\r\n\r\n      occurred in people who were HIV-coinfected, and",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "May 2012",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "StudyCondition": "Tuberculosis",
            "studyLocation": "University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program",
            "Enrollment": "3000",
            "MeshKeyword": "Infection, Communicable Diseases, HIV Infections, Tuberculosis, Latent Tuberculosis,",
            "InterventionKeyword": "Vitamins, Vitamin B 6, Pyridoxal, Pyridoxine, Isoniazid, Rifapentine, Rifampin, Vitamin B Complex,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or\r\n\r\n             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and\r\n\r\n             confirmed b",
            "EligibleGender": "All",
            "MinAge": "13 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "La Jolla",
            "State": "California",
            "Zip": "92093-0672",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 12, 2016",
            "FirstReceived": "July 26, 2011",
            "OverallOfficial": "Richard E. Chaisson, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Johns Hopkins University",
            "LocationName": "University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01404312",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110572 - ACTG/ NIAID/ NIH - Fischl",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20110572",
            "StudyNumber": "20110572 - ACTG/ NIAID/ NIH - Fischl",
            "StudyTitle": "A5279: Phase III Clinical Trial of UltraShortCourse Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIVInfected Individuals with Latent Tuberculosis Infection, Version 1.0 dated 5/11/11Letter of Amendment 2 dated May 31, 2012",
            "PIID": "825",
            "PicNum": "C00454409",
            "PILastName": "Fischl",
            "PIFirstName": "Margaret",
            "CoodCNbr": "C00454409",
            "CoordLastName": "Fischl",
            "CoordFirstName": "Margaret",
            "CoordEmail": "mfischl@med.miami.edu",
            "CoordPhone": "3052433847",
            "EnteredByCNbr": "C00454409",
            "EnteredByLastName": "Fischl",
            "EnteredByFirstName": "Margaret",
            "ActiveEnrollingDate": "08/07/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/07/2012",
            "IRBApprovedFrom": "08/02/2011",
            "IRBApprovedTo": "04/20/2016",
            "Expr1": "Phase III",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT01404312",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01410552",
            "BriefTitle": "Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination",
            "OfficialTitle": "Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination",
            "LeadSponsorClass": "LivaNova",
            "SponsorAgency": "Industry",
            "LeadSponsor": "LivaNova",
            "BriefSummary": "ISIS- ICD study has been designed to evaluate the impact of PARAD+ algorithm on\r\n\r\n      inappropriate shocks, in a general population implanted for primary or secondary prevention\r\n\r\n      with a dual or tri chamber device at one year follow-up",
            "Description": "The primary endpoint is to demonstrate that 95% of patients implanted with PARAD+ algorithm\r\n\r\n      are free from inapproporiate shock compared to 92.5% in general ICD population.",
            "OverallStatus": "Completed",
            "StartDate": "October 2011",
            "CompletionDate": "February 2016",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "LivaNova",
            "StudyCondition": "Tachycardia",
            "studyLocation": "Southwest Cardiovascular Associates",
            "Enrollment": "1013",
            "NctKeyword": "Primary prevention, Secondary prevention,",
            "MeshKeyword": "Tachycardia,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Patient eligible for implantation (according to current accepted guidelines, or\r\n\r\n             scheduled for implant (primo-implant, replacement, upgrade) with a Paradym/Paradym RF\r\n\r\n             (CRT-",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Mesa",
            "State": "Arizona",
            "Zip": "85205",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 29, 2016",
            "FirstReceived": "August 3, 2011",
            "OverallOfficial": "Ricardo RUIZ GRANELL, Dr",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Cardiology Department Arrhythmia Unit Hospital Clinico Universitario Valencia SPAIN",
            "LocationName": "Southwest Cardiovascular Associates",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01410552",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20111181 - SORIN CRM USA INC - Carrillo",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20111181",
            "StudyNumber": "20111181 - SORIN CRM USA INC - Carrillo",
            "StudyTitle": "Inappropriate Shock Reduction With PARAD Rhythm Discrimnation.",
            "PIID": "1975",
            "PicNum": "C00394135",
            "PILastName": "Carrillo",
            "PIFirstName": "Roger",
            "CoodCNbr": "C00394135",
            "CoordLastName": "Carrillo",
            "CoordFirstName": "Roger",
            "EnteredByCNbr": "C00394135",
            "EnteredByLastName": "Carrillo",
            "EnteredByFirstName": "Roger",
            "ActiveEnrollingDate": "03/04/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/04/2014",
            "IRBApprovedFrom": "02/27/2012",
            "IRBApprovedTo": "12/12/2016",
            "InfoEdNbr": "60072",
            "Expr1": "N/A",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Raiza Salceda,Rosa Khan",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01410552",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01411332",
            "BriefTitle": "A Phase III Trial of Hypofractionated External Beam Image-Guided Highly Targeted Radiotherapy: The HEIGHT Trial",
            "OfficialTitle": "A Phase III Trial of Hypofractionated External Beam Image-Guided Highly Targeted Radiotherapy: The HEIGHT Trial",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "1. Delivery of directed hypofractionated targeted (HT) radiotherapy (RT) tumor boost to\r\n\r\n           the dominant tumor lesion in the prostate as identified by multiparametric MRI will\r\n\r\n           increase tumor eradication from the prostate.",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2011",
            "CompletionDate": "May 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "University of Miami",
            "StudyCondition": "Prostate Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "72",
            "NctKeyword": "Prostate Cancer, Prostate Adenocarcinoma,",
            "MeshKeyword": "Prostatic Neoplasms, Adenocarcinoma,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  A. Biopsy confirmed adenocarcinoma of the prostate.\r\n\r\n\r\n\r\n          -  B. T1-T3a disease based on digital rectal exam.\r\n\r\n\r\n\r\n               1. T1a is permitted if peripheral zone biopsies are positive.",
            "EligibleGender": "Male",
            "MinAge": "35 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 3, 2016",
            "FirstReceived": "August 3, 2011",
            "OverallOfficial": "Alan Pollack, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01411332",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20100635 - Institutional - Pollack",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20100635",
            "StudyNumber": "20100635 - Institutional - Pollack",
            "StudyTitle": "A Phase III Trial Of Hypofractionated External Beam ImageGuided Highly Targeted Radiotherapy for Prostate Cancer: The HEIGHT Trial",
            "PIID": "428",
            "PicNum": "C00452286",
            "PILastName": "Pollack",
            "PIFirstName": "Alan",
            "CoodCNbr": "C12024321",
            "CoordLastName": "Noa Hechavarria",
            "CoordFirstName": "Pavel",
            "CoordEmail": "pavel.noa@med.miami.edu",
            "CoordPhone": "305-243-6809",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "05/16/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/16/2011",
            "IRBApprovedFrom": "12/22/2010",
            "IRBApprovedTo": "10/02/2017",
            "InfoEdNbr": "55583/52913",
            "DiseaseSiteListDesc": "Prostate",
            "Expr1": "Phase III",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "BANKHEAD COLEY FL BIOMEDICAL CANCER RES PROG",
            "Prescreened": "14",
            "Screenedfailed": "1",
            "SignedICF": "20",
            "Totalaccrued": "19",
            "InFollowUp": "12",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "28",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:72,UMD:N/A",
            "AccrualPercentageMet": "26.38888888888888888888888888888888888889",
            "ActiveCal": "3",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "72",
            "EprostState": "Approved",
            "StudyCoordinator": "Doris Martin,Zaida Abreu,Lilibet Zamora Cabezas,Lilly Sanchez,Greeyt Hernandez,Fernando Vazquez Pascual,Maggie Chislom,Marinellie Vega",
            "NationalSampleSize": "72",
            "NCTNbr": "NCT01411332",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01411345",
            "BriefTitle": "A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial",
            "OfficialTitle": "A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "1. The investigators hypothesize that increasing radiation dose to the functional\r\n\r\n           MRI-defined lesion in the prostate bed will result in an improved initial complete\r\n\r\n           response (reduction in prostate-specific antigen (PS",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2011",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "University of Miami",
            "StudyCondition": "Prostate Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "80",
            "NctKeyword": "Prostate Cancer, Prostate Adenocarcinoma,",
            "MeshKeyword": "Prostatic Neoplasms, Adenocarcinoma,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  A. Prostate cancer patients with a PSA after prostatectomy of at least 0.1 ng/mL and\r\n\r\n             up to 4.0 ng/mL within 3 months prior to enrollment.\r\n\r\n\r\n\r\n          -  B. Patients with or without p",
            "EligibleGender": "Male",
            "MinAge": "35 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 14, 2016",
            "FirstReceived": "August 4, 2011",
            "OverallOfficial": "Matthew C Abramowitz, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01411345",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20101056 - Intramural - Abramowitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20101056",
            "StudyNumber": "20101056 - Intramural - Abramowitz",
            "StudyTitle": "A Phase III Randomized Trial of MRIMapped DoseEscalated Salvage Radiotherapy PostProstatectomy: The MAPS Trial",
            "PIID": "2392",
            "PicNum": "C09437493",
            "PILastName": "Abramowitz",
            "PIFirstName": "Matthew",
            "CoodCNbr": "C12003895",
            "CoordLastName": "Vazquez Pascual",
            "CoordFirstName": "Fernando",
            "CoordEmail": "fxv109@miami.edu",
            "CoordPhone": "305-243-5620",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "06/01/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/01/2011",
            "IRBApprovedFrom": "05/16/2011",
            "IRBApprovedTo": "04/03/2017",
            "InfoEdNbr": "56284",
            "DiseaseSiteListDesc": "Prostate",
            "Expr1": "Phase III",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Federal Non-NIH",
            "Prescreened": "8",
            "Screenedfailed": "4",
            "SignedICF": "28",
            "Totalaccrued": "24",
            "InFollowUp": "19",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "34",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Doris Martin,Pavel Noa Hechavarria,Zaida Abreu,Lilibet Zamora Cabezas,Lilly Sanchez,Greeyt Hernandez,Maggie Chislom,Marinellie Vega,Radka Stoyanova",
            "NationalSampleSize": "80",
            "NCTNbr": "NCT01411345",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01412333",
            "SecondaryId": "2010-020315-36",
            "BriefTitle": "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis",
            "OfficialTitle": "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis",
            "LeadSponsorClass": "Hoffmann-La Roche",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Hoffmann-La Roche",
            "BriefSummary": "This randomized, double-blind, double-dummy, parallel-group study will evaluate the efficacy\r\n\r\n      and safety of ocrelizumab in comparison with Rebif (interferon beta-1a) in participants with\r\n\r\n      relapsing multiple sclerosis. Participant",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "September 2011",
            "CompletionDate": "January 2020",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Hoffmann-La Roche",
            "StudyCondition": "Relapsing Multiple Sclerosis",
            "Enrollment": "835",
            "MeshKeyword": "Sclerosis, Multiple Sclerosis,",
            "InterventionKeyword": "Interferons, Interferon-beta, Interferon beta-1a,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of multiple sclerosis, in accordance with the revised McDonald criteria\r\n\r\n             (2010)\r\n\r\n\r\n\r\n          -  At least 2 documented clinical attacks within the last 2 years prior to screen",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "55 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85006",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 25, 2016",
            "FirstReceived": "August 8, 2011",
            "OverallOfficial": "Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Hoffmann-La Roche",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01412333",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110636 - HOFFMAN LAROCHE INC - Sheremata",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20110636",
            "StudyNumber": "20110636 - HOFFMAN LAROCHE INC - Sheremata",
            "StudyTitle": "OPERA Study: A Randomized, DoubleBlind, DoubleDummy, ParallelGroup Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta1a (Rebif) In Patients With Relapsing Multiple Sclerosis",
            "PIID": "121",
            "PicNum": "C00457629",
            "PILastName": "Sheremata",
            "PIFirstName": "William",
            "CoodCNbr": "C00457629",
            "CoordLastName": "Sheremata",
            "CoordFirstName": "William",
            "CoordEmail": "wsherema@med.miami.edu",
            "CoordPhone": "3052436658",
            "EnteredByCNbr": "C02523614",
            "EnteredByLastName": "Babcock",
            "EnteredByFirstName": "Yanet",
            "ActiveEnrollingDate": "01/01/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/05/2012",
            "IRBApprovedFrom": "10/03/2011",
            "IRBApprovedTo": "06/26/2017",
            "AccountNbr": "66891T",
            "InfoEdNbr": "58422/62914/66357",
            "Expr1": "Phase III",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "HOFFMAN LAROCHE INC",
            "Prescreened": "2",
            "Screenedfailed": "2",
            "SignedICF": "18",
            "Totalaccrued": "17",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "13",
            "Totalpatients": "18",
            "FirstNinety": "5",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "2",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yanet Babcock,Ruta Sawant,Potyra Rosa,Gloria Rodriguez (Neurology)",
            "StudyObjective": "",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT01412333",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01414608",
            "SecondaryId": "NCI-2011-02978",
            "BriefTitle": "Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer",
            "OfficialTitle": "A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial",
            "LeadSponsorClass": "Gynecologic Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Gynecologic Oncology Group",
            "BriefSummary": "This randomized phase III trial studies how well giving cisplatin and radiation therapy\r\n\r\n      together with or without carboplatin and paclitaxel works in treating patients with locally\r\n\r\n      advanced cervical cancer. Drugs used in chemoth",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To determine if the addition of adjuvant chemotherapy to standard cisplatin-based\r\n\r\n      chemoradiation improves overall survival.\r\n\r\n\r\n\r\n      SECONDARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To determine the progress",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2012",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Gynecologic Oncology Group",
            "StudyCondition": "Cervical Adenocarcinoma",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "780",
            "MeshKeyword": "Carcinoma, Squamous Cell, Adenocarcinoma, Carcinoma, Infertility, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous,",
            "InterventionKeyword": "Paclitaxel, Albumin-Bound Paclitaxel, Cisplatin, Carboplatin, Succinylcholine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Eligible patients will have locally advanced cervical cancer suitable for primary\r\n\r\n             treatment with chemoradiation with curative intent, in addition to:\r\n\r\n\r\n\r\n               -  Histological",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 26, 2016",
            "FirstReceived": "August 10, 2011",
            "OverallOfficial": "Kathleen Moore",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Gynecologic Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01414608",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120228 - GOG - Wolfson",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20120228",
            "StudyNumber": "20120228 - GOG - Wolfson",
            "StudyTitle": "GOG0274: A Phase III Trial of Adjuvant Chemotherapy FollowingChemoradiation as Primary Treatment for Locally Advanced Cervical CancerCompared to Chemoradiation Alone: THE OUTBACK TRIAL (ANZGOG0902/RTOG 1174)",
            "PIID": "291",
            "PicNum": "C00447309",
            "PILastName": "Wolfson",
            "PIFirstName": "Aaron",
            "CoodCNbr": "C12022796",
            "CoordLastName": "Bauduy-Roy",
            "CoordFirstName": "Mae Lyssa",
            "CoordEmail": "mae.bauduy@med.miami.edu",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "05/08/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/08/2013",
            "IRBApprovedFrom": "12/04/2012",
            "IRBApprovedTo": "10/05/2016",
            "DiseaseSiteListDesc": "Cervix",
            "Expr1": "Phase III",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "GOG",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "16",
            "Totalaccrued": "11",
            "InFollowUp": "7",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "16",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UM Kendall:N/A,JMH:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diann Fernandez,Negin Habibi Khameneh,Penny Eyer,Teresa Kamar,Claudia Grandas Moreno,Evan Dadas,Michelle Mikhail,Halyna Hailes",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT01414608",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01415167",
            "BriefTitle": "PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy",
            "OfficialTitle": "Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy",
            "LeadSponsorClass": "Prometheus Laboratories",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Prometheus Laboratories",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this registry is to collect information on patients who are receiving\r\n\r\n      treatment with Proleukin in an organized way, and to learn more about patient care during\r\n\r\n      and after treatment.",
            "Description": "The PROCLAIM Registry is a US-based, multicenter Registry designed to establish a high\r\n\r\n      quality observational database of real-world clinical data on HD IL-2 when used to treat\r\n\r\n      patients with mRCC, mM or other malignancies. The R",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2011",
            "CompletionDate": "August 2016",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Prometheus Laboratories",
            "StudyCondition": "Metastatic Renal Cell Carcinoma",
            "studyLocation": "The University of Arizona Cancer Center",
            "Enrollment": "2500",
            "MeshKeyword": "Carcinoma, Renal Cell,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  18 years or older\r\n\r\n\r\n\r\n          -  Must have received at least one course of high dose IL-2 or Proleukin\r\n\r\n\r\n\r\n          -  Signed informed consent form\r\n\r\n\r\n\r\n        Exclusion Criteria:",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Tuscon",
            "State": "Arizona",
            "Zip": "85742",
            "Country": "United States",
            "VerificationDate": "May 2016",
            "LastChanged": "May 19, 2016",
            "FirstReceived": "August 9, 2011",
            "OverallOfficial": "Tharak Rao, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Prometheus Laboratories",
            "ContactName": "Theresa Luna",
            "ContactPhone": "858-882-8058",
            "ContactEmail": "tluna@prometheuslabs.com",
            "LocationStatus": "Recruiting",
            "LocationName": "The University of Arizona Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01415167",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140220 - Prometheus - Feun",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140220",
            "StudyNumber": "20140220 - Prometheus - Feun",
            "StudyTitle": "Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy",
            "PIID": "343",
            "PicNum": "C00770064",
            "PILastName": "Feun",
            "PIFirstName": "Lynn",
            "CoodCNbr": "C11979873",
            "CoordLastName": "Cianferra",
            "CoordFirstName": "Eduardo",
            "CoordEmail": "exc642@miami.edu",
            "CoordPhone": "305-243-1139",
            "EnteredByCNbr": "C04092184",
            "EnteredByLastName": "Rajakumar",
            "EnteredByFirstName": "Gopal",
            "ActiveEnrollingDate": "08/28/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/28/2014",
            "IRBApprovedFrom": "07/13/2014",
            "IRBApprovedTo": "05/03/2017",
            "AccountNbr": "663481",
            "DiseaseSiteListDesc": "Melanoma, skin",
            "Expr1": "N/A",
            "Tarea": "Melanoma and Related Skin Cancers",
            "TareaCode": "12441",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Other",
            "SponsorGroup": "Industry",
            "Sponsor": "Prometheus",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Luis,Nester Grez,Vivianne Velez-Bravo,Isabel Moya",
            "NationalSampleSize": "16",
            "NCTNbr": "NCT01415167",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT01418261",
            "BriefTitle": "Renal Denervation in Patients With Uncontrolled Hypertension (SYMPLICITY HTN-3)",
            "LeadSponsorClass": "Medtronic Vascular",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Medtronic Vascular",
            "OversightAuthority": "Yes",
            "BriefSummary": "The Symplicity HTN-3 study is a, multi-center, prospective, single-blind, randomized,\r\n\r\n      controlled study of the safety and effectiveness of renal denervation in subjects with\r\n\r\n      uncontrolled hypertension. Bilateral renal denervation",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "September 2011",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Medtronic Vascular",
            "StudyCondition": "Uncontrolled Hypertension",
            "studyLocation": "Cardiology, PC",
            "Enrollment": "530",
            "NctKeyword": "uncontrolled hypertension, renal denervation,",
            "MeshKeyword": "Hypertension,",
            "InterventionKeyword": "Antihypertensive Agents,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Individual is ≥ 18 and ≤ 80 years old at time of randomization.\r\n\r\n\r\n\r\n          -  Individual is receiving a stable medication regimen including full tolerated doses of\r\n\r\n             3 or more anti-hy",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35211",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 21, 2016",
            "FirstReceived": "August 15, 2011",
            "OverallOfficial": "George Bakris, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Professor of Medicine, Hypertension Center Director University of Chicago Medical Center",
            "LocationName": "Cardiology, PC",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01418261",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110982  - HTN3 - De Marchena",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20110982",
            "StudyNumber": "20110982  - HTN3 - De Marchena",
            "StudyTitle": "Renal Denervation in Patients with Uncontrolled Hypertension SYMPLICITY HTN3",
            "PIID": "1187",
            "PicNum": "C00491335",
            "PILastName": "De Marchena",
            "PIFirstName": "Eduardo",
            "CoodCNbr": "C04284337",
            "CoordLastName": "Marin y Kall",
            "CoordFirstName": "Christian",
            "CoordEmail": "cmarin@med.miami.edu",
            "CoordPhone": "3055856217",
            "EnteredByCNbr": "C04284337",
            "EnteredByLastName": "Marin y Kall",
            "EnteredByFirstName": "Christian",
            "ActiveEnrollingDate": "06/08/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/08/2012",
            "IRBApprovedFrom": "02/27/2012",
            "IRBApprovedTo": "01/05/2017",
            "AccountNbr": "66916M",
            "InfoEdNbr": "59562",
            "Expr1": "N/A",
            "Tarea": "Hypertension",
            "TareaCode": "13037",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "2",
            "Screenedfailed": "3",
            "SignedICF": "12",
            "Totalaccrued": "8",
            "InFollowUp": "3",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "12",
            "FirstNinety": "2",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Ximena Marincic-Sanchez,Suresh Atapattu",
            "NationalSampleSize": "50",
            "NCTNbr": "NCT01418261",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01425307",
            "SecondaryId": "R01HL095647",
            "BriefTitle": "Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea",
            "OfficialTitle": "TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III Randomized Trial to Compare Standard Therapy (Erythrocyte Transfusions) With Alternative Therapy (Hydroxyurea) for the Maintenance of Lowered TCD Velocities in Pediatric Subjects With Sic",
            "LeadSponsorClass": "Children's Hospital Medical Center, Cincinnati",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Hospital Medical Center, Cincinnati",
            "OversightAuthority": "Yes",
            "BriefSummary": "The primary goal of the Phase III TWiTCH trial is to compare 24 months of alternative\r\n\r\n      therapy (hydroxyurea) to standard therapy (transfusions) for pediatric subjects with sickle\r\n\r\n      cell anemia and abnormally high (≥200 cm/sec) Tra",
            "Description": "Despite the clear results of the STOP and the follow-up STOP II trials, the use of chronic\r\n\r\n      erythrocyte transfusions for primary stroke prevention in children with Sickle Cell Anemia\r\n\r\n      (SCA) remains controversial for many practici",
            "OverallStatus": "Terminated",
            "StartDate": "August 2011",
            "CompletionDate": "January 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Children's Hospital Medical Center, Cincinnati",
            "StudyCondition": "Sickle Cell Anemia",
            "Enrollment": "159",
            "NctKeyword": "Phase III, Sickle cell anemia, Abnormally high Transcranial Doppler velocities., Reduce risk of primary stroke, Pediatric patients, Chelation therapy,",
            "MeshKeyword": "Anemia, Anemia, Sickle Cell,",
            "InterventionKeyword": "Hydroxyurea,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Pediatric subjects with severe forms of sickle cell anemia (HbSS, HbSβ0\r\n\r\n             thalassemia,HbSOArab)\r\n\r\n\r\n\r\n          2. Age range of 4.0-15.99 years, inclusive, at the time of enrollment",
            "EligibleGender": "All",
            "MinAge": "4 Years",
            "MaxAge": "15 Years",
            "Volunteers": "No",
            "VerificationDate": "November 2015",
            "LastChanged": "November 4, 2015",
            "FirstReceived": "August 19, 2011",
            "OverallOfficial": "Russell E. Ware, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Hospital Medical Center, Cincinnati",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01425307",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110772 - ST JUDE CHILDRENS RESEARCH HOSPITAL,BAYLOR COLLEG - Alvarez",
            "FileProcessContentId": "440",
            "Division": "Pediatrics Oncology",
            "StdyDivision": "10646",
            "EprostNbr": "20110772",
            "StudyNumber": "20110772 - ST JUDE CHILDRENS RESEARCH HOSPITAL,BAYLOR COLLEG - Alvarez",
            "StudyTitle": "TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III randomized clinical trial to compare standard therapy (erythrocyte transfusions) with alternative therapy (hydroxyurea) for the maintenance of lowered TCD velocities in pediatric subjects",
            "PIID": "299",
            "PicNum": "C01335657",
            "PILastName": "Alvarez",
            "PIFirstName": "Ofelia",
            "CoodCNbr": "C01294252",
            "CoordLastName": "Hustace",
            "CoordFirstName": "Tally",
            "CoordEmail": "thustace@med.miami.edu",
            "EnteredByCNbr": "C01335657",
            "EnteredByLastName": "Alvarez",
            "EnteredByFirstName": "Ofelia",
            "ActiveEnrollingDate": "02/08/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/08/2012",
            "IRBApprovedFrom": "10/24/2011",
            "IRBApprovedTo": "04/19/2017",
            "AccountNbr": "660308",
            "InfoEdNbr": "51058/60264/62236/63628",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Tally Hustace",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT01425307",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01428596",
            "BriefTitle": "Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects",
            "OfficialTitle": "A Phase I Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Replication-defective HIV-1 Vaccine (HIVAX™) in HIV-1 Infected Subjects Receiving Highly Active Antiretroviral Therapy",
            "LeadSponsorClass": "GeneCure Biotechnologies",
            "SponsorAgency": "Industry",
            "LeadSponsor": "GeneCure Biotechnologies",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study is to test a therapeutic HIV-1 vaccine (HIVAX™) in HIV-1 infected subjects. The\r\n\r\n      safety and immune responses will be studied in vaccine recipients. The anti-viral effect of\r\n\r\n      HIVAX vaccine will be monitored during a 12-",
            "Description": "This is a randomized, placebo-controlled dose-escalation clinical trial to evaluate the\r\n\r\n      safety and the immunogenicity of two doses of a replication defective HIV-1 vaccine (HIVAX™)\r\n\r\n      in subjects receiving stable highly active ant",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2010",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "GeneCure Biotechnologies",
            "StudyCondition": "HIV Infections",
            "studyLocation": "University of Miami School of Medicine, AIDS Clinical Research unit",
            "Enrollment": "30",
            "NctKeyword": "HIV-1, therapeutic vaccine, immunotherapy, AIDS,",
            "MeshKeyword": "HIV Infections,",
            "InterventionKeyword": "Vaccines, Pharmaceutical Solutions,",
            "Eligibility": "Part I (vaccination phase) Inclusion Criteria:\r\n\r\n\r\n\r\n          1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by\r\n\r\n             Western blot, at any time prior to study entry. HIV-1 culture, HIV-1 antigen, pla",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "60 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "March 2015",
            "LastChanged": "March 9, 2015",
            "FirstReceived": "September 1, 2011",
            "OverallOfficial": "Margaret Fischl, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Margaret A. Fischl, MD",
            "ContactPhone": "305-243-3847",
            "ContactEmail": "mfischl@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami School of Medicine, AIDS Clinical Research unit",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01428596",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20080327 - GENECURE BIOTECHNOLOGIES - Fischl",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20080327",
            "StudyNumber": "20080327 - GENECURE BIOTECHNOLOGIES - Fischl",
            "StudyTitle": "A010: A phase I, dose escalation clinical trial to evaluate the safety and immunogenicity of a replication defective HIV1 vaccine (HIVAX) in HIV1 infected subjects receiving highly active antiretroviral therapy. Final Version 3.2 dated August 15, 2016",
            "PIID": "825",
            "PicNum": "C00454409",
            "PILastName": "Fischl",
            "PIFirstName": "Margaret",
            "CoodCNbr": "C00454409",
            "CoordLastName": "Fischl",
            "CoordFirstName": "Margaret",
            "CoordEmail": "mfischl@med.miami.edu",
            "CoordPhone": "3052433847",
            "EnteredByCNbr": "C00477519",
            "EnteredByLastName": "Colon",
            "EnteredByFirstName": "Lillian",
            "ActiveEnrollingDate": "07/28/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/28/2011",
            "IRBApprovedFrom": "06/07/2011",
            "IRBApprovedTo": "05/02/2017",
            "AccountNbr": "66861C",
            "InfoEdNbr": "57660",
            "Expr1": "Phase I",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "GENECURE BIOTECHNOLOGIES",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "15",
            "Totalaccrued": "15",
            "InFollowUp": "3",
            "CurrentlyEnrolled": "7",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "15",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01428596",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01457352",
            "BriefTitle": "Efficacy and Safety of SPARC0921 in Subjects With Spasticity",
            "LeadSponsorClass": "Sun Pharma Advanced Research Company Limited",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Sun Pharma Advanced Research Company Limited",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to assess whether SPARC0921 demonstrate efficacy and safety in\r\n\r\n      the treatment of spasticity.",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2012",
            "CompletionDate": "January 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Sun Pharma Advanced Research Company Limited",
            "StudyCondition": "Spasticity",
            "studyLocation": "SPARC site 1",
            "Enrollment": "300",
            "NctKeyword": "Baclofen, spasticity,",
            "MeshKeyword": "Muscle Spasticity,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Men and women age 18 years and older\r\n\r\n\r\n\r\n          -  Known history of spasticity due to MS prior to starting baclofen\r\n\r\n\r\n\r\n          -  Able and willing to comply with the protocol, including avail",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Gilbert",
            "State": "Arizona",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 20, 2016",
            "FirstReceived": "October 17, 2011",
            "OverallOfficial": "Shravanti Bhowmik, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Sun Pharma Advanced Research Centre Ltd,India",
            "ContactName": "Shravanti Bhowmik, MD",
            "ContactPhone": "+9122 66455645",
            "ContactEmail": "Shravanti.Bhowmik@sparcmail.com",
            "LocationStatus": "Recruiting",
            "LocationName": "SPARC site 1",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01457352",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140074 - Sun Pharma Advanced Research Company Ltd. - Delgado",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140074",
            "StudyNumber": "20140074 - Sun Pharma Advanced Research Company Ltd. - Delgado",
            "StudyTitle": "A PLACEBO-CONTROLLED RANDOMIZED WITHDRAWAL EVALUATION OF THE EFFICACY AND SAFETY OF BACLOFEN ER CAPSULES (GRS) IN SUBJECTS WITH SPASTICITY DUE TO MULTIPLE SCLEROSIS",
            "PIID": "122",
            "PicNum": "C00360924",
            "PILastName": "Delgado",
            "PIFirstName": "Silvia",
            "CoodCNbr": "C00168827",
            "CoordLastName": "Sawant",
            "CoordFirstName": "Ruta",
            "EnteredByCNbr": "C00360924",
            "EnteredByLastName": "Delgado",
            "EnteredByFirstName": "Silvia",
            "ActiveEnrollingDate": "10/23/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/23/2014",
            "IRBApprovedFrom": "06/02/2014",
            "IRBApprovedTo": "05/01/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Sun Pharma Advanced Research Company Ltd.",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "5",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yanet Babcock,Gloria Rodriguez (Neurology)",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT01457352",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01457755",
            "SecondaryId": "2011-000945-19",
            "BriefTitle": "Gilead Sustained Virologic Response (SVR) Registry",
            "OfficialTitle": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "No",
            "BriefSummary": "This Registry is designed to provide long term clinical and virologic follow up in\r\n\r\n      participants who have achieved sustained virologic response (SVR) while participating in a\r\n\r\n      previous Gilead sponsored hepatitis C virus (HCV) stu",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "April 2012",
            "CompletionDate": "October 2020",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "Hepatitis C, Chronic",
            "studyLocation": "Birmingham Gastroenterology Associates",
            "Enrollment": "7000",
            "NctKeyword": "Hepatitis C, HCV, Sustained Virologic Response, Direct Acting Antiviral, Combination Therapy, Tegobuvir, Registry, HCV RNA, Treatment experienced, Treatment naive, GS 9451, GS 5885, GS 7977, GS 5816, Sofosbuvir, Sovaldi™, SOF, Ledipasvir, LDV,",
            "MeshKeyword": "Hepatitis, Hepatitis A, Hepatitis C, Hepatitis C, Chronic,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Have previously participated in a Gilead-sponsored hepatitis C study and received at\r\n\r\n             least one Gilead oral antiviral agent (OAV)\r\n\r\n\r\n\r\n          -  Have achieved SVR in a Gilead-sponsore",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35209",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "June 21, 2016",
            "FirstReceived": "October 4, 2011",
            "OverallOfficial": "Theo Brandt-Sarif, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "Birmingham Gastroenterology Associates",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01457755",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20121009 - GILEAD SCIENCES - Jayaweera",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20121009",
            "StudyNumber": "20121009 - GILEAD SCIENCES - Jayaweera",
            "StudyTitle": "GSUS2480122  A Long Term Followup Registry for Subjects Who Achieve a Sustained Virologic Response to Treeatment in GileadSponsored Trials in Subjects with Chronic Hepatitis C Infection",
            "PIID": "234",
            "PicNum": "C00043390",
            "PILastName": "Jayaweera",
            "PIFirstName": "Dushyantha T.",
            "CoodCNbr": "C00212247",
            "CoordLastName": "Healy",
            "CoordFirstName": "Lynn",
            "CoordEmail": "lhealy@med.miami.edu",
            "EnteredByCNbr": "C00243042",
            "EnteredByLastName": "Tanner",
            "EnteredByFirstName": "Tom",
            "ActiveEnrollingDate": "09/17/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/17/2013",
            "IRBApprovedFrom": "04/17/2013",
            "IRBApprovedTo": "03/04/2016",
            "InfoEdNbr": "65694",
            "Expr1": "Phase IV",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "13",
            "Totalaccrued": "13",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "12",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "13",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Tom Tanner,Kenia Moreno",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT01457755",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01457755",
            "SecondaryId": "2011-000945-19",
            "BriefTitle": "Gilead Sustained Virologic Response (SVR) Registry",
            "OfficialTitle": "A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "No",
            "BriefSummary": "This Registry is designed to provide long term clinical and virologic follow up in\r\n\r\n      participants who have achieved sustained virologic response (SVR) while participating in a\r\n\r\n      previous Gilead sponsored hepatitis C virus (HCV) stu",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "April 2012",
            "CompletionDate": "October 2020",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "Hepatitis C, Chronic",
            "studyLocation": "Birmingham Gastroenterology Associates",
            "Enrollment": "7000",
            "NctKeyword": "Hepatitis C, HCV, Sustained Virologic Response, Direct Acting Antiviral, Combination Therapy, Tegobuvir, Registry, HCV RNA, Treatment experienced, Treatment naive, GS 9451, GS 5885, GS 7977, GS 5816, Sofosbuvir, Sovaldi™, SOF, Ledipasvir, LDV,",
            "MeshKeyword": "Hepatitis, Hepatitis A, Hepatitis C, Hepatitis C, Chronic,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Have previously participated in a Gilead-sponsored hepatitis C study and received at\r\n\r\n             least one Gilead oral antiviral agent (OAV)\r\n\r\n\r\n\r\n          -  Have achieved SVR in a Gilead-sponsore",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35209",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "June 21, 2016",
            "FirstReceived": "October 4, 2011",
            "OverallOfficial": "Theo Brandt-Sarif, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "Birmingham Gastroenterology Associates",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01457755",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110696 - GILEAD SCIENCES - Schiff",
            "FileProcessContentId": "440",
            "Division": "Hepatology",
            "StdyDivision": "10246",
            "EprostNbr": "20110696",
            "StudyNumber": "20110696 - GILEAD SCIENCES - Schiff",
            "StudyTitle": "GSUS2480122A Long Term Followup Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C00272649",
            "CoordLastName": "Vega",
            "CoordFirstName": "Marinellie",
            "CoordEmail": "mvega@med.miami.edu",
            "CoordPhone": "3052436809",
            "EnteredByCNbr": "C00272649",
            "EnteredByLastName": "Vega",
            "EnteredByFirstName": "Marinellie",
            "ActiveEnrollingDate": "01/11/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/11/2012",
            "IRBApprovedFrom": "10/11/2011",
            "IRBApprovedTo": "05/11/2017",
            "InfoEdNbr": "59262/65309",
            "Expr1": "N/A",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "80",
            "Totalaccrued": "80",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "47",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "80",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Odalys Rodriguez-Bravo,Andrea Elibero,Sonia Carvalho",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT01457755",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01457768",
            "SecondaryId": "2011-000946-39",
            "BriefTitle": "A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response",
            "OfficialTitle": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "No",
            "BriefSummary": "This Registry is designed to obtain long term data on participants who have failed to\r\n\r\n      achieve sustained virologic response (SVR) while receiving at least one Gilead oral\r\n\r\n      antiviral agent (OAV) in a previous Gilead-sponsored hepa",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "December 2011",
            "CompletionDate": "October 2020",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "Hepatitis C, Chronic",
            "studyLocation": "Birmingham Gastroenterology Associates",
            "Enrollment": "650",
            "NctKeyword": "Hepatitis C, HCV, Sustained Virologic Response, Direct Acting Antiviral, Combination Therapy, Tegobuvir, Registry, HCV RNA, Treatment experienced, Treatment naive, GS 9451, GS 5885, Sequence, GS 5816, GS 7977, Sofosbuvir, Sovaldi™, SOF, Ledipasvir, LDV,",
            "MeshKeyword": "Hepatitis, Hepatitis A, Hepatitis C, Hepatitis C, Chronic,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Have previously participated in a Gilead-sponsored hepatitis C study and received at\r\n\r\n             least one Gilead OAV\r\n\r\n\r\n\r\n          -  Have failed to achieve an SVR in a previous Gilead-sponsored",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35209",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "June 21, 2016",
            "FirstReceived": "October 4, 2011",
            "OverallOfficial": "Theo Brandt-Sarif, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "Birmingham Gastroenterology Associates",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01457768",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110697 - GILEAD SCIENCES - Schiff",
            "FileProcessContentId": "440",
            "Division": "Hepatology",
            "StdyDivision": "10246",
            "EprostNbr": "20110697",
            "StudyNumber": "20110697 - GILEAD SCIENCES - Schiff",
            "StudyTitle": "GSUS2480123A Long Term Followup Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C00272649",
            "CoordLastName": "Vega",
            "CoordFirstName": "Marinellie",
            "CoordEmail": "mvega@med.miami.edu",
            "CoordPhone": "3052436809",
            "EnteredByCNbr": "C00272649",
            "EnteredByLastName": "Vega",
            "EnteredByFirstName": "Marinellie",
            "ActiveEnrollingDate": "01/11/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/11/2012",
            "IRBApprovedFrom": "10/11/2011",
            "IRBApprovedTo": "04/26/2017",
            "InfoEdNbr": "59264/65306",
            "Expr1": "N/A",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "9",
            "Totalaccrued": "9",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "9",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Odalys Rodriguez-Bravo,Sonia Carvalho",
            "StudyObjective": "",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT01457768",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01457768",
            "SecondaryId": "2011-000946-39",
            "BriefTitle": "A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response",
            "OfficialTitle": "A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "No",
            "BriefSummary": "This Registry is designed to obtain long term data on participants who have failed to\r\n\r\n      achieve sustained virologic response (SVR) while receiving at least one Gilead oral\r\n\r\n      antiviral agent (OAV) in a previous Gilead-sponsored hepa",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "December 2011",
            "CompletionDate": "October 2020",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "Hepatitis C, Chronic",
            "studyLocation": "Birmingham Gastroenterology Associates",
            "Enrollment": "650",
            "NctKeyword": "Hepatitis C, HCV, Sustained Virologic Response, Direct Acting Antiviral, Combination Therapy, Tegobuvir, Registry, HCV RNA, Treatment experienced, Treatment naive, GS 9451, GS 5885, Sequence, GS 5816, GS 7977, Sofosbuvir, Sovaldi™, SOF, Ledipasvir, LDV,",
            "MeshKeyword": "Hepatitis, Hepatitis A, Hepatitis C, Hepatitis C, Chronic,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Have previously participated in a Gilead-sponsored hepatitis C study and received at\r\n\r\n             least one Gilead OAV\r\n\r\n\r\n\r\n          -  Have failed to achieve an SVR in a previous Gilead-sponsored",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35209",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "June 21, 2016",
            "FirstReceived": "October 4, 2011",
            "OverallOfficial": "Theo Brandt-Sarif, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "Birmingham Gastroenterology Associates",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01457768",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20121013 - Gilead Sciences/Gilead - Jayaweera",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20121013",
            "StudyNumber": "20121013 - Gilead Sciences/Gilead - Jayaweera",
            "StudyTitle": "GSUS2480123  A LongTerm Followup Registry Study of Subjects Who Did NOT Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection.",
            "PIID": "234",
            "PicNum": "C00043390",
            "PILastName": "Jayaweera",
            "PIFirstName": "Dushyantha T.",
            "CoodCNbr": "C00212247",
            "CoordLastName": "Healy",
            "CoordFirstName": "Lynn",
            "CoordEmail": "lhealy@med.miami.edu",
            "EnteredByCNbr": "C00243042",
            "EnteredByLastName": "Tanner",
            "EnteredByFirstName": "Tom",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "03/19/2013",
            "IRBApprovedFrom": "03/19/2013",
            "IRBApprovedTo": "01/18/2017",
            "InfoEdNbr": "65698",
            "Expr1": "Phase III",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Tom Tanner,Kenia Moreno",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01457768",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT01459679",
            "BriefTitle": "A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery",
            "OfficialTitle": "A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery",
            "LeadSponsorClass": "American-European Congress of Ophthalmic Surgery",
            "SponsorAgency": "Other",
            "LeadSponsor": "American-European Congress of Ophthalmic Surgery",
            "OversightAuthority": "No",
            "BriefSummary": "The objectives of this study are to evaluate and compare the safety and efficacy of three\r\n\r\n      treatment regimens for corneal collagen cross-linking performed with VibeX (riboflavin\r\n\r\n      ophthalmic solution) and the KXL System in impedin",
            "OverallStatus": "Terminated",
            "StartDate": "July 2012",
            "CompletionDate": "August 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "American-European Congress of Ophthalmic Surgery",
            "StudyCondition": "Keratoconus",
            "studyLocation": "John Parker",
            "Enrollment": "1719",
            "MeshKeyword": "Keratoconus, Corneal Diseases, Dilatation, Pathologic,",
            "InterventionKeyword": "Pharmaceutical Solutions, Ophthalmic Solutions, Riboflavin,",
            "Eligibility": "Inclusion Criteria (all subjects):\r\n\r\n\r\n\r\n          1. Be at least 12 years of age, male or female, of any race;\r\n\r\n\r\n\r\n          2. Provide written informed consent and sign a HIPAA form. Patients who are under the\r\n\r\n             age of 18 w",
            "EligibleGender": "All",
            "MinAge": "12 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 7, 2016",
            "FirstReceived": "September 19, 2011",
            "OverallOfficial": "John Vukich, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "American-European Congress of Ophthalmic Surgery",
            "LocationName": "John Parker",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01459679",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20100940 - Avedro - Yoo",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20100940",
            "StudyNumber": "20100940 - Avedro - Yoo",
            "StudyTitle": "A MultiCenter, Randomized, PlaceboControlled Evaluation of theSafety and Efficacy of the KXL System with vibeX (Riboflavin OphthalmicSolution) for Corneal Collagen CrossLinking in Eyes with Keratoconus",
            "PIID": "512",
            "PicNum": "C00011377",
            "PILastName": "Yoo",
            "PIFirstName": "Sonia",
            "CoodCNbr": "C03081933",
            "CoordLastName": "San Roman",
            "CoordFirstName": "Janika",
            "CoordEmail": "jsanroman@med.miami.edu",
            "CoordPhone": "3052434903",
            "EnteredByCNbr": "C00011377",
            "EnteredByLastName": "Yoo",
            "EnteredByFirstName": "Sonia",
            "ActiveEnrollingDate": "02/08/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/08/2013",
            "IRBApprovedFrom": "03/28/2011",
            "IRBApprovedTo": "04/20/2016",
            "AccountNbr": "66794K",
            "InfoEdNbr": "54441",
            "Expr1": "N/A",
            "Tarea": "Cornea",
            "TareaCode": "12036",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Device",
            "SponsorGroup": "Industry",
            "Sponsor": "Avedro, LLC",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "8",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "8",
            "FirstNinety": "5",
            "SiteSampleSize": "ABLEH:100,BPPB:100",
            "AccrualPercentageMet": "3.5",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "200",
            "EprostState": "Approved",
            "StudyCoordinator": "Ruth Vandenbroucke,Ailen Gutierrez",
            "AgentDevices": "Agent: Riboflavin 0.1% solution",
            "StudyObjective": "The objectives of this study are to evaluate the safety and efficacy of two treatment regimens for corneal collagen cross-linking performed with Riboflavin 0.1% Ophthalmic Solution and the KXL System for reducing corneal curvature and to determine if the two treatment regimens are equally efficacious.\r\n\r\nThe primary efficacy endpoint is defined as a reduction in maximum corneal curvature (Kmax) of at least 0.75 diopters (D) at 6 months after treatment compared with baseline.\r\n\r\nThis endpoint will be analyzed independently for each treatment group, and as such, both do not need to meet this endpoint for this to be considered a successful trial.\r\n\r\nThe powered secondary efficacy endpoint is the comparison of change from baseline to 6 months between treatment groups to determine if the results are equally efficacious in both groups.\r\n\r\nThe primary safety endpoints are loss of BSCVA beginning at the 6 month follow-up examination, specifically, the percentage of eyes that had a loss of 10 or more letters in BSCVA on the ETDRS chart as compared to baseline and the incidence of serious ophthalmic adverse events.",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01459679",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01483027",
            "BriefTitle": "Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer",
            "OfficialTitle": "A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy",
            "LeadSponsorClass": "BTG International Inc.",
            "SponsorAgency": "Other",
            "LeadSponsor": "BTG International Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal\r\n\r\n      cancer with metastases in the liver, who are scheduled to receive second line chemotherapy.\r\n\r\n      All patients receive the standard of care che",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2012",
            "CompletionDate": "February 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "BTG International Inc.",
            "StudyCondition": "Colorectal Cancer Metastatic",
            "studyLocation": "UCSF Helen Diller Family Comprehensive Cancer Center",
            "Enrollment": "340",
            "MeshKeyword": "Colorectal Neoplasms,",
            "Eligibility": "Inclusion Criteria\r\n\r\n\r\n\r\n          -  Must be male or female, 18 years of age or older, and of any ethnic or racial group\r\n\r\n\r\n\r\n          -  Not resected primary tumor; must be clinically stable\r\n\r\n\r\n\r\n          -  Colorectal cancer with unr",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "San Francisco",
            "State": "California",
            "Zip": "94115",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "September 15, 2016",
            "FirstReceived": "November 24, 2011",
            "OverallOfficial": "Mary F Mulcahy, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Northwestern University",
            "ContactName": "Nathan F Messinger",
            "ContactPhone": "912.656.2696",
            "ContactEmail": "Nathan.Messinger@chiltern.com",
            "LocationStatus": "Recruiting",
            "LocationName": "UCSF Helen Diller Family Comprehensive Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01483027",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150196 - BTG International - Portelance",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150196",
            "StudyNumber": "20150196 - BTG International - Portelance",
            "StudyTitle": "“A Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy”",
            "PIID": "2807",
            "PicNum": "C09960880",
            "PILastName": "Portelance",
            "PIFirstName": "Lorraine",
            "CoodCNbr": "C00294869",
            "CoordLastName": "Martin",
            "CoordFirstName": "Doris",
            "CoordEmail": "dmartin3@med.miami.edu",
            "CoordPhone": "3052435491",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "08/10/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/10/2016",
            "IRBApprovedFrom": "08/03/2015",
            "IRBApprovedTo": "07/16/2017",
            "DiseaseSiteListDesc": "Colon,Rectum",
            "Expr1": "Phase III",
            "Tarea": "Colorectal Cancer",
            "TareaCode": "12437",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "BTG International",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Marinellie Vega,Pavel Noa Hechavarria,Fernando Vazquez Pascual,Zaida Abreu,Lilibet Zamora Cabezas,Lilly Sanchez,Greeyt Hernandez",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT01483027",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01492504",
            "SecondaryId": "2011-005287-21",
            "BriefTitle": "Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial",
            "OfficialTitle": "A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatitis C",
            "LeadSponsorClass": "Bristol-Myers Squibb",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Bristol-Myers Squibb",
            "OversightAuthority": "No",
            "BriefSummary": "The primary purpose of this study is to determine whether the hepatitis C virus continues to\r\n\r\n      remain unable to be detected in subjects who were previously treated with Asunaprevir\r\n\r\n      (BMS-650032) and/or Daclatasvir (BMS-790052) and",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "February 2012",
            "CompletionDate": "February 2021",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Bristol-Myers Squibb",
            "StudyCondition": "Hepatitis C",
            "studyLocation": "Alabama Liver & Digestive Specialists (Alds)",
            "Enrollment": "1850",
            "MeshKeyword": "Hepatitis, Hepatitis A, Hepatitis C, Hepatitis, Chronic, Hepatitis C, Chronic,",
            "Eligibility": "Inclusion Criteria\r\n\r\n\r\n\r\n          -  Signed Written Informed Consent\r\n\r\n\r\n\r\n          -  Subjects must have received at least one dose of Asunaprevir and/or Daclatasvir\r\n\r\n\r\n\r\n          -  Subjects participating in Daclatasvir and/or Asunapr",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Montgomery",
            "State": "Alabama",
            "Zip": "36116",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "January 5, 2017",
            "FirstReceived": "November 30, 2011",
            "OverallOfficial": "Bristol-Myers Squibb",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Bristol-Myers Squibb",
            "LocationName": "Alabama Liver & Digestive Specialists (Alds)",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01492504",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130476 - Bristol Myers Squibb - Jayaweera",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20130476",
            "StudyNumber": "20130476 - Bristol Myers Squibb - Jayaweera",
            "StudyTitle": "BMS  AI444046  A Long Term Followup Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS650032) and/or Daclatasvir (BMS790052) was Administered for the treatment of Chroinic Hepatitis C.",
            "PIID": "234",
            "PicNum": "C00043390",
            "PILastName": "Jayaweera",
            "PIFirstName": "Dushyantha T.",
            "CoodCNbr": "C00212247",
            "CoordLastName": "Healy",
            "CoordFirstName": "Lynn",
            "CoordEmail": "lhealy@med.miami.edu",
            "EnteredByCNbr": "C00039376",
            "EnteredByLastName": "Moreno",
            "EnteredByFirstName": "Kenia",
            "ActiveEnrollingDate": "09/18/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/18/2013",
            "IRBApprovedFrom": "07/05/2013",
            "IRBApprovedTo": "05/22/2017",
            "InfoEdNbr": "66631",
            "Expr1": "Phase III",
            "Tarea": "Infectious Diseases",
            "TareaCode": "9937",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Bristol-Myers Squibb",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "4",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Tom Tanner,Annie Salvarrey,Kenia Moreno",
            "AgentDevices": "Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01492504",
            "StudyKeywords": "Hepatitis, Bristol-Myers Squibb, Asunaprevir, Daclatasvir, Liver Diseases",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01507987",
            "SecondaryId": "CRD-619",
            "BriefTitle": "St.Jude Medical Cardiac Lead Assessment Study",
            "OfficialTitle": "St.Jude Medical Cardiac Lead Assessment Study",
            "LeadSponsorClass": "St. Jude Medical",
            "SponsorAgency": "Industry",
            "LeadSponsor": "St. Jude Medical",
            "OversightAuthority": "No",
            "BriefSummary": "The objectives of the study are:\r\n\r\n\r\n\r\n        1. To determine the prevalence of externalized conductors at enrollment in Riata®, Riata®\r\n\r\n           ST Silicone, QuickSite®/QuickFlex® and Durata® leads\r\n\r\n\r\n\r\n        2. To determine the preva",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2013",
            "CompletionDate": "March 2020",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "St. Jude Medical",
            "StudyCondition": "Prevalence of Externalized Conductors and Other Visual Lead Anomalies in Certain Family of High Voltage and CRT Leads",
            "studyLocation": "The Cleveland Clinic Foundation",
            "Enrollment": "2487",
            "NctKeyword": "Externalized Conductors,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Patient has a market released SJM ICD, CRT-D or CRT-P already implanted.\r\n\r\n\r\n\r\n          2. Patient has at least one market released Riata/ Riata ST/QuickSite/QuickFlex/Durata\r\n\r\n             already im",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Cleveland",
            "State": "Ohio",
            "Zip": "44195",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 12, 2016",
            "FirstReceived": "January 6, 2012",
            "ContactName": "Grant Kim, B.S.",
            "ContactPhone": "8184933147",
            "ContactEmail": "gkim@sjm.com",
            "LocationStatus": "Recruiting",
            "LocationName": "The Cleveland Clinic Foundation",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01507987",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120007 - PACESETTER INC - Carrillo",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20120007",
            "StudyNumber": "20120007 - PACESETTER INC - Carrillo",
            "StudyTitle": "Riata Lead Evaluation Post Market Study.",
            "PIID": "1975",
            "PicNum": "C00394135",
            "PILastName": "Carrillo",
            "PIFirstName": "Roger",
            "CoodCNbr": "C00330817",
            "CoordLastName": "Kassira",
            "CoordFirstName": "Wedad",
            "CoordEmail": "wkassira2@med.miami.edu",
            "CoordPhone": "3052435852",
            "EnteredByCNbr": "C00394135",
            "EnteredByLastName": "Carrillo",
            "EnteredByFirstName": "Roger",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "03/19/2012",
            "IRBApprovedFrom": "03/19/2012",
            "IRBApprovedTo": "04/08/2015",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "SiteSampleSize": "UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Raiza Salceda,Rosa Khan",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01507987",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01515787",
            "SecondaryId": "CDR0000715321",
            "BriefTitle": "PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery",
            "OfficialTitle": "A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Exci",
            "LeadSponsorClass": "Alliance for Clinical Trials in Oncology",
            "SponsorAgency": "Other",
            "LeadSponsor": "Alliance for Clinical Trials in Oncology",
            "OversightAuthority": "Yes",
            "BriefSummary": "The standard treatment for locally advanced rectal cancer involves chemotherapy and\r\n\r\n      radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and\r\n\r\n      radiation therapy) prior to surgery. Although radiation the",
            "Description": "OUTLINE: This is a multicenter, phase II/III study. Patients are stratified according to\r\n\r\n      ECOG performance status (0 or 1 vs 2) and randomized to 1 of 2 treatment regimens. Patients\r\n\r\n      will receive full supportive care while on thi",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2012",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "Alliance for Clinical Trials in Oncology",
            "StudyCondition": "Colorectal Cancer",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "1060",
            "NctKeyword": "stage IIA rectal cancer, stage IIIA rectal cancer, stage IIIB rectal cancer,",
            "MeshKeyword": "Colorectal Neoplasms, Rectal Neoplasms,",
            "InterventionKeyword": "Fluorouracil,",
            "Eligibility": "Registration Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age ≥ 18 years at diagnosis\r\n\r\n\r\n\r\n          2. Diagnosis of rectal adenocarcinoma\r\n\r\n\r\n\r\n          3. Radiologically measurable or clinically evaluable disease as defined in the protocol",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 16, 2016",
            "FirstReceived": "January 18, 2012",
            "OverallOfficial": "Deborah Schrag, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Dana-Farber Cancer Institute",
            "ContactName": "Deborah Schrag, MD",
            "ContactPhone": "617 582-8301",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01515787",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130234 - Alliance for Clinical Trials - Bahna",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20130234",
            "StudyNumber": "20130234 - Alliance for Clinical Trials - Bahna",
            "StudyTitle": "N1048 A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision",
            "PIID": "4111",
            "PicNum": "C00343204",
            "PILastName": "Bahna",
            "PIFirstName": "Heidi",
            "CoodCNbr": "C04035535",
            "CoordLastName": "Sanchez",
            "CoordFirstName": "Lilly",
            "CoordEmail": "lsanchez@med.miami.edu",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "01/09/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/09/2014",
            "IRBApprovedFrom": "10/18/2013",
            "IRBApprovedTo": "09/30/2016",
            "DiseaseSiteListDesc": "Rectum",
            "Expr1": "Phase II/III",
            "Tarea": "Colorectal Cancer",
            "TareaCode": "12437",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "Alliance for Clinical Trials",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "8",
            "Totalaccrued": "7",
            "InFollowUp": "5",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "8",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:66,UMMG:N/A,UMD:N/A",
            "AccrualPercentageMet": "10.60606060606060606060606060606060606061",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "66",
            "EprostState": "External IRB",
            "StudyCoordinator": "Marinellie Vega,Jean (Lynne) Sparling,Doris Martin",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01515787",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01525602",
            "BriefTitle": "Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors",
            "OfficialTitle": "A Phase 1b Study to Assess the Safety of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors",
            "LeadSponsorClass": "Plexxikon",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Plexxikon",
            "OversightAuthority": "No",
            "BriefSummary": "The goal of this clinical study is to learn how PLX3397 and paclitaxel work together to\r\n\r\n      affect the growth of cancer cells in advanced solid tumors.",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2012",
            "CompletionDate": "June 2018",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Plexxikon",
            "StudyCondition": "Solid Tumors",
            "studyLocation": "Plexxikon Investigative Site",
            "Enrollment": "90",
            "NctKeyword": "advanced, incurable solid tumors,",
            "InterventionKeyword": "Paclitaxel, Albumin-Bound Paclitaxel,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients with:\r\n\r\n\r\n\r\n               -  Part 1 (enrollment closed): an advanced, incurable solid tumor\r\n\r\n\r\n\r\n               -  Part 2 (enrollment closed): an advanced, incurable solid tumor for whom a t",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 21, 2016",
            "FirstReceived": "January 31, 2012",
            "ContactName": "Isabel Luther",
            "ContactEmail": "Iluther@plexxikon.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Plexxikon Investigative Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01525602",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20151095 - Plexxikon - Huang",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151095",
            "StudyNumber": "20151095 - Plexxikon - Huang",
            "StudyTitle": "A Phase 1b Study to Assess the Safety of PLX3397 and Paclitaxel in Patients with Advanced Solid Tumors",
            "PIID": "25456",
            "PicNum": "C11974849",
            "PILastName": "Huang",
            "PIFirstName": "Marilyn",
            "CoodCNbr": "C00349551",
            "CoordLastName": "Blackburn",
            "CoordFirstName": "Karen",
            "CoordEmail": "k.blackburn@med.miami.edu",
            "CoordPhone": "3052430863",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "05/17/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/17/2016",
            "IRBApprovedFrom": "03/01/2016",
            "IRBApprovedTo": "02/28/2017",
            "AccountNbr": "664249",
            "DiseaseSiteListDesc": "Ovary,Other Female Genital,Bones and Joints",
            "Expr1": "Phase I",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "3",
            "FirstNinety": "2",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Tamara Leon Aliz,Juan Salvador,Daniel Sumarriva,Sandra Pineda,Yvonne Dinh",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT01525602",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01528046",
            "SecondaryId": "SP003",
            "BriefTitle": "Metformin in Children With Relapsed or Refractory Solid Tumors",
            "OfficialTitle": "A Phase I Trial of Dose Escalation of Metformin in Combination With Vincristine, Irinotecan, and Temozolomide in Children With Relapsed or Refractory Solid Tumors",
            "LeadSponsorClass": "H. Lee Moffitt Cancer Center and Research Institute",
            "SponsorAgency": "Other",
            "LeadSponsor": "H. Lee Moffitt Cancer Center and Research Institute",
            "OversightAuthority": "Yes",
            "BriefSummary": "H. Lee Moffitt Cancer Center and Research Institute will be the Sunshine Project\r\n\r\n      Coordinator, but will not be recruiting locally.\r\n\r\n\r\n\r\n      The purpose of this study is to evaluate the tolerability and safety of escalating doses of",
            "Description": "Metformin is an oral anti-diabetes medication that activates AMP-activated protein kinase\r\n\r\n      (AMPK). Recent data from in vitro and in vivo experiments, as well as epidemiologic\r\n\r\n      retrospective analyses, suggest that metformin has an",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2012",
            "CompletionDate": "December 2017",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "H. Lee Moffitt Cancer Center and Research Institute",
            "StudyCondition": "Solid Tumors",
            "studyLocation": "Connecticut Children's Medical Center",
            "Enrollment": "25",
            "NctKeyword": "central nervous system (CNS), malignancy, relapsed, refractory, pediatric, recurrent,",
            "MeshKeyword": "Neoplasms, Brain Neoplasms,",
            "InterventionKeyword": "Metformin, Irinotecan, Camptothecin, Vincristine, Temozolomide, Dacarbazine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Age: Patients must be > 1 year of age and ≤ 18 years of age at time of initiation of\r\n\r\n             protocol therapy.\r\n\r\n\r\n\r\n          -  Diagnosis: Patients have a histologically or radiographically co",
            "EligibleGender": "All",
            "MinAge": "1 Year",
            "MaxAge": "18 Years",
            "Volunteers": "No",
            "City": "Hartford",
            "State": "Connecticut",
            "Zip": "06106",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 13, 2016",
            "FirstReceived": "February 3, 2012",
            "OverallOfficial": "Jonathan Gill, M.D.",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "The Children's Hospital at Montefiore, Pediatric Cancer Foundation, Sunshine Project",
            "ContactName": "Tiffany Smith",
            "ContactPhone": "813-745-6250",
            "ContactEmail": "tiffany.smith@moffitt.org",
            "LocationStatus": "Recruiting",
            "LocationName": "Connecticut Children's Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01528046",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120420 - Pediatric Cancer Foundation - Trucco",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20120420",
            "StudyNumber": "20120420 - Pediatric Cancer Foundation - Trucco",
            "StudyTitle": "A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors",
            "PIID": "26577",
            "PicNum": "C12027657",
            "PILastName": "Trucco",
            "PIFirstName": "Matteo",
            "CoodCNbr": "C00110674",
            "CoordLastName": "Zayas",
            "CoordFirstName": "Myriam",
            "CoordEmail": "MZayas2@med.miami.edu",
            "EnteredByCNbr": "C07181703",
            "EnteredByLastName": "Zhang",
            "EnteredByFirstName": "Lei",
            "ActiveEnrollingDate": "09/28/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/28/2012",
            "IRBApprovedFrom": "08/23/2012",
            "IRBApprovedTo": "07/27/2017",
            "InfoEdNbr": "63663",
            "DiseaseSiteListDesc": "Brain and Nervous System,Bones and Joints",
            "Expr1": "Phase I",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "Pediatric Cancer Foundation",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "4",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A,UMHC:5",
            "AccrualPercentageMet": "80",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "5",
            "EprostState": "Approved",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT01528046",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01531374",
            "BriefTitle": "Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement",
            "OfficialTitle": "Medtronic CoreValve® Continued Access Study",
            "LeadSponsorClass": "Medtronic Cardiovascular",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Medtronic Cardiovascular",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of the study is to evaluate the safety and efficacy of the Medtronic CoreValve®\r\n\r\n      System in the treatment of symptomatic severe aortic stenosis in subjects who have a\r\n\r\n      predicted very high risk and high risk for aortic",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "February 2012",
            "CompletionDate": "October 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Medtronic Cardiovascular",
            "StudyCondition": "Severe Aortic Stenosis",
            "studyLocation": "Banner Good Samaritan",
            "Enrollment": "1690",
            "NctKeyword": "Valvular Heart Disease, Critical Aortic Stenosis, Severe Aortic Stenosis, Extreme Risk, High Risk, Aortic Valve Replacement,",
            "MeshKeyword": "Constriction, Pathologic, Aortic Valve Stenosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. High Risk: Subject must have co-morbidities such that one cardiologist and two\r\n\r\n             cardiac surgeons agree that predicted risk of operative mortality is ≥15% (and\r\n\r\n             predicted ope",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85006",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 26, 2016",
            "FirstReceived": "February 3, 2012",
            "OverallOfficial": "Jeffrey J Popma, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Beth Israel Deaconess Medical Center",
            "LocationName": "Banner Good Samaritan",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01531374",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120129 - CAS - De Marchena",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20120129",
            "StudyNumber": "20120129 - CAS - De Marchena",
            "StudyTitle": "Medtronic CoreValve Continued Access Study (High Risk and Extreme Risk Patients)",
            "PIID": "1187",
            "PicNum": "C00491335",
            "PILastName": "De Marchena",
            "PIFirstName": "Eduardo",
            "CoodCNbr": "C00491335",
            "CoordLastName": "De Marchena",
            "CoordFirstName": "Eduardo",
            "CoordEmail": "e.demarchena@miami.edu",
            "CoordPhone": "3052432105",
            "EnteredByCNbr": "C04284337",
            "EnteredByLastName": "Marin y Kall",
            "EnteredByFirstName": "Christian",
            "ActiveEnrollingDate": "03/15/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/15/2012",
            "IRBApprovedFrom": "03/05/2012",
            "IRBApprovedTo": "02/16/2015",
            "AccountNbr": "66930A",
            "InfoEdNbr": "60696",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Medtronic",
            "Prescreened": "5",
            "Screenedfailed": "24",
            "SignedICF": "71",
            "Totalaccrued": "47",
            "InFollowUp": "31",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "71",
            "FirstNinety": "2",
            "SiteSampleSize": "UMHC:N/A,JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Suresh Atapattu,Ximena Marincic-Sanchez,Christian Marin y Kall",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT01531374",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01537393",
            "SecondaryId": "1U10EY020798-01A1",
            "BriefTitle": "Cornea Preservation Time Study",
            "OfficialTitle": "Effect of Corneal Preservation Time on Long-Term Graft Success",
            "LeadSponsorClass": "Case Western Reserve University",
            "SponsorAgency": "Other",
            "LeadSponsor": "Case Western Reserve University",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine if the 3-year graft failure rate following\r\n\r\n      endothelial keratoplasty performed with donor corneas with a preservation time of 8 to 14\r\n\r\n      days is non-inferior to the failure rate when donor",
            "Description": "When the donor cornea is removed from the person who died, it is prepared for\r\n\r\n      transplantation by an eye bank. The donor cornea is placed into a liquid that helps preserve\r\n\r\n      the cornea until it is transplanted. The Food and Drug A",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "March 2012",
            "CompletionDate": "August 2017",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "Case Western Reserve University",
            "StudyCondition": "Cornea Preservation Time",
            "studyLocation": "Keck Medical Center",
            "Enrollment": "1330",
            "NctKeyword": "cornea, transplant, preservation, endothelial keratoplasty,",
            "MeshKeyword": "Corneal Diseases,",
            "Eligibility": "Study Participant Eligibility Criteria\r\n\r\n\r\n\r\n          -  Study Participant Inclusion Criteria\r\n\r\n\r\n\r\n               1. Age range 30-<91 years with minimum life expectancy of at least 3 years.\r\n\r\n\r\n\r\n               2. Willingness to return fo",
            "EligibleGender": "All",
            "MinAge": "30 Years",
            "MaxAge": "90 Years",
            "Volunteers": "No",
            "City": "Beverly Hills",
            "State": "California",
            "Zip": "90211",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 2, 2017",
            "FirstReceived": "February 15, 2012",
            "OverallOfficial": "Jonathan Lass, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Case Western Reserve University",
            "LocationName": "Keck Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01537393",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20111088 - JAEB CENTER FOR HEALTH RESEARCH FND - Yoo",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20111088",
            "StudyNumber": "20111088 - JAEB CENTER FOR HEALTH RESEARCH FND - Yoo",
            "StudyTitle": "Effect of Corneal Preservation Time on LongTerm Graft Success",
            "PIID": "512",
            "PicNum": "C00011377",
            "PILastName": "Yoo",
            "PIFirstName": "Sonia",
            "CoodCNbr": "C03081933",
            "CoordLastName": "San Roman",
            "CoordFirstName": "Janika",
            "CoordEmail": "jsanroman@med.miami.edu",
            "CoordPhone": "3052434903",
            "EnteredByCNbr": "C03081933",
            "EnteredByLastName": "San Roman",
            "EnteredByFirstName": "Janika",
            "ActiveEnrollingDate": "07/03/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/03/2012",
            "IRBApprovedFrom": "06/11/2012",
            "IRBApprovedTo": "05/22/2017",
            "AccountNbr": "66935E",
            "InfoEdNbr": "60845",
            "Expr1": "Phase II",
            "Tarea": "Cornea",
            "TareaCode": "12036",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "SponsorGroup": "NIH",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "17",
            "Totalaccrued": "17",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "6",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "17",
            "FirstNinety": "2",
            "SiteSampleSize": "ABLEH:N/A,UMMG:N/A,BPPB:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Ailen Gutierrez",
            "NationalSampleSize": "11",
            "NCTNbr": "NCT01537393",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01567150",
            "BriefTitle": "Wound Fluid Protease Levels During Use of Novel Wound Dressing",
            "OfficialTitle": "Wound Fluid Protease Levels During Use of Novel Wound Dressing",
            "LeadSponsorClass": "Hollister Incorporated",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Hollister Incorporated",
            "OversightAuthority": "No",
            "BriefSummary": "This study is being conducted to characterize the way leg wounds respond to a new type of\r\n\r\n      wound dressing, compared to wounds in patients who are not using the new dressing. The\r\n\r\n      investigators will collect wound fluid for biochem",
            "Description": "Abnormal wound healing is characterized by prolonged inflammation and excess degradation of\r\n\r\n      the extracellular matrix through the activity of proteinases and other enzymes. Wound fluids\r\n\r\n      can provide biochemical information about",
            "OverallStatus": "Completed",
            "StartDate": "February 2012",
            "CompletionDate": "January 2014",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "Hollister Incorporated",
            "StudyCondition": "Venous Stasis Ulcers",
            "studyLocation": "Arizona Heart Hospital",
            "Enrollment": "35",
            "MeshKeyword": "Varicose Ulcer, Postphlebitic Syndrome, Postthrombotic Syndrome,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of venous insufficiency\r\n\r\n\r\n\r\n          -  One or more partial or full-thickness venous leg ulcers 5-24 sq. cm in size without\r\n\r\n             evidence of clinical infection\r\n\r\n\r\n\r\n          -",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85006",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 4, 2016",
            "FirstReceived": "March 23, 2012",
            "OverallOfficial": "Ginger Salvadalena, PhD, RN",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Hollister Incorporated",
            "LocationName": "Arizona Heart Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01567150",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20111048 - HOLLISTER INC - Goldstein",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20111048",
            "StudyNumber": "20111048 - HOLLISTER INC - Goldstein",
            "StudyTitle": "WOUND FLUID PROTEASE LEVELS DURING USE OF ENDOFORM DERMAL TEMPLATE",
            "PIID": "3734",
            "PicNum": "C08165348",
            "PILastName": "Goldstein",
            "PIFirstName": "Lee",
            "CoodCNbr": "C00245987",
            "CoordLastName": "Sparling",
            "CoordFirstName": "Jean (Lynne)",
            "CoordEmail": "lsparlin@med.miami.edu",
            "CoordPhone": "3052437298",
            "EnteredByCNbr": "C00245987",
            "EnteredByLastName": "Sparling",
            "EnteredByFirstName": "Jean (Lynne)",
            "ActiveEnrollingDate": "03/20/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/20/2012",
            "IRBApprovedFrom": "03/20/2012",
            "IRBApprovedTo": "03/17/2014",
            "AccountNbr": "66944M",
            "InfoEdNbr": "60217",
            "Expr1": "N/A",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "HOLLISTER INC",
            "Prescreened": "8",
            "Screenedfailed": "3",
            "SignedICF": "7",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "9",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Kay Salinas",
            "NationalSampleSize": "14",
            "NCTNbr": "NCT01567150",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01567722",
            "SecondaryId": "CDR0000729843",
            "BriefTitle": "Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies",
            "OfficialTitle": "Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies",
            "LeadSponsorClass": "AIDS Malignancy Consortium",
            "SponsorAgency": "Other",
            "LeadSponsor": "AIDS Malignancy Consortium",
            "OversightAuthority": "No",
            "BriefSummary": "RATIONALE: Collecting and studying tissue samples from patients with cancer in the\r\n\r\n      laboratory may help doctors learn more about changes that occur in DNA and identify\r\n\r\n      biomarkers related to cancer.\r\n\r\n\r\n\r\n      PURPOSE: This res",
            "Description": "OBJECTIVES:\r\n\r\n\r\n\r\n        -  To obtain high-quality, clinically annotated tissue from patients with human\r\n\r\n           immunodeficiency virus (HIV)-1 malignancy.\r\n\r\n\r\n\r\n        -  To study clinical, genetic, and immunologic parameters that hav",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2012",
            "CompletionDate": "June 2020",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "AIDS Malignancy Consortium",
            "StudyCondition": "Anal Cancer",
            "studyLocation": "Moores UCSD Cancer Center",
            "Enrollment": "300",
            "NctKeyword": "HIV infection, adult diffuse large cell lymphoma, anal cancer, cervical cancer, non-small cell lung cancer, AIDS-related diffuse large cell lymphoma,",
            "MeshKeyword": "Uterine Cervical Neoplasms, Anus Neoplasms,",
            "Eligibility": "DISEASE CHARACTERISTICS:\r\n\r\n\r\n\r\n          -  Participants must have a diagnosis of a malignancy or clinical findings suggestive of\r\n\r\n             a possible HIV-associated malignancy of one of three types:\r\n\r\n\r\n\r\n               -  Diffuse lar",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "La Jolla",
            "State": "California",
            "Zip": "92093-0658",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "November 9, 2016",
            "FirstReceived": "March 29, 2012",
            "OverallOfficial": "Lee Ratner, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Washington University Siteman Cancer Center",
            "LocationStatus": "Recruiting",
            "LocationName": "Moores UCSD Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01567722",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120412 - AIDS Malignancy Con - Ramos",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20120412",
            "StudyNumber": "20120412 - AIDS Malignancy Con - Ramos",
            "StudyTitle": "AMC PROTOCOL 083: Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV1 Associated Malignancies",
            "PIID": "433",
            "PicNum": "C03978871",
            "PILastName": "Ramos",
            "PIFirstName": "Juan Carlos",
            "CoodCNbr": "C11923689",
            "CoordLastName": "Mohan",
            "CoordFirstName": "Vivin",
            "CoordEmail": "vxm153@miami.edu",
            "EnteredByCNbr": "C11964150",
            "EnteredByLastName": "Smith",
            "EnteredByFirstName": "Nyesha",
            "ActiveEnrollingDate": "10/02/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/02/2012",
            "IRBApprovedFrom": "10/02/2012",
            "IRBApprovedTo": "05/30/2017",
            "DiseaseSiteListDesc": "Other Hematopoietic",
            "Expr1": "N/A",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "Externally Peer Reviewed",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "5",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Sandra O'Mellan",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01567722",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01567891",
            "SecondaryId": "230612",
            "BriefTitle": "CT Antigen TCR-redirected T Cells for Ovarian Cancer.",
            "OfficialTitle": "A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.",
            "LeadSponsorClass": "Adaptimmune",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Adaptimmune",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study, will take a subject's \"T cells\" and \"teach\" them to be able to recognize and\r\n\r\n      attack the ovarian cancer cells. This is done by putting in a gene or genetic material that\r\n\r\n      will change how a subject's T cells work and h",
            "Description": "This is an open label clinical trial. Patients with the HLA-A201, HLA-A205, and/or HLA-A206\r\n\r\n      allele and whose tumor expresses the NY-ESO-1 tumor antigen will be eligible to receive\r\n\r\n      NY-ESO-1ᶜ²⁵⁹T. The trial is conducted entirely",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2013",
            "CompletionDate": "January 2019",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Adaptimmune",
            "StudyCondition": "Ovarian Cancer",
            "studyLocation": "City of Hope National Medical Center",
            "Enrollment": "10",
            "NctKeyword": "Ovarian Cancer, Cell Therapy, T Cell Therapy, NY-ESO-1, Immuno-oncology, Metastatic, Previously treated, T Cell Receptor,",
            "MeshKeyword": "Ovarian Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Must have a diagnosis of recurrent epithelial ovarian, primary peritoneal or\r\n\r\n             fallopian tube carcinoma with refractory or platinum resistant disease and/or have\r\n\r\n             received ≥",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Durate",
            "State": "California",
            "Zip": "91010",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 4, 2016",
            "FirstReceived": "March 16, 2012",
            "OverallOfficial": "Kunle Odunsi, MD, PhD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Roswell Park Cancer Institute",
            "ContactName": "RPCI Hotline",
            "ContactPhone": "877-275-7724",
            "ContactEmail": "askrpci@roswellpark.org",
            "LocationStatus": "Recruiting",
            "LocationName": "City of Hope National Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01567891",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150887 - Adaptimmune - Slomovitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150887",
            "StudyNumber": "20150887 - Adaptimmune - Slomovitz",
            "StudyTitle": "A Phase I/IIa, Open Label, Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients with Recurrent or Treatment Refractory Ovarian Cancer",
            "PIID": "22712",
            "PicNum": "C11916703",
            "PILastName": "Slomovitz",
            "PIFirstName": "Brian",
            "CoodCNbr": "C11982423",
            "CoordLastName": "Grandas Moreno",
            "CoordFirstName": "Claudia",
            "CoordEmail": "c.grandas@miami.edu",
            "CoordPhone": "305-243-7530",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "04/28/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/28/2016",
            "IRBApprovedFrom": "03/15/2016",
            "IRBApprovedTo": "03/14/2017",
            "DiseaseSiteListDesc": "Ovary",
            "Expr1": "Phase I/II",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Adaptimmune",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "27",
            "Totalaccrued": "21",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "27",
            "FirstNinety": "7",
            "SiteSampleSize": "UMD:N/A,UMMG:N/A,UMHC:N/A,Plantation:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Isabel Moya,Evan Dadas,Halyna Hailes,Anthony Minichiello,Mohammad El-Sorady,Penny Eyer,Vivin Mohan,Nohelia Gonzalez,Negin Habibi Khameneh",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01567891",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01570036",
            "SecondaryId": "1137008 / 20130058",
            "BriefTitle": "Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax",
            "OfficialTitle": "Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence",
            "LeadSponsorClass": "George E. Peoples",
            "SponsorAgency": "Industry",
            "LeadSponsor": "George E. Peoples",
            "OversightAuthority": "Yes",
            "BriefSummary": "The study will be a multi-center, prospective, randomized, single-blinded,\r\n\r\n      placebo-controlled Phase II trial of Herceptin + NeuVax(TM) vaccine (E75 peptide/granulocyte\r\n\r\n      macrophage-colony stimulating factor) (GM-CSF) versus Herce",
            "Description": "In this study, the investigators intend to assess the ability of the combination of\r\n\r\n      Herceptin and NeuVax vaccine (HER2 protein E75 peptide administered with the immunoadjuvant\r\n\r\n      GM-CSF) given in the adjuvant setting to prevent re",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2013",
            "CompletionDate": "June 2019",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Cancer Insight, LLC",
            "StudyCondition": "Breast Cancer",
            "studyLocation": "Samuel Oschin Comprehensive Cancer Institute - Cedars Sinai Medical Center",
            "Enrollment": "300",
            "NctKeyword": "stage I breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, male breast cancer,",
            "MeshKeyword": "Breast Neoplasms,",
            "InterventionKeyword": "Vaccines, Trastuzumab,",
            "Eligibility": "Patients will be included in the study based on the following criteria:\r\n\r\n\r\n\r\n          -  Women 18 years or older\r\n\r\n\r\n\r\n          -  Node-positive breast cancer (AJCC N1, N2, or N3)\r\n\r\n\r\n\r\n          -  Node-negative breast cancer if negativ",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Beverly Hills",
            "State": "California",
            "Zip": "90211",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 2, 2017",
            "FirstReceived": "March 25, 2012",
            "OverallOfficial": "COL (ret.) George E. Peoples, MD, FACS",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Cancer Insight, LLC",
            "ContactName": "Karen Arrington, RN, BSN, CCRP",
            "ContactPhone": "210-243-5711",
            "ContactEmail": "karrington@cancerinsight.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Samuel Oschin Comprehensive Cancer Institute - Cedars Sinai Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01570036",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150975 - Genentech Inc - Calfa",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150975",
            "StudyNumber": "20150975 - Genentech Inc - Calfa",
            "StudyTitle": "Combination immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence",
            "PIID": "25231",
            "PicNum": "C00214960",
            "PILastName": "Calfa",
            "PIFirstName": "Carmen",
            "CoodCNbr": "C12024030",
            "CoordLastName": "Conte",
            "CoordFirstName": "Deborah",
            "CoordEmail": "dmc238@med.miami.edu",
            "CoordPhone": "954-830-2360",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "06/21/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/21/2016",
            "IRBApprovedFrom": "05/16/2016",
            "IRBApprovedTo": "07/31/2016",
            "AccountNbr": "666620",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase II",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Expr2": "Prevention",
            "StudyType_Code": "6163",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Genentech, Inc",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "7",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "4",
            "Totalpatients": "7",
            "FirstNinety": "3",
            "SiteSampleSize": "UMHC:N/A,Plantation:N/A,UM Coral Springs:N/A,UM Kendall:N/A,UMMG:N/A,UM Hollywood:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Michelle Liendo,Anthony Minichiello,Evan Dadas,Onaidy Torres,Cristina Rojas-Mejia,Halyna Hailes,Penny Eyer",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT01570036",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01582932",
            "BriefTitle": "To Evaluate the Safety, Tolerability and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) With Plaque Psoriasis",
            "OfficialTitle": "A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety, Efficacy, Systemic Exposure, and Pharmacodynamics of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2 to 11 Years) With Plaque Psoriasis",
            "LeadSponsorClass": "GlaxoSmithKline",
            "SponsorAgency": "Industry",
            "LeadSponsor": "GlaxoSmithKline",
            "OversightAuthority": "No",
            "BriefSummary": "Calcipotriene is a vitamin D3 analog that has been used as topical therapy in adult subjects\r\n\r\n      with plaque-type psoriasis since 1993. Calcipotriene foam, 0.005%, was approved in 2010 for\r\n\r\n      the treatment of plaque psoriasis in adult",
            "Description": "This is a multicenter, randomized, double-blind, Phase 3 study comparing calcipotriene foam,\r\n\r\n      0.005%, with vehicle foam in pediatric subjects, ages 2 to 11 years, inclusive, with mild to\r\n\r\n      moderate plaque psoriasis. Subjects will",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2013",
            "CompletionDate": "April 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "GlaxoSmithKline",
            "StudyCondition": "Psoriasis",
            "studyLocation": "GSK Investigational Site",
            "Enrollment": "180",
            "NctKeyword": "plaque psoriasis,",
            "MeshKeyword": "Psoriasis,",
            "InterventionKeyword": "Calcipotriene, Calcitriol,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male or female subjects, ages 2 to 11 years, inclusive, at the time of consent\r\n\r\n\r\n\r\n          -  Clinical diagnosis of mild to moderate plaque psoriasis, as defined by body ISGA\r\n\r\n             score o",
            "EligibleGender": "All",
            "MinAge": "2 Years",
            "MaxAge": "11 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 4, 2016",
            "FirstReceived": "March 29, 2012",
            "OverallOfficial": "GSK Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "GlaxoSmithKline",
            "ContactName": "US GSK Clinical Trials Call Center",
            "ContactPhone": "877-379-3718",
            "ContactEmail": "GSKClinicalSupportHD@gsk.com",
            "LocationStatus": "Terminated",
            "LocationName": "GSK Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01582932",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130199 - STIEFEL LAB INC - Schachner",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20130199",
            "StudyNumber": "20130199 - STIEFEL LAB INC - Schachner",
            "StudyTitle": "A Multicenter, Randomized, DoubleBlind, Phase 3 Study of the Safety, Efficacy, Systemic Exposure, and Pharmacodynamics of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis",
            "PIID": "793",
            "PicNum": "C00433811",
            "PILastName": "Schachner",
            "PIFirstName": "Lawrence",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C03413356",
            "EnteredByLastName": "Kittles",
            "EnteredByFirstName": "Carol",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "05/20/2013",
            "IRBApprovedFrom": "05/20/2013",
            "IRBApprovedTo": "04/20/2016",
            "InfoEdNbr": "64941",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "STIEFEL LAB INC",
            "SiteSampleSize": "UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carol Kittles",
            "NationalSampleSize": "24",
            "NCTNbr": "NCT01582932",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01586910",
            "BriefTitle": "Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).",
            "OfficialTitle": "Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI)",
            "LeadSponsorClass": "Medtronic Cardiovascular",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Medtronic Cardiovascular",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of the study is to investigate the safety and efficacy of transcatheter aortic\r\n\r\n      valve implantation (TAVI) in patients with severe, symptomatic Aortic Stenosis (AS) at\r\n\r\n      intermediate surgical risk by randomizing patient",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2012",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Medtronic Cardiovascular",
            "StudyCondition": "Severe Aortic Stenosis",
            "studyLocation": "Banner Good Samaritan Medical Center",
            "Enrollment": "2500",
            "MeshKeyword": "Constriction, Pathologic, Aortic Valve Stenosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject must have co-morbidities such that Heart Team agrees predicted risk of\r\n\r\n             operative mortality is ≥3% and <15% at 30 days (Intermediate Clinical Risk\r\n\r\n             classification).",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85006",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 13, 2017",
            "FirstReceived": "April 24, 2012",
            "OverallOfficial": "Stephan Windecker, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Bern University Hospital",
            "ContactName": "Mike Boulware",
            "ContactEmail": "surtavi@medtronic.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Banner Good Samaritan Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01586910",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130067 - Surtavi - De Marchena",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20130067",
            "StudyNumber": "20130067 - Surtavi - De Marchena",
            "StudyTitle": "Surgical Replacement and Transcatheter Aortic Valve Implantation  SURTAVI",
            "PIID": "1187",
            "PicNum": "C00491335",
            "PILastName": "De Marchena",
            "PIFirstName": "Eduardo",
            "CoodCNbr": "C04284337",
            "CoordLastName": "Marin y Kall",
            "CoordFirstName": "Christian",
            "CoordEmail": "cmarin@med.miami.edu",
            "CoordPhone": "3055856217",
            "EnteredByCNbr": "C10564365",
            "EnteredByLastName": "Marincic-Sanchez",
            "EnteredByFirstName": "Ximena",
            "ActiveEnrollingDate": "11/07/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/07/2013",
            "IRBApprovedTo": "10/09/2017",
            "AccountNbr": "661444",
            "InfoEdNbr": "65488",
            "Expr1": "N/A",
            "Tarea": "Aortic valve stenosis",
            "TareaCode": "16636",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "MEDTRONIC INC",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "8",
            "Totalaccrued": "5",
            "InFollowUp": "3",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "8",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A,UMH:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Suresh Atapattu,Ximena Marincic-Sanchez,Christian Marin y Kall",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT01586910",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01594762",
            "BriefTitle": "Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers",
            "OfficialTitle": "A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers",
            "LeadSponsorClass": "Dipexium Pharmaceuticals, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Dipexium Pharmaceuticals, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to establish the clinical superiority and the safety of topical\r\n\r\n      pexiganan cream 0.8% plus standard local wound care as compared to placebo cream plus\r\n\r\n      standard local wound care, in the treatment of m",
            "OverallStatus": "Completed",
            "StartDate": "June 2014",
            "CompletionDate": "July 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Dipexium Pharmaceuticals, Inc.",
            "StudyCondition": "Diabetic Foot Infection",
            "Enrollment": "200",
            "NctKeyword": "Diabetic Foot Ulcer Infection,",
            "MeshKeyword": "Infection, Communicable Diseases, Diabetic Foot, Foot Ulcer,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Diabetes mellitus.\r\n\r\n\r\n\r\n          2. Male or female at least 18 years old.\r\n\r\n\r\n\r\n          3. Subject must agree to adhere to all protocol procedures and return for all scheduled\r\n\r\n             visit",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 6, 2016",
            "FirstReceived": "May 7, 2012",
            "OverallOfficial": "Michael H. Silverman, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Biostrategics Consulting Ltd",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01594762",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140238 - Dipexium Pharmaceuticals/ LLC - Kirsner",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20140238",
            "StudyNumber": "20140238 - Dipexium Pharmaceuticals/ LLC - Kirsner",
            "StudyTitle": "A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults with Mild Infections of Diabetic Foot Ulcers",
            "PIID": "717",
            "PicNum": "C00519753",
            "PILastName": "Kirsner",
            "PIFirstName": "Robert",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C00519753",
            "EnteredByLastName": "Kirsner",
            "EnteredByFirstName": "Robert",
            "ActiveEnrollingDate": "10/24/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/24/2014",
            "IRBApprovedFrom": "06/17/2014",
            "IRBApprovedTo": "05/11/2017",
            "InfoEdNbr": "70957",
            "Expr1": "Phase II/III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Dipexium Pharmaceuticals/ LLC",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Aliette Espinosa,Carol Kittles",
            "NationalSampleSize": "18",
            "NCTNbr": "NCT01594762",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01597778",
            "SecondaryId": "2U10HL069294-11",
            "BriefTitle": "Double Cord Versus Haploidentical (BMT CTN 1101)",
            "OfficialTitle": "A Multi-Center, Phase III, Randomized Trial of Reduced Intensity Conditioning (RIC) and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients With Hematologic Malignancies (BMT C",
            "LeadSponsorClass": "Medical College of Wisconsin",
            "SponsorAgency": "Other",
            "LeadSponsor": "Medical College of Wisconsin",
            "OversightAuthority": "Yes",
            "BriefSummary": "Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or\r\n\r\n      lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar\r\n\r\n      tissue type can be used for HCT. This study wil",
            "Description": "Reduced intensity conditioning (RIC) blood or marrow transplantation (BMT) has allowed older\r\n\r\n      and less clinically fit patients to receive potentially curative treatment with allogeneic\r\n\r\n      HCT for high risk or advanced hematological",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2012",
            "CompletionDate": "June 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Medical College of Wisconsin",
            "StudyCondition": "Acute Lymphocytic Leukemia",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "410",
            "NctKeyword": "Haplo identical transplant, Cord blood transplant, Reduced intensity conditioning regimen, Lymphoma, Leukemia,",
            "MeshKeyword": "Lymphoma, Follicular, Lymphoma, Leukemia, Leukemia, Myeloid, Lymphoma, Non-Hodgkin, Leukemia, Lymphoid, Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Mantle-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma,",
            "InterventionKeyword": "Mycophenolate mofetil,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients 18 to 70 years old\r\n\r\n\r\n\r\n          -  Patients must have available both: a)One or more potential related mismatched donors\r\n\r\n             (biologic parent(s) or siblings (full or half) or chil",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "70 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 1, 2016",
            "FirstReceived": "May 10, 2012",
            "OverallOfficial": "Mary Horowitz, MD, MS",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin",
            "ContactName": "Heather Wittsack",
            "ContactEmail": "hwittsack@emmes.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01597778",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140107 - Blood and Marrow Transplant - Lekakis",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140107",
            "StudyNumber": "20140107 - Blood and Marrow Transplant - Lekakis",
            "StudyTitle": "A Multi-Center Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies",
            "PIID": "2809",
            "PicNum": "C09984957",
            "PILastName": "Lekakis",
            "PIFirstName": "Lazaros",
            "CoodCNbr": "C10180073",
            "CoordLastName": "Gonzalez",
            "CoordFirstName": "Nohelia",
            "CoordEmail": "ngonzalez5@med.miami.edu",
            "CoordPhone": "3052434903",
            "EnteredByCNbr": "C11964150",
            "EnteredByLastName": "Smith",
            "EnteredByFirstName": "Nyesha",
            "ActiveEnrollingDate": "05/20/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/20/2015",
            "IRBApprovedFrom": "01/16/2015",
            "IRBApprovedTo": "09/26/2017",
            "DiseaseSiteListDesc": "Other Hematopoietic",
            "Expr1": "Phase III",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Other",
            "Sponsor": "Externally Peer Review",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Luis,Yvonne Dinh,Rachel Pallapati",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT01597778",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01618162",
            "SecondaryId": "2012-000140-97",
            "BriefTitle": "The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy",
            "OfficialTitle": "The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy",
            "LeadSponsorClass": "Novo Nordisk A/S",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novo Nordisk A/S",
            "OversightAuthority": "No",
            "BriefSummary": "This trial is conducted in Asia, Europe and the United States of America (USA). The aim of\r\n\r\n      this trial is to investigate the efficacy and safety of insulin degludec/liraglutide in\r\n\r\n      insulin naïve subjects inadequately controlled w",
            "OverallStatus": "Completed",
            "StartDate": "August 2012",
            "CompletionDate": "October 2013",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Novo Nordisk A/S",
            "StudyCondition": "Diabetes",
            "studyLocation": "Novo Nordisk Clinical Trial Call Center",
            "Enrollment": "435",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 2,",
            "InterventionKeyword": "Insulin, Globin Zinc, Insulin, Metformin, Liraglutide, Insulin, Long-Acting,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subjects with type 2 diabetes mellitus\r\n\r\n\r\n\r\n          -  HbA1c 7.0-9.0% (53-75 mmol/mol) (both inclusive)\r\n\r\n\r\n\r\n          -  Subjects on stable daily dose of sulphonylurea (above or equal to half of t",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Anaheim",
            "State": "California",
            "Zip": "92801",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 9, 2016",
            "FirstReceived": "June 11, 2012",
            "OverallOfficial": "Global Clinical Registry (GCR, 1452)",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Novo Nordisk A/S",
            "LocationName": "Novo Nordisk Clinical Trial Call Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01618162",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120632 - NOVO NORDISK PHARM - Miranda-Palma",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20120632",
            "StudyNumber": "20120632 - NOVO NORDISK PHARM - Miranda-Palma",
            "StudyTitle": "The efficacy of insulin degludec/liraglutide as add-on therapy\nin controlling glycaemia in adults with type 2 diabetes\ninadequately controlled on sulphonylurea with or without\nmetformin therapy\nTrial ID: NN9068-3951\nDUAL IV - SU Add-On",
            "PIID": "1111",
            "PicNum": "C02129536",
            "PILastName": "Miranda-Palma",
            "PIFirstName": "Bresta",
            "CoodCNbr": "C00121533",
            "CoordLastName": "Masters",
            "CoordFirstName": "Burlett",
            "CoordEmail": "bmasters2@med.miami.edu",
            "CoordPhone": "305-243-5354",
            "EnteredByCNbr": "C02008596",
            "EnteredByLastName": "Suarez",
            "EnteredByFirstName": "Rogelio",
            "ActiveEnrollingDate": "12/06/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/06/2012",
            "IRBApprovedFrom": "10/22/2012",
            "IRBApprovedTo": "10/13/2014",
            "InfoEdNbr": "63296",
            "Expr1": "Phase III",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "NOVO NORDISK PHARM",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "4",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Burlett Masters,Marlon Parra,Rogelio Suarez,Ada Konwai",
            "NationalSampleSize": "50",
            "NCTNbr": "NCT01618162",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01620203",
            "BriefTitle": "Observational Study in Preterm Infants With Intracranial Hemorrhage",
            "OfficialTitle": "Observational Study in Preterm Infants With and Without Intracranial Hemorrhage: Longitudinal Assessment of Cerebral Oxygenation, Perfusion and Function",
            "LeadSponsorClass": "Nelson Claure",
            "SponsorAgency": "Other",
            "LeadSponsor": "Nelson Claure",
            "OversightAuthority": "No",
            "BriefSummary": "Intracranial Hemorrhage (ICH) is an important morbidity affecting premature infants and can\r\n\r\n      have considerable effects on neurodevelopmental outcome.\r\n\r\n\r\n\r\n      The investigators showed that preterm infants with severe ICH have decreas",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2012",
            "CompletionDate": "December 2017",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Intracranial Hemorrhage",
            "studyLocation": "Holtz Children's Hospital, Jackson Memorial Hospital/University of Miami Medical Center",
            "Enrollment": "40",
            "NctKeyword": "Premature infants, Intracranial hemorrhage, Intraventricular hemorrhage, Cerebral oxygenation, Brain function, Cerebral perfusion,",
            "MeshKeyword": "Hemorrhage, Intracranial Hemorrhages, Cerebral Hemorrhage, Hypoxia, Brain,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Preterm infants born between 23 and 28 weeks of gestation\r\n\r\n\r\n\r\n          -  Diagnosed with ICH grades II or higher during the first week after birth\r\n\r\n\r\n\r\n          -  Matched control infants without",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "28 Days",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 9, 2017",
            "FirstReceived": "June 5, 2012",
            "OverallOfficial": "Nelson Claure, M.Sc.,Ph.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Nelson Claure, M.Sc., Ph.D.",
            "ContactPhone": "3055856408",
            "ContactEmail": "nclaure@miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Holtz Children's Hospital, Jackson Memorial Hospital/University of Miami Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01620203",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120065 - COVIDIEN U.S. - Claure",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20120065",
            "StudyNumber": "20120065 - COVIDIEN U.S. - Claure",
            "StudyTitle": "Observational study in preterm infants with and without intracranial hemorrhage: Longitudinal assessment of cerebral oxygenation, perfusion and function",
            "PIID": "2769",
            "PicNum": "C00405474",
            "PILastName": "Claure",
            "PIFirstName": "Nelson",
            "CoodCNbr": "C00096109",
            "CoordLastName": "D'Ugard",
            "CoordFirstName": "Carmen",
            "CoordEmail": "cdugard@miami.edu",
            "CoordPhone": "3055856408",
            "EnteredByCNbr": "C00096109",
            "EnteredByLastName": "D'Ugard",
            "EnteredByFirstName": "Carmen",
            "ActiveEnrollingDate": "08/16/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/16/2012",
            "IRBApprovedFrom": "03/12/2012",
            "IRBApprovedTo": "02/18/2016",
            "InfoEdNbr": "62700",
            "Tarea": "Neonatology",
            "TareaCode": "10436",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "SponsorGroup": "Industry",
            "Sponsor": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "23",
            "Totalaccrued": "19",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "23",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Carmen D'Ugard",
            "NationalSampleSize": "60",
            "NCTNbr": "NCT01620203",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01622868",
            "SecondaryId": "NCI-2012-01977",
            "BriefTitle": "Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer",
            "OfficialTitle": "Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "No",
            "BriefSummary": "This randomized phase II trial studies how well whole-brain radiation therapy or\r\n\r\n      stereotactic radiosurgery with or without lapatinib ditosylate works in treating patients\r\n\r\n      with breast cancer that has too many of a protein called",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To determine if there is a signal for an increase in complete response (CR) rate in the\r\n\r\n      measurable brain metastases at 12 weeks post radiation therapy (RT) (whole brain or\r\n\r\n      stereotactic radios",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2012",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "HER2 Positive Breast Carcinoma",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "143",
            "MeshKeyword": "Breast Neoplasms, Carcinoma, Neoplasms, Neoplasms, Second Primary, Brain Neoplasms,",
            "InterventionKeyword": "Lapatinib,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Pathologically (histologically or cytologically) proven diagnosis of invasive breast\r\n\r\n             cancer\r\n\r\n\r\n\r\n          -  HER2-overexpressing breast cancer (3+ staining by immunohistochemistry or H",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "June 15, 2012",
            "OverallOfficial": "In Kim",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "NRG Oncology",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01622868",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140570 - RTOG - Samuels",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140570",
            "StudyNumber": "20140570 - RTOG - Samuels",
            "StudyTitle": "Phase II Randomized Study of Whole Brain Radiotherapy Combined with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer: A collaborative study of NRG Oncology and KROG",
            "PIID": "278",
            "PicNum": "C00550352",
            "PILastName": "Takita",
            "PIFirstName": "Cristiane",
            "CoodCNbr": "C00294869",
            "CoordLastName": "Martin",
            "CoordFirstName": "Doris",
            "CoordEmail": "dmartin3@med.miami.edu",
            "CoordPhone": "3052435491",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "09/30/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/30/2014",
            "IRBApprovedFrom": "08/19/2014",
            "IRBApprovedTo": "08/01/2017",
            "DiseaseSiteListDesc": "Brain and Nervous System,Breast-Female",
            "Expr1": "Phase II",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "RTOG",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Marinellie Vega,Lilibet Zamora Cabezas,Lilly Sanchez,Greeyt Hernandez,Maggie Chislom,Heather Brunell",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT01622868",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01625091",
            "BriefTitle": "Clinical Trial to Reduce Drinking in Women With HIV",
            "OfficialTitle": "Pharmacotherapy for Alcohol Consumption in HIV Infected Women: Randomized Trial",
            "LeadSponsorClass": "University of Florida",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Florida",
            "OversightAuthority": "Yes",
            "BriefSummary": "The primary objective of this study is to evaluate whether an intervention that involves the\r\n\r\n      medication naltrexone, will reduce drinking and improve health outcomes in women with HIV\r\n\r\n      infection and hazardous drinking. Our centra",
            "Description": "The primary objective of this study is to evaluate the acceptability and effectiveness of a\r\n\r\n      treatment program for hazardous drinking, delivered within HIV-clinic outpatient settings,\r\n\r\n      that involves oral naltrexone. The central h",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "December 2012",
            "CompletionDate": "March 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "University of Florida",
            "StudyCondition": "HIV Infection",
            "studyLocation": "University of Miami",
            "Enrollment": "240",
            "NctKeyword": "HIV, women, drinking, Naltrexone,",
            "MeshKeyword": "HIV Infections,",
            "InterventionKeyword": "Naltrexone,",
            "Eligibility": "Inclusion Criteria: (must meet all of following):\r\n\r\n\r\n\r\n          -  Hazardous drinking, on average, during the preceding 4 weeks. Defined as binge\r\n\r\n             drinking (4 or more drinks per occasion at least twice monthly) and/or high to",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Coral Gables",
            "State": "Florida",
            "Zip": "33124",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "June 16, 2016",
            "FirstReceived": "June 12, 2012",
            "OverallOfficial": "Robert L Cook, MD, MPH",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Florida",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01625091",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120021 - UNIV OF FLORIDA - Lewis",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20120021",
            "StudyNumber": "20120021 - UNIV OF FLORIDA - Lewis",
            "StudyTitle": "Pharmacotherapy for Hazardous Drinking in HIVInfected Women: A Randomized, Clinical Trial",
            "PIID": "1645",
            "PicNum": "C00787316",
            "PILastName": "Lewis",
            "PIFirstName": "John",
            "CoodCNbr": "C00787316",
            "CoordLastName": "Lewis",
            "CoordFirstName": "John",
            "CoordEmail": "jelewis@miami.edu",
            "CoordPhone": "3052436227",
            "EnteredByCNbr": "C00787316",
            "EnteredByLastName": "Lewis",
            "EnteredByFirstName": "John",
            "ActiveEnrollingDate": "12/10/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/10/2012",
            "IRBApprovedFrom": "04/16/2012",
            "IRBApprovedTo": "03/06/2017",
            "InfoEdNbr": "65564",
            "Expr1": "N/A",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "15",
            "SignedICF": "218",
            "Totalaccrued": "204",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "12",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "218",
            "FirstNinety": "9",
            "SiteSampleSize": "JMH:N/A,University of Florida:N/A,Florida International University (FIU):N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Clery Quiros",
            "NationalSampleSize": "240",
            "NCTNbr": "NCT01625091",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01625182",
            "SecondaryId": "2011-005280-24",
            "BriefTitle": "Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.",
            "OfficialTitle": "A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneurop",
            "LeadSponsorClass": "Novartis Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novartis Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "The study is designed to evaluate the efficacy and safety of fingolimod in the treatment of\r\n\r\n      chronic inflammatory demyelinating polyradiculoneuropathy compared with placebo.",
            "Description": "This study is a double-blind, randomized, multicenter, placebo-controlled, parallel-group\r\n\r\n      study in patients with a diagnosis of chronic inflammatory demyelinating\r\n\r\n      polyradiculoneuropathy and treated with IVIg, corticosteroids, o",
            "OverallStatus": "Completed",
            "StartDate": "December 2012",
            "CompletionDate": "September 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Novartis",
            "StudyCondition": "Chronic Inflammatory Demyelinating Polyradiculoneuropathy",
            "studyLocation": "Novartis Investigative Site",
            "Enrollment": "106",
            "NctKeyword": "chronic inflammatory demyelinating polyradiculoneuropathy, CIDP, FTY720, fingolimod.,",
            "MeshKeyword": "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Polyradiculoneuropathy,",
            "InterventionKeyword": "Fingolimod Hydrochloride,",
            "Eligibility": "Inclusion Criteria\r\n\r\n\r\n\r\n          -  written informed consent must be obtained before any assessment is performed\r\n\r\n\r\n\r\n          -  The diagnosis of CIDP will use the definition of the EFNS/PNS Task Force First\r\n\r\n             Revision. Pa",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Orange",
            "State": "California",
            "Zip": "92868",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 11, 2016",
            "FirstReceived": "June 19, 2012",
            "OverallOfficial": "Novartis Pharmaceuticals",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Novartis Pharmaceuticals",
            "LocationName": "Novartis Investigative Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01625182",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120893 - NOVARTIS PHARM CORP - Sharma",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20120893",
            "StudyNumber": "20120893 - NOVARTIS PHARM CORP - Sharma",
            "StudyTitle": "(CIDP) CFTY720I2201: A doubleblind, randomized, multicenter, placebocontrolled, parallelgroup study to evaluate the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients with chronic inflammatory demyelinating polyradiculoneuropathy",
            "PIID": "198",
            "PicNum": "C00576419",
            "PILastName": "Sharma",
            "PIFirstName": "Khema",
            "CoodCNbr": "C00565231",
            "CoordLastName": "Steele",
            "CoordFirstName": "Julie",
            "CoordEmail": "j.steele@med.miami.edu",
            "CoordPhone": "3052437336",
            "EnteredByCNbr": "C11319669",
            "EnteredByLastName": "Khavarian",
            "EnteredByFirstName": "Leyla",
            "ActiveEnrollingDate": "03/10/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/10/2014",
            "IRBApprovedFrom": "07/08/2013",
            "IRBApprovedTo": "03/13/2017",
            "InfoEdNbr": "65277",
            "Expr1": "Phase II/III",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "NOVARTIS PHARM CORP",
            "Prescreened": "3",
            "Screenedfailed": "1",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Julie Steele,Jennifer Verriotto,Lilian Cadet,Monica Quesada,Yanet Babcock",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT01625182",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01629667",
            "BriefTitle": "A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis",
            "OfficialTitle": "A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis",
            "LeadSponsorClass": "MedImmune LLC",
            "SponsorAgency": "Industry",
            "LeadSponsor": "MedImmune LLC",
            "OversightAuthority": "Yes",
            "BriefSummary": "To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary\r\n\r\n      function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a\r\n\r\n      chronic, progressive, irreversible, and usually fatal l",
            "Description": "The primary objective of this study is to determine the effect of multiple doses of\r\n\r\n      tralokinumab on pulmonary function in adults with mild to moderate IPF",
            "OverallStatus": "Terminated",
            "StartDate": "October 2012",
            "CompletionDate": "January 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "MedImmune LLC",
            "StudyCondition": "Idiopathic Pulmonary Fibrosis",
            "studyLocation": "Research Site",
            "Enrollment": "409",
            "MeshKeyword": "Fibrosis, Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonias, Pulmonary Fibrosis,",
            "InterventionKeyword": "Antibodies, Monoclonal,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  1) IPF diagnosis for ≤ 5 years prior to Visit 1 (screening). Confirmation of\r\n\r\n             diagnosis of IPF in accordance is required for subject inclusion 2) Confirmed\r\n\r\n             diagnosis of",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "79 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Country": "United States",
            "VerificationDate": "February 2016",
            "LastChanged": "February 29, 2016",
            "FirstReceived": "June 12, 2012",
            "OverallOfficial": "Joseph Parker, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "MedImmune LLC",
            "LocationName": "Research Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01629667",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130539 - F. Hoffmann-La Roche Ltd./Roche - Glassberg",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20130539",
            "StudyNumber": "20130539 - F. Hoffmann-La Roche Ltd./Roche - Glassberg",
            "StudyTitle": "A PHASE II, RANDOMIZED, DOUBLEBLIND,PLACEBOCONTROLLED, STUDY TO ASSESS THEEFFICACY AND SAFETY OF LEBRIKIZUMAB INPATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS",
            "PIID": "839",
            "PicNum": "C00393339",
            "PILastName": "Glassberg Csete",
            "PIFirstName": "Marilyn",
            "CoodCNbr": "C00047281",
            "CoordLastName": "Simonet",
            "CoordFirstName": "Emmanuelle",
            "CoordEmail": "esimonet@med.miami.edu",
            "CoordPhone": "3052433728",
            "EnteredByCNbr": "C00047281",
            "EnteredByLastName": "Simonet",
            "EnteredByFirstName": "Emmanuelle",
            "ActiveEnrollingDate": "11/22/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/22/2013",
            "IRBApprovedFrom": "10/29/2013",
            "IRBApprovedTo": "08/01/2017",
            "AccountNbr": "662210",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase II",
            "Tarea": "Idiopathic Pulmonary Fibrosis (IPF)",
            "TareaCode": "13536",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "10",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Patricia Rebolledo,Esther Diaz,Lilian Cadet,Johana Arana,Eliana Mendes",
            "AgentDevices": "LEBRIKIZUMAB",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01629667",
            "StudyKeywords": "LUNG, IDIOPATHIC PULMONARY FIBROSIS, IPF, LEBRIKIZUMAB",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01632241",
            "SecondaryId": "HGS1006-C1112",
            "BriefTitle": "Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)",
            "OfficialTitle": "A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE)",
            "LeadSponsorClass": "Human Genome Sciences Inc., a GSK Company",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Human Genome Sciences Inc., a GSK Company",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab\r\n\r\n      in adult patients of black race with systemic lupus erythematosus (SLE; lupus).",
            "Description": "Study participants receive stable standard therapy for lupus in addition to receiving either\r\n\r\n      placebo (no active medicine) or belimumab. The controlled period of the study is 52 weeks.\r\n\r\n      The random assignment in this study is \"2 t",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2013",
            "CompletionDate": "March 2019",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "GlaxoSmithKline",
            "StudyCondition": "Systemic Lupus Erythematosus",
            "studyLocation": "GSK Investigational Site",
            "Enrollment": "816",
            "NctKeyword": "Systemic Lupus Erythematosus, African Continental Ancestry Group, Autoimmune Disease, Antibodies, Minority Groups, Black Race, African Americans, SLE, Belimumab, Lupus,",
            "MeshKeyword": "Lupus Erythematosus, Systemic,",
            "InterventionKeyword": "Belimumab,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Black race.\r\n\r\n\r\n\r\n          -  Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.\r\n\r\n\r\n\r\n          -  Active SLE disease.\r\n\r\n\r\n\r\n          -  Autoantibody-positive.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35216",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 7, 2016",
            "FirstReceived": "June 28, 2012",
            "OverallOfficial": "GSK Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "GlaxoSmithKline",
            "ContactName": "US GSK Clinical Trials Call Center",
            "ContactPhone": "877-379-3718",
            "ContactEmail": "GSKClinicalSupportHD@gsk.com",
            "LocationStatus": "Recruiting",
            "LocationName": "GSK Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01632241",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20121017 - QUINTILES INC - Carpintero",
            "FileProcessContentId": "440",
            "Division": "Rheumatology and Immunology",
            "StdyDivision": "10260",
            "EprostNbr": "20121017",
            "StudyNumber": "20121017 - QUINTILES INC - Carpintero",
            "StudyTitle": "A Phase 3/4, MultiCenter, Randomized, DoubleBlind, Placebo Controlled, 52Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE)",
            "PIID": "3095",
            "PicNum": "C09933446",
            "PILastName": "Carpintero",
            "PIFirstName": "Maria",
            "CoodCNbr": "C02440329",
            "CoordLastName": "Pignac-Kobinger",
            "CoordFirstName": "Judith",
            "CoordEmail": "jpignac@med.miami.edu",
            "CoordPhone": "3052438567",
            "EnteredByCNbr": "C02440329",
            "EnteredByLastName": "Pignac-Kobinger",
            "EnteredByFirstName": "Judith",
            "ActiveEnrollingDate": "07/16/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/16/2014",
            "IRBApprovedFrom": "04/02/2013",
            "IRBApprovedTo": "02/28/2017",
            "InfoEdNbr": "63289",
            "Expr1": "Phase IV",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "4",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "1",
            "SiteSampleSize": "Clinical Research Center (CRC):N/A,UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Judith Pignac-Kobinger,Lisa Harlow,Bethly Aubourg",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT01632241",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01632345",
            "SecondaryId": "MK-1439-007",
            "BriefTitle": "A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)",
            "OfficialTitle": "Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients",
            "LeadSponsorClass": "Merck Sharp & Dohme Corp.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Merck Sharp & Dohme Corp.",
            "OversightAuthority": "No",
            "BriefSummary": "Part 1 - Dose-Ranging. Part 1 will evaluate the (1) safety and tolerability and (2) efficacy\r\n\r\n      (antiretroviral activity) of 4 doses of doravirine (MK-1439) compared with efavirenz, when\r\n\r\n      each is given in combination with TRUVADA®",
            "OverallStatus": "Completed",
            "StartDate": "October 2012",
            "CompletionDate": "March 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Merck Sharp & Dohme Corp.",
            "StudyCondition": "HIV Infections",
            "Enrollment": "342",
            "MeshKeyword": "HIV Infections, Acquired Immunodeficiency Syndrome,",
            "InterventionKeyword": "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Efavirenz,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  HIV-1 positive\r\n\r\n\r\n\r\n          -  No previous use of antiretroviral therapy (ART)\r\n\r\n\r\n\r\n          -  No signs of active pulmonary disease within 45 days before the start of study\r\n\r\n             treatm",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "VerificationDate": "April 2016",
            "LastChanged": "April 5, 2016",
            "FirstReceived": "June 28, 2012",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01632345",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120854 - Merck & Co./Merck/Parexel - Campo",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20120854",
            "StudyNumber": "20120854 - Merck & Co./Merck/Parexel - Campo",
            "StudyTitle": "MK1439PN007  Multicenter, DoubleBlind, Randomized, 2Part, Dose RangingStudy to Compare the Safety, and Antiretroviral Activity of MK1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in AntiretroviralTreatmentNaive, HIV1 Infected Patients.",
            "PIID": "235",
            "PicNum": "C00552940",
            "PILastName": "Campo",
            "PIFirstName": "Rafael E.",
            "CoodCNbr": "C00212247",
            "CoordLastName": "Healy",
            "CoordFirstName": "Lynn",
            "CoordEmail": "lhealy@med.miami.edu",
            "EnteredByCNbr": "C00243042",
            "EnteredByLastName": "Tanner",
            "EnteredByFirstName": "Tom",
            "ActiveEnrollingDate": "03/11/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/11/2014",
            "IRBApprovedFrom": "02/19/2013",
            "IRBApprovedTo": "04/04/2017",
            "InfoEdNbr": "64503",
            "Expr1": "Phase III",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Kenia Moreno,Tom Tanner",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01632345",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01639339",
            "BriefTitle": "Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis",
            "OfficialTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab Plus Standard of Care Versus Placebo Plus Standard of Care in Adult Subjects With Active Lupus Nephritis",
            "LeadSponsorClass": "Human Genome Sciences Inc., a GSK Company",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Human Genome Sciences Inc., a GSK Company",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab\r\n\r\n      in adult patients with active lupus nephritis.",
            "Description": "Study participants receive standard therapy (induction and maintenance) for lupus nephritis\r\n\r\n      in addition to receiving either placebo (no active medicine) or belimumab. Induction therapy\r\n\r\n      starts before the first dose of study drug",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2012",
            "CompletionDate": "September 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "GlaxoSmithKline",
            "StudyCondition": "Lupus Nephritis",
            "studyLocation": "GSK Investigational Site",
            "Enrollment": "464",
            "NctKeyword": "Antibodies, Systemic Lupus Erythematosus, Autoimmune Disease, Glomerulonephritis, Belimumab, Lupus, Nephritis, Kidney Diseases, SLE,",
            "MeshKeyword": "Lupus Nephritis, Nephritis,",
            "InterventionKeyword": "Belimumab,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.\r\n\r\n\r\n\r\n          -  Biopsy confirmed active lupus nephritis.\r\n\r\n\r\n\r\n          -  Clinically active lupus renal disease at",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Mobile",
            "State": "Alabama",
            "Zip": "36617",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 16, 2017",
            "FirstReceived": "July 10, 2012",
            "OverallOfficial": "GSK Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "GlaxoSmithKline",
            "ContactName": "US GSK Clinical Trials Call Center",
            "ContactPhone": "877-379-3718",
            "ContactEmail": "GSKClinicalSupportHD@gsk.com",
            "LocationStatus": "Terminated",
            "LocationName": "GSK Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01639339",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120694 - HUMAN GENOME SCIENCES INC. - Contreras",
            "FileProcessContentId": "440",
            "Division": "Nephrology",
            "StdyDivision": "10250",
            "EprostNbr": "20120694",
            "StudyNumber": "20120694 - HUMAN GENOME SCIENCES INC. - Contreras",
            "StudyTitle": "A Phase 3, Randomized, DoubleBlind, PlaceboControlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis (BLISS Study)",
            "PIID": "522",
            "PicNum": "C00210471",
            "PILastName": "Contreras",
            "PIFirstName": "Gabriel",
            "CoodCNbr": "C00329755",
            "CoordLastName": "Vassallo",
            "CoordFirstName": "Jacqueline",
            "CoordEmail": "JVassall@med.miami.edu",
            "EnteredByCNbr": "C00329755",
            "EnteredByLastName": "Vassallo",
            "EnteredByFirstName": "Jacqueline",
            "ActiveEnrollingDate": "06/17/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/17/2013",
            "IRBApprovedFrom": "12/18/2012",
            "IRBApprovedTo": "12/05/2017",
            "AccountNbr": "660709",
            "InfoEdNbr": "62692",
            "Expr1": "Phase III",
            "Tarea": "Lupus",
            "TareaCode": "13039",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "HUMAN GENOME SCIENCES INC.",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "13",
            "Totalaccrued": "10",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "5",
            "Totalpatients": "13",
            "FirstNinety": "2",
            "SiteSampleSize": "JMH:N/A,UMMG:8,UMHC:N/A",
            "AccrualPercentageMet": "125",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "8",
            "EprostState": "Approved",
            "StudyCoordinator": "Jacqueline Vassallo,Maria Carpintero,Judith Pignac-Kobinger",
            "AgentDevices": "BENLYSTA (belimumab)",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT01639339",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01639872",
            "BriefTitle": "Clozapine for Cannabis Use in Schizophrenia",
            "OfficialTitle": "Clozapine for Cannabis Use Disorder in Schizophrenia",
            "LeadSponsorClass": "Dartmouth-Hitchcock Medical Center",
            "SponsorAgency": "Other",
            "LeadSponsor": "Dartmouth-Hitchcock Medical Center",
            "OversightAuthority": "Yes",
            "BriefSummary": "Many individuals with schizophrenia also suffer from marijuana addiction that worsens their\r\n\r\n      problems related to schizophrenia. Most of the medications prescribed for schizophrenia have\r\n\r\n      no effect on reducing marijuana use. Preli",
            "Description": "Cannabis use disorder (CUD), which is up to ten times more common in patients with\r\n\r\n      schizophrenia (SCZ) than in the general population, worsens the course of this severe\r\n\r\n      psychiatric disorder. Since SCZ occurs in 1% of the popula",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "April 2013",
            "CompletionDate": "June 2018",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "Dartmouth-Hitchcock Medical Center",
            "StudyCondition": "Schizophrenia",
            "studyLocation": "CNS Network Inc",
            "Enrollment": "132",
            "NctKeyword": "Schizophrenia, Cannabis Abuse, Cannabis Dependence, Dual Diagnosis, Clozapine, Risperidone,",
            "MeshKeyword": "Schizophrenia, Marijuana Abuse,",
            "InterventionKeyword": "Risperidone, Clozapine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Clinical diagnosis of schizophrenia\r\n\r\n\r\n\r\n          -  Clinical diagnosis of a cannabis use disorder (abuse or dependence)\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -  Pregnant,trying to becom",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "55 Years",
            "Volunteers": "No",
            "City": "Garden Grove",
            "State": "California",
            "Zip": "92845",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 4, 2017",
            "FirstReceived": "July 11, 2012",
            "OverallOfficial": "Alan I Green, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Dartmouth College",
            "LocationName": "CNS Network Inc",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01639872",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120940 - DARTMOUTH COLLEGE - Harvey",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20120940",
            "StudyNumber": "20120940 - DARTMOUTH COLLEGE - Harvey",
            "StudyTitle": "Clozapine for Cannabis Use Disorder in Schizophrenia (CLOCS)",
            "PIID": "3581",
            "PicNum": "C09911652",
            "PILastName": "Harvey",
            "PIFirstName": "Philip",
            "CoodCNbr": "C00145327",
            "CoordLastName": "Guardia",
            "CoordFirstName": "Tania",
            "CoordEmail": "tguardia@med.miami.edu",
            "EnteredByCNbr": "C04892431",
            "EnteredByLastName": "Brenson",
            "EnteredByFirstName": "Nicole",
            "ActiveEnrollingDate": "07/02/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/02/2013",
            "IRBApprovedFrom": "12/18/2012",
            "IRBApprovedTo": "10/31/2017",
            "InfoEdNbr": "66106",
            "Expr1": "Phase IV",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "26",
            "SignedICF": "34",
            "Totalaccrued": "9",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "34",
            "FirstNinety": "1",
            "SiteSampleSize": "Non University of Miami:N/A,UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Gabriela Vargas,Belinda Robertson,Tania Guardia,Nicole Brenson",
            "NationalSampleSize": "124",
            "NCTNbr": "NCT01639872",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01643850",
            "SecondaryId": "2011-002951-32",
            "BriefTitle": "MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS)",
            "OfficialTitle": "A Phase II Randomized, Double -Blind, Placebo Controlled Study Followed by Open Label Dosing to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)",
            "LeadSponsorClass": "Novartis Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novartis Pharmaceuticals",
            "OversightAuthority": "No",
            "BriefSummary": "This study, designed as a proof of concept study of MCS110 in pigmented villonodular\r\n\r\n      synovitis, will assess the clinical response to MCS110 treatment in Pigmented Villonodular\r\n\r\n      Synovitis (PVNS) and Giant cell tumor of the tendon",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2012",
            "CompletionDate": "December 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Novartis",
            "StudyCondition": "Pigmented Villonodular Synovitis",
            "studyLocation": "Novartis Investigative Site",
            "Enrollment": "37",
            "NctKeyword": "Pigmented Villonodular Synovitis, PVNS, Giant cell tumor of the tendon sheath, GCCTS, Tenosynovial giant cell tumor (localized or diffused type), MCS110,",
            "MeshKeyword": "Neoplasms, Synovitis, Giant Cell Tumors, Synovitis, Pigmented Villonodular,",
            "Eligibility": "Inclusion criteria:\r\n\r\n\r\n\r\n          -  Patients with PVNS or GCTTS with, at least, one measurable site of disease on MRI.\r\n\r\n\r\n\r\n          -  Vital signs within the ranges: systolic blood pressure 80-150 mmHg , diastolic blood",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "San Diego",
            "State": "California",
            "Zip": "92103-8894",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 6, 2016",
            "FirstReceived": "March 8, 2012",
            "OverallOfficial": "Novartis Pharmaceuticals",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Novartis Pharmaceuticals",
            "ContactName": "Novartis Pharmaceuticals",
            "ContactPhone": "1-888-669-6682",
            "LocationStatus": "Recruiting",
            "LocationName": "Novartis Investigative Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01643850",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120056 - Novartis - Wilky",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20120056",
            "StudyNumber": "20120056 - Novartis - Wilky",
            "StudyTitle": "A Phase II randomized, doubleblind (Part A,B, and C), placebo controlled (Part A and B only), study to assess safety, tolerability and efficacy of MCS110 on tumor size in patients with pigmented villonodular synovitis (PVNS)",
            "PIID": "4630",
            "PicNum": "C11848802",
            "PILastName": "Wilky",
            "PIFirstName": "Breelyn",
            "CoodCNbr": "C11958101",
            "CoordLastName": "Tahhan",
            "CoordFirstName": "Georges",
            "CoordEmail": "gxt202@miami.edu",
            "CoordPhone": "305-243-0862",
            "EnteredByCNbr": "C07181703",
            "EnteredByLastName": "Zhang",
            "EnteredByFirstName": "Lei",
            "ActiveEnrollingDate": "02/21/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/21/2013",
            "IRBApprovedFrom": "11/19/2012",
            "IRBApprovedTo": "10/16/2017",
            "AccountNbr": "66964L",
            "InfoEdNbr": "61110",
            "DiseaseSiteListDesc": "Bones and Joints",
            "Expr1": "Phase II",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Novartis",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "12",
            "Totalaccrued": "10",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "4",
            "Totalpatients": "12",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMH:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Thankam Solomon,Nathalie Luis",
            "NationalSampleSize": "24",
            "NCTNbr": "NCT01643850",
            "StudyKeywords": "Therapeutic Area: Bone and Soft Tissue Cancers",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01649089",
            "SecondaryId": "NCI-2012-01990",
            "BriefTitle": "Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer",
            "OfficialTitle": "Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (=/&lt;2CM) Cervical Cancer",
            "LeadSponsorClass": "Gynecologic Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Gynecologic Oncology Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "This clinical trial studies the physical function and quality-of-life before and after\r\n\r\n      surgery in patients with stage I cervical cancer. Studying quality-of-life in patients\r\n\r\n      undergoing surgery for cervical cancer may help deter",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To examine the changes before and after non-radical surgical treatment (simple\r\n\r\n      hysterectomy or cone biopsy [fertility preservation]) and pelvic lymphadenectomy) on\r\n\r\n      functional outcomes of blad",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2012",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Gynecologic Oncology Group",
            "StudyCondition": "Cervical Adenocarcinoma",
            "studyLocation": "University of Arizona Cancer Center at Saint Joseph's",
            "Enrollment": "600",
            "MeshKeyword": "Carcinoma, Squamous Cell, Adenocarcinoma, Carcinoma, Infertility, Uterine Cervical Neoplasms, Lymphedema, Carcinoma, Adenosquamous,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patient must consent for the appropriate surgery\r\n\r\n\r\n\r\n          -  Patients with a histologic diagnosis of squamous cell carcinoma, adenocarcinoma, or\r\n\r\n             adenosquamous cell carcinoma of th",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85004",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 26, 2016",
            "FirstReceived": "July 21, 2012",
            "OverallOfficial": "Allan Covens",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "NRG Oncology",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Arizona Cancer Center at Saint Joseph's",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01649089",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150507 - GOG - Huang",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150507",
            "StudyNumber": "20150507 - GOG - Huang",
            "StudyTitle": "“Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB2 (=2CM) Cervical Cancer”",
            "PIID": "25456",
            "PicNum": "C11974849",
            "PILastName": "Huang",
            "PIFirstName": "Marilyn",
            "CoodCNbr": "C11920201",
            "CoordLastName": "Moya",
            "CoordFirstName": "Isabel",
            "CoordEmail": "iam18@miami.edu",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "12/07/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/07/2015",
            "IRBApprovedFrom": "10/06/2015",
            "IRBApprovedTo": "09/27/2017",
            "AccountNbr": "666212",
            "DiseaseSiteListDesc": "Cervix",
            "Expr1": "N/A",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Supportive",
            "StudyType_Code": "13736",
            "ResearchType": "Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "GOG",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "2",
            "SiteSampleSize": "UMD:N/A,UMMG:N/A,UMHC:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Penny Eyer,Mae Lyssa Bauduy-Roy,Negin Habibi Khameneh,Evan Dadas,Kristen Sheely",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01649089",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01652027",
            "SecondaryId": "HSC-MS-11-0202",
            "BriefTitle": "Hemophilia Inhibitor Previously Untreated Patient Study",
            "OfficialTitle": "Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia",
            "LeadSponsorClass": "The University of Texas Health Science Center, Houston",
            "SponsorAgency": "Other",
            "LeadSponsor": "The University of Texas Health Science Center, Houston",
            "OversightAuthority": "Yes",
            "BriefSummary": "Hemophilia A is a congenital bleeding disorder caused by deficiency of factor VIII (FVIII)\r\n\r\n      and is treated by replacement therapy with FVIII concentrate. Approximately 30% of people\r\n\r\n      with severe hemophilia A develop neutralizing",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2011",
            "CompletionDate": "December 2020",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "The University of Texas Health Science Center, Houston",
            "StudyCondition": "Hemophilia A",
            "studyLocation": "Emory University",
            "Enrollment": "50",
            "NctKeyword": "FVIII inhibitors,",
            "MeshKeyword": "Hemophilia A,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Severe hemophilia A with FVIII activity < 1% normal\r\n\r\n\r\n\r\n          -  Weight > 3.5 kg at the time of baseline study evaluation\r\n\r\n\r\n\r\n          -  Informed consent, approved by appropriate Institutiona",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Atlanta",
            "State": "Georgia",
            "Zip": "30322",
            "Country": "United States",
            "VerificationDate": "May 2016",
            "LastChanged": "May 27, 2016",
            "FirstReceived": "June 3, 2011",
            "OverallOfficial": "Elena Santagostino, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Maggiore Hospital and University of Milan",
            "ContactName": "Deborah L. Brown, M.D.",
            "ContactPhone": "713-500-8360",
            "ContactEmail": "deborah.brown@uth.tmc.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Emory University",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01652027",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150046 - Baxter - Corrales Medina",
            "FileProcessContentId": "440",
            "Division": "Pediatrics Oncology",
            "StdyDivision": "10646",
            "EprostNbr": "20150046",
            "StudyNumber": "20150046 - Baxter - Corrales Medina",
            "StudyTitle": "HEMOPHILIA INHIBITOR PUP STUDY (HIPS)",
            "PIID": "23193",
            "PicNum": "C11918839",
            "PILastName": "Corrales Medina",
            "PIFirstName": "Fernando",
            "CoodCNbr": "C05045811",
            "CoordLastName": "Prado",
            "CoordFirstName": "Cecilia",
            "CoordEmail": "cprado@med.miami.edu",
            "CoordPhone": "3052436925",
            "EnteredByCNbr": "C11918839",
            "EnteredByLastName": "Corrales Medina",
            "EnteredByFirstName": "Fernando",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "04/06/2015",
            "IRBApprovedFrom": "04/06/2015",
            "IRBApprovedTo": "04/05/2016",
            "Expr1": "Approved Drug/Off-Label use",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Baxter",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Maria Santaella,Cecilia Prado",
            "NationalSampleSize": "4",
            "NCTNbr": "NCT01652027",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01656603",
            "BriefTitle": "Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation",
            "OfficialTitle": "A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients",
            "LeadSponsorClass": "New York Blood Center",
            "SponsorAgency": "Other",
            "LeadSponsor": "New York Blood Center",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will evaluate the safety of infusion of the investigational cord blood units by\r\n\r\n      carefully documenting all infusion-related problems.",
            "Description": "The primary aim of this study is to examine the safety of administration of the unlicensed\r\n\r\n      investigational NCBP HPC-CORD BLOOD products in a multi-institution setting. Therefore, the\r\n\r\n      study will evaluate prospectively the incide",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2012",
            "CompletionDate": "December 2020",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "New York Blood Center",
            "StudyCondition": "Infusion Reactions",
            "studyLocation": "Children's of Alabama",
            "Enrollment": "9999",
            "NctKeyword": "cord blood, transplantation, stem cells, adverse event,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Diagnosis: Patients with disorders affecting the hematopoietic system that are\r\n\r\n             inherited, acquired, or result from myeloablative treatment.\r\n\r\n\r\n\r\n          2. Patients: Patients of any a",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "March 2016",
            "LastChanged": "March 9, 2016",
            "FirstReceived": "July 31, 2012",
            "OverallOfficial": "Andromachi Scaradavou, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "NY Blood Center",
            "ContactName": "Andromachi Scaradavou, MD",
            "ContactPhone": "718-706-5207",
            "ContactEmail": "ascaradavou@nybloodcenter.org",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01656603",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120231 - National Cord Blood Program - Andreansky",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20120231",
            "StudyNumber": "20120231 - National Cord Blood Program - Andreansky",
            "StudyTitle": "NCBP 663701: A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult p",
            "PIID": "590",
            "PicNum": "C06466265",
            "PILastName": "Andreansky",
            "PIFirstName": "Martin",
            "CoodCNbr": "C00046839",
            "CoordLastName": "Willumsen",
            "CoordFirstName": "Silvia",
            "CoordEmail": "swillums@med.miami.edu",
            "CoordPhone": "3055857359",
            "EnteredByCNbr": "C06466265",
            "EnteredByLastName": "Andreansky",
            "EnteredByFirstName": "Martin",
            "ActiveEnrollingDate": "06/11/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/11/2012",
            "IRBApprovedFrom": "06/11/2012",
            "IRBApprovedTo": "06/26/2017",
            "DiseaseSiteListDesc": "Lymphoid Leukemia",
            "Expr1": "Phase II",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "National Cord Blood Program",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Jennifer Reichbach Douglas,Gabriela D'Antonio",
            "NationalSampleSize": "50",
            "NCTNbr": "NCT01656603",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01658787",
            "BriefTitle": "Global Registry for Endovascular Aortic Treatment (GREAT)",
            "OfficialTitle": "'GREAT' Global Registry for Endovascular Aortic Treatment - Outcomes Evaluation",
            "LeadSponsorClass": "W.L.Gore & Associates",
            "SponsorAgency": "Industry",
            "LeadSponsor": "W.L.Gore & Associates",
            "OversightAuthority": "Yes",
            "BriefSummary": "Prospective, observational Registry to obtain data on device performance and clinical\r\n\r\n      outcomes.",
            "Description": "This is a prospective observational cohort Registry designed to obtain data on device\r\n\r\n      performance and clinical outcomes of patients treated with Gore Endovascular Aortic\r\n\r\n      products.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "December 2010",
            "CompletionDate": "September 2026",
            "Phase": "N/A",
            "StudyType": "Observational [Patient Registry]",
            "StudyPhase": "N/A",
            "StudySource": "W.L.Gore & Associates",
            "StudyCondition": "Multiple Pathologies",
            "studyLocation": "USC Cardiovascular Thoracic Institute",
            "Enrollment": "4625",
            "NctKeyword": "Aorta,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Minimum age required by state regulations\r\n\r\n\r\n\r\n          -  Indication for aortic endovascular stent graft repair\r\n\r\n\r\n\r\n          -  Signed informed consent\r\n\r\n\r\n\r\n        Exclusion Criteria:",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90033",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 27, 2016",
            "FirstReceived": "August 3, 2012",
            "OverallOfficial": "Ross Milner, MD, FACS",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "The University of Chicago Medicine & Biological Sciences",
            "LocationName": "USC Cardiovascular Thoracic Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01658787",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130407 - W. L. Gore & Associates/W.L. Gore & Associates - Karwowski",
            "FileProcessContentId": "440",
            "Division": "Surgery",
            "StdyDivision": "7805",
            "EprostNbr": "20130407",
            "StudyNumber": "20130407 - W. L. Gore & Associates/W.L. Gore & Associates - Karwowski",
            "StudyTitle": "GREAT Global Registry for Endovascular Aortic Treatment Outcomes Evaluation. Registry Number: GRT 1011",
            "PIID": "22444",
            "PicNum": "C11848433",
            "PILastName": "Karwowski",
            "PIFirstName": "John",
            "CoodCNbr": "C00792691",
            "CoordLastName": "Salinas",
            "CoordFirstName": "Kay",
            "CoordEmail": "ksalinas2@med.miami.edu",
            "CoordPhone": "3052431147",
            "EnteredByCNbr": "C08165348",
            "EnteredByLastName": "Goldstein",
            "EnteredByFirstName": "Lee",
            "ActiveEnrollingDate": "01/27/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/27/2014",
            "IRBApprovedFrom": "10/18/2013",
            "IRBApprovedTo": "05/25/2019",
            "Expr1": "Other",
            "Tarea": "Vascular and Endovascular Surgery",
            "TareaCode": "16744",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Registry",
            "StudyType_Code": "6148",
            "ResearchType": "Other",
            "SponsorGroup": "Other",
            "Sponsor": "W. L. Gore",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "21",
            "Totalaccrued": "19",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "15",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "21",
            "FirstNinety": "5",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Jean (Lynne) Sparling,Kay Salinas",
            "NationalSampleSize": "45",
            "NCTNbr": "NCT01658787",
            "StudyKeywords": "?GREAT?, Global Registry, for Endovascular Aortic Treatment, \r\nOutcomes, Evaluation. \r\nRegistry, Number: GRT 10-11",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT01665053",
            "SecondaryId": "G120123",
            "BriefTitle": "The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)",
            "OfficialTitle": "EVOLVE II: A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)",
            "LeadSponsorClass": "Boston Scientific Corporation",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Boston Scientific Corporation",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to assess the safety and effectiveness of the SYNERGY\r\n\r\n      Everolimus-Eluting Platinum Chromium Coronary Stent System for the treatment of subjects\r\n\r\n      with atherosclerotic lesion(s) ≤ 34 mm in length (by vi",
            "Description": "A concurrent, non-randomized, single-arm, pharmacokinetic (PK) substudy and a consecutive,\r\n\r\n      non-randomized, single-arm, Diabetes substudy will also enroll under the EVOLVE II protocol.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "November 2012",
            "CompletionDate": "August 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Boston Scientific Corporation",
            "StudyCondition": "Coronary Artery Disease",
            "studyLocation": "Baptist Medical Center - Princeton",
            "Enrollment": "1684",
            "NctKeyword": "Drug-Eluting Stents,",
            "MeshKeyword": "Coronary Artery Disease, Myocardial Ischemia, Coronary Disease,",
            "InterventionKeyword": "Everolimus, Sirolimus, Chromium,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject must be at least 18 years of age\r\n\r\n\r\n\r\n          -  Subject (or legal guardian) understands the trial requirements and the treatment\r\n\r\n             procedures and provides written informed cons",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35211",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 11, 2016",
            "FirstReceived": "August 7, 2012",
            "OverallOfficial": "Peter M Maurer, MPH",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Boston Scientific Corporation",
            "LocationName": "Baptist Medical Center - Princeton",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01665053",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120641 - BOSTON SCIENTIFIC - Heldman",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20120641",
            "StudyNumber": "20120641 - BOSTON SCIENTIFIC - Heldman",
            "StudyTitle": "EVOLVE II:  A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY EverolimusEluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)",
            "PIID": "2126",
            "PicNum": "C00236539",
            "PILastName": "Alfonso",
            "PIFirstName": "Carlos",
            "CoodCNbr": "C06968089",
            "CoordLastName": "Lang",
            "CoordFirstName": "Barbara",
            "CoordEmail": "blang@med.miami.edu",
            "CoordPhone": "3052434950",
            "EnteredByCNbr": "C00491335",
            "EnteredByLastName": "De Marchena",
            "EnteredByFirstName": "Eduardo",
            "ActiveEnrollingDate": "06/26/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/26/2013",
            "IRBApprovedFrom": "11/12/2012",
            "IRBApprovedTo": "10/08/2015",
            "AccountNbr": "660697",
            "InfoEdNbr": "62868/66689",
            "Expr1": "N/A",
            "Tarea": "Atherosclerosis",
            "TareaCode": "16638",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Boston Scientific Corp",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "10",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "6",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "6",
            "SiteSampleSize": "UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Laura Hudson,Barbara Lang",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01665053",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01672853",
            "SecondaryId": "2012-002473-61",
            "BriefTitle": "Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Subjects With Primary Sclerosing Cholangitis (PSC)",
            "OfficialTitle": "A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC)",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate whether Simtuzumab (GS-6624) is effective at\r\n\r\n      preventing the progression of liver fibrosis in subjects with PSC.",
            "OverallStatus": "Completed",
            "StartDate": "February 2013",
            "CompletionDate": "August 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "Primary Sclerosing Cholangitis (PSC)",
            "studyLocation": "Mayo Clinic Hospital",
            "Enrollment": "235",
            "NctKeyword": "PSC, Sclerosis, Monoclonal antibody, LOXL2, Simtuzumab, Primary sclerosing cholangitis, Liver fibrosis, Liver disease, MRCP, MRE, Liver biopsy,",
            "MeshKeyword": "Cholangitis, Cholangitis, Sclerosing,",
            "InterventionKeyword": "Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Adult subjects (aged 18-70) with chronic cholestatic liver disease of at least 6\r\n\r\n             months.\r\n\r\n\r\n\r\n          -  Liver biopsy consistent with PSC: If a liver biopsy has been performed within",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "70 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85054",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 29, 2016",
            "FirstReceived": "August 22, 2012",
            "OverallOfficial": "Rob Myers, M.D.",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "Mayo Clinic Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01672853",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130033 - GILEAD SCIENCES - Levy",
            "FileProcessContentId": "440",
            "Division": "Hepatology",
            "StdyDivision": "10246",
            "EprostNbr": "20130033",
            "StudyNumber": "20130033 - GILEAD SCIENCES - Levy",
            "StudyTitle": "GSUS3210102  A Phase 2b, DoseRanging, Randomized, DoubleBlind,PlaceboControlled Trial Evaluating the Safety and Efficacy of GS6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)",
            "PIID": "2230",
            "PicNum": "C09420731",
            "PILastName": "Levy",
            "PIFirstName": "Cynthia",
            "CoodCNbr": "C00445302",
            "CoordLastName": "McGregory",
            "CoordFirstName": "Marlene",
            "CoordEmail": "mmcgregory@med.miami.edu",
            "CoordPhone": "3052432184",
            "EnteredByCNbr": "C04191427",
            "EnteredByLastName": "Onate-Silva",
            "EnteredByFirstName": "Maria",
            "ActiveEnrollingDate": "05/07/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/07/2013",
            "IRBApprovedFrom": "03/11/2013",
            "IRBApprovedTo": "01/10/2017",
            "AccountNbr": "660634",
            "InfoEdNbr": "65146",
            "Expr1": "Phase II",
            "Tarea": "Hepatic Encephalopathy (HE)",
            "TareaCode": "12642",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "GILEAD SCIENCES",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "8",
            "Totalaccrued": "8",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "8",
            "FirstNinety": "4",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Sonia Carvalho,Diane Sabogal,Odalys Rodriguez-Bravo",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01672853",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01672879",
            "SecondaryId": "2012-002489-11",
            "BriefTitle": "Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH",
            "OfficialTitle": "A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects With Compensated Cirrhosis Secondary to Non-Alcoholic Steat",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study is to evaluate the safety and efficacy of simtuzumab (GS-6624) in adults with\r\n\r\n      compensated cirrhosis due to Non-Alcoholic Steatohepatitis (NASH). It will consist of 2\r\n\r\n      phases:\r\n\r\n\r\n\r\n        -  Randomized Double-Blind",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "October 2012",
            "CompletionDate": "February 2024",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "Non-Alcoholic Steatohepatitis (NASH)",
            "studyLocation": "Mayo Clinic Hospital",
            "Enrollment": "259",
            "NctKeyword": "NASH, cirrhosis, Compensated Liver disease, Monoclonal antibody, LOXL2, Simtuzumab, Nonalcoholic Steatohepatitis, Hepatic venous pressure gradient, HVPG, NAFLD, MRE, Liver biopsy,",
            "MeshKeyword": "Fibrosis, Liver Cirrhosis, Fatty Liver, Non-alcoholic Fatty Liver Disease,",
            "InterventionKeyword": "Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Adult subjects (aged 18-65) with cirrhosis of the liver defined as an Ishak fibrosis\r\n\r\n             stage ≥ 5\r\n\r\n\r\n\r\n          -  Liver biopsy consistent with NASH or cryptogenic cirrhosis",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85054",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 15, 2016",
            "FirstReceived": "August 22, 2012",
            "OverallOfficial": "Rob Myers, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "Mayo Clinic Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01672879",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130003 - GILEAD SCIENCES - Schiff",
            "FileProcessContentId": "440",
            "Division": "Hepatology",
            "StdyDivision": "10246",
            "EprostNbr": "20130003",
            "StudyNumber": "20130003 - GILEAD SCIENCES - Schiff",
            "StudyTitle": "GSUS3210106  A Phase 2b, DoseRanging, Randomized, DoubleBlind,PlaceboControlled Trial Evaluating the Safety and Efficacy ofGS6624, a Monoclonal Antibody Against Lysyl OxidaseLike2 (LOXL2), in Subjects with Compensated Cirrhosis Secondaryto NonAlcoholic Steatohepatitis (NASH)",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C00445302",
            "CoordLastName": "McGregory",
            "CoordFirstName": "Marlene",
            "CoordEmail": "mmcgregory@med.miami.edu",
            "CoordPhone": "3052432184",
            "EnteredByCNbr": "C00505692",
            "EnteredByLastName": "Marini",
            "EnteredByFirstName": "Angela",
            "ActiveEnrollingDate": "08/02/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/02/2013",
            "IRBApprovedFrom": "04/08/2013",
            "IRBApprovedTo": "03/13/2017",
            "AccountNbr": "660707",
            "InfoEdNbr": "65379",
            "Expr1": "Phase II",
            "Tarea": "Liver Disease",
            "TareaCode": "12638",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "4",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Maria Onate-Silva,Diane Sabogal,Odalys Rodriguez-Bravo,Sonia Carvalho",
            "NationalSampleSize": "2",
            "NCTNbr": "NCT01672879",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01675440",
            "BriefTitle": "Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement",
            "OfficialTitle": "Medtronic CoreValve® U.S. Expanded Use Study",
            "LeadSponsorClass": "Medtronic Cardiovascular",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Medtronic Cardiovascular",
            "OversightAuthority": "Yes",
            "BriefSummary": "To evaluate the safety and efficacy of the Medtronic CoreValve® System for the treatment of\r\n\r\n      symptomatic severe aortic stenosis in subjects with significant comorbidities in whom the\r\n\r\n      risk of surgical aortic valve replacement has",
            "Description": "The primary objective of the study is to evaluate the safety and effectiveness of the\r\n\r\n      Medtronic CoreValve® System (MCS) in a subset of subjects excluded from the U.S. Extreme\r\n\r\n      Risk Pivotal Trial population due to one or more add",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "August 2012",
            "CompletionDate": "April 2021",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Medtronic Cardiovascular",
            "StudyCondition": "Severe Aortic Stenosis",
            "studyLocation": "Banner Good Samaritan",
            "Enrollment": "782",
            "MeshKeyword": "Constriction, Pathologic, Aortic Valve Stenosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject must have co-morbidities such that one cardiologist and two cardiac surgeons\r\n\r\n             agree that medical factors preclude operation, based on a conclusion that the\r\n\r\n             probabil",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85006",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 26, 2016",
            "FirstReceived": "August 22, 2012",
            "LocationName": "Banner Good Samaritan",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01675440",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120883 - Expanded Use - De Marchena",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20120883",
            "StudyNumber": "20120883 - Expanded Use - De Marchena",
            "StudyTitle": "Medtronic CoreValve U.S. Expanded Use Study",
            "PIID": "1187",
            "PicNum": "C00491335",
            "PILastName": "De Marchena",
            "PIFirstName": "Eduardo",
            "CoodCNbr": "C04284337",
            "CoordLastName": "Marin y Kall",
            "CoordFirstName": "Christian",
            "CoordEmail": "cmarin@med.miami.edu",
            "CoordPhone": "3055856217",
            "EnteredByCNbr": "C10564365",
            "EnteredByLastName": "Marincic-Sanchez",
            "EnteredByFirstName": "Ximena",
            "ActiveEnrollingDate": "07/23/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/23/2013",
            "IRBApprovedFrom": "01/28/2013",
            "IRBApprovedTo": "01/08/2018",
            "AccountNbr": "660704",
            "InfoEdNbr": "63294",
            "Expr1": "N/A",
            "Tarea": "Aortic valve stenosis",
            "TareaCode": "16636",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "3",
            "Screenedfailed": "4",
            "SignedICF": "18",
            "Totalaccrued": "14",
            "InFollowUp": "10",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "18",
            "FirstNinety": "2",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A,UMH:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carlos Alfonso,Ximena Marincic-Sanchez,Christian Marin y Kall,Suresh Atapattu",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT01675440",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01688050",
            "BriefTitle": "TRANSFIX Zenith® Transection Clinical Study",
            "OfficialTitle": "TRANSFIX - Zenith® TX2® Low Profile Endovascular Graft for Blunt Thoracic Aortic Injury",
            "LeadSponsorClass": "Cook",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Cook",
            "BriefSummary": "The TRANSFIX study is a clinical trial approved by US FDA to study the safety and\r\n\r\n      effectiveness of the Zenith® TX2® Low Profile Endovascular Graft for treatment of Blunt\r\n\r\n      Thoracic Aortic Injury.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "January 2013",
            "CompletionDate": "May 2019",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Cook",
            "StudyCondition": "Thoracic Aorta",
            "studyLocation": "University of Arkansas",
            "Enrollment": "50",
            "NctKeyword": "Blunt thoracic aortic injury, Transection, Endovascular graft,",
            "MeshKeyword": "Wounds and Injuries, Wounds, Nonpenetrating, Thoracic Injuries,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Vessels suitable for endovascular access and stent graft placement\r\n\r\n\r\n\r\n          -  Blunt thoracic aortic injury of the descending thoracic aorta\r\n\r\n\r\n\r\n          -  At least 16 years of age",
            "EligibleGender": "All",
            "MinAge": "16 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Zip": "72205",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 30, 2016",
            "FirstReceived": "September 14, 2012",
            "OverallOfficial": "Benjamin Starnes, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Washington - Harborview, Division of Vascular Surgery",
            "LocationName": "University of Arkansas",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01688050",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120541 - Cook Incorporated - Bornak",
            "FileProcessContentId": "440",
            "Division": "Surgery",
            "StdyDivision": "7805",
            "EprostNbr": "20120541",
            "StudyNumber": "20120541 - Cook Incorporated - Bornak",
            "StudyTitle": "Zenith TX2 Low Profile Endovascular Graft for Blunt Thoracic Aortic Injury Clinical Study (TRANSFIX)",
            "PIID": "3735",
            "PicNum": "C10165569",
            "PILastName": "Bornak",
            "PIFirstName": "Arash",
            "CoodCNbr": "C00792691",
            "CoordLastName": "Salinas",
            "CoordFirstName": "Kay",
            "CoordEmail": "ksalinas2@med.miami.edu",
            "CoordPhone": "3052431147",
            "EnteredByCNbr": "C00792691",
            "EnteredByLastName": "Salinas",
            "EnteredByFirstName": "Kay",
            "ActiveEnrollingDate": "08/30/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/30/2013",
            "IRBApprovedFrom": "11/26/2012",
            "IRBApprovedTo": "06/25/2017",
            "InfoEdNbr": "62886",
            "DiseaseSiteListDesc": "Other Respiratory and Intrathoracic Organs,Multiple",
            "Expr1": "N/A",
            "Tarea": "Vascular and Endovascular Surgery",
            "TareaCode": "16744",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Device",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A,UMH:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Jean (Lynne) Sparling",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01688050",
            "StudyKeywords": "Zenith, TX2, Low Profile Endovascular Graft, for Blunt Thoracic Aortic Injury, Clinical Study, (TRANSFIX), Lee Goldstein",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01695005",
            "SecondaryId": "I6F-MC-JJCA",
            "BriefTitle": "A Study of LY3039478 in Participants With Advanced Cancer",
            "OfficialTitle": "A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer",
            "LeadSponsorClass": "Eli Lilly and Company",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Eli Lilly and Company",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to find a recommended dose level of LY3039478 that can safely\r\n\r\n      be taken by participants with advanced cancer or cancer that has spread to other parts of\r\n\r\n      the body, including but not limited to lymphom",
            "Description": "In Part A of this study, participants with advanced/metastatic cancer (including lymphoma)\r\n\r\n      will receive increasing doses of LY3039478 to define the dose level for Part B, C, D and E.\r\n\r\n      In Part B, C, D and E LY3039478 will be expl",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2012",
            "CompletionDate": "May 2019",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Eli Lilly and Company",
            "StudyCondition": "Neoplasms",
            "studyLocation": "University of Miami School of Medicine",
            "Enrollment": "227",
            "MeshKeyword": "Neoplasms, Neoplasm Metastasis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  For all parts: The participant must be, in the judgment of the investigator, an\r\n\r\n             appropriate candidate for experimental therapy after available standard therapies\r\n\r\n             have fail",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 3, 2016",
            "FirstReceived": "September 24, 2012",
            "OverallOfficial": "1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Eli Lilly and Company",
            "ContactName": "There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559)",
            "ContactPhone": "1-317-615-4559",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01695005",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140394 - Eli Lilly - Merchan",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140394",
            "StudyNumber": "20140394 - Eli Lilly - Merchan",
            "StudyTitle": "A Phase 1 Study of LY3039478 in Patients with Advanced or Metastatic Cancer",
            "PIID": "407",
            "PicNum": "C00251535",
            "PILastName": "Merchan",
            "PIFirstName": "Jaime",
            "CoodCNbr": "C12016748",
            "CoordLastName": "Sumarriva",
            "CoordFirstName": "Daniel",
            "CoordEmail": "dss173@med.miami.edu",
            "EnteredByCNbr": "C11917328",
            "EnteredByLastName": "Englund",
            "EnteredByFirstName": "Kristen",
            "ActiveEnrollingDate": "05/12/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/12/2015",
            "IRBApprovedFrom": "08/04/2014",
            "IRBApprovedTo": "06/13/2017",
            "AccountNbr": "663418",
            "DiseaseSiteListDesc": "Multiple",
            "Expr1": "Phase I",
            "Tarea": "Pancreatic, Liver, and Related Cancers",
            "TareaCode": "12443",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Eli Lilly and Company",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "20",
            "Totalaccrued": "18",
            "InFollowUp": "8",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "20",
            "FirstNinety": "5",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Karen Blackburn,Juan Salvador,Sandra Pineda,Yvonne Dinh,Tamara Leon Aliz",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT01695005",
            "StudyKeywords": "Therapeutic Area: Pancreatic, Liver, and Related Cancers  Old number: 20140096",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01705574",
            "SecondaryId": "2012-003708-11",
            "BriefTitle": "Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women",
            "OfficialTitle": "A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, An",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will evaluate the safety, efficacy, and tolerability of a regimen containing\r\n\r\n      elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF)\r\n\r\n      fixed-dose combination (FDC) versus ritonavir (R",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "October 2012",
            "CompletionDate": "March 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "Acquired Immunodeficiency Syndrome",
            "studyLocation": "University of Southern California AIDS Clinical Trials Group",
            "Enrollment": "583",
            "NctKeyword": "HIV-1, HIV, Treatment-Naive, Women, WAVES,",
            "MeshKeyword": "HIV Infections, Immunologic Deficiency Syndromes, Acquired Immunodeficiency Syndrome,",
            "InterventionKeyword": "Tenofovir, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Emtricitabine, Cobicistat, Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Female (at birth), age ≥ 18 years\r\n\r\n\r\n\r\n          -  Ability to understand and sign a written informed consent form\r\n\r\n\r\n\r\n          -  Plasma HIV-1 RNA levels ≥ 500 copies/mL\r\n\r\n\r\n\r\n          -  No pri",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90033",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 19, 2016",
            "FirstReceived": "October 10, 2012",
            "OverallOfficial": "Huyen Cao, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "University of Southern California AIDS Clinical Trials Group",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01705574",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130060 - GILEAD SCIENCES - Jayaweera",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20130060",
            "StudyNumber": "20130060 - GILEAD SCIENCES - Jayaweera",
            "StudyTitle": "GSUS 2360128  A Randomized, Doubleblind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus RitonavirBoosted Atazanavir Plus Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV1",
            "PIID": "234",
            "PicNum": "C00043390",
            "PILastName": "Jayaweera",
            "PIFirstName": "Dushyantha T.",
            "CoodCNbr": "C00212247",
            "CoordLastName": "Healy",
            "CoordFirstName": "Lynn",
            "CoordEmail": "lhealy@med.miami.edu",
            "EnteredByCNbr": "C00039376",
            "EnteredByLastName": "Moreno",
            "EnteredByFirstName": "Kenia",
            "ActiveEnrollingDate": "08/20/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/20/2013",
            "IRBApprovedFrom": "04/01/2013",
            "IRBApprovedTo": "01/31/2017",
            "InfoEdNbr": "65651",
            "Expr1": "Phase III",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "GILEAD SCIENCES",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "10",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "2",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Tom Tanner,Kenia Moreno",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01705574",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01707992",
            "BriefTitle": "The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)",
            "OfficialTitle": "A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod (0.6 mg/d or 1.2 mg/d) in Subjects W",
            "LeadSponsorClass": "Teva Pharmaceutical Industries",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Teva Pharmaceutical Industries",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a multinational, multicenter, randomized, double-blind, parallel-group,\r\n\r\n      placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and\r\n\r\n      tolerability of two doses of oral administration of laq",
            "Description": "Eligible subjects with confirmed relapsing-remitting multiple sclerosis will be randomized\r\n\r\n      in a 1:1:1 ratio into one of the following treatment arms: Laquinimod capsules 0.6 mg,\r\n\r\n      Laquinimod capsules 1.2 mg and matching placebo.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "February 2013",
            "CompletionDate": "April 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Teva Pharmaceutical Industries",
            "StudyCondition": "Multiple Sclerosis (MS)",
            "studyLocation": "Teva Investigational Site 10329",
            "Enrollment": "2199",
            "MeshKeyword": "Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subjects must have a confirmed and documented MS diagnosis as defined by the Revised\r\n\r\n             McDonald criteria, with relapse onset disease or a relapsing-remitting disease\r\n\r\n             course.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "55 Years",
            "Volunteers": "No",
            "City": "Cullman",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 1, 2016",
            "FirstReceived": "September 28, 2012",
            "OverallOfficial": "Teva Medical Expert, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "TEVA",
            "LocationName": "Teva Investigational Site 10329",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01707992",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120783 - TEVA PHARM USA - Delgado",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20120783",
            "StudyNumber": "20120783 - TEVA PHARM USA - Delgado",
            "StudyTitle": "TEVA (CONCERTO Study): A multinational, multicenter, randomized, doubleblind, parallelgroup, placebocontrolled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimo",
            "PIID": "122",
            "PicNum": "C00360924",
            "PILastName": "Delgado",
            "PIFirstName": "Silvia",
            "CoodCNbr": "C04183653",
            "CoordLastName": "Riesgo",
            "CoordFirstName": "Vincent",
            "CoordEmail": "vriesgo@med.miami.edu",
            "CoordPhone": "3052437001",
            "EnteredByCNbr": "C02523614",
            "EnteredByLastName": "Babcock",
            "EnteredByFirstName": "Yanet",
            "ActiveEnrollingDate": "12/12/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/12/2013",
            "IRBApprovedFrom": "05/06/2013",
            "IRBApprovedTo": "04/03/2017",
            "AccountNbr": "661300",
            "InfoEdNbr": "61851",
            "Expr1": "Phase III",
            "Tarea": "Multiple Sclerosis",
            "TareaCode": "9837",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "TEVA PHARM USA",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "4",
            "SiteSampleSize": "Non University of Miami:N/A,UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "2",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Gloria Rodriguez (Neurology),Ruta Sawant,Yanet Babcock",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT01707992",
            "StudyKeywords": "Multiple Sclerosis",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01714817",
            "SecondaryId": "2012-000714-11",
            "BriefTitle": "Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis",
            "OfficialTitle": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lup",
            "LeadSponsorClass": "Bristol-Myers Squibb",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Bristol-Myers Squibb",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate (Abatacept) for treatment of lupus nephritis when\r\n\r\n      used on a background of Cellcept (mycophenolate) and prednisone (corticosteroids)",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "January 2013",
            "CompletionDate": "May 2021",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Bristol-Myers Squibb",
            "StudyCondition": "Lupus Nephritis",
            "studyLocation": "University Of Alabama At Birmingham (Uab)",
            "Enrollment": "400",
            "MeshKeyword": "Lupus Nephritis, Nephritis,",
            "InterventionKeyword": "Prednisone, Mycophenolic Acid, Mycophenolate mofetil, Abatacept,",
            "Eligibility": "For additional information please contact the BMS Lupus Nephritis Clinical Trial Matching\r\n\r\n        Service at 855-56-LUPUS. Please visit www.BMSStudyConnect.com for more information on\r\n\r\n        clinical trial participation.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "January 2016",
            "LastChanged": "January 5, 2017",
            "FirstReceived": "October 24, 2012",
            "OverallOfficial": "Bristol-Myers Squibb",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Bristol-Myers Squibb",
            "LocationName": "University Of Alabama At Birmingham (Uab)",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01714817",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130718 - Bristol-Myers Squibb - Carpintero",
            "FileProcessContentId": "440",
            "Division": "Rheumatology and Immunology",
            "StdyDivision": "10260",
            "EprostNbr": "20130718",
            "StudyNumber": "20130718 - Bristol-Myers Squibb - Carpintero",
            "StudyTitle": "A Phase 3 Randomized, DoubleBlind, PlaceboControlled Study to Evaluate the Efficacy and Safety of BMS188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticosteroids in Subjects with Active Class III or IV Lupus Nephritis",
            "PIID": "3095",
            "PicNum": "C09933446",
            "PILastName": "Carpintero",
            "PIFirstName": "Maria",
            "CoodCNbr": "C02440329",
            "CoordLastName": "Pignac-Kobinger",
            "CoordFirstName": "Judith",
            "CoordEmail": "jpignac@med.miami.edu",
            "CoordPhone": "3052438567",
            "EnteredByCNbr": "C07183089",
            "EnteredByLastName": "Riveron",
            "EnteredByFirstName": "Reldy",
            "ActiveEnrollingDate": "04/28/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/28/2014",
            "IRBApprovedFrom": "01/07/2014",
            "IRBApprovedTo": "12/14/2016",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "2",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Jacqueline Vassallo,Bethly Aubourg,Judith Pignac-Kobinger",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT01714817",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01727336",
            "SecondaryId": "ACE-041",
            "BriefTitle": "Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma",
            "OfficialTitle": "A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma",
            "LeadSponsorClass": "Acceleron Pharma, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Acceleron Pharma, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of Part 1 of this study is to evaluate the safety and tolerability of\r\n\r\n      dalantercept in combination with axitinib in patients with advanced renal cell carcinoma\r\n\r\n      (RCC) to determine the recommended dose level of dalante",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2012",
            "CompletionDate": "December 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Acceleron Pharma, Inc.",
            "StudyCondition": "Advanced Renal Cell Carcinoma",
            "studyLocation": "Arizona Oncology Associates, PC - HOPE",
            "Enrollment": "174",
            "MeshKeyword": "Carcinoma, Carcinoma, Renal Cell,",
            "InterventionKeyword": "Immunoglobulin Fc Fragments, Axitinib,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Histologically confirmed, advanced, predominantly clear cell renal cell carcinoma\r\n\r\n             (RCC).\r\n\r\n\r\n\r\n          -  Part 1: Progression of disease following up to three lines of prior therap",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Tucson",
            "State": "Arizona",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 22, 2016",
            "FirstReceived": "November 8, 2012",
            "ContactName": "Clinical Trials Manager",
            "ContactEmail": "dalanterceptclinicaltrials@acceleronpharma.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Arizona Oncology Associates, PC - HOPE",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01727336",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140820 - Acceleron Pharm - Merchan",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140820",
            "StudyNumber": "20140820 - Acceleron Pharm - Merchan",
            "StudyTitle": "A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma",
            "PIID": "407",
            "PicNum": "C00251535",
            "PILastName": "Merchan",
            "PIFirstName": "Jaime",
            "CoodCNbr": "C12026538",
            "CoordLastName": "Grez",
            "CoordFirstName": "Nester",
            "CoordEmail": "Nester.Grez@med.miami.edu",
            "CoordPhone": "305-243-4033",
            "EnteredByCNbr": "C12021320",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Paul",
            "ActiveEnrollingDate": "05/12/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/12/2015",
            "IRBApprovedFrom": "03/17/2015",
            "IRBApprovedTo": "02/28/2017",
            "AccountNbr": "662731",
            "DiseaseSiteListDesc": "Kidney",
            "Expr1": "Phase II",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Acceleron Pharma Inc",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "3",
            "Totalaccrued": "1",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Vivianne Velez-Bravo",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT01727336",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01728402",
            "BriefTitle": "Pathogenesis of Hematologic Malignancies",
            "OfficialTitle": "Pathogenesis of Acute Leukemia, Lymphoproliferative Disorders, and Myeloproliferative Disorders",
            "LeadSponsorClass": "OHSU Knight Cancer Institute",
            "SponsorAgency": "Other",
            "LeadSponsor": "OHSU Knight Cancer Institute",
            "OversightAuthority": "No",
            "BriefSummary": "The cause of blood and bone marrow cancers is poorly understood; however, most research\r\n\r\n      focuses on how cancer cells grow and develop. Because the causes of these cancers are\r\n\r\n      unknown, current treatments may be unnecessarily hars",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "September 2008",
            "CompletionDate": "October 2020",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "OHSU Knight Cancer Institute",
            "StudyCondition": "Acute Leukemia",
            "studyLocation": "OHSU Knight Cancer Institute",
            "Enrollment": "5000",
            "MeshKeyword": "Disease, Leukemia, Myelodysplastic Syndromes, Preleukemia, Acute Disease, Myeloproliferative Disorders, Lymphoproliferative Disorders,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Suspected or confirmed diagnosis of AL, LPD, MDS, or MPD\r\n\r\n\r\n\r\n          -  Male or female of all ages\r\n\r\n\r\n\r\n          -  Willing and able to sign informed consent\r\n\r\n\r\n\r\n          -  Willing guardian",
            "EligibleGender": "All",
            "MinAge": "1 Year",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Portland",
            "State": "Oregon",
            "Zip": "97239",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 18, 2016",
            "FirstReceived": "November 13, 2012",
            "LocationName": "OHSU Knight Cancer Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01728402",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150431 - Oregon Health and Sciences - Watts",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150431",
            "StudyNumber": "20150431 - Oregon Health and Sciences - Watts",
            "StudyTitle": "“PATHOGENESIS OF ACUTE LEUKEMIA, LYMPHOPROLIFERATIVE DISORDERS, MYELODYSPLASTIC SYNDROMES, AND MYELOPROLIFERATIVE DISORDERS”",
            "PIID": "22711",
            "PicNum": "C11915545",
            "PILastName": "Watts",
            "PIFirstName": "Justin",
            "CoodCNbr": "C11964599",
            "CoordLastName": "Martinez",
            "CoordFirstName": "Micaela",
            "CoordEmail": "mem334@miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "11/06/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/06/2015",
            "IRBApprovedFrom": "08/04/2015",
            "IRBApprovedTo": "08/01/2017",
            "DiseaseSiteListDesc": "Leukemia, not otherwise specified",
            "Expr1": "N/A",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Correlative",
            "StudyType_Code": "140",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Oregon Health & Science University",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "51",
            "Totalaccrued": "49",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "24",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "51",
            "FirstNinety": "7",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Rachel Pallapati",
            "NationalSampleSize": "120",
            "NCTNbr": "NCT01728402",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01730170",
            "SecondaryId": "2U01NS038455-11A1",
            "BriefTitle": "Maternal and Neurodevelopmental Outcomes of in Utero Antiepileptic Drug (AED) Exposure",
            "OfficialTitle": "Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs",
            "LeadSponsorClass": "Emory University",
            "SponsorAgency": "Other",
            "LeadSponsor": "Emory University",
            "OversightAuthority": "No",
            "BriefSummary": "Epilepsy is one of the most common neurological disorders affecting women of childbearing\r\n\r\n      age. Poor pregnancy outcomes are increased in these women and their children. The proposed\r\n\r\n      studies will increase our knowledge on multipl",
            "Description": "There is a compelling need for prospective, properly controlled studies in women with\r\n\r\n      epilepsy (WWE) during pregnancy to improve maternal and child outcomes. The proposed\r\n\r\n      investigations are pertinent to the National Institute o",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "January 2013",
            "CompletionDate": "July 2017",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Emory University",
            "StudyCondition": "Epilepsy",
            "studyLocation": "University of Alabama Birmingham Hospital- UAB",
            "Enrollment": "565",
            "NctKeyword": "Epilepsy, Pregnancy,",
            "MeshKeyword": "Epilepsy,",
            "InterventionKeyword": "Anticonvulsants,",
            "Eligibility": "Inclusion Criteria for All Women\r\n\r\n\r\n\r\n          -  Pregnant women with epilepsy up to 20 weeks gestation, healthy pregnant women without\r\n\r\n             epilepsy up to 20 weeks gestation, or non-pregnant women with epilepsy.",
            "EligibleGender": "Female",
            "MinAge": "14 Years",
            "MaxAge": "45 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294-0021",
            "Country": "United States",
            "VerificationDate": "February 2016",
            "LastChanged": "February 12, 2016",
            "FirstReceived": "November 9, 2012",
            "OverallOfficial": "Kimford J Meador, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Emory University",
            "LocationName": "University of Alabama Birmingham Hospital- UAB",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01730170",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120793 - EMORY UNIV - Serrano",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20120793",
            "StudyNumber": "20120793 - EMORY UNIV - Serrano",
            "StudyTitle": "Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD)",
            "PIID": "2238",
            "PicNum": "C09412656",
            "PILastName": "Serrano",
            "PIFirstName": "Enrique",
            "CoodCNbr": "C10597879",
            "CoordLastName": "Figueredo",
            "CoordFirstName": "Pedro",
            "CoordEmail": "pfigueredo@med.miami.edu",
            "CoordPhone": "3052438829",
            "EnteredByCNbr": "C10597879",
            "EnteredByLastName": "Figueredo",
            "EnteredByFirstName": "Pedro",
            "ActiveEnrollingDate": "04/26/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/26/2013",
            "IRBApprovedFrom": "03/15/2013",
            "IRBApprovedTo": "03/22/2017",
            "Expr1": "N/A",
            "Tarea": "Epilepsy",
            "TareaCode": "8936",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "15",
            "Totalaccrued": "14",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "9",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "15",
            "FirstNinety": "1",
            "SiteSampleSize": "Non University of Miami:N/A,UMMG:N/A,JMH:N/A,Clinical Research Center (CRC):N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "6",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Pedro Figueredo,Carlos Millan,Maria Palomeque",
            "NationalSampleSize": "85",
            "NCTNbr": "NCT01730170",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01730937",
            "SecondaryId": "NCI-2012-02057",
            "BriefTitle": "Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer",
            "OfficialTitle": "Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma",
            "LeadSponsorClass": "Radiation Therapy Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Radiation Therapy Oncology Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation\r\n\r\n      therapy to see how well they work compared to sorafenib tosylate alone in treating patients\r\n\r\n      with liver cancer. Sorafenib tosylate may st",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To determine if stereotactic body radiation therapy (SBRT) improves overall survival in\r\n\r\n      hepatocellular carcinoma (HCC) patients treated with sorafenib (sorafenib tosylate).\r\n\r\n\r\n\r\n      SECONDARY OBJE",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2013",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Radiation Therapy Oncology Group",
            "StudyCondition": "Adult Primary Hepatocellular Carcinoma",
            "studyLocation": "USC / Norris Comprehensive Cancer Center",
            "Enrollment": "368",
            "MeshKeyword": "Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms,",
            "InterventionKeyword": "Sorafenib, Niacinamide,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must have a diagnosis of HCC by at least one criterion listed below within\r\n\r\n             360 days prior to study entry:\r\n\r\n\r\n\r\n               -  Pathologically (histologically or cytologically",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90033",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 11, 2016",
            "FirstReceived": "November 15, 2012",
            "OverallOfficial": "Laura Dawson",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Radiation Therapy Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "USC / Norris Comprehensive Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01730937",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150255 - RTOG - Yechieli",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150255",
            "StudyNumber": "20150255 - RTOG - Yechieli",
            "StudyTitle": "RTOG 1112\r\nRandomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma",
            "PIID": "23357",
            "PicNum": "C11918100",
            "PILastName": "Yechieli",
            "PIFirstName": "Raphael",
            "CoodCNbr": "C12003895",
            "CoordLastName": "Vazquez Pascual",
            "CoordFirstName": "Fernando",
            "CoordEmail": "fxv109@miami.edu",
            "CoordPhone": "305-243-5620",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "08/05/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/05/2016",
            "IRBApprovedFrom": "08/06/2015",
            "IRBApprovedTo": "12/16/2016",
            "DiseaseSiteListDesc": "Liver",
            "Expr1": "Phase III",
            "Tarea": "Pancreatic, Liver, and Related Cancers",
            "TareaCode": "12443",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "RTOG",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UM Kendall:N/A,UMMG:N/A,Plantation:N/A,JMH:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Doris Martin,Cristina Rojas-Mejia,Lilibet Zamora Cabezas,Lilly Sanchez,Greeyt Hernandez,Penny Eyer,Marinellie Vega",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01730937",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01739023",
            "BriefTitle": "Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI",
            "OfficialTitle": "The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute Spinal Cord Injury (SCI)",
            "LeadSponsorClass": "W. Dalton Dietrich",
            "SponsorAgency": "Other",
            "LeadSponsor": "W. Dalton Dietrich",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to assess the safety of autologous human Schwann cells (ahSC)\r\n\r\n      transplantation in subjects with subacute SCI.\r\n\r\n\r\n\r\n      For humans with subacute SCI, we hypothesize that axons might show improved function",
            "Description": "Schwann cells are excellent candidates for transplantation into humans with SCI. Large\r\n\r\n      numbers of ahSC can be derived for autologous implantation after a minor surgery for\r\n\r\n      peripheral nerve harvesting, and purification and expan",
            "OverallStatus": "Completed",
            "StartDate": "November 2012",
            "CompletionDate": "August 2016",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Spinal Cord Injury",
            "studyLocation": "University of Miami Miller School of Medicine",
            "Enrollment": "9",
            "NctKeyword": "paraplegia, cell therapy, Schwann cells, spinal cord injury,",
            "MeshKeyword": "Wounds and Injuries, Spinal Cord Injuries, Paraplegia,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  1) Persons with traumatic SCI that occurred within the previous 30 days.\r\n\r\n\r\n\r\n          -  2) Between the ages of 18 and 60 at last birthday.\r\n\r\n\r\n\r\n          -  3) SCI at a thoracic level between T3-T",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "60 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 10, 2017",
            "FirstReceived": "November 28, 2012",
            "OverallOfficial": "Dalton Dietrich, PhD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "University of Miami",
            "LocationName": "University of Miami Miller School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01739023",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20081061 - Schwann cells - Levi",
            "FileProcessContentId": "440",
            "Division": "Neurosurgery",
            "StdyDivision": "9636",
            "EprostNbr": "20081061",
            "StudyNumber": "20081061 - Schwann cells - Levi",
            "StudyTitle": "The Safety of Autologous Human Schwann Cells (ahSC) in Subjects with Subacute Spinal Cord Injury (SCI)",
            "PIID": "167",
            "PicNum": "C00155778",
            "PILastName": "Levi",
            "PIFirstName": "Allan",
            "CoodCNbr": "C08177251",
            "CoordLastName": "Anderson",
            "CoordFirstName": "Kimberly",
            "CoordEmail": "kanderson3@med.miami.edu",
            "CoordPhone": "305-243-5569",
            "EnteredByCNbr": "C06010405",
            "EnteredByLastName": "Dididze",
            "EnteredByFirstName": "Marine",
            "ActiveEnrollingDate": "11/16/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/16/2012",
            "IRBApprovedFrom": "10/15/2012",
            "IRBApprovedTo": "08/02/2016",
            "InfoEdNbr": "61656",
            "Expr1": "Phase I",
            "Tarea": "Spine",
            "TareaCode": "9641",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Device/Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "8",
            "Totalaccrued": "8",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "8",
            "FirstNinety": "1",
            "SiteSampleSize": "Non University of Miami:N/A,UMMG:16,UMH:N/A,UMHC:N/A,JMH:N/A",
            "AccrualPercentageMet": "50",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "16",
            "EprostState": "Approved",
            "StudyCoordinator": "Katie Gant,George Jimsheleishvili,Jessica Cambridge",
            "AgentDevices": "Autologous Schwann cells",
            "NationalSampleSize": "16",
            "NCTNbr": "NCT01739023",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01751724",
            "BriefTitle": "Caffeine to Reduce Mechanical Ventilation in Preterm Infants",
            "OfficialTitle": "Use of Caffeine to Reduce Length of Mechanical Ventilation in Preterm Infants",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "Most premature infants require mechanical ventilation for prolonged periods of time and a\r\n\r\n      significant proportion of them develop Bronchopulmonary Dysplasia (BPD). Caffeine is a\r\n\r\n      stimulant of the respiratory center and has been u",
            "OverallStatus": "Terminated",
            "StartDate": "December 2012",
            "CompletionDate": "January 2016",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Prematurity",
            "studyLocation": "NICU, Holtz Children's Hospital, Jackson Health System",
            "Enrollment": "88",
            "NctKeyword": "Premature infants, Caffeine, Methylxanthines, Mechanical ventilation, Oxygen, Weaning, Bronchopulmonary dysplasia,",
            "MeshKeyword": "Respiratory Insufficiency,",
            "InterventionKeyword": "Citric Acid, Caffeine, Caffeine citrate,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Premature neonates born between 23 and 30 completed weeks of gestation.\r\n\r\n\r\n\r\n          -  Requiring mechanical ventilation within the first 5 postnatal days\r\n\r\n\r\n\r\n          -  Written-informed parenta",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "5 Days",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 29, 2016",
            "FirstReceived": "December 12, 2012",
            "OverallOfficial": "Eduardo Bancalari, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "NICU, Holtz Children's Hospital, Jackson Health System",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01751724",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120786 - Intramural - Bancalari",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20120786",
            "StudyNumber": "20120786 - Intramural - Bancalari",
            "StudyTitle": "Use of Caffeine to reduce length of mechanical ventilation in preterm infants",
            "PIID": "1186",
            "PicNum": "C00161505",
            "PILastName": "Bancalari",
            "PIFirstName": "Eduardo",
            "CoodCNbr": "C00096109",
            "CoordLastName": "D'Ugard",
            "CoordFirstName": "Carmen",
            "CoordEmail": "cdugard@miami.edu",
            "CoordPhone": "3055856408",
            "EnteredByCNbr": "C00495432",
            "EnteredByLastName": "Vanbuskirk",
            "EnteredByFirstName": "Silvia",
            "ActiveEnrollingDate": "01/02/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/02/2013",
            "IRBApprovedFrom": "12/04/2012",
            "IRBApprovedTo": "05/04/2016",
            "InfoEdNbr": "66041",
            "Expr1": "Other",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "88",
            "Totalaccrued": "86",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "88",
            "FirstNinety": "15",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carmen D'Ugard",
            "NationalSampleSize": "110",
            "NCTNbr": "NCT01751724",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01751906",
            "BriefTitle": "ABSORB III Randomized Controlled Trial (RCT)",
            "OfficialTitle": "A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.",
            "LeadSponsorClass": "Abbott Vascular",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Abbott Vascular",
            "OversightAuthority": "Yes",
            "BriefSummary": "The ABSORB III RCT is a prospective randomized, single-blind, multi-center trial. It is the\r\n\r\n      pivotal trial to support the US pre-market approval (PMA) of Absorb™ Bioresorbable Vascular\r\n\r\n      Scaffold (BVS).\r\n\r\n\r\n\r\n      The ABSORB III",
            "Description": "ABSORB III RCT:\r\n\r\n\r\n\r\n      A. Primary Objective: The pivotal trial to support the US pre-market approval (PMA) of\r\n\r\n      Absorb BVS. ABSORB III will evaluate the safety and effectiveness of the Absorb BVS System\r\n\r\n      compared to the XIEN",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2012",
            "CompletionDate": "December 2019",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Abbott Vascular",
            "StudyCondition": "Coronary Artery Disease",
            "studyLocation": "Baptist Medical Center Princeton",
            "Enrollment": "2250",
            "NctKeyword": "Absorb™ BVS, Angioplasty, Bioabsorbable, BVS, Bioresorbable, Coronary Artery Disease, Coronary Artery Endothelial Responsiveness, Coronary artery restenosis, Coronary artery stenosis, Coronary scaffold, Coronary Stent, Drug eluting stents, Everolimus, Myo",
            "MeshKeyword": "Coronary Artery Disease, Myocardial Ischemia, Coronary Disease, Constriction, Pathologic, Coronary Stenosis,",
            "InterventionKeyword": "Everolimus,",
            "Eligibility": "General Inclusion Criteria:\r\n\r\n\r\n\r\n          1. 18 years of age.\r\n\r\n\r\n\r\n          2. Subject or a legally authorized representative must provide written Informed Consent\r\n\r\n             prior to any study related procedure, per site requiremen",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35211",
            "Country": "United States",
            "VerificationDate": "October 2015",
            "LastChanged": "October 11, 2015",
            "FirstReceived": "December 13, 2012",
            "OverallOfficial": "Stephen G Ellis, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Cleveland Clinic, Cleveland OH",
            "ContactName": "Diane Williams",
            "ContactPhone": "408 845-3000",
            "ContactEmail": "AbsorbRCT@abbott.com",
            "LocationStatus": "Active, not recruiting",
            "LocationName": "Baptist Medical Center Princeton",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01751906",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110915 - Abbott - Cohen",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20110915",
            "StudyNumber": "20110915 - Abbott - Cohen",
            "StudyTitle": "ABSORB RANDOMIZED CONTROLLED TRIALA Clinical Evaluation of ABSORB BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions- Version 10.0",
            "PIID": "1752",
            "PicNum": "C07441231",
            "PILastName": "Cohen",
            "PIFirstName": "Mauricio",
            "CoodCNbr": "C06968089",
            "CoordLastName": "Lang",
            "CoordFirstName": "Barbara",
            "CoordEmail": "blang@med.miami.edu",
            "CoordPhone": "3052434950",
            "EnteredByCNbr": "C06968089",
            "EnteredByLastName": "Lang",
            "EnteredByFirstName": "Barbara",
            "ActiveEnrollingDate": "09/30/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/30/2013",
            "IRBApprovedFrom": "04/22/2013",
            "IRBApprovedTo": "01/10/2018",
            "AccountNbr": "661636",
            "InfoEdNbr": "65402",
            "Expr1": "N/A",
            "Tarea": "Atherosclerosis",
            "TareaCode": "16638",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Abbott Vascular",
            "Prescreened": "0",
            "Screenedfailed": "24",
            "SignedICF": "26",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "26",
            "FirstNinety": "2",
            "SiteSampleSize": "UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Barbara Lang",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT01751906",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01753310",
            "BriefTitle": "Efficacy and Safety of DYSPORT Using 2mL Dilution in Adults With Cervical Dystonia.",
            "OfficialTitle": "A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of DYSPORT Using 2mL Dilution in Adults With Cervical Dystonia.",
            "LeadSponsorClass": "Ipsen",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Ipsen",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of the protocol is to evaluate the efficacy of Dysport using 2 mL dilution\r\n\r\n      compared with placebo for the treatment of Cervical Dystonia.",
            "OverallStatus": "Completed",
            "StartDate": "January 2013",
            "CompletionDate": "January 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Ipsen",
            "StudyCondition": "Cervical Dystonia",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "134",
            "MeshKeyword": "Dystonia, Dystonic Disorders, Torticollis,",
            "InterventionKeyword": "abobotulinumtoxinA, Botulinum Toxins, Type A, onabotulinumtoxinA, incobotulinumtoxinA,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Primary diagnosis of Cervical Dystonia at least 9 months since onset and either\r\n\r\n             previously untreated with botulinum toxin or currently treated with Botox at a total\r\n\r\n             dosing",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "February 2015",
            "LastChanged": "February 16, 2015",
            "FirstReceived": "December 17, 2012",
            "OverallOfficial": "Medical Director, Neurology, M.D.",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Ipsen",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01753310",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130135 - IPSEN LTD - Singer",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20130135",
            "StudyNumber": "20130135 - IPSEN LTD - Singer",
            "StudyTitle": "ATL52120169Dysport: A phase IIIb, multicentre, randomised, doubleblind,placebocontrolled study evaluating the efficacy and safety ofDysport using 2 mL dilution in adults with cervical dystonia",
            "PIID": "143",
            "PicNum": "C00407776",
            "PILastName": "Singer",
            "PIFirstName": "Carlos",
            "CoodCNbr": "C06927480",
            "CoordLastName": "Padron",
            "CoordFirstName": "Nathalie",
            "CoordEmail": "npadron@med.miami.edu",
            "CoordPhone": "3052433530",
            "EnteredByCNbr": "C06927480",
            "EnteredByLastName": "Padron",
            "EnteredByFirstName": "Nathalie",
            "ActiveEnrollingDate": "10/23/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/23/2013",
            "IRBApprovedFrom": "07/15/2013",
            "IRBApprovedTo": "06/09/2016",
            "InfoEdNbr": "66273",
            "Expr1": "Phase III",
            "Tarea": "Movement Disorders",
            "TareaCode": "8937",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "IPSEN LTD",
            "Prescreened": "6",
            "Screenedfailed": "0",
            "SignedICF": "5",
            "Totalaccrued": "5",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "4",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Angela Russell,Nathalie Padron",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01753310",
            "StudyKeywords": "Cervical Dystonia, Dysport, AbobotulinumtoxinA",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01753336",
            "BriefTitle": "Long Term Safety And Effectiveness Of Dysport In Adults With Cervical Dystonia",
            "OfficialTitle": "A Phase IIIb, Prospective, Multicentre, Open-Label Extension Study To Assess Long Term Safety And Effectiveness Of Dysport Using 2 mL Dilution In Adults With Cervical Dystonia",
            "LeadSponsorClass": "Ipsen",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Ipsen",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of the protocol is to assess the long term safety of repeat treatment cycles of\r\n\r\n      Dysport 500 U using 2 mL dilution scheme for the treatment of Cervical Dystonia. This is an\r\n\r\n      extension study to study A-TL-52120-169 (he",
            "OverallStatus": "Completed",
            "StartDate": "July 2013",
            "CompletionDate": "October 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Ipsen",
            "StudyCondition": "Cervical Dystonia",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "112",
            "MeshKeyword": "Dystonia, Dystonic Disorders, Torticollis,",
            "InterventionKeyword": "abobotulinumtoxinA, Botulinum Toxins, Type A, onabotulinumtoxinA, incobotulinumtoxinA,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subjects enrolled in Study 169 that have no ongoing adverse events, which in the\r\n\r\n             opinion of the Investigator are related to study treatment and that precludes them\r\n\r\n             from re",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "December 2015",
            "LastChanged": "December 21, 2015",
            "FirstReceived": "December 17, 2012",
            "OverallOfficial": "Medical Director Neurology, M.D.",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Ipsen",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01753336",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130482 - Ipsen Biopharmaceuticals/ Inc - Singer",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20130482",
            "StudyNumber": "20130482 - Ipsen Biopharmaceuticals/ Inc - Singer",
            "StudyTitle": "ATL52120170Dysport: A PHASE IIIb, PROSPECTIVE, MULTICENTRE, OPENLABEL EXTENSION STUDY TO ASSESS LONG TERM SAFETY AND EFFECTIVENESS OF DYSPORT USING 2 mL DILUTION IN ADULTS WITH CERVICAL DYSTONIA.",
            "PIID": "143",
            "PicNum": "C00407776",
            "PILastName": "Singer",
            "PIFirstName": "Carlos",
            "CoodCNbr": "C06927480",
            "CoordLastName": "Padron",
            "CoordFirstName": "Nathalie",
            "CoordEmail": "npadron@med.miami.edu",
            "CoordPhone": "3052433530",
            "EnteredByCNbr": "C06927480",
            "EnteredByLastName": "Padron",
            "EnteredByFirstName": "Nathalie",
            "ActiveEnrollingDate": "11/26/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/26/2013",
            "IRBApprovedFrom": "08/19/2013",
            "IRBApprovedTo": "06/07/2016",
            "Expr1": "Phase III",
            "Tarea": "Movement Disorders",
            "TareaCode": "8937",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "3",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Angela Russell,Nathalie Padron",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01753336",
            "StudyKeywords": "Cervical Dystonia, Dysport, AbobotulinumtoxinA",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01771107",
            "SecondaryId": "NCI-2013-00046",
            "BriefTitle": "Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma",
            "OfficialTitle": "A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "No",
            "BriefSummary": "This pilot phase I/II trial studies the side effects and the best dose of brentuximab\r\n\r\n      vedotin when given together with combination chemotherapy and to see how well they work in\r\n\r\n      treating patients with stage II-IV human immunodef",
            "Description": "PRIMARY OBJECTIVES I. To identify the maximum tolerated dose (MTD) of brentuximab vedotin\r\n\r\n      when combined with the doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine (AVD)\r\n\r\n      chemotherapy regimen in the treatment of HIV",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2013",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "AIDS-Related Hodgkin Lymphoma",
            "studyLocation": "UC San Diego Moores Cancer Center",
            "Enrollment": "70",
            "MeshKeyword": "Lymphoma, HIV Infections, Hodgkin Disease,",
            "InterventionKeyword": "Doxorubicin, Liposomal doxorubicin, Dacarbazine, Vinblastine, Imidazole, Antibodies, Monoclonal, Antibodies, Immunoglobulins, Immunoconjugates,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  HIV positive; documentation of HIV-1 infection by means of any one of the following:\r\n\r\n\r\n\r\n               -  Documentation of HIV diagnosis in the medical record by a licensed health care",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "La Jolla",
            "State": "California",
            "Zip": "92093",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "January 16, 2013",
            "OverallOfficial": "Paul Rubinstein",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "AIDS Malignancy Consortium",
            "LocationStatus": "Recruiting",
            "LocationName": "UC San Diego Moores Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01771107",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130992 - AIDS Malignancy Consortium - Ramos",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20130992",
            "StudyNumber": "20130992 - AIDS Malignancy Consortium - Ramos",
            "StudyTitle": "A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the treatment of stage II-IV HIV-associated Hodgkin Lymphoma",
            "PIID": "433",
            "PicNum": "C03978871",
            "PILastName": "Ramos",
            "PIFirstName": "Juan Carlos",
            "CoodCNbr": "C11923689",
            "CoordLastName": "Mohan",
            "CoordFirstName": "Vivin",
            "CoordEmail": "vxm153@miami.edu",
            "EnteredByCNbr": "C11964150",
            "EnteredByLastName": "Smith",
            "EnteredByFirstName": "Nyesha",
            "ActiveEnrollingDate": "05/15/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/15/2014",
            "IRBApprovedFrom": "05/05/2014",
            "IRBApprovedTo": "04/03/2017",
            "InfoEdNbr": "71980",
            "DiseaseSiteListDesc": "Hodgkins Lymphoma",
            "Expr1": "Pilot/Feasibility",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "5",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "5",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Luis,Sandra O'Mellan",
            "StudyObjective": "AMC-085",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01771107",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01773707",
            "BriefTitle": "CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1",
            "OfficialTitle": "CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes",
            "LeadSponsorClass": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
            "OversightAuthority": "Yes",
            "BriefSummary": "The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial.\r\n\r\n\r\n\r\n      All subjects will receive close monitoring for development of AGT or T1DM. Subjects will\r\n\r\n      receive Abatacept or placebo and close monitorin",
            "Description": "Study Purpose and Rationale:\r\n\r\n\r\n\r\n      In this study, relatives who are confirmed to have two or more antibodies, not including\r\n\r\n      mIAA, and normal glucose tolerance will be eligible for randomization to experimental\r\n\r\n      treatment",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2013",
            "CompletionDate": "February 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
            "StudyCondition": "Abnormal Glucose Tolerance",
            "studyLocation": "University of California - San Francisco",
            "Enrollment": "206",
            "NctKeyword": "prevention of type 1 diabetes, prevention of abnormal glucose tolerance,",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Intolerance,",
            "InterventionKeyword": "Abatacept,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Participant in TrialNet Natural History/Pathway to Prevention Study and thus, a\r\n\r\n             relative of a proband with T1DM.\r\n\r\n\r\n\r\n          -  Between the ages of 1-45 years at the time of enrollme",
            "EligibleGender": "All",
            "MinAge": "6 Years",
            "MaxAge": "45 Years",
            "Volunteers": "No",
            "City": "San Francisco",
            "State": "California",
            "Zip": "94143",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 12, 2016",
            "FirstReceived": "January 10, 2013",
            "OverallOfficial": "Carla J Greenbaum, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Type 1 Diabetes TrialNet",
            "ContactName": "Lisa E Rafkin, MS",
            "ContactPhone": "305-243-6146",
            "ContactEmail": "lrafkin@miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of California - San Francisco",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01773707",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120996 - NIH - Marks",
            "FileProcessContentId": "440",
            "Division": "Endocrinology",
            "StdyDivision": "10241",
            "EprostNbr": "20120996",
            "StudyNumber": "20120996 - NIH - Marks",
            "StudyTitle": "CTLA4Ig (Abatacept) For Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At Risk for Type 1 Diabetes Mellitus",
            "PIID": "877",
            "PicNum": "C00763957",
            "PILastName": "Marks",
            "PIFirstName": "Jennifer",
            "CoodCNbr": "C00694387",
            "CoordLastName": "Matheson",
            "CoordFirstName": "Della",
            "CoordEmail": "dmatheso@miami.edu",
            "CoordPhone": "3052433781",
            "EnteredByCNbr": "C04339507",
            "EnteredByLastName": "Arazo",
            "EnteredByFirstName": "Luz",
            "ActiveEnrollingDate": "03/25/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/25/2013",
            "IRBApprovedFrom": "01/22/2013",
            "IRBApprovedTo": "10/31/2017",
            "DiseaseSiteListDesc": "Pancreas",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Prevention",
            "StudyType_Code": "6163",
            "ResearchType": "Drug",
            "SponsorGroup": "NIH",
            "Sponsor": "NIH/NIDDK",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Della Matheson,Natalia Sanders,Carlos Blaschke",
            "AgentDevices": "Abatacept",
            "StudyObjective": "Researchers are testing Abatacept in people at risk for development of type 1 diabetes to see if this medication can help prevent or delay progression toward type 1 diabetes in people who have antibodies and have a risk for developing type 1 diabetes in the future.",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT01773707",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01774097",
            "SecondaryId": "UM1HL087318-06",
            "BriefTitle": "Patients With Intermittent Claudication Injected With ALDH Bright Cells",
            "OfficialTitle": "Clinical and MR Imaging Assessments in Patients With Intermittent Claudication Following Injection of Bone Marrow Derived ALDH Bright Cells",
            "LeadSponsorClass": "The University of Texas Health Science Center, Houston",
            "SponsorAgency": "Other",
            "LeadSponsor": "The University of Texas Health Science Center, Houston",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to find out if aldehyde dehydrogenase bright (ALDHbr) cells\r\n\r\n      taken from a patient's bone marrow can be placed safely, via intramuscular injections, into\r\n\r\n      their affected calf and lower thigh muscles an",
            "Description": "Peripheral Artery Disease (PAD) occurs when arteries in the arms and legs (most often the\r\n\r\n      legs) become narrowed by plaque. Because of this plaque, patients with PAD are also at\r\n\r\n      increased risk for heart attacks and strokes. Thos",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "June 2013",
            "CompletionDate": "March 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "The University of Texas Health Science Center, Houston",
            "StudyCondition": "Peripheral Artery Disease",
            "studyLocation": "Stanford University School of Medicine (Falk Cardiovascular Research Center)",
            "Enrollment": "82",
            "NctKeyword": "Peripheral Artery Disease, Intermittent Claudication, Autologous Stem Cells, ALDH cells, Claudicants, PAD, Peak Walking Time, MRI, Vascular Flow, Anatomy, Perfusion,",
            "MeshKeyword": "Intermittent Claudication, Peripheral Arterial Disease,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Patients with atherosclerotic peripheral artery disease with classic claudication\r\n\r\n             (exercise-induced pain, cramps, fatigue, or other equivalent discomfort involving\r\n\r\n             large m",
            "EligibleGender": "All",
            "MinAge": "40 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Stanford",
            "State": "California",
            "Zip": "94305",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "October 13, 2016",
            "FirstReceived": "January 18, 2013",
            "OverallOfficial": "Robert Simari, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Cardiovascular Cell Therapy Research Network",
            "LocationName": "Stanford University School of Medicine (Falk Cardiovascular Research Center)",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01774097",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130018 - UNIV OF TEXAS HEALTH SCIENCE CENTER - Hare",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20130018",
            "StudyNumber": "20130018 - UNIV OF TEXAS HEALTH SCIENCE CENTER - Hare",
            "StudyTitle": "Clinical and MR Imaging Assessments in Patients with Intermittent Claudication Following Injection of Bone Marrow Derived ALDH Bright Cells.Patients with Intermittent Caludication Injected with ALDH Bright Cells (PACE).",
            "PIID": "896",
            "PicNum": "C05065867",
            "PILastName": "Hare",
            "PIFirstName": "Joshua",
            "CoodCNbr": "C11258453",
            "CoordLastName": "Sierra",
            "CoordFirstName": "Julio",
            "CoordEmail": "jsierra@med.miami.edu",
            "CoordPhone": "3052437444",
            "EnteredByCNbr": "C05065867",
            "EnteredByLastName": "Hare",
            "EnteredByFirstName": "Joshua",
            "ActiveEnrollingDate": "09/23/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/23/2013",
            "IRBApprovedFrom": "05/22/2013",
            "IRBApprovedTo": "04/17/2017",
            "AccountNbr": "661238",
            "InfoEdNbr": "65995",
            "Expr1": "Phase I/II",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "UNIV OF TEXAS HEALTH SCIENCE CENTER",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "7",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Darcy Difede,Russell Saltzman,Mayra Vidro Casiano,Cindy Delgado,Marietsy Pujol",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT01774097",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01775618",
            "SecondaryId": "2012-004434-42",
            "BriefTitle": "Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A",
            "OfficialTitle": "A Multi-center, Phase III, Non-controlled, Open-label Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of BAY94-9027 for Prophylaxis and Treatment of Bleeding in Previously Treated Children (Age <12 Years) With Severe Hemophilia A",
            "LeadSponsorClass": "Bayer",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Bayer",
            "OversightAuthority": "Yes",
            "BriefSummary": "Hemophilia A is an inherited blood disorder in which one protein, Factor VIII, needed to\r\n\r\n      form blood clots is missing or not present in sufficient levels. Hemophilia A causes the\r\n\r\n      clotting process to be slowed and the person expe",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "May 2013",
            "CompletionDate": "December 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Bayer",
            "StudyCondition": "Hemophilia A",
            "Enrollment": "77",
            "NctKeyword": "Hemophilia A, Factor VIII, Prophylaxis, Pediatric,",
            "MeshKeyword": "Hemophilia A,",
            "InterventionKeyword": "Factor VIII,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Males < 12 years of age\r\n\r\n\r\n\r\n          -  Subjects with severe hemophilia A\r\n\r\n\r\n\r\n          -  Previously treated with FVIII for > 50 exposure days\r\n\r\n\r\n\r\n        Exclusion Criteria:",
            "EligibleGender": "Male",
            "MinAge": "N/A",
            "MaxAge": "12 Years",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Zip": "72202",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 19, 2016",
            "FirstReceived": "January 23, 2013",
            "OverallOfficial": "Bayer Study Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Bayer",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01775618",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120134 - BAYER HEALTHCARE,BAYER CORP PHARM DIV - Davis",
            "FileProcessContentId": "440",
            "Division": "Pediatrics Oncology",
            "StdyDivision": "10646",
            "EprostNbr": "20120134",
            "StudyNumber": "20120134 - BAYER HEALTHCARE,BAYER CORP PHARM DIV - Davis",
            "StudyTitle": "A Phase II/III, multicenter, partially randomized, open label trial investigating safety and efficacy of ondemand and prophylactic treatment with BAY 949027 in Severe Hemophilia A.",
            "PIID": "326",
            "PicNum": "C00603684",
            "PILastName": "Davis",
            "PIFirstName": "Joanna",
            "CoodCNbr": "C00076779",
            "CoordLastName": "Santaella",
            "CoordFirstName": "Maria",
            "CoordEmail": "msantaella@med.miami.edu",
            "EnteredByCNbr": "C00603684",
            "EnteredByLastName": "Davis",
            "EnteredByFirstName": "Joanna",
            "ActiveEnrollingDate": "12/03/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/03/2012",
            "IRBApprovedFrom": "10/15/2012",
            "IRBApprovedTo": "09/20/2016",
            "AccountNbr": "660031",
            "InfoEdNbr": "63361/66360",
            "Expr1": "Phase II/III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "Non University of Miami:N/A,UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Maria Santaella,Leandro Pisani",
            "NationalSampleSize": "1",
            "NCTNbr": "NCT01775618",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01781468",
            "SecondaryId": "N10C3",
            "BriefTitle": "Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma",
            "OfficialTitle": "A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma",
            "LeadSponsorClass": "Alliance for Clinical Trials in Oncology",
            "SponsorAgency": "Other",
            "LeadSponsor": "Alliance for Clinical Trials in Oncology",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase III trial studies armodafinil to see how well it works in reducing\r\n\r\n      cancer-related fatigue in patients with high grade glioma. Armodafinil may help relieve\r\n\r\n      fatigue in patients with high grade glioma.",
            "Description": "Patients experiencing fatigue related to cancer will be asked to take part in this study.\r\n\r\n      Cancer-related fatigue is a very common symptom in patients with cancer. Patients will\r\n\r\n      receive armodafinil or placebo. Please see the \"Ar",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2013",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Alliance for Clinical Trials in Oncology",
            "StudyCondition": "Fatigue",
            "studyLocation": "Alaska Breast Care and Surgery LLC",
            "Enrollment": "330",
            "MeshKeyword": "Fatigue,",
            "InterventionKeyword": "Armodafinil, Modafinil,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Age ≥ 18 years\r\n\r\n\r\n\r\n          -  Diagnosed with glioblastoma, gliosarcoma, small cell or large cell glioblastoma,\r\n\r\n             glioblastoma with oligo features, glioblastoma with primitive neuroecto",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Anchorage",
            "State": "Alaska",
            "Zip": "99508",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 16, 2016",
            "FirstReceived": "January 29, 2013",
            "OverallOfficial": "Alyx B. Porter Umphrey, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Mayo Clinic",
            "ContactName": "Alyx B. Porter Umphrey, MD",
            "ContactPhone": "(507) 266-5230",
            "LocationStatus": "Recruiting",
            "LocationName": "Alaska Breast Care and Surgery LLC",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01781468",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130376 - Alliance for Clinical Trials - Heros",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20130376",
            "StudyNumber": "20130376 - Alliance for Clinical Trials - Heros",
            "StudyTitle": "A Phase III Randomized Double Blind Placebo Controlled Study of Armodafonil (Nuvigil) To Reduce CancerRelated Fatigue in Patients With High Grade Glioma",
            "PIID": "615",
            "PicNum": "C00470451",
            "PILastName": "Heros",
            "PIFirstName": "Deborah",
            "CoodCNbr": "C06033307",
            "CoordLastName": "Caldwell",
            "CoordFirstName": "Doris",
            "CoordEmail": "dcaldwell@med.miami.edu",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "10/04/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/04/2013",
            "IRBApprovedFrom": "08/12/2013",
            "IRBApprovedTo": "06/19/2017",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "Phase III",
            "Tarea": "Neurological Cancer",
            "TareaCode": "12442",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "NIH",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "9",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "9",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:50,Plantation:N/A,UMMG:N/A,UMD:N/A",
            "AccrualPercentageMet": "12",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "50",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Luis,Helen Garcia,Teresa Kamar,Michelle Mikhail",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01781468",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01783990",
            "BriefTitle": "Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol",
            "OfficialTitle": "Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol",
            "LeadSponsorClass": "National Heart, Lung, and Blood Institute (NHLBI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
            "OversightAuthority": "Yes",
            "BriefSummary": "The BABY HUG Treatment Study was designed to see if treatment with the drug hydroxyurea\r\n\r\n      (also called HU) in children with sickle cell disease could prevent organ damage, especially\r\n\r\n      in the spleen and kidneys. There was also a ch",
            "Description": "The current observational trial, Follow-Up Study II (designated FUS II) includes enhanced\r\n\r\n      neuropsychological, brain, cardiac, and pulmonary evaluations for this very well\r\n\r\n      characterized cohort of subjects. Measures of spleen and",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "October 2012",
            "CompletionDate": "December 2016",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "National Heart, Lung, and Blood Institute (NHLBI)",
            "StudyCondition": "Sickle Cell Anemia",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "158",
            "MeshKeyword": "Anemia, Sickle Cell,",
            "InterventionKeyword": "Hydroxyurea,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  All subjects enrolled in the BABY HUG Follow-Up I Study who participated for at least\r\n\r\n             24 months are eligible for the Follow-Up Study II\r\n\r\n\r\n\r\n        Exclusion Criteria:",
            "EligibleGender": "All",
            "MinAge": "24 Months",
            "MaxAge": "18 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 23, 2016",
            "FirstReceived": "February 1, 2013",
            "OverallOfficial": "Susan Assmann, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "New England Research Institutes, Watertown, MA",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01783990",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120442 - National Heart Lung & Blood Institude - Alvarez",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20120442",
            "StudyNumber": "20120442 - National Heart Lung & Blood Institude - Alvarez",
            "StudyTitle": "PEDIATRIC HYDROXYUREA PHASE III CLINICAL TRIAL (BABY HUG)FOLLOWUP OBSERVATIONAL STUDY II",
            "PIID": "299",
            "PicNum": "C01335657",
            "PILastName": "Alvarez",
            "PIFirstName": "Ofelia",
            "CoodCNbr": "C01294252",
            "CoordLastName": "Hustace",
            "CoordFirstName": "Tally",
            "CoordEmail": "thustace@med.miami.edu",
            "EnteredByCNbr": "C01294252",
            "EnteredByLastName": "Hustace",
            "EnteredByFirstName": "Tally",
            "ActiveEnrollingDate": "02/13/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/13/2013",
            "IRBApprovedFrom": "07/16/2012",
            "IRBApprovedTo": "04/17/2017",
            "InfoEdNbr": "56701",
            "DiseaseSiteListDesc": "Leukemia, Other,Leukemia, not otherwise specified,Other Hematopoietic",
            "Expr1": "Phase III",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Epidemiological",
            "StudyType_Code": "6146",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "Nation Heart Lung & Blood Institude",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "3",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT01783990",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01783990",
            "BriefTitle": "Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol",
            "OfficialTitle": "Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol",
            "LeadSponsorClass": "National Heart, Lung, and Blood Institute (NHLBI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
            "OversightAuthority": "Yes",
            "BriefSummary": "The BABY HUG Treatment Study was designed to see if treatment with the drug hydroxyurea\r\n\r\n      (also called HU) in children with sickle cell disease could prevent organ damage, especially\r\n\r\n      in the spleen and kidneys. There was also a ch",
            "Description": "The current observational trial, Follow-Up Study II (designated FUS II) includes enhanced\r\n\r\n      neuropsychological, brain, cardiac, and pulmonary evaluations for this very well\r\n\r\n      characterized cohort of subjects. Measures of spleen and",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "October 2012",
            "CompletionDate": "December 2016",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "National Heart, Lung, and Blood Institute (NHLBI)",
            "StudyCondition": "Sickle Cell Anemia",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "158",
            "MeshKeyword": "Anemia, Sickle Cell,",
            "InterventionKeyword": "Hydroxyurea,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  All subjects enrolled in the BABY HUG Follow-Up I Study who participated for at least\r\n\r\n             24 months are eligible for the Follow-Up Study II\r\n\r\n\r\n\r\n        Exclusion Criteria:",
            "EligibleGender": "All",
            "MinAge": "24 Months",
            "MaxAge": "18 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 23, 2016",
            "FirstReceived": "February 1, 2013",
            "OverallOfficial": "Susan Assmann, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "New England Research Institutes, Watertown, MA",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01783990",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20080953 - NHLBI - Alvarez",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20080953",
            "StudyNumber": "20080953 - NHLBI - Alvarez",
            "StudyTitle": "PEDIATRIC HYDROXYUREA PHASE III CLINICAL TRIAL (BABY HUG) FOLLOWUP OBSERVATIONAL STUDY",
            "PIID": "299",
            "PicNum": "C01335657",
            "PILastName": "Alvarez",
            "PIFirstName": "Ofelia",
            "CoodCNbr": "C01294252",
            "CoordLastName": "Hustace",
            "CoordFirstName": "Tally",
            "CoordEmail": "thustace@med.miami.edu",
            "EnteredByCNbr": "C00541877",
            "EnteredByLastName": "Williams",
            "EnteredByFirstName": "Patrice",
            "ActiveEnrollingDate": "06/04/2009",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/04/2009",
            "IRBApprovedFrom": "12/22/2008",
            "IRBApprovedTo": "09/25/2017",
            "InfoEdNbr": "37073",
            "Expr1": "Phase III",
            "Tarea": "Hematology/Oncology",
            "TareaCode": "13338",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "National Heart, Lung and Blood Institute",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "5",
            "Totalaccrued": "5",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "3",
            "Totalpatients": "5",
            "FirstNinety": "4",
            "SiteSampleSize": "JMH:10",
            "AccrualPercentageMet": "50",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "10",
            "EprostState": "Approved",
            "StudyCoordinator": "Tally Hustace,Vanessa Cumming",
            "StudyObjective": "The specific aims of this follow-up study are:\r\n1. To identify and define possible long-term toxicities in children who receive treatment with HU.\r\n2. To determine if prolonged treatment with HU changes the risk and benefits of its use.\r\n3. To investigate the optimal age for initiation of treatment with HU (early vs. late).",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT01783990",
            "StudyKeywords": "ORIM: Kanchan Sakhrani (QA: 11/1/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01789840",
            "SecondaryId": "2012-003446-33",
            "BriefTitle": "Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia",
            "OfficialTitle": "Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia",
            "LeadSponsorClass": "Merit Medical Systems, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Merit Medical Systems, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate improvement of symptoms from benign prostatic\r\n\r\n      hyperplasia (BPH) as assessed by the International Prostate Symptom Score (IPSS) for\r\n\r\n      prostatic artery embolization (PAE) using Embosphere Mi",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2013",
            "CompletionDate": "May 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Merit Medical Systems, Inc.",
            "StudyCondition": "Benign Prostatic Hyperplasia",
            "studyLocation": "Long Beach VA",
            "Enrollment": "186",
            "NctKeyword": "BPH, Prostate, Prostatic Hyperplasia, enlarged prostate, LUTS, urinary retention,",
            "MeshKeyword": "Hyperplasia, Prostatic Hyperplasia,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Patient is age 50 to 79, inclusive\r\n\r\n\r\n\r\n          2. Patient has signed informed consent\r\n\r\n\r\n\r\n          3. Patient has had lower urinary tract symptoms (LUTS) secondary to BPH for at least 6",
            "EligibleGender": "Male",
            "MinAge": "50 Years",
            "MaxAge": "79 Years",
            "Volunteers": "No",
            "City": "Long Beach",
            "State": "California",
            "Zip": "90822",
            "Country": "United States",
            "VerificationDate": "October 2015",
            "LastChanged": "August 25, 2016",
            "FirstReceived": "February 8, 2013",
            "OverallOfficial": "Francisco Cesar Carnevale, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Sao Paolo, Brazil",
            "ContactName": "Melodie Domurad, PhD",
            "ContactPhone": "7816817900",
            "ContactEmail": "BEST@merit.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Long Beach VA",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01789840",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140259 - Merit Medical Systems - Bhatia",
            "FileProcessContentId": "440",
            "Division": "Radiology",
            "StdyDivision": "10262",
            "EprostNbr": "20140259",
            "StudyNumber": "20140259 - Merit Medical Systems - Bhatia",
            "StudyTitle": "PROSPECTIVE, CONTROLLED\nINVESTIGATION OF PROSTATE ARTERY\nEMBOLIZATION WITH EMBOSPHERE® MICROSPHERES\nCOMPARED TO TRANSURETHRAL RESECTION OF THE\nPROSTATE FOR THE TREATMENT OF SYMPTOMATIC\nBENIGN PROSTATIC HYPERPLASIA",
            "PIID": "2294",
            "PicNum": "C05038444",
            "PILastName": "Bhatia",
            "PIFirstName": "Shivank",
            "CoodCNbr": "C05023785",
            "CoordLastName": "Barbery",
            "CoordFirstName": "Katuska",
            "CoordEmail": "kbarbery@med.miami.edu",
            "CoordPhone": "3052432474",
            "EnteredByCNbr": "C05038444",
            "EnteredByLastName": "Bhatia",
            "EnteredByFirstName": "Shivank",
            "ActiveEnrollingDate": "10/13/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/13/2014",
            "IRBApprovedFrom": "05/19/2014",
            "IRBApprovedTo": "05/01/2017",
            "AccountNbr": "663143",
            "DiseaseSiteListDesc": "Prostate",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Merit Medical Systems",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "10",
            "Totalaccrued": "10",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "1",
            "SiteSampleSize": "VA:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Fanchette Auguste,Lia Quezada,Katuska Barbery,Murugesan Manoharan,Clara Morales",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT01789840",
            "StudyKeywords": "Prostate, hyperplasia",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01794403",
            "BriefTitle": "Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer",
            "OfficialTitle": "A Randomized Study of Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "Accelerated Hypofractionation Radiotherapy for prostate cancer of 36.25 Gy delivered in 5\r\n\r\n      fractions will not be inferior to the standard treatment of 70.2 Gy given in 26 fractions\r\n\r\n      with respect to two-year failure defined as a p",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2013",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "University of Miami",
            "StudyCondition": "Prostate Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "456",
            "NctKeyword": "Prostate Cancer, Prostate, Radiation Therapy, Hypofractionation Radiotherapy, Extended Hypofractionation Radiotherapy, Accelerated Hypofractionation Radiotherapy, AHRT, EHRT,",
            "MeshKeyword": "Prostatic Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Histologically proven prostate adenocarcinoma.\r\n\r\n\r\n\r\n               -  Gleason score 2-7 (reviewed by reference lab at UM).\r\n\r\n\r\n\r\n               -  Biopsy within one year of date of enrollment.",
            "EligibleGender": "Male",
            "MinAge": "35 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 9, 2016",
            "FirstReceived": "February 14, 2013",
            "OverallOfficial": "Matthew Abramowitz, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01794403",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110491 - Intramural - Abramowitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20110491",
            "StudyNumber": "20110491 - Intramural - Abramowitz",
            "StudyTitle": "A Randomized Study of Radiation Hypofractionation via Extended versus Accelerated Therapy (HEAT) For Prostate Cancer",
            "PIID": "2392",
            "PicNum": "C09437493",
            "PILastName": "Abramowitz",
            "PIFirstName": "Matthew",
            "CoodCNbr": "C12003895",
            "CoordLastName": "Vazquez Pascual",
            "CoordFirstName": "Fernando",
            "CoordEmail": "fxv109@miami.edu",
            "CoordPhone": "305-243-5620",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "02/27/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/27/2013",
            "IRBApprovedFrom": "08/23/2012",
            "IRBApprovedTo": "07/31/2017",
            "AccountNbr": "661565",
            "InfoEdNbr": "65145",
            "DiseaseSiteListDesc": "Prostate",
            "Expr1": "Phase III",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "3",
            "Screenedfailed": "7",
            "SignedICF": "43",
            "Totalaccrued": "35",
            "InFollowUp": "29",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "43",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,Northern Sydney Local Health District:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "4",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Marinellie Vega,Pavel Noa Hechavarria,Zaida Abreu,Lilly Sanchez,Greeyt Hernandez,Lilibet Zamora Cabezas,Maggie Chislom,Doris Martin",
            "NationalSampleSize": "456",
            "NCTNbr": "NCT01794403",
            "StudyKeywords": "Open in Australia (Multi-center)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01797185",
            "BriefTitle": "An Open Label and Safety Study of the Safety Of SPARC1104",
            "LeadSponsorClass": "Sun Pharma Advanced Research Company Limited",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Sun Pharma Advanced Research Company Limited",
            "OversightAuthority": "No",
            "BriefSummary": "Open-label, safety study of SPARC1104 in subjects with spasticity due to multiple sclerosis",
            "Description": "Safety study of SPARC1104",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2013",
            "CompletionDate": "January 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Sun Pharma Advanced Research Company Limited",
            "StudyCondition": "Spasticity",
            "studyLocation": "SPARC Site 1",
            "Enrollment": "100",
            "NctKeyword": "baclofen, spasticity,",
            "MeshKeyword": "Muscle Spasticity,",
            "Eligibility": "-  Willingness to participate and give written informed consent\r\n\r\n\r\n\r\n          -  Men and women ≥ 18 years of age\r\n\r\n\r\n\r\n          -  Sexually active women who are of child bearing potential will practice an acceptable\r\n\r\n             method",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "90 Years",
            "Volunteers": "No",
            "City": "Gilbert",
            "State": "Arizona",
            "Zip": "85234",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 28, 2016",
            "FirstReceived": "February 16, 2013",
            "ContactName": "Shravanti Bhowmik, MD",
            "ContactPhone": "+91 22 66455645",
            "ContactEmail": "shravanti.bhowmik@sparcmail.com",
            "LocationStatus": "Recruiting",
            "LocationName": "SPARC Site 1",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01797185",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140075 - Sun Pharma Advanced Research Company Ltd. - Delgado",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140075",
            "StudyNumber": "20140075 - Sun Pharma Advanced Research Company Ltd. - Delgado",
            "StudyTitle": "A CLINICAL EVALUATION OF THE SAFETY OF BACLOFEN ER CAPSULES (GRS) WHEN ADMINISTERED ONCE DAILY TO SUBJECTS WITH SPASTICITY DUE TO MULTIPLE SCLEROSIS (MS): AN OPEN LABEL, LONG TERM, SAFETY TRIAL",
            "PIID": "122",
            "PicNum": "C00360924",
            "PILastName": "Delgado",
            "PIFirstName": "Silvia",
            "CoodCNbr": "C00168827",
            "CoordLastName": "Sawant",
            "CoordFirstName": "Ruta",
            "EnteredByCNbr": "C00360924",
            "EnteredByLastName": "Delgado",
            "EnteredByFirstName": "Silvia",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "06/02/2014",
            "IRBApprovedFrom": "06/02/2014",
            "IRBApprovedTo": "04/17/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Sun Pharma Advanced Research Company Ltd.",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yanet Babcock,Gloria Rodriguez (Neurology)",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT01797185",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01802866",
            "BriefTitle": "Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride",
            "OfficialTitle": "A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration",
            "LeadSponsorClass": "Acucela Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Acucela Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the\r\n\r\n      rate of progression of geographic atrophy compared to placebo in subjects with dry\r\n\r\n      age-related macular degeneration.",
            "OverallStatus": "Completed",
            "StartDate": "February 2013",
            "CompletionDate": "May 2016",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "Acucela Inc.",
            "StudyCondition": "Geographic Atrophy",
            "Enrollment": "508",
            "NctKeyword": "Geographic atrophy, GA, Dry AMD,",
            "MeshKeyword": "Atrophy, Geographic Atrophy,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Males or females, age ≥55 years.\r\n\r\n\r\n\r\n          2. Clinical diagnosis of GA associated with AMD\r\n\r\n\r\n\r\n          3. Able and willing to provide written informed consent.\r\n\r\n\r\n\r\n          4. Able to rel",
            "EligibleGender": "All",
            "MinAge": "55 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Country": "United States",
            "VerificationDate": "May 2016",
            "LastChanged": "May 31, 2016",
            "FirstReceived": "February 28, 2013",
            "OverallOfficial": "Acucela Medical Monitor",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Acucela Inc.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01802866",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20121068 - ACUCELA INC - Yehoshua",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20121068",
            "StudyNumber": "20121068 - ACUCELA INC - Yehoshua",
            "StudyTitle": "A Phase 2b/3 Multicenter, Randomized, DoubleMasked, DoseRanging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU4429) with Placebo for the Treatment of Geographic Atrophy Associated with Dry AgeRelated Macular Degeneration",
            "PIID": "1823",
            "PicNum": "C06958118",
            "PILastName": "Yehoshua",
            "PIFirstName": "Zohar",
            "CoodCNbr": "C01984187",
            "CoordLastName": "Esquiabro",
            "CoordFirstName": "Maria",
            "CoordEmail": "mesquiabro@med.miami.edu",
            "EnteredByCNbr": "C00286276",
            "EnteredByLastName": "Lage-Rodriguez",
            "EnteredByFirstName": "Cristina",
            "ActiveEnrollingDate": "07/02/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/02/2013",
            "IRBApprovedFrom": "04/08/2013",
            "IRBApprovedTo": "03/12/2017",
            "AccountNbr": "660861",
            "InfoEdNbr": "63202",
            "Expr1": "Phase II/III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "ACUCELA INC",
            "Prescreened": "0",
            "Screenedfailed": "8",
            "SignedICF": "15",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "15",
            "FirstNinety": "5",
            "SiteSampleSize": "BPPB:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Cristina Lage-Rodriguez,Maria Esquiabro,Belen Rodriguez,Monica Arango",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT01802866",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01802866",
            "BriefTitle": "Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride",
            "OfficialTitle": "A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration",
            "LeadSponsorClass": "Acucela Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Acucela Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the\r\n\r\n      rate of progression of geographic atrophy compared to placebo in subjects with dry\r\n\r\n      age-related macular degeneration.",
            "OverallStatus": "Completed",
            "StartDate": "February 2013",
            "CompletionDate": "May 2016",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "Acucela Inc.",
            "StudyCondition": "Geographic Atrophy",
            "Enrollment": "508",
            "NctKeyword": "Geographic atrophy, GA, Dry AMD,",
            "MeshKeyword": "Atrophy, Geographic Atrophy,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Males or females, age ≥55 years.\r\n\r\n\r\n\r\n          2. Clinical diagnosis of GA associated with AMD\r\n\r\n\r\n\r\n          3. Able and willing to provide written informed consent.\r\n\r\n\r\n\r\n          4. Able to rel",
            "EligibleGender": "All",
            "MinAge": "55 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Country": "United States",
            "VerificationDate": "May 2016",
            "LastChanged": "May 31, 2016",
            "FirstReceived": "February 28, 2013",
            "OverallOfficial": "Acucela Medical Monitor",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Acucela Inc.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01802866",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130072 - ACUCELA INC - Rosenfeld",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20130072",
            "StudyNumber": "20130072 - ACUCELA INC - Rosenfeld",
            "StudyTitle": "A Phase 2b/3 Multicenter, Randomized, DoubleMasked, DoseRanging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU4429) with Placebo for the Treatment of Geographic Atrophy Associated with Dry AgeRelated Macular Degeneration",
            "PIID": "491",
            "PicNum": "C00522634",
            "PILastName": "Rosenfeld",
            "PIFirstName": "Philip",
            "CoodCNbr": "C01984187",
            "CoordLastName": "Esquiabro",
            "CoordFirstName": "Maria",
            "CoordEmail": "mesquiabro@med.miami.edu",
            "EnteredByCNbr": "C00293224",
            "EnteredByLastName": "Arango",
            "EnteredByFirstName": "Monica",
            "ActiveEnrollingDate": "06/21/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/21/2013",
            "IRBApprovedFrom": "05/13/2013",
            "IRBApprovedTo": "04/10/2017",
            "AccountNbr": "660914",
            "InfoEdNbr": "65535",
            "Expr1": "Phase II/III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "ACUCELA INC",
            "Prescreened": "0",
            "Screenedfailed": "12",
            "SignedICF": "26",
            "Totalaccrued": "14",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "26",
            "FirstNinety": "5",
            "SiteSampleSize": "BPPB:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Cristina Lage-Rodriguez,Maria Esquiabro,Monica Arango",
            "NationalSampleSize": "200",
            "NCTNbr": "NCT01802866",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01803152",
            "BriefTitle": "Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma",
            "OfficialTitle": "A Phase I Trial of Dendritic Cell Vaccination With and Without Inhibition of Myeloid Derived Suppressor Cells by Gemcitabine Pre-Treatment For Children And Adults With Sarcoma",
            "LeadSponsorClass": "Edward Ziga",
            "SponsorAgency": "Other",
            "LeadSponsor": "Edward Ziga",
            "OversightAuthority": "Yes",
            "BriefSummary": "The use of adjuvant vaccination with autologous dendritic cells (DC) matured in situ after\r\n\r\n      being loaded with tumor lysates derived from autologous refractory sarcoma tissue will be\r\n\r\n      safe, feasible and potentially beneficial for",
            "Description": "This is a dose finding / dose escalation study of dendritic cell (DC) vaccination\r\n\r\n      administered through imiquimod (Aldara®) treated skin for refractory sarcoma patients, which\r\n\r\n      includes a subsequent cohort of subjects who will re",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2012",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Sarcoma",
            "studyLocation": "University of Miami",
            "Enrollment": "56",
            "NctKeyword": "Metastatic Sarcoma, Relapsed Sarcoma, Dendritic Cell, Myeloid Derived Suppressor Cells, MDSC, MDSC Inhibition,",
            "MeshKeyword": "Sarcoma, Osteosarcoma,",
            "InterventionKeyword": "Vaccines, Gemcitabine, Imiquimod,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age: 1 - 100 years old.\r\n\r\n\r\n\r\n          2. Histologically or cytologically confirmed sarcoma either relapsed or without known\r\n\r\n             curative therapies. Both bone sarcomas and soft tissue sarco",
            "EligibleGender": "All",
            "MinAge": "1 Year",
            "MaxAge": "100 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 9, 2016",
            "FirstReceived": "February 27, 2013",
            "OverallOfficial": "Breelyn Wilky, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01803152",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110462 - Intramural - Wilky",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20110462",
            "StudyNumber": "20110462 - Intramural - Wilky",
            "StudyTitle": "A Phase I Trial of Dendritic Cell Vaccination With and Without Inhibition of Myeloid Derived Suppressor Cells by Gemcitabine PreTreatment For Children And Adults With Sarcoma.",
            "PIID": "4630",
            "PicNum": "C11848802",
            "PILastName": "Wilky",
            "PIFirstName": "Breelyn",
            "CoodCNbr": "C11958101",
            "CoordLastName": "Tahhan",
            "CoordFirstName": "Georges",
            "CoordEmail": "gxt202@miami.edu",
            "CoordPhone": "305-243-0862",
            "EnteredByCNbr": "C11865446",
            "EnteredByLastName": "Kamar",
            "EnteredByFirstName": "Emil",
            "ActiveEnrollingDate": "07/16/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/16/2012",
            "IRBApprovedFrom": "07/16/2012",
            "IRBApprovedTo": "08/07/2017",
            "InfoEdNbr": "68935",
            "DiseaseSiteListDesc": "Bones and Joints",
            "Expr1": "Phase I",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "18",
            "Totalaccrued": "14",
            "InFollowUp": "4",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "3",
            "Totalpatients": "18",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMHC:56,UMMG:N/A",
            "AccrualPercentageMet": "25",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "56",
            "EprostState": "Approved",
            "StudyCoordinator": "Matteo Trucco",
            "NationalSampleSize": "56",
            "NCTNbr": "NCT01803152",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01804829",
            "BriefTitle": "Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.",
            "OfficialTitle": "A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients",
            "LeadSponsorClass": "Biotest Pharmaceuticals Corporation",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Biotest Pharmaceuticals Corporation",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to test the safety and efficacy of Civacir® to prevent the\r\n\r\n      recurrence of Hepatitis C Virus (HCV) after liver transplant.",
            "Description": "Civacir® 10%, Hepatitis C Immune Globulin Intravenous (Human) is a high-titer human\r\n\r\n      polyclonal immune globulin (IgG) containing a diversity of antibodies that target and bind\r\n\r\n      the hepatitis C virus (HCV) to prevent infection. Su",
            "OverallStatus": "Completed",
            "StartDate": "June 2013",
            "CompletionDate": "June 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Biotest Pharmaceuticals Corporation",
            "StudyCondition": "Hepatitis C Infection",
            "studyLocation": "University of Southern California / Keck Hospital",
            "Enrollment": "80",
            "NctKeyword": "HCV Liver Transplant Immunoglobulin PCR SVR,",
            "MeshKeyword": "Hepatitis, Hepatitis A, Hepatitis C, Carcinoma, Hepatocellular, Liver Cirrhosis, Hepatitis, Viral, Human,",
            "InterventionKeyword": "Immunoglobulins, Antibodies, gamma-Globulins, Immunoglobulins, Intravenous, Rho(D) Immune Globulin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Written informed consent obtained prior to any study-specific assessments and within\r\n\r\n             3 months (reconsent) of orthotopic liver transplantation (OLT).\r\n\r\n\r\n\r\n          -  HCV Genotype 1 thr",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90033",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 30, 2016",
            "FirstReceived": "March 4, 2013",
            "OverallOfficial": "Norah Terrault, MD, MPH",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of California, San Francisco",
            "LocationName": "University of Southern California / Keck Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01804829",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130157 - BIOTEST DIAGNOSTICS CORP - Bhamidimarri",
            "FileProcessContentId": "440",
            "Division": "Medicine",
            "StdyDivision": "7803",
            "EprostNbr": "20130157",
            "StudyNumber": "20130157 - BIOTEST DIAGNOSTICS CORP - Bhamidimarri",
            "StudyTitle": "Biotest 988  A MultiCenter, Randomized, Prospective, OpenLabel Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin (HCIG) in Orthotopic Liver Transplant Recipients.",
            "PIID": "3536",
            "PicNum": "C10581001",
            "PILastName": "Bhamidimari",
            "PIFirstName": "Kalyan",
            "CoodCNbr": "C10581001",
            "CoordLastName": "Bhamidimari",
            "CoordFirstName": "Kalyan",
            "EnteredByCNbr": "C10581001",
            "EnteredByLastName": "Bhamidimari",
            "EnteredByFirstName": "Kalyan",
            "ActiveEnrollingDate": "06/06/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/06/2013",
            "IRBApprovedFrom": "05/20/2013",
            "IRBApprovedTo": "05/10/2016",
            "InfoEdNbr": "65893",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "6",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Maria Onate-Silva,Odalys Rodriguez-Bravo,Eva Pavicic,Diane Sabogal,Sonia Carvalho",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01804829",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01806064",
            "BriefTitle": "A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma",
            "OfficialTitle": "A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a lead-in Phase 1B Dose Escalation Portion) in Patients With Advanced or Metastatic Renal Cell Carcinoma",
            "LeadSponsorClass": "Tracon Pharmaceuticals Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Tracon Pharmaceuticals Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "Phase 1b: To evaluate safety and tolerability and determine a recommended phase 2 dose for\r\n\r\n      TRC105 when added to standard dose axitinib in patients with advanced renal cell carcinoma.\r\n\r\n\r\n\r\n      Phase 2: To estimate the PFS of patients",
            "Description": "Axitinib is an oral inhibitor of multiple receptor tyrosine kinases including vascular\r\n\r\n      endothelial growth factor receptor VEGFR-1, VEGFR-2, and VEGFR-3 at therapeutic plasma\r\n\r\n      concentrations. These receptors are implicated in pat",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2013",
            "CompletionDate": "June 2017",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Tracon Pharmaceuticals Inc.",
            "StudyCondition": "Renal Cell Carcinoma",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "168",
            "NctKeyword": "TRC105, CD105, RCC, Renal Cell Carcinoma, Axitinib, INLYTA, Advanced Renal Cell Carcinoma,",
            "MeshKeyword": "Carcinoma, Carcinoma, Renal Cell,",
            "InterventionKeyword": "Axitinib, Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Histologically confirmed advanced or metastatic renal cell carcinoma with a clear\r\n\r\n             cell component that has progressed by investigator assessment following treatment\r\n\r\n             with on",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 16, 2016",
            "FirstReceived": "February 26, 2013",
            "ContactName": "Clinical Trials Information",
            "ContactEmail": "Clinicaltrials@traconpharma.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01806064",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140840 - Tracon Pharma - Merchan",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140840",
            "StudyNumber": "20140840 - Tracon Pharma - Merchan",
            "StudyTitle": "A Randomized Phase 2 Trial of Axitinib and TRC 105 Versus Axitinib Alone (Including a Lead-in Phase 1B Dose-Escalation Portion) in Patients with Advanced or Metastatic Renal Cell Carcinoma",
            "PIID": "407",
            "PicNum": "C00251535",
            "PILastName": "Merchan",
            "PIFirstName": "Jaime",
            "CoodCNbr": "C12026538",
            "CoordLastName": "Grez",
            "CoordFirstName": "Nester",
            "CoordEmail": "Nester.Grez@med.miami.edu",
            "CoordPhone": "305-243-4033",
            "EnteredByCNbr": "C12021320",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Paul",
            "ActiveEnrollingDate": "05/06/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/06/2015",
            "IRBApprovedFrom": "01/20/2015",
            "IRBApprovedTo": "01/04/2017",
            "AccountNbr": "664837",
            "DiseaseSiteListDesc": "Kidney",
            "Expr1": "Phase I/II",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Tracon Pharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Vivianne Velez-Bravo",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT01806064",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01808820",
            "BriefTitle": "Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma",
            "OfficialTitle": "Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects",
            "LeadSponsorClass": "Edward Ziga",
            "SponsorAgency": "Other",
            "LeadSponsor": "Edward Ziga",
            "OversightAuthority": "Yes",
            "BriefSummary": "Dendritic Cell vaccine manufactured and partially matured using our standard operating\r\n\r\n      procedures, developed in collaboration with the HGG Immuno Group, then administered through\r\n\r\n      imiquimod treated skin will be safe and feasible",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2013",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Malignant Glioma",
            "studyLocation": "University of Miami",
            "Enrollment": "20",
            "NctKeyword": "Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma, HGG, Dendritic Cell Vaccine, DC Vaccine, Leukapheresis,",
            "MeshKeyword": "Glioblastoma, Glioma, Astrocytoma,",
            "InterventionKeyword": "Vaccines, Imiquimod,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age: ≥ 13 years and ≤ 99 years.\r\n\r\n\r\n\r\n          2. (2a) Relapse of high grade glioma (anaplastic astrocytoma World Health Organization\r\n\r\n             (WHO) grade III or glioblastoma multiforme WHO grad",
            "EligibleGender": "All",
            "MinAge": "13 Years",
            "MaxAge": "99 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 9, 2016",
            "FirstReceived": "March 6, 2013",
            "OverallOfficial": "Macarena De La Fuente, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01808820",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120750 - Intramural - De La Fuente",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20120750",
            "StudyNumber": "20120750 - Intramural - De La Fuente",
            "StudyTitle": "DENDRITIC CELL VACCINE FOR MALIGNANT GLIOMA AND GLIOBLASTOMA MULTIFORME IN ADULT AND PEDIATRIC SUBJECTS.",
            "PIID": "22734",
            "PicNum": "C11916526",
            "PILastName": "De La Fuente",
            "PIFirstName": "Macarena",
            "CoodCNbr": "C04228283",
            "CoordLastName": "Garcia",
            "CoordFirstName": "Helen",
            "CoordEmail": "heg32@med.miami.edu",
            "EnteredByCNbr": "C11972191",
            "EnteredByLastName": "Harris",
            "EnteredByFirstName": "Bretinsa",
            "ActiveEnrollingDate": "07/02/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/02/2013",
            "IRBApprovedFrom": "03/04/2013",
            "IRBApprovedTo": "02/28/2017",
            "InfoEdNbr": "68269",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "Phase I",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "11",
            "SignedICF": "19",
            "Totalaccrued": "8",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "19",
            "FirstNinety": "2",
            "SiteSampleSize": "UMHC:N/A,JMH:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Georges Tahhan,Nathalie Luis",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT01808820",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01819766",
            "BriefTitle": "Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease",
            "OfficialTitle": "Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study",
            "LeadSponsorClass": "Exact Sciences Corporation",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Exact Sciences Corporation",
            "OversightAuthority": "No",
            "BriefSummary": "This study aims to determine the performance of the Exact IBD-ACRN surveillance test to\r\n\r\n      detect colorectal cancer (CRC) and colorectal neoplasia in patients with inflammatory bowel\r\n\r\n      disease (IBD). Patients with an IBD diagnosis f",
            "Description": "This is a prospective, cross sectional, multi-center study to determine the sensitivity and\r\n\r\n      specificity of the Exact IBD-ACRN surveillance test for detecting CRC alone and in\r\n\r\n      combination with high grade dysplasia (HGD) and low",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "March 2013",
            "CompletionDate": "April 2017",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Exact Sciences Corporation",
            "StudyCondition": "Inflammatory Bowel Disease (IBD)",
            "studyLocation": "Mayo Clinic Arizona",
            "Enrollment": "440",
            "NctKeyword": "Cancer, Colorectal Cancer, Neoplasm, Colorectal Neoplasm, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseas",
            "MeshKeyword": "Neoplasms, Colorectal Neoplasms, Intestinal Diseases, Inflammatory Bowel Diseases, Cholangitis, Cholangitis, Sclerosing,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male or female 18-84 years of age, inclusive.\r\n\r\n\r\n\r\n          -  Diagnosis of IBD or a diagnosis of PSC with IBD prior to enrollment date of this\r\n\r\n             study.\r\n\r\n\r\n\r\n          -  Must be a can",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "84 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85054",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 9, 2016",
            "FirstReceived": "March 25, 2013",
            "OverallOfficial": "Steven Itzkowitz, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Icahn School of Medicine at Mount Sinai",
            "LocationName": "Mayo Clinic Arizona",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01819766",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130330 - Exact Sciences - Sussman",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20130330",
            "StudyNumber": "20130330 - Exact Sciences - Sussman",
            "StudyTitle": "Detection of Advanced Colorectal Neoplasia by StoolDNA in Inflammatory Bowel Disease: OCEANIAStudy",
            "PIID": "1152",
            "PicNum": "C00499067",
            "PILastName": "Sussman",
            "PIFirstName": "Daniel",
            "CoodCNbr": "C10569914",
            "CoordLastName": "Quintero-Cusguen",
            "CoordFirstName": "Maria Alejandra",
            "CoordEmail": "MQuintero2@med.miami.edu",
            "EnteredByCNbr": "C09950089",
            "EnteredByLastName": "Morillo",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "10/25/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/25/2013",
            "IRBApprovedFrom": "08/17/2013",
            "IRBApprovedTo": "04/17/2017",
            "DiseaseSiteListDesc": "Colon",
            "Expr1": "N/A",
            "Tarea": "Colorectal Cancer",
            "TareaCode": "12437",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "ExactSciences",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "14",
            "Totalaccrued": "14",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "14",
            "FirstNinety": "7",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diana Morillo,Francia Carabali,Maria Alejandra Quintero-Cusguen",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT01819766",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01822496",
            "SecondaryId": "NCI-2013-00737",
            "BriefTitle": "Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer",
            "OfficialTitle": "A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with\r\n\r\n      chemoradiation therapy works in treating patients with stage III non-small cell lung cancer.\r\n\r\n      Radiation therapy uses high energy x rays t",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To assess whether patients with unresectable local-regionally advanced non-small cell\r\n\r\n      lung cancer (NSCLC) treated with targeted agents based on molecular characteristics have a\r\n\r\n      longer progres",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2013",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Stage IIIA Non-Small Cell Lung Cancer",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "234",
            "MeshKeyword": "Lung Neoplasms, Carcinoma, Non-Small-Cell Lung,",
            "InterventionKeyword": "Etoposide phosphate, Erlotinib Hydrochloride, Etoposide, Carboplatin, Cisplatin, Podophyllotoxin, Crizotinib, Succinylcholine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Histologically or cytologically confirmed, newly diagnosed non-squamous NSCLC\r\n\r\n\r\n\r\n          -  Unresectable stage IIIA or IIIB disease; patients must be surgically staged to\r\n\r\n             confirm N2",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "April 1, 2013",
            "OverallOfficial": "Ramaswamy Govindan",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "NRG Oncology",
            "LocationStatus": "Active, not recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01822496",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140950 - RTOG - Ishkanian",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140950",
            "StudyNumber": "20140950 - RTOG - Ishkanian",
            "StudyTitle": "A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non- Small Cell Lung Cancer (NSCLC)",
            "PIID": "4324",
            "PicNum": "C11277917",
            "PILastName": "Ishkanian",
            "PIFirstName": "Adrian",
            "CoodCNbr": "C11931359",
            "CoordLastName": "Chislom",
            "CoordFirstName": "Maggie",
            "CoordEmail": "mmc116@miami.edu",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "09/02/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/02/2015",
            "IRBApprovedFrom": "03/03/2015",
            "IRBApprovedTo": "02/01/2017",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase II",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "RTOG",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "4",
            "Totalaccrued": "2",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Marinellie Vega,Deborah Conte,Mohammad El-Sorady,Cristina Rojas-Mejia,Pavel Noa Hechavarria,Fernando Vazquez Pascual,Zaida Abreu,Lilibet Zamora Cabezas,Lilly Sanchez,Greeyt Hernandez,Teresa Kamar,Doris Martin",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT01822496",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01832714",
            "BriefTitle": "Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event",
            "OfficialTitle": "Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event",
            "LeadSponsorClass": "Neuro Kinetics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Neuro Kinetics",
            "OversightAuthority": "No",
            "BriefSummary": "This study is designed to evaluate the use of a collection of tests that measure the eye\r\n\r\n      response, balance, oculomotor and reaction time tests to aid in the diagnosis of mTBI. The\r\n\r\n      tests use highly precise measurement tools to a",
            "Description": "The study uses a prospective, between-subjects design comparing an Investigational (mTBI)\r\n\r\n      Group to a Control Group. The Investigational Group includes SM who had been diagnosed with\r\n\r\n      an mTBI. The Control Group consists of SM who",
            "OverallStatus": "Unknown status",
            "StartDate": "September 2013",
            "CompletionDate": "November 2015",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Neuro Kinetics",
            "StudyCondition": "Concussion, Mild",
            "studyLocation": "Naval Medical Center San Diego",
            "Enrollment": "180",
            "NctKeyword": "Concussion, mTBI, military, MACE, NKI, NOTC, VNG, VOG, Neuro Kinetics, oculomotor, vestibular, reaction time, I-Portal, eye tracking, Dizziness Handicap Inventory,",
            "MeshKeyword": "Brain Concussion,",
            "Eligibility": "Inclusion criteria for all subjects (Control and mTBI) - Males or females from 19 -\r\n\r\n        45years of age and of all races.\r\n\r\n\r\n\r\n        Additional Inclusion criteria for mTBI Subjects\r\n\r\n\r\n\r\n        - Diagnosed with traumatic brain inju",
            "EligibleGender": "All",
            "MinAge": "19 Years",
            "MaxAge": "45 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "San Diego",
            "State": "California",
            "Zip": "92134",
            "Country": "United States",
            "VerificationDate": "September 2014",
            "LastChanged": "September 25, 2014",
            "FirstReceived": "April 10, 2013",
            "OverallOfficial": "Alex Kiderman, PhD ME",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Neuro Kinetics, Inc",
            "LocationName": "Naval Medical Center San Diego",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01832714",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140742 - General Electric/National Football League (NFL)/Un - Hoffer",
            "FileProcessContentId": "440",
            "Division": "Otolaryngology",
            "StdyDivision": "10136",
            "EprostNbr": "20140742",
            "StudyNumber": "20140742 - General Electric/National Football League (NFL)/Un - Hoffer",
            "StudyTitle": "Assessment of oculomotor, vestibular and reaction time response following a concussive event",
            "PIID": "23064",
            "PicNum": "C11915566",
            "PILastName": "Hoffer",
            "PIFirstName": "Michael",
            "CoodCNbr": "C04264070",
            "CoordLastName": "Murphy",
            "CoordFirstName": "Sara",
            "EnteredByCNbr": "C11915566",
            "EnteredByLastName": "Hoffer",
            "EnteredByFirstName": "Michael",
            "ActiveEnrollingDate": "01/07/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/07/2015",
            "IRBApprovedFrom": "10/21/2014",
            "IRBApprovedTo": "10/17/2016",
            "Expr1": "Other",
            "ResearchType": "Device",
            "SponsorGroup": "Other",
            "Sponsor": "General Electric/National Football League (NFL)/Under Armour/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "75",
            "Totalaccrued": "74",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "74",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "75",
            "FirstNinety": "12",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Sara Murphy,James Buskirk,Constanza Pelusso",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT01832714",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01834235",
            "BriefTitle": "QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer",
            "OfficialTitle": "A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX",
            "LeadSponsorClass": "Precision Biologics, Inc",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Precision Biologics, Inc",
            "OversightAuthority": "No",
            "BriefSummary": "This is a randomized phase II multi-institution prospective open label study in which up to\r\n\r\n      90 subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer\r\n\r\n      who previously received treatment with chemot",
            "Description": "During Part 1 of the study, the safe and tolerable dose of NPC-1C in combination with\r\n\r\n      Gemcitabine will be determined. Upon completion of the phase I study up to 90 patients be\r\n\r\n      randomized to one of two arms:\r\n\r\n\r\n\r\n      A: Pati",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2013",
            "CompletionDate": "October 2017",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Precision Biologics, Inc",
            "StudyCondition": "Pancreatic Cancer, Adult",
            "studyLocation": "California Pacific Medical Center",
            "Enrollment": "90",
            "NctKeyword": "Pancreatic neoplasms, Pancreatic cancer, Pancreatic cancer, adult, Adenoma of the pancreas, Carcinoma of the pancreas,",
            "MeshKeyword": "Pancreatic Neoplasms, Carcinoma,",
            "InterventionKeyword": "Paclitaxel, Gemcitabine, Albumin-Bound Paclitaxel,",
            "Eligibility": "Inclusion Criteria\r\n\r\n\r\n\r\n          -  Subjects with recurrent, locally advanced unresectable or metastatic adenocarcinoma\r\n\r\n             of the pancreas who have progressed after primary therapy with FOLFIRINOX or\r\n\r\n             FOLFIRINOX-",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "San Francisco",
            "State": "California",
            "Zip": "94115",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "October 24, 2016",
            "FirstReceived": "April 12, 2013",
            "OverallOfficial": "Philip M Arlen, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Precision Biologics, Inc",
            "ContactName": "Philip M Arlen, MD",
            "ContactPhone": "301-917-6890",
            "ContactEmail": "parlen@Precision-Biologics.com",
            "LocationStatus": "Recruiting",
            "LocationName": "California Pacific Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01834235",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150341 - Precision Biologics - Acquavella",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150341",
            "StudyNumber": "20150341 - Precision Biologics - Acquavella",
            "StudyTitle": "“A Multicenter Randomized Phase II Study of NPC-1C in Combination with Gemcitabine and nab-Paclitaxel versus Gemcitabine and nab-Paclitaxel alone in Patients with Metastatic or Locally Advanced Pancreatic Cancer previously Treated with FOLFIRINOX”",
            "PIID": "23755",
            "PicNum": "C11919904",
            "PILastName": "Acquavella",
            "PIFirstName": "Nicolas",
            "CoodCNbr": "C11979873",
            "CoordLastName": "Cianferra",
            "CoordFirstName": "Eduardo",
            "CoordEmail": "exc642@miami.edu",
            "CoordPhone": "305-243-1139",
            "EnteredByCNbr": "C12021320",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Paul",
            "ActiveEnrollingDate": "12/10/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/10/2015",
            "IRBApprovedFrom": "07/06/2015",
            "IRBApprovedTo": "06/19/2017",
            "AccountNbr": "665872",
            "DiseaseSiteListDesc": "Pancreas",
            "Expr1": "Phase II",
            "Tarea": "Pancreatic, Liver, and Related Cancers",
            "TareaCode": "12443",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Precision Biologic",
            "Prescreened": "11",
            "Screenedfailed": "10",
            "SignedICF": "19",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "4",
            "Totalpatients": "19",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Michelle Mikhail,Halyna Hailes",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT01834235",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01839396",
            "SecondaryId": "CDM00049710",
            "BriefTitle": "Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease",
            "OfficialTitle": "Implantable Neurostimulator for the Treatment of Parkinson's Disease",
            "LeadSponsorClass": "Boston Scientific Corporation",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Boston Scientific Corporation",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate the safety and effectiveness of Boston Scientific's\r\n\r\n      Vercise Deep Brain Stimulation (DBS) system in the treatment of patients with with advanced,\r\n\r\n      levodopa-responsive bilateral Parkinson's",
            "Description": "The study is multi-center, prospective, double-blind, randomized (3:1) controlled trial.",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2013",
            "CompletionDate": "July 2021",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Boston Scientific Corporation",
            "StudyCondition": "Parkinson's Disease",
            "studyLocation": "Boston Scientific Clinical Research Information Toll Free Number",
            "Enrollment": "310",
            "NctKeyword": "Intrepid, Vercise, PD, DBS, Boston Scientific,",
            "MeshKeyword": "Parkinson Disease,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of bilateral idiopathic PD (H&Y ≥ 2) with a duration of PD ≥ 5 years.\r\n\r\n\r\n\r\n          -  Persistent disabling Parkinson's disease symptoms or drug side effects (e.g.,\r\n\r\n             dyski",
            "EligibleGender": "All",
            "MinAge": "22 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Valencia",
            "State": "California",
            "Zip": "91355",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 15, 2016",
            "FirstReceived": "April 22, 2013",
            "OverallOfficial": "Jerrold Vitek, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Minnesota, Neurology Department",
            "ContactName": "Roshini Jain",
            "ContactPhone": "(469) 766-9888",
            "ContactEmail": "roshini.jain@bsci.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Boston Scientific Clinical Research Information Toll Free Number",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01839396",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130736 - Boston Scientific Intrepid Study/Boston Scientific - Luca",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20130736",
            "StudyNumber": "20130736 - Boston Scientific Intrepid Study/Boston Scientific - Luca",
            "StudyTitle": "INTREPID STUDY Implantable Neurostimulator for the Treatment of Parkinsons disease CLINICAL PROTOCOL NUMBER:  A5002 STUDY REFERENCE NUMBER:  IDE G120075INTREPID Study",
            "PIID": "2567",
            "PicNum": "C02023921",
            "PILastName": "Luca",
            "PIFirstName": "Corneliu",
            "CoodCNbr": "C10189041",
            "CoordLastName": "Perez",
            "CoordFirstName": "Lissette",
            "CoordEmail": "LPerez4@med.miami.edu",
            "CoordPhone": "3052432781",
            "EnteredByCNbr": "C10189041",
            "EnteredByLastName": "Perez",
            "EnteredByFirstName": "Lissette",
            "ActiveEnrollingDate": "07/22/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/22/2014",
            "IRBApprovedFrom": "02/13/2014",
            "IRBApprovedTo": "04/10/2017",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "2",
            "Screenedfailed": "1",
            "SignedICF": "11",
            "Totalaccrued": "9",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "7",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "12",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Lissette Perez,Stacy Merritt",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT01839396",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01846052",
            "SecondaryId": "1R24EY022023",
            "BriefTitle": "Clinical and Genetic Characterization of Individuals With Achromatopsia",
            "OfficialTitle": "Clinical and Genetic Characterization of Individuals With Achromatopsia",
            "LeadSponsorClass": "Applied Genetic Technologies Corp",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Applied Genetic Technologies Corp",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to identify individuals with achromatopsia caused by mutations\r\n\r\n      in the CNGB3 gene and characterize their clinical condition using several tests of visual\r\n\r\n      function every 6 months for up to 1.5 years.",
            "Description": "Individuals with a clinical diagnosis of achromatopsia will be asked to provide informed\r\n\r\n      consent and will then have a single 5 mL blood sample drawn for DNA sequence analysis of\r\n\r\n      genes known to cause achromatopsia, including the",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "June 2013",
            "CompletionDate": "July 2017",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Applied Genetic Technologies Corp",
            "StudyCondition": "Achromatopsia",
            "studyLocation": "VitreoRetinal Associates",
            "Enrollment": "150",
            "NctKeyword": "achromatopsia, CNGB3,",
            "MeshKeyword": "Color Vision Defects,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Clinical diagnosis of achromatopsia (screening portion of study);\r\n\r\n\r\n\r\n          2. Molecular confirmation of mutations in the CNGB3 gene (main portion of study);\r\n\r\n\r\n\r\n          3. At least 6 years o",
            "EligibleGender": "All",
            "MinAge": "6 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Gainesville",
            "State": "Florida",
            "Zip": "32607",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 29, 2016",
            "FirstReceived": "May 1, 2013",
            "OverallOfficial": "Richard G Weleber, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Casey Eye Institute, Oregon Health & Science University",
            "LocationName": "VitreoRetinal Associates",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01846052",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130604 - National Eye Institute - Lam",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20130604",
            "StudyNumber": "20130604 - National Eye Institute - Lam",
            "StudyTitle": "Clinical and Genetic Characterization of Individuals with Achromatopsia",
            "PIID": "1115",
            "PicNum": "C00679155",
            "PILastName": "Lam",
            "PIFirstName": "Byron",
            "CoodCNbr": "C11276867",
            "CoordLastName": "Verriotto",
            "CoordFirstName": "Jennifer",
            "CoordEmail": "j.verriotto@med.miami.edu",
            "CoordPhone": "3054825186",
            "EnteredByCNbr": "C09893122",
            "EnteredByLastName": "Rosa",
            "EnteredByFirstName": "Potyra",
            "ActiveEnrollingDate": "09/02/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/02/2014",
            "IRBApprovedFrom": "01/07/2014",
            "IRBApprovedTo": "12/16/2016",
            "Expr1": "Other",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "1",
            "Screenedfailed": "8",
            "SignedICF": "14",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "14",
            "FirstNinety": "2",
            "SiteSampleSize": "BPPB:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Alexis Morante,Jennifer Verriotto,Potyra Rosa",
            "NationalSampleSize": "150",
            "NCTNbr": "NCT01846052",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01846611",
            "SecondaryId": "ET743OVC3006",
            "BriefTitle": "A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
            "OfficialTitle": "A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
            "LeadSponsorClass": "Janssen Research & Development, LLC",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Janssen Research & Development, LLC",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a\r\n\r\n      third-line chemotherapy regimen (treatment) in patients with platinum-sensitive\r\n\r\n      advanced-relapsed epithelial ovarian, primary peritoneal,",
            "Description": "This is a randomized (individuals assigned to study treatment by chance), open - label\r\n\r\n      (identity of assigned study drug will be known), active - controlled study in adult female\r\n\r\n      patients with platinum-sensitive advanced - relap",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2013",
            "CompletionDate": "December 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Janssen Research & Development, LLC",
            "StudyCondition": "Ovarian Neoplasms",
            "Enrollment": "670",
            "NctKeyword": "Ovarian neoplasms, Peritoneal neoplasms, Fallopian tube neoplasms, Advanced-relapsed epithelial ovarian cancer, Advanced-relapsed primary peritoneal cancer, Advanced-relapsed fallopian tube cancer, Trabectedin, Yondelis, Doxil, Caelyx, Platinum sensitive,",
            "MeshKeyword": "Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms,",
            "InterventionKeyword": "Dexamethasone, Trabectedin, Liposomal doxorubicin, Doxorubicin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Histologically proven advanced-relapsed epithelial ovarian, primary peritoneal, or\r\n\r\n             fallopian tube cancer\r\n\r\n\r\n\r\n          -  Eastern Cooperative Oncology Group (ECOG) performance status g",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "May 1, 2013",
            "OverallOfficial": "Janssen Research & Development, LLC Clinical Trial",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Janssen Research & Development, LLC",
            "ContactName": "Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:",
            "ContactEmail": "JNJ.CT@sylogent.com",
            "LocationStatus": "Completed",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01846611",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150559 - Janssen Research - Slomovitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150559",
            "StudyNumber": "20150559 - Janssen Research - Slomovitz",
            "StudyTitle": "A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX with DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
            "PIID": "22712",
            "PicNum": "C11916703",
            "PILastName": "Slomovitz",
            "PIFirstName": "Brian",
            "CoodCNbr": "C11920201",
            "CoordLastName": "Moya",
            "CoordFirstName": "Isabel",
            "CoordEmail": "iam18@miami.edu",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "03/17/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/17/2016",
            "IRBApprovedFrom": "12/15/2015",
            "IRBApprovedTo": "12/14/2016",
            "DiseaseSiteListDesc": "Ovary,Other Female Genital",
            "Expr1": "Phase III",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "janssen",
            "SiteSampleSize": "UMMG:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Penny Eyer,Negin Habibi Khameneh,Evan Dadas,Claudia Grandas Moreno,Halyna Hailes,Mohammad El-Sorady",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT01846611",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01848327",
            "SecondaryId": "5559072",
            "BriefTitle": "Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis",
            "OfficialTitle": "A Randomized Double-Blind Placebo-Controlled Study of Caprylic Triglyceride for Cognitive Impairment in Subjects With Multiple Sclerosis.",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "Background/Rationale: Cognitive problems are a common symptom in individuals with Multiple\r\n\r\n      Sclerosis (MS). Treatment options are limited, and there is a pressing need for new\r\n\r\n      interventions to treat MS-related cognitive impairme",
            "Description": "Patients with all types of MS (Relapsing Remitting, Secondary Progressive, or Primary\r\n\r\n      Progressive) are eligible to participate. Participants will undergo detailed cognitive\r\n\r\n      assessment before initiating treatment and again after",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2013",
            "CompletionDate": "March 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Relapsing Remitting MS",
            "studyLocation": "University of Miami Miller School of Medicine",
            "Enrollment": "158",
            "NctKeyword": "Cognition, Neuropsychology, Multiple Sclerosis,",
            "MeshKeyword": "Sclerosis, Multiple Sclerosis, Cognition Disorders,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Institutional Review Board (IRB)-approved Informed Consent Form signed by patient\r\n\r\n\r\n\r\n          2. A diagnosis of MS as defined by the Revised McDonald criteria.\r\n\r\n\r\n\r\n          3. All subtypes of MS",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "59 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 1, 2016",
            "FirstReceived": "April 16, 2013",
            "OverallOfficial": "Leticia Tornes, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Gloria Rodriguez",
            "ContactPhone": "305-243-8052",
            "ContactEmail": "G.Rodriguez8@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Miller School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01848327",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120415 - NATL MULTIPLE SCLEROSIS SOCIETY - Ortega",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20120415",
            "StudyNumber": "20120415 - NATL MULTIPLE SCLEROSIS SOCIETY - Ortega",
            "StudyTitle": "(FastForward) A Randomized DoubleBlind PlaceboControlled Study of Caprylic Triglyceride for Cognitive Impairment in Subjects with Multiple Sclerosis",
            "PIID": "3131",
            "PicNum": "C02493513",
            "PILastName": "Tornes",
            "PIFirstName": "Leticia",
            "CoodCNbr": "C06062326",
            "CoordLastName": "Rodriguez (Neurology)",
            "CoordFirstName": "Gloria",
            "CoordEmail": "grodriguez13@med.miami.edu",
            "CoordPhone": "3052438052",
            "EnteredByCNbr": "C00091169",
            "EnteredByLastName": "Levin",
            "EnteredByFirstName": "Bonnie",
            "ActiveEnrollingDate": "01/31/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/31/2013",
            "IRBApprovedFrom": "01/18/2013",
            "IRBApprovedTo": "12/18/2017",
            "AccountNbr": "66987T",
            "InfoEdNbr": "62350",
            "DiseaseSiteListDesc": "Multiple Sclerosis",
            "Expr1": "Phase II",
            "Tarea": "Multiple Sclerosis",
            "TareaCode": "9837",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "NATL MULTIPLE SCLEROSIS SOCIETY",
            "Prescreened": "7",
            "Screenedfailed": "48",
            "SignedICF": "119",
            "Totalaccrued": "69",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "9",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "119",
            "FirstNinety": "12",
            "SiteSampleSize": "Clinical Research Center (CRC):N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yanet Babcock,Ruta Sawant,Gloria Rodriguez (Neurology)",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01848327",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01854567",
            "SecondaryId": "2012-0166",
            "BriefTitle": "P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies",
            "OfficialTitle": "A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment",
            "LeadSponsorClass": "Mesoblast, Ltd.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Mesoblast, Ltd.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The study investigates the time to engraftment of a mesenchymal expanded cord blood unit in\r\n\r\n      patients with hematologic malignancies undergoing transplantation with myeloablative\r\n\r\n      conditioning.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "February 2013",
            "CompletionDate": "July 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Mesoblast, Ltd.",
            "StudyCondition": "Acute Myelogenous Leukemia",
            "studyLocation": "University of Miami Health System Sylvester Comprehensive Cancer Center",
            "Enrollment": "240",
            "NctKeyword": "Cord Blood, Stem Cells, MPC, Mesoblast, Expanded, AML, ALL, NHL, Leukemia, Lymphoma,",
            "MeshKeyword": "Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, Leukemia, Myeloid, Lymphoma, Non-Hodgkin, Hodgkin Disease, Leukemia, Myeloid, Acute,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patient must have one of the following:\r\n\r\n\r\n\r\n               -  Acute myelogenous leukemia (AML) in complete morphological remission at study\r\n\r\n                  screening (Complete Remission with Inco",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 21, 2016",
            "FirstReceived": "May 13, 2013",
            "OverallOfficial": "Donna Skerrett, MD, MS",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Mesoblast, Ltd.",
            "LocationName": "University of Miami Health System Sylvester Comprehensive Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01854567",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140789 - Mesoblast - Pereira",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140789",
            "StudyNumber": "20140789 - Mesoblast - Pereira",
            "StudyTitle": "A 1-Year Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Umbilical Cord Blood Cells Expanded Ex Vivo with Mesenchymal Precursor Cells for Hematopoietic Recovery in Patients With Hematologic Malignancies After Myeloablative Conditioning",
            "PIID": "423",
            "PicNum": "C00601856",
            "PILastName": "Pereira",
            "PIFirstName": "Denise",
            "CoodCNbr": "C10180073",
            "CoordLastName": "Gonzalez",
            "CoordFirstName": "Nohelia",
            "CoordEmail": "ngonzalez5@med.miami.edu",
            "CoordPhone": "3052434903",
            "EnteredByCNbr": "C11964150",
            "EnteredByLastName": "Smith",
            "EnteredByFirstName": "Nyesha",
            "ActiveEnrollingDate": "09/10/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/10/2015",
            "IRBApprovedFrom": "05/05/2015",
            "IRBApprovedTo": "04/25/2017",
            "AccountNbr": "665336",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma,Multiple Myeloma,Leukemia, Other",
            "Expr1": "Phase III",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Mesoblast, Inc.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Luis",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT01854567",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01857193",
            "BriefTitle": "Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer",
            "OfficialTitle": "A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer",
            "LeadSponsorClass": "Novartis Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novartis Pharmaceuticals",
            "OversightAuthority": "No",
            "BriefSummary": "Dose Escalation part of the study: To estimate the MTD(s) and/ or RP2D of LEE011 in\r\n\r\n      combination with everolimus + exemestane, and LEE011 in combination with exemestane, and to\r\n\r\n      characterize the safety and tolerability of the com",
            "Description": "The primary purpose of the phase Ib part of this study is to determine the maximum tolerated\r\n\r\n      dose(s) (MTD(s)) and/or recommended phase II dose (RP2D) of LEE011 + everolimus + exemestane\r\n\r\n      in patients with ER+ Her2- advanced breas",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2013",
            "CompletionDate": "December 2017",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Novartis",
            "StudyCondition": "Breast Cancer",
            "studyLocation": "Highlands Oncology Group Dept of Highlands Oncology Grp",
            "Enrollment": "142",
            "NctKeyword": "Open label; dose escalation; ER+; LEE011; CDK4/6; everolimus; advanced breast cancer; mTOR; HR positive; HER2 negative,",
            "MeshKeyword": "Breast Neoplasms,",
            "InterventionKeyword": "Exemestane, Everolimus, Sirolimus, Hormones,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Adult women (≥ 18 years of age) with metastatic or locally advanced breast cancer\r\n\r\n\r\n\r\n          -  Histological or cytological confirmation of ER+ and/or PR+ breast cancer\r\n\r\n\r\n\r\n          -  A repres",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Fayetteville",
            "State": "Arkansas",
            "Zip": "72703",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 16, 2017",
            "FirstReceived": "May 16, 2013",
            "OverallOfficial": "Novartis Pharmaceuticals",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Novartis Pharmaceuticals",
            "ContactName": "Novartis Pharmaceuticals",
            "ContactPhone": "1-888-669-6682",
            "LocationStatus": "Recruiting",
            "LocationName": "Highlands Oncology Group Dept of Highlands Oncology Grp",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01857193",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20160061 - Novartis - Mani",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160061",
            "StudyNumber": "20160061 - Novartis - Mani",
            "StudyTitle": "A phase Ib trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with hormone receptor positive HER2 negative locally advanced or metastatic breast cancer",
            "PIID": "25266",
            "PicNum": "C11971128",
            "PILastName": "Mani",
            "PIFirstName": "Aruna",
            "CoodCNbr": "C12030188",
            "CoordLastName": "Salvador",
            "CoordFirstName": "Juan",
            "CoordEmail": "juan.salvador@miami.edu",
            "EnteredByCNbr": "C11917328",
            "EnteredByLastName": "Englund",
            "EnteredByFirstName": "Kristen",
            "ActiveEnrollingDate": "06/01/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/01/2016",
            "IRBApprovedFrom": "03/11/2016",
            "IRBApprovedTo": "03/10/2017",
            "AccountNbr": "666921",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase I",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Novatis",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Yvonne Dinh,Daniel Sumarriva,Sandra Pineda,Tamara Leon Aliz,Karen Blackburn",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01857193",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01858519",
            "BriefTitle": "Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy",
            "OfficialTitle": "A Point Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors",
            "LeadSponsorClass": "AbbVie",
            "SponsorAgency": "Industry",
            "LeadSponsor": "AbbVie",
            "OversightAuthority": "No",
            "BriefSummary": "This is a point prevalence study conducted entirely in the United States (US) to establish\r\n\r\n      the prevalence of antibodies to hepatitis E virus (HEV) and other selected porcine viruses\r\n\r\n      in cystic fibrosis (CF) patients receiving pa",
            "Description": "This is a multicenter, non-interventional point-prevalence study conducted in the US to\r\n\r\n      determine the seroprevalence of antibodies to selected porcine viruses in pancreatic enzyme\r\n\r\n      replacement therapy-exposed CF patients and in",
            "OverallStatus": "Completed",
            "StartDate": "August 2013",
            "CompletionDate": "September 2016",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "AbbVie",
            "StudyCondition": "Cystic Fibrosis",
            "studyLocation": "Site Reference ID/Investigator# 116382",
            "Enrollment": "1310",
            "NctKeyword": "pancreatic enzyme replacement therapy, antibodies, porcine viruses, epidemiology, prospective,",
            "MeshKeyword": "Fibrosis, Cystic Fibrosis,",
            "InterventionKeyword": "Antibodies, Immunoglobulins,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        All Patients (PERT-exposed and unexposed controls) must meet the following criteria:\r\n\r\n\r\n\r\n          -  Have a blood draw planned as part of their standard of care following enrollment into\r\n\r\n             t",
            "EligibleGender": "All",
            "MinAge": "2 Years",
            "MaxAge": "99 Years",
            "Volunteers": "No",
            "City": "Anchorage",
            "State": "Alaska",
            "Zip": "99508",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 19, 2016",
            "FirstReceived": "May 17, 2013",
            "OverallOfficial": "Gerhard J Leitz, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Janssen Research & Development, LLC",
            "LocationName": "Site Reference ID/Investigator# 116382",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01858519",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130454 - Aptalis Pharma/ Inc./Janssen Pharmaceuticals/AbbVi - Salathe",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20130454",
            "StudyNumber": "20130454 - Aptalis Pharma/ Inc./Janssen Pharmaceuticals/AbbVi - Salathe",
            "StudyTitle": "JSPP1201  A Point Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients with Cystic Fibrosis Who Are Receiving PorcineDerived Pancreatic Enzyme Replacement Therapy: A HarmonizedProtocol Across Sponsors",
            "PIID": "528",
            "PicNum": "C00319179",
            "PILastName": "Salathe",
            "PIFirstName": "Matthias",
            "CoodCNbr": "C00319179",
            "CoordLastName": "Salathe",
            "CoordFirstName": "Matthias",
            "CoordEmail": "MSalathe@med.miami.edu",
            "CoordPhone": "305-243-2975",
            "EnteredByCNbr": "C00319179",
            "EnteredByLastName": "Salathe",
            "EnteredByFirstName": "Matthias",
            "ActiveEnrollingDate": "05/05/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/05/2014",
            "IRBApprovedFrom": "01/24/2014",
            "IRBApprovedTo": "11/02/2016",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "Aptalis Pharma/ Inc./Janssen Pharmaceuticals/AbbVie",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "26",
            "Totalaccrued": "26",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "26",
            "FirstNinety": "11",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Eliana Mendes,Henry Boza,Carolina Aguiar,Patricia Graham-Borras,Johana Arana",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT01858519",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01862640",
            "BriefTitle": "A Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",
            "OfficialTitle": "A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of th",
            "LeadSponsorClass": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "To compare the efficacy of 2 fixed doses of brexpiprazole with placebo in subjects with\r\n\r\n      agitation associated with dementia of the Alzheimer's type.",
            "Description": "Behavioral symptoms, such as agitation, are core features in subjects with Alzheimer's\r\n\r\n      disease and related dementias and develop in the majority of dementia subjects. The presence\r\n\r\n      of agitation in subjects with Alzheimer's disea",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "July 2013",
            "CompletionDate": "April 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
            "StudyCondition": "Agitation Associated With",
            "Enrollment": "433",
            "NctKeyword": "OPC-34712, brexpiprazole, Dementia, Alzheimer's Disease, Cognitive Disorders, Memory, Agitation,",
            "MeshKeyword": "Alzheimer Disease, Dementia, Psychomotor Agitation, Mental Disorders, Psychotic Disorders, Nervous System Diseases,",
            "InterventionKeyword": "Brexpiprazole,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male and female subjects 55 to 90 years of age, inclusive, at the time of informed\r\n\r\n             consent.\r\n\r\n\r\n\r\n          -  Subjects who are residing at their current location for at least 14 days be",
            "EligibleGender": "All",
            "MinAge": "55 Years",
            "MaxAge": "90 Years",
            "Volunteers": "No",
            "City": "Tuscaloosa",
            "State": "Alabama",
            "Zip": "35404",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 6, 2017",
            "FirstReceived": "May 22, 2013",
            "OverallOfficial": "Eva Kohegyi, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01862640",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140411 - Otsuka America Pharmaceutical - Crocco",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20140411",
            "StudyNumber": "20140411 - Otsuka America Pharmaceutical - Crocco",
            "StudyTitle": "A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole (OPC-34712) in the Treatment of Subjects with Agitation Associated with Dementia of the Alzheimer’s Type",
            "PIID": "3693",
            "PicNum": "C00802143",
            "PILastName": "Crocco",
            "PIFirstName": "Elizabeth",
            "CoodCNbr": "C04892431",
            "CoordLastName": "Brenson",
            "CoordFirstName": "Nicole",
            "CoordEmail": "nbrenson@med.miami.edu",
            "CoordPhone": "3053558186",
            "EnteredByCNbr": "C00802143",
            "EnteredByLastName": "Crocco",
            "EnteredByFirstName": "Elizabeth",
            "ActiveEnrollingDate": "05/04/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/04/2015",
            "IRBApprovedFrom": "10/07/2014",
            "IRBApprovedTo": "08/15/2017",
            "AccountNbr": "brobertson",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Otsuka America Pharmaceutical",
            "Prescreened": "6",
            "Screenedfailed": "5",
            "SignedICF": "4",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Tania Guardia,Gabriela Vargas,Belinda Robertson,Nicole Brenson",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01862640",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01863550",
            "SecondaryId": "NCI-2012-02608",
            "BriefTitle": "Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma",
            "OfficialTitle": "Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma",
            "LeadSponsorClass": "ECOG-ACRIN Cancer Research Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "ECOG-ACRIN Cancer Research Group",
            "BriefSummary": "This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see\r\n\r\n      how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating\r\n\r\n      patients with newly diagnosed multiple myeloma. B",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To compare the overall survival between two strategies of lenalidomide maintenance\r\n\r\n      following induction with a proteasome inhibitor-IMiD (lenalidomide) combination: limited\r\n\r\n      duration of mainten",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2013",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Eastern Cooperative Oncology Group",
            "StudyCondition": "Stage I Multiple Myeloma",
            "studyLocation": "Mayo Clinic in Arizona",
            "Enrollment": "756",
            "MeshKeyword": "Multiple Myeloma, Neoplasms, Plasma Cell,",
            "InterventionKeyword": "Dexamethasone acetate, Dexamethasone, Dexamethasone 21-phosphate, Lenalidomide, Thalidomide, Bortezomib, BB 1101,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  STEP I: Patients must be diagnosed with symptomatic standard-risk multiple myeloma\r\n\r\n             (SR-MM) as defined by all of the following:\r\n\r\n\r\n\r\n               -  No evidence of t(4;14), t(14;16),t(",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Scottsdale",
            "State": "Arizona",
            "Zip": "85259",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 14, 2016",
            "FirstReceived": "May 6, 2013",
            "OverallOfficial": "Shaji Kumar",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Eastern Cooperative Oncology Group",
            "LocationStatus": "Suspended",
            "LocationName": "Mayo Clinic in Arizona",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01863550",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20160548 - ECOG - Hoffman",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160548",
            "StudyNumber": "20160548 - ECOG - Hoffman",
            "StudyTitle": "Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).",
            "PIID": "4418",
            "PicNum": "C11465246",
            "PILastName": "Hoffman",
            "PIFirstName": "James",
            "CoodCNbr": "C11964599",
            "CoordLastName": "Martinez",
            "CoordFirstName": "Micaela",
            "CoordEmail": "mem334@miami.edu",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "12/19/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/19/2016",
            "IRBApprovedFrom": "11/15/2013",
            "IRBApprovedTo": "02/17/2017",
            "DiseaseSiteListDesc": "Multiple Myeloma",
            "Expr1": "Phase III",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UMD:N/A,UMHC:N/A,UM Kendall:N/A,SCCC Plantation:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Penny Eyer,Rachel Pallapati,Nathalie Luis,Carla Munevar,Evan Dadas,Halyna Hailes,Anthony Minichiello",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01863550",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01865812",
            "BriefTitle": "Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis",
            "OfficialTitle": "A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis",
            "LeadSponsorClass": "Intercept Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Intercept Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine if obeticholic acid (OCA) has an effect on\r\n\r\n      cholesterol levels in the blood in patients with PBC.",
            "Description": "This was a phase 2, open-label, multicenter study evaluating the effects of OCA on\r\n\r\n      lipoprotein metabolism in subjects with PBC; in particular, OCA's effects on high density\r\n\r\n      lipoprotein (HDL) cholesterol. Nuclear magnetic resona",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "November 2013",
            "CompletionDate": "October 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Intercept Pharmaceuticals",
            "StudyCondition": "Primary Biliary Cirrhosis",
            "studyLocation": "Scripps Clinic",
            "Enrollment": "26",
            "MeshKeyword": "Fibrosis, Liver Cirrhosis, Liver Cirrhosis, Biliary,",
            "InterventionKeyword": "Chenodeoxycholic Acid,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Definite or probable primary biliary cirrhosis (PBC) diagnosis as demonstrated by the\r\n\r\n             presence of ≥ 2 of the following 3 diagnostic factors:\r\n\r\n\r\n\r\n               -  History of elevated a",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "La Jolla",
            "State": "California",
            "Zip": "92037",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 25, 2016",
            "FirstReceived": "May 23, 2013",
            "OverallOfficial": "David Shapiro, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Intercept Pharmaceuticals",
            "LocationName": "Scripps Clinic",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01865812",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130468 - Intercept Pharmaceuticals/ Inc./Intercept Pharmace - Levy",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20130468",
            "StudyNumber": "20130468 - Intercept Pharmaceuticals/ Inc./Intercept Pharmace - Levy",
            "StudyTitle": "Intercept 747205 Obeticholic Acid (OCA) A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects with Primary Biliary Cirrhosis",
            "PIID": "2230",
            "PicNum": "C09420731",
            "PILastName": "Levy",
            "PIFirstName": "Cynthia",
            "CoodCNbr": "C09867766",
            "CoordLastName": "Rodriguez-Bravo",
            "CoordFirstName": "Odalys",
            "CoordEmail": "obravo@med.miami.edu",
            "CoordPhone": "3052434648",
            "EnteredByCNbr": "C05096461",
            "EnteredByLastName": "Quezada",
            "EnteredByFirstName": "Lia",
            "ActiveEnrollingDate": "11/12/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/12/2013",
            "IRBApprovedFrom": "08/26/2013",
            "IRBApprovedTo": "05/08/2017",
            "AccountNbr": "662035",
            "InfoEdNbr": "67233",
            "Expr1": "Phase II",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "4",
            "FirstNinety": "2",
            "SiteSampleSize": "UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Sonia Carvalho,Odalys Rodriguez-Bravo",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT01865812",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01867580",
            "BriefTitle": "A Prospective, Multi-Center Trial Evaluating the Effectiveness of the V.A.C. Ulta Negative Pressure Wound Therapy System With V.A.C. VeraFlo Dressing System in Operatively Debrided Wounds",
            "OfficialTitle": "A Prospective, Randomized, Multi-Center Trial Evaluating the Effectiveness of the V.A.C. Ulta Negative Pressure Wound Therapy System With V.A.C. VeraFlo Dressing System in Operatively Debrided Wounds",
            "LeadSponsorClass": "KCI USA, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "KCI USA, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to examine the effectiveness of the V.A.C.Ulta Negative\r\n\r\n      Pressure Wound Therapy System and V.A.C. VeraFlo Dressing System in wounds that require\r\n\r\n      operative debridement.",
            "OverallStatus": "Completed",
            "StartDate": "May 2013",
            "CompletionDate": "November 2015",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "KCI USA, Inc.",
            "StudyCondition": "Wounds and Injuries",
            "studyLocation": "Medstar Georgetown University Hospital",
            "Enrollment": "183",
            "MeshKeyword": "Wounds and Injuries,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        The Subject:\r\n\r\n\r\n\r\n          -  has a wound prior to informed consent\r\n\r\n\r\n\r\n          -  will be admitted as an inpatient\r\n\r\n\r\n\r\n          -  is >= 18 years of age at time of consent\r\n\r\n\r\n\r\n          -  is",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Washington DC",
            "State": "District of Columbia",
            "Zip": "20007",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 30, 2016",
            "FirstReceived": "May 9, 2013",
            "LocationName": "Medstar Georgetown University Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01867580",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130299 - Kinetic Concepts/ Inc. (KCI)/KCI/KCI USA/ Inc. - Salgado",
            "FileProcessContentId": "440",
            "Division": "Surgery",
            "StdyDivision": "7805",
            "EprostNbr": "20130299",
            "StudyNumber": "20130299 - Kinetic Concepts/ Inc. (KCI)/KCI/KCI USA/ Inc. - Salgado",
            "StudyTitle": "A Prospective, Randomized, MultiCenter Trial Evaluating the Effectiveness of the V.A.C. Ulta Negative Pressure Wound Therapy System with V.A.C. Veraflo Dressing System in Operatively Debrided Wounds",
            "PIID": "4590",
            "PicNum": "C09894081",
            "PILastName": "Salgado",
            "PIFirstName": "Christopher",
            "CoodCNbr": "C09894081",
            "CoordLastName": "Salgado",
            "CoordFirstName": "Christopher",
            "EnteredByCNbr": "C09894081",
            "EnteredByLastName": "Salgado",
            "EnteredByFirstName": "Christopher",
            "ActiveEnrollingDate": "06/13/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/13/2014",
            "IRBApprovedFrom": "09/17/2013",
            "IRBApprovedTo": "12/17/2016",
            "InfoEdNbr": "66161",
            "Expr1": "Other",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "25",
            "Totalaccrued": "22",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "25",
            "FirstNinety": "7",
            "SiteSampleSize": "UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Priscila Sanchez,Natalie Joumblat",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01867580",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01868997",
            "SecondaryId": "FD004792-01A1",
            "BriefTitle": "Teprotumumab Treatment in Patients With Active Thyroid Eye Disease",
            "OfficialTitle": "A Multicenter, Double-masked, Placebo-controlled, Efficacy and Safety Study of an Insulin-like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), in Patients With Active Thyroid Eye Disease",
            "LeadSponsorClass": "River Vision Development Corporation",
            "SponsorAgency": "Industry",
            "LeadSponsor": "River Vision Development Corporation",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate the safety, tolerability and effectiveness of a\r\n\r\n      fully human antibody compared to placebo in the treatment of patients with active thyroid\r\n\r\n      eye disease.\r\n\r\n\r\n\r\n      \"Funding Source - FDA",
            "Description": "A multicenter, double-masked, placebo-controlled, efficacy and safety study of RV 001, an\r\n\r\n      insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human),\r\n\r\n      administered every 3 weeks (q3W) by intravenous (iv) in",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "July 2013",
            "CompletionDate": "March 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "River Vision Development Corporation",
            "StudyCondition": "Thyroid Associated Ophthalmopathies",
            "studyLocation": "Jules Stein Eye Institute at UCLA",
            "Enrollment": "84",
            "NctKeyword": "Thyroid Eye Disease, Graves Orbitopathy, Thyroid Associated, Ophthalmopathy,",
            "MeshKeyword": "Thyroid Diseases, Eye Diseases, Graves Ophthalmopathy,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Clinical diagnosis of Graves'disease associated with active thyroid eye disease and a\r\n\r\n             clinical activity score of >4\r\n\r\n\r\n\r\n          -  Fewer than 9 months from onset of thyroid eye disea",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90095",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 23, 2016",
            "FirstReceived": "May 2, 2013",
            "OverallOfficial": "Raymond S Douglas, MD,PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Michigan",
            "LocationName": "Jules Stein Eye Institute at UCLA",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01868997",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130104 - RIVER VISION DEV CORP - Lam",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20130104",
            "StudyNumber": "20130104 - RIVER VISION DEV CORP - Lam",
            "StudyTitle": "A multicenter, doublemasked, placebocontrolled, efficacy and safety study of RV 001, an insulinlike growth factor1 receptor (IGF1R) antagonist antibody (fully human), administered every 3 weeks (q3W) by intravenous (iv) infusion in patients suffering from",
            "PIID": "1115",
            "PicNum": "C00679155",
            "PILastName": "Lam",
            "PIFirstName": "Byron",
            "CoodCNbr": "C11276867",
            "CoordLastName": "Verriotto",
            "CoordFirstName": "Jennifer",
            "CoordEmail": "j.verriotto@med.miami.edu",
            "CoordPhone": "3054825186",
            "EnteredByCNbr": "C07458455",
            "EnteredByLastName": "Morante",
            "EnteredByFirstName": "Alexis",
            "ActiveEnrollingDate": "02/05/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/05/2014",
            "IRBApprovedFrom": "06/10/2013",
            "IRBApprovedTo": "05/22/2015",
            "InfoEdNbr": "65616",
            "Tarea": "Neuro-Ophthalmology",
            "TareaCode": "13137",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "0",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "BPPB:N/A,UMMG:N/A,ABLEH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Potyra Rosa,Jennifer Verriotto",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01868997",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01872975",
            "SecondaryId": "NCI-2012-03198",
            "BriefTitle": "Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery",
            "OfficialTitle": "A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axilla",
            "LeadSponsorClass": "NSABP Foundation Inc",
            "SponsorAgency": "Other",
            "LeadSponsor": "NSABP Foundation Inc",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase III trial studies standard or comprehensive radiation therapy in\r\n\r\n      treating patients with early-stage breast cancer who have undergone surgery. Radiation\r\n\r\n      therapy uses high-energy x rays to kill tumor cells.",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      To evaluate whether the addition of chest wall + regional nodal radiation therapy (XRT)\r\n\r\n      after mastectomy or breast + regional nodal XRT after breast conserving surgery will\r\n\r\n      significantly reduce",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2013",
            "CompletionDate": "August 2028",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "NSABP Foundation Inc",
            "StudyCondition": "Stage IB Breast Cancer",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "1636",
            "MeshKeyword": "Breast Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  The patient must have signed and dated an Institutional Review Board (IRB)-approved\r\n\r\n             consent form that conforms to federal and institutional guidelines\r\n\r\n\r\n\r\n          -  The patient must",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 4, 2016",
            "FirstReceived": "June 3, 2013",
            "OverallOfficial": "Norman Wolmark, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "NSABP Foundation Inc",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01872975",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130534 - NSABP - Takita",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20130534",
            "StudyNumber": "20130534 - NSABP - Takita",
            "StudyTitle": "RTOG1304: NSABP B51:  A Randomized Phase III Clinical Trial Evaluating PostMastectomy Chestwall and Reginal Nodal XRT and PostLumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy",
            "PIID": "278",
            "PicNum": "C00550352",
            "PILastName": "Takita",
            "PIFirstName": "Cristiane",
            "CoodCNbr": "C00294869",
            "CoordLastName": "Martin",
            "CoordFirstName": "Doris",
            "CoordEmail": "dmartin3@med.miami.edu",
            "CoordPhone": "3052435491",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "08/14/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/18/2014",
            "IRBApprovedFrom": "01/16/2014",
            "IRBApprovedTo": "04/06/2017",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase III",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "NSABP",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "8",
            "Totalaccrued": "7",
            "InFollowUp": "5",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "8",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,JMH:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Marinellie Vega,Fernando Vazquez Pascual,Lilibet Zamora Cabezas,Maggie Chislom,Lilly Sanchez,Greeyt Hernandez",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01872975",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01891760",
            "BriefTitle": "Long-Term Follow-Up to the DEVO Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers",
            "OfficialTitle": "A Prospective, Multi-center, Longitudinal, Cohort Study of Dermagraft in Subjects With Venous Leg Ulcers: A Long-term Follow-up to the DEVO-Trial",
            "LeadSponsorClass": "Shire Regenerative Medicine, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Shire Regenerative Medicine, Inc.",
            "BriefSummary": "-  Observe the long-term (1-year) outcomes of Dermagraft, compared with conventional\r\n\r\n           treatment of four-layer compression bandaging therapy alone, in subjects who completed\r\n\r\n           the ABH-Dermagraft-001-08 study.",
            "OverallStatus": "Completed",
            "StartDate": "May 2010",
            "CompletionDate": "June 2012",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Shire Regenerative Medicine, Inc.",
            "StudyCondition": "Venous Leg Ulcer",
            "studyLocation": "Carl T. Hayden VA Medical Center",
            "Enrollment": "225",
            "MeshKeyword": "Ulcer, Leg Ulcer, Varicose Ulcer,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Subject has completed study ABH-Dermagraft-001-08\r\n\r\n\r\n\r\n          2. Subject understands study requirements\r\n\r\n\r\n\r\n          3. Subject is available to participate in the 1 year-long observational follo",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85012",
            "Country": "United States",
            "VerificationDate": "August 2013",
            "LastChanged": "August 9, 2013",
            "FirstReceived": "June 28, 2013",
            "OverallOfficial": "Mollie Carter, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Shire Regenerative Medicine",
            "LocationName": "Carl T. Hayden VA Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01891760",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20100317 - Advanced BioHealing - Kirsner",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20100317",
            "StudyNumber": "20100317 - Advanced BioHealing - Kirsner",
            "StudyTitle": "A Prospective, Multicenter, Longitudinal, Cohort Study of Dermagraft in Subjects with Venous leg Ulcers: A long-Term Follow Up to the DEVO Trial.",
            "PIID": "717",
            "PicNum": "C00519753",
            "PILastName": "Kirsner",
            "PIFirstName": "Robert",
            "CoodCNbr": "C03040252",
            "CoordLastName": "Espinosa",
            "CoordFirstName": "Aliette",
            "CoordEmail": "aespinosa@med.miami.edu",
            "CoordPhone": "3056893376",
            "EnteredByCNbr": "C00519753",
            "EnteredByLastName": "Kirsner",
            "EnteredByFirstName": "Robert",
            "ActiveEnrollingDate": "05/25/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/25/2010",
            "IRBApprovedFrom": "05/18/2010",
            "IRBApprovedTo": "02/21/2014",
            "InfoEdNbr": "52834",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "Advanced BioHealing",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMH:15",
            "AccrualPercentageMet": "6.66666666666666666666666666666666666667",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "15",
            "EprostState": "Approved",
            "StudyCoordinator": "Martha Doty,Aliette Espinosa,Carol Kittles",
            "AgentDevices": "Device: Dermagraft",
            "StudyObjective": "The primary objective is to observe the long-term (1 year) outcomes of Dermagraft, compared with conventional treatment of 4 layer compression bandaging therapy alone, in subjects who completed the study ABH-Dermagraft-001-08, eProst # 20090226. This will be measured by the incidence of study ulcer recurrence during the 1 year observational period.\r\nThis primary outcome will be evaluated only on subjects from each cohort who entered the i year follow up period with a healed ulcer.\r\n\r\nA secondary objective will be the incidence of complete study ulcer healing over the 1 year observational period for all study ulcers not healed at the time of enrollment.",
            "NationalSampleSize": "450",
            "NCTNbr": "NCT01891760",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "1",
            "StudyInvINDNbr": "G090056",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT01892345",
            "BriefTitle": "A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study)",
            "OfficialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)",
            "LeadSponsorClass": "Alexion Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Alexion Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "The primary objective of the study is to assess the efficacy and safety of eculizumab\r\n\r\n      treatment as compared to placebo in relapsing NMO patients using a time to first relapse\r\n\r\n      study design.",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2014",
            "CompletionDate": "December 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Alexion Pharmaceuticals",
            "StudyCondition": "Neuromyelitis Optica",
            "studyLocation": "Alabama Neurology Associates",
            "Enrollment": "132",
            "NctKeyword": "Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Devic's disease, Transverse Myelitis, Optic Neuritis, relapse, eculizumab, soliris, NMO-IgG, CNS Autoimmune Disorders, Demyelinating Disorders,",
            "MeshKeyword": "Neuromyelitis Optica,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Male or female patients ≥ 18 years old\r\n\r\n\r\n\r\n          2. Diagnosis of NMO or NMO spectrum disorder\r\n\r\n\r\n\r\n          3. All patients must be NMO-IgG seropositive\r\n\r\n\r\n\r\n          4. Clinical evidenc",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Homewood",
            "State": "Alabama",
            "Zip": "35209",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 11, 2016",
            "FirstReceived": "June 20, 2013",
            "ContactName": "Alexion Pharmaceuticals (Sponsor)",
            "ContactPhone": "1-855-687-1988",
            "ContactEmail": "clinicaltrials@alxn.com",
            "LocationStatus": "Withdrawn",
            "LocationName": "Alabama Neurology Associates",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01892345",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140126 - Alexion Pharmaceuticals - Sheremata",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140126",
            "StudyNumber": "20140126 - Alexion Pharmaceuticals - Sheremata",
            "StudyTitle": "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,\nMULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF\nECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)",
            "PIID": "121",
            "PicNum": "C00457629",
            "PILastName": "Sheremata",
            "PIFirstName": "William",
            "CoodCNbr": "C00168827",
            "CoordLastName": "Sawant",
            "CoordFirstName": "Ruta",
            "EnteredByCNbr": "C00457629",
            "EnteredByLastName": "Sheremata",
            "EnteredByFirstName": "William",
            "ActiveEnrollingDate": "11/17/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/17/2014",
            "IRBApprovedFrom": "06/02/2014",
            "IRBApprovedTo": "05/15/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Alexion Pharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "2",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yanet Babcock,Gloria Rodriguez (Neurology)",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT01892345",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01892397",
            "BriefTitle": "Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma",
            "OfficialTitle": "Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma",
            "LeadSponsorClass": "Memorial Sloan Kettering Cancer Center",
            "SponsorAgency": "Other",
            "LeadSponsor": "Memorial Sloan Kettering Cancer Center",
            "BriefSummary": "The purpose of this study is to find out what effects, good or bad, the Optune device has on\r\n\r\n      the patient and meningioma. This study is being done because currently there are no proven\r\n\r\n      effective medical treatments for a progress",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2013",
            "CompletionDate": "June 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Memorial Sloan Kettering Cancer Center",
            "StudyCondition": "Brain Cancer",
            "studyLocation": "Cedars-Sinai Medical Center",
            "Enrollment": "21",
            "NctKeyword": "intracranial supratentorial meningioma, Atypical and Anaplastic Meningioma, Optune (NovoTTF-100A), 13-067,",
            "MeshKeyword": "Meningioma, Brain Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Histologically proven recurrent WHO grade II (atypical) or grade III (anaplastic)\r\n\r\n             intracranial supratentorial meningioma. MSKCC central review of histology is not\r\n\r\n             required",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "11725",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 17, 2016",
            "FirstReceived": "July 1, 2013",
            "OverallOfficial": "Thomas Kaley, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Memorial Sloan Kettering Cancer Center",
            "ContactName": "Thomas Kaley, MD",
            "ContactPhone": "212-639-5122",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "Cedars-Sinai Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01892397",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20141010 - Memorial Sloan Kettering - De La Fuente",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20141010",
            "StudyNumber": "20141010 - Memorial Sloan Kettering - De La Fuente",
            "StudyTitle": "Pilot Study of NovoTTF-100A for Recurrent Atypical and Anaplastic Meningioma",
            "PIID": "22734",
            "PicNum": "C11916526",
            "PILastName": "De La Fuente",
            "PIFirstName": "Macarena",
            "CoodCNbr": "C04228283",
            "CoordLastName": "Garcia",
            "CoordFirstName": "Helen",
            "CoordEmail": "heg32@med.miami.edu",
            "EnteredByCNbr": "C07181703",
            "EnteredByLastName": "Zhang",
            "EnteredByFirstName": "Lei",
            "ActiveEnrollingDate": "10/19/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/19/2015",
            "IRBApprovedFrom": "06/02/2015",
            "IRBApprovedTo": "05/16/2017",
            "AccountNbr": "665796",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "Pilot/Feasibility",
            "Tarea": "Neurological Cancer",
            "TareaCode": "12442",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "Externally Peer Reviewed",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Luis",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT01892397",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01892722",
            "SecondaryId": "2011-005677-23",
            "BriefTitle": "Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis",
            "OfficialTitle": "Two-year, Double-blind, Randomzied, Multicenter, Active-controlled Study to Evaluate Safety and Efficacy of Oral Fingolimod Versus Interferon Beta-1a i.m. in Pediatric Patients With Multiple Sclerosis",
            "LeadSponsorClass": "Novartis Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novartis Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pedaitric\r\n\r\n      patients with multiple sclerosis",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2013",
            "CompletionDate": "March 2023",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Novartis",
            "StudyCondition": "Multiple Sclerosis",
            "studyLocation": "Novartis Investigative Site",
            "Enrollment": "190",
            "NctKeyword": "pediatric, multiple sclerosis,",
            "MeshKeyword": "Sclerosis, Multiple Sclerosis,",
            "InterventionKeyword": "Interferons, Interferon-beta, Interferon beta-1a, Fingolimod Hydrochloride,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  diagnosis of multiple sclerosis\r\n\r\n\r\n\r\n          -  at least one MS relapse during the previous year or two MS relapses in the previous 2\r\n\r\n             years or evidence of Gd enhancing lesions on MRI",
            "EligibleGender": "All",
            "MinAge": "10 Years",
            "MaxAge": "17 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 10, 2016",
            "FirstReceived": "May 8, 2013",
            "OverallOfficial": "Novartis Pharmaceuticals",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Novartis Pharmaceuticals",
            "ContactName": "Novartis Pharmaceuticals",
            "ContactPhone": "1-888-669-6682",
            "LocationStatus": "Active, not recruiting",
            "LocationName": "Novartis Investigative Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01892722",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130971 - Novartis - Rammohan",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20130971",
            "StudyNumber": "20130971 - Novartis - Rammohan",
            "StudyTitle": "A two-year, double-blind, randomized, multicenter, activecontrolled\nCore Phase study to evaluate the safety and\nefficacy of fingolimod administered orally once daily\nversus interferon ß-1a i.m. once weekly in pediatric\npatients with multiple sclerosis with five-year fingolimod\nExtension Phase",
            "PIID": "3260",
            "PicNum": "C09913828",
            "PILastName": "Rammohan",
            "PIFirstName": "Kottil",
            "CoodCNbr": "C00168827",
            "CoordLastName": "Sawant",
            "CoordFirstName": "Ruta",
            "EnteredByCNbr": "C09913828",
            "EnteredByLastName": "Rammohan",
            "EnteredByFirstName": "Kottil",
            "ActiveEnrollingDate": "02/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/08/2016",
            "IRBApprovedFrom": "06/02/2014",
            "IRBApprovedTo": "04/17/2017",
            "InfoEdNbr": "68612",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Novartis",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Gloria Rodriguez (Neurology),Yanet Babcock",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT01892722",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01897532",
            "SecondaryId": "2011-004148-23",
            "BriefTitle": "Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)",
            "OfficialTitle": "CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular",
            "LeadSponsorClass": "Boehringer Ingelheim",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Boehringer Ingelheim",
            "BriefSummary": "The aim of the study is to investigate the longterm impact on cardiovascular morbidity,\r\n\r\n      mortality and renal function of treatment with linagliptin in a selected population of\r\n\r\n      patients with T2DM and to compare outcomes against p",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "July 2013",
            "CompletionDate": "January 2018",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "Boehringer Ingelheim",
            "StudyCondition": "Diabetes Mellitus, Type 2",
            "studyLocation": "Boehringer Ingelheim Investigational Site",
            "Enrollment": "8300",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 2,",
            "InterventionKeyword": "Linagliptin,",
            "Eligibility": "Inclusion criteria:\r\n\r\n\r\n\r\n          1. Documented diagnosis of T2DM before visit 1(screening).\r\n\r\n\r\n\r\n          2. Male or female patients who are drug-naïve or pre-treated with any antidiabetic\r\n\r\n             background medication, excludin",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Huntsville",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 21, 2016",
            "FirstReceived": "July 9, 2013",
            "OverallOfficial": "Boehringer Ingelheim",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Boehringer Ingelheim",
            "LocationName": "Boehringer Ingelheim Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01897532",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150622 - Boehringer Ingelheim - Miranda-Palma",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20150622",
            "StudyNumber": "20150622 - Boehringer Ingelheim - Miranda-Palma",
            "StudyTitle": "A multicenter, international, randomized, parallel group, double blind,\nplacebo-controlled CArdiovascular Safety & Renal Microvascular\noutcomE study with LINAgliptin, 5 mg once daily in patients with type 2\ndiabetes mellitus at high vascular risk\nCARMELINA",
            "PIID": "1111",
            "PicNum": "C02129536",
            "PILastName": "Miranda-Palma",
            "PIFirstName": "Bresta",
            "CoodCNbr": "C00121533",
            "CoordLastName": "Masters",
            "CoordFirstName": "Burlett",
            "CoordEmail": "bmasters2@med.miami.edu",
            "CoordPhone": "305-243-5354",
            "EnteredByCNbr": "C02129536",
            "EnteredByLastName": "Miranda-Palma",
            "EnteredByFirstName": "Bresta",
            "ActiveEnrollingDate": "04/27/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/27/2016",
            "IRBApprovedFrom": "09/01/2015",
            "IRBApprovedTo": "09/05/2017",
            "Expr1": "Phase IV",
            "Tarea": "Diabetes (Type II)",
            "TareaCode": "12544",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Boehringer Ingelheim",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Burlett Masters,Ada Konwai",
            "NationalSampleSize": "40",
            "NCTNbr": "NCT01897532",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01897896",
            "BriefTitle": "Alternatives for Reducing Chorea in HD",
            "OfficialTitle": "An Open Label, Long Term Safety Study of SD-809 ER in Patients With Chorea Associated With Huntington Disease",
            "LeadSponsorClass": "Auspex Pharmaceuticals, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Auspex Pharmaceuticals, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of\r\n\r\n      SD-809 ER in subjects switching from tetrabenazine to SD-809 ER. In addition, the safety and\r\n\r\n      tolerability of long term treatment with SD-",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "November 2013",
            "CompletionDate": "October 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Teva Pharmaceutical Industries",
            "StudyCondition": "Chorea Associated With Huntington Disease",
            "studyLocation": "Teva Investigational Site 057",
            "Enrollment": "238",
            "NctKeyword": "Chorea, Huntington Disease,",
            "MeshKeyword": "Huntington Disease, Chorea,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Subject is at least 18 years of age or the age of majority (whichever is older) at\r\n\r\n             Screening.\r\n\r\n\r\n\r\n          2. Subject has been diagnosed with manifest HD, as indicated by characterist",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 1, 2016",
            "FirstReceived": "June 14, 2013",
            "OverallOfficial": "Teva Medical Expert, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "TEVA",
            "LocationName": "Teva Investigational Site 057",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01897896",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130799 - Auspex Pharmaceuticals/ Inc. - Singer",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20130799",
            "StudyNumber": "20130799 - Auspex Pharmaceuticals/ Inc. - Singer",
            "StudyTitle": "ARC HD Study:  An OpenLabel, Long Term Safety Study of SD809 ER in Subjects With Chorea Associated With Huntington Disease.",
            "PIID": "143",
            "PicNum": "C00407776",
            "PILastName": "Singer",
            "PIFirstName": "Carlos",
            "CoodCNbr": "C06927480",
            "CoordLastName": "Padron",
            "CoordFirstName": "Nathalie",
            "CoordEmail": "npadron@med.miami.edu",
            "CoordPhone": "3052433530",
            "EnteredByCNbr": "C06927480",
            "EnteredByLastName": "Padron",
            "EnteredByFirstName": "Nathalie",
            "ActiveEnrollingDate": "08/20/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/20/2014",
            "IRBApprovedFrom": "07/21/2014",
            "IRBApprovedTo": "05/25/2017",
            "InfoEdNbr": "68637",
            "Expr1": "Phase III",
            "Tarea": "Movement Disorders",
            "TareaCode": "8937",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Angela Russell,Nathalie Padron",
            "NationalSampleSize": "2",
            "NCTNbr": "NCT01897896",
            "StudyKeywords": "Huntington Disease, Chorea, d6-Tetrabenazine",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01898494",
            "SecondaryId": "NCI-2013-00814",
            "BriefTitle": "Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer",
            "OfficialTitle": "Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer",
            "LeadSponsorClass": "Eastern Cooperative Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Eastern Cooperative Oncology Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase II trial studies how well transoral surgery followed by low-dose or\r\n\r\n      standard-dose radiation therapy works in treating patients with human papilloma virus (HPV)\r\n\r\n      positive stage III-IVA oropharyngeal cancer.",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. Accrual, risk distribution, and surgical quality will be used to determine the\r\n\r\n      feasibility of a prospective multi-institutional study of transoral surgery for HPV positive\r\n\r\n      (+) oropharynx canc",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2013",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Eastern Cooperative Oncology Group",
            "StudyCondition": "Human Papilloma Virus Infection",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "377",
            "MeshKeyword": "Carcinoma, Squamous Cell, Carcinoma, Oropharyngeal Neoplasms, Virus Diseases, Papilloma, Papillomavirus Infections,",
            "InterventionKeyword": "Cisplatin, Carboplatin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  REGISTRATION TO SURGERY (ARM S)\r\n\r\n\r\n\r\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\r\n\r\n\r\n\r\n          -  Patients must have newly diagnosed, histologically or cytolo",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 1, 2016",
            "FirstReceived": "July 10, 2013",
            "OverallOfficial": "Robert Ferris",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "ECOG-ACRIN Cancer Research Group",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01898494",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130617 - ECOG - Thomas",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20130617",
            "StudyNumber": "20130617 - ECOG - Thomas",
            "StudyTitle": "Phase II Randomized Trial of Transoral Surgical Resection followed by Lowdose or Standarddose IMRT in Resectable p16 Locally Advanced Oropharynx Cancer",
            "PIID": "281",
            "PicNum": "C00075981",
            "PILastName": "Thomas",
            "PIFirstName": "Giovana R",
            "CoodCNbr": "C11971840",
            "CoordLastName": "Zamora Cabezas",
            "CoordFirstName": "Lilibet",
            "CoordEmail": "Lxz267@med.miami.edu",
            "CoordPhone": "305-243-0124",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "06/17/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/17/2014",
            "IRBApprovedFrom": "02/10/2014",
            "IRBApprovedTo": "01/24/2017",
            "DiseaseSiteListDesc": "Lip, Oral Cavity and Pharynx",
            "Expr1": "Phase II",
            "Tarea": "Head and Neck Cancer",
            "TareaCode": "12440",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "ECOG",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "32",
            "Totalaccrued": "28",
            "InFollowUp": "13",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "3",
            "Totalpatients": "32",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A,UMD:N/A,Plantation:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Maggie Chislom,Heather Brunell,Pavel Noa Hechavarria,Zaida Abreu,Fernando Vazquez Pascual,Lilly Sanchez,Marinellie Vega,Doris Martin,Penny Eyer",
            "NationalSampleSize": "60",
            "NCTNbr": "NCT01898494",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01909791",
            "SecondaryId": "EY14231",
            "BriefTitle": "Treatment for CI-DME in Eyes With Very Good VA Study",
            "OfficialTitle": "Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity",
            "LeadSponsorClass": "Jaeb Center for Health Research",
            "SponsorAgency": "Other",
            "LeadSponsor": "Jaeb Center for Health Research",
            "OversightAuthority": "Yes",
            "BriefSummary": "Although multiple studies have clearly demonstrated that ranibizumab therapy is more\r\n\r\n      effective than laser alone for vision gain and avoiding vision loss in patients with\r\n\r\n      central-involved Diabetic Macular Edema (DME), only eyes",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2013",
            "CompletionDate": "August 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Jaeb Center for Health Research",
            "StudyCondition": "Diabetic Macular Edema",
            "studyLocation": "Arizona Retina and Vitreous Consultants",
            "Enrollment": "702",
            "NctKeyword": "Diabetic Macular Edema, anti-vascular endothelial growth factor,",
            "MeshKeyword": "Macular Edema, Edema,",
            "InterventionKeyword": "Bevacizumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age >= 18 years\r\n\r\n\r\n\r\n          2. Diagnosis of diabetes mellitus (type 1 or type 2)\r\n\r\n\r\n\r\n             Any one of the following will be considered to be sufficient evidence that diabetes",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85021",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 9, 2016",
            "FirstReceived": "July 23, 2013",
            "OverallOfficial": "Carl Baker, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Paducah Retina Center",
            "LocationStatus": "Recruiting",
            "LocationName": "Arizona Retina and Vitreous Consultants",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01909791",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150426 - Intramural - Rosenfeld",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20150426",
            "StudyNumber": "20150426 - Intramural - Rosenfeld",
            "StudyTitle": "Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration",
            "PIID": "491",
            "PicNum": "C00522634",
            "PILastName": "Rosenfeld",
            "PIFirstName": "Philip",
            "CoodCNbr": "C00479172",
            "CoordLastName": "Rodriguez",
            "CoordFirstName": "Belen",
            "CoordEmail": "brodrig1@med.miami.edu",
            "CoordPhone": "3053266349",
            "EnteredByCNbr": "C00522634",
            "EnteredByLastName": "Rosenfeld",
            "EnteredByFirstName": "Philip",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "09/14/2015",
            "IRBApprovedFrom": "09/14/2015",
            "IRBApprovedTo": "08/05/2017",
            "Expr1": "N/A",
            "Tarea": "Retina",
            "TareaCode": "12038",
            "ResearchType": "Device",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Cristina Lage-Rodriguez,Fabiola Salvador,Maria Esquiabro,Belen Rodriguez",
            "NationalSampleSize": "56",
            "NCTNbr": "NCT01909791",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01909791",
            "SecondaryId": "EY14231",
            "BriefTitle": "Treatment for CI-DME in Eyes With Very Good VA Study",
            "OfficialTitle": "Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity",
            "LeadSponsorClass": "Jaeb Center for Health Research",
            "SponsorAgency": "Other",
            "LeadSponsor": "Jaeb Center for Health Research",
            "OversightAuthority": "Yes",
            "BriefSummary": "Although multiple studies have clearly demonstrated that ranibizumab therapy is more\r\n\r\n      effective than laser alone for vision gain and avoiding vision loss in patients with\r\n\r\n      central-involved Diabetic Macular Edema (DME), only eyes",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2013",
            "CompletionDate": "August 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Jaeb Center for Health Research",
            "StudyCondition": "Diabetic Macular Edema",
            "studyLocation": "Arizona Retina and Vitreous Consultants",
            "Enrollment": "702",
            "NctKeyword": "Diabetic Macular Edema, anti-vascular endothelial growth factor,",
            "MeshKeyword": "Macular Edema, Edema,",
            "InterventionKeyword": "Bevacizumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age >= 18 years\r\n\r\n\r\n\r\n          2. Diagnosis of diabetes mellitus (type 1 or type 2)\r\n\r\n\r\n\r\n             Any one of the following will be considered to be sufficient evidence that diabetes",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85021",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 9, 2016",
            "FirstReceived": "July 23, 2013",
            "OverallOfficial": "Carl Baker, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Paducah Retina Center",
            "LocationStatus": "Recruiting",
            "LocationName": "Arizona Retina and Vitreous Consultants",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01909791",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140624 - National Eye Institute/Regeneron Pharmaceuticals/  - Townsend",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20140624",
            "StudyNumber": "20140624 - National Eye Institute/Regeneron Pharmaceuticals/  - Townsend",
            "StudyTitle": "Treatment for Central -Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity",
            "PIID": "2251",
            "PicNum": "C09879746",
            "PILastName": "Townsend",
            "PIFirstName": "Justin",
            "CoodCNbr": "C00479172",
            "CoordLastName": "Rodriguez",
            "CoordFirstName": "Belen",
            "CoordEmail": "brodrig1@med.miami.edu",
            "CoordPhone": "3053266349",
            "EnteredByCNbr": "C09879746",
            "EnteredByLastName": "Townsend",
            "EnteredByFirstName": "Justin",
            "ActiveEnrollingDate": "02/16/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/16/2015",
            "IRBApprovedFrom": "10/27/2014",
            "IRBApprovedTo": "08/21/2017",
            "Expr1": "N/A",
            "Tarea": "Retina",
            "TareaCode": "12038",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "National Eye Institute/Regeneron Pharmaceuticals/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "4",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,ABLEH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Belen Rodriguez,Monica Arango,Cristina Lage-Rodriguez",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01909791",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01919489",
            "SecondaryId": "(UTN) U1111-1139-2991",
            "BriefTitle": "Liraglutide Hospital Discharge Trial",
            "OfficialTitle": "A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide Versus Glargine Insulin for the Management of Patients With Type 2 Diabetes After Hospital Discharge",
            "LeadSponsorClass": "Emory University",
            "SponsorAgency": "Other",
            "LeadSponsor": "Emory University",
            "OversightAuthority": "Yes",
            "BriefSummary": "High blood glucose levels in hospitalized patients with diabetes are associated with\r\n\r\n      increased risk of medical complications and death. Improved glucose control with insulin\r\n\r\n      injections may improve clinical outcome and prevent s",
            "Description": "Specific Aim: To determine whether treatment with liraglutide (Victoza®) will result in\r\n\r\n      similar glycemic control (HbA1c at 26 weeks) and a lower rate of hypoglycemic events\r\n\r\n      compared to treatment with glargine (Lantus®) in non-s",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2014",
            "CompletionDate": "December 2017",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "Emory University",
            "StudyCondition": "Type 2 Diabetes",
            "studyLocation": "Grady Memorial Hospital",
            "Enrollment": "280",
            "NctKeyword": "Incretins, Liraglutide, Glargine, Randomized controlled trial, basal insulin, hospital discharge, inpatient diabetes,",
            "MeshKeyword": "Diabetes Mellitus, Type 2,",
            "InterventionKeyword": "Insulin Glargine, Liraglutide,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Males or females between the ages of 18 and 80 years discharged after hospital\r\n\r\n             admission from general medicine services (non-surgical and non-ICU setting).\r\n\r\n\r\n\r\n          2. Admission H",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "Atlanta",
            "State": "Georgia",
            "Zip": "30303",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 3, 2016",
            "FirstReceived": "July 30, 2013",
            "OverallOfficial": "Guillermo E Umpierrez, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Emory University SOM",
            "ContactName": "Guillermo E Umpierrez, MD",
            "ContactPhone": "404-778-1665",
            "ContactEmail": "geumpie@emory.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Grady Memorial Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01919489",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150703 - Novo Nordisk - Iacobellis",
            "FileProcessContentId": "440",
            "Division": "Endocrinology",
            "StdyDivision": "10241",
            "EprostNbr": "20150703",
            "StudyNumber": "20150703 - Novo Nordisk - Iacobellis",
            "StudyTitle": "Liraglutide Hospital Discharge Trial: A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide versus Glargine insulin for the Management of Patients with Type 2 Diabetes After Hospital Discharge",
            "PIID": "26212",
            "PicNum": "C09951125",
            "PILastName": "Iacobellis",
            "PIFirstName": "Gianluca",
            "CoodCNbr": "C09951125",
            "CoordLastName": "Iacobellis",
            "CoordFirstName": "Gianluca",
            "CoordEmail": "giacobellis@med.miami.edu",
            "EnteredByCNbr": "C09951125",
            "EnteredByLastName": "Iacobellis",
            "EnteredByFirstName": "Gianluca",
            "ActiveEnrollingDate": "04/26/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/26/2016",
            "IRBApprovedFrom": "10/20/2015",
            "IRBApprovedTo": "10/19/2016",
            "Expr1": "Phase IV",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Novo Nordisk",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Juan Palacios Merchan",
            "NationalSampleSize": "55",
            "NCTNbr": "NCT01919489",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01922297",
            "SecondaryId": "R01DA027216",
            "BriefTitle": "Juvenile Offender HIV Prevention and Drug Abuse Services",
            "OfficialTitle": "Juvenile Offender HIV Prevention and Drug Abuse Services",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "This study will determine the clinical effectiveness, moderators and mechanisms of change,\r\n\r\n      and economic impact of an integrative, family-based intervention that concurrently targets\r\n\r\n      change in HIV/Sexually Transmitted Disease (S",
            "Description": "Adolescents committed to three school-based day treatment programs located in Miami-Dade\r\n\r\n      County will be randomized to either Day Treatment MDFT-HIV (DT-MDFT-HIV) or Day Treatment\r\n\r\n      Program Services as Usual (DT-SAU). Youth in bot",
            "OverallStatus": "Completed",
            "StartDate": "January 2010",
            "CompletionDate": "April 2015",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Risk Behavior",
            "studyLocation": "University of Miami Miller School of Medicine",
            "Enrollment": "121",
            "NctKeyword": "Delinquency, HIV Associated Risk Behavior, Juveniles, Family based treatment, Multidimensional Family Therapy,",
            "MeshKeyword": "Substance-Related Disorders,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Between the ages of 13 and 18\r\n\r\n\r\n\r\n          -  Committed to a juvenile justice day treatment program\r\n\r\n\r\n\r\n          -  Meet criteria for substance use disorder on the DISC Predictive Scales",
            "EligibleGender": "All",
            "MinAge": "13 Years",
            "MaxAge": "18 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2015",
            "LastChanged": "August 21, 2015",
            "FirstReceived": "August 10, 2013",
            "OverallOfficial": "Howard A Liddle, EdD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "University of Miami Miller School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01922297",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20090438 - NIDA - Liddle",
            "FileProcessContentId": "440",
            "Division": "Epidemiology",
            "StdyDivision": "10636",
            "EprostNbr": "20090438",
            "StudyNumber": "20090438 - NIDA - Liddle",
            "StudyTitle": "Juvenile Offender HIV Prevention and Drug Abuse Services",
            "PIID": "1765",
            "PicNum": "C00238613",
            "PILastName": "Liddle",
            "PIFirstName": "Howard",
            "CoodCNbr": "C00781530",
            "CoordLastName": "Alberga",
            "CoordFirstName": "Linda",
            "CoordEmail": "lalberga@med.miami.edu",
            "CoordPhone": "3052433325",
            "EnteredByCNbr": "C00238613",
            "EnteredByLastName": "Liddle",
            "EnteredByFirstName": "Howard",
            "ActiveEnrollingDate": "07/09/2009",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/09/2009",
            "IRBApprovedFrom": "07/09/2009",
            "IRBApprovedTo": "04/02/2015",
            "AccountNbr": "66593N",
            "InfoEdNbr": "34514",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "National Institute on Drug Abuse",
            "SiteSampleSize": "UMMG:250",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "250",
            "EprostState": "Approved",
            "StudyCoordinator": "Linda Alberga",
            "StudyObjective": "The study has four aims: \r\nAim 1: Intervention Effectiveness  To experimentally compare, in a day treatment setting, the short and long-term clinical outcomes of the Experimental Intervention  MDFT-HIV Integrated intervention (DT-MDFT-HIV) for sexually active drug abusing juvenile offenders with Day Treatment Services as Usual (DT-SAU).\r\nHypothesis 1a. Youths assigned to DT-MDFT-HIV will show a greater decrease in HIV-associated sexual risk behaviors, laboratory-confirmed STD incidence, drug use, arrests and out of home placements, and mental health symptoms from baseline assessment through 6 months post-baseline than youths in SAU.\r\nHypothesis 1b. Youths assigned to DT-MDFT-HIV will show a greater decrease in HIV-associated sexual risk behaviors, laboratory-confirmed STD incidence, drug use, arrests and out of home placements, and mental health symptoms from 6 months post baseline to 24 months post-baseline than youths in SAU.\r\nHypothesis 1C. Youths assigned to DT-MDFT-HIV will be more likely to successfully transition out of the juvenile justice day treatment program--and return to regular school placement--than those assigned to services as usual.\r\n\r\nAim 2: Moderating Effects  To identify baseline client characteristics that moderate intervention outcomes.\r\nHypothesis 2. For youths with high baseline levels of co-morbidity, HIV-associated sexual risk behaviors, drug use and delinquency, the DT-MDFT-HIV intervention will reduce HIV-associated sexual risk behaviors and laboratory-confirmed STD incidence, drug use, and arrests and out of home placements more significantly than the DT-SAU condition. For youths with low baseline levels of HIV-associated sexual risk behaviors, drug use and delinquency, the two interventions will be comparably effective.\r\n\r\nAim 3: Mechanisms of Action  To identify the mechanisms through which the experimental intervention achieves its effects.\r\nHypothesis 3a. For youths assigned to DT-MDFT-HIV, reductions in HIV-associated sexual risk behaviors and laboratory-confirmed STD incidence will be achieved through (a) increases in HIV/STD knowledge and risk-reduction skills, (b) enhanced self-efficacy regarding condom use, (c) improved communication and refusal skills with partners, (d) greater perceived peer norms supportive of safer sex, (e) open communication with parents about HIV and sexual risk behaviors, and (f) more effective parenting and improved family functioning. \r\nHypothesis 3b. For youths assigned to DT-MDFT-HIV, reductions in drug use and delinquency will be achieved through (a) increases in adolescents bonding to prosocial peers and activities (e.g. school), (b) increases in parents emotional bonding to their adolescent, and improvements in parenting practices, and (c) more positive family environment.\r\n\r\nAim 4: Economic Analyses - To evaluate and compare the economic costs, benefits, and cost effectiveness to society and to the juvenile justice system of DT-MDFT-HIV and DT-SAU.\r\nHypothesis 4a. DT-MDFT-HIV will generate significantly higher total and net monetary benefits to society and to the juvenile justice system than youths in DT-SAU.\r\nHypothesis 4b. DT-MDFT-HIV will be relatively more cost effective in terms of cases of HIV/STD averted than DT-SAU.",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT01922297",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT01925209",
            "BriefTitle": "Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients",
            "OfficialTitle": "Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability of i.v. BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility in Sporadic Inclusion Body Myositis Patients",
            "LeadSponsorClass": "Novartis Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novartis Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "To evaluate the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs\r\n\r\n      placebo, when administered intravenously (i.v.), on physical function, muscle strength, and\r\n\r\n      mobility in patients with sporadic inclusio",
            "OverallStatus": "Completed",
            "StartDate": "September 2013",
            "CompletionDate": "January 2016",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "Novartis",
            "StudyCondition": "Sporadic Inclusion Body Myositis",
            "studyLocation": "Novartis Investigative Site",
            "Enrollment": "251",
            "NctKeyword": "sporadic inclusion body myositis,, myositis,, muscle wasting,, controlled clinical trial,, randomized,, body mass,, muscle function,, strength,, performance,, physical function,",
            "MeshKeyword": "Myositis, Myositis, Inclusion Body,",
            "InterventionKeyword": "Antibodies, Monoclonal, Antibodies, Blocking,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosed with sporadic inclusion body myositis;\r\n\r\n\r\n\r\n          -  Must be able to walk (assistive aids allowed, including intermittent use of\r\n\r\n             wheelchair);\r\n\r\n\r\n\r\n        Exclusion Crit",
            "EligibleGender": "All",
            "MinAge": "36 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85028",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 21, 2016",
            "FirstReceived": "August 15, 2013",
            "OverallOfficial": "Novartis Pharmaceuticals",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Novartis Pharmaceuticals",
            "LocationName": "Novartis Investigative Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01925209",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150833 - Novartis - Ascherman",
            "FileProcessContentId": "440",
            "Division": "Rheumatology and Immunology",
            "StdyDivision": "10260",
            "EprostNbr": "20150833",
            "StudyNumber": "20150833 - Novartis - Ascherman",
            "StudyTitle": "Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tolerability of intravenous BYM338 in patients with sporadic inclusion body myositis",
            "PIID": "3094",
            "PicNum": "C09951490",
            "PILastName": "Ascherman",
            "PIFirstName": "Dana",
            "CoodCNbr": "C02440329",
            "CoordLastName": "Pignac-Kobinger",
            "CoordFirstName": "Judith",
            "CoordEmail": "jpignac@med.miami.edu",
            "CoordPhone": "3052438567",
            "EnteredByCNbr": "C09951490",
            "EnteredByLastName": "Ascherman",
            "EnteredByFirstName": "Dana",
            "ActiveEnrollingDate": "11/04/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/04/2015",
            "IRBApprovedFrom": "10/26/2015",
            "IRBApprovedTo": "10/16/2017",
            "Expr1": "Phase II/III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Novartis",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "10",
            "Totalaccrued": "10",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "10",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "10",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Judith Pignac-Kobinger,Bethly Aubourg,Lisa Harlow",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT01925209",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01931839",
            "BriefTitle": "A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis",
            "OfficialTitle": "A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation",
            "LeadSponsorClass": "Vertex Pharmaceuticals Incorporated",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Vertex Pharmaceuticals Incorporated",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate the efficacy and safety of long-term treatment with\r\n\r\n      lumacaftor in combination with ivacaftor in people 12 years and older with Cystic Fibrosis.",
            "Description": "This is a Phase 3, parallel group, multicenter, rollover study in subjects with CF who are\r\n\r\n      homozygous or heterozygous for the F508del CFTR mutation and who previously participated in\r\n\r\n      Study 103, Study 104, or Cohort 4 of Study 1",
            "OverallStatus": "Completed",
            "StartDate": "October 2013",
            "CompletionDate": "April 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Vertex Pharmaceuticals Incorporated",
            "StudyCondition": "Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation",
            "Enrollment": "1165",
            "MeshKeyword": "Fibrosis, Cystic Fibrosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Signed informed consent form (ICF), and where appropriate, signed assent form.\r\n\r\n\r\n\r\n          -  Subjects entering the Part A Treatment Cohort: Completed 24 weeks of study drug\r\n\r\n             treatmen",
            "EligibleGender": "All",
            "MinAge": "12 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 27, 2016",
            "FirstReceived": "August 26, 2013",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01931839",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130614 - vertex pharmaceuticals inc/Vertex Pharmaceuticals - Salathe",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20130614",
            "StudyNumber": "20130614 - vertex pharmaceuticals inc/Vertex Pharmaceuticals - Salathe",
            "StudyTitle": "VX12809105: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of LongTerm Treatment With Lumacaftor in Combination  With Ivacaftor",
            "PIID": "528",
            "PicNum": "C00319179",
            "PILastName": "Salathe",
            "PIFirstName": "Matthias",
            "CoodCNbr": "C02159596",
            "CoordLastName": "Mendes",
            "CoordFirstName": "Eliana",
            "CoordEmail": "emendes@med.miami.edu",
            "CoordPhone": "3052432568",
            "EnteredByCNbr": "C00402760",
            "EnteredByLastName": "Velasco",
            "EnteredByFirstName": "Maribeth",
            "ActiveEnrollingDate": "01/21/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/21/2014",
            "IRBApprovedFrom": "11/19/2013",
            "IRBApprovedTo": "10/05/2016",
            "Expr1": "Phase III",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Patricia Graham-Borras,Lilian Cadet,Johana Arana,Maribeth Velasco,Patricia Rebolledo,Eliana Mendes,Carolina Aguiar",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT01931839",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01940471",
            "SecondaryId": "2013-000636-10",
            "BriefTitle": "Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B",
            "OfficialTitle": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "The primary objective of this study is to compare the efficacy, safety, and tolerability of\r\n\r\n      tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive\r\n\r\n      and treatment-experienced adults with hepatit",
            "Description": "This study GS-US-320-0110 is an international study planned to enroll participants in global\r\n\r\n      countries, including China. However, due to the review timeline difference in China, full\r\n\r\n      enrollment was reached in the main study bef",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "September 2013",
            "CompletionDate": "October 2022",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "HBV",
            "studyLocation": "Asian Pacific Liver Center",
            "Enrollment": "875",
            "NctKeyword": "Hepatitis, Tenofovir, Viread,",
            "MeshKeyword": "Hepatitis, Hepatitis B,",
            "InterventionKeyword": "Tenofovir,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Ability to understand and sign a written informed consent form, which must be\r\n\r\n             obtained prior to initiation of study procedures\r\n\r\n\r\n\r\n          -  Adult males and non-pregnant, non-lactat",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90057",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 23, 2016",
            "FirstReceived": "August 20, 2013",
            "OverallOfficial": "John Flaherty, PharmD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "Asian Pacific Liver Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01940471",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130552 - Gilead Sciences Inc. - Schiff",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20130552",
            "StudyNumber": "20130552 - Gilead Sciences Inc. - Schiff",
            "StudyTitle": "GSUS3200110 A Phase 3, Randomized, DoubleBlind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C05034487",
            "CoordLastName": "Sabogal",
            "CoordFirstName": "Diane",
            "CoordEmail": "d.sabogal@med.miami.edu",
            "CoordPhone": "3052432168",
            "EnteredByCNbr": "C09867766",
            "EnteredByLastName": "Rodriguez-Bravo",
            "EnteredByFirstName": "Odalys",
            "ActiveEnrollingDate": "01/08/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/08/2014",
            "IRBApprovedFrom": "10/07/2013",
            "IRBApprovedTo": "07/31/2017",
            "AccountNbr": "661927",
            "InfoEdNbr": "67606",
            "Expr1": "Phase III",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "5",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "1",
            "SiteSampleSize": "BPPB:N/A,UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diane Sabogal,Sonia Carvalho",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT01940471",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01945775",
            "SecondaryId": "U1111-1155-7579",
            "BriefTitle": "A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",
            "OfficialTitle": "A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of Talazoparib (BMN 673) Versus Physician's Choice in Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regime",
            "LeadSponsorClass": "Medivation, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Medivation, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and\r\n\r\n      efficacy of talazoparib (also known as BMN 673) versus protocol-specific physician's choice\r\n\r\n      in patients who have locally advanced and/o",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2013",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Medivation, Inc.",
            "StudyCondition": "Breast Neoplasms",
            "Enrollment": "429",
            "NctKeyword": "Breast cancer, BRCA mutation, PARP inhibitor, BRCA 1, BRCA 2,",
            "MeshKeyword": "Breast Neoplasms,",
            "InterventionKeyword": "Talazoparib, Poly(ADP-ribose) Polymerase Inhibitors,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Histologically or cytologically confirmed carcinoma of the breast\r\n\r\n\r\n\r\n          -  Locally advanced breast cancer that is not amenable to curative radiation or surgical\r\n\r\n             cure and/or met",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Avondale",
            "State": "Arizona",
            "Zip": "85392",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "December 8, 2016",
            "FirstReceived": "September 11, 2013",
            "ContactName": "Medivation Clinical Operations",
            "ContactPhone": "+1 (415) 543-3470",
            "ContactEmail": "dg-embraca@medivation.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01945775",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130570 - BioMarin Pharm. - Mahtani",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20130570",
            "StudyNumber": "20130570 - BioMarin Pharm. - Mahtani",
            "StudyTitle": "BioMarin 301: A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who have Received No More than 2 Prior Chemotherapy Regimens for Metastatic Disease",
            "PIID": "2603",
            "PicNum": "C09937436",
            "PILastName": "Mahtani",
            "PIFirstName": "Reshma",
            "CoodCNbr": "C11975723",
            "CoordLastName": "Minichiello",
            "CoordFirstName": "Anthony",
            "CoordEmail": "agm112@miami.edu",
            "EnteredByCNbr": "C12001301",
            "EnteredByLastName": "Delgado",
            "EnteredByFirstName": "Yisenny",
            "ActiveEnrollingDate": "11/25/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/25/2013",
            "IRBApprovedFrom": "10/21/2013",
            "IRBApprovedTo": "10/02/2017",
            "AccountNbr": "662203",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase III",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "BioMarin",
            "Prescreened": "3",
            "Screenedfailed": "8",
            "SignedICF": "11",
            "Totalaccrued": "3",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "11",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,Plantation:N/A,UMD:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Onaidy Torres,Deborah Conte,Sarah Raybin,Carla Munevar,Halyna Hailes,Cristina Rojas-Mejia,Penny Eyer",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT01945775",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01946880",
            "BriefTitle": "Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)",
            "OfficialTitle": "An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)",
            "LeadSponsorClass": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "OversightAuthority": "Yes",
            "BriefSummary": "This trial seeks to describe the effect of withdrawal from mycophenolate mofetil (MMF) on\r\n\r\n      risk of clinically significant disease reactivation in quiescent SLE patients who have been\r\n\r\n      on long-term MMF therapy.",
            "Description": "Participants who have had inactive disease for at least 24 weeks will be enrolled. Half the\r\n\r\n      subjects will continue on MMF and half the subjects will be tapered off their MMF within 12\r\n\r\n      weeks. All subjects will continue hydroxych",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2013",
            "CompletionDate": "December 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "StudyCondition": "Systemic Lupus Erythematosus",
            "studyLocation": "Cedars-Sinai Medical Center",
            "Enrollment": "120",
            "NctKeyword": "Systemic Lupus Erythematosus, Mycophenolate Mofetil (MMF),",
            "MeshKeyword": "Lupus Erythematosus, Systemic,",
            "InterventionKeyword": "Chloroquine diphosphate, Prednisone, Mycophenolic Acid, Mycophenolate mofetil, Hydroxychloroquine, Chloroquine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Able and willing to give written informed consent and comply with requirements of the\r\n\r\n             study.\r\n\r\n\r\n\r\n          2. Age 18 - 70 years, inclusive, at randomization.\r\n\r\n\r\n\r\n          3. Diagno",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "70 Years",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90048",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 6, 2016",
            "FirstReceived": "September 13, 2013",
            "OverallOfficial": "Eliza Chakravarty, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Oklahoma Medical Research Foundation",
            "LocationStatus": "Recruiting",
            "LocationName": "Cedars-Sinai Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01946880",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130972 - Intramural - Contreras",
            "FileProcessContentId": "440",
            "Division": "Nephrology",
            "StdyDivision": "10250",
            "EprostNbr": "20130972",
            "StudyNumber": "20130972 - Intramural - Contreras",
            "StudyTitle": "An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients with Stable, Quiescent Systemic Lupus Erythematosus (SLE)",
            "PIID": "522",
            "PicNum": "C00210471",
            "PILastName": "Contreras",
            "PIFirstName": "Gabriel",
            "CoodCNbr": "C00329755",
            "CoordLastName": "Vassallo",
            "CoordFirstName": "Jacqueline",
            "EnteredByCNbr": "C00210471",
            "EnteredByLastName": "Contreras",
            "EnteredByFirstName": "Gabriel",
            "ActiveEnrollingDate": "05/01/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/01/2014",
            "IRBApprovedFrom": "01/27/2014",
            "IRBApprovedTo": "01/08/2018",
            "Expr1": "Phase II",
            "Tarea": "Lupus",
            "TareaCode": "13039",
            "Blinding": "None",
            "Randomization": "Randomized",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "10",
            "Totalaccrued": "8",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "3",
            "Totalpatients": "10",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Jacqueline Vassallo",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT01946880",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01949324",
            "BriefTitle": "A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel",
            "OfficialTitle": "A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)",
            "LeadSponsorClass": "Neurotech Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Neurotech Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study is a phase 2, randomized, multi-center, single-masked study to evaluate the\r\n\r\n      efficacy and safety of the NT-501 implants in participants with Mactel.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "April 2014",
            "CompletionDate": "July 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Neurotech Pharmaceuticals",
            "StudyCondition": "Macular Telangiectasia Type 2",
            "studyLocation": "Jules Stein Eye Institute",
            "Enrollment": "68",
            "NctKeyword": "MacTel,",
            "MeshKeyword": "Telangiectasis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Participant must be offered sufficient opportunity to review and to understand the\r\n\r\n             informed consent form, agree to the form's contents and sign the protocol's informed\r\n\r\n             con",
            "EligibleGender": "All",
            "MinAge": "21 Years",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90095",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 21, 2016",
            "FirstReceived": "September 19, 2013",
            "LocationName": "Jules Stein Eye Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01949324",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130677 - Lowy Medical Research Institute/Neurotech - Rosenfeld",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20130677",
            "StudyNumber": "20130677 - Lowy Medical Research Institute/Neurotech - Rosenfeld",
            "StudyTitle": "A Phase 2 Multicenter Randomized Clinical Trialof Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)",
            "PIID": "491",
            "PicNum": "C00522634",
            "PILastName": "Rosenfeld",
            "PIFirstName": "Philip",
            "CoodCNbr": "C00286276",
            "CoordLastName": "Lage-Rodriguez",
            "CoordFirstName": "Cristina",
            "CoordEmail": "clage@med.miami.edu",
            "EnteredByCNbr": "C00522634",
            "EnteredByLastName": "Rosenfeld",
            "EnteredByFirstName": "Philip",
            "ActiveEnrollingDate": "07/18/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/18/2014",
            "IRBApprovedFrom": "02/13/2014",
            "IRBApprovedTo": "12/11/2017",
            "InfoEdNbr": "68217",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Lowy Medical Research Institute/Neurotech",
            "Prescreened": "10",
            "Screenedfailed": "4",
            "SignedICF": "11",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "5",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "11",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Cristina Lage-Rodriguez,Fabiola Salvador,Maria Esquiabro,Belen Rodriguez,Monica Arango",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT01949324",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01953601",
            "SecondaryId": "2012-005542-38",
            "BriefTitle": "Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)",
            "OfficialTitle": "A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)",
            "LeadSponsorClass": "Merck Sharp & Dohme Corp.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Merck Sharp & Dohme Corp.",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study consists of two parts, Part I and Part II. The purpose of Part I of the study is\r\n\r\n      to assess the efficacy and safety of verubecestat (MK-8931) compared with placebo\r\n\r\n      administered for 104 weeks in the treatment of amnest",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "November 2013",
            "CompletionDate": "March 2021",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Merck Sharp & Dohme Corp.",
            "StudyCondition": "Amnestic Mild Cognitive Impairment",
            "Enrollment": "1500",
            "MeshKeyword": "Alzheimer Disease, Cognition Disorders, Mild Cognitive Impairment,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Diagnosis of prodromal AD, including the following:\r\n\r\n\r\n\r\n               1. History of subjective memory decline with gradual onset and slow progression for\r\n\r\n                  at least one year corrob",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "VerificationDate": "December 2016",
            "LastChanged": "December 7, 2016",
            "FirstReceived": "September 25, 2013",
            "OverallOfficial": "Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Merck Sharp & Dohme Corp.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01953601",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140719 - Merck & Co. - Wright",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140719",
            "StudyNumber": "20140719 - Merck & Co. - Wright",
            "StudyTitle": "A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).",
            "PIID": "2698",
            "PicNum": "C06958355",
            "PILastName": "Wright",
            "PIFirstName": "Clinton",
            "CoodCNbr": "C03834528",
            "CoordLastName": "Perez",
            "CoordFirstName": "Carmen",
            "CoordEmail": "c.perez71@med.miami.edu",
            "CoordPhone": "3052435610",
            "EnteredByCNbr": "C06958355",
            "EnteredByLastName": "Wright",
            "EnteredByFirstName": "Clinton",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "06/22/2015",
            "IRBApprovedFrom": "06/22/2015",
            "IRBApprovedTo": "06/14/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Merck & Co.",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Maria Carolina Mendoza-Puccini,Jonathan Landman,Carmen Perez",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT01953601",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01953926",
            "SecondaryId": "2013-002872-42",
            "BriefTitle": "An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification",
            "OfficialTitle": "An Open-label, Multicenter, Multinational, Phase 2 Study Exploring the Efficacy and Safety of Neratinib Therapy in Patients With Solid Tumors With Activating HER2, HER3 or EGFR Mutations or With EGFR Gene Amplification.",
            "LeadSponsorClass": "Puma Biotechnology, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Puma Biotechnology, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "This is an open-label, multicenter, multinational, Phase 2 study exploring the efficacy and\r\n\r\n      safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR\r\n\r\n      mutations or with EGFR gene amplification.",
            "Description": "This is an open-label, multicenter, multinational, Phase 2 study exploring the efficacy and\r\n\r\n      safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR\r\n\r\n      mutations or with EGFR gene amplification.",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2013",
            "CompletionDate": "December 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Puma Biotechnology, Inc.",
            "StudyCondition": "Solid Tumors",
            "studyLocation": "University of Southern California",
            "Enrollment": "292",
            "NctKeyword": "Neratinib, Fulvestrant, Breast, Gastroesophageal, Endometrial Ovarian Cancer, Biliary Tract, Solid tumors, HER2, Paclitaxel, Bladder/Urinary Tract,",
            "InterventionKeyword": "Paclitaxel, Fulvestrant, Albumin-Bound Paclitaxel, Estradiol,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Histologically confirmed cancers for which no curative therapy exists.\r\n\r\n\r\n\r\n          -  Documented HER2 mutation.\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -  Prior treatment with any pan-HE",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90089",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "January 9, 2017",
            "FirstReceived": "September 26, 2013",
            "ContactName": "Puma Biotechnology, Clinical Operations",
            "ContactPhone": "(424) 248-6500",
            "ContactEmail": "ClinicalTrials@pumabiotechnology.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Southern California",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01953926",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150716 - Puma Biotechnology - De La Fuente",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150716",
            "StudyNumber": "20150716 - Puma Biotechnology - De La Fuente",
            "StudyTitle": "AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2,HER3) MUTATIONS OR EGFR GENE AMPLIFICATION",
            "PIID": "22734",
            "PicNum": "C11916526",
            "PILastName": "De La Fuente",
            "PIFirstName": "Macarena",
            "CoodCNbr": "C04228283",
            "CoordLastName": "Garcia",
            "CoordFirstName": "Helen",
            "CoordEmail": "heg32@med.miami.edu",
            "EnteredByCNbr": "C07181703",
            "EnteredByLastName": "Zhang",
            "EnteredByFirstName": "Lei",
            "ActiveEnrollingDate": "07/27/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/27/2016",
            "IRBApprovedFrom": "02/22/2016",
            "IRBApprovedTo": "02/21/2017",
            "AccountNbr": "666907",
            "DiseaseSiteListDesc": "Brain and Nervous System,Breast-Female,Bones and Joints",
            "Expr1": "Phase II",
            "Tarea": "Neurological Cancer",
            "TareaCode": "12442",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Puma Biotechonology",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nyesha Smith,Nicole Procaccini,Negin Habibi Khameneh,Sarah Raybin,Evan Dadas,Mahlako Masemola-Dublin,Sharon Khadaran,Sheilla Jerome,Isabel Moya,Teresa Kamar,Deborah Conte",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT01953926",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01959529",
            "SecondaryId": "2013-002371-17",
            "BriefTitle": "A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events",
            "OfficialTitle": "A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events",
            "LeadSponsorClass": "Novo Nordisk A/S",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novo Nordisk A/S",
            "OversightAuthority": "Yes",
            "BriefSummary": "This trial is conducted globally. The aim of this trial is to compare cardiovascular safety\r\n\r\n      of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of\r\n\r\n      cardiovascular events.",
            "OverallStatus": "Completed",
            "StartDate": "October 2013",
            "CompletionDate": "September 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Novo Nordisk A/S",
            "StudyCondition": "Diabetes",
            "studyLocation": "Novo Nordisk Investigational Site",
            "Enrollment": "7637",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 2,",
            "InterventionKeyword": "Insulin, Globin Zinc, Insulin, Insulin Glargine, Insulin, Long-Acting,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Type 2 diabetes\r\n\r\n\r\n\r\n          -  Age above or equal to 50 years with predefined previous cardiovascular disease(s) or\r\n\r\n             renal disease or age above or equal to 60 years with predefined ca",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35216",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 15, 2016",
            "FirstReceived": "October 8, 2013",
            "OverallOfficial": "Global Clinical Registry (GCR, 1452)",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Novo Nordisk A/S",
            "LocationName": "Novo Nordisk Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01959529",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130884 - Novo Nordisk - Solano",
            "FileProcessContentId": "440",
            "Division": "Medicine",
            "StdyDivision": "7803",
            "EprostNbr": "20130884",
            "StudyNumber": "20130884 - Novo Nordisk - Solano",
            "StudyTitle": "A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events DEVOTETrial ID: EX12504080",
            "PIID": "835",
            "PicNum": "C00590445",
            "PILastName": "Solano",
            "PIFirstName": "Maria del Pilar",
            "CoodCNbr": "C00590445",
            "CoordLastName": "Solano",
            "CoordFirstName": "Maria del Pilar",
            "CoordPhone": "3052436504",
            "EnteredByCNbr": "C00590445",
            "EnteredByLastName": "Solano",
            "EnteredByFirstName": "Maria del Pilar",
            "ActiveEnrollingDate": "05/06/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/06/2014",
            "IRBApprovedFrom": "01/27/2014",
            "IRBApprovedTo": "01/10/2017",
            "Expr1": "Phase III",
            "Tarea": "Diabetes (Type II)",
            "TareaCode": "12544",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Novo Nordisk",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "18",
            "Totalaccrued": "17",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "18",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Burlett Masters,Ada Konwai",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT01959529",
            "StudyKeywords": "Diabetes, Diabetes Mellitus Type 2, insulin degludec, insulin glargine",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01964755",
            "BriefTitle": "Phase II of Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma",
            "OfficialTitle": "Phase II Study of Chemotherapy (Doxorubicin, Methotrexate and Leucovorin) in Combination With Antiviral-Based Therapy (Zidovudine + Hydroxyurea) for AIDS, Immunocompromised, or Immunocompetent Patients With Relapsed or CNS Positive Epstein Barr Virus Asso",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "By combining a variety of agents that potentiate Zidovudine (ZDV), the investigators hope to\r\n\r\n      induce remission in this generally fatal disease. Most therapies for aggressive B cell\r\n\r\n      lymphomas are based upon intensive chemotherape",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2011",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Epstein Barr Virus Associated Non Hodgkin's Lymphoma",
            "studyLocation": "University of Miami",
            "Enrollment": "26",
            "NctKeyword": "EBV+, NHL, HL, Non Hodgkin's Lymphoma, Hodgkin's Lymphoma, Epstein Barr Virus, Epstein Barr Virus Associated Non Hodgkin's Lymphoma, Epstein Barr Virus Associated Hodgkin's Lymphoma, Post-Transplant Lymphoproliferative Disease,",
            "MeshKeyword": "Virus Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Hodgkin Disease, Lymphoproliferative Disorders,",
            "InterventionKeyword": "Doxorubicin, Liposomal doxorubicin, Rituximab, Methotrexate, Hydroxyurea, Zidovudine, Antiviral Agents, Leucovorin, Levoleucovorin, Formyltetrahydrofolates, Tetrahydrofolates,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Any stage, histologically or cytologically documented intermediate to high grade\r\n\r\n             relapsed or refractory EBV+ non-Hodgkin's (NHL) or Hodgkin's lymphoma (HL), or any\r\n\r\n             treated",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 23, 2016",
            "FirstReceived": "October 14, 2013",
            "OverallOfficial": "Juan Carlos Ramos, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01964755",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20090166 - Leukemia Lymphoma Society - Ramos",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20090166",
            "StudyNumber": "20090166 - Leukemia Lymphoma Society - Ramos",
            "StudyTitle": "Phase II Study of Chemotherapy (Doxorubicin, Methotrexate and Leucovorin) in Combination with AntiviralBased Therapy (Zidovudine  Hydroxyurea) for Relapsed Epstein Barr Virus Associated Lymphoma",
            "PIID": "433",
            "PicNum": "C03978871",
            "PILastName": "Ramos",
            "PIFirstName": "Juan Carlos",
            "CoodCNbr": "C11923689",
            "CoordLastName": "Mohan",
            "CoordFirstName": "Vivin",
            "CoordEmail": "vxm153@miami.edu",
            "EnteredByCNbr": "C11964150",
            "EnteredByLastName": "Smith",
            "EnteredByFirstName": "Nyesha",
            "ActiveEnrollingDate": "03/06/2009",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/06/2009",
            "IRBApprovedFrom": "03/06/2009",
            "IRBApprovedTo": "11/15/2016",
            "InfoEdNbr": "53630",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma,Hodgkins Lymphoma,Lymphoid Leukemia",
            "Expr1": "Phase II",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "The Leukemia & Lymphoma Society",
            "Prescreened": "2",
            "Screenedfailed": "0",
            "SignedICF": "6",
            "Totalaccrued": "6",
            "InFollowUp": "4",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:32,JMH:N/A",
            "AccrualPercentageMet": "18.75",
            "ActiveCal": "3",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "32",
            "EprostState": "Lapsed",
            "CancerCenterNbr": "2009002",
            "StudyCoordinator": "Sandra O'Mellan",
            "AgentDevices": "Drug: hydrea; Adriamycin; Leucovorin Calcium; Methotrexate; Retrovir",
            "StudyObjective": "OBJECTIVES\r\n\r\nPrimary Objectives\r\n\r\nThe primary objective of this phase II study is to determine the overall survival of patients with relapsed Epstein Barr Virus (EBV+) associated non-Hodgkins lymphoma treated with high dose parenteral zidovudine (ZDV), oral hydroxyurea and combination chemotherapy with Doxorubicin, Methotrexate (MTX), and Leucovorin.\r\n\r\nSecondary Objectives\r\n\r\n2.2.1 Evaluate response and failure-free survival of this treatment.\r\n2.2.2 Assess the toxicity of this treatment regimen.\r\n2.2.3 Assess the effect of ZVD and chemotherapy on circulating EBV viral load.",
            "NationalSampleSize": "26",
            "NCTNbr": "NCT01964755",
            "StudyKeywords": "ORIM: Kanchan Sakhrani",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01966419",
            "BriefTitle": "Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)",
            "OfficialTitle": "Multicenter, Randomized Phase 2B Study Evaluating Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Cirrhotic Patients With Associated Hyperammonemia and an Episode of Hepatic Encephalopathy STOP-HE Study",
            "LeadSponsorClass": "Ocera Therapeutics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Ocera Therapeutics",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine whether ornithine phenylacetate can speed recovery\r\n\r\n      from an acute hepatic encephalopathy episode requiring hospitalization in cirrhotic\r\n\r\n      patients.",
            "Description": "This is a multicenter, randomized, double-blind, placebo-controlled study of ornithine\r\n\r\n      phenylacetate (OCR-002) administered intravenously to hospitalized patients with cirrhosis,\r\n\r\n      hyperammonemia, and an acute episode of hepatic",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2013",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Ocera Therapeutics",
            "StudyCondition": "Acute Episode of Overt Hepatic Encephalopathy",
            "Enrollment": "230",
            "NctKeyword": "hepatic encephalopathy, hyperammonemia, cirrhosis, ornithine phenylacetate, OCR-002,",
            "MeshKeyword": "Brain Diseases, Hepatic Encephalopathy, Hyperammonemia,",
            "InterventionKeyword": "Phenylacetic acid,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Hospitalized with an acute episode of hepatic encephalopathy as complication of\r\n\r\n             cirrhosis\r\n\r\n\r\n\r\n          -  Elevated venous ammonia\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85054",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 21, 2016",
            "FirstReceived": "October 11, 2013",
            "OverallOfficial": "Stan Bukofzer, M.D.",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Ocera Therapeutics, Inc.",
            "ContactName": "Jennifer Atwell",
            "ContactPhone": "919-328-1122",
            "ContactEmail": "jatwell@ocerainc.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01966419",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130634 - Ocera Therapeutics/ Inc - Bhamidimarri",
            "FileProcessContentId": "440",
            "Division": "Hepatology",
            "StdyDivision": "10246",
            "EprostNbr": "20130634",
            "StudyNumber": "20130634 - Ocera Therapeutics/ Inc - Bhamidimarri",
            "StudyTitle": "OCR002HE209  Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR002 (ornithine phenylacetate) in Hospitalized Patients with Cirrhosis and Associated Hyperammonemia with an Episode of Hepatic Encephalopathy (STOPHE Study).",
            "PIID": "3536",
            "PicNum": "C10581001",
            "PILastName": "Bhamidimari",
            "PIFirstName": "Kalyan",
            "CoodCNbr": "C10581001",
            "CoordLastName": "Bhamidimari",
            "CoordFirstName": "Kalyan",
            "EnteredByCNbr": "C10581001",
            "EnteredByLastName": "Bhamidimari",
            "EnteredByFirstName": "Kalyan",
            "ActiveEnrollingDate": "06/06/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/06/2014",
            "IRBApprovedFrom": "10/28/2013",
            "IRBApprovedTo": "11/27/2017",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "10",
            "Totalaccrued": "9",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "1",
            "SiteSampleSize": "UMH:N/A,JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diane Sabogal,Sonia Carvalho",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT01966419",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01966458",
            "BriefTitle": "A Clinical Trial to Evaluate the HeartWare® Ventricular Assist System (ENDURANCE SUPPLEMENTAL TRIAL)",
            "OfficialTitle": "A Prospective, Randomized, Controlled, Unblinded, Multi-Center Clinical Trial to Evaluate the HeartWare® Ventricular Assist Device System for Destination Therapy of Advanced Heart Failure",
            "LeadSponsorClass": "HeartWare, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "HeartWare, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a prospective, randomized, controlled, unblinded, multi-center evaluation of the\r\n\r\n      stroke incidence in patients implanted with a HeartWare® HVAD who receive optimal blood\r\n\r\n      pressure management. The study compares results of",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "October 2013",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "HeartWare, Inc.",
            "StudyCondition": "Chronic Heart Failure",
            "studyLocation": "The University of Alabama at Birmingham",
            "Enrollment": "465",
            "MeshKeyword": "Heart Failure,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Must be ≥18 years of age at consent\r\n\r\n\r\n\r\n          2. Body Surface Area (BSA) ≥ 1.2 m2\r\n\r\n\r\n\r\n          3. Patients with advanced heart failure symptoms (Class IIIB or IV) who are: (patient",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "September 2015",
            "LastChanged": "September 8, 2015",
            "FirstReceived": "October 17, 2013",
            "OverallOfficial": "Francis Pagani, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Michigan Hospital",
            "LocationName": "The University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01966458",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130675 - HeartWare - Chaparro",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20130675",
            "StudyNumber": "20130675 - HeartWare - Chaparro",
            "StudyTitle": "A Prospective, Randomized, Controlled, Unblinded, MultiCenter Clinical Trial to Evaluate the HeartWare(R) Ventricular Assist Device System for Destination Therapy of Advanced Heart Failure [Additional Internal ID: Continued Access with Optimal BP Mgmt",
            "PIID": "735",
            "PicNum": "C06969678",
            "PILastName": "Chaparro",
            "PIFirstName": "Sandra",
            "CoodCNbr": "C00059801",
            "CoordLastName": "Hudson",
            "CoordFirstName": "Laura",
            "CoordEmail": "LJHudson@med.miami.edu",
            "CoordPhone": "3052435678",
            "EnteredByCNbr": "C00538786",
            "EnteredByLastName": "Bauerlein",
            "EnteredByFirstName": "Eugene",
            "ActiveEnrollingDate": "03/17/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/21/2014",
            "IRBApprovedFrom": "11/25/2013",
            "IRBApprovedTo": "11/13/2017",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "HeartWare, Inc.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "6",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "0",
            "SiteSampleSize": "Non University of Miami:N/A,UMMG:N/A,UMH:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carmen Baez-Garcia,Barbara Lang",
            "AgentDevices": "HeartWare LVAS",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT01966458",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01971515",
            "BriefTitle": "First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies",
            "OfficialTitle": "A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies",
            "LeadSponsorClass": "EMD Serono",
            "SponsorAgency": "Industry",
            "LeadSponsor": "EMD Serono",
            "BriefSummary": "This is a Phase 1, first-in-human, open-label, non-randomized, dose escalation, trial to\r\n\r\n      explore the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical\r\n\r\n      activity signals of MSC2363318A.",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2013",
            "CompletionDate": "April 2018",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "EMD Serono",
            "StudyCondition": "Solid Tumor",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "130",
            "NctKeyword": "MSC2363318A, Maximum tolerated dose, Dose limiting toxicities, Recommended phase 2 dose, M2698, Metastatic Breast Cancer, HER2+ Metastatic Breast Cancer, ER+ and/or PgR+ and HER2-, Tamoxifen,",
            "InterventionKeyword": "Trastuzumab, Tamoxifen,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Age greater than or equal to (>=)18 years\r\n\r\n\r\n\r\n          -  Confirmed diagnosis of advanced malignancies that may be controlled with p70S6K or\r\n\r\n             Akt inhibition based on already identified",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 28, 2016",
            "FirstReceived": "October 23, 2013",
            "OverallOfficial": "Olaf Christensen",
            "OverallRole": "Study Director",
            "OverallAffilitation": "EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany",
            "ContactName": "Please Contact U.S. Medical Information Located in Rockland, MA, United States",
            "ContactPhone": "888-275-7376",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01971515",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20151064 - EMD Serono - Mani",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151064",
            "StudyNumber": "20151064 - EMD Serono - Mani",
            "StudyTitle": "A Phase I, First in Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects with Advanced Malignancies",
            "PIID": "26989",
            "PicNum": "C12030842",
            "PILastName": "Lopes",
            "PIFirstName": "Gilberto",
            "CoodCNbr": "C12030188",
            "CoordLastName": "Salvador",
            "CoordFirstName": "Juan",
            "CoordEmail": "juan.salvador@miami.edu",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "06/22/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/22/2016",
            "IRBApprovedFrom": "02/02/2016",
            "IRBApprovedTo": "02/01/2017",
            "AccountNbr": "666608",
            "DiseaseSiteListDesc": "Breast-Female,Bones and Joints",
            "Expr1": "Phase I",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "EMD Serono",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yvonne Dinh,Daniel Sumarriva,Sandra Pineda,Tamara Leon Aliz,Karen Blackburn",
            "NationalSampleSize": "7",
            "NCTNbr": "NCT01971515",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01976104",
            "SecondaryId": "2013-000934-36",
            "BriefTitle": "Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure",
            "OfficialTitle": "A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure",
            "LeadSponsorClass": "Eisai Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Eisai Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel group\r\n\r\n      study using avatrombopag to treat adults with thrombocytopenia associated with liver\r\n\r\n      disease. The study will evaluate avatrombopag in t",
            "Description": "This study will consist of 3 phases: Prerandomization, Randomization, and a Follow-up Phase.\r\n\r\n      The Prerandomization Phase includes one Screening Visit that will take place from Day -14\r\n\r\n      through Day -1; the Randomization Phase incl",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2013",
            "CompletionDate": "December 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Eisai Inc.",
            "StudyCondition": "Thrombocytopenia Associated With Liver Disease",
            "Enrollment": "300",
            "NctKeyword": "Thrombocytopenia, Chronic Liver Disease,",
            "MeshKeyword": "Liver Diseases, Thrombocytopenia,",
            "Eligibility": "Inclusion Criteria\r\n\r\n\r\n\r\n          1. Participants greater than or equal to 18 years of age at Screening with chronic liver\r\n\r\n             disease\r\n\r\n\r\n\r\n          2. Participants who have a mean baseline platelet count of less than 50 x 10^",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "May 5, 2016",
            "FirstReceived": "October 24, 2013",
            "ContactName": "Eisai Medical Services",
            "ContactPhone": "1-888-422-4743",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01976104",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140776 - Eisai - Martin",
            "FileProcessContentId": "440",
            "Division": "Hepatology",
            "StdyDivision": "10246",
            "EprostNbr": "20140776",
            "StudyNumber": "20140776 - Eisai - Martin",
            "StudyTitle": "A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group\nStudy to Evaluate the Efficacy and Safety of Once-daily Oral\nAvatrombopag for the Treatment of Adults with Thrombocytopenia\nAssociated with Liver Disease Prior to an Elective Procedure",
            "PIID": "697",
            "PicNum": "C06441920",
            "PILastName": "Martin",
            "PIFirstName": "Paul",
            "CoodCNbr": "C09950089",
            "CoordLastName": "Morillo",
            "CoordFirstName": "Diana",
            "CoordEmail": "dmorillo@med.miami.edu",
            "CoordPhone": "3052436405",
            "EnteredByCNbr": "C06441920",
            "EnteredByLastName": "Martin",
            "EnteredByFirstName": "Paul",
            "ActiveEnrollingDate": "01/13/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/13/2016",
            "IRBApprovedFrom": "01/20/2015",
            "IRBApprovedTo": "12/05/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Eisai",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "7",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diana Morillo,Marianela Carvajal,Francia Carabali",
            "NationalSampleSize": "16",
            "NCTNbr": "NCT01976104",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01976936",
            "SecondaryId": "2P50NS049060",
            "BriefTitle": "Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2",
            "OfficialTitle": "A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.",
            "LeadSponsorClass": "Mitchell S Elkind",
            "SponsorAgency": "Other",
            "LeadSponsor": "Mitchell S Elkind",
            "OversightAuthority": "Yes",
            "BriefSummary": "This trial will be a phase 2 randomized safety study in which ischemic stroke patients will\r\n\r\n      be randomly assigned within 24 hours of symptom onset to placebo or standard dose lovastatin\r\n\r\n      versus short-term high-dose lovastatin 640",
            "Description": "This is a phase 2 randomized, blinded and controlled safety study in patients with ischemic\r\n\r\n      stroke. The time window for enrollment will be within 0-24 hours of symptom onset. For\r\n\r\n      patients who are found with the stroke on awaken",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "February 2009",
            "CompletionDate": "March 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Columbia University",
            "StudyCondition": "Stroke",
            "studyLocation": "University of California, Los Angeles Stroke Network",
            "Enrollment": "164",
            "NctKeyword": "Stroke, Rhabdomyolysis, Jaundice,",
            "MeshKeyword": "Stroke, Jaundice, Rhabdomyolysis,",
            "InterventionKeyword": "Lovastatin, L 647318, Dihydromevinolin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age >18\r\n\r\n\r\n\r\n          2. Satisfies the criteria for ischemic stroke: acute focal neurological deficit of\r\n\r\n             likely ischemic vascular origin.\r\n\r\n\r\n\r\n          3. Patient or legally authori",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90024",
            "Country": "United States",
            "VerificationDate": "May 2016",
            "LastChanged": "May 5, 2016",
            "FirstReceived": "October 30, 2013",
            "OverallOfficial": "Mitchell S Elkind, MD, MS",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Columbia University",
            "LocationName": "University of California, Los Angeles Stroke Network",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01976936",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20090692 - COLUMBIA UNIV - Romano",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20090692",
            "StudyNumber": "20090692 - COLUMBIA UNIV - Romano",
            "StudyTitle": "Neuroprotection with Statin Therapy for Acute Recovery Trial 2 (NeuSTART 2): A Phase 2 safety and pilot efficacy study of lovastatin for the treatment of acute ischemic stroke.",
            "PIID": "149",
            "PicNum": "C00607800",
            "PILastName": "Romano",
            "PIFirstName": "Jose",
            "CoodCNbr": "C00460088",
            "CoordLastName": "Campo-Bustillo",
            "CoordFirstName": "Iszet",
            "CoordEmail": "icampo@med.miami.edu",
            "CoordPhone": "3052438018",
            "EnteredByCNbr": "C00460088",
            "EnteredByLastName": "Campo-Bustillo",
            "EnteredByFirstName": "Iszet",
            "ActiveEnrollingDate": "05/30/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/03/2013",
            "IRBApprovedFrom": "11/03/2009",
            "IRBApprovedTo": "06/29/2017",
            "AccountNbr": "662254",
            "InfoEdNbr": "62986,68724",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "Phase II",
            "Tarea": "Stroke",
            "TareaCode": "8943",
            "Randomization": "Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "NIH",
            "Prescreened": "12",
            "Screenedfailed": "0",
            "SignedICF": "14",
            "Totalaccrued": "14",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "14",
            "FirstNinety": "2",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Iszet Campo-Bustillo,Jorge Bracho, II,Andrea Escobar,Mario Perez",
            "AgentDevices": "Lovastatin",
            "StudyObjective": "Primary Aim: To determine whether lovastatin 640 mg daily for 3 days beginning within 24 hours after acute stroke can be administered safely (<10 percentage points higher risk of myotoxicity and/or hepatotoxicity).\r\nSecondary Aim: To assess efficacy of lovastatin administered at high doses in reducing neurological injury in acute stroke.",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT01976936",
            "StudyInvIND": "1",
            "StudyInvINDNbr": "72,443",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01982942",
            "SecondaryId": "1U01NS082329-01A1",
            "BriefTitle": "Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis",
            "OfficialTitle": "A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis",
            "LeadSponsorClass": "MediciNova",
            "SponsorAgency": "Industry",
            "LeadSponsor": "MediciNova",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study\r\n\r\n      designed to evaluate the safety, tolerability and activity of ibudilast administered twice\r\n\r\n      daily over a 96 week period in subjects with p",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "November 2013",
            "CompletionDate": "May 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "MediciNova",
            "StudyCondition": "Multiple Sclerosis, Primary Progressive",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "250",
            "MeshKeyword": "Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive,",
            "InterventionKeyword": "Ibudilast,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Written informed consent is obtained and willing and able to comply with the protocol\r\n\r\n             in the opinion of the Investigator.\r\n\r\n\r\n\r\n          -  Male or female subjects ages 21 to 65, inclus",
            "EligibleGender": "All",
            "MinAge": "21 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "June 2, 2016",
            "FirstReceived": "October 29, 2013",
            "OverallOfficial": "Robert J Fox, MD, FAAN",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "The Cleveland Clinic",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01982942",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130645 - Intramural - Delgado",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20130645",
            "StudyNumber": "20130645 - Intramural - Delgado",
            "StudyTitle": "SPRINT-MS A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis",
            "PIID": "122",
            "PicNum": "C00360924",
            "PILastName": "Delgado",
            "PIFirstName": "Silvia",
            "CoodCNbr": "C00578829",
            "CoordLastName": "Waltz",
            "CoordFirstName": "Alexandra",
            "CoordEmail": "awaltz@med.miami.edu",
            "CoordPhone": "3052433329",
            "EnteredByCNbr": "C00578829",
            "EnteredByLastName": "Waltz",
            "EnteredByFirstName": "Alexandra",
            "ActiveEnrollingDate": "04/24/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/24/2014",
            "IRBApprovedFrom": "09/05/2013",
            "AccountNbr": "662679",
            "InfoEdNbr": "68183",
            "Expr1": "Phase II",
            "Tarea": "Multiple Sclerosis",
            "TareaCode": "9837",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Federal Non-NIH",
            "Prescreened": "5",
            "Screenedfailed": "2",
            "SignedICF": "8",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "3",
            "Totalpatients": "8",
            "FirstNinety": "2",
            "SiteSampleSize": "Non University of Miami:N/A,UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Expedited Review Complete: Awaiting Correspondence",
            "StudyCoordinator": "Alexandra Waltz,Gloria Rodriguez (Neurology)",
            "NationalSampleSize": "250",
            "NCTNbr": "NCT01982942",
            "StudyInvIND": "0",
            "StudyInvINDNbr": "118,318",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01983241",
            "BriefTitle": "Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)",
            "OfficialTitle": "A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin D",
            "LeadSponsorClass": "Grifols Therapeutics Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Grifols Therapeutics Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "This is a multi-center, randomized, placebo-controlled, double blind clinical study to\r\n\r\n      assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo\r\n\r\n      for 156 weeks (i.e., 3 years) using computed tomog",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2013",
            "CompletionDate": "August 2021",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Grifols Therapeutics Inc.",
            "StudyCondition": "Pulmonary Emphysema in Alpha-1 PI Deficiency",
            "studyLocation": "St. Joseph's Hospital and Medical Center",
            "Enrollment": "339",
            "NctKeyword": "Pulmonary Emphysema, Alpha-1 Antitrypsin Deficiency, AATD, Alpha-1 PI Deficiency, Alpha-1 Protienase Inhibitor,",
            "MeshKeyword": "Emphysema, Pulmonary Emphysema, Alpha 1-Antitrypsin Deficiency,",
            "InterventionKeyword": "Alpha 1-Antitrypsin, Protein C Inhibitor, Protease Inhibitors,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Have a documented total alpha1-PI serum level < 11 µM.\r\n\r\n\r\n\r\n          -  Have a diagnosis of congenital AATD with an allelic combination of ZZ, SZ, Z(null),\r\n\r\n             (null)(null), S(null), or \"a",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "70 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85013",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 1, 2016",
            "FirstReceived": "October 28, 2013",
            "ContactName": "Susan Sorrells",
            "ContactEmail": "Susan.Sorrells@grifols.com",
            "LocationStatus": "Recruiting",
            "LocationName": "St. Joseph's Hospital and Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01983241",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130620 - Grifols - Campos",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20130620",
            "StudyNumber": "20130620 - Grifols - Campos",
            "StudyTitle": "SPARTAA Randomized, DoubleBlind, PlaceboControlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1Proteinase Inhibitor (Human) in Subjects with Pulmonary Emphysema due to Alpha1Antitrypsin Deficiency",
            "PIID": "529",
            "PicNum": "C00065005",
            "PILastName": "Campos",
            "PIFirstName": "Michael",
            "CoodCNbr": "C00065005",
            "CoordLastName": "Campos",
            "CoordFirstName": "Michael",
            "CoordEmail": "MCampos1@med.miami.edu",
            "CoordPhone": "305-243-3045",
            "EnteredByCNbr": "C00065005",
            "EnteredByLastName": "Campos",
            "EnteredByFirstName": "Michael",
            "ActiveEnrollingDate": "08/20/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/20/2014",
            "IRBApprovedFrom": "01/21/2014",
            "IRBApprovedTo": "12/05/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Grifols",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "4",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Patricia Rebolledo,Esther Diaz,Johana Arana,Eliana Mendes",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT01983241",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01990040",
            "BriefTitle": "A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome",
            "OfficialTitle": "A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome",
            "LeadSponsorClass": "Shire",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Shire",
            "OversightAuthority": "No",
            "BriefSummary": "This is a global prospective, observational, multi-center registry to evaluate the long-term\r\n\r\n      safety profile for patients with short bowel syndrome (SBS) who are treated with teduglutide\r\n\r\n      in a routine clinical setting. The regist",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2014",
            "CompletionDate": "December 2029",
            "Phase": "N/A",
            "StudyType": "Observational [Patient Registry]",
            "StudyPhase": "N/A",
            "StudySource": "Shire",
            "StudyCondition": "Short Bowel Syndrome",
            "studyLocation": "Childrens Hospital of Alabama",
            "Enrollment": "1310",
            "NctKeyword": "Short Bowel Syndrome, SBS, teduglutide, Gattex,",
            "MeshKeyword": "Syndrome, Short Bowel Syndrome,",
            "Eligibility": "This is an observational registry study. Data will be collected during routine\r\n\r\n        consultations and clinical staff will enter this information into a system at baseline\r\n\r\n        (when a patient consents into the study) and approximat",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 5, 2017",
            "FirstReceived": "November 11, 2013",
            "OverallOfficial": "Shire Study Physician",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Shire",
            "ContactName": "Shire Contact",
            "ContactEmail": "clinicaltransparency@shire.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Childrens Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01990040",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140777 - NPS Pharmaceuticals/ Inc. - Deshpande",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20140777",
            "StudyNumber": "20140777 - NPS Pharmaceuticals/ Inc. - Deshpande",
            "StudyTitle": "A prospective, multi-center registry for patients with Short Bowel Syndrome.",
            "PIID": "26608",
            "PicNum": "C00070691",
            "PILastName": "Deshpande",
            "PIFirstName": "Amar",
            "CoodCNbr": "C11914779",
            "CoordLastName": "Carabali",
            "CoordFirstName": "Francia",
            "CoordEmail": "fxc123@miami.edu",
            "EnteredByCNbr": "C00070691",
            "EnteredByLastName": "Deshpande",
            "EnteredByFirstName": "Amar",
            "ActiveEnrollingDate": "11/24/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/24/2015",
            "IRBApprovedFrom": "11/26/2014",
            "IRBApprovedTo": "09/27/2016",
            "Expr1": "N/A",
            "Tarea": "Gastrointestinal, Stomach, Esophageal",
            "TareaCode": "6187",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diana Morillo,Francia Carabali",
            "NationalSampleSize": "4",
            "NCTNbr": "NCT01990040",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT01992861",
            "SecondaryId": "NCI-2013-01935",
            "BriefTitle": "MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer",
            "OfficialTitle": "MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix",
            "LeadSponsorClass": "University of Washington",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Washington",
            "OversightAuthority": "No",
            "BriefSummary": "This clinical trial studies magnetic resonance imaging (MRI) and positron emission\r\n\r\n      tomography (PET) imaging in predictive treatment response in patients with stage IB-IVA\r\n\r\n      cervical cancer. MRI is a procedure in which radio waves",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To assess the value of MRI and PET as a non-invasive predictive assay for therapy outcome\r\n\r\n      in cervical cancer.\r\n\r\n\r\n\r\n      OUTLINE:\r\n\r\n\r\n\r\n      Patients undergo radiation therapy and receive chemothe",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2014",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Washington",
            "StudyCondition": "Cervical Adenocarcinoma",
            "studyLocation": "University of Miami Miller School of Medicine-Sylvester Cancer Center",
            "Enrollment": "237",
            "MeshKeyword": "Carcinoma, Squamous Cell, Adenocarcinoma, Carcinoma, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous,",
            "InterventionKeyword": "Fluorodeoxyglucose F18,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must have histologically confirmed stage IB2-IVA epithelial carcinoma of the\r\n\r\n             cervix, including squamous cell, adeno-, and undifferentiated carcinoma, and\r\n\r\n             excludin",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 19, 2016",
            "FirstReceived": "November 5, 2013",
            "OverallOfficial": "Nina Mayr",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Fred Hutch/University of Washington Cancer Consortium",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Miller School of Medicine-Sylvester Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01992861",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20151110 - Uni of Washington - Wolfson",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151110",
            "StudyNumber": "20151110 - Uni of Washington - Wolfson",
            "StudyTitle": "MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix",
            "PIID": "291",
            "PicNum": "C00447309",
            "PILastName": "Wolfson",
            "PIFirstName": "Aaron",
            "CoodCNbr": "C11281485",
            "CoordLastName": "Abreu",
            "CoordFirstName": "Zaida",
            "CoordEmail": "z.abreu@med.miami.edu",
            "CoordPhone": "305-243-4243",
            "EnteredByCNbr": "C01299429",
            "EnteredByLastName": "McCullough",
            "EnteredByFirstName": "Nicole",
            "ActiveEnrollingDate": "09/23/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/23/2016",
            "IRBApprovedFrom": "06/20/2016",
            "IRBApprovedTo": "06/19/2017",
            "DiseaseSiteListDesc": "Cervix",
            "Expr1": "Pilot/Feasibility",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Screening",
            "StudyType_Code": "6181",
            "ResearchType": "Other",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:N/A,UMD:N/A,UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Marinellie Vega,Maggie Chislom,Pavel Noa Hechavarria,Doris Martin",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT01992861",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01996826",
            "BriefTitle": "A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival",
            "OfficialTitle": "A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival",
            "LeadSponsorClass": "Massachusetts Eye and Ear Infirmary",
            "SponsorAgency": "Other",
            "LeadSponsor": "Massachusetts Eye and Ear Infirmary",
            "OversightAuthority": "Yes",
            "BriefSummary": "The goal of this study is to investigate whether using bevacizumab (Avastin®) is both safe\r\n\r\n      and effective at decreasing the likelihood of a high-risk corneal graft rejection. Patients\r\n\r\n      who are \"high-risk\" for rejection have blood",
            "Description": "The purpose of this study is to test the effectiveness of a drug, bevacizumab (Avastin), in\r\n\r\n      preventing blood vessels that often occur after a corneal transplantation which are\r\n\r\n      considered at \"high-risk\" for rejection. In many ca",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2014",
            "CompletionDate": "September 2018",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Massachusetts Eye and Ear Infirmary",
            "StudyCondition": "Corneal Neovascularization",
            "studyLocation": "Bascom Palmer Eye Institute",
            "Enrollment": "90",
            "NctKeyword": "Corneal Neovascularization, Cornea Blood Vessels, Corneal Graft Failure, High-Risk Penetrating Keratoplasty, Corneal Transplant,",
            "MeshKeyword": "Neovascularization, Pathologic, Corneal Neovascularization,",
            "InterventionKeyword": "Bevacizumab, Carboxymethylcellulose Sodium,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Age > 18 years\r\n\r\n\r\n\r\n          -  Participant willing and able to provide written informed consent\r\n\r\n\r\n\r\n          -  Willing and able to comply with study assessments for the full duration of the stud",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 10, 2016",
            "FirstReceived": "November 22, 2013",
            "OverallOfficial": "Reza Dana, MD, MPH, MSc",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Massachusetts Eye and Ear Infirmary",
            "ContactName": "Cornea Research",
            "ContactPhone": "617-573-3313",
            "ContactEmail": "Cornea_Research@MEEI.Harvard.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Bascom Palmer Eye Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01996826",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20110739 - Department of Defense  - Perez",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20110739",
            "StudyNumber": "20110739 - Department of Defense  - Perez",
            "StudyTitle": "A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk\nCorneal Transplant Survival",
            "PIID": "946",
            "PicNum": "C05063045",
            "PILastName": "Perez quinones",
            "PIFirstName": "Victor",
            "CoodCNbr": "C09923487",
            "CoordLastName": "Betancurt",
            "CoordFirstName": "Carolina",
            "CoordEmail": "cbetancurt@med.miami.edu",
            "CoordPhone": "3053266365",
            "EnteredByCNbr": "C05063045",
            "EnteredByLastName": "Perez quinones",
            "EnteredByFirstName": "Victor",
            "ActiveEnrollingDate": "04/13/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/13/2015",
            "IRBApprovedFrom": "09/10/2012",
            "IRBApprovedTo": "07/31/2017",
            "Expr1": "Phase I/II",
            "Tarea": "Cornea",
            "TareaCode": "12036",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Federal Non-NIH",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "9",
            "Totalaccrued": "9",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "9",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Esdras  Arrieta Quintero,Marisa Braun",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT01996826",
            "StudyKeywords": "cornea transplant",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01997333",
            "BriefTitle": "Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",
            "OfficialTitle": "A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)",
            "LeadSponsorClass": "Celldex Therapeutics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Celldex Therapeutics",
            "OversightAuthority": "Yes",
            "BriefSummary": "The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an\r\n\r\n      antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative\r\n\r\n      Breast Cancer (TNBC), and whose tumor cells make a",
            "Description": "CDX-011 consists of an antibody attached to a drug, monomethyl auristatin E (MMAE), that can\r\n\r\n      kill cancer cells. The antibody delivers the drug to cancer cells by attaching to a protein\r\n\r\n      called glycoprotein NMB (gpNMB) that is ex",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2013",
            "CompletionDate": "November 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Celldex Therapeutics",
            "StudyCondition": "Metastatic gpNMB Over-expressing Triple Negative Breast Cancer",
            "studyLocation": "Alabama Oncology",
            "Enrollment": "300",
            "NctKeyword": "Metastatic Breast Cancer, Locally advanced breast cancer, Breast cancer, Triple negative, Estrogen, Progesterone, HER2 receptors, Targeted treatment for breast cancer, Antibody-drug-conjugate, Breast Neoplasms, CDX-011, gpNMB, METRIC, Glembatumumab vedoti",
            "MeshKeyword": "Breast Neoplasms, Triple Negative Breast Neoplasms,",
            "InterventionKeyword": "Capecitabine, Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        Among other criteria, patients must meet all of the following conditions to be eligible\r\n\r\n        for the study:\r\n\r\n\r\n\r\n          1. Diagnosed with metastatic (i.e., cancer that has spread) TNBC",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35211",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 17, 2017",
            "FirstReceived": "November 18, 2013",
            "ContactName": "Celldex Therapeutics",
            "ContactEmail": "info@celldex.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Alabama Oncology",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01997333",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130879 - Celldex Therapeutics - Vogel",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20130879",
            "StudyNumber": "20130879 - Celldex Therapeutics - Vogel",
            "StudyTitle": "A Randomized Multi-center Pivotal Study of CDX011 (CR011vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The \"Metric\" Study)",
            "PIID": "2271",
            "PicNum": "C00189505",
            "PILastName": "Vogel",
            "PIFirstName": "Charles",
            "CoodCNbr": "C11975723",
            "CoordLastName": "Minichiello",
            "CoordFirstName": "Anthony",
            "CoordEmail": "agm112@miami.edu",
            "EnteredByCNbr": "C12001301",
            "EnteredByLastName": "Delgado",
            "EnteredByFirstName": "Yisenny",
            "ActiveEnrollingDate": "03/21/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/21/2014",
            "IRBApprovedFrom": "01/30/2014",
            "IRBApprovedTo": "10/23/2017",
            "AccountNbr": "662659",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase III",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Celldex Therapeutics",
            "Prescreened": "6",
            "Screenedfailed": "14",
            "SignedICF": "33",
            "Totalaccrued": "20",
            "InFollowUp": "3",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "33",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UM Kendall:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Karen Henry,Halyna Hailes,Cristina Rojas-Mejia,Penny Eyer,Onaidy Torres,Deborah Conte,Sarah Raybin,Pascale Timothee",
            "AgentDevices": "Capecitabine",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT01997333",
            "StudyKeywords": "Capecitabine",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01999361",
            "BriefTitle": "Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss",
            "OfficialTitle": "Myfortic® Monotherapy to Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss",
            "LeadSponsorClass": "Rodolfo Alejandro",
            "SponsorAgency": "Other",
            "LeadSponsor": "Rodolfo Alejandro",
            "OversightAuthority": "No",
            "BriefSummary": "This is a single-center, prospective, open label study in islet transplant recipients after\r\n\r\n      complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.",
            "Description": "After complete islet graft loss is determined, patient's maintenance immunosuppression (i.e.\r\n\r\n      sirolimus and tacrolimus) will be discontinued and they will be placed on Myfortic®\r\n\r\n      monotherapy for 2 years thereafter. After completi",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2009",
            "CompletionDate": "December 2020",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Type 1 Diabetes Mellitus",
            "studyLocation": "Diabetes Research Institute",
            "Enrollment": "18",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1,",
            "InterventionKeyword": "Mycophenolate mofetil, Mycophenolic Acid,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Male and female patients age 18-70 years of age.\r\n\r\n\r\n\r\n          2. Ability to provide written informed consent.\r\n\r\n\r\n\r\n          3. Mentally stable and able to comply with the procedures of the study p",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "70 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 9, 2016",
            "FirstReceived": "November 25, 2013",
            "OverallOfficial": "Rodolfo Alejandro, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "Diabetes Research Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01999361",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20071058 - DIABETES RESEARCH INSTITUTE - Alejandro",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20071058",
            "StudyNumber": "20071058 - DIABETES RESEARCH INSTITUTE - Alejandro",
            "StudyTitle": "Myfortic Monotherapy to Prevent de novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss.",
            "PIID": "473",
            "PicNum": "C00309269",
            "PILastName": "Alejandro",
            "PIFirstName": "Rodolfo",
            "CoodCNbr": "C00051652",
            "CoordLastName": "Wilkes",
            "CoordFirstName": "John",
            "EnteredByCNbr": "C00309269",
            "EnteredByLastName": "Alejandro",
            "EnteredByFirstName": "Rodolfo",
            "ActiveEnrollingDate": "03/10/2008",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/10/2008",
            "IRBApprovedFrom": "02/05/2008",
            "IRBApprovedTo": "09/19/2017",
            "InfoEdNbr": "32176",
            "Expr1": "N/A",
            "Tarea": "Islet Transplant",
            "TareaCode": "12545",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "6",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Elina Linetsky,Ana Alvarez",
            "StudyObjective": "Prevent allosensitization after complete islet graft loss after completion of two years of Myfortic® maintenance monotherapy.",
            "NationalSampleSize": "18",
            "NCTNbr": "NCT01999361",
            "StudyKeywords": "ORIM - Shawn",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT01999374",
            "BriefTitle": "Long Term Follow up of Recipients of Functional Islet Allografts",
            "OfficialTitle": "Long Term Follow up of Recipients of Functional Islet Allografts",
            "LeadSponsorClass": "Rodolfo Alejandro",
            "SponsorAgency": "Other",
            "LeadSponsor": "Rodolfo Alejandro",
            "OversightAuthority": "No",
            "BriefSummary": "Since its inception, the Diabetes Research Institute (DRI) has made significant\r\n\r\n      contributions to the field of diabetes, pioneering many of the techniques used in diabetes\r\n\r\n      centers around the world. Through several clinical trial",
            "Description": "To provide long term follow up in subjects with functional islet allografts.",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2013",
            "CompletionDate": "December 2018",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Type 1 Diabetes Mellitus",
            "studyLocation": "Diabetes Research Institute",
            "Enrollment": "30",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Participation in any of the following parent studies: 2000/0329; 2000/0196;\r\n\r\n             2004/0205; 2000/0024; 2006/0200; 2006/0508; 2006/0210\r\n\r\n\r\n\r\n          2. A functioning pancreatic islet graft",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 9, 2016",
            "FirstReceived": "November 25, 2013",
            "OverallOfficial": "Rodolfo Alejandro, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "Diabetes Research Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT01999374",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130034 - Intramural - Alejandro",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20130034",
            "StudyNumber": "20130034 - Intramural - Alejandro",
            "StudyTitle": "LONGTERM FOLLOWUP OF RECIPIENTS OF FUNCTIONAL ISLET ALLOGRAFTS",
            "PIID": "473",
            "PicNum": "C00309269",
            "PILastName": "Alejandro",
            "PIFirstName": "Rodolfo",
            "CoodCNbr": "C09431526",
            "CoordLastName": "Moraes Leao Peixoto",
            "CoordFirstName": "Eduardo",
            "CoordEmail": "epeixoto@med.miami.edu",
            "CoordPhone": "3052433389",
            "EnteredByCNbr": "C09431526",
            "EnteredByLastName": "Moraes Leao Peixoto",
            "EnteredByFirstName": "Eduardo",
            "ActiveEnrollingDate": "04/10/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/10/2013",
            "IRBApprovedFrom": "03/05/2013",
            "IRBApprovedTo": "11/30/2017",
            "InfoEdNbr": "68280",
            "Expr1": "N/A",
            "Tarea": "Diabetes (Type I)",
            "TareaCode": "12541",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "15",
            "Totalaccrued": "15",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "13",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "15",
            "FirstNinety": "4",
            "SiteSampleSize": "Clinical Research Center (CRC):N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "3",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Elina Linetsky",
            "NationalSampleSize": "50",
            "NCTNbr": "NCT01999374",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02000687",
            "BriefTitle": "Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss",
            "OfficialTitle": "Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss",
            "LeadSponsorClass": "Rodolfo Alejandro",
            "SponsorAgency": "Other",
            "LeadSponsor": "Rodolfo Alejandro",
            "OversightAuthority": "No",
            "BriefSummary": "This is a single-center, prospective, open label study in islet transplant recipients\r\n\r\n      following islet graft loss.",
            "Description": "After complete islet graft loss is determined, patient's maintenance immunosuppression (i.e.\r\n\r\n      sirolimus, tacrolimus, MMF and/or Myfortic®) will be discontinued and they will be monitored\r\n\r\n      for 10 years thereafter, for the appearan",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2008",
            "CompletionDate": "July 2021",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Type 1 Diabetes Mellitus",
            "studyLocation": "Diabetes Research Institute",
            "Enrollment": "60",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        1. History of at least one islet alone transplant (ie islet transplant in the absence of\r\n\r\n        any other organ transplant).\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          1. Inability to provide wri",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 9, 2016",
            "FirstReceived": "November 26, 2013",
            "OverallOfficial": "Rodolfo Alejandro, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "Diabetes Research Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02000687",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20080127 - Intramural - Alejandro",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20080127",
            "StudyNumber": "20080127 - Intramural - Alejandro",
            "StudyTitle": "Long term Surveillance of Islet Transplant Recipients Following Complete Graft Loss",
            "PIID": "473",
            "PicNum": "C00309269",
            "PILastName": "Alejandro",
            "PIFirstName": "Rodolfo",
            "CoodCNbr": "C00051652",
            "CoordLastName": "Wilkes",
            "CoordFirstName": "John",
            "EnteredByCNbr": "C00309269",
            "EnteredByLastName": "Alejandro",
            "EnteredByFirstName": "Rodolfo",
            "ActiveEnrollingDate": "12/05/2008",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/05/2008",
            "IRBApprovedFrom": "12/05/2008",
            "IRBApprovedTo": "12/26/2017",
            "AccountNbr": "66728W",
            "InfoEdNbr": "50789",
            "Expr1": "N/A",
            "Tarea": "Islet Transplant",
            "TareaCode": "12545",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "20",
            "Totalaccrued": "20",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "18",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "20",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:60",
            "AccrualPercentageMet": "33.33333333333333333333333333333333333333",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "60",
            "EprostState": "Approved",
            "StudyCoordinator": "Ana Alvarez",
            "StudyObjective": "2.1. Primary Objective\r\n\r\na. Determine the timing, frequency, severity and persistence of allosensitization by monitoring PRA levels after withdrawal of all immunosuppression (tacrolimus, sirolimus MMF or Myfortic®).\r\n\r\n2.2. Secondary Objectives\r\n\r\na. Detect timing, frequency, and level of change in PRA throughout the duration of the study.\r\nb. Determine the fate of autoantibodies.\r\nc. Monitor metabolic function including Hemoglobin A1C and lipid panels.\r\nd. Monitor kidney function with serum creatinine.\r\ne. Determine number of subjects who have required any other organ transplant and time subject has spent on waiting list.\r\nf. Determine if subjects have required any organ transplant and its outcome..\r\ng. Determine glycemic lability using Lability Index over time\r\nh. Determine hypoglycemia unawareness using Clarke Score and Hypo Score. \r\ni. Determine changes in quality of life following islet allograft failure.",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02000687",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02000895",
            "SecondaryId": "66787R",
            "BriefTitle": "Early Detection of Progressive Kidney Disease in Preterm Infants",
            "OfficialTitle": "Early Detection of Progressive Kidney Disease in Preterm Infants",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "Infants born preterm and of low birth weight are known to be at increased risk for early\r\n\r\n      onset of cardiovascular and renal disease in adult life. This has been related to low\r\n\r\n      nephron mass due to inadequate or early termination",
            "Description": "Objectives and Hypotheses:\r\n\r\n\r\n\r\n      Infants born preterm and of low birth weight are known to be at increased risk for early\r\n\r\n      onset of cardiovascular and renal disease in later life. This has been related to low\r\n\r\n      nephron mass",
            "OverallStatus": "Not yet recruiting",
            "StartDate": "September 2017",
            "CompletionDate": "January 2024",
            "Phase": "N/A",
            "StudyType": "Observational [Patient Registry]",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Kidney Disease",
            "studyLocation": "University of Miami/ Holtz Children's Hospital",
            "Enrollment": "200",
            "MeshKeyword": "Cardiovascular Diseases, Kidney Diseases,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        Stable preterm infants <37 weeks' gestational age; Stable term infants >37 weeks'\r\n\r\n        gestational age\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n        <24 weeks gestational age; <600 grams Any anomali",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "1 Week",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 9, 2016",
            "FirstReceived": "November 22, 2013",
            "OverallOfficial": "Carolyn L Abitbol, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Active, not recruiting",
            "LocationName": "University of Miami/ Holtz Children's Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02000895",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20100986 - The Gerber Foundation  - Abitbol",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20100986",
            "StudyNumber": "20100986 - The Gerber Foundation  - Abitbol",
            "StudyTitle": "Early Detection of Progressive Kidney Disease in Preterm Infants",
            "PIID": "2819",
            "PicNum": "C00302983",
            "PILastName": "Abitbol",
            "PIFirstName": "Carolyn",
            "CoodCNbr": "C00488705",
            "CoordLastName": "Francoeur",
            "CoordFirstName": "Denise",
            "CoordEmail": "d.francoeur@miami.edu",
            "CoordPhone": "305-585-6726",
            "EnteredByCNbr": "C00302983",
            "EnteredByLastName": "Abitbol",
            "EnteredByFirstName": "Carolyn",
            "ActiveEnrollingDate": "07/21/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/21/2011",
            "IRBApprovedFrom": "02/14/2011",
            "IRBApprovedTo": "12/13/2017",
            "AccountNbr": "66787R",
            "InfoEdNbr": "54243",
            "Expr1": "N/A",
            "Tarea": "Nephrology",
            "TareaCode": "13342",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "The Gerber Foundation",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "161",
            "Totalaccrued": "160",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "56",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "161",
            "FirstNinety": "91",
            "SiteSampleSize": "JMH:150",
            "AccrualPercentageMet": "106.666666666666666666666666666666666667",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "150",
            "EprostState": "Approved",
            "StudyObjective": "Our long-term goal is for early diagnosis of those infants who are at risk for future development of hypertension and kidney disease so that we might intervene to potentially avert progression to adult disease. The objective of this clinical trial is to acquire data on the natural history of neonatal kidney function and size in infants born preterm during the first 2 years of life. This will be done through the use of standard serum and urine markers as well as non-invasive ultrasound technology. The central hypothesis of this clinical trial is that a subgroup of patients born preterm and of low birth weight will demonstrate early markers of kidney injury including elevated serum cystatin C, proteinuria and low kidney size. Our hypothesis has been formulated on the basis of preliminary data from our group studying this question retrospectively in older children born prematurely who have developed overt kidney disease. The rationale for the proposed research is to develop early serum and demographic markers of pre-clinical kidney disease so that early intervention can occur.",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02000895",
            "StudyKeywords": "Kidney Diseases, Urologic Diseases, Infants",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02001623",
            "BriefTitle": "Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors",
            "OfficialTitle": "First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor",
            "LeadSponsorClass": "Genmab",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Genmab",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed\r\n\r\n      population of patients with specified solid tumors",
            "Description": "The study is conducted in two parts. The dose escalation portion of the trial subjects are\r\n\r\n      enrolled into cohorts at increasing dose levels of HuMax-TF-ADC in 21 day treatment cycles.\r\n\r\n\r\n\r\n      In the Cohort Expansion part of the tria",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2013",
            "CompletionDate": "February 2018",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Genmab",
            "StudyCondition": "Ovary Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "144",
            "NctKeyword": "ovary cancer, cervix cancer, endometrium cancer, bladder cancer, prostate cancer (CRPC), esophagus cancer, lung cancer(NSCLC), Squamous cell carcinoma of the head and neck (SCCHN),",
            "MeshKeyword": "Prostatic Neoplasms, Carcinoma, Squamous Cell, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        - Patients with relapsed, advanced and/or metastatic cancer who have failed available\r\n\r\n        standard treatments or who are not candidates for standard therapy.\r\n\r\n\r\n\r\n        Patients must have measurabl",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 22, 2016",
            "FirstReceived": "November 14, 2013",
            "OverallOfficial": "Johann de Bono, Professor",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust",
            "ContactName": "Charlotte Langer",
            "ContactPhone": "+4533779518",
            "ContactEmail": "c.langer@genmab.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02001623",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20151076 - Genmab - Slomovitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151076",
            "StudyNumber": "20151076 - Genmab - Slomovitz",
            "StudyTitle": "FIRST-IN-HUMAN, DOSE-ESCALATING SAFETY STUDY OF TISSUE FACTOR SPECIFIC ANTIBODY DRUG CONJUGATE (HUMAX®-TF-ADC) IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC SOLID TUMORS KNOWN TO EXPRESS TISSUE FACTOR",
            "PIID": "22712",
            "PicNum": "C11916703",
            "PILastName": "Slomovitz",
            "PIFirstName": "Brian",
            "CoodCNbr": "C12022809",
            "CoordLastName": "Habibi Khameneh",
            "CoordFirstName": "Negin",
            "CoordEmail": "negin.khameneh@med.miami.edu",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "04/28/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/28/2016",
            "IRBApprovedFrom": "03/01/2016",
            "IRBApprovedTo": "02/28/2017",
            "AccountNbr": "666922",
            "DiseaseSiteListDesc": "Cervix,Corpus Uteri,Ovary",
            "Expr1": "Phase I/II",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "8",
            "Totalaccrued": "5",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "3",
            "Totalpatients": "8",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMD:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Halyna Hailes,Isabel Moya,Michelle Mikhail,Evan Dadas,Claudia Grandas Moreno",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02001623",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02003144",
            "SecondaryId": "2013-001151-12",
            "BriefTitle": "An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients",
            "OfficialTitle": "A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)",
            "LeadSponsorClass": "Alexion Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Alexion Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine whether eculizumab long-term use is safe and\r\n\r\n      effective in patients with relapsing NMO.",
            "Description": "This study is an open label extension study to confirm the long term safety and efficacy of\r\n\r\n      eculizumab in subjects with relapsing NMO who have completed the initial double-blind,\r\n\r\n      randomized, placebo-controlled trial ECU-NMO-301",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "January 2015",
            "CompletionDate": "December 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Alexion Pharmaceuticals",
            "StudyCondition": "Neuromyelitis Optica",
            "studyLocation": "Mayo Clinic Arizona",
            "Enrollment": "132",
            "NctKeyword": "Long-term safety study, Extension trial, Eculizumab, Neuromyelitis Optica Spectrum Disorder, Devic's disease, Transverse Myelitis, Optic Neuritis, Relapse, NMO-IgG, CNS Autoimmune Disorders, Demyelinating Disorders,",
            "MeshKeyword": "Neuromyelitis Optica,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Patient completed the ECU-NMO-301 trial\r\n\r\n\r\n\r\n          2. Patient has given written informed consent\r\n\r\n\r\n\r\n        Key Exclusion Criteria:\r\n\r\n\r\n\r\n          1. Patients who have withdrawn from the",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Scottsdale",
            "State": "Arizona",
            "Zip": "85259",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 15, 2016",
            "FirstReceived": "November 18, 2013",
            "LocationName": "Mayo Clinic Arizona",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02003144",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140153 - Alexion Pharmaceuticals - Sheremata",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140153",
            "StudyNumber": "20140153 - Alexion Pharmaceuticals - Sheremata",
            "StudyTitle": "A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)",
            "PIID": "121",
            "PicNum": "C00457629",
            "PILastName": "Sheremata",
            "PIFirstName": "William",
            "CoodCNbr": "C00168827",
            "CoordLastName": "Sawant",
            "CoordFirstName": "Ruta",
            "EnteredByCNbr": "C00457629",
            "EnteredByLastName": "Sheremata",
            "EnteredByFirstName": "William",
            "ActiveEnrollingDate": "04/01/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/01/2015",
            "IRBApprovedFrom": "06/02/2014",
            "IRBApprovedTo": "05/01/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Alexion Pharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "2",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yanet Babcock,Gloria Rodriguez (Neurology)",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT02003144",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02004964",
            "BriefTitle": "Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation",
            "OfficialTitle": "Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation",
            "LeadSponsorClass": "Rodolfo Alejandro",
            "SponsorAgency": "Other",
            "LeadSponsor": "Rodolfo Alejandro",
            "OversightAuthority": "No",
            "BriefSummary": "Protocol to screen potential subjects for islet transplantation",
            "Description": "Subjects with Type 1 diabetes and history of severe hypoglycemia will undergo screening\r\n\r\n      similar to the screening done for islet transplantation including: history; physical; chest\r\n\r\n      X rays; upper GI series if history of ulcer; ab",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2009",
            "CompletionDate": "December 2019",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Type 1 Diabetes Mellitus",
            "studyLocation": "Diabetes Research Institute",
            "Enrollment": "600",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Patients between 18 and 65 years of age\r\n\r\n\r\n\r\n          2. Patients with type 1 diabetes mellitus for more than 5 years duration\r\n\r\n\r\n\r\n          3. Body Mass Index (BMI)\r\n\r\n\r\n\r\n          4. Fulfill one",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 9, 2016",
            "FirstReceived": "November 25, 2013",
            "OverallOfficial": "Rodolfo Alejandro, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "Diabetes Research Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02004964",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20053135 - MEDICINE - Alejandro",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20053135",
            "StudyNumber": "20053135 - MEDICINE - Alejandro",
            "StudyTitle": "Screening of Subjects with Type I Diabetes to Determine Eligibility for Islet Transplantation",
            "PIID": "473",
            "PicNum": "C00309269",
            "PILastName": "Alejandro",
            "PIFirstName": "Rodolfo",
            "CoodCNbr": "C00622014",
            "CoordLastName": "Pavicic",
            "CoordFirstName": "Eva",
            "CoordEmail": "eherrada@med.miami.edu",
            "CoordPhone": "3052436070",
            "EnteredByCNbr": "C00309269",
            "EnteredByLastName": "Alejandro",
            "EnteredByFirstName": "Rodolfo",
            "ActiveEnrollingDate": "08/10/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/10/2011",
            "IRBApprovedFrom": "05/27/2005",
            "IRBApprovedTo": "01/18/2018",
            "InfoEdNbr": "52546",
            "WIrb": "20050887",
            "Expr1": "N/A",
            "Tarea": "Diabetes (Type I)",
            "TareaCode": "12541",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "18",
            "Totalaccrued": "14",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "5",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "18",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:200",
            "AccrualPercentageMet": "7",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "200",
            "EprostState": "Approved",
            "StudyCoordinator": "Elina Linetsky,Nathalia Padilla,Ana Alvarez",
            "AgentDevices": "Device: Continuous Glucose Monitoring System - GOLD",
            "StudyObjective": "To determine the eligibility of subjects with Type 1 diabetes mellitus to join islet transplantation studies.",
            "NationalSampleSize": "600",
            "NCTNbr": "NCT02004964",
            "StudyKeywords": "Diabetes Type I",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT02006433",
            "SecondaryId": "W81XWH-12-1-0559",
            "BriefTitle": "Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury With Deep Brain Stimulation",
            "OfficialTitle": "Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury With Deep Brain Stimulation",
            "LeadSponsorClass": "Jonathan Jagid",
            "SponsorAgency": "Other",
            "LeadSponsor": "Jonathan Jagid",
            "OversightAuthority": "Yes",
            "BriefSummary": "The Investigators propose an investigation of the safety of deep brain stimulation (DBS) for\r\n\r\n      the alleviation of chronic neuropathic pain in patients with spinal cord injury (SCI).\r\n\r\n\r\n\r\n      Aim 1 is to determine whether DBS in the pe",
            "Description": "The current study attempts to utilize deep brain stimulation of the periaqueductal grey\r\n\r\n      (PAG) for diminution of both neuropathic and nociceptive pain in spinal cord injury\r\n\r\n      patients. Likewise, the study will look at the effects",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2013",
            "CompletionDate": "September 2017",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Pain",
            "studyLocation": "University of Miami Hospital",
            "Enrollment": "12",
            "MeshKeyword": "Spinal Cord Injuries, Autonomic Dysreflexia,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age 22-60 years of age\r\n\r\n\r\n\r\n          2. Level of injury at or above T12\r\n\r\n\r\n\r\n          3. Neuropathic pain at or below the level of injury, as determined based on pain in an\r\n\r\n             area wit",
            "EligibleGender": "All",
            "MinAge": "22 Years",
            "MaxAge": "60 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 4, 2017",
            "FirstReceived": "October 25, 2013",
            "OverallOfficial": "Jonathan R Jagid, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Jonathan R Jagid, M.D.",
            "ContactPhone": "(305) 243-2359",
            "ContactEmail": "JJagid@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02006433",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120429 - Department of Defense - Jagid",
            "FileProcessContentId": "440",
            "Division": "Neurosurgery",
            "StdyDivision": "9636",
            "EprostNbr": "20120429",
            "StudyNumber": "20120429 - Department of Defense - Jagid",
            "StudyTitle": "Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation",
            "PIID": "526",
            "PicNum": "C02000304",
            "PILastName": "Jagid",
            "PIFirstName": "Jonathan",
            "CoodCNbr": "C00161858",
            "CoordLastName": "Fisher",
            "CoordFirstName": "Letitia",
            "CoordEmail": "lfisher@med.miami.edu",
            "EnteredByCNbr": "C00568509",
            "EnteredByLastName": "Martinez-Arizala",
            "EnteredByFirstName": "Alberto",
            "ActiveEnrollingDate": "01/16/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/14/2014",
            "IRBApprovedFrom": "06/03/2013",
            "IRBApprovedTo": "04/03/2017",
            "InfoEdNbr": "70036",
            "Expr1": "N/A",
            "Tarea": "Cranial",
            "TareaCode": "9639",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "1",
            "SiteSampleSize": "Non University of Miami:N/A,UMMG:N/A,UMH:N/A,VA:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Ian Hentall,Jessica Cambridge,Letitia Fisher",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT02006433",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02006550",
            "BriefTitle": "Interrogation of Wnt, Notch and Hedgehog Activity in Primary Tumor Samples",
            "OfficialTitle": "Interrogation of Wnt, Notch and Hedgehog Activity in Primary Tumor Samples",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "BriefSummary": "Cancer results when undifferentiated cells grow in an uncontrolled manner, crowding out\r\n\r\n      normal cells, causing morbidity and ultimately mortality. The cancer stem cell theory\r\n\r\n      suggests that most tumors undergo a process of differ",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2010",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "250",
            "NctKeyword": "Wnt, Notch, Hedgehog, Tumor Sample,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients diagnosed with a primary cancer tumor scheduled for a surgery to remove it.\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients not diagnosed with a primary cancer scheduled for a st",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 6, 2016",
            "FirstReceived": "December 4, 2013",
            "OverallOfficial": "Anthony Capobianco, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02006550",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20100200 - Intramural - Capobianco",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20100200",
            "StudyNumber": "20100200 - Intramural - Capobianco",
            "StudyTitle": "Interrogation of  Wnt, Notch and Hedgehog Activity in primary  tumor samples",
            "PIID": "3897",
            "PicNum": "C00722072",
            "PILastName": "Capobianco",
            "PIFirstName": "Anthony",
            "CoodCNbr": "C04290297",
            "CoordLastName": "Zamora",
            "CoordFirstName": "Tania",
            "CoordEmail": "tzamora@med.miami.edu",
            "CoordPhone": "3052433813",
            "EnteredByCNbr": "C04035535",
            "EnteredByLastName": "Sanchez",
            "EnteredByFirstName": "Lilly",
            "ActiveEnrollingDate": "06/11/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/11/2010",
            "IRBApprovedFrom": "06/02/2010",
            "IRBApprovedTo": "11/22/2017",
            "InfoEdNbr": "52656",
            "DiseaseSiteListDesc": "Stomach",
            "Expr1": "N/A",
            "Tarea": "Stomach and Esophageal Cancer",
            "TareaCode": "12538",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Correlative",
            "StudyType_Code": "140",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "40",
            "Screenedfailed": "32",
            "SignedICF": "230",
            "Totalaccrued": "198",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "230",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:250,UMH:N/A,JMH:N/A,UMHC:N/A",
            "AccrualPercentageMet": "79.2",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "250",
            "EprostState": "Approved",
            "StudyCoordinator": "Jean (Lynne) Sparling,Claudia Escobar",
            "StudyObjective": "Specific Aims\r\n\r\n identify and isolate the cancer stem cell populations from primary tumor samples.\r\n interrogate the status of the Notch, Wnt and Hedghog pathways in the bulk tumor as well as in specific cell populations, such as the CSC.\r\n determine the degree of cross-talk between these pathways and which of these pathways is essential for the self renewal properties and tumorigenic properties of the CSC population.\r\n Identify critical targets for therapeutic intervention in CSC populations.",
            "NationalSampleSize": "250",
            "NCTNbr": "NCT02006550",
            "StudyKeywords": "ORIM: Kanchan Sakhrani (QA: 9/9/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02006563",
            "BriefTitle": "Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors",
            "OfficialTitle": "Evaluation of Metabolic Tumor Volumes in Radiation of Primary Brain Tumors",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "-  Metabolic Tumor Volume (MTV), identified by Magnetic Resonance Spectroscopic Imaging\r\n\r\n           (MRSI) is different from the Clinical Target Volume (CTV) used for radiation dose\r\n\r\n           delivery in the treatment of brain tumors.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "January 2011",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Brain Tumor",
            "studyLocation": "University of Miami",
            "Enrollment": "20",
            "NctKeyword": "Brain Tumor, Glioblastoma multiforme, GBM, Metabolic Tumor Volume, MTV, Clinical Tumor Volume, CTV,",
            "MeshKeyword": "Glioblastoma, Brain Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must have histologically confirmed primary brain tumor.\r\n\r\n\r\n\r\n          -  Patients may be enrolled prior to surgery, after surgical resection or with\r\n\r\n             unresectable tumors.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 12, 2016",
            "FirstReceived": "December 4, 2013",
            "OverallOfficial": "Radka Stoyanova, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02006563",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20100809 - Intramural - Stoyanova",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20100809",
            "StudyNumber": "20100809 - Intramural - Stoyanova",
            "StudyTitle": "Evaluation of Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors",
            "PIID": "1714",
            "PicNum": "C06980336",
            "PILastName": "Stoyanova",
            "PIFirstName": "Radka",
            "CoodCNbr": "C11903350",
            "CoordLastName": "Mikhail",
            "CoordFirstName": "Michelle",
            "CoordEmail": "mxm752@med.miami.edu",
            "CoordPhone": "305-243-4903",
            "EnteredByCNbr": "C06980336",
            "EnteredByLastName": "Stoyanova",
            "EnteredByFirstName": "Radka",
            "ActiveEnrollingDate": "06/08/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/08/2011",
            "IRBApprovedFrom": "02/01/2011",
            "IRBApprovedTo": "06/15/2017",
            "AccountNbr": "66863A",
            "InfoEdNbr": "62140/56105",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "Pilot/Feasibility",
            "Tarea": "Neurological Cancer",
            "TareaCode": "12442",
            "Expr2": "Screening",
            "StudyType_Code": "6181",
            "ResearchType": "Other",
            "SponsorGroup": "Intramural",
            "Prescreened": "1",
            "Screenedfailed": "1",
            "SignedICF": "23",
            "Totalaccrued": "22",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "23",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "40",
            "NCTNbr": "NCT02006563",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02007746",
            "BriefTitle": "Liver Fibrosis in Sickle Cell Disease",
            "OfficialTitle": "Assessment of Liver Fibrosis in Patients With Sickle Cell Disease",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "Patients with sickle cell disease many have a number of systemic complications, including\r\n\r\n      liver problems. Some of these liver problems lead to liver fibrosis/cirrhosis, secondary to\r\n\r\n      chronic blood transfusions. The purpose of th",
            "Description": "Liver biopsy is the gold standard to examine the liver for iron deposits and histology.\r\n\r\n      However, liver biopsy is invasive and involves a risk of bleeding and pain. Biopsy may also\r\n\r\n      miss significant pathology if the small biopsy",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2012",
            "CompletionDate": "December 2017",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Sickle Cell Disease",
            "studyLocation": "University of Miami",
            "Enrollment": "30",
            "NctKeyword": "sickle cell disease, hemochromatosis, liver fibrosis, liver cirrhosis, FibroScan, Ferriscan, liver iron,",
            "MeshKeyword": "Fibrosis, Anemia, Sickle Cell, Liver Cirrhosis,",
            "InterventionKeyword": "Liver Extracts, Iron,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  pediatric patients age 10 years and older with sickle cell disease\r\n\r\n\r\n\r\n          -  meeting other criteria:\r\n\r\n\r\n\r\n               1. history of chronic transfusion and iron overload and/or",
            "EligibleGender": "All",
            "MinAge": "10 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 14, 2016",
            "FirstReceived": "December 6, 2013",
            "OverallOfficial": "Ofelia Alvarez, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami - Director Sickle Cell Services Pediatric Hematology/Oncology",
            "ContactName": "Ofelia Alvarez, MD",
            "ContactPhone": "305.243.0846",
            "ContactEmail": "oalvarez2@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02007746",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120222 - Intramural - Alvarez",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20120222",
            "StudyNumber": "20120222 - Intramural - Alvarez",
            "StudyTitle": "Assessment of Liver Fibrosis in Patients with Sickle Cell Disease",
            "PIID": "299",
            "PicNum": "C01335657",
            "PILastName": "Alvarez",
            "PIFirstName": "Ofelia",
            "CoodCNbr": "C10711892",
            "CoordLastName": "D'Antonio",
            "CoordFirstName": "Gabriela",
            "CoordEmail": "Gabriela.Dantonio@jhsmiami.org",
            "CoordPhone": "3058560601",
            "EnteredByCNbr": "C11875174",
            "EnteredByLastName": "Cumming",
            "EnteredByFirstName": "Vanessa",
            "ActiveEnrollingDate": "11/26/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/06/2012",
            "IRBApprovedFrom": "11/26/2012",
            "IRBApprovedTo": "09/11/2017",
            "DiseaseSiteListDesc": "Other Hematopoietic",
            "Expr1": "N/A",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "10",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Vanessa Cumming,Tally Hustace",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02007746",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02011204",
            "BriefTitle": "Study of Electrical Impedance Myography (EIM) in ALS",
            "OfficialTitle": "Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance",
            "LeadSponsorClass": "Skulpt, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Skulpt, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "This trial is studying Electrical Impedance Myography (EIM) for measuring muscle health. The\r\n\r\n      trial is studying people with Amyotrophic Lateral Sclerosis (ALS), other neuromuscular\r\n\r\n      diseases, and healthy volunteers to see if the",
            "Description": "This is a multicenter, 9-month study evaluating the effectiveness of electrical impedance\r\n\r\n      myography (EIM) as a diagnostic and disease-tracking tool. In addition, the following will\r\n\r\n      be studied:\r\n\r\n\r\n\r\n        1. Determine EIM de",
            "OverallStatus": "Completed",
            "StartDate": "November 2013",
            "CompletionDate": "March 2016",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Skulpt, Inc.",
            "StudyCondition": "Amyotrophic Lateral Sclerosis",
            "studyLocation": "St. Joseph's Hospital & Medical Center",
            "Enrollment": "106",
            "MeshKeyword": "Sclerosis, Multiple Sclerosis, Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Charcot-Marie-Tooth Disease, Nerve Compression Syndromes, Hereditary Sensory and Motor Neuropathy, Tooth Diseases,",
            "Eligibility": "Early ALS Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Sporadic or familial ALS (as defined by revised El Escorial criteria)\r\n\r\n\r\n\r\n          -  Onset of weakness or spasticity due to ALS ≤ 36 months prior to the\r\n\r\n             Screening/Baseline",
            "EligibleGender": "All",
            "MinAge": "35 Years",
            "MaxAge": "80 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85013",
            "Country": "United States",
            "VerificationDate": "May 2016",
            "LastChanged": "May 10, 2016",
            "FirstReceived": "December 3, 2013",
            "OverallOfficial": "Jeremy Shefner, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "State University of New York - Upstate Medical University",
            "LocationName": "St. Joseph's Hospital & Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02011204",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130499 - Convergence Medical Devices/ Inc via funding from  - Benatar",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20130499",
            "StudyNumber": "20130499 - Convergence Medical Devices/ Inc via funding from  - Benatar",
            "StudyTitle": "Noninvasive assessment of neuromuscular disease using electrical impedance",
            "PIID": "3255",
            "PicNum": "C09944978",
            "PILastName": "Benatar",
            "PIFirstName": "Michael",
            "CoodCNbr": "C11281958",
            "CoordLastName": "Michon",
            "CoordFirstName": "Sara-Claude",
            "CoordEmail": "scmichon@med.miami.edu",
            "CoordPhone": "305-243-6481",
            "EnteredByCNbr": "C11338617",
            "EnteredByLastName": "Hussain",
            "EnteredByFirstName": "Sumaira",
            "ActiveEnrollingDate": "01/17/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/17/2014",
            "IRBApprovedFrom": "09/06/2013",
            "IRBApprovedTo": "08/17/2015",
            "InfoEdNbr": "67158",
            "Expr1": "N/A",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "24",
            "Totalaccrued": "24",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "24",
            "FirstNinety": "6",
            "SiteSampleSize": "Non University of Miami:N/A,UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Sara-Claude Michon,Danielle Dauphin,Sumaira Hussain",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02011204",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02012777",
            "BriefTitle": "Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease",
            "OfficialTitle": "Propanolol Effect on Red Cell Adhesion in Non-Asthmatic Children With Sickle Cell Disease: A Dose Finding Study",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "Propanolol is a beta blocker which has been found to inhibit the ability of epinephrine to\r\n\r\n      upregulate sickle red cell adhesion to laminin and endothelial cells in vitro. The purpose\r\n\r\n      of this pilot study is to administer one dose",
            "Description": "A similar pilot study has already been conducted in adults and is now being tried in\r\n\r\n      children to gather preliminary data for a grant submission. No safety issues were found in\r\n\r\n      the adult pilot study. This study will evaluate the",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2010",
            "CompletionDate": "December 2017",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Sickle Cell Disease",
            "studyLocation": "University of Miami",
            "Enrollment": "20",
            "NctKeyword": "sickle cell disease, propanolol, red blood cell adhesion,",
            "MeshKeyword": "Anemia, Sickle Cell, Tissue Adhesions,",
            "InterventionKeyword": "Propranolol,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. diagnosis of HbSS or HbSBeta0Thal\r\n\r\n\r\n\r\n          2. age 10-17 years\r\n\r\n\r\n\r\n          3. Weight 30kg or greater\r\n\r\n\r\n\r\n          4. Hb 7mg/dL or greater\r\n\r\n\r\n\r\n          5. informed consent",
            "EligibleGender": "All",
            "MinAge": "7 Years",
            "MaxAge": "17 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 24, 2016",
            "FirstReceived": "December 6, 2013",
            "OverallOfficial": "Ofelia A Alvarez, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Ofelia Alvarez, MD",
            "ContactPhone": "305.243.0846",
            "ContactEmail": "oalvarez2@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02012777",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20100334 - PEDIATRICS - Alvarez",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20100334",
            "StudyNumber": "20100334 - PEDIATRICS - Alvarez",
            "StudyTitle": "Propranolol Effect on Red Cell Adhesion in NonAsthmatic Children with Sickle Cell Disease: A DoseFinding Study",
            "PIID": "299",
            "PicNum": "C01335657",
            "PILastName": "Alvarez",
            "PIFirstName": "Ofelia",
            "CoodCNbr": "C01335657",
            "CoordLastName": "Alvarez",
            "CoordFirstName": "Ofelia",
            "EnteredByCNbr": "C01335657",
            "EnteredByLastName": "Alvarez",
            "EnteredByFirstName": "Ofelia",
            "ActiveEnrollingDate": "07/29/2010",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/29/2010",
            "IRBApprovedFrom": "06/07/2010",
            "IRBApprovedTo": "04/03/2017",
            "InfoEdNbr": "55024",
            "Expr1": "Phase I",
            "Tarea": "Hematology/Oncology",
            "TareaCode": "13338",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "10",
            "Totalaccrued": "8",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:20,UMMG:N/A",
            "AccrualPercentageMet": "40",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "20",
            "EprostState": "Approved",
            "StudyCoordinator": "Tally Hustace,Vanessa Cumming",
            "AgentDevices": "Agent: Propranolol",
            "StudyObjective": "The purpose of this pilot study is to administer one dose of propranolol to children with sickle cell disease and to measure pre and post red cell adhesion. The hypothesis is that a single dose of propranolol will decrease red cell adhesion to laminin and endothelial cells as compared to baseline. This pilot has been already conducted in adults and is done in order to gather preliminary data for a grant submission. No safety issues were found in that pilot study. We will study the effect of different doses of propranolol. The risks of this study involves the risks of blood draws (3 occasions) and the risks of propranolol. In order to minimize the risks we will exclude children with sickle cell disease and asthma because asthma is a contraindication for the use of propranolol. In addition, the participants should not have hypotension or be bradycardic.",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02012777",
            "StudyKeywords": "ORIM: Kanchan Sakhrani (QA: 11/1/10)",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02013674",
            "BriefTitle": "The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)",
            "OfficialTitle": "A Phase II, Randomized, Blinded, Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Human Mesenchymal Stem Cells (hMSCs) (20 Million or 100 Million Total MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Second",
            "LeadSponsorClass": "Joshua M Hare",
            "SponsorAgency": "Other",
            "LeadSponsor": "Joshua M Hare",
            "OversightAuthority": "Yes",
            "BriefSummary": "Thirty (30) patients with chronic ischemic left ventricular dysfunction secondary to MI\r\n\r\n      scheduled to undergo cardiac catheterization will be enrolled in the study. This is a phase\r\n\r\n      II study intended to gain additional safety and",
            "Description": "Thirty (30) patients with chronic ischemic left ventricular dysfunction secondary to MI\r\n\r\n      scheduled to undergo cardiac catheterization will be enrolled in the study.This is a phase\r\n\r\n      II study intended to gain additional safety and",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "November 2013",
            "CompletionDate": "June 2019",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Chronic Ischemic Left Ventricular Dysfunction",
            "studyLocation": "ISCI / University of Miami",
            "Enrollment": "30",
            "NctKeyword": "Cardiovascular, Chronic Ischemic Left Ventricular Dysfunction,",
            "MeshKeyword": "Infarction, Ischemia, Myocardial Infarction, Ventricular Dysfunction, Ventricular Dysfunction, Left,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  In order to participate in this study, a patient MUST:\r\n\r\n\r\n\r\n               1. Be ≥ 21 and < 90 years of age.\r\n\r\n\r\n\r\n               2. Provide written informed consent.\r\n\r\n\r\n\r\n               3. Have a d",
            "EligibleGender": "All",
            "MinAge": "21 Years",
            "MaxAge": "90 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 11, 2016",
            "FirstReceived": "December 2, 2013",
            "OverallOfficial": "Joshua M Hare, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "ISCI / University of Miami Miller School of Medicine",
            "LocationName": "ISCI / University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02013674",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120660 - Intramural - Hare",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20120660",
            "StudyNumber": "20120660 - Intramural - Hare",
            "StudyTitle": "A phase II Randomized, Blinded Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Mesenchymal Stem Cells in Patients with Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction. (The TRIDENT Study)",
            "PIID": "896",
            "PicNum": "C05065867",
            "PILastName": "Hare",
            "PIFirstName": "Joshua",
            "CoodCNbr": "C06971497",
            "CoordLastName": "Delgado",
            "CoordFirstName": "Cindy",
            "CoordEmail": "cdelgado5@med.miami.edu",
            "CoordPhone": "3052438484",
            "EnteredByCNbr": "C00130574",
            "EnteredByLastName": "Difede",
            "EnteredByFirstName": "Darcy",
            "ActiveEnrollingDate": "10/07/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/07/2013",
            "IRBApprovedFrom": "06/24/2013",
            "IRBApprovedTo": "03/27/2017",
            "AccountNbr": "700823",
            "InfoEdNbr": "65734",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Device/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "1",
            "Screenedfailed": "25",
            "SignedICF": "43",
            "Totalaccrued": "32",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "43",
            "FirstNinety": "2",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Darcy Difede,Lina Caceres Cardenas,Jairo Tovar,Mayra Vidro Casiano,Cindy Delgado,Marietsy Pujol",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02013674",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02013700",
            "BriefTitle": "Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)",
            "OfficialTitle": "A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Idiopathic Pulmonary Fibrosis",
            "LeadSponsorClass": "Joshua M Hare",
            "SponsorAgency": "Other",
            "LeadSponsor": "Joshua M Hare",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a phase I, randomized, blinded, placebo-controlled 9 subjects pilot safety run-in\r\n\r\n      followed by an additional 16 randomized subjects for a total of 25 subjects. In the pilot\r\n\r\n      phase subjects will be randomized into three tr",
            "Description": "Idiopathic Pulmonary Fibrosis (IPF) is a progressive and debilitating lung disease\r\n\r\n      characterized by interstitial fibrosis with decreasing lung volumes and pulmonary\r\n\r\n      insufficiency eventually resulting in death. Patients with Idi",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "August 2013",
            "CompletionDate": "August 2019",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Idiopathic Pulmonary Fibrosis (IPF)",
            "studyLocation": "Interdisciplinary Stem Cell Institute / University of Miami",
            "Enrollment": "25",
            "NctKeyword": "IPF, Pulmonary fibrosis,",
            "MeshKeyword": "Fibrosis, Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonias, Pulmonary Fibrosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Provide written informed consent.\r\n\r\n\r\n\r\n          -  Subjects age equal to or greater than 40 and equal to or less than 90 years at the\r\n\r\n             time of signing the Informed Consent Form.",
            "EligibleGender": "All",
            "MinAge": "40 Years",
            "MaxAge": "90 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 29, 2016",
            "FirstReceived": "December 2, 2013",
            "OverallOfficial": "Marilyn K. Glassberg, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "Interdisciplinary Stem Cell Institute / University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02013700",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120946 - Lester and Susan Smith Foundation - Glassberg",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20120946",
            "StudyNumber": "20120946 - Lester and Susan Smith Foundation - Glassberg",
            "StudyTitle": "A Phase I, Randomized, Blinded and Placebocontrolled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients with Idiopathic Pulmonary Fibrosis.",
            "PIID": "839",
            "PicNum": "C00393339",
            "PILastName": "Glassberg Csete",
            "PIFirstName": "Marilyn",
            "CoodCNbr": "C00047281",
            "CoordLastName": "Simonet",
            "CoordFirstName": "Emmanuelle",
            "CoordEmail": "esimonet@med.miami.edu",
            "CoordPhone": "3052433728",
            "EnteredByCNbr": "C00047281",
            "EnteredByLastName": "Simonet",
            "EnteredByFirstName": "Emmanuelle",
            "ActiveEnrollingDate": "03/11/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/23/2016",
            "IRBApprovedFrom": "02/05/2013",
            "IRBApprovedTo": "11/02/2016",
            "AccountNbr": "700974",
            "InfoEdNbr": "64686",
            "Expr1": "Pilot/Feasibility",
            "Tarea": "Idiopathic Pulmonary Fibrosis (IPF)",
            "TareaCode": "13536",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Foundation",
            "Prescreened": "0",
            "Screenedfailed": "9",
            "SignedICF": "22",
            "Totalaccrued": "13",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "22",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Emmanuelle Simonet,Esther Diaz,Valeria Bagley",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02013700",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02014740",
            "BriefTitle": "Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes",
            "OfficialTitle": "Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this research study is to learn about the effect of Liraglutide, (Victoza®),\r\n\r\n      on the fat surrounding the heart.Excessive amount of the fat around the heart is common in\r\n\r\n      people with type 2 diabetes and can be assoc",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2014",
            "CompletionDate": "June 2017",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "University of Miami",
            "StudyCondition": "Type 2 Diabetes",
            "studyLocation": "University of Miami",
            "Enrollment": "100",
            "NctKeyword": "Epicardial fat, Type 2 diabetes, Obesity, GLP-1 analogs,",
            "MeshKeyword": "Diabetes Mellitus, Type 2, Diabetes Mellitus, Overweight,",
            "InterventionKeyword": "Metformin, Liraglutide,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Type 2 diabetes, as defined by ADA criteria\r\n\r\n\r\n\r\n          -  HbA1c < 8% measured at least 1 month prior to this study\r\n\r\n\r\n\r\n          -  BMI ≥27 kg/m2\r\n\r\n\r\n\r\n          -  Pre-treatment with Metformin",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 15, 2016",
            "FirstReceived": "December 12, 2013",
            "ContactName": "Gianluca Iacobellis, MD PhD",
            "ContactEmail": "giacobellis@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02014740",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120811 - Novo Nordisk Initiated Investigator Grant  - Iacobellis",
            "FileProcessContentId": "440",
            "Division": "Endocrinology",
            "StdyDivision": "10241",
            "EprostNbr": "20120811",
            "StudyNumber": "20120811 - Novo Nordisk Initiated Investigator Grant  - Iacobellis",
            "StudyTitle": "EFFECT OF LIRAGLUTIDE ON EPICARDIAL FATIN SUBJECTS WITH TYPE 2 DIABETES",
            "PIID": "26212",
            "PicNum": "C09951125",
            "PILastName": "Iacobellis",
            "PIFirstName": "Gianluca",
            "CoodCNbr": "C10762064",
            "CoordLastName": "Young",
            "CoordFirstName": "Michael",
            "CoordEmail": "myoung@med.miami.edu",
            "EnteredByCNbr": "C10762064",
            "EnteredByLastName": "Young",
            "EnteredByFirstName": "Michael",
            "ActiveEnrollingDate": "03/17/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/17/2014",
            "IRBApprovedFrom": "07/15/2013",
            "IRBApprovedTo": "02/01/2017",
            "AccountNbr": "662159",
            "DiseaseSiteListDesc": "Multiple",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "Single",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Novo Nordisk",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "100",
            "Totalaccrued": "61",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "23",
            "CurrentlyActiveTreatment": "33",
            "Totalpatients": "100",
            "FirstNinety": "13",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Mahshid Mohseni,Pritisheel Banga",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02014740",
            "StudyKeywords": "diabetes, Metformin, Glumetza, Fortamet, Riomet, Glucophage,  victoza, liraglutide, abdominal fat, epicardial fat, weight loss",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02017964",
            "SecondaryId": "NCI-2013-02379",
            "BriefTitle": "Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma",
            "OfficialTitle": "A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age",
            "LeadSponsorClass": "Children's Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Oncology Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "This phase II trial studies how well combination chemotherapy works in treating younger\r\n\r\n      patients with newly diagnosed, non-metastatic desmoplastic medulloblastoma. Drugs used in\r\n\r\n      chemotherapy, such as vincristine sulfate, cyclop",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. Estimate of the progression free survival (PFS) distribution for patients 0-<4 years of\r\n\r\n      age with M0 desmoplastic medulloblastoma (nodular desmoplastic or medulloblastoma with\r\n\r\n      extensive nodula",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "December 2013",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Children's Oncology Group",
            "StudyCondition": "Untreated Childhood Medulloblastoma",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "26",
            "MeshKeyword": "Medulloblastoma,",
            "InterventionKeyword": "Etoposide, Vincristine, Etoposide phosphate, Cyclophosphamide, Carboplatin, Methotrexate,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must be newly diagnosed and have a confirmed histologic diagnosis of nodular\r\n\r\n             desmoplastic (ND) medulloblastoma or medulloblastoma with extensive nodularity (MBEN)",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "47 Months",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 9, 2017",
            "FirstReceived": "December 13, 2013",
            "OverallOfficial": "Lucie Lafay-Cousin, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02017964",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150160 - COG - Barredo",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150160",
            "StudyNumber": "20150160 - COG - Barredo",
            "StudyTitle": "ACNS1221: A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C11973083",
            "CoordLastName": "Best",
            "CoordFirstName": "Wendy",
            "CoordEmail": "wtbest@med.miami.edu",
            "CoordPhone": "305-243-7130",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "09/12/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/12/2013",
            "IRBApprovedFrom": "09/12/2013",
            "IRBApprovedTo": "06/11/2015",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "Phase II",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "COG",
            "SiteSampleSize": "JMH:N/A,UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Pre-Submission",
            "StudyCoordinator": "Myriam Zayas",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02017964",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02022735",
            "BriefTitle": "Deep Brain Stimulation Effects on Gait and Balance in Patients With Parkinson's Disease",
            "OfficialTitle": "Deep Brain Stimulation Effects on Gait and Balance in Patients With Parkinson's Disease.",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to evaluate the effect of Deep Brain stimulation (DBS) on\r\n\r\n      walking in patients with Parkinson's disease that have had DBS. While DBS improves\r\n\r\n      Parkinson's disease (PD) symptoms and walking in many pat",
            "Description": "Parkinson disease (PD) is defined by the presence of a resting tremor, slowness, stiffness\r\n\r\n      and problems with balance and walking. Gait disorder in Parkinson's disease is common and\r\n\r\n      has a greater impact on quality of life. Curre",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2013",
            "CompletionDate": "December 2020",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Parkinson's Disease",
            "studyLocation": "University of Miami",
            "Enrollment": "50",
            "NctKeyword": "Deep Brain Stimulation,",
            "MeshKeyword": "Parkinson Disease,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Parkinson's disease stage 1-3\r\n\r\n\r\n\r\n          -  walking impairment\r\n\r\n\r\n\r\n             •Exclusion Criteria:\r\n\r\n\r\n\r\n          -  stage 4,5\r\n\r\n\r\n\r\n          -  dementia",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 6, 2016",
            "FirstReceived": "December 5, 2013",
            "OverallOfficial": "Corneliu Luca, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Corneliu Luca, MD, PhD",
            "ContactPhone": "3052432235",
            "ContactEmail": "cluca@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02022735",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130225 - Intramural - Luca",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20130225",
            "StudyNumber": "20130225 - Intramural - Luca",
            "StudyTitle": "Deep brain stimulation effects on gait and balance in patients with Parkinson's disease.",
            "PIID": "2567",
            "PicNum": "C02023921",
            "PILastName": "Luca",
            "PIFirstName": "Corneliu",
            "CoodCNbr": "C10189041",
            "CoordLastName": "Perez",
            "CoordFirstName": "Lissette",
            "CoordEmail": "LPerez4@med.miami.edu",
            "CoordPhone": "3052432781",
            "EnteredByCNbr": "C00484213",
            "EnteredByLastName": "Gallo",
            "EnteredByFirstName": "Bruno",
            "ActiveEnrollingDate": "10/02/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/02/2013",
            "IRBApprovedFrom": "09/06/2013",
            "IRBApprovedTo": "08/02/2016",
            "InfoEdNbr": "68817",
            "Expr1": "N/A",
            "Tarea": "Movement Disorders",
            "TareaCode": "8937",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Other",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "8",
            "Screenedfailed": "0",
            "SignedICF": "11",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "11",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Lissette Perez,Stacy Merritt,Nathalie Padron",
            "NationalSampleSize": "130",
            "NCTNbr": "NCT02022735",
            "StudyKeywords": "Parkinson disease, Deep brain stimulation, Gait, Balance",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02022826",
            "BriefTitle": "Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis",
            "OfficialTitle": "Clinical Management With SmartPill Motility Monitoring System and Validation of the SmartPill Five Hour Cutoff in Patients With Symptoms of Gastroparesis",
            "LeadSponsorClass": "Medtronic - MITG",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Medtronic - MITG",
            "OversightAuthority": "No",
            "BriefSummary": "This protocol is designed to validate use of the SPM for diagnosis of delayed gastric\r\n\r\n      emptying in patients with symptoms of gastroparesis and assess impact of a SmartPill study\r\n\r\n      on patient management in the gastroparetic populat",
            "OverallStatus": "Terminated",
            "StartDate": "January 2014",
            "CompletionDate": "March 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Medtronic - MITG",
            "StudyCondition": "Gastroparesis",
            "studyLocation": "Stanford University",
            "Enrollment": "167",
            "NctKeyword": "Gastroparesis, SmartPill Monitoring System (SPM), Gastric Emptying Scintigraphy (GES),",
            "MeshKeyword": "Gastroparesis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Males and females between ages of 18-80 years of age with symptoms of gastroparesis\r\n\r\n             for at least 12 weeks.\r\n\r\n\r\n\r\n          -  Presenting with 2 or more of the following symptoms or signs",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "Palo Alto",
            "State": "California",
            "Zip": "94305",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 29, 2016",
            "FirstReceived": "December 15, 2013",
            "OverallOfficial": "Braden Kuo, Dr.",
            "OverallRole": "Principal Investigator",
            "LocationName": "Stanford University",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02022826",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140666 - Given Imaging - Moshiree",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20140666",
            "StudyNumber": "20140666 - Given Imaging - Moshiree",
            "StudyTitle": "Clinical Management with SmartPill Motility\nMonitoring System and Validation of the SmartPill\nFive Hour Cutoff in Patients with Symptoms of\nGastroparesis",
            "PIID": "4218",
            "PicNum": "C10864502",
            "PILastName": "Moshiree",
            "PIFirstName": "Baharak",
            "CoodCNbr": "C11862359",
            "CoordLastName": "Escobar",
            "CoordFirstName": "Claudia",
            "CoordEmail": "c.escobar3@med.miami.edu",
            "EnteredByCNbr": "C10864502",
            "EnteredByLastName": "Moshiree",
            "EnteredByFirstName": "Baharak",
            "ActiveEnrollingDate": "02/24/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/24/2015",
            "IRBApprovedFrom": "11/04/2014",
            "IRBApprovedTo": "10/19/2016",
            "Expr1": "N/A",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Given Imaging",
            "Prescreened": "1",
            "Screenedfailed": "1",
            "SignedICF": "9",
            "Totalaccrued": "8",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "9",
            "FirstNinety": "6",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT02022826",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02030067",
            "BriefTitle": "Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies",
            "OfficialTitle": "A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies",
            "LeadSponsorClass": "Rexahn Pharmaceuticals, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Rexahn Pharmaceuticals, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects\r\n\r\n      with advanced or metastatic solid tumors (Phase 1). The purpose of the Phase 2 portion is to\r\n\r\n      estimate anti-tumor activity in subjects w",
            "Description": "This is a dose-finding, open-label, single agent study of RX-3117. Once the maximum\r\n\r\n      tolerated dose is identified additional subjects will be treated in a dose expansion\r\n\r\n      followed by a 2-stage Phase 2 study. Subjects will be trea",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2013",
            "CompletionDate": "December 2017",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Rexahn Pharmaceuticals, Inc.",
            "StudyCondition": "Solid Tumor",
            "studyLocation": "Rexahn Site",
            "Enrollment": "72",
            "NctKeyword": "oncology, tumor, metastatic,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Males or females who are 18 years or older\r\n\r\n\r\n\r\n          -  Able to swallow capsules\r\n\r\n\r\n\r\n          -  Histological or cytological evidence of confirmed metastatic pancreatic or advanced",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Duarte",
            "State": "California",
            "Zip": "91010",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "October 12, 2016",
            "FirstReceived": "December 24, 2013",
            "OverallOfficial": "Ely Benaim, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Rexahn Pharmaceuticals, Inc.",
            "ContactName": "Christine Peterson, PhD",
            "ContactPhone": "240-268-5300",
            "ContactEmail": "petersonc@rexahn.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Rexahn Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02030067",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140254 - Rexahn Pharma - Merchan",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140254",
            "StudyNumber": "20140254 - Rexahn Pharma - Merchan",
            "StudyTitle": "A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects with Advanced Malignancies.",
            "PIID": "407",
            "PicNum": "C00251535",
            "PILastName": "Merchan",
            "PIFirstName": "Jaime",
            "CoodCNbr": "C12016748",
            "CoordLastName": "Sumarriva",
            "CoordFirstName": "Daniel",
            "CoordEmail": "dss173@med.miami.edu",
            "EnteredByCNbr": "C11917328",
            "EnteredByLastName": "Englund",
            "EnteredByFirstName": "Kristen",
            "ActiveEnrollingDate": "02/12/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/12/2015",
            "IRBApprovedFrom": "08/04/2014",
            "IRBApprovedTo": "07/31/2017",
            "AccountNbr": "664090",
            "DiseaseSiteListDesc": "Multiple",
            "Expr1": "Phase I",
            "Tarea": "Pancreatic, Liver, and Related Cancers",
            "TareaCode": "12443",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Rexahn Pharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "7",
            "SignedICF": "24",
            "Totalaccrued": "17",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "24",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Karen Blackburn,Sandra Pineda,Tamara Leon Aliz,Yvonne Dinh",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02030067",
            "StudyKeywords": "Therapeutic Area: Pancreatic, Liver and Related Cancer",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02032004",
            "BriefTitle": "Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.",
            "OfficialTitle": "Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic)",
            "LeadSponsorClass": "Mesoblast, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Mesoblast, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The primary objective of this study is to determine whether transendocardial delivery of\r\n\r\n      allogeneic human bone marrow-derived MPCs (rexlemestrocel-L) is effective in the treatment\r\n\r\n      of chronic heart failure due to LV systolic dys",
            "Description": "The purpose of this study is to evaluate the efficacy and safety of a single\r\n\r\n      transendocardial delivery in the cardiac catheterization laboratory of human bone\r\n\r\n      marrow-derived allogeneic MPCs (rexlemestrocel-L) for improvement in",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2014",
            "CompletionDate": "February 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Mesoblast, Ltd.",
            "StudyCondition": "Chronic Heart Failure",
            "studyLocation": "Mesoblast Investigational Site 10757",
            "Enrollment": "600",
            "NctKeyword": "Chronic Heart Failure, CHF, Left Ventricular Systolic Dysfunction, Ischemic Heart Failure, Nonischemic Heart Failure, Stem Cells, Allogeneic Mesenchymal Precursor Cells,",
            "MeshKeyword": "Heart Failure,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  The patient is 18 to 80 years of age, inclusive; both men and women will be enrolled.\r\n\r\n\r\n\r\n          -  The patient has a diagnosis of chronic HF of ischemic or nonischemic etiology for at",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 27, 2016",
            "FirstReceived": "January 8, 2014",
            "OverallOfficial": "Donna Skerrett, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Mesoblast, Ltd.",
            "ContactName": "inVentiv Health",
            "LocationStatus": "Recruiting",
            "LocationName": "Mesoblast Investigational Site 10757",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02032004",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140098 - Teva Pharmaceutical Industries - Chaparro",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20140098",
            "StudyNumber": "20140098 - Teva Pharmaceutical Industries - Chaparro",
            "StudyTitle": "TEVA: A Double-Blind, Randomized, Sham-Procedure-Controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients With Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Nonischemic Etiology.",
            "PIID": "735",
            "PicNum": "C06969678",
            "PILastName": "Chaparro",
            "PIFirstName": "Sandra",
            "CoodCNbr": "C00194136",
            "CoordLastName": "Pujol",
            "CoordFirstName": "Marietsy",
            "EnteredByCNbr": "C06969678",
            "EnteredByLastName": "Chaparro",
            "EnteredByFirstName": "Sandra",
            "ActiveEnrollingDate": "08/05/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/05/2014",
            "IRBApprovedFrom": "06/23/2014",
            "IRBApprovedTo": "04/10/2017",
            "AccountNbr": "663252",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Screening",
            "StudyType_Code": "6181",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Teva Pharmaceutical Industries",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "11",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "5",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "11",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Darcy Difede,Lina Caceres Cardenas,Moisaniel Dafonseca,Jairo Tovar,Russell Saltzman,Mayra Vidro Casiano,Cindy Delgado,Marietsy Pujol",
            "NationalSampleSize": "1165",
            "NCTNbr": "NCT02032004",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02032641",
            "BriefTitle": "Evaluation of Non-Ablative Laser for Treatment of Direct Brow Lift Scars",
            "OfficialTitle": "Evaluation of Non-Ablative Laser for Treatment of Direct Brow Lift Scars",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to determine the efficacy of the 1064nm Neodymium yttrium\r\n\r\n      aluminum garnet (Nd:YAG) laser (Laser Genesis, Cutera TM) in the treatment of surgical scar\r\n\r\n      after direct brow lift.",
            "Description": "Patients who undergo a direct brow lift may participate in this study. Participants will\r\n\r\n      receive laser treatment on one of the two surgical wounds (side of treatment will be chosen\r\n\r\n      randomly by an independent source). Treatment",
            "OverallStatus": "Completed",
            "StartDate": "June 2013",
            "CompletionDate": "May 2015",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Scar",
            "studyLocation": "Bascom Palmer Eye Institute",
            "Enrollment": "9",
            "NctKeyword": "Non-ablative laser, Scar revision, direct brow lift,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Undergoing or have undergone direct brow lift\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -  under 18 years old\r\n\r\n\r\n\r\n          -  history of photodermatoses\r\n\r\n\r\n\r\n          -  receiving system",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "June 2015",
            "LastChanged": "June 1, 2015",
            "FirstReceived": "June 24, 2013",
            "OverallOfficial": "Sara Wester, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "Bascom Palmer Eye Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02032641",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20120936 - Intramural - Wester",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20120936",
            "StudyNumber": "20120936 - Intramural - Wester",
            "StudyTitle": "Evaluation of NonAblative Laser for Treatment of Direct Brow Lift Scars",
            "PIID": "737",
            "PicNum": "C04282212",
            "PILastName": "Wester",
            "PIFirstName": "Sara",
            "CoodCNbr": "C04282212",
            "CoordLastName": "Wester",
            "CoordFirstName": "Sara",
            "CoordPhone": "3053266000",
            "EnteredByCNbr": "C04282212",
            "EnteredByLastName": "Wester",
            "EnteredByFirstName": "Sara",
            "ActiveEnrollingDate": "05/23/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/23/2013",
            "IRBApprovedFrom": "04/22/2013",
            "IRBApprovedTo": "02/01/2017",
            "Expr1": "N/A",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "10",
            "Totalaccrued": "10",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "10",
            "FirstNinety": "5",
            "SiteSampleSize": "BPPB:N/A,ABLEH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02032641",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT02032823",
            "SecondaryId": "NSABP B-55",
            "BriefTitle": "Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer",
            "OfficialTitle": "A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast C",
            "LeadSponsorClass": "AstraZeneca",
            "SponsorAgency": "Industry",
            "LeadSponsor": "AstraZeneca",
            "OversightAuthority": "Yes",
            "BriefSummary": "Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative\r\n\r\n      primary breast cancer who have completed definitive local treatment and neoadjuvant or\r\n\r\n      adjuvant chemotherapy",
            "Description": "Patients will be randomised in 1:1 ratio to either olaparib or placebo. Randomisation will\r\n\r\n      be stratified by Hormone receptor status (ER and/or PgR positive/HER2 negative versus TNBC),\r\n\r\n      prior neoadjuvant versus adjuvant chemother",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2014",
            "CompletionDate": "February 2028",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "AstraZeneca",
            "StudyCondition": "Breast Cancer",
            "studyLocation": "Research Site",
            "Enrollment": "330",
            "NctKeyword": "Breast Cancer, Adjuvant, Olaparib, BRCA 1/2, HER2,",
            "MeshKeyword": "Breast Neoplasms,",
            "InterventionKeyword": "Olaparib,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast\r\n\r\n             that is one of the following phenotypes:\r\n\r\n\r\n\r\n               1. Triple negative breast cancer defin",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "130 Years",
            "Volunteers": "No",
            "City": "Fairbanks",
            "State": "Alaska",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "January 3, 2014",
            "OverallOfficial": "Andrew Tutt, Doctor of Medicine",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Integrated Cancer Centre Guy's Hospital, King's College, London School of Medicine, London, UK",
            "ContactName": "AstraZeneca Clinical Study Information Center",
            "ContactPhone": "1-877-240-9479",
            "ContactEmail": "information.center@astrazeneca.com",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "Research Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02032823",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140905 - NSABP - Mahtani",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140905",
            "StudyNumber": "20140905 - NSABP - Mahtani",
            "StudyTitle": "NSABP B-55: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy",
            "PIID": "2603",
            "PicNum": "C09937436",
            "PILastName": "Mahtani",
            "PIFirstName": "Reshma",
            "CoodCNbr": "C11975723",
            "CoordLastName": "Minichiello",
            "CoordFirstName": "Anthony",
            "CoordEmail": "agm112@miami.edu",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "02/19/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/19/2015",
            "IRBApprovedFrom": "04/03/2014",
            "IRBApprovedTo": "08/17/2017",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase III",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Prevention",
            "StudyType_Code": "6163",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "3",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A,UM Kendall:N/A,Plantation:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Halyna Hailes,Sarah Raybin,Deborah Conte,Michelle Liendo,Onaidy Torres,Cristina Rojas-Mejia,Penny Eyer",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02032823",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02037555",
            "BriefTitle": "Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass",
            "OfficialTitle": "A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiac Surgery With Cardiopulmonary Bypass",
            "LeadSponsorClass": "Grifols Therapeutics Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Grifols Therapeutics Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. The\r\n\r\n      purpose of this study is to determine the safety and effectiveness of human-derived\r\n\r\n      antithrombin III (AT-III [Human]) supplementation p",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2014",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Grifols Therapeutics Inc.",
            "StudyCondition": "Cardiac Surgery",
            "studyLocation": "UCI Medical Center",
            "Enrollment": "404",
            "NctKeyword": "Antithrombin, Cardiopulmonary bypass,",
            "InterventionKeyword": "Antithrombin III, Antithrombins,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject needs non-emergency cardiac surgery with cardiopulmonary bypass.\r\n\r\n\r\n\r\n          -  Types of cardiac operations permitted:\r\n\r\n\r\n\r\n               1. Complex/combined procedures (coronary artery b",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Orange",
            "State": "California",
            "Zip": "92868",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 25, 2016",
            "FirstReceived": "January 14, 2014",
            "ContactName": "Michael Woodward, M.Sc.",
            "ContactEmail": "mwoodward@grifols.com",
            "LocationStatus": "Recruiting",
            "LocationName": "UCI Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02037555",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20150082 - Grifols - Rodriguez",
            "FileProcessContentId": "440",
            "Division": "Anesthesiology",
            "StdyDivision": "10236",
            "EprostNbr": "20150082",
            "StudyNumber": "20150082 - Grifols - Rodriguez",
            "StudyTitle": "a prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of preoperative antithrombin supplementation in patients undergoing high-risk cardiac surgery with cardiopulmonary bypass",
            "PIID": "1070",
            "PicNum": "C03849637",
            "PILastName": "Rodriguez",
            "PIFirstName": "Yiliam",
            "CoodCNbr": "C10588120",
            "CoordLastName": "Antor",
            "CoordFirstName": "Maria",
            "CoordEmail": "mantor@med.miami.edu",
            "CoordPhone": "3055857677",
            "EnteredByCNbr": "C03849637",
            "EnteredByLastName": "Rodriguez",
            "EnteredByFirstName": "Yiliam",
            "ActiveEnrollingDate": "02/25/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/25/2016",
            "IRBApprovedFrom": "06/02/2015",
            "IRBApprovedTo": "06/20/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Grifols",
            "Prescreened": "0",
            "Screenedfailed": "7",
            "SignedICF": "9",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "9",
            "FirstNinety": "2",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Isabel Jaraba,Angelica Jaramillo Virgen,Alessandro Colantuono Esaa,Ana  Mavarez,Maria Antor",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02037555",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02057744",
            "BriefTitle": "MIS ReFRESH: Robotic vs. Freehand Minimally Invasive Spinal Surgeries",
            "OfficialTitle": "Multi-center, Partially Randomized, Controlled Trial of MIS Robotic vs. Freehand in Short Adult Degenerative Spinal Fusion Surgeries",
            "LeadSponsorClass": "Mazor Robotics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Mazor Robotics",
            "OversightAuthority": "No",
            "BriefSummary": "To quantify potential short- and long-term benefits of robotically-guided minimally invasive\r\n\r\n      spine surgery (MIS) for adult patients with lower back degeneration, in comparison a\r\n\r\n      matching group of control patients operated in a",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2014",
            "CompletionDate": "March 2027",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Mazor Robotics",
            "StudyCondition": "Degenerative Spine Disease",
            "studyLocation": "Florida Hospital Celebration Health",
            "Enrollment": "2000",
            "NctKeyword": "Robotic-guided surgery, Minimally invasive spinal surgery, Spinal fusion, Pedicle screws,",
            "MeshKeyword": "Spondylolisthesis, Spondylosis, Spinal Diseases,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Adult patients (age over 21 years), undergoing short (4 or less consecutive\r\n\r\n             vertebrae) lumbar or lumbosacral percutaneous/MIS spinal fixation surgery.\r\n\r\n\r\n\r\n          2. May include surg",
            "EligibleGender": "All",
            "MinAge": "21 Years",
            "MaxAge": "99 Years",
            "Volunteers": "No",
            "City": "Celebration",
            "State": "Florida",
            "Zip": "34747",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 13, 2016",
            "FirstReceived": "February 5, 2014",
            "OverallOfficial": "Doron Dinstein, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Mazor Robotics, Ltd",
            "ContactName": "Doron Dinstein, MD",
            "ContactPhone": "(800) 80 - MAZOR",
            "ContactEmail": "clinicalstudy@mazorrobotics.com",
            "LocationStatus": "Active, not recruiting",
            "LocationName": "Florida Hospital Celebration Health",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02057744",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140823 - Mazor Robotics/ Ltd. - Wang",
            "FileProcessContentId": "440",
            "Division": "Neurosurgery",
            "StdyDivision": "9636",
            "EprostNbr": "20140823",
            "StudyNumber": "20140823 - Mazor Robotics/ Ltd. - Wang",
            "StudyTitle": "Multi-center, partially randomized, controlled trial of MIS Robotic vs. Freehand in Short Adult Degenerative Spinal Fusion Surgeries",
            "PIID": "472",
            "PicNum": "C06025344",
            "PILastName": "Wang",
            "PIFirstName": "Michael",
            "CoodCNbr": "C11326651",
            "CoordLastName": "Boyer",
            "CoordFirstName": "Brenda",
            "CoordEmail": "b.boyer@med.miami.edu",
            "CoordPhone": "305-243-4903",
            "EnteredByCNbr": "C06025344",
            "EnteredByLastName": "Wang",
            "EnteredByFirstName": "Michael",
            "ActiveEnrollingDate": "08/25/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/25/2015",
            "IRBApprovedFrom": "06/15/2015",
            "IRBApprovedTo": "06/14/2016",
            "Expr1": "N/A",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "Mazor Robotics/ Ltd.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "77",
            "Totalaccrued": "71",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "71",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "77",
            "FirstNinety": "14",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Leon Smith",
            "NationalSampleSize": "200",
            "NCTNbr": "NCT02057744",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02058238",
            "BriefTitle": "ADDRESS - Adult Deformity Robotic vs. Freehand Surgery to Correct Spinal Deformity",
            "OfficialTitle": "ADDRESS - Multicenter, Partially-randomized Controlled Trial of Adult Deformity Robotic vs. Freehand Surgery to Correct Adult Spine Deformity",
            "LeadSponsorClass": "Mazor Robotics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Mazor Robotics",
            "OversightAuthority": "No",
            "BriefSummary": "To quantify potential short- and long-term benefits of robotically-guided minimally invasive\r\n\r\n      (MIS) or open-approach spine surgery in adult patients undergoing multi-level spinal\r\n\r\n      instrumentation surgery, in comparison to image-",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2014",
            "CompletionDate": "January 2027",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Mazor Robotics",
            "StudyCondition": "Scoliosis",
            "studyLocation": "Orthopaedic Specialists of North County",
            "Enrollment": "2000",
            "NctKeyword": "Robotic-guided spinal fusions, Scoliosis, Kyphoscoliosis, Spinal deformity, Spondylosis,",
            "MeshKeyword": "Scoliosis, Congenital Abnormalities, Spondylosis, Kyphosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Adult patients (age 21 years and older), undergoing long (5 consecutive vertebrae or\r\n\r\n             more) spinal fusion surgery, between T1 to the sacrum.\r\n\r\n\r\n\r\n          2. Cases may include surgeries",
            "EligibleGender": "All",
            "MinAge": "21 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Oceanside",
            "State": "California",
            "Zip": "92056",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 7, 2016",
            "FirstReceived": "February 6, 2014",
            "OverallOfficial": "Doron Dinstein, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Mazor Robotics",
            "ContactName": "Doron Dinstein, MD",
            "ContactPhone": "800-80-MAZOR",
            "ContactEmail": "clinicalstudy@mazorrobotics.com",
            "LocationStatus": "Suspended",
            "LocationName": "Orthopaedic Specialists of North County",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02058238",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140824 - Mazor Robotics/ Ltd. - Wang",
            "FileProcessContentId": "440",
            "Division": "Neurosurgery",
            "StdyDivision": "9636",
            "EprostNbr": "20140824",
            "StudyNumber": "20140824 - Mazor Robotics/ Ltd. - Wang",
            "StudyTitle": "Multicenter, partially-randomized controlled trial of adult deformity robotic vs. freehand surgery to correct adult spine deformity",
            "PIID": "472",
            "PicNum": "C06025344",
            "PILastName": "Wang",
            "PIFirstName": "Michael",
            "CoodCNbr": "C11326651",
            "CoordLastName": "Boyer",
            "CoordFirstName": "Brenda",
            "CoordEmail": "b.boyer@med.miami.edu",
            "CoordPhone": "305-243-4903",
            "EnteredByCNbr": "C06025344",
            "EnteredByLastName": "Wang",
            "EnteredByFirstName": "Michael",
            "ActiveEnrollingDate": "08/25/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/25/2015",
            "IRBApprovedFrom": "04/09/2015",
            "IRBApprovedTo": "04/06/2016",
            "Expr1": "Other",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "Mazor Robotics/ Ltd.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "3",
            "SiteSampleSize": "JMH:N/A,UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Leon Smith",
            "NationalSampleSize": "200",
            "NCTNbr": "NCT02058238",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT02065245",
            "BriefTitle": "AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery.",
            "OfficialTitle": "A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty.",
            "LeadSponsorClass": "Joshua M Hare",
            "SponsorAgency": "Other",
            "LeadSponsor": "Joshua M Hare",
            "OversightAuthority": "Yes",
            "BriefSummary": "Before initiating the full randomized study, a Pilot Safety Phase will be performed. The\r\n\r\n      randomized portion of this trial will be conducted after a full review of the safety data\r\n\r\n      from the Pilot Phase by the Data safety monitori",
            "Description": "A Pilot Phase will be performed to test the safety of dose and volume escalation of cells\r\n\r\n      administered via peripheral intravenous infusion. The randomized portion of the study will\r\n\r\n      be conducted after a full review of the safety",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2014",
            "CompletionDate": "December 2020",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Aging Frailty",
            "studyLocation": "ISCI/University of Miami Miller School of Medicine",
            "Enrollment": "65",
            "NctKeyword": "Aging Frailty, Frailty, Cardiovascular, stem cells,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Provide written informed consent.\r\n\r\n\r\n\r\n          -  Subjects age greater than or equal to 60 and less than or equal to 95 years at the\r\n\r\n             time of signing the Informed Consent Form.",
            "EligibleGender": "All",
            "MinAge": "60 Years",
            "MaxAge": "95 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 14, 2016",
            "FirstReceived": "February 14, 2014",
            "OverallOfficial": "Joshua M Hare, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "ISCI / University of Miami Miller School of Medicine",
            "ContactName": "Joshua M Hare, MD",
            "ContactPhone": "305-243-5579",
            "ContactEmail": "jhare@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "ISCI/University of Miami Miller School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02065245",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20130646 - NIH - Hare",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20130646",
            "StudyNumber": "20130646 - NIH - Hare",
            "StudyTitle": "CRATUS: A Phase I/II, Randomized, Blinded and Placebocontrolled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients with Aging Frailty. AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients with Aging FRAilTy via IntravenoUS Delivery.",
            "PIID": "896",
            "PicNum": "C05065867",
            "PILastName": "Hare",
            "PIFirstName": "Joshua",
            "CoodCNbr": "C11258453",
            "CoordLastName": "Sierra",
            "CoordFirstName": "Julio",
            "CoordEmail": "jsierra@med.miami.edu",
            "CoordPhone": "3052437444",
            "EnteredByCNbr": "C00130574",
            "EnteredByLastName": "Difede",
            "EnteredByFirstName": "Darcy",
            "ActiveEnrollingDate": "11/22/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/22/2013",
            "IRBApprovedFrom": "11/21/2013",
            "IRBApprovedTo": "10/16/2017",
            "AccountNbr": "700823",
            "InfoEdNbr": "68405",
            "Expr1": "Phase I/II",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "17",
            "SignedICF": "89",
            "Totalaccrued": "69",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "13",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "89",
            "FirstNinety": "3",
            "SiteSampleSize": "UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Darcy Difede,Lina Caceres Cardenas,Jairo Tovar,Mayra Vidro Casiano,Courtney Premer,Cindy Delgado,Marietsy Pujol",
            "NationalSampleSize": "60",
            "NCTNbr": "NCT02065245",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02072226",
            "BriefTitle": "A Study of the Efficacy and Safety of Activase (Alteplase) in Patients With Mild Stroke (PRISMS)",
            "OfficialTitle": "A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Neurologic Deficits (PRISMS)",
            "LeadSponsorClass": "Genentech, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Genentech, Inc.",
            "BriefSummary": "PRISMS is a double-blind, multicenter, randomized, Phase IIIb study to evaluate the efficacy\r\n\r\n      and safety of intravenous (IV) Activase in patients with mild acute ischemic strokes that do\r\n\r\n      not appear to be clearly disabling.",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2014",
            "CompletionDate": "May 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Genentech, Inc.",
            "StudyCondition": "Brain Ischemia",
            "Enrollment": "948",
            "MeshKeyword": "Ischemia, Brain Ischemia,",
            "InterventionKeyword": "Aspirin, Tissue Plasminogen Activator,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Age >/= 18 years.\r\n\r\n\r\n\r\n          -  Mild ischemic stroke defined as the most recent pre-treatment NIHSS score of </= 5\r\n\r\n             and determined as not clearly disabling by the investigator.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35291-3300",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 1, 2016",
            "FirstReceived": "February 24, 2014",
            "OverallOfficial": "Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Genentech, Inc.",
            "ContactName": "Reference Study ID Number: ML29093 www.roche.com/about_roche/roche_worldwide.htm",
            "ContactPhone": "888-662-6728 (U.S. and Canada)",
            "ContactEmail": "global.rochegenentechtrials@roche.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02072226",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140431 - Genentech - Romano",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140431",
            "StudyNumber": "20140431 - Genentech - Romano",
            "StudyTitle": "A Phase IIIb, Double-Blind,Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients with Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)",
            "PIID": "22508",
            "PicNum": "C11907142",
            "PILastName": "Malik",
            "PIFirstName": "Amer",
            "CoodCNbr": "C00519151",
            "CoordLastName": "Escobar",
            "CoordFirstName": "Andrea",
            "CoordEmail": "aescobar@med.miami.edu",
            "CoordPhone": "3052432766",
            "EnteredByCNbr": "C00607800",
            "EnteredByLastName": "Romano",
            "EnteredByFirstName": "Jose",
            "ActiveEnrollingDate": "10/06/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/06/2015",
            "IRBApprovedFrom": "07/21/2014",
            "IRBApprovedTo": "05/01/2017",
            "AccountNbr": "664404",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Genentech",
            "Prescreened": "2",
            "Screenedfailed": "0",
            "SignedICF": "6",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "2",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Andrea Escobar",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02072226",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02073279",
            "BriefTitle": "Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD",
            "OfficialTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)",
            "LeadSponsorClass": "Chugai Pharmaceutical",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Chugai Pharmaceutical",
            "OversightAuthority": "Yes",
            "BriefSummary": "The objective of this study is to evaluate the efficacy, safety, pharmacodynamic,\r\n\r\n      pharmacokinetic and immunogenic profiles of SA237 in patients with NMO and NMOSD",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2014",
            "CompletionDate": "March 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Chugai Pharmaceutical",
            "StudyCondition": "Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)",
            "studyLocation": "UC Irvine Institute for Clinical and Translational Science",
            "Enrollment": "90",
            "MeshKeyword": "Neuromyelitis Optica,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  1. NMO or NMOSD\r\n\r\n\r\n\r\n          -  2. Age 18 to 74 years, inclusive at the time of informed consent.\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -  1. Pregnancy or lactation.\r\n\r\n\r\n\r\n          -",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "74 Years",
            "Volunteers": "No",
            "City": "Orange",
            "State": "California",
            "Zip": "92868",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 7, 2016",
            "FirstReceived": "February 25, 2014",
            "OverallOfficial": "Athos Gianella-Borradori, MD.",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Chugai Pharmaceutical",
            "ContactName": "Clinical trials information",
            "ContactEmail": "clinical-trials@chugai-pharm.co.jp",
            "LocationStatus": "Recruiting",
            "LocationName": "UC Irvine Institute for Clinical and Translational Science",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02073279",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140727 - Chugai Pharmaceutical Co./ Ltd - Sheremata",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140727",
            "StudyNumber": "20140727 - Chugai Pharmaceutical Co./ Ltd - Sheremata",
            "StudyTitle": "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY, OF SA237 AS MONOTHERAPY IN PATIENTS WITH NEUROMYELITIS OPTICA (NMO) AND NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)",
            "PIID": "121",
            "PicNum": "C00457629",
            "PILastName": "Sheremata",
            "PIFirstName": "William",
            "CoodCNbr": "C00168827",
            "CoordLastName": "Sawant",
            "CoordFirstName": "Ruta",
            "CoordEmail": "rsawant@med.miami.edu",
            "CoordPhone": "305-243-2905",
            "EnteredByCNbr": "C00457629",
            "EnteredByLastName": "Sheremata",
            "EnteredByFirstName": "William",
            "ActiveEnrollingDate": "06/06/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/06/2016",
            "IRBApprovedFrom": "04/27/2015",
            "IRBApprovedTo": "04/03/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Chugai Pharmaceutical Co./ Ltd",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "2",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yanet Babcock,Gloria Rodriguez (Neurology)",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02073279",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02074839",
            "BriefTitle": "Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation",
            "OfficialTitle": "A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation",
            "LeadSponsorClass": "Agios Pharmaceuticals, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Agios Pharmaceuticals, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics,\r\n\r\n      pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that\r\n\r\n      harbor an IDH1 mutation. The first portion o",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2014",
            "CompletionDate": "September 2018",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Agios Pharmaceuticals, Inc.",
            "StudyCondition": "Relapsed or Refractory Acute Myeloid Leukemia (AML)",
            "Enrollment": "236",
            "NctKeyword": "acute myeloid leukemia, AML, myelodysplastic syndrome, MDS, hematologic malignancies, IDH, Untreated AML, IDH1, relapsed AML, refractory AML,",
            "MeshKeyword": "Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject must be ≥18 years of age.\r\n\r\n\r\n\r\n          -  Subjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy\r\n\r\n             based on local or central evaluation.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 23, 2016",
            "FirstReceived": "February 21, 2014",
            "OverallOfficial": "Clinical Development",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Agios Pharmaceuticals, Inc.",
            "ContactName": "Stephanie Kapsalis, OTR",
            "ContactPhone": "201.314.6893",
            "ContactEmail": "stephanie.kapsalis@agios.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02074839",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140124 - Agios Pharmaceuticals - Swords",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140124",
            "StudyNumber": "20140124 - Agios Pharmaceuticals - Swords",
            "StudyTitle": "A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation.",
            "PIID": "4223",
            "PicNum": "C11249826",
            "PILastName": "Swords",
            "PIFirstName": "Ronan",
            "CoodCNbr": "C05734393",
            "CoordLastName": "Byrne",
            "CoordFirstName": "Jennifer",
            "CoordEmail": "j.byrne2@umiami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "10/06/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/06/2014",
            "IRBApprovedFrom": "08/25/2014",
            "IRBApprovedTo": "07/24/2017",
            "AccountNbr": "663884",
            "DiseaseSiteListDesc": "Other Hematopoietic",
            "Expr1": "Phase I",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Agios Pharmaceuticals, Inc.",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "17",
            "Totalaccrued": "11",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "17",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "3",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yvonne Dinh,Randy Astaiza,Jillian Ogden,Tamara Leon Aliz",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02074839",
            "StudyKeywords": "Therapeutic Area: Leukemia, Lymphoma and Myeloma",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02075047",
            "BriefTitle": "Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder",
            "OfficialTitle": "A Phase 3, Multicenter, Four-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Current Or Most Recent Episode Manic)",
            "LeadSponsorClass": "Pfizer",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Pfizer",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine if ziprasidone is safe and effective for the\r\n\r\n      treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2014",
            "CompletionDate": "January 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Pfizer",
            "StudyCondition": "Bipolar Disorder",
            "studyLocation": "Harmonex Neuroscience Research, Inc.",
            "Enrollment": "180",
            "NctKeyword": "Bipolar I Disorder (current or most recent episode manic). Children and adolescents aged 10 to 17 years.,",
            "MeshKeyword": "Disease, Bipolar Disorder,",
            "InterventionKeyword": "Ziprasidone,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  DSM V criteria for Bipolar I disorder (manic or mixed); age 10 - 17 years.\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -  Imminent risk of suicide or homicide, as judged by the site investigator;",
            "EligibleGender": "All",
            "MinAge": "10 Years",
            "MaxAge": "17 Years",
            "Volunteers": "No",
            "City": "Dothan",
            "State": "Alabama",
            "Zip": "36303",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 17, 2017",
            "FirstReceived": "February 27, 2014",
            "OverallOfficial": "Pfizer CT.gov Call Center",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Pfizer",
            "ContactName": "Pfizer CT.gov Call Center",
            "ContactPhone": "1-800-718-1021",
            "LocationStatus": "Recruiting",
            "LocationName": "Harmonex Neuroscience Research, Inc.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02075047",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.1700000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.1700000",
            "StudyId": "20140880 - Pfizer - Buford",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20140880",
            "StudyNumber": "20140880 - Pfizer - Buford",
            "StudyTitle": "A PHASE 3, MULTICENTER, FOUR-WEEK, RANDOMIZED, DOUBLE-BLIND, \nPLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY \nTRIAL OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND \nADOLESCENTS WITH BIPOLAR I DISORDER (CURRENT OR MOST RECENT \nEPISODE MANIC)",
            "PIID": "4307",
            "PicNum": "C06958059",
            "PILastName": "Vasiliu-Feltes",
            "PIFirstName": "Ingrid",
            "CoodCNbr": "C04892431",
            "CoordLastName": "Brenson",
            "CoordFirstName": "Nicole",
            "CoordEmail": "nbrenson@med.miami.edu",
            "CoordPhone": "3053558186",
            "EnteredByCNbr": "C08159485",
            "EnteredByLastName": "Buford",
            "EnteredByFirstName": "Ushimbra",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "05/18/2015",
            "IRBApprovedFrom": "05/18/2015",
            "IRBApprovedTo": "04/03/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Pfizer",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Tania Guardia,Nicole Brenson",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02075047",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02079883",
            "BriefTitle": "Ocriplasmin Research to Better Inform Treatment (ORBIT)",
            "OfficialTitle": "Ocriplasmin Research to Better Inform Treatment (ORBIT)",
            "LeadSponsorClass": "ThromboGenics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "ThromboGenics",
            "OversightAuthority": "No",
            "BriefSummary": "This is a multicenter, prospective, observational, Phase 4 study that will assess clinical\r\n\r\n      outcomes and safety of JETREA® administered in a real-world setting for the treatment of\r\n\r\n      symptomatic vitreomacular adhesion (VMA) by ass",
            "Description": "The sites will prospectively enroll consecutive patients eligible for participation in the\r\n\r\n      study. Informed consent will be obtained prior to any data being collected. This study is\r\n\r\n      observational; therefore, all treatment decisi",
            "OverallStatus": "Completed",
            "StartDate": "May 2014",
            "CompletionDate": "May 2016",
            "Phase": "N/A",
            "StudyType": "Observational [Patient Registry]",
            "StudyPhase": "N/A",
            "StudySource": "ThromboGenics",
            "StudyCondition": "Symptomatic Vitreomacular Adhesion",
            "studyLocation": "Retinal COnsultants of Arizona",
            "Enrollment": "540",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Adults 18 years or older diagnosed with symptomatic VMA treated with JETREA ® at the\r\n\r\n             physician's discretion in a manner consistent with the product label.\r\n\r\n\r\n\r\n          -  Willing and",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85014",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "June 20, 2016",
            "FirstReceived": "March 4, 2014",
            "LocationName": "Retinal COnsultants of Arizona",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02079883",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140293 - ThromboGenics - Fortun",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20140293",
            "StudyNumber": "20140293 - ThromboGenics - Fortun",
            "StudyTitle": "TG-MV-018:  Ocriplasmin Research to Better Inform Treatment",
            "PIID": "3572",
            "PicNum": "C09939295",
            "PILastName": "Fortun",
            "PIFirstName": "Jorge",
            "CoodCNbr": "C11963475",
            "CoordLastName": "Larez",
            "CoordFirstName": "Lorena",
            "CoordEmail": "llarez@med.miami.edu",
            "EnteredByCNbr": "C09939295",
            "EnteredByLastName": "Fortun",
            "EnteredByFirstName": "Jorge",
            "ActiveEnrollingDate": "09/16/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/16/2014",
            "IRBApprovedFrom": "06/09/2014",
            "IRBApprovedTo": "05/25/2017",
            "Expr1": "Phase IV",
            "Tarea": "Retina",
            "TareaCode": "12038",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "ThromboGenics",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Lorena Larez",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02079883",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02080871",
            "BriefTitle": "[Trial of device that is not approved or cleared by the U.S. FDA]",
            "OfficialTitle": "[Trial of device that is not approved or cleared by the U.S. FDA]",
            "LeadSponsorClass": "[Redacted]",
            "SponsorAgency": "Industry",
            "LeadSponsor": "[Redacted]",
            "OverallStatus": "Withheld",
            "StartDate": "July 2014",
            "Phase": "N/A",
            "StudyType": "N/A",
            "StudyPhase": "N/A",
            "StudySource": "[Redacted]",
            "LastChanged": "April 18, 2016",
            "FirstReceived": "March 4, 2014",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02080871",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140371 - W. L. Gore & Associates - Rey",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20140371",
            "StudyNumber": "20140371 - W. L. Gore & Associates - Rey",
            "StudyTitle": "Evaluation of the GORE® VIABAHN BALLOON EXPANDABLE ENDOPROSTHESIS (VIABAHN BX) for the Treatment of Occlusive Disease in the Common and External Iliac Arteries. BES 10-07.",
            "PIID": "3817",
            "PicNum": "C01335228",
            "PILastName": "Rey",
            "PIFirstName": "Jorge",
            "CoodCNbr": "C00792691",
            "CoordLastName": "Salinas",
            "CoordFirstName": "Kay",
            "CoordEmail": "ksalinas2@med.miami.edu",
            "CoordPhone": "3052431147",
            "EnteredByCNbr": "C01335228",
            "EnteredByLastName": "Rey",
            "EnteredByFirstName": "Jorge",
            "ActiveEnrollingDate": "01/09/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/09/2015",
            "IRBApprovedFrom": "08/05/2014",
            "IRBApprovedTo": "05/11/2017",
            "Expr1": "Phase II",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "W. L. Gore & Associates",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "3",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Jean (Lynne) Sparling",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT02080871",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02081352",
            "BriefTitle": "A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers",
            "OfficialTitle": "Phase IV Prospective, Multi-Center, Randomized, Single-Blind, Active and Standard Care-Controlled Study of DermaPure™ in Patients With \"Hard to Heal\" Chronic, Neuropathic Diabetic Foot Ulcers With Crossover Design for Standard Care Arm",
            "LeadSponsorClass": "TRx Wound Care Limited",
            "SponsorAgency": "Industry",
            "LeadSponsor": "TRx Wound Care Limited",
            "OversightAuthority": "No",
            "BriefSummary": "This study has been designed to help determine how safe and effective DermaPure™ may be in\r\n\r\n      treating hard-to-heal diabetic foot ulcers compared to the current standard of care.",
            "Description": "DermaPure™ is a decellularized dermal skin substitute using the Tissue Regenix dCELL®\r\n\r\n      patented Technology to remove cells and other components from human and animal tissue while\r\n\r\n      maintaining the native structural and biomechanic",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2014",
            "CompletionDate": "February 2017",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "TRx Wound Care Limited",
            "StudyCondition": "Diabetic Foot Ulcers",
            "studyLocation": "Carl T. Hayden Medical Research Foundation",
            "Enrollment": "50",
            "NctKeyword": "Dermis, Diabetic foot ulcers, Skin substitutes, Decellularized,",
            "MeshKeyword": "Ulcer, Diabetic Foot, Foot Ulcer,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Type 1 or Type 2 diabetes with HbA1c ≤12%\r\n\r\n\r\n\r\n          -  Adequate perfusion\r\n\r\n\r\n\r\n          -  A full thickness chronic, neuropathic diabetic foot plantar ulcer defined by Texas or",
            "EligibleGender": "All",
            "MinAge": "19 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85012-1892",
            "Country": "United States",
            "VerificationDate": "November 2015",
            "LastChanged": "November 4, 2015",
            "FirstReceived": "March 5, 2014",
            "ContactName": "sheila nicholson",
            "ContactPhone": "+44 3304303066",
            "ContactEmail": "s.nicholson@tissueregenix.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Carl T. Hayden Medical Research Foundation",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02081352",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140199 - Tissue Regenix/ Inc. - Kirsner",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20140199",
            "StudyNumber": "20140199 - Tissue Regenix/ Inc. - Kirsner",
            "StudyTitle": "A Phase IV Prospective, Multi-Center, Randomized, Single-Blind, Active and Standard Care-Controlled Clinical Investigation of DermaPure™ in Patients with \"Hard to Heal\" Chronic, Neuropathic Diabetic Foot Ulcers with Crossover Design for Standard Care Arm\n\nDermaPure™ is a decellularized dermal allograft prepared from split thickness skin grafts harvested from human donors and processed using the Tissue Regenix dCELL® platform technology. The dCELL® process removes the epidermis, cells and cell remnants from the dermis while maintaining the native biological and biomechanical properties of the tissue,\nresulting in an acellular matrix that can be used without the need for anti-rejection drugs.\nDermaPure™ will be supplied for clinical application as a sterile graft.",
            "PIID": "717",
            "PicNum": "C00519753",
            "PILastName": "Kirsner",
            "PIFirstName": "Robert",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C00519753",
            "EnteredByLastName": "Kirsner",
            "EnteredByFirstName": "Robert",
            "ActiveEnrollingDate": "10/27/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/27/2014",
            "IRBApprovedFrom": "06/03/2014",
            "IRBApprovedTo": "06/01/2016",
            "Expr1": "Phase IV",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Tissue Regenix/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "11",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "11",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Aliette Espinosa,Carol Kittles",
            "NationalSampleSize": "14",
            "NCTNbr": "NCT02081352",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02081391",
            "SecondaryId": "2012-004359-35",
            "BriefTitle": "An Efficacy and Safety Study of Tapentadol in the Treatment of Post-operative Acute Pain Requiring Opioid Treatment in Pediatric Participants",
            "OfficialTitle": "An Evaluation of the Efficacy and Safety of Tapentadol Oral Solution in the Treatment of Post-operative Acute Pain Requiring Opioid Treatment in Pediatric Subjects Aged From Birth to Less Than 18 Years Old",
            "LeadSponsorClass": "Grünenthal GmbH",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Grünenthal GmbH",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of the study is to evaluate the efficacy of tapentadol oral solution, based on\r\n\r\n      the total amount of supplemental opioid analgesic used over 12 hours or 24 hours after\r\n\r\n      initiation of investigational medicinal product i",
            "Description": "This is a randomized (the study medication is assigned by chance), multi-site, double-blind\r\n\r\n      (neither physician nor participant knows the treatment that the participant receives),\r\n\r\n      placebo-controlled (placebo is compared with the",
            "OverallStatus": "Suspended",
            "StartDate": "January 2015",
            "CompletionDate": "December 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Grünenthal GmbH",
            "StudyCondition": "Acute Pain",
            "studyLocation": "US008",
            "Enrollment": "200",
            "NctKeyword": "Acute Pain, Post-operative, Tapentadol, Opioid Treatment, Pediatric Participants,",
            "MeshKeyword": "Acute Pain,",
            "InterventionKeyword": "Pharmaceutical Solutions, Analgesics, Opioid,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Informed consent, and if applicable assent, given according to local regulations.\r\n\r\n\r\n\r\n          2. Male or female participant aged from birth to less than 18 years.\r\n\r\n\r\n\r\n          3. A female subjec",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "18 Years",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Zip": "72202",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 12, 2017",
            "FirstReceived": "March 5, 2014",
            "OverallOfficial": "Study Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Grünenthal GmbH",
            "LocationName": "US008",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02081391",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140407 - Janssen Research & Development/ LLC - Gebhard",
            "FileProcessContentId": "440",
            "Division": "Anesthesiology",
            "StdyDivision": "10236",
            "EprostNbr": "20140407",
            "StudyNumber": "20140407 - Janssen Research & Development/ LLC - Gebhard",
            "StudyTitle": "An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old.",
            "PIID": "706",
            "PicNum": "C04976318",
            "PILastName": "Gebhard",
            "PIFirstName": "Ralf",
            "CoodCNbr": "C10565278",
            "CoordLastName": "Gutierrez",
            "CoordFirstName": "Juan",
            "CoordEmail": "JGutierrez4@med.miami.edu",
            "EnteredByCNbr": "C04976318",
            "EnteredByLastName": "Gebhard",
            "EnteredByFirstName": "Ralf",
            "ActiveEnrollingDate": "04/06/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/06/2016",
            "IRBApprovedFrom": "03/09/2015",
            "IRBApprovedTo": "02/25/2017",
            "Expr1": "Phase III",
            "Tarea": "Pain Management",
            "TareaCode": "16648",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Janssen Research & Development/ LLC",
            "Prescreened": "3",
            "Screenedfailed": "4",
            "SignedICF": "9",
            "Totalaccrued": "5",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "9",
            "FirstNinety": "4",
            "SiteSampleSize": "JMH:5,UMMG:N/A",
            "AccrualPercentageMet": "100",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "5",
            "EprostState": "Approved",
            "StudyCoordinator": "Juan Gutierrez,Lilibet Fernandez,Maria Antor",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02081391",
            "StudyKeywords": "pain, opioids, surgery, PCA, pain management, pain control, pain in kids, adolescent pain,",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02085499",
            "BriefTitle": "Flow-synchronized Nasal IMV in Preterm Infants",
            "OfficialTitle": "Effects of Flow-synchronized Nasal Intermittent Mandatory Ventilation in Preterm Infants",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The use of non-invasive methods of respiratory support to reduce complications of prolonged\r\n\r\n      invasive mechanical ventilation in preterm infants has increased.\r\n\r\n\r\n\r\n      The most common mode is nasal intermittent mandatory ventilation",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2014",
            "CompletionDate": "December 2018",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Premature Infants Requiring Non-invasive Respiratory Support",
            "studyLocation": "Holtz Childrens Hospital-Jackson Health System-University of Miami",
            "Enrollment": "16",
            "NctKeyword": "nasal ventilation, premature infants, synchronized ventilation,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Preterm infants of 30 or less weeks of gestational age\r\n\r\n\r\n\r\n          -  Receiving NIMV\r\n\r\n\r\n\r\n          -  Requiring Fi02 >= 0.25 to keep Sp02 > 90%\r\n\r\n\r\n\r\n          -  Parental written informed conse",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 14, 2016",
            "FirstReceived": "March 10, 2014",
            "OverallOfficial": "Nelson Claure, MSc, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Carmen D'Ugard, MD/RRT",
            "ContactPhone": "3055856408",
            "ContactEmail": "cdugard@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Holtz Childrens Hospital-Jackson Health System-University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02085499",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20130844 - Intramural - Claure",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20130844",
            "StudyNumber": "20130844 - Intramural - Claure",
            "StudyTitle": "Effects of flow synchronized nasal intermittent mandatory ventilation in preterm infants",
            "PIID": "2769",
            "PicNum": "C00405474",
            "PILastName": "Claure",
            "PIFirstName": "Nelson",
            "CoodCNbr": "C00096109",
            "CoordLastName": "D'Ugard",
            "CoordFirstName": "Carmen",
            "CoordEmail": "cdugard@miami.edu",
            "CoordPhone": "3055856408",
            "EnteredByCNbr": "C00096109",
            "EnteredByLastName": "D'Ugard",
            "EnteredByFirstName": "Carmen",
            "ActiveEnrollingDate": "03/12/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/12/2014",
            "IRBApprovedFrom": "01/13/2014",
            "IRBApprovedTo": "12/13/2016",
            "InfoEdNbr": "34740",
            "Expr1": "N/A",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "6",
            "SignedICF": "14",
            "Totalaccrued": "8",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "14",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carmen D'Ugard",
            "NationalSampleSize": "32",
            "NCTNbr": "NCT02085499",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02089217",
            "SecondaryId": "U01NS080168",
            "BriefTitle": "Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial",
            "OfficialTitle": "CAROTID REVASCULARIZATION AND MEDICAL MANAGEMENT FOR ASYMPTOMATIC CAROTID STENOSIS TRIAL",
            "LeadSponsorClass": "Thomas G. Brott, M.D.",
            "SponsorAgency": "Other",
            "LeadSponsor": "Thomas G. Brott, M.D.",
            "OversightAuthority": "Yes",
            "BriefSummary": "Carotid revascularization for primary prevention of stroke (CREST-2) is two independent\r\n\r\n      multicenter, randomized controlled trials of carotid revascularization and intensive medical\r\n\r\n      management versus medical management alone in",
            "Description": "Prevention of stroke involves managing and treating risk factors. Most strokes are caused\r\n\r\n      when blood flow to a portion of the brain is blocked. One place this often happens is in the\r\n\r\n      carotid artery. This blockage is called athe",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2014",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Mayo Clinic",
            "StudyCondition": "Carotid Stenosis",
            "studyLocation": "The University of Alabama at Birmingham",
            "Enrollment": "2480",
            "NctKeyword": "asymptomatic, carotid, stent, endarterectomy, embolic protection, medical management, hypertension, hyperlipidemia, cognition, risk factor control,",
            "MeshKeyword": "Constriction, Pathologic, Carotid Stenosis,",
            "Eligibility": "General Inclusion Criteria\r\n\r\n\r\n\r\n          1. Patients ≥35 years old.\r\n\r\n\r\n\r\n          2. Carotid stenosis defined as:\r\n\r\n\r\n\r\n               -  Stenosis ≥70% by catheter angiography (NASCET Criteria); OR\r\n\r\n\r\n\r\n               -  by DUS with ≥",
            "EligibleGender": "All",
            "MinAge": "35 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 11, 2017",
            "FirstReceived": "March 13, 2014",
            "OverallOfficial": "Thomas G. Brott, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Mayo Clinic Florida",
            "ContactName": "CREST-2 Administrative Center",
            "ContactPhone": "844-956-1826",
            "LocationStatus": "Recruiting",
            "LocationName": "The University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02089217",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151058 - Intramural - Chaturvedi",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20151058",
            "StudyNumber": "20151058 - Intramural - Chaturvedi",
            "StudyTitle": "Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2)",
            "PIID": "24807",
            "PicNum": "C11920039",
            "PILastName": "Chaturvedi",
            "PIFirstName": "Seemant",
            "CoodCNbr": "C11877018",
            "CoordLastName": "Ramdas",
            "CoordFirstName": "Kevin",
            "CoordEmail": "k.ramdas@med.miami.edu",
            "CoordPhone": "305-243-1132",
            "EnteredByCNbr": "C11920039",
            "EnteredByLastName": "Chaturvedi",
            "EnteredByFirstName": "Seemant",
            "ActiveEnrollingDate": "01/12/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/12/2016",
            "IRBApprovedFrom": "11/06/2015",
            "IRBApprovedTo": "09/08/2016",
            "Expr1": "Phase III",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "5",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Pre-Review",
            "StudyCoordinator": "Iszet Campo-Bustillo,Kevin Ramdas,Luis Guada,Andrea Escobar",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02089217",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02091999",
            "BriefTitle": "A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4",
            "OfficialTitle": "A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4",
            "LeadSponsorClass": "Agensys, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Agensys, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to evaluate the safety and pharmacokinetics ASG-22CE as well as\r\n\r\n      assess the immunogenicity and antitumor activity in subjects with metastatic urothelial\r\n\r\n      cancer and other malignant solid tumors.",
            "Description": "All subjects will receive a single 30 minute IV infusion of ASG-22CE once weekly for 3 weeks\r\n\r\n      of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 4 weeks.\r\n\r\n\r\n\r\n      This is a 3 part study. Part A will evaluate ASG-22CE in subjec",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2014",
            "CompletionDate": "January 2018",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Astellas Pharma Inc",
            "StudyCondition": "Metastatic Urothelial Cancer and Other Malignant Solid Tumors",
            "studyLocation": "Site US00006",
            "Enrollment": "200",
            "NctKeyword": "Metastatic Urothelial Cancer, Safety, AGS-22C3E, Nectin 4 protein, humans, Clinical Trial, Phase 1, ASG-22CE, ASG-22ME, Pharmacokinetics of ASG-22CE,",
            "MeshKeyword": "Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Dose Escalation, Cis-ineligible and CPI-Treated Expansion cohorts: Subjects must have\r\n\r\n             histologically confirmed Transitional Cell Carcinoma of the Urothelium (TCCU) (i.e.,",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "New Haven",
            "State": "Connecticut",
            "Zip": "06520",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 15, 2016",
            "FirstReceived": "March 18, 2014",
            "OverallOfficial": "Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Agensys, Inc.",
            "ContactName": "Agensys Clinical Research and Development",
            "ContactPhone": "424-280-5000",
            "ContactEmail": "Astellas.registration@astellas.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Site US00006",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02091999",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140090 - Agensys Inc. - Merchan",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140090",
            "StudyNumber": "20140090 - Agensys Inc. - Merchan",
            "StudyTitle": "A Phase 1 Study of the Safety and Pharmacokinetics of escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4",
            "PIID": "407",
            "PicNum": "C00251535",
            "PILastName": "Merchan",
            "PIFirstName": "Jaime",
            "CoodCNbr": "C12016748",
            "CoordLastName": "Sumarriva",
            "CoordFirstName": "Daniel",
            "CoordEmail": "dss173@med.miami.edu",
            "EnteredByCNbr": "C11917328",
            "EnteredByLastName": "Englund",
            "EnteredByFirstName": "Kristen",
            "ActiveEnrollingDate": "09/02/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/02/2014",
            "IRBApprovedFrom": "07/21/2014",
            "IRBApprovedTo": "06/19/2017",
            "AccountNbr": "663470",
            "DiseaseSiteListDesc": "Urinary Bladder,Other Urinary",
            "Expr1": "Phase I",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Agensys, Inc.",
            "Prescreened": "2",
            "Screenedfailed": "20",
            "SignedICF": "25",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "25",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:5",
            "AccrualPercentageMet": "60",
            "ActiveCal": "3",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "5",
            "EprostState": "Approved",
            "StudyCoordinator": "Karen Blackburn,Sandra Pineda,Yvonne Dinh,Tamara Leon Aliz",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02091999",
            "StudyKeywords": "Therapeutic Area: Prostate, Bladder, and Kidney Cancer",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02097134",
            "SecondaryId": "NCI-2014-00618",
            "BriefTitle": "Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma",
            "OfficialTitle": "A Multi-institutional Feasibility Study of Intra-arterial Chemotherapy Given in the Ophthalmic Artery of Children With Retinoblastoma",
            "LeadSponsorClass": "Children's Oncology Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "Children's Oncology Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "This pilot clinical trial studies whether unilateral group D retinoblastoma, or\r\n\r\n      retinoblastoma affecting one eye that has spread to the inner jelly like part of the eye,\r\n\r\n      can be treated with a new technique for delivering chemot",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To study the feasibility of delivering melphalan directly into the ophthalmic artery in\r\n\r\n      children with newly diagnosed unilateral group D retinoblastoma, who would otherwise be\r\n\r\n      considered for",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2014",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Children's Oncology Group",
            "StudyCondition": "Unilateral Retinoblastoma",
            "studyLocation": "Children's Hospital Los Angeles",
            "Enrollment": "50",
            "MeshKeyword": "Retinoblastoma,",
            "InterventionKeyword": "Melphalan, Mechlorethamine, Nitrogen Mustard Compounds,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Newly diagnosed patients with unilateral group D retinoblastoma\r\n\r\n\r\n\r\n          -  Magnetic resonance imaging (MRI) (or computed tomography [CT] if MRI is not\r\n\r\n             available) of the brain mus",
            "EligibleGender": "All",
            "MinAge": "6 Months",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90027",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 8, 2016",
            "FirstReceived": "March 25, 2014",
            "OverallOfficial": "Murali Chintagumpala, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital Los Angeles",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02097134",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140378 - COG - Barredo",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140378",
            "StudyNumber": "20140378 - COG - Barredo",
            "StudyTitle": "ARET12P1 - A Multi-Institutional Feasibility Study of Intra-Arterial Chemotherapy Given in the Ophthalmic Artery of Children with Retinoblastoma",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C00722004",
            "CoordLastName": "Garantiva",
            "CoordFirstName": "Nuria",
            "CoordEmail": "nfc19@miami.edu",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "12/12/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/12/2013",
            "IRBApprovedFrom": "12/12/2013",
            "IRBApprovedTo": "05/11/2017",
            "DiseaseSiteListDesc": "Eye and Orbit",
            "Expr1": "Pilot/Feasibility",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "COG",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Wendy Best,Myriam Zayas",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02097134",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02101385",
            "BriefTitle": "Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer",
            "OfficialTitle": "A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158",
            "LeadSponsorClass": "Bryan Schneider, MD",
            "SponsorAgency": "Other",
            "LeadSponsor": "Bryan Schneider, MD",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will test the theory that therapy designed for each individual's tumor will\r\n\r\n      improve outcomes over standard of care in a population that needs a better standard.",
            "Description": "OUTLINE: This is a multi-center trial.\r\n\r\n\r\n\r\n      SEQUENCING:\r\n\r\n\r\n\r\n      DNA from archived tumor samples collected at the time of surgery (residual disease post\r\n\r\n      neoadjuvant chemotherapy) will be extracted and sequenced. The resultin",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2014",
            "CompletionDate": "December 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Hoosier Cancer Research Network",
            "StudyCondition": "Malignant Neoplasm of Breast",
            "studyLocation": "University of Alabama Hematology Oncology Clinic at Medical West",
            "Enrollment": "136",
            "NctKeyword": "Genomically-Directed Therapy, DNA Sequencing, RNA Sequencing,",
            "MeshKeyword": "Breast Neoplasms, Neoplasms, Triple Negative Breast Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Must have histologically or cytologically confirmed triple negative (ER-/PR-/HER2-)\r\n\r\n             invasive breast cancer, clinical stage I-III at diagnosis (AJCC 6th edition) based on\r\n\r\n             i",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "March 21, 2014",
            "OverallOfficial": "Bryan Schneider, M.D.",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Hoosier Cancer Research Network",
            "ContactName": "Bryan Schneider, M.D.",
            "ContactPhone": "317.944.0920",
            "ContactEmail": "bpschnei@iu.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama Hematology Oncology Clinic at Medical West",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02101385",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150031 - Hoosier Cancer Research - Lippman",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150031",
            "StudyNumber": "20150031 - Hoosier Cancer Research - Lippman",
            "StudyTitle": "A Phase II Randomized Controlled Trial of Genomically Directed Therapy after Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer",
            "PIID": "392",
            "PicNum": "C05569827",
            "PILastName": "Lippman",
            "PIFirstName": "Marc",
            "CoodCNbr": "C11973673",
            "CoordLastName": "Khadaran",
            "CoordFirstName": "Sharon",
            "CoordEmail": "s.khadaran@miami.edu",
            "CoordPhone": "305-243-7091",
            "EnteredByCNbr": "C12021320",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Paul",
            "ActiveEnrollingDate": "11/30/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/30/2015",
            "IRBApprovedFrom": "06/16/2015",
            "IRBApprovedTo": "06/06/2017",
            "AccountNbr": "665974",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase III",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "Externally Peer Reviewed",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "5",
            "Totalaccrued": "1",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UM Kendall:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Olga Machado-Aguero,Deborah Conte,Sarah Raybin,Halyna Hailes,Anthony Minichiello,Cristina Rojas-Mejia,Pascale Timothee,Karen Henry,Penny Eyer,Onaidy Torres",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02101385",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02101554",
            "SecondaryId": "EMBEDA",
            "BriefTitle": "Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain",
            "OfficialTitle": "An Open-label Study To Evaluate The Safety And Pharmacokinetics Of Pf-06412528 In Children 7-17 Years For The Treatment Of Moderate-to-severe Pain",
            "LeadSponsorClass": "Pfizer",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Pfizer",
            "OversightAuthority": "No",
            "BriefSummary": "Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of morphine\r\n\r\n      sulfate with a sequestered naltrexone core in children 7-17 with moderate-severe pain.",
            "Description": "Subjects, once stabilized to Embeda, need only complete a minimum of 2 of the 6 week study\r\n\r\n      duration to satisfy the PK endpoint. A safety follow-up visit is required at 1 week\r\n\r\n      post-last dose.",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2015",
            "CompletionDate": "September 2018",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "Pfizer",
            "StudyCondition": "Moderate-severe Pain (All Types)",
            "studyLocation": "Gottschalk Medical Plaza",
            "Enrollment": "140",
            "NctKeyword": "Pediatric, pain indication, controlled release morphine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Children 7-17 with moderate to severe pain requiring around the clock treatment with\r\n\r\n             an opioid analgesic.\r\n\r\n\r\n\r\n          -  Be an experienced opioid user, defined as any subject treated",
            "EligibleGender": "All",
            "MinAge": "7 Years",
            "MaxAge": "17 Years",
            "Volunteers": "No",
            "City": "Irvine",
            "State": "California",
            "Zip": "92697",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 4, 2017",
            "FirstReceived": "March 5, 2014",
            "OverallOfficial": "Pfizer CT.gov Call Center",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Pfizer",
            "ContactName": "Pfizer CT.gov Call Center",
            "ContactPhone": "1-800-718-1021",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "Gottschalk Medical Plaza",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02101554",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140986 - Pfizer - Gebhard",
            "FileProcessContentId": "440",
            "Division": "Anesthesiology",
            "StdyDivision": "10236",
            "EprostNbr": "20140986",
            "StudyNumber": "20140986 - Pfizer - Gebhard",
            "StudyTitle": "An Open-Label study to evaluate the safety and pharmacokinetics of PF 06412528 in children 7-17 years for the treatment of moderate to severe Chronic Pain.",
            "PIID": "706",
            "PicNum": "C04976318",
            "PILastName": "Gebhard",
            "PIFirstName": "Ralf",
            "CoodCNbr": "C10565278",
            "CoordLastName": "Gutierrez",
            "CoordFirstName": "Juan",
            "CoordEmail": "JGutierrez4@med.miami.edu",
            "EnteredByCNbr": "C04976318",
            "EnteredByLastName": "Gebhard",
            "EnteredByFirstName": "Ralf",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "06/02/2015",
            "IRBApprovedFrom": "06/02/2015",
            "IRBApprovedTo": "03/29/2017",
            "Expr1": "Phase IV",
            "Tarea": "Pain Management",
            "TareaCode": "16648",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Pfizer",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Juan Gutierrez,Lilibet Fernandez Valdes",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02101554",
            "StudyKeywords": "Pediatric pain, children pain, pain control, kids in pain, opioids, pain management",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02101788",
            "SecondaryId": "NCI-2014-00629",
            "BriefTitle": "Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer",
            "OfficialTitle": "A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase II/III trial studies how well trametinib works and compares it to\r\n\r\n      standard treatment with either letrozole, tamoxifen citrate, paclitaxel, pegylated liposomal\r\n\r\n      doxorubicin hydrochloride, or topotecan hydroc",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To estimate the progression-free survival (PFS) hazard ratio of trametinib compared to\r\n\r\n      that of \"commercially available therapies\" consisting of one of five commercially available\r\n\r\n      agents in wo",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2014",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Micropapillary Serous Carcinoma",
            "studyLocation": "Tennessee Valley Gynecologic Oncology",
            "Enrollment": "250",
            "MeshKeyword": "Adenocarcinoma, Carcinoma, Ovarian Neoplasms, Cystadenocarcinoma, Serous,",
            "InterventionKeyword": "Paclitaxel, Liposomal doxorubicin, Letrozole, Trametinib, Albumin-Bound Paclitaxel, Doxorubicin, Tamoxifen, Topotecan, Citric Acid,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients with the following tumors are included in the study:\r\n\r\n\r\n\r\n               -  Patients initially diagnosed with low-grade serous ovarian or peritoneal\r\n\r\n                  carcinoma that recur a",
            "EligibleGender": "Female",
            "MinAge": "19 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Huntsville",
            "State": "Alabama",
            "Zip": "35805",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "March 28, 2014",
            "OverallOfficial": "David Gershenson",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "NRG Oncology",
            "LocationStatus": "Recruiting",
            "LocationName": "Tennessee Valley Gynecologic Oncology",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02101788",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140660 - GOG - Slomovitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140660",
            "StudyNumber": "20140660 - GOG - Slomovitz",
            "StudyTitle": "A RANDOMIZED PHASE II/III STUDY TO ASSESS THE EFFICACY OF TRAMETINIB (GSK 1120212) IN PATIENTS WITH RECURRENT OR PROGRESSIVE LOW-GRADE SEROUS OVARIAN CANCER OR PERITONEAL CANCER.",
            "PIID": "22712",
            "PicNum": "C11916703",
            "PILastName": "Slomovitz",
            "PIFirstName": "Brian",
            "CoodCNbr": "C11920201",
            "CoordLastName": "Moya",
            "CoordFirstName": "Isabel",
            "CoordEmail": "iam18@miami.edu",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "01/22/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/22/2015",
            "IRBApprovedFrom": "05/29/2014",
            "IRBApprovedTo": "08/31/2017",
            "DiseaseSiteListDesc": "Ovary",
            "Expr1": "Phase II/III",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "GOG",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "11",
            "Totalaccrued": "5",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "4",
            "Totalpatients": "11",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Maggie Chislom,Halyna Hailes,Penny Eyer,Reshma Mahtani,Negin Habibi Khameneh,Mae Lyssa Bauduy-Roy,Evan Dadas,Claudia Grandas Moreno,Michelle Mikhail,Marinellie Vega",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02101788",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02101853",
            "SecondaryId": "NCI-2014-00631",
            "BriefTitle": "Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia",
            "OfficialTitle": "Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "No",
            "BriefSummary": "This randomized phase III trial studies how well blinatumomab works compared with standard\r\n\r\n      combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that\r\n\r\n      has returned after a period of improvement (",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To compare disease free survival (DFS) of high-risk (HR) and intermediate-risk (IR)\r\n\r\n      relapse B-cell acute lymphoblastic leukemia (B-ALL) patients who are randomized following\r\n\r\n      induction block 1",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2014",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "B Acute Lymphoblastic Leukemia",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "598",
            "MeshKeyword": "Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, Burkitt Lymphoma,",
            "InterventionKeyword": "Hydrocortisone 17-butyrate 21-propionate, Cortisol succinate, Hydrocortisone acetate, Dexamethasone acetate, Dexamethasone, Hydrocortisone, Dexamethasone 21-phosphate, Pegaspargase, Blinatumomab, Etoposide phosphate, Etoposide, Cytarabine, Cyclophosphamid",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  First relapse of B-ALL, allowable sites of disease include isolated bone marrow,\r\n\r\n             combined bone marrow and CNS and/or testicular, and isolated CNS and/or testicular;\r\n\r\n             extram",
            "EligibleGender": "All",
            "MinAge": "1 Year",
            "MaxAge": "30 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "March 28, 2014",
            "OverallOfficial": "Patrick Brown",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02101853",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150152 - COG - Barredo",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150152",
            "StudyNumber": "20150152 - COG - Barredo",
            "StudyTitle": "AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C00722004",
            "CoordLastName": "Garantiva",
            "CoordFirstName": "Nuria",
            "CoordEmail": "nfc19@miami.edu",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "10/23/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/23/2014",
            "IRBApprovedFrom": "10/23/2014",
            "IRBApprovedTo": "11/09/2017",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma,Lymphoid Leukemia,Other Hematopoietic",
            "Expr1": "Phase III",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "COG",
            "SiteSampleSize": "JMH:N/A,UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Myriam Zayas,Wendy Best",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02101853",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02104245",
            "BriefTitle": "Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis",
            "OfficialTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28",
            "LeadSponsorClass": "Aradigm Corporation",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Aradigm Corporation",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study (ARD-3150-1201, ORBIT-4) will evaluate the safety and efficacy of inhaled\r\n\r\n      Pulmaquin compared to inhaled placebo in subjects who have a confirmed diagnosis of\r\n\r\n      non-cystic fibrosis (non-CF) bronchiectasis with a history",
            "Description": "This is a multinational, multicenter, randomized, double-blind, placebo-controlled study to\r\n\r\n      evaluate the safety and efficacy of Pulmaquin compared to placebo in the management of\r\n\r\n      chronic lung infections with P. aeruginosa in su",
            "OverallStatus": "Completed",
            "StartDate": "April 2014",
            "CompletionDate": "October 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Aradigm Corporation",
            "StudyCondition": "Non Cystic Fibrosis Bronchiectasis",
            "Enrollment": "304",
            "NctKeyword": "Non Cystic Fibrosis Bronchiectasis, Pulmaquin, Ciprofloxacin, Pseudomonas aeruginosa,",
            "MeshKeyword": "Fibrosis, Bronchiectasis,",
            "InterventionKeyword": "Ciprofloxacin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Confirmed diagnosis of non-CF bronchiectasis\r\n\r\n\r\n\r\n          -  History of P. aeruginosa respiratory infections\r\n\r\n\r\n\r\n          -  At least two pulmonary exacerbations treated with antibiotics in the p",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 2, 2016",
            "FirstReceived": "March 28, 2014",
            "OverallOfficial": "Juergen Froehlich, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Aradigm Corporation",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02104245",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140304 - Aradigm Corporation - Salathe",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20140304",
            "StudyNumber": "20140304 - Aradigm Corporation - Salathe",
            "StudyTitle": "ARD-3150-1201 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subjects with Non-Cystic Fibrosis Bronchiectasis, including 28 Day Open-Label Extension (ORBIT-4)",
            "PIID": "528",
            "PicNum": "C00319179",
            "PILastName": "Salathe",
            "PIFirstName": "Matthias",
            "CoodCNbr": "C09943370",
            "CoordLastName": "Aguiar",
            "CoordFirstName": "Carolina",
            "EnteredByCNbr": "C00319179",
            "EnteredByLastName": "Salathe",
            "EnteredByFirstName": "Matthias",
            "ActiveEnrollingDate": "07/08/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/08/2014",
            "IRBApprovedFrom": "05/20/2014",
            "IRBApprovedTo": "05/16/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Aradigm Corporation",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "8",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "8",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Eliana Mendes,Patricia Rebolledo,Lilian Cadet,Carolina Aguiar,Patricia Graham-Borras,Johana Arana",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02104245",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02104713",
            "BriefTitle": "Stem Cell Therapy to Improve Burn Wound Healing",
            "OfficialTitle": "A Pilot Safety Study of the Administration of Mesenchymal Stem Cells (MSC) in the Treatment of Burn Wounds",
            "LeadSponsorClass": "Dr. E.Badiavas",
            "SponsorAgency": "Other",
            "LeadSponsor": "Dr. E.Badiavas",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will determine the safety of allogeneic stem cell therapy from healthy donors,\r\n\r\n      for 2nd degree burn wounds of less than 20% Total Body Surface Area (TBSA), at four\r\n\r\n      different dose levels.\r\n\r\n\r\n\r\n      Clinical evaluati",
            "Description": "The study will include a Phase 1 trial. A tissue repository will be collected. The\r\n\r\n      recipients in the Phases 1 of the study will be inpatients at Jackson. Their enrollment will\r\n\r\n      continue into the outpatient setting. The donors wi",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2014",
            "CompletionDate": "June 2018",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Skin Burn Degree Second",
            "studyLocation": "University of Miami",
            "Enrollment": "20",
            "NctKeyword": "Skin Burn Degree Second, Second degree Burn, Burn wound,",
            "MeshKeyword": "Burns,",
            "Eligibility": "- Donors:\r\n\r\n\r\n\r\n        Eligibility Criteria:\r\n\r\n\r\n\r\n          -  No history of malignancy\r\n\r\n\r\n\r\n          -  No active coagulopathy and/or hypocoagulable state\r\n\r\n\r\n\r\n          -  No history of cardio/pulmonary conditions\r\n\r\n\r\n\r\n          -",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 23, 2016",
            "FirstReceived": "April 1, 2014",
            "OverallOfficial": "Carl Schulman, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02104713",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20120925 - Department of Defense/Department of Defence - Schulman",
            "FileProcessContentId": "440",
            "Division": "Surgery",
            "StdyDivision": "7805",
            "EprostNbr": "20120925",
            "StudyNumber": "20120925 - Department of Defense/Department of Defence - Schulman",
            "StudyTitle": "A Pilot Safety Study of the Administration of Mesenchymal Stem Cells (MSC) in the Treatment of Burn Wounds",
            "PIID": "1116",
            "PicNum": "C02474366",
            "PILastName": "Schulman",
            "PIFirstName": "Carl",
            "CoodCNbr": "C11878871",
            "CoordLastName": "Orozco",
            "CoordFirstName": "Olga",
            "CoordEmail": "oorozco@med.miami.edu",
            "CoordPhone": "305-585-8160",
            "EnteredByCNbr": "C11878871",
            "EnteredByLastName": "Orozco",
            "EnteredByFirstName": "Olga",
            "ActiveEnrollingDate": "04/10/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/10/2014",
            "IRBApprovedFrom": "07/30/2013",
            "IRBApprovedTo": "04/24/2017",
            "DiseaseSiteListDesc": "Other Skin",
            "Expr1": "Phase I/II",
            "Tarea": "Trauma and Surgical Critical Care",
            "TareaCode": "16743",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Prescreened": "0",
            "Screenedfailed": "7",
            "SignedICF": "18",
            "Totalaccrued": "11",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "6",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "18",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Ronald Manning,Jeffrey McBride,Eric Maranda,Wellington Guzman",
            "AgentDevices": "Allogeneic Mesenchymal Stem Cells",
            "StudyObjective": "Determine the safety of allogeneic stem cell therapy for 2nd degree burn wounds of less than 20% TBSA, at four different dose levels. \r\nEvaluate the efficacy of allogeneic stem cell therapy in the treatment of 2nd degree burn wounds.",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT02104713",
            "StudyKeywords": "Stem Cell, Stem Cell for Burns",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02110706",
            "BriefTitle": "Phase II Trial of Rituximab In Myasthenia Gravis",
            "OfficialTitle": "A Phase II Trial of Rituximab In Myasthenia Gravis",
            "LeadSponsorClass": "Yale University",
            "SponsorAgency": "Other",
            "LeadSponsor": "Yale University",
            "OversightAuthority": "Yes",
            "BriefSummary": "The specific primary objective of this study is to determine whether rituximab is a safe and\r\n\r\n      beneficial therapeutic for Myasthenia Gravis (MG) that warrants further study in a phase III\r\n\r\n      efficacy trial.",
            "Description": "Investigators plan on conducting a multicenter randomized, double-blind, placebo controlled\r\n\r\n      Phase II clinical trial utilizing a futility design. The study would include acetylcholine\r\n\r\n      receptor (AChR) antibody positive generalize",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "May 2014",
            "CompletionDate": "December 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Yale University",
            "StudyCondition": "Myasthenia Gravis",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "50",
            "NctKeyword": "Myasthenia Gravis, Rituximab,",
            "MeshKeyword": "Muscle Weakness, Myasthenia Gravis,",
            "InterventionKeyword": "Rituximab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Subjects 21 to 90 years old\r\n\r\n\r\n\r\n          2. Subjects must have generalized MG, defined as MGFA clinical classification grades 2\r\n\r\n             (mild), 3 (moderate), or 4 (severe, but not intubated)",
            "EligibleGender": "All",
            "MinAge": "21 Years",
            "MaxAge": "90 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 15, 2016",
            "FirstReceived": "April 7, 2014",
            "OverallOfficial": "Richard J Nowak, MD, MS",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Yale University",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02110706",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140291 - Myasthenia Gravis Foundation of America (MGFA)/Gen - Benatar",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140291",
            "StudyNumber": "20140291 - Myasthenia Gravis Foundation of America (MGFA)/Gen - Benatar",
            "StudyTitle": "A Phase II Trial of Rituximab In Myasthenia Gravis",
            "PIID": "3255",
            "PicNum": "C09944978",
            "PILastName": "Benatar",
            "PIFirstName": "Michael",
            "CoodCNbr": "C00578829",
            "CoordLastName": "Waltz",
            "CoordFirstName": "Alexandra",
            "CoordEmail": "awaltz@med.miami.edu",
            "CoordPhone": "3052433329",
            "EnteredByCNbr": "C09944978",
            "EnteredByLastName": "Benatar",
            "EnteredByFirstName": "Michael",
            "ActiveEnrollingDate": "09/01/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/01/2014",
            "IRBApprovedFrom": "03/19/2014",
            "IRBApprovedTo": "03/02/2017",
            "InfoEdNbr": "70904",
            "Expr1": "Phase II",
            "Tarea": "Neuro-Muscular Disorders",
            "TareaCode": "8938",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Federal Non-NIH",
            "Prescreened": "2",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "4",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Julie Steele,Danielle Sheldon,Eliana Reyes,Alexandra Waltz",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02110706",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02111577",
            "SecondaryId": "2012-002814-38",
            "BriefTitle": "Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer",
            "OfficialTitle": "A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy",
            "LeadSponsorClass": "Sotio a.s.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Sotio a.s.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine whether DCVAC/PCa added onto Standard of Care\r\n\r\n      Chemotherapy can improve survival times for patients with Metastatic Castration Resistant\r\n\r\n      Prostate Cancer.",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2014",
            "CompletionDate": "June 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Sotio a.s.",
            "StudyCondition": "Metastatic Castrate Resistant Prostate Cancer",
            "studyLocation": "University of South Alabama Mitchell Cancer Institute",
            "Enrollment": "1170",
            "NctKeyword": "Immunotherapy, Metastatic, Castrate Resistant, Prostate Cancer, Biological, Vaccine,",
            "MeshKeyword": "Prostatic Neoplasms,",
            "InterventionKeyword": "Prednisone, Docetaxel,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male 18 years and older\r\n\r\n\r\n\r\n          -  Histologically or cytologically confirmed prostate adenocarcinoma\r\n\r\n\r\n\r\n          -  Presence of skeletal, and/or soft-tissue/visceral/nodal metastasis",
            "EligibleGender": "Male",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Mobile",
            "State": "Alabama",
            "Zip": "36604",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 15, 2016",
            "FirstReceived": "April 9, 2014",
            "OverallOfficial": "Rostislav Kuklik, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Sotio a.s.",
            "ContactName": "Richard Kapsa",
            "ContactPhone": "420-224-174-448",
            "ContactEmail": "kapsa@sotio.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of South Alabama Mitchell Cancer Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02111577",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140714 - Sotio Pharm - Singal",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140714",
            "StudyNumber": "20140714 - Sotio Pharm - Singal",
            "StudyTitle": "A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy",
            "PIID": "459",
            "PicNum": "C03089847",
            "PILastName": "Singal",
            "PIFirstName": "Rakesh",
            "CoodCNbr": "C12026538",
            "CoordLastName": "Grez",
            "CoordFirstName": "Nester",
            "CoordEmail": "Nester.Grez@med.miami.edu",
            "CoordPhone": "305-243-4033",
            "EnteredByCNbr": "C12021320",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Paul",
            "ActiveEnrollingDate": "11/20/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/20/2015",
            "IRBApprovedFrom": "02/17/2015",
            "IRBApprovedTo": "01/04/2017",
            "AccountNbr": "665786",
            "DiseaseSiteListDesc": "Prostate",
            "Expr1": "Phase III",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Sotio Pharmaceutical",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "5",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:10,UMMG:N/A,UMD:N/A",
            "AccrualPercentageMet": "30",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "10",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Luis,Vivianne Velez-Bravo,Penny Eyer",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02111577",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02112916",
            "SecondaryId": "NCI-2014-00712",
            "BriefTitle": "Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma",
            "OfficialTitle": "A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase III trial compares how well combination chemotherapy works when given\r\n\r\n      with or without bortezomib in treating patients with newly diagnosed T-cell acute\r\n\r\n      lymphoblastic leukemia or stage II-IV T-cell lymphobl",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To compare event-free survival (EFS) in patients with newly diagnosed T-cell acute\r\n\r\n      lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LLy) who are randomized\r\n\r\n      to a modified au",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2014",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Adult T Acute Lymphoblastic Leukemia",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "1400",
            "MeshKeyword": "Lymphoma, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,",
            "InterventionKeyword": "Hydrocortisone 17-butyrate 21-propionate, Cortisol succinate, Hydrocortisone acetate, Dexamethasone acetate, Dexamethasone, Hydrocortisone, Dexamethasone 21-phosphate, Liposomal doxorubicin, Isophosphamide mustard, Pegaspargase, Etoposide phosphate, Doxor",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  T-ALL: T-ALL patients must be enrolled on Project Every Child (APEC14B1) prior to\r\n\r\n             treatment and enrollment on AALL1231\r\n\r\n\r\n\r\n               -  T-LLy: if Project: Every Child (APEC14B1) i",
            "EligibleGender": "All",
            "MinAge": "2 Years",
            "MaxAge": "30 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "April 9, 2014",
            "OverallOfficial": "David Teachey",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02112916",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150052 - NCCF/COG - Barredo",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150052",
            "StudyNumber": "20150052 - NCCF/COG - Barredo",
            "StudyTitle": "AALL1231 - A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C11973083",
            "CoordLastName": "Best",
            "CoordFirstName": "Wendy",
            "CoordEmail": "wtbest@med.miami.edu",
            "CoordPhone": "305-243-7130",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "01/23/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/23/2015",
            "IRBApprovedFrom": "08/27/2014",
            "IRBApprovedTo": "11/09/2017",
            "DiseaseSiteListDesc": "Lymphoid Leukemia,Leukemia, Other,Leukemia, not otherwise specified",
            "Expr1": "Phase III",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Myriam Zayas,Nuria Garantiva",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02112916",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02115282",
            "SecondaryId": "NCI-2014-00746",
            "BriefTitle": "Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic",
            "OfficialTitle": "A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase III trial studies exemestane and entinostat to see how well they work\r\n\r\n      compared to exemestane alone in treating patients with hormone receptor-positive breast\r\n\r\n      cancer that has spread to nearby tissue or lymp",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To evaluate whether the addition of entinostat to endocrine therapy (exemestane) improves\r\n\r\n      progression-free survival (PFS) and/or overall survival (OS) in patients with hormone\r\n\r\n      receptor (HR)-p",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2014",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Estrogen Receptor Positive",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "600",
            "MeshKeyword": "Breast Neoplasms, Carcinoma, Breast Neoplasms, Male,",
            "InterventionKeyword": "Hormones, Entinostat, Exemestane, Goserelin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Estrogen receptor (ER) and/or progesterone receptor (PR) positive histologically\r\n\r\n             confirmed adenocarcinoma of the breast with staining of >= 1% cells will be\r\n\r\n             considered pos",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "April 14, 2014",
            "OverallOfficial": "Roisin Connolly",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "ECOG-ACRIN Cancer Research Group",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02115282",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140388 - ECOG - Calfa",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140388",
            "StudyNumber": "20140388 - ECOG - Calfa",
            "StudyTitle": "A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer",
            "PIID": "25231",
            "PicNum": "C00214960",
            "PILastName": "Calfa",
            "PIFirstName": "Carmen",
            "CoodCNbr": "C12024030",
            "CoordLastName": "Conte",
            "CoordFirstName": "Deborah",
            "CoordEmail": "dmc238@med.miami.edu",
            "CoordPhone": "954-830-2360",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "02/25/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/25/2015",
            "IRBApprovedFrom": "01/05/2015",
            "IRBApprovedTo": "04/06/2017",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase III",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "ECOG",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "5",
            "Totalaccrued": "4",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UM Kendall:N/A,Plantation:N/A,UMHC:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Halyna Hailes,Sarah Raybin,Anthony Minichiello,Cristina Rojas-Mejia,LAWRENCE NEGRET,Onaidy Torres",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02115282",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02119182",
            "SecondaryId": "1U01NS086090-01",
            "BriefTitle": "Transforming Research and Clinical Knowledge in Traumatic Brain Injury",
            "OfficialTitle": "Transforming Research and Clinical Knowledge in Traumatic Brain Injury",
            "LeadSponsorClass": "University of California, San Francisco",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of California, San Francisco",
            "OversightAuthority": "No",
            "BriefSummary": "The overall goal of Transforming Research and Clinical Knowledge in Traumatic Brain Injury\r\n\r\n      (TRACK-TBI) study is to determine the relationships among the clinical, neuroimaging,\r\n\r\n      cognitive, genetic and proteomic biomarker charact",
            "Description": "Effective treatment of traumatic brain injury (TBI) remains one of the greatest unmet needs\r\n\r\n      in public health. After 3 decades of failed clinical trials, a new approach is needed. Our\r\n\r\n      proposal, Transforming Research and Clinical",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2014",
            "CompletionDate": "August 2018",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of California, San Francisco",
            "StudyCondition": "Traumatic Brain Injury",
            "studyLocation": "University of California, San Francisco",
            "Enrollment": "3000",
            "NctKeyword": "Traumatic Brain Injury, Biomarkers, Neuroimaging, Psychological Health, Comparative Effectiveness Research,",
            "MeshKeyword": "Wounds and Injuries, Brain Injuries,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Age 18-100\r\n\r\n\r\n\r\n          -  Documented/verified TBI by ACRM Criteria\r\n\r\n\r\n\r\n          -  Injury occurred within 24 hours of ED arrival\r\n\r\n\r\n\r\n          -  Acute brain CT as part of clinical care",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "100 Years",
            "Volunteers": "No",
            "City": "San Francisco",
            "State": "California",
            "Zip": "94110",
            "Country": "United States",
            "VerificationDate": "December 2015",
            "LastChanged": "December 7, 2015",
            "FirstReceived": "March 22, 2014",
            "OverallOfficial": "Geoffrey T. Manley, MD, PhD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "University of California, San Francisco",
            "ContactName": "John Yue, BA, CCRC",
            "ContactPhone": "415-206-4457",
            "ContactEmail": "yuej@neurosurg.ucsf.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of California, San Francisco",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02119182",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20131004 - National Institute of Neurological Disorders and S - Hotz",
            "FileProcessContentId": "440",
            "Division": "Neurosurgery",
            "StdyDivision": "9636",
            "EprostNbr": "20131004",
            "StudyNumber": "20131004 - National Institute of Neurological Disorders and S - Hotz",
            "StudyTitle": "Transforming Research and Clinical Knowledge in Traumatic Brain Injury",
            "PIID": "205",
            "PicNum": "C06067380",
            "PILastName": "Bullock",
            "PIFirstName": "Ross",
            "CoodCNbr": "C04999192",
            "CoordLastName": "Muniz",
            "CoordFirstName": "Maria",
            "EnteredByCNbr": "C00582851",
            "EnteredByLastName": "Hotz",
            "EnteredByFirstName": "Gillian",
            "ActiveEnrollingDate": "05/02/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/02/2014",
            "IRBApprovedFrom": "03/10/2014",
            "IRBApprovedTo": "02/11/2017",
            "Expr1": "N/A",
            "Tarea": "Trauma",
            "TareaCode": "9638",
            "SponsorGroup": "Other",
            "Sponsor": "National Institute of Neurological Disorders and Stroke",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "120",
            "Totalaccrued": "119",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "119",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "120",
            "FirstNinety": "13",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carlos J. Bidot,Lester Pola Alvarado,Maria Muniz",
            "NationalSampleSize": "279",
            "NCTNbr": "NCT02119182",
            "StudyKeywords": "Miami Project",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02121028",
            "BriefTitle": "Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease",
            "OfficialTitle": "Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The objective of this study is to determine the mechanisms of stroke in patients with\r\n\r\n      Intracranial Atherosclerotic Disease (IAD) by specifically evaluating limitations of\r\n\r\n      antegrade flow through the stenotic artery, distal tissu",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2015",
            "CompletionDate": "February 2019",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Intracranial Vascular Disorders",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "175",
            "NctKeyword": "Intracranial Atherosclerotic Disease, Stroke, Transient Ischemic Attack, Imaging,",
            "MeshKeyword": "Recurrence, Vascular Diseases, Cerebrovascular Disorders,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Stroke defined as symptoms lasting >24 hours and associated with imaging evidence of\r\n\r\n             acute ischemia in the distribution of the stenotic vessel on CT or MRI.\r\n\r\n\r\n\r\n          2. Eligible T",
            "EligibleGender": "All",
            "MinAge": "30 Years",
            "MaxAge": "99 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 21, 2016",
            "FirstReceived": "April 18, 2014",
            "OverallOfficial": "Jose G Romano, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Jose G Romano, MD",
            "ContactPhone": "305-243-8018",
            "ContactEmail": "jromano@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02121028",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140056 - National Institute of Neurological Disorders and S - Romano",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140056",
            "StudyNumber": "20140056 - National Institute of Neurological Disorders and S - Romano",
            "StudyTitle": "Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease (MyRIAD)",
            "PIID": "149",
            "PicNum": "C00607800",
            "PILastName": "Romano",
            "PIFirstName": "Jose",
            "CoodCNbr": "C00460088",
            "CoordLastName": "Bustillo",
            "CoordFirstName": "Iszet",
            "EnteredByCNbr": "C00607800",
            "EnteredByLastName": "Romano",
            "EnteredByFirstName": "Jose",
            "ActiveEnrollingDate": "01/12/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/12/2015",
            "IRBApprovedFrom": "02/10/2014",
            "IRBApprovedTo": "01/10/2017",
            "AccountNbr": "662706",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "N/A",
            "Tarea": "Stroke",
            "TareaCode": "8943",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Other",
            "SponsorGroup": "NIH",
            "Sponsor": "National Institute of Neurological Disorders and Stroke",
            "Prescreened": "10",
            "Screenedfailed": "6",
            "SignedICF": "12",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "12",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Iszet Bustillo,Andrea Escobar,Iszet Campo-Bustillo",
            "StudyObjective": "The objective of this study is to determine the mechanisms of stroke in patients with Intracranial Atherosclerotic Disease (IAD) by specifically evaluating limitations of antegrade flow through the stenotic artery, distal tissue perfusion to the affected territory, and artery-to-artery embolism.",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT02121028",
            "StudyKeywords": "Stroke, Transient Ischemic Attack, TIA,infarct, stenosis, recurrent stroke",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02126774",
            "BriefTitle": "The Human Epilepsy Project",
            "OfficialTitle": "The Human Epilepsy Project",
            "LeadSponsorClass": "New York University School of Medicine",
            "SponsorAgency": "Other",
            "LeadSponsor": "New York University School of Medicine",
            "OversightAuthority": "No",
            "BriefSummary": "HEP is a five-year, prospective, observational study whose primary goal is to identify\r\n\r\n      clinical characteristics and biomarkers predictive of disease outcome, progression, and\r\n\r\n      treatment response in participants with newly treate",
            "Description": "Epilepsy is a serious disease. It affects approximately 2.4 million Americans, with a\r\n\r\n      lifetime risk estimated at 3%. More than 181,000 Americans develop epilepsy every year, and\r\n\r\n      a substantial proportion has seizures that cannot",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2012",
            "CompletionDate": "May 2018",
            "Phase": "N/A",
            "StudyType": "Observational [Patient Registry]",
            "StudyPhase": "N/A",
            "StudySource": "New York University School of Medicine",
            "StudyCondition": "Focal Epilepsy",
            "studyLocation": "University of Alabama",
            "Enrollment": "600",
            "NctKeyword": "epilepsy, focal epilepsy,",
            "MeshKeyword": "Epilepsy, Epilepsies, Partial,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Clinical seizure(s) and history consistent with focal epilepsy\r\n\r\n\r\n\r\n          -  At least two confirmed spontaneous seizures, at least 24 hours apart, in the 12\r\n\r\n             months prior to enrollme",
            "EligibleGender": "All",
            "MinAge": "12 Years",
            "MaxAge": "60 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 11, 2016",
            "FirstReceived": "April 28, 2014",
            "OverallOfficial": "Ruben Kuzniecky, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "New York University, Comprehensive Epilepsy Center",
            "ContactName": "Sabrina Cristofaro",
            "ContactEmail": "sabrina.cristofaro@nyumc.org",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02126774",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20120894 - NEW YORK UNIV - Kanner",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20120894",
            "StudyNumber": "20120894 - NEW YORK UNIV - Kanner",
            "StudyTitle": "Human Epilepsy Project",
            "PIID": "4412",
            "PicNum": "C11317264",
            "PILastName": "Kanner",
            "PIFirstName": "Andres",
            "CoodCNbr": "C10597879",
            "CoordLastName": "Figueredo",
            "CoordFirstName": "Pedro",
            "CoordEmail": "pfigueredo@med.miami.edu",
            "CoordPhone": "3052438829",
            "EnteredByCNbr": "C10597879",
            "EnteredByLastName": "Figueredo",
            "EnteredByFirstName": "Pedro",
            "ActiveEnrollingDate": "11/26/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/26/2013",
            "IRBApprovedFrom": "07/01/2013",
            "IRBApprovedTo": "07/10/2017",
            "AccountNbr": "661481",
            "InfoEdNbr": "66011",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "SponsorGroup": "Foundation",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "16",
            "Totalaccrued": "15",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "12",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "16",
            "FirstNinety": "1",
            "SiteSampleSize": "Non University of Miami:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Pedro Figueredo,Carlos Millan,Maria Palomeque",
            "NationalSampleSize": "35",
            "NCTNbr": "NCT02126774",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02129348",
            "SecondaryId": "1R01AG047146-01",
            "BriefTitle": "Treatment of Psychosis and Agitation in Alzheimer's Disease",
            "OfficialTitle": "Treatment of Psychosis and Agitation in Alzheimer's Disease",
            "LeadSponsorClass": "New York State Psychiatric Institute",
            "SponsorAgency": "Other",
            "LeadSponsor": "New York State Psychiatric Institute",
            "OversightAuthority": "Yes",
            "BriefSummary": "Clinically, many patients with AD show no response or minimal response to antipsychotics for\r\n\r\n      symptoms of agitation/aggression or psychosis, or they have intolerable side effects on\r\n\r\n      these medications. Antipsychotics have a wide",
            "Description": "Symptoms of psychosis or agitation are common in Alzheimer's disease. These symptoms are\r\n\r\n      associated with distress for the patient, an increased burden for caregivers, more rapid\r\n\r\n      cognitive decline, greater risk of institutionali",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2014",
            "CompletionDate": "April 2019",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "New York State Psychiatric Institute",
            "StudyCondition": "Alzheimer's Disease",
            "studyLocation": "New York State Psychiatric Institute",
            "Enrollment": "80",
            "NctKeyword": "Alzheimer's disease, psychosis, agitation, aggression, Lithium, delusions, hallucinations,",
            "MeshKeyword": "Alzheimer Disease, Psychotic Disorders, Mental Disorders, Psychomotor Agitation,",
            "InterventionKeyword": "Lithium Carbonate,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age 55-95 years\r\n\r\n\r\n\r\n          2. Diagnosis of possible or probable AD by standard NIA criteria (McKahnn et al, 1984;\r\n\r\n             McKhann et all, 2011)\r\n\r\n\r\n\r\n          3. Folstein MMSE 5-26 out of",
            "EligibleGender": "All",
            "MinAge": "55 Years",
            "MaxAge": "95 Years",
            "Volunteers": "No",
            "City": "New York",
            "State": "New York",
            "Zip": "10032",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 20, 2016",
            "FirstReceived": "April 29, 2014",
            "OverallOfficial": "DP Devanand, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Columbia University",
            "ContactName": "DP Devanand, MD",
            "ContactPhone": "646 774 8658",
            "ContactEmail": "dpd3@columbia.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "New York State Psychiatric Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02129348",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150554 - Lithium- Crocco",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20150554",
            "StudyNumber": "20150554 - Lithium- Crocco",
            "StudyTitle": "Treatment of Psychosis and Agitation in Alzheimer’s Disease",
            "PIID": "3693",
            "PicNum": "C00802143",
            "PILastName": "Crocco",
            "PIFirstName": "Elizabeth",
            "CoodCNbr": "C06046616",
            "CoordLastName": "Robertson",
            "CoordFirstName": "Belinda",
            "CoordEmail": "BRobertson@med.miami.edu",
            "EnteredByCNbr": "C00802143",
            "EnteredByLastName": "Crocco",
            "EnteredByFirstName": "Elizabeth",
            "ActiveEnrollingDate": "01/25/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/25/2016",
            "IRBApprovedFrom": "08/17/2015",
            "IRBApprovedTo": "07/31/2017",
            "AccountNbr": "brobertson",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "National Institute on Aging",
            "Prescreened": "0",
            "Screenedfailed": "6",
            "SignedICF": "10",
            "Totalaccrued": "5",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Tania Guardia,Lina Garcia,Belinda Robertson,Nicole Brenson,Gabriela Vargas",
            "StudyObjective": "Currently, there is no FDA-approved medication for the treatment of psychosis or\r\nagitation in AD.\r\nOur initial open treatment pilot data show that patients with no response or partial response to antipsychotics clearly improve on lithium, supporting the systematic study of lithium treatment for agitation/aggression with or without psychosis in AD. Our innovative project will examine the efficacy and side effects of low dose lithium treatment of agitation/aggression with or without psychosis in 80 patients with AD in a randomized, doubleblind, 12-week trial (essentially a Phase II trial). The results will determine the potential for a large-scale clinical trial (Phase III) to establish the utility of lithium in these patients.",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02129348",
            "StudyKeywords": "Lithium, NIH, NIA, Alzheimers, Dementia, Agitation, Psychosis",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02129543",
            "BriefTitle": "Immune Reconstitution in Stem Cell Transplant Recipients",
            "OfficialTitle": "Collection of Peripheral Blood Samples From Donors and Recipients of Blood and Marrow Transplants for Laboratory Research in Immune Reconstitution",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The investigators are collecting blood samples to learn more about how the body's immune\r\n\r\n      system recovers after stem cell transplant (SCT). Participants are either previous\r\n\r\n      recipients of a stem cell transplant, or a donor of ste",
            "Description": "The investigators propose to systematically collect specimens of blood and plasma from\r\n\r\n      donors and recipients of SCT. For recipients, samples may be collected at the following time\r\n\r\n      points or transplant milestones. If the recipie",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2011",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "200",
            "NctKeyword": "SCT, Stem Cell Transplantation, Stem Cell Transplant,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Stem Cell Transplant Donor\r\n\r\n\r\n\r\n          -  Stem Cell Transplant Recipient\r\n\r\n\r\n\r\n        Exclusion Criteria:",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 4, 2016",
            "FirstReceived": "April 30, 2014",
            "OverallOfficial": "Krishna V Komanduri, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02129543",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20080899 - NCI - Komanduri",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20080899",
            "StudyNumber": "20080899 - NCI - Komanduri",
            "StudyTitle": "Collection of Peripheral Blood Samples from Donors and Recipients of Blood and Marrow Transplants for Laboratory Research in Immune Reconstitution.Recipient/Donor Consent",
            "PIID": "1930",
            "PicNum": "C06948118",
            "PILastName": "Komanduri",
            "PIFirstName": "Krishna",
            "CoodCNbr": "C11923689",
            "CoordLastName": "Mohan",
            "CoordFirstName": "Vivin",
            "CoordEmail": "vxm153@miami.edu",
            "EnteredByCNbr": "C11964150",
            "EnteredByLastName": "Smith",
            "EnteredByFirstName": "Nyesha",
            "ActiveEnrollingDate": "08/18/2011",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/18/2011",
            "IRBApprovedFrom": "01/22/2009",
            "IRBApprovedTo": "07/25/2017",
            "AccountNbr": "66549W",
            "InfoEdNbr": "51189",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma,Hodgkins Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Myeloid and Monocytic Leukemia,Leukemia, not otherwise specified,Other Hematopoietic,Kaposis sarcoma,Multiple,Monocytic Leukemia",
            "Expr1": "N/A",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Randomization": "Non - Randomized",
            "Expr2": "Correlative",
            "StudyType_Code": "140",
            "ResearchType": "Specimen",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "265",
            "Totalaccrued": "265",
            "InFollowUp": "133",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "265",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:500",
            "AccrualPercentageMet": "53",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "500",
            "EprostState": "Approved",
            "CancerCenterNbr": "2008134",
            "StudyCoordinator": "Nohelia Gonzalez,Micaela Martinez,Nathalie Luis",
            "NationalSampleSize": "500",
            "NCTNbr": "NCT02129543",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02135419",
            "SecondaryId": "NCI-2014-00636",
            "BriefTitle": "Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions",
            "OfficialTitle": "ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study",
            "LeadSponsorClass": "AIDS Malignancy Consortium",
            "SponsorAgency": "Other",
            "LeadSponsor": "AIDS Malignancy Consortium",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase III trial compares topical or ablative treatment with active\r\n\r\n      monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and\r\n\r\n      high-grade squamous intraepithelial lesions (HSIL).",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To determine the effectiveness of treating anal HSIL to reduce the incidence of anal\r\n\r\n      cancer in human immunodeficiency virus (HIV)-infected men and women.\r\n\r\n\r\n\r\n      SECONDARY OBJECTIVES:",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2014",
            "CompletionDate": "June 2022",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "AIDS Malignancy Consortium",
            "StudyCondition": "Anal Cancer",
            "studyLocation": "UCLA CARE Clinic",
            "Enrollment": "5058",
            "MeshKeyword": "Infection, Communicable Diseases, HIV Infections, Virus Diseases, Anus Neoplasms, Papilloma, Squamous Intraepithelial Lesions of the Cervix, Papillomavirus Infections,",
            "InterventionKeyword": "Fluorouracil, Imiquimod,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  HIV-1 infection, as documented by any federally approved, licensed HIV test performed\r\n\r\n             in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA], test\r\n\r\n             kit",
            "EligibleGender": "All",
            "MinAge": "35 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90035",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "December 30, 2016",
            "FirstReceived": "May 8, 2014",
            "OverallOfficial": "Joel Palefsky, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "AIDS Malignancy Consortium",
            "ContactName": "Bob Siedle-Khan",
            "ContactPhone": "844-448-2888",
            "ContactEmail": "bsiedle-khan@ucsf.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "UCLA CARE Clinic",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02135419",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160316 - AMC - Rosa-Cunha",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160316",
            "StudyNumber": "20160316 - AMC - Rosa-Cunha",
            "StudyTitle": "ANCHOR: Anal Cancer Prevention Study\nAnal Cancer/HSIL Outcomes Research Study",
            "PIID": "1260",
            "PicNum": "C05021649",
            "PILastName": "Rosa-cunha",
            "PIFirstName": "Isabella",
            "CoodCNbr": "C09926085",
            "CoordLastName": "Sandoval",
            "CoordFirstName": "Carlos",
            "CoordEmail": "c.sandoval1@med.miami.edu",
            "EnteredByCNbr": "C09926085",
            "EnteredByLastName": "Sandoval",
            "EnteredByFirstName": "Carlos",
            "ActiveEnrollingDate": "06/23/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/23/2016",
            "IRBApprovedFrom": "06/21/2016",
            "IRBApprovedTo": "06/20/2017",
            "DiseaseSiteListDesc": "Anus",
            "Expr1": "N/A",
            "Tarea": "Colorectal Cancer",
            "TareaCode": "12437",
            "Expr2": "Prevention",
            "StudyType_Code": "6163",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "National Cancer Institute",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "16",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "16",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "4",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Sam-mosley Ayuk,Sindy Jaramillo,Carlos Sandoval",
            "NationalSampleSize": "1000",
            "NCTNbr": "NCT02135419",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02139306",
            "SecondaryId": "2013-004581-34",
            "BriefTitle": "Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)",
            "OfficialTitle": "A Phase 3 Efficacy and Safety Study of Ataluren (PTC124®) in Patients With Nonsense Mutation Cystic Fibrosis",
            "LeadSponsorClass": "PTC Therapeutics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "PTC Therapeutics",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled,\r\n\r\n      efficacy and safety study of ataluren in patients with nonsense mutation cystic fibrosis\r\n\r\n      (nmCF) not receiving chronic inhaled aminogly",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "June 2014",
            "CompletionDate": "November 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "PTC Therapeutics",
            "StudyCondition": "Cystic Fibrosis",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "208",
            "MeshKeyword": "Fibrosis, Cystic Fibrosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Evidence of signed and dated informed consent/assent document(s) indicating that the\r\n\r\n             subject (and/or his parent/legal guardian) has been informed of all pertinent aspects",
            "EligibleGender": "All",
            "MinAge": "6 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2015",
            "LastChanged": "November 25, 2015",
            "FirstReceived": "May 13, 2014",
            "OverallOfficial": "Joseph McIntosh, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "PTC Therapeutics",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02139306",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140582 - PTC Therapeutics/ Inc. - Salathe",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20140582",
            "StudyNumber": "20140582 - PTC Therapeutics/ Inc. - Salathe",
            "StudyTitle": "A PHASE 3 EFFICACY AND SAFETY STUDY OF ATALUREN (PTC124®)\nIN PATIENTS WITH NONSENSE MUTATION CYSTIC FIBROSIS",
            "PIID": "528",
            "PicNum": "C00319179",
            "PILastName": "Salathe",
            "PIFirstName": "Matthias",
            "CoodCNbr": "C09943370",
            "CoordLastName": "Aguiar",
            "CoordFirstName": "Carolina",
            "CoordEmail": "caguiar2@med.miami.edu",
            "CoordPhone": "3052435545",
            "EnteredByCNbr": "C00319179",
            "EnteredByLastName": "Salathe",
            "EnteredByFirstName": "Matthias",
            "ActiveEnrollingDate": "01/08/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/08/2015",
            "IRBApprovedFrom": "08/19/2014",
            "IRBApprovedTo": "07/18/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "PTC Therapeutics/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "10",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "5",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Patricia Rebolledo,Lilian Cadet,Carolina Aguiar,Patricia Graham-Borras,Johana Arana,Eliana Mendes",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02139306",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02142283",
            "BriefTitle": "Trevo and Medical Management Versus Medical Management Alone in Wake Up and Late Presenting Strokes",
            "OfficialTitle": "Diffusion Weighted Imaging (DWI) or Computerized Tomography Perfusion (CTP) Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention",
            "LeadSponsorClass": "Stryker Neurovascular",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Stryker Neurovascular",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of the study is to evaluate the hypothesis that Trevo thrombectomy plus medical\r\n\r\n      management leads to superior clinical outcomes at 90 days as compared to medical management\r\n\r\n      alone in appropriately selected subjects ex",
            "Description": "The study is a prospective, randomized, multi-center, Phase II/III (feasibility/pivotal),\r\n\r\n      adaptive, controlled trial, designed to demonstrate that mechanical thrombectomy using the\r\n\r\n      Trevo Retriever with medical management is sup",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2014",
            "CompletionDate": "July 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Stryker Neurovascular",
            "StudyCondition": "Ischemic Stroke",
            "studyLocation": "Kaiser Permanente Los Angeles Medical Center",
            "Enrollment": "500",
            "NctKeyword": "Mechanical thrombectomy, Acute ischemic stroke, Wake up stroke, Late presenting stroke,",
            "MeshKeyword": "Stroke,",
            "Eligibility": "General Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Clinical signs and symptoms consistent with the diagnosis of an acute ischemic\r\n\r\n             stroke, and subject belongs to one of the following subgroups:\r\n\r\n\r\n\r\n               1. Subject has",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90027",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 1, 2016",
            "FirstReceived": "May 15, 2014",
            "OverallOfficial": "Tudor G Jovin, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Pittsburg Medical Center Stroke Institute",
            "ContactName": "Christine Yang",
            "ContactPhone": "510-413-2841",
            "ContactEmail": "christine.yang@stryker.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Kaiser Permanente Los Angeles Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02142283",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150572 - Stryker - Yavagal",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20150572",
            "StudyNumber": "20150572 - Stryker - Yavagal",
            "StudyTitle": "DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention (DAWN™ Trial)",
            "PIID": "252",
            "PicNum": "C06459010",
            "PILastName": "Yavagal",
            "PIFirstName": "Dileep",
            "CoodCNbr": "C11877018",
            "CoordLastName": "Ramdas",
            "CoordFirstName": "Kevin",
            "CoordEmail": "k.ramdas@med.miami.edu",
            "CoordPhone": "305-243-1132",
            "EnteredByCNbr": "C06459010",
            "EnteredByLastName": "Yavagal",
            "EnteredByFirstName": "Dileep",
            "ActiveEnrollingDate": "09/14/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/14/2016",
            "IRBApprovedFrom": "10/12/2015",
            "IRBApprovedTo": "08/04/2017",
            "Expr1": "Phase IV",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "Stryker",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "7",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "4",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Luis Guada,Karen Bates,Silvia Balladares-Huete",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT02142283",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02145390",
            "BriefTitle": "Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy",
            "OfficialTitle": "A Phase II Study of Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "Bladder preservation in patients with complete response after neoadjuvant chemotherapy will\r\n\r\n      lead to equivalent or superior relapse free rates compared to cystectomy rates from\r\n\r\n      historical controls.",
            "Description": "1. Transurethral Resection of the Bladder Tumor (TURBT) and Cystoscopy performed by\r\n\r\n           participating urologist:\r\n\r\n\r\n\r\n             -  cystoscopic evaluation\r\n\r\n\r\n\r\n             -  bimanual examination under anesthesia,",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2014",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Bladder Cancer",
            "studyLocation": "University of Miami Sylvester Comprehensive Cancer Center",
            "Enrollment": "68",
            "NctKeyword": "Bladder Cancer, Bladder Carcinoma, Transition Cell Cancer, TCC, Muscle Invasive Bladder Carcinoma,",
            "MeshKeyword": "Carcinoma, Urinary Bladder Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Pathologically proven diagnosis of primary carcinoma of the bladder(transitional cell\r\n\r\n             cancer). Must be operable patients with muscularis propria invasion and American\r\n\r\n             Join",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 4, 2016",
            "FirstReceived": "May 20, 2014",
            "OverallOfficial": "Adrian S Ishkanian, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami Sylvester Comprehensive Cancer Center",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Sylvester Comprehensive Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02145390",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20130896 - Intramural - Ishkanian",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20130896",
            "StudyNumber": "20130896 - Intramural - Ishkanian",
            "StudyTitle": "A Phase II Study of chemoradiation for Bladder Preservation in Patients with Muscle Invasive Bladder Carcinoma after Complete Response to Neoadjuvant Chemotherapy",
            "PIID": "4324",
            "PicNum": "C11277917",
            "PILastName": "Ishkanian",
            "PIFirstName": "Adrian",
            "CoodCNbr": "C06442607",
            "CoordLastName": "Ishteiwy",
            "CoordFirstName": "Reema",
            "CoordEmail": "rishteiwy@med.miami.edu",
            "CoordPhone": "305-243-0974",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "06/30/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/30/2014",
            "IRBApprovedFrom": "05/19/2014",
            "IRBApprovedTo": "03/24/2017",
            "DiseaseSiteListDesc": "Urinary Bladder",
            "Expr1": "Phase II",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Marinellie Vega,Pavel Noa Hechavarria,Fernando Vazquez Pascual,Maggie Chislom,Zaida Abreu,Mohammad El-Sorady,Lilibet Zamora Cabezas,Lilly Sanchez,Doris Martin",
            "NationalSampleSize": "85",
            "NCTNbr": "NCT02145390",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02160041",
            "BriefTitle": "BGJ398 for Patients With Tumors With FGFR Genetic Alterations",
            "OfficialTitle": "Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations",
            "LeadSponsorClass": "Novartis Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novartis Pharmaceuticals",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this signal seeking study is to determine whether treatment with BGJ398\r\n\r\n      demonstrates sufficient efficacy in select FGFR pathway-regulated solid tumors and/or\r\n\r\n      hematologic malignancies to warrant further study.",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2014",
            "CompletionDate": "March 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Novartis",
            "StudyCondition": "Solid Tumor",
            "studyLocation": "Alabama Oncology St. Vincent's Birmingham",
            "Enrollment": "90",
            "NctKeyword": "Solid tumor malignancy, hematologic malignancy, mutation, translocations, amplifications,, fusions, signature, FGFR, ligand, BGJ398,",
            "MeshKeyword": "Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        Patient has a confirmed diagnosis of a select solid tumor (except with a primary diagnosis\r\n\r\n        of Urothelial cell carcinoma, Cholangiocarcinoma, Endometrial cancer, and Glioblastoma\r\n\r\n        multifor",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35211",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 30, 2016",
            "FirstReceived": "June 6, 2014",
            "ContactName": "Novartis Pharmaceuticals",
            "ContactPhone": "1-888-669-6682",
            "LocationStatus": "Completed",
            "LocationName": "Alabama Oncology St. Vincent's Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02160041",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160245 - Novartis - De La Fuente",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160245",
            "StudyNumber": "20160245 - Novartis - De La Fuente",
            "StudyTitle": "Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 6 – BGJ398 for patients with tumors with FGFR genetic alterations",
            "PIID": "22734",
            "PicNum": "C11916526",
            "PILastName": "De La Fuente",
            "PIFirstName": "Macarena",
            "CoodCNbr": "C04228283",
            "CoordLastName": "Garcia",
            "CoordFirstName": "Helen",
            "CoordEmail": "heg32@med.miami.edu",
            "EnteredByCNbr": "C11964150",
            "EnteredByLastName": "Smith",
            "EnteredByFirstName": "Nyesha",
            "ActiveEnrollingDate": "04/19/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/19/2016",
            "IRBApprovedFrom": "04/05/2016",
            "IRBApprovedTo": "10/05/2016",
            "AccountNbr": "666907",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "Phase II",
            "Tarea": "Neurological Cancer",
            "TareaCode": "12442",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02160041",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02161380",
            "SecondaryId": "1U10EY023558-01A1",
            "BriefTitle": "Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy",
            "OfficialTitle": "An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA",
            "LeadSponsorClass": "John Guy",
            "SponsorAgency": "Other",
            "LeadSponsor": "John Guy",
            "OversightAuthority": "Yes",
            "BriefSummary": "Hypotheses:\r\n\r\n\r\n\r\n      The primary hypothesis being tested is that there will be no toxicity resulting in loss of\r\n\r\n      vision to no light perception in injected eyes.",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2014",
            "CompletionDate": "March 2019",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Leber's Hereditary Optic Neuropathy",
            "studyLocation": "Bascom Palmer Eye Institute, University of Miami",
            "Enrollment": "27",
            "NctKeyword": "Gene therapy, Mitochondrial Genes, Leber's, AAV2 Viral vectors,",
            "MeshKeyword": "Optic Nerve Diseases, Optic Atrophy, Hereditary, Leber,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age 15 or older;\r\n\r\n\r\n\r\n          2. Patients with LHON and the G11778A mitochondrial DNA mutation. A previous CLIA\r\n\r\n             certified genetic lab result showing the LHON G11778A mutation will be",
            "EligibleGender": "All",
            "MinAge": "15 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 10, 2017",
            "FirstReceived": "June 6, 2014",
            "OverallOfficial": "JOHN GUY, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL 33136",
            "ContactName": "JOHN GUY, MD",
            "ContactPhone": "302-326-6036",
            "ContactEmail": "jguy@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Bascom Palmer Eye Institute, University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02161380",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140248 - National Eye Institute - Guy",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20140248",
            "StudyNumber": "20140248 - National Eye Institute - Guy",
            "StudyTitle": "An-Open label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) caused by the G11778 mutation in mitochondrial DNA",
            "PIID": "2918",
            "PicNum": "C00171308",
            "PILastName": "Guy",
            "PIFirstName": "John",
            "CoodCNbr": "C00171308",
            "CoordLastName": "Guy",
            "CoordFirstName": "John",
            "EnteredByCNbr": "C00171308",
            "EnteredByLastName": "Guy",
            "EnteredByFirstName": "John",
            "ActiveEnrollingDate": "08/27/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/27/2014",
            "IRBApprovedFrom": "07/14/2014",
            "IRBApprovedTo": "05/22/2017",
            "Expr1": "Phase I",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "NIH",
            "Sponsor": "National Eye Institute",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "20",
            "Totalaccrued": "15",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "14",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "20",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Phillip Gonzalez,Potyra Rosa",
            "NationalSampleSize": "27",
            "NCTNbr": "NCT02161380",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02161718",
            "BriefTitle": "A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder",
            "OfficialTitle": "A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder",
            "LeadSponsorClass": "Alkermes, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Alkermes, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "This double-blind, randomized study will evaluate the efficacy, safety and tolerability of\r\n\r\n      ALKS 3831 in subjects with schizophrenia and alcohol use disorder (AUD).",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "May 2014",
            "CompletionDate": "April 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Alkermes, Inc.",
            "StudyCondition": "Schizophrenia",
            "studyLocation": "Alkermes Investigational Site",
            "Enrollment": "300",
            "NctKeyword": "Alkermes, Schizophrenia, Alcohol Use Disorder, ALKS 3831,",
            "MeshKeyword": "Schizophrenia, Disease, Alcohol Drinking,",
            "InterventionKeyword": "Ethanol, Olanzapine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Has a BMI between 18.0 and 40.0 kg/m2, inclusive\r\n\r\n\r\n\r\n          -  Has a diagnosis of schizophrenia\r\n\r\n\r\n\r\n          -  Has a diagnosis of alcohol use disorder (AUD)\r\n\r\n\r\n\r\n          -  Has experienced",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Zip": "72211",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 12, 2016",
            "FirstReceived": "May 28, 2014",
            "OverallOfficial": "David McDonnell, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Alkermes, Inc.",
            "LocationName": "Alkermes Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02161718",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140522 - Alkermes - Strassnig",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20140522",
            "StudyNumber": "20140522 - Alkermes - Strassnig",
            "StudyTitle": "ALK3831-401: A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder",
            "PIID": "3521",
            "PicNum": "C10569677",
            "PILastName": "Durand",
            "PIFirstName": "Dante",
            "CoodCNbr": "C04892431",
            "CoordLastName": "Brenson",
            "CoordFirstName": "Nicole",
            "CoordEmail": "nbrenson@med.miami.edu",
            "CoordPhone": "3053558186",
            "EnteredByCNbr": "C10560217",
            "EnteredByLastName": "Strassnig",
            "EnteredByFirstName": "Martin",
            "ActiveEnrollingDate": "04/16/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/16/2015",
            "IRBApprovedFrom": "10/21/2014",
            "IRBApprovedTo": "10/17/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Alkermes",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "6",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Gabriela Vargas,Tania Guardia,Nicole Brenson",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02161718",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02167945",
            "BriefTitle": "A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",
            "OfficialTitle": "An Open-Label, Multicenter Study to Evaluate Long-term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)",
            "LeadSponsorClass": "AbbVie",
            "SponsorAgency": "Industry",
            "LeadSponsor": "AbbVie",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to evaluate Long-term Outcomes following treatment with\r\n\r\n      ABT-450/r/ABT-267, ABT-333 with or without RBV in Adults With Genotype 1 Chronic Hepatitis C\r\n\r\n      Virus (HCV) Infection",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "June 2014",
            "CompletionDate": "March 2020",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "AbbVie",
            "StudyCondition": "Chronic Hepatitis C Virus (HCV) Infection Genotype 1",
            "studyLocation": "Site Reference ID/Investigator# 127800",
            "Enrollment": "600",
            "NctKeyword": "Naïve, Hepatitis C, Non responder, Relapser, Null responder, Treatment-Experienced, Cirrhosis, Hepatitis C Genotype 1, Compensated Cirrhosis, Hepatitis C Virus,",
            "MeshKeyword": "Infection, Communicable Diseases, Hepatitis, Hepatitis A, Hepatitis C, Hepatitis, Chronic, Hepatitis C, Chronic,",
            "InterventionKeyword": "Ribavirin, Ritonavir,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Females must be post-menopausal for more than 2 years or surgically sterile or\r\n\r\n             practicing specific forms of birth control\r\n\r\n\r\n\r\n          2. Chronic hepatitis C, genotype 1-infection (HC",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "99 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85013",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 13, 2016",
            "FirstReceived": "June 18, 2014",
            "OverallOfficial": "Jeffrey Enejosa, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "AbbVie",
            "LocationName": "Site Reference ID/Investigator# 127800",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02167945",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140417 - AbbVie - Martin",
            "FileProcessContentId": "440",
            "Division": "Hepatology",
            "StdyDivision": "10246",
            "EprostNbr": "20140417",
            "StudyNumber": "20140417 - AbbVie - Martin",
            "StudyTitle": "AbbVie M14-222 - An Open-Label, Multicenter Study to Evaluate\nLong-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1\nChronic Hepatitis C Virus (HCV) Infection (TOPAZ II)",
            "PIID": "697",
            "PicNum": "C06441920",
            "PILastName": "Martin",
            "PIFirstName": "Paul",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C06441920",
            "EnteredByLastName": "Martin",
            "EnteredByFirstName": "Paul",
            "ActiveEnrollingDate": "10/15/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/15/2014",
            "IRBApprovedFrom": "09/05/2014",
            "IRBApprovedTo": "06/26/2017",
            "AccountNbr": "663758",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "AbbVie",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "5",
            "Totalaccrued": "5",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "5",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "5",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "110",
            "NCTNbr": "NCT02167945",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02168842",
            "SecondaryId": "U01NS080818-01A1",
            "BriefTitle": "Efficacy of Isradipine in Early Parkinson Disease",
            "OfficialTitle": "Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease",
            "LeadSponsorClass": "University of Rochester",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Rochester",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of the study is to determine whether treatment with isradipine is effective in\r\n\r\n      slowing the progression of Parkinson disease disability.",
            "Description": "The study will enroll 336 participants in this multi-center study at approximately 56 sites\r\n\r\n      across the US and Canada. In this study, we are comparing 10 mg of Isradipine to Placebo for\r\n\r\n      treatment of newly diagnosed PD patients.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "September 2014",
            "CompletionDate": "March 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "University of Rochester",
            "StudyCondition": "Parkinson Disease",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "336",
            "NctKeyword": "Parkinson, Parkinson Disease, Parkinson's Disease,",
            "MeshKeyword": "Parkinson Disease,",
            "InterventionKeyword": "Isradipine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subjects with early idiopathic PD (presence of at least two out of three cardinal\r\n\r\n             manifestations of PD). If tremor is not present, subjects must have unilateral onset\r\n\r\n             and",
            "EligibleGender": "All",
            "MinAge": "30 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 12, 2017",
            "FirstReceived": "June 18, 2014",
            "OverallOfficial": "Tanya Simuni, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Northwestern University",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02168842",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140500 - National Institute of Neurological Disorders and S - Luca",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140500",
            "StudyNumber": "20140500 - National Institute of Neurological Disorders and S - Luca",
            "StudyTitle": "A Phase 3 double-blind placebo-controlled parallel group study of isradipine as a disease modifying agent in subjects with early Parkinson disease",
            "PIID": "2567",
            "PicNum": "C02023921",
            "PILastName": "Luca",
            "PIFirstName": "Corneliu",
            "CoodCNbr": "C06927480",
            "CoordLastName": "Padron",
            "CoordFirstName": "Nathalie",
            "CoordEmail": "npadron@med.miami.edu",
            "CoordPhone": "3052433530",
            "EnteredByCNbr": "C02023921",
            "EnteredByLastName": "Luca",
            "EnteredByFirstName": "Corneliu",
            "ActiveEnrollingDate": "11/05/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/05/2014",
            "IRBApprovedFrom": "09/19/2014",
            "IRBApprovedTo": "08/14/2017",
            "InfoEdNbr": "72344",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "National Institute of Neurological Disorders and Stroke",
            "Prescreened": "9",
            "Screenedfailed": "0",
            "SignedICF": "8",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "7",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Padron",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02168842",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02172950",
            "SecondaryId": "2013-003262-13",
            "BriefTitle": "An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A",
            "OfficialTitle": "A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII‑SingleChain, CSL627) in Subjects With Severe Hemophilia A",
            "LeadSponsorClass": "CSL Behring",
            "SponsorAgency": "Industry",
            "LeadSponsor": "CSL Behring",
            "OversightAuthority": "Yes",
            "BriefSummary": "This multicenter, open-label, phase 3 extension study will investigate the safety and\r\n\r\n      efficacy of rVIII‑SingleChain for prophylaxis and on‑demand treatment of bleeding episodes\r\n\r\n      in at least 200 previously treated patients (PTPs)",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2014",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "CSL Behring",
            "StudyCondition": "Hemophilia A",
            "studyLocation": "Study Site 8400213",
            "Enrollment": "250",
            "MeshKeyword": "Hemophilia A,",
            "InterventionKeyword": "Factor VIII,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        PTPs:\r\n\r\n\r\n\r\n          -  Males of any age who have been diagnosed with severe congenital hemophilia A (FVIII\r\n\r\n             activity levels < 1%) and who participated in a previous CSL-sponsored clinical st",
            "EligibleGender": "Male",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "San Diego",
            "State": "California",
            "Zip": "92103-8651",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 6, 2017",
            "FirstReceived": "June 23, 2014",
            "OverallOfficial": "Program Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "CSL Behring",
            "ContactName": "Trial Registration Coordinator",
            "ContactEmail": "clinicaltrials@cslbehring.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Study Site 8400213",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02172950",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140451 - CSL Behring - Davis",
            "FileProcessContentId": "440",
            "Division": "Pediatrics Oncology",
            "StdyDivision": "10646",
            "EprostNbr": "20140451",
            "StudyNumber": "20140451 - CSL Behring - Davis",
            "StudyTitle": "A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII-SingleChain, CSL627) in Subjects with Severe Hemophilia A",
            "PIID": "326",
            "PicNum": "C00603684",
            "PILastName": "Davis",
            "PIFirstName": "Joanna",
            "CoodCNbr": "C11956115",
            "CoordLastName": "Pisani",
            "CoordFirstName": "Leandro",
            "CoordEmail": "LFP34@miami.edu",
            "CoordPhone": "305-243-6925",
            "EnteredByCNbr": "C00603684",
            "EnteredByLastName": "Davis",
            "EnteredByFirstName": "Joanna",
            "ActiveEnrollingDate": "11/25/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/25/2014",
            "IRBApprovedFrom": "08/19/2014",
            "IRBApprovedTo": "07/04/2017",
            "DiseaseSiteListDesc": "Other Hematopoietic",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "CSL Behring",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Maria Santaella,Leandro Pisani",
            "AgentDevices": "rVIII-SingleChain, CSL627",
            "StudyObjective": "The primary objective of this study is to evaluate the safety of long term\r\nuse of rVIII-SingleChain.",
            "NationalSampleSize": "2",
            "NCTNbr": "NCT02172950",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02173522",
            "BriefTitle": "Phase II Investigation of Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients",
            "OfficialTitle": "Phase II Open Label Investigation of the Safety and Efficacy of Pre-Operative Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients",
            "LeadSponsorClass": "Shivank Bhatia",
            "SponsorAgency": "Other",
            "LeadSponsor": "Shivank Bhatia",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine whether pre-operative prostate artery embolization\r\n\r\n      (PAE) reduces intra-operative blood loss and improves surgical outcomes among prostate\r\n\r\n      cancer patients undergoing robot-assisted lapar",
            "Description": "Duration of study:\r\n\r\n\r\n\r\n      This study will enroll 20 patients, with a target enrollment period of 18 months. Patients\r\n\r\n      who undergo prostate artery embolization (PAE) will have follow-up visits 2 weeks and 6\r\n\r\n      weeks after PAE.",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2014",
            "CompletionDate": "September 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Prostate Cancer",
            "studyLocation": "Sylvester Comprehensive Cancer Center",
            "Enrollment": "20",
            "NctKeyword": "Prostate cancer, Prostate artery embolization, Robot-assisted laparoscopic radical prostatectomy,",
            "MeshKeyword": "Prostatic Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patient is 45-79 years old\r\n\r\n\r\n\r\n          -  Patient has signed informed consent\r\n\r\n\r\n\r\n          -  Patient has biopsy-proven prostate adenocarcinoma with localized disease\r\n\r\n\r\n\r\n          -  Patient",
            "EligibleGender": "Male",
            "MinAge": "45 Years",
            "MaxAge": "79 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 27, 2016",
            "FirstReceived": "May 22, 2014",
            "OverallOfficial": "Shivank Bhatia, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Shivank Bhatia, MD",
            "ContactEmail": "SBhatia1@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Sylvester Comprehensive Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02173522",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20131034 - Intramural - Bhatia",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20131034",
            "StudyNumber": "20131034 - Intramural - Bhatia",
            "StudyTitle": "PHASE II OPEN LABEL INVESTIGATION OF THE SAFETY AND EFFICACY OF PRE-OPERATIVE PROSTATE ARTERY EMBOLIZATION (PAE) BEFORE RADICAL PROSTATECTOMY IN PROSTATE CANCER PATIENTS.",
            "PIID": "2294",
            "PicNum": "C05038444",
            "PILastName": "Bhatia",
            "PIFirstName": "Shivank",
            "CoodCNbr": "C05096461",
            "CoordLastName": "Quezada",
            "CoordFirstName": "Lia",
            "CoordEmail": "lquezada@med.miami.edu",
            "CoordPhone": "3052433404",
            "EnteredByCNbr": "C05096461",
            "EnteredByLastName": "Quezada",
            "EnteredByFirstName": "Lia",
            "ActiveEnrollingDate": "12/02/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/02/2014",
            "IRBApprovedFrom": "03/05/2014",
            "IRBApprovedTo": "05/15/2017",
            "DiseaseSiteListDesc": "Prostate",
            "Expr1": "Phase II",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Merit Medical System",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "2",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "2",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Fanchette Auguste,Katuska Barbery,Govindarajan Narayanan",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02173522",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02176928",
            "SecondaryId": "# W81XWH-13-1-0479",
            "BriefTitle": "Sleep-Disordered Breathing in Chronic SCI",
            "OfficialTitle": "Sleep-Disordered Breathing in Chronic SCI: A Randomized Controlled Trial of Treatment Impact on Cognition, Quality of Life, and Cardiovascular Disease",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to examine impact of Sleep Disordered Breathing (SDB) treatment\r\n\r\n      in persons with chronic Spinal Cord Injury (SCI). The central hypothesis is that the\r\n\r\n      treatment of SDB with Positive Airway Pressure (P",
            "Description": "Investigators will examine the effect of PAP therapy and sleep apnea on thinking (especially\r\n\r\n      memory, learning and concentration), quality of life, sleep quality, and risks for future\r\n\r\n      heart (cardiovascular) problems in persons w",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2014",
            "CompletionDate": "February 2019",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Spinal Cord Injury",
            "studyLocation": "Miami VA Hospital",
            "Enrollment": "200",
            "MeshKeyword": "Spinal Cord Injuries, Sleep Apnea, Obstructive, Respiratory Aspiration,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Chronic tetraplegia or paraplegia (C4-L1)\r\n\r\n\r\n\r\n          -  American Spinal Injury Association (ASIA) Impairment Scale A, B, C or D\r\n\r\n\r\n\r\n          -  18 years and older\r\n\r\n\r\n\r\n          -  At least o",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33125",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 28, 2016",
            "FirstReceived": "June 25, 2014",
            "OverallOfficial": "Shirin Shafazand, MD, MS",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami Miller School of Medicine; Pulmonary and Critical Care Medicine",
            "ContactName": "Patricia A Burns, MS",
            "ContactPhone": "305-243-7122",
            "ContactEmail": "pburns@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Miami VA Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02176928",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20130161 - DOD - Shafazand",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20130161",
            "StudyNumber": "20130161 - DOD - Shafazand",
            "StudyTitle": "SleepDisordered Breathing in Chronic SCI: A Randomized Controlled Trial of Treatment Impact on Cognition, Quality of Life, and Cardiovascular Disease",
            "PIID": "1767",
            "PicNum": "C03967344",
            "PILastName": "Shafazand",
            "PIFirstName": "Shirin",
            "CoodCNbr": "C00137246",
            "CoordLastName": "Nash",
            "CoordFirstName": "Mark",
            "CoordEmail": "msnash@miami.edu",
            "CoordPhone": "3052433628",
            "EnteredByCNbr": "C03121195",
            "EnteredByLastName": "Burns",
            "EnteredByFirstName": "Patricia",
            "ActiveEnrollingDate": "05/20/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/20/2014",
            "IRBApprovedFrom": "09/18/2013",
            "IRBApprovedTo": "06/23/2017",
            "Expr1": "Other",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Diagnostic",
            "StudyType_Code": "6179",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "75",
            "Totalaccrued": "61",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "43",
            "CurrentlyActiveTreatment": "13",
            "Totalpatients": "75",
            "FirstNinety": "8",
            "SiteSampleSize": "VA:N/A,Wayne State:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "4",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Mark Nash,Sarah Vaughan,Patricia Burns",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT02176928",
            "StudyKeywords": "sleep apnea, spinal cord injury, SCI",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02180867",
            "SecondaryId": "NCI-2014-01340",
            "BriefTitle": "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery",
            "OfficialTitle": "Pazopanib Neoadjuvant Trial in Non-rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "No",
            "BriefSummary": "This randomized phase II/III trial studies how well pazopanib hydrochloride, combination\r\n\r\n      chemotherapy, and radiation therapy work and compares it to radiation therapy alone or in\r\n\r\n      combination with pazopanib hydrochloride or comb",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To identify the dose of pazopanib (pazopanib hydrochloride) that is feasible when given\r\n\r\n      in combination with radiation or chemoradiation in pediatric and adult patients newly\r\n\r\n      diagnosed with un",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2014",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Adult Fibrosarcoma",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "340",
            "MeshKeyword": "Neoplasms, Sarcoma, Osteosarcoma, Leiomyosarcoma, Liposarcoma, Chondrosarcoma, Sarcoma, Clear Cell, Sarcoma, Synovial, Histiocytoma, Sarcoma, Alveolar Soft Part, Nerve Sheath Neoplasms, Neurofibroma, Histiocytoma, Benign Fibrous, Neurilemmoma, Neurofibros",
            "InterventionKeyword": "Doxorubicin, Liposomal doxorubicin, Isophosphamide mustard, Ifosfamide,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Newly diagnosed and histopathologically confirmed, potentially resectable NRSTS of\r\n\r\n             the extremity and trunk will be eligible for the chemotherapy or non-chemotherapy\r\n\r\n             cohort",
            "EligibleGender": "All",
            "MinAge": "2 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "July 1, 2014",
            "OverallOfficial": "Aaron Weiss",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02180867",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150116 - COG - Wilky",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150116",
            "StudyNumber": "20150116 - COG - Wilky",
            "StudyTitle": "ARST1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC#737754, IND#118613)",
            "PIID": "4630",
            "PicNum": "C11848802",
            "PILastName": "Wilky",
            "PIFirstName": "Breelyn",
            "CoodCNbr": "C12022610",
            "CoordLastName": "Solomon",
            "CoordFirstName": "Thankam",
            "CoordEmail": "thankam.solomon@med.miami.edu",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "06/16/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/16/2015",
            "IRBApprovedFrom": "03/21/2015",
            "IRBApprovedTo": "08/10/2017",
            "DiseaseSiteListDesc": "Soft Tissue",
            "Expr1": "Phase II/III",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "COG",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Marinellie Vega,Georges Tahhan,Penny Eyer,Melody Sorrell,Nathalie Luis",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02180867",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02180867",
            "SecondaryId": "NCI-2014-01340",
            "BriefTitle": "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery",
            "OfficialTitle": "Pazopanib Neoadjuvant Trial in Non-rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "No",
            "BriefSummary": "This randomized phase II/III trial studies how well pazopanib hydrochloride, combination\r\n\r\n      chemotherapy, and radiation therapy work and compares it to radiation therapy alone or in\r\n\r\n      combination with pazopanib hydrochloride or comb",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To identify the dose of pazopanib (pazopanib hydrochloride) that is feasible when given\r\n\r\n      in combination with radiation or chemoradiation in pediatric and adult patients newly\r\n\r\n      diagnosed with un",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2014",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Adult Fibrosarcoma",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "340",
            "MeshKeyword": "Neoplasms, Sarcoma, Osteosarcoma, Leiomyosarcoma, Liposarcoma, Chondrosarcoma, Sarcoma, Clear Cell, Sarcoma, Synovial, Histiocytoma, Sarcoma, Alveolar Soft Part, Nerve Sheath Neoplasms, Neurofibroma, Histiocytoma, Benign Fibrous, Neurilemmoma, Neurofibros",
            "InterventionKeyword": "Doxorubicin, Liposomal doxorubicin, Isophosphamide mustard, Ifosfamide,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Newly diagnosed and histopathologically confirmed, potentially resectable NRSTS of\r\n\r\n             the extremity and trunk will be eligible for the chemotherapy or non-chemotherapy\r\n\r\n             cohort",
            "EligibleGender": "All",
            "MinAge": "2 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "July 1, 2014",
            "OverallOfficial": "Aaron Weiss",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Children's Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02180867",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140686 - COG - Barredo",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140686",
            "StudyNumber": "20140686 - COG - Barredo",
            "StudyTitle": "ARST1321: Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)",
            "PIID": "309",
            "PicNum": "C05020454",
            "PILastName": "Barredo",
            "PIFirstName": "Julio",
            "CoodCNbr": "C00722004",
            "CoordLastName": "Garantiva",
            "CoordFirstName": "Nuria",
            "CoordEmail": "nfc19@miami.edu",
            "EnteredByCNbr": "C12024097",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Charles",
            "ActiveEnrollingDate": "04/10/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/10/2014",
            "IRBApprovedFrom": "04/10/2014",
            "IRBApprovedTo": "08/10/2017",
            "DiseaseSiteListDesc": "Bones and Joints,Soft Tissue",
            "Expr1": "Phase II/III",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "COG",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMD:N/A,UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Marinellie Vega,Wendy Best,Myriam Zayas,Doris Martin",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02180867",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02187003",
            "BriefTitle": "Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease",
            "OfficialTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy And Safety Of Rivipansel (Gmi-1070) In The Treatment Of Vaso-occlusive Crisis In Hospitalized Subjects With Sickle Cell Disease",
            "LeadSponsorClass": "Pfizer",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Pfizer",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a clinical study evaluating the efficacy and safety of rivipansel (GMI-1070) in\r\n\r\n      treating subjects with sickle cell disease (SCD) who are 6 years of age or older\r\n\r\n      experiencing a pain crisis necessitating hospitalization.",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2015",
            "CompletionDate": "July 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Pfizer",
            "StudyCondition": "Anemia, Sickle Cell",
            "studyLocation": "University of South Alabama Children's and Women's Hospital",
            "Enrollment": "350",
            "NctKeyword": "Sickle Cell Anemia, Sickle Cell Disease, Sickle Cell Disorders, pain crisis, vaso-occlusive crisis, rivipansel, GMI-1070, selectin inhibitor, SCD, VOC,",
            "MeshKeyword": "Anemia, Sickle Cell,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  At least 6 years of age.\r\n\r\n\r\n\r\n          -  Documented diagnosis of sickle cell disease.\r\n\r\n\r\n\r\n          -  Diagnosis of vaso-occlusive crisis necessitating admission to the hospital with",
            "EligibleGender": "All",
            "MinAge": "6 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Mobile",
            "State": "Alabama",
            "Zip": "36604",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 5, 2017",
            "FirstReceived": "June 12, 2014",
            "OverallOfficial": "Pfizer CT.gov Call Center",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Pfizer",
            "ContactName": "Pfizer CT.gov Call Center",
            "ContactPhone": "1-800-718-1021",
            "LocationStatus": "Recruiting",
            "LocationName": "University of South Alabama Children's and Women's Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02187003",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140687 - Pfizer - Alvarez",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20140687",
            "StudyNumber": "20140687 - Pfizer - Alvarez",
            "StudyTitle": "A phase 3, multicenter, randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of RIVIPANSEL (GMI 1070) in the treatment of vaso occlusive crisis in HOSPITALIZED subjects with sickle cell disease",
            "PIID": "299",
            "PicNum": "C01335657",
            "PILastName": "Alvarez",
            "PIFirstName": "Ofelia",
            "CoodCNbr": "C11875174",
            "CoordLastName": "Cumming",
            "CoordFirstName": "Vanessa",
            "CoordEmail": "v.cumming@med.miami.edu",
            "CoordPhone": "9542947473",
            "EnteredByCNbr": "C11875174",
            "EnteredByLastName": "Cumming",
            "EnteredByFirstName": "Vanessa",
            "ActiveEnrollingDate": "08/25/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/25/2016",
            "IRBApprovedFrom": "10/26/2015",
            "IRBApprovedTo": "08/16/2017",
            "DiseaseSiteListDesc": "Other Hematopoietic",
            "Expr1": "Phase III",
            "Tarea": "Adolescent",
            "TareaCode": "13139",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Pfizer",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "10",
            "Totalaccrued": "5",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "2",
            "SiteSampleSize": "JMH:N/A,UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT02187003",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02189720",
            "BriefTitle": "Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients",
            "OfficialTitle": "An Open-Label, Expanded Access Protocol for Amifampridine Phosphate Treatment in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS) and Downbeat Nystagmus",
            "LeadSponsorClass": "Catalyst Pharmaceuticals, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Catalyst Pharmaceuticals, Inc.",
            "BriefSummary": "The primary objective of the study is:\r\n\r\n\r\n\r\n      • To provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate\r\n\r\n      therapy until the product becomes commercially available.\r\n\r\n\r\n\r\n      The secondary objective",
            "OverallStatus": "Available",
            "Phase": "N/A",
            "StudyType": "Expanded Access",
            "StudyPhase": "N/A",
            "StudySource": "Catalyst Pharmaceuticals, Inc.",
            "StudyCondition": "Lambert-Eaton Myasthenic Syndrome",
            "studyLocation": "Office of Dr. Khema Sharma",
            "NctKeyword": "Amifampridine Phosphate, Amifampridine, 3,4-Diaminopyridine Phosphate, 3,4-Diaminopyridine, 3,4-DAP, LEMS, CMS, Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome, Neuromuscular disorders, Neuromuscular, eye movement, electromyography, EMG,",
            "MeshKeyword": "Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Pathologic, Myasthenic Syndromes, Congenital,",
            "InterventionKeyword": "3,4-diaminopyridine, 4-Aminopyridine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male or female:\r\n\r\n\r\n\r\n               -  2 years of age at 4 pediatric CMS study sites\r\n\r\n\r\n\r\n               -  10 years of age at other study sites.\r\n\r\n\r\n\r\n          -  Confirmed physician diagnosis of",
            "EligibleGender": "All",
            "MinAge": "10 Years",
            "MaxAge": "N/A",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 12, 2016",
            "FirstReceived": "July 5, 2014",
            "OverallOfficial": "Khema Sharma, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Office of Dr. Khema Sharma",
            "ContactName": "Jonathan Rubine, MD",
            "ContactPhone": "305-420-3200",
            "ContactEmail": "jrubine@catalystpharma.com",
            "LocationName": "Office of Dr. Khema Sharma",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02189720",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140645 - LEMS-EAP 001 - Sharma",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140645",
            "StudyNumber": "20140645 - LEMS-EAP 001 - Sharma",
            "StudyTitle": "EAP-001(Phase IV) IND 106,263: An Open-Label, Expanded Access Protocol for Amifampridine Phosphate (3,4-Diaminopyridine Phosphate) Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome and Downbeat Nystagmus\r\nProtocol Number:\r\nEAP-001",
            "PIID": "198",
            "PicNum": "C00576419",
            "PILastName": "Sharma",
            "PIFirstName": "Khema",
            "CoodCNbr": "C01939845",
            "CoordLastName": "Quesada",
            "CoordFirstName": "Monica",
            "CoordEmail": "mquesada2@med.miami.edu",
            "CoordPhone": "3052433647",
            "EnteredByCNbr": "C00576419",
            "EnteredByLastName": "Sharma",
            "EnteredByFirstName": "Khema",
            "ActiveEnrollingDate": "02/09/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/09/2015",
            "IRBApprovedFrom": "12/02/2014",
            "IRBApprovedTo": "12/01/2015",
            "AccountNbr": "664456",
            "Expr1": "Phase IV",
            "Tarea": "Neuro-Muscular Disorders",
            "TareaCode": "8938",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Intramural",
            "Prescreened": "3",
            "Screenedfailed": "0",
            "SignedICF": "7",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "7",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Clarification Requested (Pre-Review)",
            "StudyCoordinator": "Julie Steele,Monica Quesada",
            "AgentDevices": "Amifampridine",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02189720",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02193282",
            "SecondaryId": "NCI-2014-01508",
            "BriefTitle": "Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)",
            "OfficialTitle": "Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo\r\n\r\n      works in treating patients with stage IB-IIIA non-small cell lung cancer that has been\r\n\r\n      completely removed by surgery. Erlotinib hydroc",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To assess whether adjuvant therapy with erlotinib (erlotinib hydrochloride) will result\r\n\r\n      in improved overall survival (OS) over placebo for patients with completely resected stage\r\n\r\n      IB (>= 4 cm)",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2014",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Stage IB Non-Small Cell Lung Carcinoma",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "450",
            "MeshKeyword": "Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma,",
            "InterventionKeyword": "Erlotinib Hydrochloride,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Previously registered to A151216, with the result of lung cancer harboring an EGFR\r\n\r\n             exon 19 deletion or L858R mutation; the testing must have been performed by one of\r\n\r\n             the f",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "July 15, 2014",
            "OverallOfficial": "Ramaswamy Govindan",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Alliance for Clinical Trials in Oncology",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02193282",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140690 - Alliance for Clinical Trials - Mudad",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140690",
            "StudyNumber": "20140690 - Alliance for Clinical Trials - Mudad",
            "StudyTitle": "A081105: Randomized double blind placebo controlled study of Erlontinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)",
            "PIID": "22226",
            "PicNum": "C11878042",
            "PILastName": "Mudad",
            "PIFirstName": "Raja",
            "CoodCNbr": "C11982423",
            "CoordLastName": "Grandas Moreno",
            "CoordFirstName": "Claudia",
            "CoordEmail": "c.grandas@miami.edu",
            "CoordPhone": "305-243-7530",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "11/07/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/07/2014",
            "IRBApprovedFrom": "04/17/2014",
            "IRBApprovedTo": "09/14/2017",
            "AccountNbr": "665312",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase III",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "Alliance for Clinical Trials in Oncology",
            "SiteSampleSize": "UMMG:N/A,UM Kendall:N/A,UM Hollywood:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Michelle Mikhail,Halyna Hailes,Anthony Minichiello,Cristina Rojas-Mejia,Penny Eyer",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02193282",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02194738",
            "SecondaryId": "NCI-2014-01509",
            "BriefTitle": "Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)",
            "OfficialTitle": "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "No",
            "BriefSummary": "This research trial studies genetic testing in screening patients with stage IB-IIIA\r\n\r\n      non-small cell lung cancer that has been or will be removed by surgery. Studying the genes\r\n\r\n      in a patient's tumor cells may help doctors select",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To centrally test resected non-small cell lung cancer (NSCLC) for genetic mutations to\r\n\r\n      facilitate accrual to randomized adjuvant studies.\r\n\r\n\r\n\r\n      II. To obtain clinically annotated tumor tissue a",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2014",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Large Cell Lung Carcinoma",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "8300",
            "MeshKeyword": "Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Carcinoma,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  PATIENT PRE-REGISTRATION ELIGIBILITY CRITERIA:\r\n\r\n\r\n\r\n          -  For pre-surgical patients\r\n\r\n\r\n\r\n               -  Suspected diagnosis of resectable non-small cell lung cancer; patients with",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "July 16, 2014",
            "OverallOfficial": "Geoffrey Oxnard",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Alliance for Clinical Trials in Oncology",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02194738",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140691 - Alliance for Clinical Trials - Mudad",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140691",
            "StudyNumber": "20140691 - Alliance for Clinical Trials - Mudad",
            "StudyTitle": "A151215: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)",
            "PIID": "22226",
            "PicNum": "C11878042",
            "PILastName": "Mudad",
            "PIFirstName": "Raja",
            "CoodCNbr": "C11982423",
            "CoordLastName": "Grandas Moreno",
            "CoordFirstName": "Claudia",
            "CoordEmail": "c.grandas@miami.edu",
            "CoordPhone": "305-243-7530",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "11/07/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/07/2014",
            "IRBApprovedFrom": "05/01/2014",
            "IRBApprovedTo": "08/31/2017",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "N/A",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Blinding": "None",
            "Expr2": "Screening",
            "StudyType_Code": "6181",
            "ResearchType": "Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "Alliance for Clinical Trials in Oncology",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "10",
            "Totalaccrued": "6",
            "InFollowUp": "3",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UM Kendall:N/A,UM Hollywood:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Penny Eyer,Cristina Rojas-Mejia,Halyna Hailes,Anthony Minichiello",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02194738",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02201992",
            "SecondaryId": "NCI-2014-01507",
            "BriefTitle": "Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)",
            "OfficialTitle": "A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein",
            "LeadSponsorClass": "ECOG-ACRIN Cancer Research Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "ECOG-ACRIN Cancer Research Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase III trial studies how well crizotinib works and compares it to placebo\r\n\r\n      in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by\r\n\r\n      surgery and has a mutation in a protein ca",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To evaluate whether adjuvant therapy with crizotinib will result in improved overall\r\n\r\n      survival (OS) over placebo for patients with stage IB >= 4 cm, II and IIIA, ALK-positive\r\n\r\n      non-small cell lu",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2014",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Eastern Cooperative Oncology Group",
            "StudyCondition": "Stage IB Non-Small Cell Lung Carcinoma",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "378",
            "MeshKeyword": "Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma,",
            "InterventionKeyword": "Crizotinib,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must have undergone complete surgical resection of their stage IB (>= 4 cm),\r\n\r\n             II, or non-squamous IIIA NSCLC per American Joint Committee on Cancer (AJCC) 7th\r\n\r\n             edit",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "March 2016",
            "LastChanged": "March 8, 2016",
            "FirstReceived": "July 21, 2014",
            "OverallOfficial": "David Gerber",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "ECOG-ACRIN Cancer Research Group",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02201992",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140692 - Alliance for Clinical Trials - Mudad",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140692",
            "StudyNumber": "20140692 - Alliance for Clinical Trials - Mudad",
            "StudyTitle": "E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer:  Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein",
            "PIID": "22226",
            "PicNum": "C11878042",
            "PILastName": "Mudad",
            "PIFirstName": "Raja",
            "CoodCNbr": "C11982423",
            "CoordLastName": "Grandas Moreno",
            "CoordFirstName": "Claudia",
            "CoordEmail": "c.grandas@miami.edu",
            "CoordPhone": "305-243-7530",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "11/07/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/07/2014",
            "IRBApprovedFrom": "12/05/2013",
            "IRBApprovedTo": "04/20/2017",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase III",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "Alliance of Clinical Trial for Oncology",
            "SiteSampleSize": "UMMG:N/A,UM Kendall:N/A,UM Hollywood:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Michelle Mikhail,Halyna Hailes,Anthony Minichiello,Cristina Rojas-Mejia,Penny Eyer",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02201992",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02202109",
            "SecondaryId": "1R01CA183612-01",
            "BriefTitle": "Using CHWs or Mailing Self Sampling Home Tests to Increase Cervical Cancer Screening in South Florida",
            "OfficialTitle": "Addressing Cervical Cancer Disparity in South Florida: CBPR in Action",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The study will test the significance of community health worker (CHW) participation by\r\n\r\n      comparing self-sampling provided by a community health worker and self-sampling provided by\r\n\r\n      mail. The study will enroll 700 participants in",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2015",
            "CompletionDate": "April 2018",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Cervical Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "700",
            "NctKeyword": "Screen, self-sampler, cervical, cancer, women, community health workers, Hispanic/ Latinas, Haitian, Focus of study is cervical cancer,",
            "MeshKeyword": "Uterine Cervical Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Women\r\n\r\n\r\n\r\n          -  Haitian, Hispanic, or African American\r\n\r\n\r\n\r\n          -  Ages 30-65 years\r\n\r\n\r\n\r\n          -  Report not having had a pap smear in the last three years live in the cities of",
            "EligibleGender": "Female",
            "MinAge": "30 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 17, 2017",
            "FirstReceived": "July 9, 2014",
            "OverallOfficial": "Erin Kobetz, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Erin Kobetz, PhD",
            "ContactPhone": "305-243-8345",
            "ContactEmail": "ekobetz@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02202109",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140249 - National Cancer Institute - Kobetz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140249",
            "StudyNumber": "20140249 - National Cancer Institute - Kobetz",
            "StudyTitle": "Addressing Cervical Cancer Disparity in South Florida: CBPR in Action",
            "PIID": "380",
            "PicNum": "C03948164",
            "PILastName": "Kobetz",
            "PIFirstName": "Erin",
            "CoodCNbr": "C00712578",
            "CoordLastName": "Poitevien",
            "CoordFirstName": "Martine",
            "CoordEmail": "mpoitevien@med.miami.edu",
            "CoordPhone": "3052439054",
            "EnteredByCNbr": "C03948164",
            "EnteredByLastName": "Kobetz",
            "EnteredByFirstName": "Erin",
            "ActiveEnrollingDate": "04/25/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/25/2014",
            "IRBApprovedFrom": "04/25/2014",
            "IRBApprovedTo": "02/22/2017",
            "DiseaseSiteListDesc": "Cervix",
            "Expr1": "N/A",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Screening",
            "StudyType_Code": "6181",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "700",
            "NCTNbr": "NCT02202109",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02202434",
            "BriefTitle": "Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement",
            "OfficialTitle": "REPRISE III: Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Randomized Clinical Evaluation",
            "LeadSponsorClass": "Boston Scientific Corporation",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Boston Scientific Corporation",
            "OversightAuthority": "Yes",
            "BriefSummary": "The objective of this study is to evaluate the safety and effectiveness of the Lotus™ Valve\r\n\r\n      System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with\r\n\r\n      calcific, severe native aortic stenosis who are c",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "September 2014",
            "CompletionDate": "March 2021",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Boston Scientific Corporation",
            "StudyCondition": "Aortic Stenosis",
            "studyLocation": "Banner Good Samaritan",
            "Enrollment": "2052",
            "MeshKeyword": "Aortic Valve Stenosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Subject has documented calcific, severe native aortic stenosis with an initial aortic\r\n\r\n             valve area (AVA) of ≤1.0 cm2 (or AVA index of ≤0.6 cm2/m2) and a mean pressure\r\n\r\n             gradie",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85018",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 13, 2016",
            "FirstReceived": "July 21, 2014",
            "OverallOfficial": "Ted Feldman, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "NorthShore University HealthSystem Research Institute",
            "LocationName": "Banner Good Samaritan",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02202434",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140628 - Boston Scientific - Cohen",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20140628",
            "StudyNumber": "20140628 - Boston Scientific - Cohen",
            "StudyTitle": "REPRISE III:  Repositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of Lotus Valve System- Randomized Clinical Evaluation",
            "PIID": "1752",
            "PicNum": "C07441231",
            "PILastName": "Cohen",
            "PIFirstName": "Mauricio",
            "CoodCNbr": "C06968089",
            "CoordLastName": "Lang",
            "CoordFirstName": "Barbara",
            "CoordEmail": "blang@med.miami.edu",
            "CoordPhone": "3052434950",
            "EnteredByCNbr": "C07441231",
            "EnteredByLastName": "Cohen",
            "EnteredByFirstName": "Mauricio",
            "ActiveEnrollingDate": "01/20/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/20/2015",
            "IRBApprovedFrom": "09/22/2014",
            "IRBApprovedTo": "08/23/2016",
            "AccountNbr": "664375",
            "Expr1": "N/A",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Boston Scientific",
            "Prescreened": "0",
            "Screenedfailed": "9",
            "SignedICF": "19",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "19",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carmen Baez-Garcia,Laura Hudson,Barbara Lang",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT02202434",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02202551",
            "BriefTitle": "Open-Label Safety Study of ADS-5102 in PD Patients With LID",
            "OfficialTitle": "Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)",
            "LeadSponsorClass": "Adamas Pharmaceuticals, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Adamas Pharmaceuticals, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "This is a 105-week open-label study to evaluate the safety and tolerability of ADS-5102 oral\r\n\r\n      capsules, an extended release formulation of amantadine, in Parkinson's Disease (PD)\r\n\r\n      patients with Levodopa Induced Dyskinesia (LID).",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "July 2014",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Adamas Pharmaceuticals, Inc.",
            "StudyCondition": "Dyskinesia",
            "Enrollment": "250",
            "NctKeyword": "Levodopa Induced Dyskinesia, LID, Parkinsonism, Parkinson's Disease,",
            "MeshKeyword": "Parkinson Disease, Dyskinesias,",
            "InterventionKeyword": "Levodopa, Amantadine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Signed a current IRB/REB/IEC-approved informed consent form\r\n\r\n\r\n\r\n          -  Completed all study visits in previous Adamas efficacy study or were ineligible for\r\n\r\n             participation in previo",
            "EligibleGender": "All",
            "MinAge": "30 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "May 2016",
            "LastChanged": "May 16, 2016",
            "FirstReceived": "July 25, 2014",
            "OverallOfficial": "Clinical Trials Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Adamas Pharmaceuticals, Inc.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02202551",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150551 - Adamas Pharmaceuticals/ Inc. - Singer",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20150551",
            "StudyNumber": "20150551 - Adamas Pharmaceuticals/ Inc. - Singer",
            "StudyTitle": "Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (ADS-AMT-PD302)",
            "PIID": "143",
            "PicNum": "C00407776",
            "PILastName": "Singer",
            "PIFirstName": "Carlos",
            "CoodCNbr": "C11907212",
            "CoordLastName": "Vargas",
            "CoordFirstName": "Silvia",
            "CoordEmail": "s.vargasparra@med.miami.edu",
            "EnteredByCNbr": "C00407776",
            "EnteredByLastName": "Singer",
            "EnteredByFirstName": "Carlos",
            "ActiveEnrollingDate": "02/19/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/19/2016",
            "IRBApprovedFrom": "09/28/2015",
            "IRBApprovedTo": "09/27/2016",
            "Expr1": "Phase III",
            "Tarea": "Movement Disorders",
            "TareaCode": "8937",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Adamas Pharmaceuticals/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Padron,Silvia Vargas",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02202551",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02205411",
            "BriefTitle": "Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation",
            "OfficialTitle": "A Prospective, Randomized, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of the HeartAssist 5® VAD System Compared to the Thoratec HeartMate II® VAD and HeartWare® HVAD for Left Ventricular Support in Patients Awaiting Cardiac Transplanta",
            "LeadSponsorClass": "ReliantHeart Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "ReliantHeart Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of the study is to evaluate the safety and effectiveness of the ReliantHeart\r\n\r\n      HeartAssist 5® VAD System in patients listed for heart transplantation and at risk of death\r\n\r\n      from refractory end-stage heart failure.",
            "Description": "The HeartAssist 5® VAD System is intended for use as a bridge to heart transplantation and\r\n\r\n      will be compared to the HeartMate II and HVAD devices.\r\n\r\n\r\n\r\n      Patients that meet the study criteria will be randomized 1:1 to either the He",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2014",
            "CompletionDate": "January 2018",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "ReliantHeart Inc.",
            "StudyCondition": "Heart Failure",
            "studyLocation": "University of California San Francisco",
            "Enrollment": "192",
            "NctKeyword": "heart assist device, ventricular assist device,",
            "MeshKeyword": "Heart Failure,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Able to sign Informed Consent.\r\n\r\n\r\n\r\n          2. Age ≥ 18\r\n\r\n\r\n\r\n          3. Body Surface Area (BSA) ≥ 1.2 m2.\r\n\r\n\r\n\r\n          4. Cardiac transplant candidate, defined as: Listed for cardiac transpla",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "San Francisco",
            "State": "California",
            "Zip": "94143",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 26, 2016",
            "FirstReceived": "July 24, 2014",
            "ContactName": "Bryan Lynch",
            "ContactPhone": "713-457-1388",
            "ContactEmail": "blynch@reliantheart.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of California San Francisco",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02205411",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150517 - ReliantHeart/ Inc. - Chaparro",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20150517",
            "StudyNumber": "20150517 - ReliantHeart/ Inc. - Chaparro",
            "StudyTitle": "A Prospective, Randomized, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of the HeartAssist 5® VAD System Compared to the HeartMate II® VAD and HVAD® for Left Ventricular Support in Patients Awaiting Cardiac Transplantation",
            "PIID": "735",
            "PicNum": "C06969678",
            "PILastName": "Chaparro",
            "PIFirstName": "Sandra",
            "CoodCNbr": "C00059801",
            "CoordLastName": "Hudson",
            "CoordFirstName": "Laura",
            "CoordEmail": "LJHudson@med.miami.edu",
            "CoordPhone": "3052435678",
            "EnteredByCNbr": "C06969678",
            "EnteredByLastName": "Chaparro",
            "EnteredByFirstName": "Sandra",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "12/07/2015",
            "IRBApprovedFrom": "12/07/2015",
            "IRBApprovedTo": "10/04/2017",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "ReliantHeart/ Inc.",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carmen Baez-Garcia,Barbara Lang",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02205411",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02206334",
            "SecondaryId": "NCI-2014-00702",
            "BriefTitle": "Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer",
            "OfficialTitle": "A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases",
            "LeadSponsorClass": "NRG Oncology",
            "SponsorAgency": "Other",
            "LeadSponsor": "NRG Oncology",
            "OversightAuthority": "Yes",
            "BriefSummary": "This phase I trial studies the side effects and the best dose of stereotactic body radiation\r\n\r\n      therapy in treating patients with breast cancer, non-small cell lung cancer, or prostate\r\n\r\n      cancer that has spread to other parts of the",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To determine the recommended stereotactic body radiation therapy (SBRT) dose for each of\r\n\r\n      the metastatic locations being treated given the individual and overlapping fields when\r\n\r\n      multiple metas",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2014",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "NRG Oncology",
            "StudyCondition": "Male Breast Carcinoma",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "84",
            "MeshKeyword": "Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Breast Neoplasms, Male,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Metastatic breast cancer (MBC) OR metastatic non-small cell lung cancer (NSCLC) OR\r\n\r\n             metastatic adenocarcinoma of the prostate; the sites of allowed metastases are:\r\n\r\n             peripher",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "June 17, 2016",
            "FirstReceived": "July 30, 2014",
            "OverallOfficial": "Steven Chmura",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "NRG Oncology",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02206334",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150685 - NRG - Portelance",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150685",
            "StudyNumber": "20150685 - NRG - Portelance",
            "StudyTitle": "Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases",
            "PIID": "2807",
            "PicNum": "C09960880",
            "PILastName": "Portelance",
            "PIFirstName": "Lorraine",
            "CoodCNbr": "C00294869",
            "CoordLastName": "Martin",
            "CoordFirstName": "Doris",
            "CoordEmail": "dmartin3@med.miami.edu",
            "CoordPhone": "3052435491",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "11/10/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/10/2016",
            "IRBApprovedFrom": "09/25/2015",
            "IRBApprovedTo": "08/01/2017",
            "DiseaseSiteListDesc": "Prostate,Urinary Bladder,Kidney,Breast-Female,Lung",
            "Expr1": "Phase I",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SiteSampleSize": "UMHC:N/A,UMD:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Maggie Chislom,Pavel Noa Hechavarria,Zaida Abreu,Fernando Vazquez Pascual,Lilibet Zamora Cabezas,Lilly Sanchez,Greeyt Hernandez,Marinellie Vega",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02206334",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02213003",
            "BriefTitle": "Allogeneic Islet Cells Transplanted Onto the Omentum",
            "OfficialTitle": "Allogeneic Islet Cells Transplanted Onto the Omentum",
            "LeadSponsorClass": "Rodolfo Alejandro",
            "SponsorAgency": "Other",
            "LeadSponsor": "Rodolfo Alejandro",
            "OversightAuthority": "Yes",
            "BriefSummary": "Current islet transplantation into the portal vein of the liver has shown the unique ability\r\n\r\n      of islets to stabilize blood glucose levels and prevent severe hypoglycemia in a selected\r\n\r\n      group of subjects with Type 1 diabetes. The",
            "Description": "Islet transplantation will be performed in subjects with unstable Type 1 diabetes mellitus\r\n\r\n      under permanent immunosuppression. Islets are re-suspended in autologous plasma and\r\n\r\n      distributed on the omental surface by a minimal inva",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2014",
            "CompletionDate": "May 2019",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Type 1 Diabetes Mellitus",
            "studyLocation": "Diabetes Research Institute, University of Miami Miller School of Medicine",
            "Enrollment": "6",
            "NctKeyword": "islet transplantation,",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1, Hypoglycemia, Unconsciousness,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Male and female patients age 18 to 65 years of age.\r\n\r\n\r\n\r\n          2. Ability to provide written informed consent.\r\n\r\n\r\n\r\n          3. Mentally stable and able to comply with the procedures of the stud",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 9, 2016",
            "FirstReceived": "August 7, 2014",
            "OverallOfficial": "Rodolfo Alejandro",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Rodolfo Alejandro, MD",
            "ContactPhone": "3052435324",
            "ContactEmail": "ralejand@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Diabetes Research Institute, University of Miami Miller School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02213003",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140144 - Juvenile Diabetes Research Foundation - Alejandro",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20140144",
            "StudyNumber": "20140144 - Juvenile Diabetes Research Foundation - Alejandro",
            "StudyTitle": "Allogeneic Islet Cells (Human, University of Miami) Administered into the Omental Pouch and Immunosuppressive Therapy",
            "PIID": "473",
            "PicNum": "C00309269",
            "PILastName": "Alejandro",
            "PIFirstName": "Rodolfo",
            "CoodCNbr": "C03968208",
            "CoordLastName": "Alvarez",
            "CoordFirstName": "Ana",
            "CoordEmail": "axa383@med.miami.edu",
            "CoordPhone": "305-243-5321",
            "EnteredByCNbr": "C00309269",
            "EnteredByLastName": "Alejandro",
            "EnteredByFirstName": "Rodolfo",
            "ActiveEnrollingDate": "09/08/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/08/2014",
            "IRBApprovedFrom": "07/15/2014",
            "IRBApprovedTo": "07/04/2017",
            "Expr1": "N/A",
            "Tarea": "Islet Transplant",
            "TareaCode": "12545",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "96",
            "Screenedfailed": "17",
            "SignedICF": "35",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "6",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "124",
            "FirstNinety": "4",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "2",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Elina Linetsky,Stephanie Calle,Alina Cuervo,Ana Alvarez",
            "NationalSampleSize": "60",
            "NCTNbr": "NCT02213003",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02213744",
            "BriefTitle": "MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients",
            "OfficialTitle": "A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer",
            "LeadSponsorClass": "Merrimack Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Merrimack Pharmaceuticals",
            "BriefSummary": "This study is an open label, randomized, multicenter trial of MM-302 plus trastuzumab. The\r\n\r\n      trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the\r\n\r\n      chemotherapy of physician's choice (CPC) plu",
            "OverallStatus": "Terminated",
            "StartDate": "July 2014",
            "CompletionDate": "June 2017",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "Merrimack Pharmaceuticals",
            "StudyCondition": "Breast Cancer",
            "studyLocation": "Palo Verde Cancer Center",
            "Enrollment": "113",
            "NctKeyword": "HER2-positive, HER2+, HER2, Locally Advanced Breast Cancer, Metastatic Breast Cancer, trastuzumab, Herceptin, pertuzumab, ado-trastuzumab emtansine, TDM-1, Perjeta, Kadcyla,",
            "MeshKeyword": "Breast Neoplasms,",
            "InterventionKeyword": "Gemcitabine, Capecitabine, Vinorelbine, Trastuzumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must have histologically or cytologically confirmed invasive cancer of the\r\n\r\n             breast\r\n\r\n\r\n\r\n          -  Patients must have documented locally advanced/metastatic disease, defined b",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Glendale",
            "State": "Arizona",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 4, 2017",
            "FirstReceived": "August 6, 2014",
            "LocationName": "Palo Verde Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02213744",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151151 - Merrimack Pharm - Calfa",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151151",
            "StudyNumber": "20151151 - Merrimack Pharm - Calfa",
            "StudyTitle": "A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician’s Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer",
            "PIID": "25231",
            "PicNum": "C00214960",
            "PILastName": "Calfa",
            "PIFirstName": "Carmen",
            "CoodCNbr": "C12024030",
            "CoordLastName": "Conte",
            "CoordFirstName": "Deborah",
            "CoordEmail": "dmc238@med.miami.edu",
            "CoordPhone": "954-830-2360",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "08/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/08/2016",
            "IRBApprovedFrom": "05/31/2016",
            "IRBApprovedTo": "11/30/2016",
            "AccountNbr": "667363",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase II/III",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Merrimack Pharmaceuticals",
            "SiteSampleSize": "Plantation:N/A,UMD:N/A,UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Onaidy Torres,Cristina Rojas-Mejia,Mohammad El-Sorady,Michelle Liendo,Anthony Minichiello,Penny Eyer",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT02213744",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02217475",
            "BriefTitle": "Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Subjects With Liver Fibrosis",
            "OfficialTitle": "CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis",
            "LeadSponsorClass": "Tobira Therapeutics, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Tobira Therapeutics, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine whether Cenicriviroc is effective and safe in the\r\n\r\n      treatment of nonalcoholic steatohepatitis (NASH) in adult subjects with liver fibrosis.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "September 2014",
            "CompletionDate": "October 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Tobira Therapeutics, Inc.",
            "StudyCondition": "Nonalcoholic Steatohepatitis",
            "Enrollment": "289",
            "MeshKeyword": "Fatty Liver, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease,",
            "InterventionKeyword": "TAK-652,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Adult subjects aged between 18-75\r\n\r\n\r\n\r\n          -  Histological evidence of NASH, based on biopsy, with a NAS of >= 4 with at least 1 in\r\n\r\n             each component of NAS\r\n\r\n\r\n\r\n          -  Histo",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Dothan",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 19, 2016",
            "FirstReceived": "August 13, 2014",
            "OverallOfficial": "Eric Lefebvre, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Tobira Therapeutics, Inc.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02217475",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140965 - Tobira Therapeutics/ Inc. - Hernandez",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20140965",
            "StudyNumber": "20140965 - Tobira Therapeutics/ Inc. - Hernandez",
            "StudyTitle": "Tobira-CENTAUR 652-2-203 - Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis",
            "PIID": "22138",
            "PicNum": "C11868323",
            "PILastName": "Hernandez",
            "PIFirstName": "Maria Del Pilar",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C11868323",
            "EnteredByLastName": "Hernandez",
            "EnteredByFirstName": "Maria Del Pilar",
            "ActiveEnrollingDate": "03/11/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/11/2015",
            "IRBApprovedFrom": "12/29/2014",
            "IRBApprovedTo": "10/10/2017",
            "Expr1": "N/A",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Tobira Therapeutics/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "4",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Odalys Rodriguez-Bravo",
            "NationalSampleSize": "4",
            "NCTNbr": "NCT02217475",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02218372",
            "SecondaryId": "2013-000508-40",
            "BriefTitle": "A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",
            "OfficialTitle": "A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects W",
            "LeadSponsorClass": "Astellas Pharma Europe B.V.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Astellas Pharma Europe B.V.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to investigate the clinical response to fidaxomicin oral\r\n\r\n      suspension or tablets and vancomycin oral liquid or capsules in pediatric subjects with\r\n\r\n      Clostridium difficile-associated diarrhea (CDAD). It",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2014",
            "CompletionDate": "July 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Astellas Pharma Inc",
            "StudyCondition": "Clostridium Difficile-associated Diarrhea (CDAD)",
            "studyLocation": "Site US10015",
            "Enrollment": "144",
            "NctKeyword": "Clostridium difficile-associated Diarrhea (CDAD), vancomycin, Clostridium difficile infection, fidaxomicin,",
            "MeshKeyword": "Diarrhea,",
            "InterventionKeyword": "Vancomycin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject is diagnosed with CDAD according to local diagnostic criteria. As a minimum\r\n\r\n             there must be positive detection, within 72 hours prior to randomization, of either\r\n\r\n             tox",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "17 Years",
            "Volunteers": "No",
            "City": "Orange",
            "State": "California",
            "Zip": "92868",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 30, 2016",
            "FirstReceived": "August 11, 2014",
            "OverallOfficial": "Clinical Research Physician",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Astellas Pharma Europe B.V.",
            "ContactName": "Global Clinical Science",
            "ContactPhone": "+31 (0)71 5455 500",
            "ContactEmail": "Astellas.registration@astellas.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Site US10015",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02218372",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140751 - Astellas Pharma - Miller",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20140751",
            "StudyNumber": "20140751 - Astellas Pharma - Miller",
            "StudyTitle": "A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken every 12h, and Vancomycin Oral Liquid or Capsules taken every 6h, for 10 Days in Pediatric Subjects with Clostridium difficile-associated Diarrhea",
            "PIID": "940",
            "PicNum": "C03103866",
            "PILastName": "Miller",
            "PIFirstName": "Tracie",
            "CoodCNbr": "C02526159",
            "CoordLastName": "Somarriba",
            "CoordFirstName": "Gabriel",
            "CoordEmail": "gsomarriba2@med.miami.edu",
            "CoordPhone": "3052434304",
            "EnteredByCNbr": "C03103866",
            "EnteredByLastName": "Miller",
            "EnteredByFirstName": "Tracie",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "07/06/2015",
            "IRBApprovedFrom": "07/06/2015",
            "IRBApprovedTo": "06/06/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Astellas Pharma",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT02218372",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02221245",
            "BriefTitle": "Wnt, Notch and Hedgehog Activity in Chemo-Naive Tumors Collected During Staging of Esophageal Cancer Patients",
            "OfficialTitle": "Interrogation of Wnt, Notch, and Hedgehog Activity in Chemonaive Tumors Collected During the Staging Ultrasound Endoscopies of Patients Diagnosed With Esophageal Cancer",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "BriefSummary": "Cancer results when undifferentiated cells grow in an uncontrolled manner, crowding out\r\n\r\n      normal cells, causing morbidity and ultimately mortality. the cancer stem cell theory\r\n\r\n      suggests that most tumors undergo a process of differ",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2013",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Esophageal Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "50",
            "NctKeyword": "Esophageal cancer, Cancer Stem Cell, CSC, Wnt, Hegdehog, Notch, Signaling, Pathway, Chemo-naive,",
            "MeshKeyword": "Esophageal Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients diagnosed with an esophageal cancer and scheduled for a standard of care\r\n\r\n             endoscopic ultrasound.\r\n\r\n\r\n\r\n          -  Patient must sign a consent to be a participant in this protoc",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 7, 2016",
            "FirstReceived": "August 18, 2014",
            "OverallOfficial": "Anthony Capobianco, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02221245",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20120959 - Intramural - Capobianco",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20120959",
            "StudyNumber": "20120959 - Intramural - Capobianco",
            "StudyTitle": "Interrogation of Wnt, Notch, and Hedgehog Activity in Chemonaive Tumors Collected During the Staging Ultrasound Endoscopies of Patients Diagnosed with Esophageal Cancer.",
            "PIID": "3897",
            "PicNum": "C00722072",
            "PILastName": "Capobianco",
            "PIFirstName": "Anthony",
            "CoodCNbr": "C00245987",
            "CoordLastName": "Sparling",
            "CoordFirstName": "Jean (Lynne)",
            "CoordEmail": "lsparlin@med.miami.edu",
            "CoordPhone": "3052437298",
            "EnteredByCNbr": "C00245987",
            "EnteredByLastName": "Sparling",
            "EnteredByFirstName": "Jean (Lynne)",
            "ActiveEnrollingDate": "04/05/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/05/2013",
            "IRBApprovedFrom": "03/11/2013",
            "IRBApprovedTo": "01/31/2017",
            "DiseaseSiteListDesc": "Esophagus",
            "Expr1": "N/A",
            "Tarea": "Stomach and Esophageal Cancer",
            "TareaCode": "12538",
            "Expr2": "Correlative",
            "StudyType_Code": "140",
            "ResearchType": "Specimen",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "24",
            "Totalaccrued": "23",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "24",
            "FirstNinety": "2",
            "SiteSampleSize": "UMHC:50,UMMG:N/A",
            "AccrualPercentageMet": "46",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "50",
            "EprostState": "Approved",
            "StudyCoordinator": "Claudia Escobar",
            "NationalSampleSize": "50",
            "NCTNbr": "NCT02221245",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02224781",
            "SecondaryId": "NCI-2014-01747",
            "BriefTitle": "Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma",
            "OfficialTitle": "A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "No",
            "BriefSummary": "This randomized phase III trial studies how well initial treatment with ipilimumab and\r\n\r\n      nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment\r\n\r\n      with dabrafenib and trametinib followed by ipilim",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To determine whether initial treatment with either combination ipilimumab-nivolumab (with\r\n\r\n      subsequent dabrafenib in combination with trametinib) or dabrafenib in combination with\r\n\r\n      trametinib (w",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "BRAF V600E Mutation Present",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "300",
            "MeshKeyword": "Melanoma,",
            "InterventionKeyword": "Nivolumab, Trametinib, Dabrafenib, Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  STEP 1\r\n\r\n\r\n\r\n          -  Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1\r\n\r\n\r\n\r\n          -  Women must not be pregnant or breast-feeding\r\n\r\n\r\n\r\n               -  All females of ch",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "August 22, 2014",
            "OverallOfficial": "Michael Atkins",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "ECOG-ACRIN Cancer Research Group",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02224781",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150765 - ECOG - Acquavella",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150765",
            "StudyNumber": "20150765 - ECOG - Acquavella",
            "StudyTitle": "A Randomized Phase III trial of Dabrafenib+Trametinib followed by Ipilimumab+Nivolumab at Progression vs. Ipilimumab+Nivolumab followed by Debrafenib+Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma.",
            "PIID": "23755",
            "PicNum": "C11919904",
            "PILastName": "Acquavella",
            "PIFirstName": "Nicolas",
            "CoodCNbr": "C05004058",
            "CoordLastName": "Wang",
            "CoordFirstName": "Weiwen",
            "CoordEmail": "wwang1@med.miami.edu",
            "CoordPhone": "305-243-2122",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "01/11/2017",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/11/2017",
            "IRBApprovedFrom": "07/14/2015",
            "IRBApprovedTo": "08/14/2017",
            "AccountNbr": "667837",
            "DiseaseSiteListDesc": "Melanoma, skin",
            "Expr1": "Phase III",
            "Tarea": "Melanoma and Related Skin Cancers",
            "TareaCode": "12441",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "SiteSampleSize": "UMMG:N/A,Plantation:N/A,UMHC:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Vivianne Velez-Bravo,Eduardo Cianferra",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02224781",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02227147",
            "BriefTitle": "Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 Neurotrophic Keratitis",
            "OfficialTitle": "An 8-week Phase II, Multicenter, Randomized, Double-masked, Vehicle Controlled Parallel Group Study With a 24 or 32 Week Follow-up Period to Evaluate the Efficacy of a Formulation Containing Anti-oxidant of Recombinant Human Nerve Growth Factor (rhNGF) 20",
            "LeadSponsorClass": "Dompé Farmaceutici S.p.A",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Dompé Farmaceutici S.p.A",
            "OversightAuthority": "No",
            "BriefSummary": "The primary objective of this study is to evaluate the efficacy of 20 µg/ml 6 times a day of\r\n\r\n      rhNGF eye drops solution (formulation containing anti-oxidant) compared to vehicle\r\n\r\n      (formulation containing anti-oxidant) given 6 times",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2015",
            "CompletionDate": "September 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Dompé Farmaceutici S.p.A",
            "StudyCondition": "Neurotrophic Keratitis",
            "studyLocation": "Loma Linda University Ophthalmology",
            "Enrollment": "48",
            "NctKeyword": "Neurotrophic Keratitis,",
            "MeshKeyword": "Keratitis,",
            "InterventionKeyword": "Ophthalmic Solutions, Antioxidants,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients 18 years of age or older.\r\n\r\n\r\n\r\n          -  Patients with stage 2 (persistent epithelial defect, PED) or stage 3 (corneal ulcer)\r\n\r\n             neurotrophic keratitis.\r\n\r\n\r\n\r\n          -  PED",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Loma Linda",
            "State": "California",
            "Zip": "021111",
            "Country": "United States",
            "VerificationDate": "August 2015",
            "LastChanged": "August 13, 2015",
            "FirstReceived": "August 26, 2014",
            "OverallOfficial": "Flavio Mantelli, MD, PhD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Dompé s.p.a., Milan",
            "ContactName": "Flavio Mantelli, MD, PhD",
            "ContactEmail": "Flavio.Mantelli@dopme.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Loma Linda University Ophthalmology",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02227147",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140981 - Dompe Farmaceutici SPA - Perez",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20140981",
            "StudyNumber": "20140981 - Dompe Farmaceutici SPA - Perez",
            "StudyTitle": "An 8-week phase II, multicenter, randomized, double-masked, vehicle controlled parallel group study with a 24 or 32 week follow-up period to evaluate the efficacy of a formulation containing anti-oxidant of recombinant human nerve growth factor (rhNGF) 20 µg/ml, eye drops solution versus vehicle containing anti-oxidant in patients with Stage 2 and 3 Neurotrophic Keratitis",
            "PIID": "946",
            "PicNum": "C05063045",
            "PILastName": "Perez quinones",
            "PIFirstName": "Victor",
            "CoodCNbr": "C04107119",
            "CoordLastName": "Waren",
            "CoordFirstName": "Daniel",
            "CoordEmail": "d.waren@med.miami.edu",
            "CoordPhone": "305-243-2158",
            "EnteredByCNbr": "C05063045",
            "EnteredByLastName": "Perez quinones",
            "EnteredByFirstName": "Victor",
            "ActiveEnrollingDate": "09/22/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/22/2015",
            "IRBApprovedFrom": "06/08/2015",
            "IRBApprovedTo": "05/22/2017",
            "Expr1": "Phase II",
            "Tarea": "Cornea",
            "TareaCode": "12036",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "8",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "8",
            "FirstNinety": "7",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Marisa Braun,Esdras  Arrieta Quintero",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT02227147",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02228382",
            "SecondaryId": "2013-003250-25",
            "BriefTitle": "Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors",
            "OfficialTitle": "A Phase 4 Safety And Efficacy Study Of Bosutinib (Bosulif (Registered)) In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors",
            "LeadSponsorClass": "Pfizer",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Pfizer",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to fulfill the post-authorization commitment made by Pfizer to\r\n\r\n      the European Medicines Agency in providing additional safety and efficacy data in\r\n\r\n      approximately 150 Philadelphia Chromosome Positive Ch",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2014",
            "CompletionDate": "July 2021",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "Pfizer",
            "StudyCondition": "Previously Treated PH + CML",
            "studyLocation": "Keck Hospital of USC",
            "Enrollment": "165",
            "NctKeyword": "Bosutinib, Chronic Myeloid Leukemia, CML, Leukemia, Myelogenous, Chronic, BC-ABL Positive,",
            "MeshKeyword": "Leukemia, Myeloid, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Philadelphia Chromosome,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Confirmed Philadelphia Chromosome positive Chronic Myeloid Leukemia or Confirmed\r\n\r\n             BCR-ABL1 (Abelson-break point cluster) Positive if Philadelphia Chromosome negative\r\n\r\n             Chroni",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90033",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 14, 2017",
            "FirstReceived": "August 27, 2014",
            "OverallOfficial": "Pfizer CT.gov Call Center",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Pfizer",
            "ContactName": "Pfizer CT.gov Call Center",
            "ContactPhone": "1-800-718-1021",
            "LocationStatus": "Recruiting",
            "LocationName": "Keck Hospital of USC",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02228382",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140336 - Pfizer - Swords",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140336",
            "StudyNumber": "20140336 - Pfizer - Swords",
            "StudyTitle": "A PHASE 4 SAFETY AND EFFICACY STUDY OF BOSUTINIB (BOSULIF®) IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA PREVIOUSLY TREATED WITH ONE OR MORE TYROSINE KINASE INHIBITORS",
            "PIID": "4223",
            "PicNum": "C11249826",
            "PILastName": "Swords",
            "PIFirstName": "Ronan",
            "CoodCNbr": "C11908603",
            "CoordLastName": "Pallapati",
            "CoordFirstName": "Rachel",
            "CoordEmail": "rpallapati@med.miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "03/03/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/03/2015",
            "IRBApprovedFrom": "10/21/2014",
            "IRBApprovedTo": "08/01/2017",
            "AccountNbr": "664505",
            "DiseaseSiteListDesc": "Myeloid and Monocytic Leukemia",
            "Expr1": "Phase IV",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Pfizer",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "6",
            "Totalaccrued": "4",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "6",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Luis,Micaela Martinez",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT02228382",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02235909",
            "BriefTitle": "An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension",
            "OfficialTitle": "A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension",
            "LeadSponsorClass": "Arbor Pharmaceuticals, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Arbor Pharmaceuticals, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of the study is to evaluate the efficacy and safety of the study drug relative\r\n\r\n      to an active comparator losartan which the same class of drug and is approved for use in the\r\n\r\n      pediatric population aged 6 years and older",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2014",
            "CompletionDate": "August 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Arbor Pharmaceuticals, Inc.",
            "StudyCondition": "Hypertension",
            "studyLocation": "Advanced Research Center, INC",
            "Enrollment": "260",
            "NctKeyword": "Pediatric Hypertension, High Blood Pressure, Hypertension, Pediatric, Primary Hypertension, Secondary Hypertension,",
            "MeshKeyword": "Hypertension,",
            "InterventionKeyword": "Losartan,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  The subject has hypertension (primary or secondary) defined as clinic Seated\r\n\r\n             Diastolic BP ≥95th percentile (by age, gender, and height) or ≥90th percentile (by\r\n\r\n             age, gender",
            "EligibleGender": "All",
            "MinAge": "6 Years",
            "MaxAge": "18 Years",
            "Volunteers": "No",
            "City": "Anaheim",
            "State": "California",
            "Zip": "92805",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 28, 2016",
            "FirstReceived": "September 8, 2014",
            "ContactName": "Steve Caras, MD",
            "ContactPhone": "470 235-2327",
            "ContactEmail": "scaras@arborpharma.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Advanced Research Center, INC",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02235909",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140828 - Arbor Pharmaceuticals - Seeherunvong",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20140828",
            "StudyNumber": "20140828 - Arbor Pharmaceuticals - Seeherunvong",
            "StudyTitle": "A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) of Age Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years With Hypertension",
            "PIID": "2780",
            "PicNum": "C05091301",
            "PILastName": "Seeherunvong",
            "PIFirstName": "Wacharee",
            "CoodCNbr": "C02526159",
            "CoordLastName": "Somarriba",
            "CoordFirstName": "Gabriel",
            "CoordEmail": "gsomarriba2@med.miami.edu",
            "CoordPhone": "3052434304",
            "EnteredByCNbr": "C05091301",
            "EnteredByLastName": "Seeherunvong",
            "EnteredByFirstName": "Wacharee",
            "ActiveEnrollingDate": "06/23/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/23/2016",
            "IRBApprovedFrom": "03/02/2015",
            "IRBApprovedTo": "01/31/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02235909",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02239120",
            "SecondaryId": "2013-003444-24",
            "BriefTitle": "Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)",
            "OfficialTitle": "Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embol",
            "LeadSponsorClass": "Boehringer Ingelheim",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Boehringer Ingelheim",
            "BriefSummary": "This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown\r\n\r\n      source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1\r\n\r\n      ratio) and have visits every three months. T",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2014",
            "CompletionDate": "June 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Boehringer Ingelheim",
            "StudyCondition": "Stroke",
            "studyLocation": "Boehringer Ingelheim Investigational Site",
            "Enrollment": "6000",
            "MeshKeyword": "Stroke, Neoplasm Metastasis,",
            "InterventionKeyword": "Dabigatran,",
            "Eligibility": "Inclusion criteria:\r\n\r\n\r\n\r\n          -  Ischemic stroke with a brain lesion visualized by neuroimaging (either brain Computed\r\n\r\n             Tomography (CT) or Magnetic Resonance Image (MRI)). The visualized stroke is a\r\n\r\n             non-la",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "150 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 3, 2017",
            "FirstReceived": "September 10, 2014",
            "OverallOfficial": "Boehringer Ingelheim",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Boehringer Ingelheim",
            "ContactName": "Boehringer Ingelheim Call Center",
            "ContactPhone": "1-800-243-0127",
            "ContactEmail": "clintriage.rdg@boehringer-ingelheim.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Boehringer Ingelheim Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02239120",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150033 - Boehringer Ingelheim - Koch",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20150033",
            "StudyNumber": "20150033 - Boehringer Ingelheim - Koch",
            "StudyTitle": "Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral q.d.) in patients with Embolic Stroke of Undetermined Source",
            "PIID": "171",
            "PicNum": "C00123749",
            "PILastName": "Koch",
            "PIFirstName": "Sebastian",
            "CoodCNbr": "C03059821",
            "CoordLastName": "Bracho, II DO NOT USE",
            "CoordFirstName": "Jorge",
            "CoordEmail": "jeb94@med.miami.edu",
            "EnteredByCNbr": "C00123749",
            "EnteredByLastName": "Koch",
            "EnteredByFirstName": "Sebastian",
            "ActiveEnrollingDate": "02/25/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/25/2016",
            "IRBApprovedFrom": "05/05/2015",
            "IRBApprovedTo": "05/02/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Boehringer Ingelheim",
            "Prescreened": "3",
            "Screenedfailed": "2",
            "SignedICF": "4",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Andrea Escobar,Avi Landman",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02239120",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02239640",
            "BriefTitle": "Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry",
            "OfficialTitle": "Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry",
            "LeadSponsorClass": "Medtronic Neurovascular Clinical Affairs",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Medtronic Neurovascular Clinical Affairs",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this registry is to assess outcomes associated with the use of devices\r\n\r\n      intended to restore blood flow in patients experiencing acute ischemic stroke.",
            "Description": "This is a registry evaluating the use of devices in patients diagnosed with an acute\r\n\r\n      ischemic stroke. This registry may enroll up to 1000 patients.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "August 2014",
            "CompletionDate": "December 2018",
            "Phase": "N/A",
            "StudyType": "Observational [Patient Registry]",
            "StudyPhase": "N/A",
            "StudySource": "Medtronic Neurovascular Clinical Affairs",
            "StudyCondition": "Ischemic Stroke",
            "studyLocation": "Delray Medical Center",
            "Enrollment": "1000",
            "MeshKeyword": "Stroke, Ischemia, Cerebral Infarction,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  An informed consent or waiver\r\n\r\n\r\n\r\n          -  Patient has experienced an acute ischemic stroke\r\n\r\n\r\n\r\n          -  Treatment within 8 hours of stroke onset\r\n\r\n\r\n\r\n        Exclusion Criteria:",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Delray Beach",
            "State": "Florida",
            "Zip": "33484",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 11, 2016",
            "FirstReceived": "September 8, 2014",
            "OverallOfficial": "Nils Mueller-Kronast, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Delray Medical Center",
            "LocationName": "Delray Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02239640",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140643 - Covidien - Yavagal",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140643",
            "StudyNumber": "20140643 - Covidien - Yavagal",
            "StudyTitle": "Systematic Evaluation of Patients treated with Neurothrombectomy devices for Acute Ischemic Stroke Registry (Covidien)",
            "PIID": "252",
            "PicNum": "C06459010",
            "PILastName": "Yavagal",
            "PIFirstName": "Dileep",
            "CoodCNbr": "C11877018",
            "CoordLastName": "Ramdas",
            "CoordFirstName": "Kevin",
            "CoordEmail": "k.ramdas@med.miami.edu",
            "CoordPhone": "305-243-1132",
            "EnteredByCNbr": "C06459010",
            "EnteredByLastName": "Yavagal",
            "EnteredByFirstName": "Dileep",
            "ActiveEnrollingDate": "01/29/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/29/2015",
            "IRBApprovedFrom": "09/27/2014",
            "IRBApprovedTo": "06/23/2017",
            "Expr1": "N/A",
            "SponsorGroup": "Industry",
            "Sponsor": "Covidien",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "62",
            "Totalaccrued": "62",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "13",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "62",
            "FirstNinety": "12",
            "SiteSampleSize": "JMH:N/A,UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Luis Guada,Karen Bates",
            "NationalSampleSize": "72",
            "NCTNbr": "NCT02239640",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02240108",
            "BriefTitle": "One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease",
            "OfficialTitle": "A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks",
            "LeadSponsorClass": "Valeant Pharmaceuticals International, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Valeant Pharmaceuticals International, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "The primary objective is to determine the efficacy of rifaximin DR tablets vs. placebo for\r\n\r\n      the induction of clinical remission and endoscopic response following 16 weeks of treatment\r\n\r\n      in subjects presenting with active moderate",
            "Description": "RECD3126 is a double-blind, placebo-controlled, parallel-group, multicenter, multiregional,\r\n\r\n      52-week study to assess the efficacy and safety of rifaximin DR tablets for the induction of\r\n\r\n      clinical remission and endoscopic response",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2014",
            "CompletionDate": "November 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Valeant Pharmaceuticals International, Inc.",
            "StudyCondition": "Crohn's Disease",
            "Enrollment": "660",
            "NctKeyword": "Crohn's Disease, Rifaximin, Clinical remission with endoscopic response, Inflammatory Bowel Disease,",
            "MeshKeyword": "Crohn Disease,",
            "InterventionKeyword": "Rifaximin, Rifamycins,",
            "Eligibility": "Major Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Moderate, non-fistulizing Crohn's disease in the ileum and/or prior to randomization;\r\n\r\n             and a SES-CD score of ≥7 (confirmed by centralized endoscopy reading).\r\n\r\n\r\n\r\n          -  Duri",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Huntsville",
            "State": "Alabama",
            "Zip": "35802",
            "Country": "United States",
            "VerificationDate": "September 2014",
            "LastChanged": "June 11, 2015",
            "FirstReceived": "September 11, 2014",
            "ContactName": "Mary Jo Bullard",
            "ContactPhone": "919 415 3390",
            "ContactEmail": "maryjo.bullard@salix.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02240108",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140850 - Salix Pharmaceuticals/ Inc.  - Deshpande",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20140850",
            "StudyNumber": "20140850 - Salix Pharmaceuticals/ Inc.  - Deshpande",
            "StudyTitle": "A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn’s Disease.",
            "PIID": "26608",
            "PicNum": "C00070691",
            "PILastName": "Deshpande",
            "PIFirstName": "Amar",
            "CoodCNbr": "C11914779",
            "CoordLastName": "Carabali",
            "CoordFirstName": "Francia",
            "CoordEmail": "fxc123@miami.edu",
            "EnteredByCNbr": "C00070691",
            "EnteredByLastName": "Deshpande",
            "EnteredByFirstName": "Amar",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "01/16/2015",
            "IRBApprovedFrom": "01/16/2015",
            "IRBApprovedTo": "11/12/2016",
            "Expr1": "Phase III",
            "Tarea": "Gastrointestinal, Stomach, Esophageal",
            "TareaCode": "6187",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Salix Pharmaceuticals/ Inc.",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Oriana Damas,Francia Carabali,Baharak Moshiree,Diana Morillo",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT02240108",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02242773",
            "SecondaryId": "1R01CA189295-01",
            "BriefTitle": "The Miami MAST Trial",
            "OfficialTitle": "MRI-Guided Active Selection for Treatment of Prostate Cancer: The Miami MAST Trial",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "1. Multiparametric MRI ultrasound (MRIus)-guided or direct MRI-guided biopsies will allow\r\n\r\n           for more directed sampling of the tumors from compartments with distinct\r\n\r\n           multiparametric-MRI (MP-MRI) characteristics, termed h",
            "Description": "Single arm therapeutic trial investigating the impact of MRI and MRI-US fusion biopsy to\r\n\r\n      identify higher grade or volume tumors early on for better selection of patients for active\r\n\r\n      surveillance and improved outcomes for those u",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2014",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Prostate Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "165",
            "NctKeyword": "Prostate Cancer, Active Surveillance, MRI-Guided Biopsy, Multi-parametric MRI, MP-MRI,",
            "MeshKeyword": "Prostatic Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Biopsy confirmed adenocarcinoma of the prostate within 18 months prior to enrollment;\r\n\r\n\r\n\r\n          2. Pre-enrollment prostate biopsy must consist of at least 8 cores;\r\n\r\n\r\n\r\n          3. Biopsy revie",
            "EligibleGender": "Male",
            "MinAge": "35 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 2, 2016",
            "FirstReceived": "September 13, 2014",
            "OverallOfficial": "Sanoj Punnen, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02242773",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140372 - Intramural - Punnen",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140372",
            "StudyNumber": "20140372 - Intramural - Punnen",
            "StudyTitle": "MRI-Guided Active Selection for Treatment of Prostate Cancer:  The Miami MAST Trial",
            "PIID": "4718",
            "PicNum": "C11876129",
            "PILastName": "Punnen",
            "PIFirstName": "Sanoj",
            "CoodCNbr": "C02516296",
            "CoordLastName": "Hernandez",
            "CoordFirstName": "Greeyt",
            "CoordEmail": "g.hernandez3@med.miami.edu",
            "CoordPhone": "305-243-5589",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "10/10/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/10/2014",
            "IRBApprovedFrom": "09/05/2014",
            "IRBApprovedTo": "08/28/2017",
            "InfoEdNbr": "73599",
            "DiseaseSiteListDesc": "Prostate",
            "Expr1": "Phase II",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "9",
            "SignedICF": "104",
            "Totalaccrued": "63",
            "InFollowUp": "47",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "5",
            "Totalpatients": "104",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A,JMH:N/A,Plantation:N/A,UM Kendall:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "2",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Marinellie Vega,Pavel Noa Hechavarria,Zaida Abreu,Lilibet Zamora Cabezas,Lilly Sanchez,Fernando Vazquez Pascual,Maggie Chislom,Rody Barakat,Fanchette Auguste,Doris Martin",
            "NationalSampleSize": "165",
            "NCTNbr": "NCT02242773",
            "StudyKeywords": "Prostate Cancer,\r\nActive Surveillance,\r\nMRI-Guided Biopsy,\r\nMulti-parametric MRI",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02247479",
            "SecondaryId": "2014-000107-27",
            "BriefTitle": "A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)",
            "LeadSponsorClass": "Hoffmann-La Roche",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Hoffmann-La Roche",
            "BriefSummary": "This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled\r\n\r\n      study evaluating the efficacy and safety of lampalizumab administered by intravitreal\r\n\r\n      injections in participants with geographic atrop",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2014",
            "CompletionDate": "September 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Hoffmann-La Roche",
            "StudyCondition": "Geographic Atrophy",
            "Enrollment": "936",
            "MeshKeyword": "Macular Degeneration, Atrophy, Geographic Atrophy,",
            "InterventionKeyword": "Immunoglobulin Fab Fragments,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Participants aged >/= 50 years\r\n\r\n\r\n\r\n          -  Well demarcated area(s) of GA secondary to AMD with no evidence of prior or active\r\n\r\n             choroidal neovascularization (CNV) in both eyes",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 1, 2016",
            "FirstReceived": "July 15, 2014",
            "OverallOfficial": "Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Hoffmann-La Roche",
            "ContactName": "Reference Study ID Number: GX29176 www.roche.com/about_roche/roche_worldwide.htm",
            "ContactPhone": "888-662-6728 (U.S. and Canada)",
            "ContactEmail": "global.rochegenentechtrials@roche.com",
            "LocationStatus": "Active, not recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02247479",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140807 - Genentech - Fortun",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20140807",
            "StudyNumber": "20140807 - Genentech - Fortun",
            "StudyTitle": "A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE RELATED MACULAR DEGENERATION",
            "PIID": "3572",
            "PicNum": "C09939295",
            "PILastName": "Fortun",
            "PIFirstName": "Jorge",
            "CoodCNbr": "C11963475",
            "CoordLastName": "Larez",
            "CoordFirstName": "Lorena",
            "CoordEmail": "llarez@med.miami.edu",
            "EnteredByCNbr": "C09939295",
            "EnteredByLastName": "Fortun",
            "EnteredByFirstName": "Jorge",
            "ActiveEnrollingDate": "09/16/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/16/2015",
            "IRBApprovedFrom": "03/23/2015",
            "IRBApprovedTo": "03/13/2017",
            "Expr1": "Phase III",
            "Tarea": "Retina",
            "TareaCode": "12038",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Genentech",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "11",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "6",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "11",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Lorena Larez,Chantey Roberts",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT02247479",
            "StudyInvIND": "0",
            "StudyInvINDNbr": "104996",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02247531",
            "SecondaryId": "2014-000106-35",
            "BriefTitle": "A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (SPECTRI)",
            "LeadSponsorClass": "Hoffmann-La Roche",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Hoffmann-La Roche",
            "BriefSummary": "This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled\r\n\r\n      study evaluating the efficacy and safety of lampalizumab administered by intravitreal\r\n\r\n      injections in patients with geographic atrophy (",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2014",
            "CompletionDate": "November 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Hoffmann-La Roche",
            "StudyCondition": "Geographic Atrophy",
            "Enrollment": "936",
            "MeshKeyword": "Macular Degeneration, Atrophy, Geographic Atrophy,",
            "InterventionKeyword": "Immunoglobulin Fab Fragments,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Participants aged >/= 50 years\r\n\r\n\r\n\r\n          -  Well demarcated area(s) of GA secondary to AMD with no evidence of prior or active\r\n\r\n             choroidal neovascularization (CNV) in both eyes",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85020",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 1, 2016",
            "FirstReceived": "July 15, 2014",
            "OverallOfficial": "Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Hoffmann-La Roche",
            "ContactName": "Reference Study ID Number: GX29185 www.roche.com/about_roche/roche_worldwide.htm",
            "ContactPhone": "888-662-6728 (U.S. and Canada)",
            "ContactEmail": "global.rochegenentechtrials@roche.com",
            "LocationStatus": "Active, not recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02247531",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140452 - F. Hoffmann-La Roche Ltd. - Rosenfeld",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20140452",
            "StudyNumber": "20140452 - F. Hoffmann-La Roche Ltd. - Rosenfeld",
            "StudyTitle": "A PHASE III, MULTICENTER, RANDOMIZED,DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH\nGEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION",
            "PIID": "491",
            "PicNum": "C00522634",
            "PILastName": "Rosenfeld",
            "PIFirstName": "Philip",
            "CoodCNbr": "C01984187",
            "CoordLastName": "Esquiabro",
            "CoordFirstName": "Maria",
            "CoordEmail": "mesquiabro@med.miami.edu",
            "EnteredByCNbr": "C00522634",
            "EnteredByLastName": "Rosenfeld",
            "EnteredByFirstName": "Philip",
            "ActiveEnrollingDate": "10/02/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/02/2015",
            "IRBApprovedFrom": "03/23/2015",
            "IRBApprovedTo": "03/13/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "F. Hoffmann-La Roche Ltd.",
            "Prescreened": "1",
            "Screenedfailed": "3",
            "SignedICF": "8",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "9",
            "FirstNinety": "4",
            "SiteSampleSize": "UMMG:N/A,ABLEH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Cristina Lage-Rodriguez,Fabiola Salvador,Catherin Negron,Maria Esquiabro,Belen Rodriguez,Monica Arango",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02247531",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02252536",
            "BriefTitle": "HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder",
            "OfficialTitle": "Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder",
            "LeadSponsorClass": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine whether gabapentin enacarbil is effective in the\r\n\r\n      treatment of problems with alcohol.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "June 2015",
            "CompletionDate": "February 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)",
            "StudyCondition": "Alcohol Use Disorder",
            "studyLocation": "University of California Los Angeles",
            "Enrollment": "346",
            "NctKeyword": "alcohol use disorder, alcoholism, alcohol dependence, drinking alcohol,",
            "MeshKeyword": "Disease, Alcohol Drinking,",
            "InterventionKeyword": "Ethanol, Gabapentin, gamma-Aminobutyric Acid,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        Subjects must meet each one of the following inclusion criteria in order to be eligible\r\n\r\n        for participation in the study:\r\n\r\n\r\n\r\n          1. Be at least 21 years of age.\r\n\r\n\r\n\r\n          2. Have a c",
            "EligibleGender": "All",
            "MinAge": "21 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles and Santa Monica",
            "State": "California",
            "Zip": "94103",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 3, 2016",
            "FirstReceived": "September 26, 2014",
            "OverallOfficial": "Raye Z. Litten, Ph.D.",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)",
            "LocationName": "University of California Los Angeles",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02252536",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150100 - National Institute on Alcohol Abuse and Alcoholism - Salloum",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20150100",
            "StudyNumber": "20150100 - National Institute on Alcohol Abuse and Alcoholism - Salloum",
            "StudyTitle": "Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT® (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder",
            "PIID": "1254",
            "PicNum": "C05555269",
            "PILastName": "Salloum",
            "PIFirstName": "Ihsan",
            "CoodCNbr": "C11839790",
            "CoordLastName": "Hyman",
            "CoordFirstName": "Scott",
            "CoordEmail": "s.hyman1@med.miami.edu",
            "EnteredByCNbr": "C05555269",
            "EnteredByLastName": "Salloum",
            "EnteredByFirstName": "Ihsan",
            "ActiveEnrollingDate": "05/01/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/01/2015",
            "IRBApprovedFrom": "04/07/2015",
            "IRBApprovedTo": "04/04/2017",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "National Institute on Alcohol Abuse and Alcoholism",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "34",
            "Totalaccrued": "34",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "5",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "34",
            "FirstNinety": "5",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Gabriela Vargas,Ladan Khazai",
            "NationalSampleSize": "140",
            "NCTNbr": "NCT02252536",
            "StudyKeywords": "Alcohol Use Disorder",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT02254278",
            "SecondaryId": "NCI-2014-01279",
            "BriefTitle": "Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer",
            "OfficialTitle": "A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer",
            "LeadSponsorClass": "NRG Oncology",
            "SponsorAgency": "Other",
            "LeadSponsor": "NRG Oncology",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase II trial studies the side effects and how well modestly reduced-dose\r\n\r\n      intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating\r\n\r\n      patients with oropharyngeal cancer that has spr",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To select the arm(s) achieving a 2-year progression-free survival rate of >= 85% without\r\n\r\n      unacceptable swallowing toxicity at 1 year.\r\n\r\n\r\n\r\n      SECONDARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To determine pat",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2014",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "NRG Oncology",
            "StudyCondition": "Stage III Oropharyngeal Squamous Cell Carcinoma",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "296",
            "MeshKeyword": "Carcinoma, Squamous Cell, Carcinoma, Oropharyngeal Neoplasms,",
            "InterventionKeyword": "Cisplatin, Succinylcholine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  STEP 1: REGISTRATION\r\n\r\n\r\n\r\n          -  Pathologically (histologically or cytologically) proven diagnosis of squamous cell\r\n\r\n             carcinoma (including the histological variants papillary squamo",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "June 28, 2016",
            "FirstReceived": "September 29, 2014",
            "OverallOfficial": "Sue Yom",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "NRG Oncology",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02254278",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160045 - NRG Oncology - Elsayyad",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160045",
            "StudyNumber": "20160045 - NRG Oncology - Elsayyad",
            "StudyTitle": "A RANDOMIZED PHASE II TRIAL FOR PATIENTS WITH p16 POSITIVE,\nNON-SMOKING ASSOCIATED, LOCOREGIONALLY ADVANCED OROPHARYNGEAL CANCER",
            "PIID": "336",
            "PicNum": "C06037790",
            "PILastName": "Elsayyad",
            "PIFirstName": "Nagy",
            "CoodCNbr": "C04035535",
            "CoordLastName": "Sanchez",
            "CoordFirstName": "Lilly",
            "CoordEmail": "lsanchez@med.miami.edu",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "09/02/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/02/2016",
            "IRBApprovedFrom": "10/27/2014",
            "IRBApprovedTo": "04/20/2017",
            "DiseaseSiteListDesc": "Lip, Oral Cavity and Pharynx",
            "Expr1": "Phase II",
            "Tarea": "Head and Neck Cancer",
            "TareaCode": "12440",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "4",
            "Totalaccrued": "2",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "1",
            "SiteSampleSize": "UMD:N/A,UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Maggie Chislom,Mohammad El-Sorady,Fernando Vazquez Pascual,Greeyt Hernandez,Lilibet Zamora Cabezas,Marinellie Vega",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02254278",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02255552",
            "BriefTitle": "Confirmatory Study of Eteplirsen in DMD Patients",
            "OfficialTitle": "An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy",
            "LeadSponsorClass": "Sarepta Therapeutics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Sarepta Therapeutics",
            "OversightAuthority": "No",
            "BriefSummary": "The main objective of this study is to provide confirmatory evidence of efficacy of\r\n\r\n      eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD) patients that are amenable to\r\n\r\n      skipping exon 51. Additional objectives include evalua",
            "Description": "This is an open-label, multi-center, 96-week study to evaluate the efficacy and safety of\r\n\r\n      eteplirsen in patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with\r\n\r\n      genetic deletions amenable to exon 51 skipping",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2014",
            "CompletionDate": "May 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Sarepta Therapeutics",
            "StudyCondition": "Duchenne Muscular Dystrophy (DMD)",
            "studyLocation": "Neuromuscular Research Center",
            "Enrollment": "160",
            "NctKeyword": "DMD, Duchenne, Eteplirsen, dystrophy, dystrophin, exon 51,",
            "MeshKeyword": "Muscular Dystrophies, Muscular Dystrophy, Duchenne,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male 7-16 years old\r\n\r\n\r\n\r\n          -  Diagnosed with DMD, genotypically confirmed\r\n\r\n\r\n\r\n          -  Stable dose of corticosteroids for at least 24 weeks\r\n\r\n\r\n\r\n          -  Have intact right and left",
            "EligibleGender": "Male",
            "MinAge": "7 Years",
            "MaxAge": "16 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85028",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 27, 2016",
            "FirstReceived": "September 25, 2014",
            "OverallOfficial": "Petra Duda, MD, PhD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Sarepta Therapeutics",
            "ContactName": "Kara Boniface",
            "ContactEmail": "trialinfo@sarepta.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Neuromuscular Research Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02255552",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140562 - Muscular Dystrophy Association - Sharma",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140562",
            "StudyNumber": "20140562 - Muscular Dystrophy Association - Sharma",
            "StudyTitle": "An Open-Label, Multi-Center, 48-Week Study with a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy (4658-301)",
            "PIID": "198",
            "PicNum": "C00576419",
            "PILastName": "Sharma",
            "PIFirstName": "Khema",
            "CoodCNbr": "C01939845",
            "CoordLastName": "Quesada",
            "CoordFirstName": "Monica",
            "CoordEmail": "mquesada2@med.miami.edu",
            "CoordPhone": "3052433647",
            "EnteredByCNbr": "C00576419",
            "EnteredByLastName": "Sharma",
            "EnteredByFirstName": "Khema",
            "ActiveEnrollingDate": "04/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/08/2016",
            "IRBApprovedFrom": "07/13/2015",
            "IRBApprovedTo": "04/21/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Foundation",
            "Sponsor": "Muscular Dystrophy Association",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Julie Steele,Monica Quesada",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02255552",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02256917",
            "BriefTitle": "Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A",
            "OfficialTitle": "Prospective, Open-label, Multi-centre Phase 3b Study to Assess the Efficacy and Safety of Personalized Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A",
            "LeadSponsorClass": "Octapharma",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Octapharma",
            "OversightAuthority": "No",
            "BriefSummary": "The rationale of this study is to further fine-tune and individualize prophylactic treatment\r\n\r\n      of patients with severe Haemophilia A with the goal of keeping the trough FVIII level above\r\n\r\n      1% between doses. Because trough FVIII lev",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2015",
            "CompletionDate": "April 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Octapharma",
            "StudyCondition": "Severe Haemophilia A",
            "studyLocation": "UC Davis Medical Center",
            "Enrollment": "55",
            "MeshKeyword": "Hemophilia A,",
            "InterventionKeyword": "Factor VIII,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Severe Haeomophilia A (FVIII:C < 1%)\r\n\r\n\r\n\r\n          -  Male patients >= 18 years of age\r\n\r\n\r\n\r\n          -  Previous treatment with a FVIII concentrate for at least 150 EDs\r\n\r\n\r\n\r\n          -  Good doc",
            "EligibleGender": "Male",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Sacramento",
            "State": "California",
            "Zip": "95817",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 19, 2016",
            "FirstReceived": "September 30, 2014",
            "OverallOfficial": "Craig M Kessler, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Georgetown University",
            "ContactName": "Cristina Solomon, MD",
            "ContactPhone": "+41554512189",
            "ContactEmail": "cristina.solomon@octapharma.com",
            "LocationStatus": "Recruiting",
            "LocationName": "UC Davis Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02256917",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140977 - Octapharma - Corrales Medina",
            "FileProcessContentId": "440",
            "Division": "Pediatrics Oncology",
            "StdyDivision": "10646",
            "EprostNbr": "20140977",
            "StudyNumber": "20140977 - Octapharma - Corrales Medina",
            "StudyTitle": "Prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalized prophylaxis with  Human-cl rhFVIII in previously treated adult patients with severe haemophilia A",
            "PIID": "23193",
            "PicNum": "C11918839",
            "PILastName": "Corrales Medina",
            "PIFirstName": "Fernando",
            "CoodCNbr": "C11956115",
            "CoordLastName": "Pisani",
            "CoordFirstName": "Leandro",
            "CoordEmail": "LFP34@miami.edu",
            "CoordPhone": "305-243-6925",
            "EnteredByCNbr": "C11918839",
            "EnteredByLastName": "Corrales Medina",
            "EnteredByFirstName": "Fernando",
            "ActiveEnrollingDate": "11/13/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/13/2015",
            "IRBApprovedFrom": "03/16/2015",
            "IRBApprovedTo": "03/06/2017",
            "AccountNbr": "665383",
            "InfoEdNbr": "75168",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Octapharma USA, Inc.",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "3",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "5709",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Maria Santaella,Leandro Pisani,Maya Smith",
            "NationalSampleSize": "4",
            "NCTNbr": "NCT02256917",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02258581",
            "SecondaryId": "2015-001050-16",
            "BriefTitle": "Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection",
            "OfficialTitle": "A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "No",
            "BriefSummary": "This study will evaluate the long term effects of hepatitis B virus (HBV) treatment on the\r\n\r\n      HBV serologic changes and HBV DNA levels through Week 144. This registry will enroll only\r\n\r\n      individuals who were treated in a Gilead-spons",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "December 2014",
            "CompletionDate": "July 2021",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "Chronic Hepatitis B",
            "studyLocation": "Kaiser Permanente",
            "Enrollment": "500",
            "MeshKeyword": "Hepatitis, Hepatitis A, Hepatitis, Chronic, Hepatitis B, Hepatitis B, Chronic,",
            "InterventionKeyword": "Tenofovir,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Must have participated in a Gilead-sponsored chronic hepatitis B (CHB) study no more\r\n\r\n             than 120 days prior to Baseline (Day 1), except for participants from previous\r\n\r\n             Gil",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Sacramento",
            "State": "California",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 23, 2016",
            "FirstReceived": "October 3, 2014",
            "OverallOfficial": "Gilead Study Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "Kaiser Permanente",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02258581",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150066 - Gilead - Schiff",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20150066",
            "StudyNumber": "20150066 - Gilead - Schiff",
            "StudyTitle": "GS-US-330-1508 - A Long Term Follow-up Registry of Subjects Treated in a Gilead-Sponsored Trial in Subjects  with Chronic Hepatitis B Infection",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C00758491",
            "EnteredByLastName": "Schiff",
            "EnteredByFirstName": "Eugene",
            "ActiveEnrollingDate": "03/18/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/18/2015",
            "IRBApprovedFrom": "02/20/2015",
            "IRBApprovedTo": "10/20/2017",
            "Expr1": "N/A",
            "ResearchType": "Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Gilead",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "6",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "6",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "6",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diane Sabogal",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02258581",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02264288",
            "BriefTitle": "Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease",
            "OfficialTitle": "A Phase 2 Multicenter, Randomized, Doubleblind, Placebo-Controlled, Dose Range Finding Study to Evaluate the Efficacy and Safety of Intramuscular Injection of Human Placenta-derived Cells (Pda-002) in Subjects Who Have Diabetic Foot Ulcer With Peripheral",
            "LeadSponsorClass": "Celgene Corporation",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Celgene Corporation",
            "OversightAuthority": "Yes",
            "BriefSummary": "The PDA-002-DFU-002 trial is a Phase 2, multicenter, randomized, double blind, placebo\r\n\r\n      controlled, dose range finding study. The study will enroll approximately 133 subjects in\r\n\r\n      four treatment groups. The primary objective of th",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2014",
            "CompletionDate": "July 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Celgene Corporation",
            "StudyCondition": "Peripheral Arterial Disease",
            "studyLocation": "Cardiology PC",
            "Enrollment": "133",
            "NctKeyword": "Peripheral Arterial Disease, Diabetic Foot,",
            "MeshKeyword": "Diabetic Foot, Foot Ulcer, Peripheral Arterial Disease, Peripheral Vascular Diseases,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Males and females, at least 18 years of age or older at the time of signing the\r\n\r\n             informed consent document.\r\n\r\n\r\n\r\n          2. Understand and voluntarily sign an informed consent document",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35211",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 28, 2016",
            "FirstReceived": "October 2, 2014",
            "OverallOfficial": "Wolfgang Hofgartner, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Celgene Corporation",
            "ContactName": "Vilma Hernandez",
            "ContactPhone": "+1 732.652.6147",
            "ContactEmail": "vhernandez@celgene.com",
            "LocationStatus": "Completed",
            "LocationName": "Cardiology PC",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02264288",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140600 - Celgene - Bornak",
            "FileProcessContentId": "440",
            "Division": "Surgery",
            "StdyDivision": "7805",
            "EprostNbr": "20140600",
            "StudyNumber": "20140600 - Celgene - Bornak",
            "StudyTitle": "A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO–CONTROLLED, DOSE RANGE FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAMUSCULAR INJECTION OF HUMAN PLACENTA-DERIVED CELLS (PDA-002) IN SUBJECTS WHO HAVE DIABETIC FOOT ULCER\nWITH AND WITHOUT PERIPHERAL ARTERIAL DISEASE. PROTOCOL NUMBER: CCT-PDA-002-DFU-002.",
            "PIID": "3735",
            "PicNum": "C10165569",
            "PILastName": "Bornak",
            "PIFirstName": "Arash",
            "CoodCNbr": "C10165569",
            "CoordLastName": "Bornak",
            "CoordFirstName": "Arash",
            "EnteredByCNbr": "C10165569",
            "EnteredByLastName": "Bornak",
            "EnteredByFirstName": "Arash",
            "ActiveEnrollingDate": "02/19/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/19/2016",
            "IRBApprovedFrom": "03/16/2015",
            "IRBApprovedTo": "12/18/2017",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Jean (Lynne) Sparling,Kay Salinas",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT02264288",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02268214",
            "SecondaryId": "2013-004674-97",
            "BriefTitle": "Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes",
            "OfficialTitle": "A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus",
            "LeadSponsorClass": "AstraZeneca",
            "SponsorAgency": "Industry",
            "LeadSponsor": "AstraZeneca",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and\r\n\r\n      effective therapy to improve glycemic control in patients with type 1 diabetes.",
            "Description": "Study Classification: Safety, Efficacy and Pharmacokinetics/dynamics",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "November 2014",
            "CompletionDate": "August 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "AstraZeneca",
            "StudyCondition": "Type 1 Diabetes Mellitus",
            "studyLocation": "Research Site",
            "Enrollment": "768",
            "NctKeyword": "Dapagliflozin, Efficacy, Safety, Add on to insulin, Oral Antidiabetic, Type 1 diabetes,",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of Type 1 Diabetes mellitus (T1DM)\r\n\r\n\r\n\r\n          -  Central laboratory C-peptide < 0.7 ng/ml (0.23 nmol/L)\r\n\r\n\r\n\r\n          -  Insulin use for at least 12 months per patient reported or medi",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 9, 2016",
            "FirstReceived": "October 15, 2014",
            "OverallOfficial": "Anna Maria Langkilde",
            "OverallRole": "Study Director",
            "OverallAffilitation": "AstraZeneca",
            "LocationName": "Research Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02268214",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140836 - AstraZeneca - Miranda-Palma",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20140836",
            "StudyNumber": "20140836 - AstraZeneca - Miranda-Palma",
            "StudyTitle": "A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus",
            "PIID": "1111",
            "PicNum": "C02129536",
            "PILastName": "Miranda-Palma",
            "PIFirstName": "Bresta",
            "CoodCNbr": "C00121533",
            "CoordLastName": "Masters",
            "CoordFirstName": "Burlett",
            "CoordEmail": "bmasters2@med.miami.edu",
            "CoordPhone": "305-243-5354",
            "EnteredByCNbr": "C02129536",
            "EnteredByLastName": "Miranda-Palma",
            "EnteredByFirstName": "Bresta",
            "ActiveEnrollingDate": "04/17/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/17/2015",
            "IRBApprovedFrom": "02/02/2015",
            "IRBApprovedTo": "01/31/2017",
            "Expr1": "Phase III",
            "Tarea": "Diabetes (Type I)",
            "TareaCode": "12541",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "AstraZeneca",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "7",
            "Totalaccrued": "5",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Burlett Masters,Ada Konwai",
            "NationalSampleSize": "24",
            "NCTNbr": "NCT02268214",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02270645",
            "BriefTitle": "Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser",
            "OfficialTitle": "Randomized Pilot Study of Treatment for Basal Cell Carcinoma Using the Multiplex 595/1064 nm Laser",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "Laser therapy for basal cell carcinoma may be a superior option for patients who do not wish\r\n\r\n      to or cannot tolerate other treatment modalities such as topical chemotherapeutics or\r\n\r\n      surgery.\r\n\r\n\r\n\r\n      In this pilot study, we wi",
            "Description": "Basal cell carcinoma is a malignancy with significant prevalence that rarely metastasizes\r\n\r\n      but can be locally destructive. Laser therapy for this type of lesion may be a superior\r\n\r\n      option for patients who do not wish to or cannot",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2014",
            "CompletionDate": "December 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Nodular Basal Cell Carcinoma",
            "studyLocation": "University of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center",
            "Enrollment": "28",
            "MeshKeyword": "Carcinoma, Carcinoma, Basal Cell,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Adults age 18 years or older\r\n\r\n\r\n\r\n          -  Diagnostic biopsy must be no later than three months prior to enrollment\r\n\r\n\r\n\r\n          -  Lesion is biopsy-proven nodular or superficial BCC",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 16, 2016",
            "FirstReceived": "October 17, 2014",
            "OverallOfficial": "Keyvan Nouri, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami Silvester Comprenhensive Care Center",
            "ContactName": "Keyvan Nouri, MD",
            "ContactPhone": "305-243-3380",
            "ContactEmail": "knouri@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02270645",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20120815 - Intramural - Nouri",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20120815",
            "StudyNumber": "20120815 - Intramural - Nouri",
            "StudyTitle": "Randomized pilot study of treatment for basal cell carcinoma using the multiplex 595/1064 nm laser",
            "PIID": "417",
            "PicNum": "C00756321",
            "PILastName": "Nouri",
            "PIFirstName": "Keyvan",
            "CoodCNbr": "C11862748",
            "CoordLastName": "Falto",
            "CoordFirstName": "Leyre",
            "CoordEmail": "l.falto@med.miami.edu",
            "CoordPhone": "3052433380",
            "EnteredByCNbr": "C00756321",
            "EnteredByLastName": "Nouri",
            "EnteredByFirstName": "Keyvan",
            "ActiveEnrollingDate": "03/01/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/01/2013",
            "IRBApprovedFrom": "02/19/2013",
            "IRBApprovedTo": "12/14/2016",
            "DiseaseSiteListDesc": "Other Skin",
            "Expr1": "Pilot/Feasibility",
            "Tarea": "Melanoma and Related Skin Cancers",
            "TareaCode": "12441",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Device",
            "SponsorGroup": "Intramural",
            "Prescreened": "1",
            "Screenedfailed": "1",
            "SignedICF": "10",
            "Totalaccrued": "10",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "5",
            "Totalpatients": "10",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:20,UMMG:N/A",
            "AccrualPercentageMet": "50",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "20",
            "EprostState": "Approved",
            "StudyCoordinator": "Jennifer Ledon,Ariel Eva Eber",
            "NationalSampleSize": "28",
            "NCTNbr": "NCT02270645",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02272426",
            "BriefTitle": "The Safety and Tolerability of an Aerobic and Resistance Exercise Program With or Without Cognitive Training Post-stroke",
            "OfficialTitle": "The Safety and Tolerability of an Aerobic and Resistance Exercise Program With or Without Cognitive Training Post-stroke",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "It is estimated that 2 out of 3 patients with a stroke have some problems with their memory,\r\n\r\n      difficulties performing certain tasks, making decisions and learning new things. In\r\n\r\n      addition, many stroke patients do not get regular",
            "Description": "Stroke is well recognized as the leading cause of disability in the United States. Cognitive\r\n\r\n      deficits after stroke are common, even in those without dementia prior to the event, and\r\n\r\n      stroke patients with worse cognition on hospi",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2014",
            "CompletionDate": "March 2018",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Cerebral Stroke",
            "studyLocation": "Jackson Memorial Hospital",
            "Enrollment": "180",
            "NctKeyword": "Stroke, Exercise Training, Cognitive Training, Quality of Life,",
            "MeshKeyword": "Stroke,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of ischemic or hemorrhagic stroke\r\n\r\n\r\n\r\n          -  Modified Rankin Score (mRS) of <4 at screening\r\n\r\n\r\n\r\n          -  Recently discharged from the hospital or rehabilitation program",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 13, 2016",
            "FirstReceived": "October 1, 2014",
            "OverallOfficial": "Sebastian Koch, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Barbara Junco, MSc",
            "ContactPhone": "305-243-6107",
            "ContactEmail": "bxj107@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Jackson Memorial Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02272426",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140203 - American Heart Association - Wright",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20140203",
            "StudyNumber": "20140203 - American Heart Association - Wright",
            "StudyTitle": "The Safety and Tolerability of an Aerobic and Resistance Exercise Program With or Without Cognitive Training Post-stroke",
            "PIID": "171",
            "PicNum": "C00123749",
            "PILastName": "Koch",
            "PIFirstName": "Sebastian",
            "CoodCNbr": "C03925694",
            "CoordLastName": "Rodriguez",
            "CoordFirstName": "Zuzel",
            "CoordEmail": "z.rodriguez1@med.miami.edu",
            "CoordPhone": "3052432373",
            "EnteredByCNbr": "C06958355",
            "EnteredByLastName": "Wright",
            "EnteredByFirstName": "Clinton",
            "ActiveEnrollingDate": "11/03/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/03/2014",
            "IRBApprovedFrom": "06/10/2014",
            "IRBApprovedTo": "06/26/2017",
            "Tarea": "Stroke",
            "TareaCode": "8943",
            "SponsorGroup": "Foundation",
            "Sponsor": "American Heart Association",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "16",
            "Totalaccrued": "16",
            "InFollowUp": "8",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "16",
            "FirstNinety": "2",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carmen Perez,Barbara Junco,Stacy Merritt",
            "NationalSampleSize": "120",
            "NCTNbr": "NCT02272426",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT02273102",
            "BriefTitle": "Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS",
            "OfficialTitle": "An Open-Label, Dose Escalation, Phase 1 Study of Tranylcypromine (TCP) in Combination With ATRA (Tretinoin) for Adult Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "Acute Myeloid Leukemia (AML) is a diverse disease that is fatal in the majority of patients.\r\n\r\n      Acute promyelocytic leukemia (APL) however, a subtype of AML accounting for 5% of all cases,\r\n\r\n      is very curable. APL cells are highly sen",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2015",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Acute Myelogenous Leukemia",
            "studyLocation": "University of Miami",
            "Enrollment": "25",
            "NctKeyword": "Acute Myelogenous Leukemia, AML, Myelodysplastic Syndromes, MDS, Tranylcypromine, TCP, ATRA, Tretinoin,",
            "MeshKeyword": "Leukemia, Syndrome, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute,",
            "InterventionKeyword": "Tranylcypromine, Tretinoin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Confirmed diagnosis of one of the following:\r\n\r\n\r\n\r\n               -  Relapsed/refractory Acute Myelogenous Leukemia (AML) as defined by the World\r\n\r\n                  Health Organization (WHO) criteria",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 16, 2016",
            "FirstReceived": "October 20, 2014",
            "OverallOfficial": "Ronan Swords, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Ronan Swords, MD, PhD",
            "ContactPhone": "305-243-3084",
            "ContactEmail": "rswords@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02273102",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140328 - Intramural - Swords",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140328",
            "StudyNumber": "20140328 - Intramural - Swords",
            "StudyTitle": "A Phase 1 Dose Escalation Study of Tranylcypromine (TCP) in Combination with ATRA (Tretinoin) for Adult Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)",
            "PIID": "4223",
            "PicNum": "C11249826",
            "PILastName": "Swords",
            "PIFirstName": "Ronan",
            "CoodCNbr": "C11954409",
            "CoordLastName": "Ogden",
            "CoordFirstName": "Jillian",
            "CoordEmail": "jbo25@miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "02/23/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/23/2015",
            "IRBApprovedFrom": "10/07/2014",
            "IRBApprovedTo": "08/15/2017",
            "DiseaseSiteListDesc": "Myeloid and Monocytic Leukemia,Other Hematopoietic",
            "Expr1": "Phase I",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "1",
            "Screenedfailed": "1",
            "SignedICF": "10",
            "Totalaccrued": "9",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "10",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "3",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Jennifer Byrne,Randy Astaiza,Shradha Patel,Juan Salvador,Tamara Leon Aliz,Yvonne Dinh",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT02273102",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02273219",
            "SecondaryId": "CAEB071AUS01T",
            "BriefTitle": "Trial of AEB071 in Combination With BYL719 in Patients With Melanoma",
            "OfficialTitle": "Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma",
            "LeadSponsorClass": "Richard D. Carvajal",
            "SponsorAgency": "Other",
            "LeadSponsor": "Richard D. Carvajal",
            "OversightAuthority": "Yes",
            "BriefSummary": "Primary objective is to define the maximum tolerated dose (MTD) for the combination of\r\n\r\n      AEB071 and BYL719. Secondary objectives are to define the safety and tolerability of AEB071\r\n\r\n      and BYL719.",
            "Description": "Uveal melanoma is the most common primary intraocular malignancy in adults and is thought to\r\n\r\n      be particularly resistant to systemic treatment, and no systemic therapy has yet been\r\n\r\n      demonstrated to improve survival. Drugs commonly",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2014",
            "CompletionDate": "December 2018",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Columbia University",
            "StudyCondition": "Uveal Melanoma",
            "studyLocation": "Bascom Palmer Eye Institute of University Of Miami Medical Center",
            "Enrollment": "50",
            "NctKeyword": "Uveal, Melanoma, Advanced uveal melanoma,",
            "MeshKeyword": "Melanoma, Uveal Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Metastatic histologically or cytologically confirmed uveal melanoma with pathologic\r\n\r\n             confirmation at a participating center that is judged to be progressive in the\r\n\r\n             opinion",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 15, 2016",
            "FirstReceived": "October 17, 2014",
            "OverallOfficial": "Richard Carvajal, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Columbia University",
            "ContactName": "Dan Otap, CCRP",
            "ContactPhone": "212.342.3970",
            "ContactEmail": "do2267@cumc.columbia.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Bascom Palmer Eye Institute of University Of Miami Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02273219",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140808 - Novartis - Feun",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140808",
            "StudyNumber": "20140808 - Novartis - Feun",
            "StudyTitle": "Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination with BYL719, a PI3K Inhibitor, in Patients with Metastatic Uveal Melanoma",
            "PIID": "343",
            "PicNum": "C00770064",
            "PILastName": "Feun",
            "PIFirstName": "Lynn",
            "CoodCNbr": "C00349551",
            "CoordLastName": "Blackburn",
            "CoordFirstName": "Karen",
            "CoordEmail": "k.blackburn@med.miami.edu",
            "CoordPhone": "3052430863",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "12/09/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/09/2015",
            "IRBApprovedFrom": "03/09/2015",
            "IRBApprovedTo": "02/21/2017",
            "AccountNbr": "307347 / 665012",
            "DiseaseSiteListDesc": "Melanoma, skin",
            "Expr1": "Phase I",
            "Tarea": "Melanoma and Related Skin Cancers",
            "TareaCode": "12441",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yvonne Dinh,Juan Salvador,Daniel Sumarriva,Sandra Pineda,Tamara Leon Aliz",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT02273219",
            "StudyKeywords": "Melanoma and Related Skin Cancers",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02274766",
            "BriefTitle": "Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia",
            "OfficialTitle": "ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)",
            "LeadSponsorClass": "Adamas Pharmaceuticals, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Adamas Pharmaceuticals, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group\r\n\r\n      study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an\r\n\r\n      investigational formulation of amantadine, dos",
            "OverallStatus": "Completed",
            "StartDate": "October 2014",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Adamas Pharmaceuticals, Inc.",
            "StudyCondition": "Dyskinesia",
            "Enrollment": "77",
            "NctKeyword": "Levodopa-Induced Dyskinesia, LID, Parkinsonism, Parkinson's Disease,",
            "MeshKeyword": "Parkinson Disease, Dyskinesias,",
            "InterventionKeyword": "Levodopa, Amantadine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Signed a current IRB/REB/IEC-approved informed consent form;\r\n\r\n\r\n\r\n          -  Parkinson's disease, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical\r\n\r\n             Diagnostic Criteria;",
            "EligibleGender": "All",
            "MinAge": "30 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Fountain Valley",
            "State": "California",
            "Zip": "92708",
            "Country": "United States",
            "VerificationDate": "May 2016",
            "LastChanged": "May 16, 2016",
            "FirstReceived": "October 22, 2014",
            "OverallOfficial": "Clinical Trials Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Adamas Pharmaceuticals, Inc.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02274766",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150523 - Adamas Pharmaceuticals/ Inc. - Singer",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20150523",
            "StudyNumber": "20150523 - Adamas Pharmaceuticals/ Inc. - Singer",
            "StudyTitle": "ADS-5102 (amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson’s Disease Patients with Levodopa-Induced Dyskinesia (EASE LID 3 Study)",
            "PIID": "143",
            "PicNum": "C00407776",
            "PILastName": "Singer",
            "PIFirstName": "Carlos",
            "CoodCNbr": "C11907212",
            "CoordLastName": "Vargas",
            "CoordFirstName": "Silvia",
            "CoordEmail": "s.vargasparra@med.miami.edu",
            "EnteredByCNbr": "C00407776",
            "EnteredByLastName": "Singer",
            "EnteredByFirstName": "Carlos",
            "ActiveEnrollingDate": "11/10/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/10/2015",
            "IRBApprovedFrom": "09/28/2015",
            "IRBApprovedTo": "09/27/2016",
            "Expr1": "Phase III",
            "Tarea": "Movement Disorders",
            "TareaCode": "8937",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Adamas Pharmaceuticals/ Inc.",
            "Prescreened": "2",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Nathalie Padron,Silvia Vargas",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02274766",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02275780",
            "SecondaryId": "2014-001127-69",
            "BriefTitle": "Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)",
            "OfficialTitle": "A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combina",
            "LeadSponsorClass": "Merck Sharp & Dohme Corp.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Merck Sharp & Dohme Corp.",
            "OversightAuthority": "Yes",
            "BriefSummary": "To establish a new treatment option for treatment-naïve participants with HIV-1, the\r\n\r\n      efficacy and safety of doravirine will be determined relative to a protease inhibitor (PI).\r\n\r\n      Participants will receive double-blind treatment d",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "December 2014",
            "CompletionDate": "September 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Merck Sharp & Dohme Corp.",
            "StudyCondition": "HIV-1",
            "Enrollment": "680",
            "InterventionKeyword": "Ritonavir, Darunavir, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Lamivudine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Is HIV-1 positive and has HIV treatment indicated based on physician assessment.\r\n\r\n\r\n\r\n          -  Has received no (0 days of) antiretroviral therapy (ART), including investigational\r\n\r\n             an",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "VerificationDate": "October 2016",
            "LastChanged": "October 19, 2016",
            "FirstReceived": "October 23, 2014",
            "OverallOfficial": "Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Merck Sharp & Dohme Corp.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02275780",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150154 - Merck & Co. - Castro",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20150154",
            "StudyNumber": "20150154 - Merck & Co. - Castro",
            "StudyTitle": "A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical\nTrial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily\nVersus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in\nCombination with TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1\nInfected Subjects",
            "PIID": "233",
            "PicNum": "C00432804",
            "PILastName": "Castro",
            "PIFirstName": "Jose",
            "CoodCNbr": "C00548607",
            "CoordLastName": "Salvarrey",
            "CoordFirstName": "Annie",
            "CoordEmail": "als215@miami.edu",
            "CoordPhone": "+1 (305) 243-4668",
            "EnteredByCNbr": "C00432804",
            "EnteredByLastName": "Castro",
            "EnteredByFirstName": "Jose",
            "ActiveEnrollingDate": "06/29/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/29/2015",
            "IRBApprovedFrom": "04/20/2015",
            "IRBApprovedTo": "04/03/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Merck & Co.",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "10",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "5",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "6",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Kenia Moreno,Tom Tanner",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02275780",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02277990",
            "BriefTitle": "World-wide Randomized Antibiotic Envelope Infection Prevention Trial",
            "OfficialTitle": "Cardiovascular Implantable Electronic Device (CIED) Antibiotic Envelope Infection Prevention Trial",
            "LeadSponsorClass": "Medtronic Cardiac Rhythm and Heart Failure",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Medtronic Cardiac Rhythm and Heart Failure",
            "OversightAuthority": "Yes",
            "BriefSummary": "Medtronic , Inc. is sponsoring the World-wide Randomized Antibiotic Envelope Infection\r\n\r\n      Prevention Trial (WRAP-IT), a randomized, prospective, multi-center, single blinded,\r\n\r\n      post-market, interventional clinical study. This study",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2015",
            "CompletionDate": "July 2018",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "Medtronic Cardiac Rhythm and Heart Failure",
            "StudyCondition": "CIED Related Infection",
            "studyLocation": "Alaska Heart Institute",
            "Enrollment": "7764",
            "MeshKeyword": "Infection, Communicable Diseases,",
            "InterventionKeyword": "Anti-Bacterial Agents,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patient is willing to sign and date the study PIC form\r\n\r\n\r\n\r\n          -  Patient is at least 18 years of age and meets age requirements per local law\r\n\r\n\r\n\r\n          -  Patient is planned to undergo a",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Anchorage",
            "State": "Alaska",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 31, 2016",
            "FirstReceived": "October 22, 2014",
            "OverallOfficial": "Bruce Wilkoff, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "The Cleveland Clinic",
            "LocationStatus": "Enrolling by invitation",
            "LocationName": "Alaska Heart Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02277990",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150065 - Medtronic - Carrillo",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20150065",
            "StudyNumber": "20150065 - Medtronic - Carrillo",
            "StudyTitle": "World-wide Randomized Antibiotic Envelope Infection Prevention Trial.  (WRAP-IT)",
            "PIID": "1975",
            "PicNum": "C00394135",
            "PILastName": "Carrillo",
            "PIFirstName": "Roger",
            "CoodCNbr": "C06989384",
            "CoordLastName": "Khan",
            "CoordFirstName": "Rosa",
            "CoordEmail": "ekhan@med.miami.edu",
            "CoordPhone": "3056892780",
            "EnteredByCNbr": "C00394135",
            "EnteredByLastName": "Carrillo",
            "EnteredByFirstName": "Roger",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "04/20/2015",
            "IRBApprovedFrom": "04/20/2015",
            "IRBApprovedTo": "04/19/2016",
            "Expr1": "Phase IV",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "Medtronic",
            "SiteSampleSize": "UMMG:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Raiza Salceda,Rosa Khan",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT02277990",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02279498",
            "BriefTitle": "SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis",
            "OfficialTitle": "A Phase 3, Randomized, Open-Label, Assessor-Blind, Noninferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency",
            "LeadSponsorClass": "Anthera Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Anthera Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "Liprotamase powder is a non-porcine, soluble and stable mixture of three digestive enzymes\r\n\r\n      including lipase, protease, and amylase. The purpose of the present study is to provide\r\n\r\n      additional efficacy and safety data compared to",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "June 2015",
            "CompletionDate": "May 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Anthera Pharmaceuticals",
            "StudyCondition": "Exocrine Pancreatic Insufficiency",
            "studyLocation": "Investigator Site 123",
            "Enrollment": "126",
            "MeshKeyword": "Fibrosis, Cystic Fibrosis, Exocrine Pancreatic Insufficiency,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of Cystic Fibrosis based on presentation, genotype and/or sweat chloride\r\n\r\n\r\n\r\n          -  Fecal elastase <100 mcg/g stool\r\n\r\n\r\n\r\n          -  Minimum Coefficient of Fat (CFA) at screening wh",
            "EligibleGender": "All",
            "MinAge": "7 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Long Beach",
            "State": "California",
            "Zip": "90806",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "August 30, 2016",
            "FirstReceived": "October 28, 2014",
            "LocationName": "Investigator Site 123",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02279498",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150787 - Anthera Pharmaceuticals Inc. - Salathe",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20150787",
            "StudyNumber": "20150787 - Anthera Pharmaceuticals Inc. - Salathe",
            "StudyTitle": "saA Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Pancreatic Insufficiency",
            "PIID": "528",
            "PicNum": "C00319179",
            "PILastName": "Salathe",
            "PIFirstName": "Matthias",
            "CoodCNbr": "C08116061",
            "CoordLastName": "Graham-Borras",
            "CoordFirstName": "Patricia",
            "CoordEmail": "pgraham1@med.miami.edu",
            "CoordPhone": "305-243-9478",
            "EnteredByCNbr": "C00319179",
            "EnteredByLastName": "Salathe",
            "EnteredByFirstName": "Matthias",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "12/14/2015",
            "IRBApprovedFrom": "12/14/2015",
            "IRBApprovedTo": "12/13/2016",
            "Expr1": "Phase III",
            "Tarea": "Cystic Fibrosis (CF)",
            "TareaCode": "13442",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Anthera Pharmaceuticals Inc.",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Patricia Rebolledo,Lilian Cadet,Carolina Aguiar,Patricia Graham-Borras,Johana Arana,Eliana Mendes",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02279498",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02279888",
            "BriefTitle": "CardioMEMS HF System Post Approval Study",
            "OfficialTitle": "CardioMEMS HF System Post Approval Study",
            "LeadSponsorClass": "St. Jude Medical",
            "SponsorAgency": "Industry",
            "LeadSponsor": "St. Jude Medical",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of the CardioMEMS HF System Post Approval Study (PAS) is to evaluate the use of\r\n\r\n      the CardioMEMS HF System in patients with NYHA class III heart failure in a commercial\r\n\r\n      setting.",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2015",
            "CompletionDate": "June 2020",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "St. Jude Medical",
            "StudyCondition": "Heart Failure",
            "studyLocation": "West Virginia Heart Institute",
            "Enrollment": "1200",
            "NctKeyword": "Pulmonary Artery Pressure Monitoring, Implantable Hemodynamic Monitor,",
            "MeshKeyword": "Heart Failure,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of NYHA class III heart failure\r\n\r\n\r\n\r\n          -  At least 1 heart failure hospitalization within previous 12 months\r\n\r\n\r\n\r\n          -  Patients with reduced LVEF heart failure should be rec",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Morgantown",
            "State": "West Virginia",
            "Zip": "26505",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 6, 2016",
            "FirstReceived": "October 29, 2014",
            "OverallOfficial": "Lynne Stevenson, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Brigham and Women's",
            "ContactName": "Susan Neville",
            "ContactPhone": "678-651-2326",
            "ContactEmail": "sneville@sjm.com",
            "LocationStatus": "Recruiting",
            "LocationName": "West Virginia Heart Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02279888",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150018 - St. Jude Medical - Chaparro",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20150018",
            "StudyNumber": "20150018 - St. Jude Medical - Chaparro",
            "StudyTitle": "CardioMEMS HF System Post Approval Study",
            "PIID": "735",
            "PicNum": "C06969678",
            "PILastName": "Chaparro",
            "PIFirstName": "Sandra",
            "CoodCNbr": "C00059801",
            "CoordLastName": "Hudson",
            "CoordFirstName": "Laura",
            "CoordEmail": "LJHudson@med.miami.edu",
            "CoordPhone": "3052435678",
            "EnteredByCNbr": "C06969678",
            "EnteredByLastName": "Chaparro",
            "EnteredByFirstName": "Sandra",
            "ActiveEnrollingDate": "08/26/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/26/2015",
            "IRBApprovedFrom": "05/08/2015",
            "IRBApprovedTo": "05/04/2017",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "St. Jude Medical",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "14",
            "Totalaccrued": "14",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "9",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "14",
            "FirstNinety": "3",
            "SiteSampleSize": "UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carmen Baez-Garcia,Barbara Lang",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02279888",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02281084",
            "BriefTitle": "Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes",
            "OfficialTitle": "A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group to Evaluate the Efficacy and Safety of Cc-486 (Oral Azacitidine) Alone in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve a",
            "LeadSponsorClass": "Celgene",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Celgene",
            "OversightAuthority": "Yes",
            "BriefSummary": "Evaluate the safety and efficacy of CC-486 and Durvalumab in Subjects with Myelodysplastic\r\n\r\n      Syndromes who failed to achieve an objective response post iHMA treatment",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2015",
            "CompletionDate": "January 2019",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Celgene",
            "StudyCondition": "Myelodysplastic Syndromes",
            "studyLocation": "Yale University",
            "Enrollment": "194",
            "NctKeyword": "myelodysplastic syndromes, MDS, azacitidine, oral azacitidine (CC-486), decitabine, intermediate-1, intermediate-2 and high risk myelodysplastic syndromes (MDS), proliferative chronic myelomonocytic leukemia (CMML), Durvalumab, MEDI4736, hronic, Durvaluma",
            "MeshKeyword": "Syndrome, Myelodysplastic Syndromes, Preleukemia,",
            "InterventionKeyword": "Azacitidine, Decitabine, Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Male or female, ≥ 18 years of age at the time of signing the informed consent\r\n\r\n             document\r\n\r\n\r\n\r\n          2. Documented diagnosis of MDS (MYELODYSPLASTIC SYNDROMES), classified according to",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "New Haven",
            "State": "Connecticut",
            "Zip": "06520",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "October 21, 2014",
            "OverallOfficial": "DU Lam, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Celgene",
            "ContactName": "Associate Director, Clinical Trial Disclosure",
            "ContactPhone": "1-888-260-1599",
            "ContactEmail": "clinicaltrialdisclosure@celgene.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Yale University",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02281084",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160240 - Celgene Corporation - Watts",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160240",
            "StudyNumber": "20160240 - Celgene Corporation - Watts",
            "StudyTitle": "A PHASE 2, INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) ALONE AND IN COMBINATION WITH DURVALUMAB (MEDI4736) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTION OR DECITABINE",
            "PIID": "22711",
            "PicNum": "C11915545",
            "PILastName": "Watts",
            "PIFirstName": "Justin",
            "CoodCNbr": "C11908603",
            "CoordLastName": "Pallapati",
            "CoordFirstName": "Rachel",
            "CoordEmail": "rpallapati@med.miami.edu",
            "EnteredByCNbr": "C07181703",
            "EnteredByLastName": "Zhang",
            "EnteredByFirstName": "Lei",
            "ActiveEnrollingDate": "12/02/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/02/2016",
            "IRBApprovedFrom": "05/03/2016",
            "IRBApprovedTo": "03/19/2017",
            "AccountNbr": "667869",
            "DiseaseSiteListDesc": "Leukemia, Other",
            "Expr1": "Phase II",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Nohelia Gonzalez,Micaela Martinez,Vivin Mohan",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02281084",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02284217",
            "BriefTitle": "An Evaluation of Non-invasive ICP Monitoring in Patients Undergoing Invasive ICP Monitoring Via an External Ventricular Drainage (EVD) Device",
            "OfficialTitle": "A Prospective, Open-Label, Non-Randomized, Comparative Study Designed to Evaluate the Accuracy and Safety of HS-1000 Device, a Non-Invasive Intracranial Pressure (ICP) Monitor, in Patients Undergoing Invasive ICP Monitoring Procedure for Various Clinical",
            "LeadSponsorClass": "HeadSense Medical",
            "SponsorAgency": "Industry",
            "LeadSponsor": "HeadSense Medical",
            "OversightAuthority": "Yes",
            "BriefSummary": "Invasive intracranial pressure (ICP) monitoring is highly effective, but involves risks.\r\n\r\n      HS-1000 measures ICP non-invasively by assessing the acoustic properties of the patient's\r\n\r\n      head. HS-1000 device, a proprietary new non-inva",
            "Description": "HS-1000 device, a proprietary new non-invasive ICP monitor, is expected to safely and\r\n\r\n      accurately monitor ICP with minimal discomfort to patients, and provide information about\r\n\r\n      normal or elevated ICP levels to the physicians",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2014",
            "CompletionDate": "January 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "HeadSense Medical",
            "StudyCondition": "Presence of High Intracranial Pressure",
            "studyLocation": "University of Miami Hospital",
            "Enrollment": "100",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Adult men and women subjects, aged 18 years old and over at screening visit\r\n\r\n\r\n\r\n          -  Patients undergoing invasive ICP monitoring via an external ventricular drainage\r\n\r\n             (EVD) devi",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 27, 2016",
            "FirstReceived": "November 3, 2014",
            "OverallOfficial": "Alessandro Olivi, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "The Johns Hopkins Hospital",
            "ContactName": "Nichol McBee, MPH, CCRP",
            "ContactPhone": "(410) 614-6996",
            "ContactEmail": "nmcbee@jhmi.edu",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "University of Miami Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02284217",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140877 - HeadSense Medical Ltd. - Ginzburg",
            "FileProcessContentId": "440",
            "Division": "Surgery",
            "StdyDivision": "7805",
            "EprostNbr": "20140877",
            "StudyNumber": "20140877 - HeadSense Medical Ltd. - Ginzburg",
            "StudyTitle": "An evaluation of non-invasive ICP monitoring in patients undergoing invasive ICP monitoring via an external ventricular drainage (EVD) device",
            "PIID": "2219",
            "PicNum": "C00609118",
            "PILastName": "Ginzburg",
            "PIFirstName": "Enrique",
            "CoodCNbr": "C00610103",
            "CoordLastName": "Manning",
            "CoordFirstName": "Ronald",
            "CoordEmail": "rmanning@med.miami.edu",
            "CoordPhone": "3053554972",
            "EnteredByCNbr": "C00609118",
            "EnteredByLastName": "Ginzburg",
            "EnteredByFirstName": "Enrique",
            "ActiveEnrollingDate": "09/28/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/28/2015",
            "IRBApprovedFrom": "04/07/2015",
            "IRBApprovedTo": "04/04/2017",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "HeadSense Medical Ltd.",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "5",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "4",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Ronald Manning,Olga Orozco",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02284217",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT02289950",
            "BriefTitle": "A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer",
            "OfficialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA12",
            "LeadSponsorClass": "Morphotek",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Morphotek",
            "OversightAuthority": "Yes",
            "BriefSummary": "MORAb-003-011 is a global, multicenter, double-blind, randomized placebo-controlled study to\r\n\r\n      assess the safety and efficacy of farletuzumab in combination with standard chemotherapy in\r\n\r\n      subjects with low CA125 platinum sensitive",
            "Description": "Subjects will be enrolled in a targeted 1:1 stratification ratio into 1 of 2 chemotherapy\r\n\r\n      treatment arms at the investigator's discretion: carboplatin plus paclitaxel or carboplatin\r\n\r\n      plus Pegylated Liposomal Doxorubicin (PLD), a",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2015",
            "CompletionDate": "May 2020",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Morphotek",
            "StudyCondition": "Platinum-Sensitive Ovarian Cancer in First Relapse",
            "Enrollment": "210",
            "NctKeyword": "Ovarian Cancer in in first relapse, Platinum-Sensitive,",
            "MeshKeyword": "Ovarian Neoplasms, Recurrence, Hypersensitivity,",
            "InterventionKeyword": "Paclitaxel, Liposomal doxorubicin, Doxorubicin, Carboplatin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Female subjects who are at least 18 years of age at the time of informed consent\r\n\r\n\r\n\r\n          2. CA125 less than or equal to 3 x upper limit of normal (ULN) (10^5 U/mL) confirmed\r\n\r\n             with",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 23, 2016",
            "FirstReceived": "November 10, 2014",
            "ContactName": "Susan C Weil",
            "ContactPhone": "610-423-6182",
            "ContactEmail": "weil@morphotek.com",
            "LocationStatus": "Withdrawn",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02289950",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150201 - Morphotek - Slomovitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150201",
            "StudyNumber": "20150201 - Morphotek - Slomovitz",
            "StudyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Placlitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer",
            "PIID": "22712",
            "PicNum": "C11916703",
            "PILastName": "Slomovitz",
            "PIFirstName": "Brian",
            "CoodCNbr": "C12022809",
            "CoordLastName": "Habibi Khameneh",
            "CoordFirstName": "Negin",
            "CoordEmail": "negin.khameneh@med.miami.edu",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "11/25/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/25/2015",
            "IRBApprovedFrom": "10/06/2015",
            "IRBApprovedTo": "10/05/2016",
            "AccountNbr": "665818",
            "DiseaseSiteListDesc": "Ovary",
            "Expr1": "Phase II",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Morphotek",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "4",
            "Totalaccrued": "3",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMD:N/A,UMHC:N/A,UMMG:N/A,Plantation:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Isabel Moya,Halyna Hailes,Penny Eyer,Claudia Grandas Moreno,Evan Dadas,Mohammad El-Sorady",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02289950",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02291055",
            "BriefTitle": "Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer",
            "OfficialTitle": "Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer",
            "LeadSponsorClass": "Advaxis, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Advaxis, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "Part A: (ADXS11-001 + MEDI4736 Combination Therapy) will determine the safety and\r\n\r\n      tolerability of the combination and to identify a RP2D.\r\n\r\n\r\n\r\n      Part B:\r\n\r\n\r\n\r\n      Phase 2 design which will randomize subjects 1:1 to either MEDI4",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2015",
            "CompletionDate": "December 2019",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Advaxis, Inc.",
            "StudyCondition": "Cervical Cancer",
            "studyLocation": "Not Yet Recruiting",
            "Enrollment": "66",
            "MeshKeyword": "Head and Neck Neoplasms, Uterine Cervical Neoplasms,",
            "InterventionKeyword": "Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Have histological diagnosis of squamous cell cancer of the head & neck with\r\n\r\n             confirmation of HPV positivity or squamous, non-squamous, adenosquamous, carcinoma or\r\n\r\n             adenocarc",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 18, 2017",
            "FirstReceived": "November 6, 2014",
            "ContactName": "Advaxis Hotline",
            "ContactPhone": "844-783-1529",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "Not Yet Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02291055",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150446 - Adavaxis - Slomovitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150446",
            "StudyNumber": "20150446 - Adavaxis - Slomovitz",
            "StudyTitle": "Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or in Combination in Recurrent/Metastatic Cervical or HPV+ Head & Neck Cancer",
            "PIID": "22712",
            "PicNum": "C11916703",
            "PILastName": "Slomovitz",
            "PIFirstName": "Brian",
            "CoodCNbr": "C00349551",
            "CoordLastName": "Blackburn",
            "CoordFirstName": "Karen",
            "CoordEmail": "k.blackburn@med.miami.edu",
            "CoordPhone": "3052430863",
            "EnteredByCNbr": "C11917328",
            "EnteredByLastName": "Englund",
            "EnteredByFirstName": "Kristen",
            "ActiveEnrollingDate": "08/14/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/14/2015",
            "IRBApprovedFrom": "06/22/2015",
            "IRBApprovedTo": "02/23/2017",
            "AccountNbr": "665389",
            "DiseaseSiteListDesc": "Lip, Oral Cavity and Pharynx,Cervix",
            "Expr1": "Phase I",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Advaxis",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "11",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "11",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Yvonne Dinh,Juan Salvador,Daniel Sumarriva,Sandra Pineda,Tamara Leon Aliz",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02291055",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02291549",
            "BriefTitle": "RESOLVE II Clinical Evaluation of Safety and Efficacy of S8 Sinus Implant in Chronic Sinusitis Patients",
            "OfficialTitle": "RESOLVE II: A Clinical Evaluation of the Safety and Efficacy of the Steroid-Releasing S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Sinus Obstruction",
            "LeadSponsorClass": "Intersect ENT",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Intersect ENT",
            "OversightAuthority": "No",
            "BriefSummary": "The RESOLVE II Study will assess the safety and efficacy of the steroid-releasing S8 Sinus\r\n\r\n      Implant when used in post-sinus surgery patients who present with recurrent sinus\r\n\r\n      obstruction. This is a randomized, single-blind, paral",
            "OverallStatus": "Completed",
            "StartDate": "December 2014",
            "CompletionDate": "October 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Intersect ENT",
            "StudyCondition": "Chronic Sinusitis",
            "studyLocation": "The University of Alabama Birmingham",
            "Enrollment": "300",
            "MeshKeyword": "Sinusitis, Chronic Disease, Nasal Polyps,",
            "Eligibility": "Adult patients (age ≥ 18 years) diagnosed with chronic sinusitis who underwent prior\r\n\r\n        bilateral total ethmoidectomy but are currently indicated for repeat Endoscopic Sinus\r\n\r\n        Surgery because they present with recurrent sympto",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 13, 2016",
            "FirstReceived": "November 11, 2014",
            "OverallOfficial": "Robert Kern, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Northwestern Medical Faculty Foundation, Department of Otolaryngology",
            "LocationName": "The University of Alabama Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02291549",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150155 - Intersect ENT - Casiano",
            "FileProcessContentId": "440",
            "Division": "Otolaryngology",
            "StdyDivision": "10136",
            "EprostNbr": "20150155",
            "StudyNumber": "20150155 - Intersect ENT - Casiano",
            "StudyTitle": "A Clinical Evaluation of the Safety and Efficacy of the Steroid Releasing S8 Sinus Implant in Chronic Sinusitis Patients with Recurrent Sinus Obstruction",
            "PIID": "319",
            "PicNum": "C00002487",
            "PILastName": "Casiano",
            "PIFirstName": "Roy",
            "CoodCNbr": "C06931201",
            "CoordLastName": "Pelusso",
            "CoordFirstName": "Constanza",
            "CoordEmail": "cpelusso@med.miami.edu",
            "CoordPhone": "3052431653",
            "EnteredByCNbr": "C00002487",
            "EnteredByLastName": "Casiano",
            "EnteredByFirstName": "Roy",
            "ActiveEnrollingDate": "01/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/08/2016",
            "IRBApprovedFrom": "05/19/2015",
            "IRBApprovedTo": "05/16/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Intersect ENT",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "2",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Constanza Pelusso",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02291549",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02292706",
            "SecondaryId": "2014-001249-26",
            "BriefTitle": "A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection",
            "OfficialTitle": "A Registry for Subjects With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "This Registry will enroll cirrhotic participants with or without decompensated liver disease\r\n\r\n      who have achieved a sustained virologic response (SVR) after receiving a sofosbuvir\r\n\r\n      (SOF)-based regimen without interferon (IFN) while",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "December 2014",
            "CompletionDate": "November 2022",
            "Phase": "N/A",
            "StudyType": "Observational [Patient Registry]",
            "StudyPhase": "N/A",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "Hepatitis C Virus Infection",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "2000",
            "NctKeyword": "HCV Cirrhosis registry, Cirrhosis, Hepatitis C,",
            "MeshKeyword": "Infection, Communicable Diseases, Hepatitis, Hepatitis A, Hepatitis C, Hepatitis, Chronic, Hepatitis C, Chronic, Fibrosis, Liver Cirrhosis, Virus Diseases,",
            "InterventionKeyword": "Interferons, Sofosbuvir,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Willing and able to provide written informed consent\r\n\r\n\r\n\r\n          -  Have either previously participated in a Gilead-sponsored HCV study and received a\r\n\r\n             sofosbuvir-containing regimen w",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "3084",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 21, 2016",
            "FirstReceived": "November 13, 2014",
            "OverallOfficial": "Theo Brandt-Sarif, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02292706",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150013 - Gilead - Schiff",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150013",
            "StudyNumber": "20150013 - Gilead - Schiff",
            "StudyTitle": "GS-US-337-1431 - A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C00758491",
            "EnteredByLastName": "Schiff",
            "EnteredByFirstName": "Eugene",
            "ActiveEnrollingDate": "07/07/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/07/2015",
            "IRBApprovedFrom": "02/02/2015",
            "IRBApprovedTo": "12/18/2017",
            "DiseaseSiteListDesc": "Liver",
            "Expr1": "N/A",
            "Tarea": "Pancreatic, Liver, and Related Cancers",
            "TareaCode": "12443",
            "Expr2": "Screening",
            "StudyType_Code": "6181",
            "ResearchType": "Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Gilead",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "37",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "37",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Maria Onate-Silva",
            "NationalSampleSize": "50",
            "NCTNbr": "NCT02292706",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02296801",
            "SecondaryId": "WI180455",
            "BriefTitle": "A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer",
            "OfficialTitle": "A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer",
            "LeadSponsorClass": "NSABP Foundation Inc",
            "SponsorAgency": "Other",
            "LeadSponsor": "NSABP Foundation Inc",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will look at effects the combination of palbociclib and letrozole may have on\r\n\r\n      estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative\r\n\r\n      breast cancer tumors which have not yet been trea",
            "Description": "The FB-11 study is a Phase II, randomized, open label, four arm study to examine the\r\n\r\n      biological and clinical effect of neoadjuvant letrozole with or without palbociclib in the\r\n\r\n      first-line treatment of estrogen-receptor (ER) posi",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2015",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "NSABP Foundation Inc",
            "StudyCondition": "Breast Cancer",
            "studyLocation": "Long Beach Memorial Medical Center-Todd Cancer Institute",
            "Enrollment": "306",
            "MeshKeyword": "Breast Neoplasms,",
            "InterventionKeyword": "Letrozole, Palbociclib, Estrogens,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must be postmenopausal women defined as: Age 56 or older with no spontaneous\r\n\r\n             menses for at least 12 months prior to study entry; or Age 55 or younger with no\r\n\r\n             mens",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Long Beach",
            "State": "California",
            "Zip": "90806",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "June 15, 2016",
            "FirstReceived": "November 18, 2014",
            "OverallOfficial": "Norman Wolmark, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "NSABP Foundation Inc",
            "ContactName": "Diana Gosik, RN, BS",
            "ContactPhone": "412-339-5333",
            "ContactEmail": "diana.gosik@nsabp.org",
            "LocationStatus": "Recruiting",
            "LocationName": "Long Beach Memorial Medical Center-Todd Cancer Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02296801",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160452 - NSABP - Mani",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160452",
            "StudyNumber": "20160452 - NSABP - Mani",
            "StudyTitle": "A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib with Letrozole as Neoadjuvant Therapy in Post-Menopausal Women with Estrogen-Receptor Positive Primary Breast Cancer",
            "PIID": "25266",
            "PicNum": "C11971128",
            "PILastName": "Mani",
            "PIFirstName": "Aruna",
            "CoodCNbr": "C12024030",
            "CoordLastName": "Conte",
            "CoordFirstName": "Deborah",
            "CoordEmail": "dmc238@med.miami.edu",
            "CoordPhone": "954-830-2360",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "11/17/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/17/2016",
            "IRBApprovedFrom": "08/05/2016",
            "IRBApprovedTo": "07/27/2017",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase II",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "NSABP",
            "SiteSampleSize": "UMD:N/A,UMMG:N/A,UMHC:N/A,UM Kendall:N/A,Plantation:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Michelle Mikhail,Evan Dadas,Penny Eyer,Sarah Raybin,Halyna Hailes,Anthony Minichiello,Cristina Rojas-Mejia,Onaidy Torres",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02296801",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02297698",
            "BriefTitle": "Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients",
            "OfficialTitle": "Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients",
            "LeadSponsorClass": "Cancer Insight, LLC",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Cancer Insight, LLC",
            "OversightAuthority": "Yes",
            "BriefSummary": "This will be a multi-center, prospective, randomized, single-blinded, placebo-controlled\r\n\r\n      phase II trial of trastuzumab + nelipepimut-S/GM-CSF versus trastuzumab + GM-CSF alone. Our\r\n\r\n      target study population is high-risk HER2-posi",
            "Description": "In this study, the investigators intend to assess the ability of the combination of\r\n\r\n      trastuzumab and the HER2 vaccine nelipepimut-S (administered with the immunoadjuvant GM-CSF)\r\n\r\n      given in the adjuvant setting to prevent recurrenc",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2014",
            "CompletionDate": "October 2019",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Cancer Insight, LLC",
            "StudyCondition": "Breast Cancer",
            "studyLocation": "Alliance Research Centers",
            "Enrollment": "100",
            "NctKeyword": "Breast cancer, NeuVax,",
            "MeshKeyword": "Breast Neoplasms,",
            "InterventionKeyword": "Vaccines, Trastuzumab,",
            "Eligibility": "Inclusion criteria:\r\n\r\n\r\n\r\n          -  18 years or older\r\n\r\n\r\n\r\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0,1\r\n\r\n\r\n\r\n          -  AJCC stage I - III non-inflammatory, HER2-positive (according to ASCO-CAP guidel",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Laguna Hills",
            "State": "California",
            "Zip": "92653",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 5, 2017",
            "FirstReceived": "November 14, 2014",
            "OverallOfficial": "COL (ret) George E Peoples, MD, FACS",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Cancer Insight, LLC",
            "ContactName": "Karen Arrington, RN, BSN, CCRP",
            "ContactPhone": "210-243-5711",
            "ContactEmail": "karrington@cancerinsight.com",
            "LocationStatus": "Withdrawn",
            "LocationName": "Alliance Research Centers",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02297698",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150974 - Cancer Insight LLC - Calfa",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150974",
            "StudyNumber": "20150974 - Cancer Insight LLC - Calfa",
            "StudyTitle": "Phase II Trial of Combination Immunotherapy with nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in high-risk HER2+ Breast Cancer Patients",
            "PIID": "25231",
            "PicNum": "C00214960",
            "PILastName": "Calfa",
            "PIFirstName": "Carmen",
            "CoodCNbr": "C12024030",
            "CoordLastName": "Conte",
            "CoordFirstName": "Deborah",
            "CoordEmail": "dmc238@med.miami.edu",
            "CoordPhone": "954-830-2360",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "06/21/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/21/2016",
            "IRBApprovedFrom": "05/10/2016",
            "IRBApprovedTo": "10/02/2016",
            "AccountNbr": "666762",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase II",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Expr2": "Prevention",
            "StudyType_Code": "6163",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "cancer Insight, LLC",
            "Prescreened": "1",
            "Screenedfailed": "1",
            "SignedICF": "4",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "3",
            "Totalpatients": "5",
            "FirstNinety": "1",
            "SiteSampleSize": "UMD:N/A,UM Hollywood:N/A,UMHC:N/A,UMMG:N/A,UM Coral Springs:N/A,UM Kendall:N/A,Plantation:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Penny Eyer,Halyna Hailes,Anthony Minichiello,Onaidy Torres,Sarah Raybin,Evan Dadas,Cristina Rojas-Mejia,Michelle Liendo",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT02297698",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02299570",
            "BriefTitle": "Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection",
            "OfficialTitle": "A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection",
            "LeadSponsorClass": "Rebiotix Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Rebiotix Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is the first prospective, multi-center, double-blinded, randomized controlled study of\r\n\r\n      a microbiota suspension derived from intestinal microbes. Patients who have had at least two\r\n\r\n      recurrences of C. difficile infection (CDI",
            "Description": "This is the first prospective, multi-center, double-blinded, randomized controlled study of\r\n\r\n      a microbiota suspension derived from intestinal microbes. The primary assessments for this\r\n\r\n      study are (i) efficacy of RBX2660 compared t",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "November 2014",
            "CompletionDate": "December 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Rebiotix Inc.",
            "StudyCondition": "Enterocolitis Clostridium Difficile Recurrent",
            "studyLocation": "Mayo Clinic Arizona",
            "Enrollment": "117",
            "NctKeyword": "Clostridium difficile, C diff, CDI, CDAD, Fecal transplant, Fecal Microbiota Transplant, Diarrhea, FMT, Microbiota restoration therapy, Microbiota suspension, Fecal bacteriotherapy, C diff diarrhea,",
            "MeshKeyword": "Enterocolitis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  ≥ 18 years\r\n\r\n\r\n\r\n          -  Medical record documentation of recurrent CDI either: a) at least two recurrences\r\n\r\n             after a primary episode and has completed at least two rounds of standard-",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85054",
            "Country": "United States",
            "VerificationDate": "August 2015",
            "LastChanged": "May 9, 2016",
            "FirstReceived": "November 19, 2014",
            "OverallOfficial": "Teena Chopra, MD MPH",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Wayne State University",
            "LocationName": "Mayo Clinic Arizona",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02299570",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150560 - Rebiotix Inc - Kerman",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20150560",
            "StudyNumber": "20150560 - Rebiotix Inc - Kerman",
            "StudyTitle": "An Open-label Safety Assessment of Rebiotix RBX2660 (microbiota suspension) for the Treatment of Recurrent Clostridium difficile Infection",
            "PIID": "652",
            "PicNum": "C04244223",
            "PILastName": "Kerman",
            "PIFirstName": "David",
            "CoodCNbr": "C11914779",
            "CoordLastName": "Carabali",
            "CoordFirstName": "Francia",
            "CoordEmail": "fxc123@miami.edu",
            "EnteredByCNbr": "C04244223",
            "EnteredByLastName": "Kerman",
            "EnteredByFirstName": "David",
            "ActiveEnrollingDate": "05/09/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/09/2016",
            "IRBApprovedFrom": "09/21/2015",
            "IRBApprovedTo": "08/28/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Rebiotix Inc",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diana Morillo,Francia Carabali",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02299570",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02303444",
            "SecondaryId": "NX1401",
            "BriefTitle": "An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors",
            "OfficialTitle": "RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors",
            "LeadSponsorClass": "Bayer",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Bayer",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of the study is to assess the use of Multikinase Inhibitors (MKIs) in the\r\n\r\n      treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory\r\n\r\n      to radioactive iodine (RAI) who do not have any sy",
            "Description": "The primary objective of this study is to compare time to symptomatic progression (TTSP)\r\n\r\n      from study entry in asymptomatic patients with RAI-refractory progressive DTC for whom there\r\n\r\n      is a decision to initiate MKIs at study entry",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2015",
            "CompletionDate": "March 2019",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Bayer",
            "StudyCondition": "Thyroid Neoplasms",
            "Enrollment": "700",
            "NctKeyword": "Progressive radioactive iodine refractory differentiated thyroid carcinoma,",
            "MeshKeyword": "Thyroid Diseases, Thyroid Neoplasms,",
            "InterventionKeyword": "Sorafenib, Iodine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Histologically/cytologically documented DTC (papillary, follicular, Hurthle cell, and\r\n\r\n             poorly differentiated carcinoma)\r\n\r\n\r\n\r\n          -  DTC refractory to RAI\r\n\r\n\r\n\r\n          -  Radiol",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 16, 2017",
            "FirstReceived": "November 25, 2014",
            "OverallOfficial": "Bayer Study Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Bayer",
            "ContactName": "Bayer Clinical Trials Contact",
            "ContactEmail": "clinical-trials-contact@bayer.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02303444",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160142 - Bayer Health Care - Ikpeazu",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160142",
            "StudyNumber": "20160142 - Bayer Health Care - Ikpeazu",
            "StudyTitle": "RIFTOS MKI - RADIOACTIVE IODINE REFRACTORY ASYMPTOMATIC PATIENTS IN DIFFERENTIATED THYROID CANCER – AN OBSERVATIONAL STUDY TO ASSESS THE USE OF MULTIKINASE INHIBITORS",
            "PIID": "373",
            "PicNum": "C06163680",
            "PILastName": "Ikpeazu",
            "PIFirstName": "Chukwuemeka",
            "CoodCNbr": "C11971258",
            "CoordLastName": "El-Sorady",
            "CoordFirstName": "Mohammad",
            "CoordEmail": "mie25@med.miami.edu",
            "CoordPhone": "954-371-3203",
            "EnteredByCNbr": "C04092184",
            "EnteredByLastName": "Rajakumar",
            "EnteredByFirstName": "Gopal",
            "ActiveEnrollingDate": "08/16/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/16/2016",
            "IRBApprovedFrom": "05/16/2016",
            "IRBApprovedTo": "05/15/2017",
            "AccountNbr": "667405",
            "DiseaseSiteListDesc": "Thyroid",
            "Expr1": "N/A",
            "Tarea": "Thyroid and Other Endocrine Cancers",
            "TareaCode": "12540",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "5",
            "Totalaccrued": "4",
            "InFollowUp": "3",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "4",
            "SiteSampleSize": "UMHC:5,Plantation:N/A,JMH:N/A,UMMG:N/A,UMD:N/A",
            "AccrualPercentageMet": "80",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "5",
            "EprostState": "Approved",
            "StudyCoordinator": "Penny Eyer,Carla Munevar,Marinellie Vega",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02303444",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02303821",
            "SecondaryId": "2014‐001633‐84",
            "BriefTitle": "Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia",
            "OfficialTitle": "Phase 1b Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia",
            "LeadSponsorClass": "Onyx Therapeutics, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Onyx Therapeutics, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of the study is to determine the maximum tolerated dose and assess the safety,\r\n\r\n      tolerability and activity of carfilzomib, alone and in combination with induction\r\n\r\n      chemotherapy, in children with relapsed or refractory",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2014",
            "CompletionDate": "December 2017",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Onyx Pharmaceuticals",
            "StudyCondition": "Acute Lymphoblastic Leukemia (ALL)",
            "studyLocation": "Children's Hospital Los Angeles",
            "Enrollment": "36",
            "MeshKeyword": "Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid,",
            "InterventionKeyword": "Dexamethasone acetate, Hydrocortisone 17-butyrate 21-propionate, Cortisol succinate, Hydrocortisone acetate, Dexamethasone, Hydrocortisone, Dexamethasone 21-phosphate, Pegaspargase, Cytarabine, Cyclophosphamide, Methotrexate, Vincristine, Daunorubicin, As",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age 21 years or younger at the time of initial ALL diagnosis and age > 1 year at the\r\n\r\n             time of study treatment initiation.\r\n\r\n\r\n\r\n          2. Subjects must have a diagnosis of relapsed",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 7, 2016",
            "FirstReceived": "November 20, 2014",
            "OverallOfficial": "Dawn Pinchasik, MS, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Onyx Therapeutics, Inc.",
            "ContactName": "Amgen Call Center",
            "ContactPhone": "866-572-6436",
            "ContactEmail": "medinfo@amgen.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Children's Hospital Los Angeles",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02303821",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140759 - Onyx Therapeutics - Trucco",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140759",
            "StudyNumber": "20140759 - Onyx Therapeutics - Trucco",
            "StudyTitle": "Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia.",
            "PIID": "26577",
            "PicNum": "C12027657",
            "PILastName": "Trucco",
            "PIFirstName": "Matteo",
            "CoodCNbr": "C00110674",
            "CoordLastName": "Zayas",
            "CoordFirstName": "Myriam",
            "CoordEmail": "MZayas2@med.miami.edu",
            "EnteredByCNbr": "C11972191",
            "EnteredByLastName": "Harris",
            "EnteredByFirstName": "Bretinsa",
            "ActiveEnrollingDate": "01/16/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/16/2015",
            "IRBApprovedFrom": "01/16/2015",
            "IRBApprovedTo": "10/11/2017",
            "DiseaseSiteListDesc": "Lymphoid Leukemia",
            "Expr1": "Phase I/II",
            "Tarea": "Pediatric Cancer",
            "TareaCode": "12536",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Onyx Therapeutics, Inc.",
            "SiteSampleSize": "UMMG:N/A,JMH:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT02303821",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02305186",
            "BriefTitle": "Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer",
            "OfficialTitle": "A Randomized Multicenter Phase Ib/II Study to Assess the Safety and the Immunological Effect of Chemoradiation Therapy (CRT) in Combination With Pembrolizumab (MK-3475) Compared to CRT Alone in Patients With Resectable or Borderline Resectable Pancreatic",
            "LeadSponsorClass": "Osama Rahma, MD",
            "SponsorAgency": "Other",
            "LeadSponsor": "Osama Rahma, MD",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this clinical trial is to study an experimental drug called pembrolizumab or\r\n\r\n      MK-3475 for use in combination with chemotherapy and radiation therapy for patients with\r\n\r\n      resectable (surgical removal) or borderline re",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2015",
            "CompletionDate": "June 2019",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "University of Virginia",
            "StudyCondition": "Pancreatic Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "56",
            "NctKeyword": "Immunotherapy, Neoadjuvant, Resectable, Borderline resectable,",
            "MeshKeyword": "Pancreatic Neoplasms,",
            "InterventionKeyword": "Pembrolizumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.\r\n\r\n\r\n\r\n          2. Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)\r\n\r\n             Perf",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "March 2016",
            "LastChanged": "March 23, 2016",
            "FirstReceived": "November 21, 2014",
            "OverallOfficial": "Osama Rahma, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "University of Virginia",
            "ContactName": "Osama Rahma, MD",
            "ContactPhone": "(434) 243-1658",
            "ContactEmail": "or3v@virginia.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02305186",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150434 - Uni of Virginia - Acquavella",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150434",
            "StudyNumber": "20150434 - Uni of Virginia - Acquavella",
            "StudyTitle": "\"A Randomized Multicenter Phase Ib/II study to assess the safety and the immunological effect of chemoradiation  therapy (CRT) in combination with MK-3475 (anti-PD1) to CRT alone in patients with resectable or bordeline resectable pancreatic cancer”.",
            "PIID": "23755",
            "PicNum": "C11919904",
            "PILastName": "Acquavella",
            "PIFirstName": "Nicolas",
            "CoodCNbr": "C11979873",
            "CoordLastName": "Cianferra",
            "CoordFirstName": "Eduardo",
            "CoordEmail": "exc642@miami.edu",
            "CoordPhone": "305-243-1139",
            "EnteredByCNbr": "C12021320",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Paul",
            "ActiveEnrollingDate": "12/10/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/10/2015",
            "IRBApprovedFrom": "07/20/2015",
            "IRBApprovedTo": "07/17/2017",
            "AccountNbr": "665923",
            "DiseaseSiteListDesc": "Pancreas",
            "Expr1": "Phase I/II",
            "Tarea": "Pancreatic, Liver, and Related Cancers",
            "TareaCode": "12443",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "University of Virginia Cancer Center",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "4",
            "Totalaccrued": "2",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Michelle Mikhail",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT02305186",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02307058",
            "BriefTitle": "MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy",
            "OfficialTitle": "A Phase II Randomized Trial of MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy - The Miami BLaStM Trial",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "The BLaStM clinical trial extends the Phase I LEAD trial and compares the LEAD upfront\r\n\r\n      technique for increasing dose to the MP-MRI defined GTVs to the HEIGHT method of using a\r\n\r\n      moderate hypofractionated simultaneous integrated b",
            "Description": "Radiotherapy (RT) is a commonly applied primary (initial definitive) treatment alternative\r\n\r\n      to prostatectomy that allows for preservation of anatomy and the potential for improved\r\n\r\n      functional outcome with better tumor targeting a",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2014",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Prostate Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "164",
            "NctKeyword": "Prostate Cancer,",
            "MeshKeyword": "Prostatic Neoplasms,",
            "Eligibility": "Eligibility Criteria:\r\n\r\n\r\n\r\n          -  A. Biopsy confirmed adenocarcinoma (including ductal) of the prostate.\r\n\r\n\r\n\r\n          -  B. T1-T3 disease based on digital rectal exam.\r\n\r\n\r\n\r\n          -  C. No evidence of metastasis by any clinica",
            "EligibleGender": "Male",
            "MinAge": "35 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 3, 2016",
            "FirstReceived": "December 1, 2014",
            "OverallOfficial": "Alan Pollack, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Alan Pollack, MD, PhD",
            "ContactPhone": "305-243-4916",
            "ContactEmail": "apollack@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02307058",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140627 - Intramural - Pollack",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140627",
            "StudyNumber": "20140627 - Intramural - Pollack",
            "StudyTitle": "A Phase II Randomized Trial of MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy – The Miami BLaStM Trial",
            "PIID": "428",
            "PicNum": "C00452286",
            "PILastName": "Pollack",
            "PIFirstName": "Alan",
            "CoodCNbr": "C12024321",
            "CoordLastName": "Noa Hechavarria",
            "CoordFirstName": "Pavel",
            "CoordEmail": "pavel.noa@med.miami.edu",
            "CoordPhone": "305-243-6809",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "11/24/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/24/2014",
            "IRBApprovedFrom": "11/04/2014",
            "IRBApprovedTo": "10/31/2017",
            "DiseaseSiteListDesc": "Prostate",
            "Expr1": "Phase II",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "49",
            "Totalaccrued": "42",
            "InFollowUp": "35",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "49",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "4",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Doris Martin,Zaida Abreu,Fernando Vazquez Pascual,Lilibet Zamora Cabezas,Lilly Sanchez,Greeyt Hernandez,Maggie Chislom,Marinellie Vega",
            "NationalSampleSize": "200",
            "NCTNbr": "NCT02307058",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02308085",
            "SecondaryId": "Alliance A221405",
            "BriefTitle": "Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer",
            "OfficialTitle": "A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy",
            "LeadSponsorClass": "International Breast Cancer Study Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "International Breast Cancer Study Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "The best available evidence suggests that pregnancy after breast cancer does not increase a\r\n\r\n      woman's risk of developing a recurrence from her breast cancer. In particular, the most\r\n\r\n      recent data suggest that this is the case also",
            "Description": "Recent decades have witnessed a delay in childbearing for a variety of reasons including\r\n\r\n      cultural, educational, and professional. As a consequence, breast cancer in young women\r\n\r\n      often occurs before the completion of reproductive",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2014",
            "CompletionDate": "December 2028",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "International Breast Cancer Study Group",
            "StudyCondition": "Early Breast Cancer",
            "studyLocation": "Helen F. Graham Cancer Center, 4701 Ogletown-Stanton Road",
            "Enrollment": "500",
            "NctKeyword": "Premenopausal, endocrine responsive, Breast, Pregnancy,",
            "MeshKeyword": "Breast Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Age ≥ 18 and ≤ 42 years at enrollment.\r\n\r\n\r\n\r\n          -  Has received adjuvant endocrine therapy (SERM alone, GnRH analogue plus SERM or AI)\r\n\r\n             for ≥18 months but ≤30 months for early brea",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "42 Years",
            "Volunteers": "No",
            "City": "Newark",
            "State": "Delaware",
            "Zip": "19713",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 30, 2016",
            "FirstReceived": "November 21, 2014",
            "OverallOfficial": "Olivia Pagani, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Oncology Institue of Southern Switzerland (IOSI)",
            "LocationStatus": "Recruiting",
            "LocationName": "Helen F. Graham Cancer Center, 4701 Ogletown-Stanton Road",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02308085",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160146 - IBCSG - Hurley",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160146",
            "StudyNumber": "20160146 - IBCSG - Hurley",
            "StudyTitle": "PREGNANCY OUTCOME AND SAFETY OF INTERRUPTING THERAPY FOR WOMEN WITH ENDOCRINE RESPONSIVE BREAST CANCER",
            "PIID": "372",
            "PicNum": "C00249321",
            "PILastName": "Hurley",
            "PIFirstName": "Judith",
            "CoodCNbr": "C03416430",
            "CoordLastName": "Torres",
            "CoordFirstName": "Onaidy",
            "CoordEmail": "otorres@med.miami.edu",
            "CoordPhone": "3052439503",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "08/05/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/05/2016",
            "IRBApprovedFrom": "04/23/2015",
            "IRBApprovedTo": "02/24/2017",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "N/A",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Cooperative Group",
            "SiteSampleSize": "UMD:N/A,UM Kendall:N/A,UMHC:N/A,UMMG:N/A,Plantation:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Michelle Liendo,Halyna Hailes,Cristina Rojas-Mejia,Anthony Minichiello",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02308085",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02312206",
            "BriefTitle": "The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis",
            "OfficialTitle": "A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis",
            "LeadSponsorClass": "Prothena Therapeutics Ltd.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Prothena Therapeutics Ltd.",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a multi-center, international, randomized, double-blind, placebo-controlled, two-arm\r\n\r\n      efficacy and safety study in subjects newly diagnosed with AL amyloidosis. Subjects will\r\n\r\n      remain on-study until study completion, which",
            "Description": "This is a multi-center, international, randomized, double-blind, placebo-controlled, two-arm\r\n\r\n      efficacy and safety study in subjects newly diagnosed with AL amyloidosis. Approximately 236\r\n\r\n      subjects will be enrolled in ~60 centers,",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2015",
            "CompletionDate": "August 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Prothena Therapeutics Ltd.",
            "StudyCondition": "Primary Systemic (AL) Amyloidosis",
            "studyLocation": "Mayo Clinic Arizona",
            "Enrollment": "236",
            "MeshKeyword": "Amyloidosis,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age ≥ 18 years\r\n\r\n\r\n\r\n          2. Newly diagnosed, AL amyloidosis treatment naïve\r\n\r\n\r\n\r\n          3. Bone marrow consistent with plasma cell dyscrasia\r\n\r\n\r\n\r\n          4. Confirmed diagnosis of AL",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Scottsdale",
            "State": "Arizona",
            "Zip": "85259",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 9, 2016",
            "FirstReceived": "December 2, 2014",
            "ContactName": "Deb Chapman",
            "ContactEmail": "Clinicaltrials@prothena.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Mayo Clinic Arizona",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02312206",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150303 - Prothena Therapeutics - Hoffman",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150303",
            "StudyNumber": "20150303 - Prothena Therapeutics - Hoffman",
            "StudyTitle": "A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis",
            "PIID": "4418",
            "PicNum": "C11465246",
            "PILastName": "Hoffman",
            "PIFirstName": "James",
            "CoodCNbr": "C11908603",
            "CoordLastName": "Pallapati",
            "CoordFirstName": "Rachel",
            "CoordEmail": "rpallapati@med.miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "09/24/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/24/2015",
            "IRBApprovedFrom": "06/02/2015",
            "IRBApprovedTo": "05/02/2017",
            "AccountNbr": "665695",
            "DiseaseSiteListDesc": "Multiple Myeloma",
            "Expr1": "Phase III",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Prothena Therapeutic",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "5",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Micaela Martinez,Vivin Mohan,Penny Eyer",
            "NationalSampleSize": "4",
            "NCTNbr": "NCT02312206",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02315417",
            "BriefTitle": "An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum",
            "OfficialTitle": "A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum",
            "LeadSponsorClass": "XOMA (US) LLC",
            "SponsorAgency": "Industry",
            "LeadSponsor": "XOMA (US) LLC",
            "OversightAuthority": "Yes",
            "BriefSummary": "The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of\r\n\r\n      pyoderma gangrenosum (PG).",
            "OverallStatus": "Terminated",
            "StartDate": "November 2014",
            "CompletionDate": "March 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "XOMA (US) LLC",
            "StudyCondition": "Pyoderma Gangrenosum",
            "Enrollment": "16",
            "NctKeyword": "Pyoderma Gangrenosum, Classic Pyoderma Gangrenosum,",
            "MeshKeyword": "Pyoderma Gangrenosum, Pyoderma,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  A clinical diagnosis of classic pyoderma gangrenosum\r\n\r\n\r\n\r\n          -  An active pyoderma gangrenosum ulcer\r\n\r\n\r\n\r\n          -  Contraceptive measures adequate to prevent pregnancy during the study",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Coral Gables",
            "State": "Florida",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 25, 2016",
            "FirstReceived": "December 5, 2014",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02315417",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150075 - Xoma (US) LLC  - Kirsner",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20150075",
            "StudyNumber": "20150075 - Xoma (US) LLC  - Kirsner",
            "StudyTitle": "A Randomized, Double-Blind, Placebo-Controlled Study of\nthe Efficacy and Safety of Gevokizumab in Treating Active\nUlcers of Pyoderma Gangrenosum",
            "PIID": "717",
            "PicNum": "C00519753",
            "PILastName": "Kirsner",
            "PIFirstName": "Robert",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C00519753",
            "EnteredByLastName": "Kirsner",
            "EnteredByFirstName": "Robert",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "05/05/2015",
            "IRBApprovedFrom": "05/05/2015",
            "IRBApprovedTo": "05/04/2016",
            "Expr1": "Phase II/III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Xoma (US) LLC",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Aliette Espinosa,Carol Kittles",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02315417",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02318914",
            "BriefTitle": "A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum",
            "OfficialTitle": "A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum",
            "LeadSponsorClass": "XOMA (US) LLC",
            "SponsorAgency": "Industry",
            "LeadSponsor": "XOMA (US) LLC",
            "OversightAuthority": "No",
            "BriefSummary": "The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers",
            "OverallStatus": "Terminated",
            "StartDate": "November 2014",
            "CompletionDate": "February 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "XOMA (US) LLC",
            "StudyCondition": "Pyoderma Gangrenosum",
            "Enrollment": "15",
            "NctKeyword": "Pyoderma Gangrenosum, Classic Pyoderma Gangrenosum,",
            "MeshKeyword": "Pyoderma Gangrenosum, Pyoderma,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Individuals who participated in a previous study of gevokizumab in PG\r\n\r\n\r\n\r\n          -  A clinical diagnosis of classic pyoderma gangrenosum\r\n\r\n\r\n\r\n          -  Contraceptive measures adequate to preve",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 25, 2016",
            "FirstReceived": "December 8, 2014",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02318914",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150162 - Xoma (US) LLC  - Kirsner",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20150162",
            "StudyNumber": "20150162 - Xoma (US) LLC  - Kirsner",
            "StudyTitle": "A 2-Year, Open-Label, Safety Extension Study of\nGevokizumab in Patients with Pyoderma Gangrenosum",
            "PIID": "717",
            "PicNum": "C00519753",
            "PILastName": "Kirsner",
            "PIFirstName": "Robert",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C00519753",
            "EnteredByLastName": "Kirsner",
            "EnteredByFirstName": "Robert",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "05/05/2015",
            "IRBApprovedFrom": "05/05/2015",
            "IRBApprovedTo": "05/04/2016",
            "Expr1": "Phase II/III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Xoma (US) LLC",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Aliette Espinosa,Carol Kittles",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02318914",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02323399",
            "BriefTitle": "Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV",
            "OfficialTitle": "Phase 4 Open Label Study to Determine Pharmacokinetics of Phenylephrine and Pharmacodynamic Effects on BP Via IV Admin of Phenylephrine Hydrochloride Inj in Ped Subjects (≥12 to 16 Years of Age) Undergoing Gen and Neuraxial Anesthesia",
            "LeadSponsorClass": "West-Ward Pharmaceutical",
            "SponsorAgency": "Industry",
            "LeadSponsor": "West-Ward Pharmaceutical",
            "OversightAuthority": "Yes",
            "BriefSummary": "The primary objective of this study is to evaluate the dose effect of Phenylephrine\r\n\r\n      Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in\r\n\r\n      the pediatric population, ≥12 to 16 year old patien",
            "Description": "This is a Phase 4 multi-center, randomized open-label study in 100 subjects aged ≥12 to 16\r\n\r\n      years who experience a decrease in blood pressure during a procedure requiring general or\r\n\r\n      neuraxial anesthesia. At least 300 subjects wi",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2015",
            "CompletionDate": "May 2017",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "West-Ward Pharmaceutical",
            "StudyCondition": "Hypotension",
            "studyLocation": "Alfred I. DuPont Hospital for Children",
            "Enrollment": "100",
            "MeshKeyword": "Hypotension,",
            "InterventionKeyword": "Phenylephrine, Oxymetazoline,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Subject's age is between ≥12 and 16 years, inclusive\r\n\r\n\r\n\r\n          2. Subject is scheduled for a procedure that requires general or neuraxial anesthesia\r\n\r\n\r\n\r\n          3. Subjects must have normal o",
            "EligibleGender": "All",
            "MinAge": "12 Years",
            "MaxAge": "16 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Wilmington",
            "State": "Delaware",
            "Zip": "19803",
            "Country": "United States",
            "VerificationDate": "May 2016",
            "LastChanged": "May 10, 2016",
            "FirstReceived": "December 17, 2014",
            "OverallOfficial": "Cesar Ormeno, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "PRA Health Sciences",
            "ContactName": "J. Barton Kalis",
            "ContactPhone": "856 489 2247",
            "ContactEmail": "jkalis@west-ward.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Alfred I. DuPont Hospital for Children",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02323399",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150299 - West-Ward Pharmaceuticals - Gebhard",
            "FileProcessContentId": "440",
            "Division": "Anesthesiology",
            "StdyDivision": "10236",
            "EprostNbr": "20150299",
            "StudyNumber": "20150299 - West-Ward Pharmaceuticals - Gebhard",
            "StudyTitle": "A Phase 4 Multi-center, Ascending Dose, Open Label Study to Determine the Pharmacokinetics of Phenylephrine and the Pharmacodynamic Effects on Blood Pressure following Intravenous Administration of Phenylephrine Hydrochloride\nInjection, USP in Pediatric Subjects (=12 to 16 years of age) Undergoing General and Neuroaxial Anesthesia",
            "PIID": "706",
            "PicNum": "C04976318",
            "PILastName": "Gebhard",
            "PIFirstName": "Ralf",
            "CoodCNbr": "C10565278",
            "CoordLastName": "Gutierrez",
            "CoordFirstName": "Juan",
            "CoordEmail": "JGutierrez4@med.miami.edu",
            "EnteredByCNbr": "C04976318",
            "EnteredByLastName": "Gebhard",
            "EnteredByFirstName": "Ralf",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "06/16/2015",
            "IRBApprovedFrom": "06/16/2015",
            "IRBApprovedTo": "06/14/2017",
            "Expr1": "Phase IV",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "West-Ward Pharmaceuticals",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Juan Gutierrez,Maria Antor",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT02323399",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02332707",
            "SecondaryId": "2014-003304-73",
            "BriefTitle": "Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT) 1 and GT2 Infection (MK-3682-011)",
            "OfficialTitle": "A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 With Either MK-8742 or MK-8408 in Subjects With Chronic HCV GT1 and GT2 Infection",
            "LeadSponsorClass": "Merck Sharp & Dohme Corp.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Merck Sharp & Dohme Corp.",
            "OversightAuthority": "No",
            "BriefSummary": "This is a randomized, three-part, open-label trial of grazoprevir (MK-5172) (100 mg) and\r\n\r\n      MK-3682 (300 mg or 450 mg), with either elbasvir (MK-8742) (50 mg) or ruzasvir (MK-8408) (60\r\n\r\n      mg), and with or without ribavirin (RBV), in",
            "Description": "In Part A, study therapy will be administered as separate products, each taken q.d. by\r\n\r\n      mouth. In Part B and Part C, participants will take 2 MK-3682B FDC tablets q.d. by mouth;\r\n\r\n      each MK-3682B FDC tablet contains grazoprevir 50 m",
            "OverallStatus": "Completed",
            "StartDate": "January 2015",
            "CompletionDate": "December 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Merck Sharp & Dohme Corp.",
            "StudyCondition": "Hepatitis C",
            "Enrollment": "443",
            "MeshKeyword": "Hepatitis, Hepatitis C,",
            "InterventionKeyword": "Ribavirin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        Parts A and B:\r\n\r\n\r\n\r\n          -  Previously untreated chronic HCV GT1 or GT2 with no evidence of non-typeable or mixed\r\n\r\n             genotype infection\r\n\r\n\r\n\r\n          -  Has HCV ribonucleic acid (RNA) >",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "VerificationDate": "December 2016",
            "LastChanged": "December 15, 2016",
            "FirstReceived": "January 6, 2015",
            "OverallOfficial": "Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Merck Sharp & Dohme Corp.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02332707",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150307 - Merck & Co. - Schiff",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20150307",
            "StudyNumber": "20150307 - Merck & Co. - Schiff",
            "StudyTitle": "MK-3682- A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1 and GT2 Infection",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C00758491",
            "EnteredByLastName": "Schiff",
            "EnteredByFirstName": "Eugene",
            "ActiveEnrollingDate": "11/11/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/11/2015",
            "IRBApprovedFrom": "05/04/2015",
            "IRBApprovedTo": "05/01/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Merck & Co.",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "6",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "4",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Andrea Elibero",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT02332707",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02336815",
            "BriefTitle": "Selinexor Treatment of Refractory Myeloma",
            "OfficialTitle": "A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low- Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) and",
            "LeadSponsorClass": "Karyopharm Therapeutics, Inc",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Karyopharm Therapeutics, Inc",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus\r\n\r\n      dexamethasone 20 mg (Sd) dosed twice weekly in four-week cycles, in patients with\r\n\r\n      penta-refractory MM (Parts 1 and 2) or quad refractory MM (",
            "Description": "This is a Phase 2b, single-arm, open-label, multicenter study of selinexor 80 mg plus\r\n\r\n      dexamethasone 20 mg (Sd), both dosed twice weekly in each four-week cycle, in patients with\r\n\r\n      MM previously treated with lenalidomide, pomalido",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2015",
            "CompletionDate": "October 2019",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Karyopharm Therapeutics, Inc",
            "StudyCondition": "Multiple Myeloma",
            "studyLocation": "University of Alabama",
            "Enrollment": "210",
            "NctKeyword": "Multiple myeloma, Karyopharm, KPT-330, Selinexor, Refractory, Bortezomib, Carfilzomib, Lenalidomide, Pomalidomide, Dexamethasone, STORM, CD38,",
            "MeshKeyword": "Multiple Myeloma, Neoplasms, Plasma Cell,",
            "InterventionKeyword": "Dexamethasone acetate, Dexamethasone, Dexamethasone 21-phosphate, Lenalidomide, Pomalidomide, Bortezomib, BB 1101, Proteasome Inhibitors,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        Measurable MM based on modified IMWG guidelines. Defined by at least one of the following:\r\n\r\n\r\n\r\n          1. Serum M-protein ≥ 0.5 g/dL by serum electrophoresis (SPEP) or for IgA myeloma, by",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 6, 2016",
            "FirstReceived": "January 8, 2015",
            "OverallOfficial": "Michael Kauffman, MD, Ph.D",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Karyopharm Therapeutics, Inc",
            "ContactName": "Michael Kauffman, MD, PhD",
            "ContactEmail": "mkauffman@karypharm.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02336815",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150450 - Karyopharm - Hoffman",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150450",
            "StudyNumber": "20150450 - Karyopharm - Hoffman",
            "StudyTitle": "“A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies\"",
            "PIID": "4418",
            "PicNum": "C11465246",
            "PILastName": "Hoffman",
            "PIFirstName": "James",
            "CoodCNbr": "C11964599",
            "CoordLastName": "Martinez",
            "CoordFirstName": "Micaela",
            "CoordEmail": "mem334@miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "11/09/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/09/2015",
            "IRBApprovedFrom": "09/01/2015",
            "IRBApprovedTo": "08/14/2017",
            "AccountNbr": "665885",
            "DiseaseSiteListDesc": "Multiple Myeloma",
            "Expr1": "Phase II",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Karyopharm Therapeutics",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "5",
            "Totalaccrued": "1",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UM Kendall:N/A,UMMG:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Rachel Pallapati,Cristina Rojas-Mejia,Penny Eyer",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02336815",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02339571",
            "SecondaryId": "NCI-2014-02674",
            "BriefTitle": "Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery",
            "OfficialTitle": "Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase II/III trial studies the side effects and best dose of nivolumab and\r\n\r\n      ipilimumab when given together with or without sargramostim and to see how well they work in\r\n\r\n      treating patients with stage III-IV melanom",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To compare the overall survival (OS) of nivolumab/ipilimumab/GM-CSF (sargramostim) versus\r\n\r\n      nivolumab/ipilimumab.\r\n\r\n\r\n\r\n      SECONDARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To evaluate progression free survival",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2015",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Recurrent Melanoma of the Skin",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "400",
            "MeshKeyword": "Melanoma,",
            "InterventionKeyword": "Nivolumab, Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1\r\n\r\n\r\n\r\n          -  Patients must have known v-raf murine sarcoma viral oncogene homolog B1 (BRAF)\r\n\r\n             mutational status o",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "January 12, 2015",
            "OverallOfficial": "Frank Hodi",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "ECOG-ACRIN Cancer Research Group",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02339571",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150909 - ECOG - Feun",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150909",
            "StudyNumber": "20150909 - ECOG - Feun",
            "StudyTitle": "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma",
            "PIID": "343",
            "PicNum": "C00770064",
            "PILastName": "Feun",
            "PIFirstName": "Lynn",
            "CoodCNbr": "C05004058",
            "CoordLastName": "Wang",
            "CoordFirstName": "Weiwen",
            "CoordEmail": "wwang1@med.miami.edu",
            "CoordPhone": "305-243-2122",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "06/24/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/24/2016",
            "IRBApprovedFrom": "05/29/2015",
            "IRBApprovedTo": "03/17/2017",
            "AccountNbr": "666736",
            "DiseaseSiteListDesc": "Melanoma, skin",
            "Expr1": "Phase II/III",
            "Tarea": "Melanoma and Related Skin Cancers",
            "TareaCode": "12441",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A,UMD:N/A,Plantation:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Eduardo Cianferra,Vivianne Velez-Bravo",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02339571",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02341560",
            "BriefTitle": "Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)",
            "OfficialTitle": "A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)",
            "LeadSponsorClass": "Quark Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Quark Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will determine the effect of QPI-1007 on visual function in subjects with\r\n\r\n      recent-onset NAION and assess the safety and tolerability of intravitreal injections of\r\n\r\n      QPI-1007 in this population. This study will also eval",
            "Description": "This is a double masked, randomized, sham-controlled efficacy and safety study that will\r\n\r\n      enroll approximately 530 subjects with recent-onset NAION. Subjects will be randomized into\r\n\r\n      one of 5 groups in a 1:1:1:1:1 ratio, and assi",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "CompletionDate": "July 2019",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "Quark Pharmaceuticals",
            "StudyCondition": "Nonarteritic Anterior Ischemic Optic Neuropathy",
            "studyLocation": "University of Alabama at Birmingham, Callahan Eye Hospital- Department of Ophthalmology",
            "Enrollment": "530",
            "NctKeyword": "NAION,",
            "MeshKeyword": "Ischemia, Optic Nerve Diseases, Optic Neuropathy, Ischemic,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Positive diagnosis of first episode of NAION in the study eye with symptom onset\r\n\r\n             within 14 days prior to planned study drug administration/sham procedure\r\n\r\n\r\n\r\n          -  Best corr",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35223",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 5, 2016",
            "FirstReceived": "January 13, 2015",
            "OverallOfficial": "Sharon Klier, M.D.",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Quark Pharmaceuticals",
            "ContactName": "Robert Shopbell",
            "ContactPhone": "510.402.4005",
            "ContactEmail": "rshopbell@quarkpharma.com",
            "LocationStatus": "Withdrawn",
            "LocationName": "University of Alabama at Birmingham, Callahan Eye Hospital- Department of Ophthalmology",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02341560",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160208 - QUARK PHARMACEUTICALS INC - Lam",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20160208",
            "StudyNumber": "20160208 - QUARK PHARMACEUTICALS INC - Lam",
            "StudyTitle": "A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED\nTRIAL OF QPI-1007 DELIVERED BY SINGLE\nOR MULTI-DOSE INTRAVITREAL INJECTION(S) TO\nSUBJECTS WITH ACUTE NONARTERITIC ANTERIOR\nISCHEMIC OPTIC NEUROPATHY (NAION)",
            "PIID": "1115",
            "PicNum": "C00679155",
            "PILastName": "Lam",
            "PIFirstName": "Byron",
            "CoodCNbr": "C07458455",
            "CoordLastName": "Morante",
            "CoordFirstName": "Alexis",
            "CoordEmail": "amorante@med.miami.edu",
            "EnteredByCNbr": "C00679155",
            "EnteredByLastName": "Lam",
            "EnteredByFirstName": "Byron",
            "ActiveEnrollingDate": "09/14/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/14/2016",
            "IRBApprovedFrom": "03/16/2016",
            "IRBApprovedTo": "08/15/2017",
            "InfoEdNbr": "76938",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "QUARK PHARMACEUTICALS INC",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Alexis Morante,Jennifer Verriotto,Potyra Rosa",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02341560",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02343445",
            "BriefTitle": "Clearing Lungs With ENAC Inhibition in Cystic Fibrosis",
            "OfficialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of P-1037 Solution for Inhalation in Patients With Cystic Fibrosis (CF)",
            "LeadSponsorClass": "Vertex Pharmaceuticals Incorporated",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Vertex Pharmaceuticals Incorporated",
            "OversightAuthority": "No",
            "BriefSummary": "The goal of the study is to evaluate the safety and tolerability of P-1037 and to determine\r\n\r\n      whether the combination of P-1037 with hypertonic saline or P-1037 alone has a greater\r\n\r\n      effect on lung function in patients with CF than",
            "OverallStatus": "Completed",
            "StartDate": "April 2015",
            "CompletionDate": "February 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Vertex Pharmaceuticals Incorporated",
            "StudyCondition": "Cystic Fibrosis",
            "studyLocation": "Children's Hospital of Los Angeles",
            "Enrollment": "142",
            "MeshKeyword": "Fibrosis, Cystic Fibrosis,",
            "InterventionKeyword": "Pharmaceutical Solutions,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male or female, 12 years of age or older.\r\n\r\n\r\n\r\n          -  Diagnosis of cystic fibrosis as determined by the 1997 CF Consensus criteria (NIH\r\n\r\n             Consensus Statement, 1997)",
            "EligibleGender": "All",
            "MinAge": "12 Years",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90027",
            "Country": "United States",
            "VerificationDate": "March 2016",
            "LastChanged": "August 8, 2016",
            "FirstReceived": "January 13, 2015",
            "LocationName": "Children's Hospital of Los Angeles",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02343445",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150098 - Parion Sciences/ Inc. - Salathe",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20150098",
            "StudyNumber": "20150098 - Parion Sciences/ Inc. - Salathe",
            "StudyTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group\nStudy to Evaluate the Safety and Efficacy of P-1037 Solution for Inhalation in Patients with Cystic Fibrosis",
            "PIID": "528",
            "PicNum": "C00319179",
            "PILastName": "Salathe",
            "PIFirstName": "Matthias",
            "CoodCNbr": "C09943370",
            "CoordLastName": "Aguiar",
            "CoordFirstName": "Carolina",
            "CoordEmail": "caguiar2@med.miami.edu",
            "CoordPhone": "3052435545",
            "EnteredByCNbr": "C00319179",
            "EnteredByLastName": "Salathe",
            "EnteredByFirstName": "Matthias",
            "ActiveEnrollingDate": "06/08/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/08/2015",
            "IRBApprovedFrom": "04/07/2015",
            "IRBApprovedTo": "03/27/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Parion Sciences/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "8",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "8",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Patricia Rebolledo,Henry Boza,Lilian Cadet,Carolina Aguiar,Patricia Graham-Borras,Johana Arana,Eliana Mendes",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02343445",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02344004",
            "SecondaryId": "2014-005010-31",
            "BriefTitle": "Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone",
            "OfficialTitle": "A Randomized, Open-label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment",
            "LeadSponsorClass": "Insmed Incorporated",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Insmed Incorporated",
            "OversightAuthority": "Yes",
            "BriefSummary": "A study to evaluate the effectiveness of Liposomal Amikacin for Inhalation (LAI) when added\r\n\r\n      to multi-drug regimen in subjects with Nontuberculous Mycobacterial (NTM) lung infection\r\n\r\n      caused by Mycobacterium Avium Complex (MAC).",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Insmed Incorporated",
            "StudyCondition": "Mycobacterium Infections, Nontuberculous",
            "Enrollment": "350",
            "MeshKeyword": "Infection, Mycobacterium Infections, Mycobacterium Infections, Nontuberculous,",
            "InterventionKeyword": "Amikacin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Be continually positive for MAC on sputum culture while adhering to a multi-drug\r\n\r\n             treatment regimen for a minimum duration of 6 months which is either ongoing or was\r\n\r\n             comple",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 27, 2016",
            "FirstReceived": "January 9, 2015",
            "OverallOfficial": "Gina Eagle, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Insmed Incorporated",
            "ContactName": "Dianne Nowicke",
            "ContactEmail": "NTMStudy@hudsonglobal.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02344004",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150054 - Insmed - Schmid",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20150054",
            "StudyNumber": "20150054 - Insmed - Schmid",
            "StudyTitle": "A Randomized, Open-Label, Multicenter Study of Liposomal Amikacin for\nInhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM)\nLung Infections caused by Mycobacterium avium complex (MAC) that are\nrefractory to treatment.",
            "PIID": "1956",
            "PicNum": "C06974957",
            "PILastName": "Schmid",
            "PIFirstName": "Andreas",
            "CoodCNbr": "C09943370",
            "CoordLastName": "Aguiar",
            "CoordFirstName": "Carolina",
            "CoordEmail": "caguiar2@med.miami.edu",
            "CoordPhone": "3052435545",
            "EnteredByCNbr": "C06974957",
            "EnteredByLastName": "Schmid",
            "EnteredByFirstName": "Andreas",
            "ActiveEnrollingDate": "08/14/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/14/2015",
            "IRBApprovedFrom": "05/19/2015",
            "IRBApprovedTo": "05/16/2017",
            "Expr1": "Phase II/III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Insmed",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Patricia Rebolledo,Lilian Cadet,Carolina Aguiar,Patricia Graham-Borras,Johana Arana,Eliana Mendes",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02344004",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02345226",
            "SecondaryId": "2014-004779-21",
            "BriefTitle": "Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV",
            "OfficialTitle": "A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will evaluate the efficacy and safety of emtricitabine/rilpivirine/tenofovir\r\n\r\n      alafenamide (FTC/RPV/TAF) fixed dose combination (FDC) versus continuing\r\n\r\n      efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "January 2015",
            "CompletionDate": "June 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "HIV-1 Infection",
            "studyLocation": "Maricopa Integrated Health System",
            "Enrollment": "877",
            "NctKeyword": "HIV,",
            "InterventionKeyword": "Tenofovir, Efavirenz, Emtricitabine, Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Rilpivirine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  The ability to understand and sign a written informed consent form, which must be\r\n\r\n             obtained prior to initiation of study procedures\r\n\r\n\r\n\r\n          -  Currently receiving EFV/FTC/TDF FDC",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85004",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 14, 2016",
            "FirstReceived": "January 19, 2015",
            "OverallOfficial": "Huyen Cao, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "Maricopa Integrated Health System",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02345226",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150148 - Gilead - Jayaweera",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20150148",
            "StudyNumber": "20150148 - Gilead - Jayaweera",
            "StudyTitle": "GS-US-366-1160 A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV -1 Infected Subjects",
            "PIID": "234",
            "PicNum": "C00043390",
            "PILastName": "Jayaweera",
            "PIFirstName": "Dushyantha T.",
            "CoodCNbr": "C00548607",
            "CoordLastName": "Salvarrey",
            "CoordFirstName": "Annie",
            "CoordEmail": "als215@miami.edu",
            "CoordPhone": "+1 (305) 243-4668",
            "EnteredByCNbr": "C00043390",
            "EnteredByLastName": "Jayaweera",
            "EnteredByFirstName": "Dushyantha T.",
            "ActiveEnrollingDate": "07/15/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/15/2015",
            "IRBApprovedFrom": "04/06/2015",
            "IRBApprovedTo": "04/17/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Gilead",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "4",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Kenia Moreno,Tom Tanner",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02345226",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02345252",
            "SecondaryId": "2014-004545-27",
            "BriefTitle": "Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fuma",
            "OfficialTitle": "A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabin",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will evaluate the safety and efficacy of emtricitabine/rilpivirine/tenofovir\r\n\r\n      alafenamide (FTC/RPV/TAF) fixed-dose combination (FDC) versus continuing\r\n\r\n      emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/T",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "January 2015",
            "CompletionDate": "June 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "HIV-1 Infection",
            "studyLocation": "The University of Alabama at Birmingham (UAB)",
            "Enrollment": "632",
            "NctKeyword": "HIV,",
            "InterventionKeyword": "Tenofovir, Emtricitabine, Rilpivirine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  The ability to understand and sign a written informed consent form, which must be\r\n\r\n             obtained prior to initiation of study procedures\r\n\r\n\r\n\r\n          -  Currently receiving FTC/RPV/TDF FDC",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "10029",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 14, 2016",
            "FirstReceived": "January 19, 2015",
            "OverallOfficial": "Huyen Cao, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LocationName": "The University of Alabama at Birmingham (UAB)",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02345252",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150151 - Gilead - Jayaweera",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20150151",
            "StudyNumber": "20150151 - Gilead - Jayaweera",
            "StudyTitle": "A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate\nthe Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir\nAlafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in\nHIV-1 Positive Subjects who are Virologically Suppressed on\nEmtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate\n(FTC/RPV/TDF)",
            "PIID": "234",
            "PicNum": "C00043390",
            "PILastName": "Jayaweera",
            "PIFirstName": "Dushyantha T.",
            "CoodCNbr": "C00548607",
            "CoordLastName": "Salvarrey",
            "CoordFirstName": "Annie",
            "CoordEmail": "als215@miami.edu",
            "CoordPhone": "+1 (305) 243-4668",
            "EnteredByCNbr": "C00043390",
            "EnteredByLastName": "Jayaweera",
            "EnteredByFirstName": "Dushyantha T.",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "04/06/2015",
            "IRBApprovedFrom": "04/06/2015",
            "IRBApprovedTo": "04/05/2016",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Gilead",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Kenia Moreno,Tom Tanner",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02345252",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02346747",
            "BriefTitle": "Phase II/III Trial of Maintenance Vigil™ for High Risk Stage III/IV Ovarian Cancer",
            "OfficialTitle": "A Randomized, Double-Blind, Placebo-Controlled Phase II/III Trial of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Subjects With Stage III/IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy",
            "LeadSponsorClass": "Gradalis, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gradalis, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a two-part multicenter, randomized, double-blind, placebo-controlled, Phase II/III\r\n\r\n      study of maintenance Vigil™ Ovarian (gemogenovatucel-T) (formerly known as FANG™) in women\r\n\r\n      with Stages III/IV high-grade serous / endome",
            "Description": "This is a two-part multicenter, randomized, double-blind, placebo-controlled, Phase II/III\r\n\r\n      study of maintenance Vigil™ Ovarian (gemogenovatucel-T) (formerly known as FANG™) in women\r\n\r\n      with Stages III/IV high-grade serous / endome",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2015",
            "CompletionDate": "December 2019",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "Gradalis, Inc.",
            "StudyCondition": "Ovarian Cancer",
            "studyLocation": "University of South Alabama Mitchell Cancer Institute",
            "Enrollment": "574",
            "NctKeyword": "Stage III, Stage IV, Ovarian Cancer, Maintenance, Immunotherapy, primary peritoneal cancer, fallopian tube cancer, endometrioid ovarian cancer, high-grade serous ovarian cancer,",
            "MeshKeyword": "Ovarian Neoplasms,",
            "InterventionKeyword": "Modafinil, Armodafinil,",
            "Eligibility": "Inclusion Criteria\r\n\r\n\r\n\r\n        For Part 1 and Part 2, subjects will be eligible for tissue procurement for the Vigil™\r\n\r\n        manufacturing process if they meet all of the following criteria:\r\n\r\n\r\n\r\n          1. Presumptive Stage III/IV",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Mobile",
            "State": "Alabama",
            "Zip": "36604",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 1, 2016",
            "FirstReceived": "January 21, 2015",
            "OverallOfficial": "Luisa Manning, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gradalis, Inc.",
            "ContactName": "Gladice Wallraven",
            "ContactPhone": "214-442-8124",
            "ContactEmail": "info@gradalisinc.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of South Alabama Mitchell Cancer Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02346747",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150202 - Gradalis - Slomovitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150202",
            "StudyNumber": "20150202 - Gradalis - Slomovitz",
            "StudyTitle": "Double-Blind, Placebo Controlled Phase III Trial of Maintenance FANG™ (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) for High Risk Stage III/IV Ovarian Cancer",
            "PIID": "22712",
            "PicNum": "C11916703",
            "PILastName": "Slomovitz",
            "PIFirstName": "Brian",
            "CoodCNbr": "C12022809",
            "CoordLastName": "Habibi Khameneh",
            "CoordFirstName": "Negin",
            "CoordEmail": "negin.khameneh@med.miami.edu",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "07/07/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/07/2016",
            "IRBApprovedFrom": "03/01/2016",
            "IRBApprovedTo": "02/28/2017",
            "AccountNbr": "667196",
            "DiseaseSiteListDesc": "Ovary",
            "Expr1": "Phase III",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Blinding": "Double",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Gradalis, Inc",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "4",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "2",
            "SiteSampleSize": "UMD:N/A,UMMG:N/A,Plantation:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Doris Martin,Marinellie Vega,Evan Dadas,Claudia Grandas Moreno,Halyna Hailes,Mohammad El-Sorady",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02346747",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02348216",
            "BriefTitle": "A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)",
            "OfficialTitle": "A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (NHL)",
            "LeadSponsorClass": "Kite Pharma, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Kite Pharma, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and\r\n\r\n      efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell\r\n\r\n      therapy, in refractory aggressive Non-Hod",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2015",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Kite Pharma, Inc.",
            "StudyCondition": "Refractory Diffuse Large B Cell Lymphoma",
            "studyLocation": "Banner MD Anderson",
            "Enrollment": "142",
            "MeshKeyword": "Lymphoma, Follicular, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse,",
            "Eligibility": "Key Inclusion Criteria\r\n\r\n\r\n\r\n          1. Histologically confirmed:\r\n\r\n\r\n\r\n               -  Diffuse Large B Cell Lymphoma (DLBCL)\r\n\r\n\r\n\r\n               -  Primary Mediastinal Large B Cell Lymphoma (PMBCL)\r\n\r\n\r\n\r\n               -  Transformat",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Gilbert",
            "State": "Arizona",
            "Zip": "85234",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 3, 2016",
            "FirstReceived": "January 22, 2015",
            "OverallOfficial": "William Go, M.D., Ph.D.",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Kite Pharma, Inc.",
            "ContactName": "Allison Bowen, MPM, PMP, BS, BA",
            "ContactPhone": "(404) 7927824",
            "ContactEmail": "allison.bowen@theoremclinical.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Banner MD Anderson",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02348216",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150002 - Kite Pharma - Lekakis",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150002",
            "StudyNumber": "20150002 - Kite Pharma - Lekakis",
            "StudyTitle": "A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)",
            "PIID": "2809",
            "PicNum": "C09984957",
            "PILastName": "Lekakis",
            "PIFirstName": "Lazaros",
            "CoodCNbr": "C10180073",
            "CoordLastName": "Gonzalez",
            "CoordFirstName": "Nohelia",
            "CoordEmail": "ngonzalez5@med.miami.edu",
            "CoordPhone": "3052434903",
            "EnteredByCNbr": "C11964150",
            "EnteredByLastName": "Smith",
            "EnteredByFirstName": "Nyesha",
            "ActiveEnrollingDate": "11/03/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/03/2015",
            "IRBApprovedFrom": "04/06/2015",
            "IRBApprovedTo": "03/24/2017",
            "AccountNbr": "665499",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma",
            "Expr1": "Phase I/II",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Kite Pharma",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "8",
            "Totalaccrued": "7",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "8",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Luis",
            "NationalSampleSize": "18",
            "NCTNbr": "NCT02348216",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02348359",
            "BriefTitle": "X-82 to Treat Age-related Macular Degeneration",
            "OfficialTitle": "A Randomized, Double-Masked, Placebo-Controlled, Dose- Finding, Non-Inferiority Study of X-82 Plus Prn Intravitreal (Ivt) Anti-VEGF Compared to Prn Ivt Anti-VEGF Monotherapy in Neovascular AMD",
            "LeadSponsorClass": "Tyrogenex",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Tyrogenex",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of\r\n\r\n      vision loss due to wet AMD.",
            "Description": "Subjects will be randomized in a 1:1:1:1 ratio to the following dose groups:\r\n\r\n\r\n\r\n        -  X-82 50 mg plus ivt anti-VEGF prn\r\n\r\n\r\n\r\n        -  X-82 100 mg plus ivt anti-VEGF prn\r\n\r\n\r\n\r\n        -  X-82 200 mg plus ivt anti-VEGF prn",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "March 2015",
            "CompletionDate": "January 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Tyrogenex",
            "StudyCondition": "Age-Related Macular Degeneration (AMD)",
            "Enrollment": "132",
            "NctKeyword": "Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), AMD,",
            "MeshKeyword": "Macular Degeneration, Eye Diseases, Retinal Diseases, Wet Macular Degeneration, Retinal Degeneration,",
            "InterventionKeyword": "Bevacizumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Participants mush have wet AMD which has been diagnosed and treated with anti-VEGF in\r\n\r\n             one or both eyes for at least 6 months prior to joining the study and has required at",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Tucson",
            "State": "Arizona",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 12, 2017",
            "FirstReceived": "January 21, 2015",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02348359",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150130 - Xcovery Vision/ LLC. - Rosenfeld",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20150130",
            "StudyNumber": "20150130 - Xcovery Vision/ LLC. - Rosenfeld",
            "StudyTitle": "A Randomized, Double-Masked, Placebo-Controlled, Dose- Finding, Non-Inferiority Study of X-82 plus prn Eylea® compared to prn Eylea® monotherapy in neovascular AMD",
            "PIID": "491",
            "PicNum": "C00522634",
            "PILastName": "Rosenfeld",
            "PIFirstName": "Philip",
            "CoodCNbr": "C01984187",
            "CoordLastName": "Esquiabro",
            "CoordFirstName": "Maria",
            "CoordEmail": "mesquiabro@med.miami.edu",
            "EnteredByCNbr": "C00522634",
            "EnteredByLastName": "Rosenfeld",
            "EnteredByFirstName": "Philip",
            "ActiveEnrollingDate": "09/16/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/16/2015",
            "IRBApprovedFrom": "06/22/2015",
            "IRBApprovedTo": "05/22/2017",
            "Expr1": "Phase II",
            "Tarea": "Retina",
            "TareaCode": "12038",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "12",
            "SignedICF": "14",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "14",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,ABLEH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Cristina Lage-Rodriguez,Fabiola Salvador,Catherin Negron,Maria Esquiabro,Belen Rodriguez,Monica Arango",
            "NationalSampleSize": "40",
            "NCTNbr": "NCT02348359",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02354625",
            "BriefTitle": "The Safety of ahSC in Chronic SCI With Rehabilitation",
            "OfficialTitle": "The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Chronic Spinal Cord Injury (SCI) Receiving Rehabilitation",
            "LeadSponsorClass": "W. Dalton Dietrich",
            "SponsorAgency": "Other",
            "LeadSponsor": "W. Dalton Dietrich",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to assess the safety of autologous human Schwann cell (ahSC)\r\n\r\n      transplantation in participants with chronic SCI.\r\n\r\n\r\n\r\n      This trial design is phase I, open label, unblinded, non-randomized, and non-placeb",
            "Description": "For humans with chronic SCI, we hypothesize that axons might show improved function if\r\n\r\n      myelin repair is induced with the implantation of ahSC. In addition spinal cord cavitation\r\n\r\n      may be reduced, and neural sprouting and plastici",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2015",
            "CompletionDate": "January 2018",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Spinal Cord Injury",
            "studyLocation": "University of Miami",
            "Enrollment": "10",
            "NctKeyword": "Schwann cells,",
            "MeshKeyword": "Spinal Cord Injuries, Quadriplegia, Paraplegia,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Persons with traumatic SCI that occurred a minimum of 12 months prior to enrollment;\r\n\r\n\r\n\r\n          2. Between the ages of 18 and 65 at last birthday;\r\n\r\n\r\n\r\n          3. SCI between spinal levels C5-T",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 10, 2017",
            "FirstReceived": "January 29, 2015",
            "OverallOfficial": "Allan Levi, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Kimberly Anderson, PhD",
            "ContactPhone": "305-243-7108",
            "ContactEmail": "MPinfo@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02354625",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140846 - Intramural - Levi",
            "FileProcessContentId": "440",
            "Division": "Neurosurgery",
            "StdyDivision": "9636",
            "EprostNbr": "20140846",
            "StudyNumber": "20140846 - Intramural - Levi",
            "StudyTitle": "The safety of autologous human Schwann cells (ahSC) in subjects with chronic spinal cord injury (SCI) receiving rehabilitation.",
            "PIID": "167",
            "PicNum": "C00155778",
            "PILastName": "Levi",
            "PIFirstName": "Allan",
            "CoodCNbr": "C08177251",
            "CoordLastName": "Anderson",
            "CoordFirstName": "Kimberly",
            "CoordEmail": "kanderson3@med.miami.edu",
            "CoordPhone": "305-243-5569",
            "EnteredByCNbr": "C00155778",
            "EnteredByLastName": "Levi",
            "EnteredByFirstName": "Allan",
            "ActiveEnrollingDate": "02/09/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/09/2015",
            "IRBApprovedFrom": "12/16/2014",
            "IRBApprovedTo": "10/31/2017",
            "Expr1": "Phase I",
            "Tarea": "Spine",
            "TareaCode": "9641",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "16",
            "Totalaccrued": "16",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "16",
            "FirstNinety": "5",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Jessica Cambridge,George Jimsheleishvili,Katie Gant",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT02354625",
            "StudyKeywords": "Miami Project",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02358135",
            "BriefTitle": "Collaborative Connected Health (CCH) for PCORI",
            "OfficialTitle": "Collaborative Connected Health (CCH): A Pragmatic Trial Evaluating Effectiveness of CCH in Psoriasis Management Compared to In-person Visits.",
            "LeadSponsorClass": "University of Southern California",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Southern California",
            "OversightAuthority": "No",
            "BriefSummary": "The investigators propose to evaluate whether an innovative collaborative connected health\r\n\r\n      (CCH) model increases access to specialists and improves patient outcomes. CCH offers\r\n\r\n      multiple modalities for patients and primary care",
            "Description": "The investigators propose to conduct a 12-month, pragmatic, randomized controlled trial to\r\n\r\n      evaluate the impact of a collaborative connected health model for psoriasis management\r\n\r\n      compared to inperson care. The pragmatic trial wi",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "February 2015",
            "CompletionDate": "December 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Southern California",
            "StudyCondition": "Psoriasis",
            "studyLocation": "University of Southern California",
            "Enrollment": "300",
            "NctKeyword": "Pragmatic, Equivalency, Teledermatology,",
            "MeshKeyword": "Psoriasis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Be age 18 years and older\r\n\r\n\r\n\r\n          -  Have physician-diagnosed plaque psoriasis\r\n\r\n\r\n\r\n          -  Have access to internet and a digital camera or a mobile phone with camera features",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90089",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 24, 2016",
            "FirstReceived": "January 6, 2015",
            "OverallOfficial": "April Armstrong, MD MPH",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Colorado, Denver",
            "LocationName": "University of Southern California",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02358135",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150158 - Patient-Centered Outcomes Research institute (PCOR - Sharma",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20150158",
            "StudyNumber": "20150158 - Patient-Centered Outcomes Research institute (PCOR - Sharma",
            "StudyTitle": "PCORI - Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTROLS)",
            "PIID": "198",
            "PicNum": "C00576419",
            "PILastName": "Sharma",
            "PIFirstName": "Khema",
            "CoodCNbr": "C01939845",
            "CoordLastName": "Quesada",
            "CoordFirstName": "Monica",
            "CoordEmail": "mquesada2@med.miami.edu",
            "CoordPhone": "3052433647",
            "EnteredByCNbr": "C00576419",
            "EnteredByLastName": "Sharma",
            "EnteredByFirstName": "Khema",
            "ActiveEnrollingDate": "08/13/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/13/2015",
            "IRBApprovedFrom": "04/27/2015",
            "IRBApprovedTo": "03/13/2017",
            "Expr1": "Approved Drug/Off-Label use",
            "ResearchType": "Drug",
            "SponsorGroup": "Foundation",
            "Sponsor": "Patient-Centered Outcomes Research institute (PCORI)",
            "Prescreened": "2",
            "Screenedfailed": "0",
            "SignedICF": "18",
            "Totalaccrued": "17",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "5",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "18",
            "FirstNinety": "8",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Julie Steele,Monica Quesada",
            "NationalSampleSize": "26",
            "NCTNbr": "NCT02358135",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02365649",
            "SecondaryId": "2014-003240-12",
            "BriefTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to I",
            "OfficialTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to I",
            "LeadSponsorClass": "AbbVie",
            "SponsorAgency": "Industry",
            "LeadSponsor": "AbbVie",
            "OversightAuthority": "Yes",
            "BriefSummary": "To determine the efficacy and safety of multiple doses of ABT-494 in subjects with\r\n\r\n      moderately to severely active Crohn's Disease with a history of inadequate response to or\r\n\r\n      intolerance to Immunomodulators or anti-Tumor Necrosis",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "March 2015",
            "CompletionDate": "July 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "AbbVie",
            "StudyCondition": "Crohn's Disease",
            "studyLocation": "Site Reference ID/Investigator# 136868",
            "Enrollment": "210",
            "NctKeyword": "Crohn's Disease,",
            "MeshKeyword": "Crohn Disease,",
            "InterventionKeyword": "Immunologic Factors, Adjuvants, Immunologic,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Diagnosis of Crohn's disease (CD) for at least 90 days.\r\n\r\n\r\n\r\n          2. Crohn's Disease Activity Index (CDAI) greater than or equal to 220 and less than or\r\n\r\n             equal to 450.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "La Jolla",
            "State": "California",
            "Zip": "92093",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 24, 2016",
            "FirstReceived": "February 16, 2015",
            "OverallOfficial": "Ana Lacerda, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "AbbVie",
            "LocationName": "Site Reference ID/Investigator# 136868",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02365649",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20141020 - AbbVie - Kerman",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20141020",
            "StudyNumber": "20141020 - AbbVie - Kerman",
            "StudyTitle": "A Multicenter, Randomized, Double-Blind,Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn's Disease who have Inadequately\nResponded to or are Intolerant to Immunomodulators or Anti-TNF Therapy",
            "PIID": "652",
            "PicNum": "C04244223",
            "PILastName": "Kerman",
            "PIFirstName": "David",
            "CoodCNbr": "C09950089",
            "CoordLastName": "Morillo",
            "CoordFirstName": "Diana",
            "CoordEmail": "dmorillo@med.miami.edu",
            "CoordPhone": "3052436405",
            "EnteredByCNbr": "C04244223",
            "EnteredByLastName": "Kerman",
            "EnteredByFirstName": "David",
            "ActiveEnrollingDate": "11/24/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/24/2015",
            "IRBApprovedFrom": "05/05/2015",
            "IRBApprovedTo": "04/18/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "AbbVie",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "4",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diana Morillo,Marianela Carvajal,Francia Carabali",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02365649",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02367794",
            "SecondaryId": "2014-003208-59",
            "BriefTitle": "A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Participants With Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) [IMpower 131]",
            "OfficialTitle": "A Phase III, Open-label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Car",
            "LeadSponsorClass": "Hoffmann-La Roche",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Hoffmann-La Roche",
            "BriefSummary": "This randomized, open-label study will evaluate the safety and efficacy of atezolizumab\r\n\r\n      (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel\r\n\r\n      compared with treatment with carboplatin + nab-pac",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2015",
            "CompletionDate": "February 2023",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Hoffmann-La Roche",
            "StudyCondition": "Squamous Non-Small Cell Lung Cancer",
            "Enrollment": "1025",
            "MeshKeyword": "Lung Neoplasms, Carcinoma, Non-Small-Cell Lung,",
            "InterventionKeyword": "Paclitaxel, Albumin-Bound Paclitaxel, Carboplatin, Antibodies, Immunoglobulins, Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\r\n\r\n\r\n\r\n          -  Histologically or cytologically confirmed, treatment-naïve Stage IV squamous NSCLC\r\n\r\n\r\n\r\n          -  Previously o",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Gilbert",
            "State": "Arizona",
            "Zip": "85297",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 1, 2016",
            "FirstReceived": "February 13, 2015",
            "OverallOfficial": "Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Hoffmann-La Roche",
            "ContactName": "Reference Study ID Number: GO29437 www.roche.com/about_roche/roche_worldwide.htm",
            "ContactPhone": "888-662-6728 (U.S. and Canada)",
            "ContactEmail": "global.rochegenentechtrials@roche.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02367794",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150593 - F Hoffman LaRoche - Ikpeazu",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150593",
            "StudyNumber": "20150593 - F Hoffman LaRoche - Ikpeazu",
            "StudyTitle": "A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL OR MPDL3280A IN COMBINATION WITH CARBOPLATIN + NAB-PACLITAXEL VERSUS CARBOPLATIN + NAB-PACLITAXEL IN CHEMOTHERAPY NAÏVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER",
            "PIID": "373",
            "PicNum": "C06163680",
            "PILastName": "Ikpeazu",
            "PIFirstName": "Chukwuemeka",
            "CoodCNbr": "C11967166",
            "CoordLastName": "Eyer",
            "CoordFirstName": "Penny",
            "CoordEmail": "ple19@med.miami.edu",
            "CoordPhone": "954-698-3673",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "05/20/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/20/2016",
            "IRBApprovedFrom": "12/01/2015",
            "IRBApprovedTo": "11/17/2017",
            "AccountNbr": "666611",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase III",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "F. Hoffman LaRoche",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:10,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "10",
            "EprostState": "Approved",
            "StudyCoordinator": "Michelle Mikhail,Evan Dadas,Halyna Hailes,Cristina Rojas-Mejia,Pascale Timothee,Karen Henry,Carla Munevar,Deborah Conte,Claudia Grandas Moreno,Anthony Minichiello,Mohammad El-Sorady",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02367794",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02368691",
            "BriefTitle": "Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)",
            "OfficialTitle": "A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)",
            "LeadSponsorClass": "GTx",
            "SponsorAgency": "Industry",
            "LeadSponsor": "GTx",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine if GTx-024 is effective and safe in the treatment\r\n\r\n      of patients with advanced, androgen receptor positive triple negative breast cancer (AR+\r\n\r\n      TNBC).",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2015",
            "CompletionDate": "November 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "GTx",
            "StudyCondition": "Triple Negative Breast Cancer",
            "studyLocation": "Holy Cross Hospital",
            "Enrollment": "55",
            "MeshKeyword": "Breast Neoplasms, Triple Negative Breast Neoplasms,",
            "InterventionKeyword": "Androgens,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Able and willing to give voluntary, written and signed, informed consent\r\n\r\n\r\n\r\n          -  Women ≥ 18 years of age\r\n\r\n\r\n\r\n          -  Women with TNBC who have received at least one but no more than tw",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Fort Lauderdale",
            "State": "Florida",
            "Zip": "33308",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 30, 2016",
            "FirstReceived": "February 10, 2015",
            "OverallOfficial": "Hope S Rugo, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of California, San Francisco",
            "ContactName": "Mayzie Johnston, PharmD",
            "ContactPhone": "(901) 523-9700",
            "ContactEmail": "mjohnston@gtxinc.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Holy Cross Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02368691",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150788 - GTx Inc - Vogel",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150788",
            "StudyNumber": "20150788 - GTx Inc - Vogel",
            "StudyTitle": "A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The\nEfficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive\nTriple Negative Breast Cancer (AR+ TNBC)",
            "PIID": "2271",
            "PicNum": "C00189505",
            "PILastName": "Vogel",
            "PIFirstName": "Charles",
            "CoodCNbr": "C11975723",
            "CoordLastName": "Minichiello",
            "CoordFirstName": "Anthony",
            "CoordEmail": "agm112@miami.edu",
            "EnteredByCNbr": "C12001301",
            "EnteredByLastName": "Delgado",
            "EnteredByFirstName": "Yisenny",
            "ActiveEnrollingDate": "02/11/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/11/2016",
            "IRBApprovedFrom": "10/25/2015",
            "IRBApprovedTo": "05/26/2017",
            "AccountNbr": "666234",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase II",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "6",
            "Totalaccrued": "4",
            "InFollowUp": "3",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UM Kendall:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Karen Henry,Deborah Conte,Sarah Raybin,Onaidy Torres,Michelle Mikhail,Cristina Rojas-Mejia,Penny Eyer,Halyna Hailes,Pascale Timothee",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02368691",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02371369",
            "BriefTitle": "PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)",
            "OfficialTitle": "A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath",
            "LeadSponsorClass": "Daiichi Sankyo Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Daiichi Sankyo Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a Phase 3 clinical study, which aims to evaluate the effectiveness of an\r\n\r\n      investigational drug PLX3397 in the treatment of tumour of pigmented villonodular synovitis\r\n\r\n      or giant cell tumor of the tendon sheath in subjects,",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "March 2015",
            "CompletionDate": "March 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Daiichi Sankyo Inc.",
            "StudyCondition": "Pigmented Villonodular Synovitis",
            "studyLocation": "Mayo Clinic",
            "Enrollment": "121",
            "NctKeyword": "Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumour, PLX3397, Colony Stimulating Factor 1 Receptor (CSF1R) inhibitor,",
            "MeshKeyword": "Neoplasms, Synovitis, Giant Cell Tumors, Synovitis, Pigmented Villonodular,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Age ≥ 18 years.\r\n\r\n\r\n\r\n          -  A diagnosis of PVNS or GCT-TS (i) that has been histologically confirmed either by a\r\n\r\n             pathologist at the treating institution or a central pathologist,",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Scottsdale",
            "State": "Arizona",
            "Zip": "85259-5499",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 20, 2016",
            "FirstReceived": "February 19, 2015",
            "LocationName": "Mayo Clinic",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02371369",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150139 - Daiichi Sankyo - Wilky",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150139",
            "StudyNumber": "20150139 - Daiichi Sankyo - Wilky",
            "StudyTitle": "A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath",
            "PIID": "4630",
            "PicNum": "C11848802",
            "PILastName": "Wilky",
            "PIFirstName": "Breelyn",
            "CoodCNbr": "C12022610",
            "CoordLastName": "Solomon",
            "CoordFirstName": "Thankam",
            "CoordEmail": "thankam.solomon@med.miami.edu",
            "EnteredByCNbr": "C07181703",
            "EnteredByLastName": "Zhang",
            "EnteredByFirstName": "Lei",
            "ActiveEnrollingDate": "08/14/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/14/2015",
            "IRBApprovedFrom": "05/19/2015",
            "IRBApprovedTo": "05/16/2017",
            "AccountNbr": "665391",
            "DiseaseSiteListDesc": "Soft Tissue",
            "Expr1": "Phase III",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Daiichi Sankyo",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "5",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02371369",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02372084",
            "BriefTitle": "A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function",
            "OfficialTitle": "A Phase I, Open-label, Multi-center, Single Dose, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of Osilodrostat (LCI699) in Subjects With Impaired Hepatic Function Compared to Subjects With Normal Hepatic Function",
            "LeadSponsorClass": "Novartis Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novartis Pharmaceuticals",
            "OversightAuthority": "No",
            "BriefSummary": "To assess the pharmacokinetics of a single oral dose of osilodrostat (LCI699) 30 mg in\r\n\r\n      subjects with mild, moderate and severe hepatic impairment compared with subjects with\r\n\r\n      normal hepatic function.",
            "OverallStatus": "Completed",
            "StartDate": "April 2015",
            "CompletionDate": "May 2016",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Novartis",
            "StudyCondition": "Hepatic Impairment",
            "studyLocation": "University of Miami / Clinical Research Services, Inc. Boynton Beach",
            "Enrollment": "33",
            "NctKeyword": "Hepatic impairment,, osilodrostat,, LCI699,",
            "MeshKeyword": "Liver Diseases,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Weight ≥50 kg and BMI between 18-38kg/m2.\r\n\r\n\r\n\r\n          -  Stable liver cirrhosis and evidence of hepatic impairment. ‐Free of significant\r\n\r\n             medical disorders unrelated to underlying hep",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 9, 2016",
            "FirstReceived": "February 23, 2015",
            "OverallOfficial": "Novartis Pharmaceuticals",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Novartis Pharmaceuticals",
            "LocationName": "University of Miami / Clinical Research Services, Inc. Boynton Beach",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02372084",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150194 - Novartis - Preston",
            "FileProcessContentId": "440",
            "Division": "Clinical Pharmacology",
            "StdyDivision": "10237",
            "EprostNbr": "20150194",
            "StudyNumber": "20150194 - Novartis - Preston",
            "StudyTitle": "Protocol CLCI699C2103\n\nA Phase I, open-label, multi-center, single dose, parallel group study to evaluate the pharmacokinetics and safety of LCI699 in subjects with impaired hepatic function compared to subjects with normal hepatic function",
            "PIID": "714",
            "PicNum": "C00648067",
            "PILastName": "Preston",
            "PIFirstName": "Richard",
            "CoodCNbr": "C00750489",
            "CoordLastName": "Acosta",
            "CoordFirstName": "Olga",
            "CoordEmail": "OAcosta@med.miami.edu",
            "CoordPhone": "3052437630",
            "EnteredByCNbr": "C00648067",
            "EnteredByLastName": "Preston",
            "EnteredByFirstName": "Richard",
            "ActiveEnrollingDate": "04/29/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/29/2015",
            "IRBApprovedFrom": "04/13/2015",
            "IRBApprovedTo": "04/10/2017",
            "Expr1": "Phase I",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Novartis",
            "Prescreened": "0",
            "Screenedfailed": "9",
            "SignedICF": "18",
            "Totalaccrued": "10",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "18",
            "FirstNinety": "6",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Barry Materson,Alberto Alonso,Rolando Rodco",
            "NationalSampleSize": "50",
            "NCTNbr": "NCT02372084",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02374060",
            "SecondaryId": "1U10EY024527-01",
            "BriefTitle": "PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial",
            "OfficialTitle": "PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial",
            "LeadSponsorClass": "JHSPH Center for Clinical Trials",
            "SponsorAgency": "Other",
            "LeadSponsor": "JHSPH Center for Clinical Trials",
            "OversightAuthority": "Yes",
            "BriefSummary": "To evaluate the relative efficacy of three commonly utilized regional corticosteroids for\r\n\r\n      the regional treatment of uveitic macular edema: periocular triamcinolone acetonide;\r\n\r\n      intravitreal triamcinolone acetonide; intravitreal d",
            "Description": "Macular edema is the most common structural complication and leading cause of visual loss in\r\n\r\n      patients with uveitis. Regional injections of corticosteroids are the most frequently used\r\n\r\n      treatments specifically for uveitic macular",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2015",
            "CompletionDate": "July 2018",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "JHSPH Center for Clinical Trials",
            "StudyCondition": "Macular Edema",
            "studyLocation": "University of Southern California",
            "Enrollment": "267",
            "MeshKeyword": "Macular Edema, Edema, Uveitis,",
            "InterventionKeyword": "Dexamethasone acetate, Triamcinolone hexacetonide, Dexamethasone, Triamcinolone, Triamcinolone Acetonide, Dexamethasone 21-phosphate, BB 1101, Triamcinolone diacetate,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        Eye level inclusion criteria - at least one eye must meet all of the following conditions:\r\n\r\n\r\n\r\n          -  Non-infectious anterior, intermediate, posterior or panuveitis; either active or",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90033",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 13, 2016",
            "FirstReceived": "February 18, 2015",
            "OverallOfficial": "Douglas A Jabs, MD, MBA",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Icahn School of Medicine, Noutn Sinai, New York, NY",
            "ContactName": "Janet Holbrook, PhD, MPH",
            "ContactEmail": "jholbro1@jhu.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Southern California",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02374060",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150479 - National Eye Institute - Davis",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20150479",
            "StudyNumber": "20150479 - National Eye Institute - Davis",
            "StudyTitle": "PeriOcular and INTravitreal corticosteroids\nfor uveitic macular edema (POINT) Trial",
            "PIID": "861",
            "PicNum": "C00771718",
            "PILastName": "Davis",
            "PIFirstName": "Janet",
            "CoodCNbr": "C00771718",
            "CoordLastName": "Davis",
            "CoordFirstName": "Janet",
            "CoordEmail": "j.davis1@miami.edu",
            "CoordPhone": "3053266377",
            "EnteredByCNbr": "C00771718",
            "EnteredByLastName": "Davis",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "01/21/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/21/2016",
            "IRBApprovedFrom": "09/14/2015",
            "IRBApprovedTo": "08/21/2017",
            "Expr1": "Phase IV",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "National Eye Institute",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carmen Huerta,Paula Dear",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT02374060",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02375971",
            "BriefTitle": "RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity",
            "OfficialTitle": "RAINBOW Study: a Randomized, Controlled Study Evaluating the Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity",
            "LeadSponsorClass": "Novartis Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novartis Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine if intravitreal ranibizumab is superior to laser\r\n\r\n      ablation therapy in the treatment of retinopathy of prematurity (ROP).",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2015",
            "CompletionDate": "April 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Novartis",
            "StudyCondition": "Retinopathy of Prematurity",
            "studyLocation": "Novartis Investigative Site",
            "Enrollment": "300",
            "NctKeyword": "intravitreal ranibizumab, laser ablation therapy, retinopathy of prematurity, preterm infants, RAINBOW,",
            "MeshKeyword": "Retinal Diseases, Premature Birth, Retinopathy of Prematurity,",
            "InterventionKeyword": "Ranibizumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Preterm infants with a birth weight of less than 1500 g\r\n\r\n\r\n\r\n          -  Bilateral ROP with 1 of the following retinal findings in each eye:\r\n\r\n\r\n\r\n        Zone I, stage 1+, 2+, 3 or 3+ disease, or Zo",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Loma Linda",
            "State": "California",
            "Zip": "92354",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 11, 2016",
            "FirstReceived": "February 18, 2015",
            "OverallOfficial": "Novartis Pharmaceuticals",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Novartis Pharmaceuticals",
            "ContactName": "Novartis Pharmaceuticals",
            "ContactPhone": "1-888-669-6682",
            "LocationStatus": "Recruiting",
            "LocationName": "Novartis Investigative Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02375971",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151102 - Novartis - Berrocal",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20151102",
            "StudyNumber": "20151102 - Novartis - Berrocal",
            "StudyTitle": "RAINBOW study: a randomized, controlled study\nevaluating the efficacy and safety of RAnibizumab\ncompared with laser therapy for the treatment of INfants\nBOrn prematurely With retinopathy of prematurity",
            "PIID": "514",
            "PicNum": "C00260650",
            "PILastName": "Berrocal",
            "PIFirstName": "Audina",
            "CoodCNbr": "C05008647",
            "CoordLastName": "Negron",
            "CoordFirstName": "Catherin",
            "CoordEmail": "CNegron@med.miami.edu",
            "EnteredByCNbr": "C00260650",
            "EnteredByLastName": "Berrocal",
            "EnteredByFirstName": "Audina",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "04/11/2016",
            "IRBApprovedFrom": "04/11/2016",
            "IRBApprovedTo": "04/10/2017",
            "Expr1": "Phase III",
            "Tarea": "Retina",
            "TareaCode": "12038",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Novartis",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Catherin Negron",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02375971",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02376361",
            "BriefTitle": "Hemodialysis Access Surveillance Evaluation Study",
            "OfficialTitle": "Hemodialysis Access Surveillance Evaluation Study",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of the study is to learn if monitoring dialysis access blood flow during\r\n\r\n      dialysis treatment with a transonic machine (an ultrasound technique) will prevent (or\r\n\r\n      reduce) the development of dialysis access thrombosis (",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2015",
            "CompletionDate": "August 2019",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Hemodialysis Access",
            "studyLocation": "North America Research Institute",
            "Enrollment": "886",
            "NctKeyword": "Surveillance,",
            "MeshKeyword": "Thrombosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Chronic hemodialysis patients undergoing dialysis therapy via an upper extremity\r\n\r\n             arteriovenous access (arteriovenous fistula or an arteriovenous graft) will be\r\n\r\n             enrolled to",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "Azusa",
            "State": "California",
            "Zip": "91702",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 26, 2016",
            "FirstReceived": "February 24, 2015",
            "OverallOfficial": "Loay Salman, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Ivy Machado, RN",
            "ContactPhone": "786-473-0802",
            "ContactEmail": "Ixm136@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "North America Research Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02376361",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140235 - Transonic Systems - Salman",
            "FileProcessContentId": "440",
            "Division": "Nephrology",
            "StdyDivision": "10250",
            "EprostNbr": "20140235",
            "StudyNumber": "20140235 - Transonic Systems - Salman",
            "StudyTitle": "Hemodialysis Access Surveillance Evaluation Study.",
            "PIID": "522",
            "PicNum": "C00210471",
            "PILastName": "Contreras",
            "PIFirstName": "Gabriel",
            "CoodCNbr": "C04078260",
            "CoordLastName": "Barchi-Chung",
            "CoordFirstName": "Allison",
            "CoordEmail": "abarchi@med.miami.edu",
            "CoordPhone": "305-243-5870",
            "EnteredByCNbr": "C06958078",
            "EnteredByLastName": "Salman",
            "EnteredByFirstName": "Loay",
            "ActiveEnrollingDate": "02/24/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/24/2015",
            "IRBApprovedFrom": "12/05/2014",
            "IRBApprovedTo": "10/16/2017",
            "InfoEdNbr": "71554",
            "Expr1": "N/A",
            "SponsorGroup": "Industry",
            "Sponsor": "Transonic Systems",
            "Prescreened": "4",
            "Screenedfailed": "27",
            "SignedICF": "458",
            "Totalaccrued": "286",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "136",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "460",
            "FirstNinety": "122",
            "SiteSampleSize": "UMMG:400,Albany Medical College:N/A,North America Research Institute:N/A",
            "AccrualPercentageMet": "71.5",
            "ActiveCal": "2",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "400",
            "EprostState": "Approved",
            "StudyCoordinator": "Ivy Machado,Molly Pruitt,Asma Siddiqui,Amanda Colbath,Jenny Nguyen,Shari Meola,Nicolle Bateman",
            "NationalSampleSize": "450",
            "NCTNbr": "NCT02376361",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT02381509",
            "BriefTitle": "Predicting the Safety and Effectiveness of Inferior Vena Cava Filters",
            "OfficialTitle": "Predicting the Safety and Effectiveness of Inferior Vena Cava Filters",
            "LeadSponsorClass": "New England Research Institutes",
            "SponsorAgency": "Other",
            "LeadSponsor": "New England Research Institutes",
            "OversightAuthority": "Yes",
            "BriefSummary": "PRESERVE is a multi-center, prospective, open-label, non-randomized investigation of\r\n\r\n      commercially available IVC filters from 6 manufacturers placed in subjects for the\r\n\r\n      prevention of pulmonary embolism (PE). This study will enro",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "CompletionDate": "May 2019",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "New England Research Institutes",
            "StudyCondition": "Pulmonary Embolism",
            "studyLocation": "University of Arkansas for Medical Sciences",
            "Enrollment": "1800",
            "NctKeyword": "inferior vena cava filters,",
            "MeshKeyword": "Embolism, Pulmonary Embolism,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male or Female, age 18 years or older;\r\n\r\n\r\n\r\n          -  Requires IVC filter for prevention of pulmonary embolism (PE);\r\n\r\n\r\n\r\n          -  Provide written informed consent and written HIPAA authorizat",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Zip": "72205",
            "Country": "United States",
            "VerificationDate": "October 2015",
            "LastChanged": "September 27, 2016",
            "FirstReceived": "March 2, 2015",
            "OverallOfficial": "David L. Gillespie, MD, RVT, FACS",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Southcoast Health System",
            "ContactName": "Jessica Lamp, BA",
            "ContactPhone": "617-972-3140",
            "ContactEmail": "jlamp@neriscience.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Arkansas for Medical Sciences",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02381509",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150411 - IVC Filter Study Group Foundation - Narayanan",
            "FileProcessContentId": "440",
            "Division": "Radiology",
            "StdyDivision": "10262",
            "EprostNbr": "20150411",
            "StudyNumber": "20150411 - IVC Filter Study Group Foundation - Narayanan",
            "StudyTitle": "Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE)",
            "PIID": "1237",
            "PicNum": "C04213716",
            "PILastName": "Narayanan",
            "PIFirstName": "Govindarajan",
            "CoodCNbr": "C05023785",
            "CoordLastName": "Barbery",
            "CoordFirstName": "Katuska",
            "CoordEmail": "kbarbery@med.miami.edu",
            "CoordPhone": "3052432474",
            "EnteredByCNbr": "C04213716",
            "EnteredByLastName": "Narayanan",
            "EnteredByFirstName": "Govindarajan",
            "ActiveEnrollingDate": "05/03/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/03/2016",
            "IRBApprovedFrom": "08/03/2015",
            "IRBApprovedTo": "07/31/2017",
            "Expr1": "N/A",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Foundation",
            "Sponsor": "IVC Filter Study Group Foundation",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "10",
            "Totalaccrued": "10",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "10",
            "FirstNinety": "3",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Katuska Barbery,Lia Quezada,Isabelle Beulaygue,Gunjan Arora,Gabriella Guerrero",
            "NationalSampleSize": "45",
            "NCTNbr": "NCT02381509",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02383056",
            "BriefTitle": "Doubleblinded RCT of the Omnilux on Lower Extremity Surgical Wounds Left to Heal by Second Intention",
            "OfficialTitle": "Doubleblinded, Randomized, Controlled Trial to Study the Effect of Omnilux Light Emitting Diode on Wound Healing Following Lower Extremity Surgical Wounds Left to Heal by Second Intention",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The goal of the study is to evaluate the effectiveness of the light-emitting diode (LED) in\r\n\r\n      promoting healing of the wound on lower leg as a result of surgery. Wounds on the lower leg\r\n\r\n      heal more slowly than wounds on the head an",
            "Description": "Group 2 of this study will receive the LED and half will not receive treatment with LED but\r\n\r\n      will receive a \"sham light\" treatment (Group 1). Essentially, a sham light treatment refers\r\n\r\n      to regular light (not LED) exposure for 20",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2012",
            "CompletionDate": "December 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Wound",
            "studyLocation": "University of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center",
            "Enrollment": "40",
            "NctKeyword": "wound, secondary intention healing, lower extremity,",
            "MeshKeyword": "Wounds and Injuries,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Surgical defect on the lower extremity left to heal by secondary intention.\r\n\r\n\r\n\r\n          -  If women of child bearing potential, contraceptive measures should be used\r\n\r\n\r\n\r\n          -  Maximum size",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "90 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 16, 2016",
            "FirstReceived": "February 27, 2015",
            "OverallOfficial": "Keyvan Nouri, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Keyvan Nouri, MD",
            "ContactPhone": "3052433380",
            "ContactEmail": "knouri@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02383056",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20120475 - Intramural - Nouri",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20120475",
            "StudyNumber": "20120475 - Intramural - Nouri",
            "StudyTitle": "Doubleblinded, randomized, controlled trial to study the effect of Omnilux lightemitting diode on wound healing following lower extremity surgical wounds left to heal by second intention",
            "PIID": "417",
            "PicNum": "C00756321",
            "PILastName": "Nouri",
            "PIFirstName": "Keyvan",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C02502222",
            "EnteredByLastName": "Chacon",
            "EnteredByFirstName": "Anna",
            "ActiveEnrollingDate": "11/12/2012",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/12/2012",
            "IRBApprovedFrom": "10/02/2012",
            "IRBApprovedTo": "08/26/2016",
            "Expr1": "N/A",
            "Expr2": "Others",
            "StudyType_Code": "7",
            "ResearchType": "Device",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "14",
            "Totalaccrued": "14",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "14",
            "FirstNinety": "3",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carol Kittles",
            "NationalSampleSize": "40",
            "NCTNbr": "NCT02383056",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02384460",
            "SecondaryId": "2014-002288-14",
            "BriefTitle": "ESSENCE Study: Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa",
            "OfficialTitle": "A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa",
            "LeadSponsorClass": "Scioderm, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Scioderm, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "The aim is to assess the efficacy and safety of SD-101-6.0 cream versus SD-101-0.0 (placebo)\r\n\r\n      in the treatment of patients with Epidermolysis Bullosa.",
            "Description": "Epidermolysis Bullosa (EB) is a rare group of inherited disorders that typically manifest at\r\n\r\n      birth as blistering and lesion formation on the skin and, in some cases, the epithelial\r\n\r\n      lining of other organs, in response to little",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2015",
            "CompletionDate": "September 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Scioderm, Inc.",
            "StudyCondition": "Epidermolysis Bullosa",
            "studyLocation": "Phoenix Children's Hospital",
            "Enrollment": "130",
            "NctKeyword": "Simplex, Recessive Dystrophic, Junctional non-Herlitz, Epidermolysis Bullosa,",
            "MeshKeyword": "Epidermolysis Bullosa,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Informed Consent form signed by the patient or patient's legal representative; if the\r\n\r\n             patient is under the age of 18 but capable of providing assent, signed assent from\r\n\r\n             th",
            "EligibleGender": "All",
            "MinAge": "1 Month",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85016",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 9, 2016",
            "FirstReceived": "February 13, 2015",
            "LocationStatus": "Recruiting",
            "LocationName": "Phoenix Children's Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02384460",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160616 - Scioderm/ Inc - Schachner",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20160616",
            "StudyNumber": "20160616 - Scioderm/ Inc - Schachner",
            "StudyTitle": "A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients with Epidermolysis Bullosa\nProtocol Number:\tSD-005",
            "PIID": "793",
            "PicNum": "C00433811",
            "PILastName": "Schachner",
            "PIFirstName": "Lawrence",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C00433811",
            "EnteredByLastName": "Schachner",
            "EnteredByFirstName": "Lawrence",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "09/06/2016",
            "IRBApprovedFrom": "09/06/2016",
            "IRBApprovedTo": "09/05/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Scioderm/ Inc",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Aliette Espinosa,Carol Kittles",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02384460",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02388165",
            "SecondaryId": "2014-002644-40",
            "BriefTitle": "Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation",
            "OfficialTitle": "A Phase 2b, Randomized, Double-blind, Placebo-controlled Study To Evaluate The Safety And Efficacy Of Staphylococcus Aureus 4 Antigen Vaccine (sa4ag) In Adults Undergoing Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation",
            "LeadSponsorClass": "Pfizer",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Pfizer",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent\r\n\r\n      postoperative Staphylococcus aureus infections in patients who are undergoing elective\r\n\r\n      spinal fusion surgery, and to evaluate the safety",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2015",
            "CompletionDate": "November 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Pfizer",
            "StudyCondition": "Staphylococcal Vaccine",
            "studyLocation": "UAB Highlands Orthopedic Clinic",
            "Enrollment": "2600",
            "NctKeyword": "Staphylococcal Vaccine, Post-operative Surgical Site Infection, Spinal Surgery, MRSA, Staphylococcus aureus,",
            "InterventionKeyword": "Vaccines,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject must be scheduled to undergo an elective open posterior spinal fusion\r\n\r\n             procedures with multilevel instrumentation, 10 to 60 days after study vaccination.\r\n\r\n\r\n\r\n          -  Subjec",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35205",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 4, 2017",
            "FirstReceived": "March 9, 2015",
            "OverallOfficial": "Pfizer CT.gov Call Center",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Pfizer",
            "ContactName": "Pfizer CT.gov Call Center",
            "ContactPhone": "1-800-718-1021",
            "LocationStatus": "Recruiting",
            "LocationName": "UAB Highlands Orthopedic Clinic",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02388165",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150234 - Pfizer B3451002 - Wang",
            "FileProcessContentId": "440",
            "Division": "Neurosurgery",
            "StdyDivision": "9636",
            "EprostNbr": "20150234",
            "StudyNumber": "20150234 - Pfizer B3451002 - Wang",
            "StudyTitle": "A PHASE 2b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED\nSTUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS\nAUREUS 4-ANTIGEN VACCINE (SA4Ag) IN ADULTS UNDERGOING ELECTIVE\nOPEN POSTERIOR SPINAL FUSION PROCEDURES WITH MULTILEVEL\nINSTRUMENTATION",
            "PIID": "472",
            "PicNum": "C06025344",
            "PILastName": "Wang",
            "PIFirstName": "Michael",
            "CoodCNbr": "C11326651",
            "CoordLastName": "Boyer",
            "CoordFirstName": "Brenda",
            "CoordEmail": "b.boyer@med.miami.edu",
            "CoordPhone": "305-243-4903",
            "EnteredByCNbr": "C06025344",
            "EnteredByLastName": "Wang",
            "EnteredByFirstName": "Michael",
            "ActiveEnrollingDate": "11/18/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/18/2015",
            "IRBApprovedFrom": "05/11/2015",
            "IRBApprovedTo": "04/24/2017",
            "Expr1": "Phase II",
            "Tarea": "Spine",
            "TareaCode": "9641",
            "Randomization": "Randomized",
            "Expr2": "Prevention",
            "StudyType_Code": "6163",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Pfizer",
            "Prescreened": "0",
            "Screenedfailed": "5",
            "SignedICF": "54",
            "Totalaccrued": "48",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "23",
            "Totalpatients": "54",
            "FirstNinety": "13",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Leon Smith,Brenda Boyer",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT02388165",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02388620",
            "BriefTitle": "Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011",
            "OfficialTitle": "A Phase I, Open Label, Multi-center, Parallel Cohort, Single Dose Study to Evaluate the Pharmacokinetics of LEE011 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.",
            "LeadSponsorClass": "Novartis Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novartis Pharmaceuticals",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to evaluate the pharmacokinetics (PK), safety and tolerability\r\n\r\n      of a single oral dose of LEE011 in subjects with varying degrees of impaired hepatic\r\n\r\n      function (based on Child-Pugh classification) as c",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2015",
            "CompletionDate": "January 2017",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Novartis",
            "StudyCondition": "Normal Hepatic Function",
            "studyLocation": "Anaheim Clinical Trials",
            "Enrollment": "30",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        All Subjects:\r\n\r\n\r\n\r\n        Male or female (sterile or postmenopausal) subjects between 18-75 (both inclusive) years\r\n\r\n        of age and healthy as determined by absence of clinically significant deviation",
            "EligibleGender": "Male",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Anaheim",
            "State": "California",
            "Zip": "92801",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 21, 2016",
            "FirstReceived": "March 2, 2015",
            "OverallOfficial": "Novartis Pharmaceuticals",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Novartis Pharmaceuticals",
            "ContactName": "Novartis Pharmaceuticals",
            "ContactPhone": "1-888-669-6682",
            "LocationStatus": "Recruiting",
            "LocationName": "Anaheim Clinical Trials",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02388620",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150092 - Novartis - Preston",
            "FileProcessContentId": "440",
            "Division": "Clinical Pharmacology",
            "StdyDivision": "10237",
            "EprostNbr": "20150092",
            "StudyNumber": "20150092 - Novartis - Preston",
            "StudyTitle": "Protocol CLEE011A2109\n\nA phase I, open label, multi-center, parallel cohort, single dose study to evaluate the pharmacokinetics of LEE011 in healthy subjects with normal hepatic function and subjects with impaired hepatic function",
            "PIID": "714",
            "PicNum": "C00648067",
            "PILastName": "Preston",
            "PIFirstName": "Richard",
            "CoodCNbr": "C00750489",
            "CoordLastName": "Acosta",
            "CoordFirstName": "Olga",
            "CoordEmail": "OAcosta@med.miami.edu",
            "CoordPhone": "3052437630",
            "EnteredByCNbr": "C00648067",
            "EnteredByLastName": "Preston",
            "EnteredByFirstName": "Richard",
            "ActiveEnrollingDate": "03/23/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/23/2015",
            "IRBApprovedFrom": "03/09/2015",
            "IRBApprovedTo": "03/06/2017",
            "Expr1": "Phase I",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Novartis",
            "Prescreened": "0",
            "Screenedfailed": "13",
            "SignedICF": "29",
            "Totalaccrued": "16",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "29",
            "FirstNinety": "12",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Barry Materson,Alberto Alonso,Rolando Rodco",
            "NationalSampleSize": "50",
            "NCTNbr": "NCT02388620",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02390284",
            "SecondaryId": "R01EY014957",
            "BriefTitle": "Stop Retinal Ganglion Cell Dysfunction Study",
            "OfficialTitle": "Stop Retinal Ganglion Cell Dysfunction Study",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "Glaucoma is a progressive disease resulting in blindness. Determining the onset of the\r\n\r\n      disease, predicting its severity and the benefit of pressure lowering eye drops is key to\r\n\r\n      clinical management aimed at maintaining useful vi",
            "Description": "The PERG is recorded from small metallic buttons taped on the skin similarly to an\r\n\r\n      electrocardiogram, with the difference that the electrodes are around the eyes.\r\n\r\n\r\n\r\n      The only physical contact you will experience is a gentle cl",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2014",
            "CompletionDate": "July 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "University of Miami",
            "StudyCondition": "Glaucoma",
            "studyLocation": "Bascom Palmer Eye Institute - University of Miami",
            "Enrollment": "500",
            "NctKeyword": "RGCD, Glaucoma Suspect,",
            "MeshKeyword": "Glaucoma,",
            "InterventionKeyword": "Dorzolamide, Latanoprost, Bimatoprost, Timolol, Travoprost, Methazolamide, Acetazolamide, Brinzolamide,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age 18 to 85 years, inclusive\r\n\r\n\r\n\r\n          2. Refractive errors within -5 to +3 diopters\r\n\r\n\r\n\r\n          3. Best corrected visual acuity (BCVA) better than or equal to 20/30 (Snellen)",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "85 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 17, 2016",
            "FirstReceived": "March 10, 2015",
            "OverallOfficial": "Vittorio Porciattti, DSc",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Marlene Colon, RC",
            "ContactPhone": "305 482 4309",
            "ContactEmail": "mcolon@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Bascom Palmer Eye Institute - University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02390284",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140587 - National Eye Institute - Porciatti",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20140587",
            "StudyNumber": "20140587 - National Eye Institute - Porciatti",
            "StudyTitle": "Stop Retinal Ganglion Cell Dysfunction in Early Glaucoma",
            "PIID": "947",
            "PicNum": "C01976078",
            "PILastName": "Porciatti",
            "PIFirstName": "Vittorio",
            "CoodCNbr": "C01976078",
            "CoordLastName": "Porciatti",
            "CoordFirstName": "Vittorio",
            "CoordEmail": "v.porciatti@miami.edu",
            "CoordPhone": "3053266050",
            "EnteredByCNbr": "C01976078",
            "EnteredByLastName": "Porciatti",
            "EnteredByFirstName": "Vittorio",
            "ActiveEnrollingDate": "07/22/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/22/2015",
            "IRBApprovedFrom": "09/08/2014",
            "IRBApprovedTo": "06/26/2017",
            "Expr1": "Phase III",
            "Tarea": "Glaucoma",
            "TareaCode": "12037",
            "ResearchType": "Drug",
            "SponsorGroup": "Other",
            "Sponsor": "National Eye Institute",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "25",
            "Totalaccrued": "23",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "22",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "25",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A,ABLEH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Marlene P. Perez",
            "NationalSampleSize": "500",
            "NCTNbr": "NCT02390284",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02392234",
            "SecondaryId": "2014-004788-18",
            "BriefTitle": "A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation",
            "OfficialTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR",
            "LeadSponsorClass": "Vertex Pharmaceuticals Incorporated",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Vertex Pharmaceuticals Incorporated",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate the efficacy of VX-661 in combination with\r\n\r\n      ivacaftor and ivacaftor monotherapy in subjects with Cystic Fibrosis (CF).",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "March 2015",
            "CompletionDate": "March 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Vertex Pharmaceuticals Incorporated",
            "StudyCondition": "Cystic Fibrosis",
            "Enrollment": "300",
            "MeshKeyword": "Fibrosis, Cystic Fibrosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Heterozygous for F508del-CFTR and a second allele with a CFTR mutation predicted to\r\n\r\n             have residual function\r\n\r\n\r\n\r\n          -  Forced Expiratory Volume in 1 Second (FEV1) greater than or",
            "EligibleGender": "All",
            "MinAge": "12 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "August 30, 2016",
            "FirstReceived": "March 12, 2015",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02392234",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160097 - Vertex Pharmaceuticals - Salathe",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20160097",
            "StudyNumber": "20160097 - Vertex Pharmaceuticals - Salathe",
            "StudyTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function",
            "PIID": "528",
            "PicNum": "C00319179",
            "PILastName": "Salathe",
            "PIFirstName": "Matthias",
            "CoodCNbr": "C09943370",
            "CoordLastName": "Aguiar",
            "CoordFirstName": "Carolina",
            "CoordEmail": "caguiar2@med.miami.edu",
            "CoordPhone": "3052435545",
            "EnteredByCNbr": "C00319179",
            "EnteredByLastName": "Salathe",
            "EnteredByFirstName": "Matthias",
            "ActiveEnrollingDate": "06/21/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/21/2016",
            "IRBApprovedFrom": "04/26/2016",
            "IRBApprovedTo": "04/25/2017",
            "Expr1": "Phase III",
            "Tarea": "Cystic Fibrosis (CF)",
            "TareaCode": "13442",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Vertex Pharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Henry Boza,Maylen Rodriguez,Carolina Aguiar,Patricia Graham-Borras",
            "AgentDevices": "VX661 and Ivacaftor",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02392234",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02395653",
            "BriefTitle": "Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Patients",
            "OfficialTitle": "An Open Label Evaluation of the Safety and Clinical Utility of the Active, Separated System With Enhanced Controller (SSEC) Fentanyl 40mcg for the Management of Acute Postoperative Pain in Pediatric Patients 12 to Less Than 18 Years of Age",
            "LeadSponsorClass": "The Medicines Company",
            "SponsorAgency": "Industry",
            "LeadSponsor": "The Medicines Company",
            "OversightAuthority": "No",
            "BriefSummary": "The objective of this study is to evaluate the safety and clinical utility of the active,\r\n\r\n      SSEC fentanyl 40 mcg for the management of acute, postoperative pain in pediatric patients.",
            "Description": "An open label evaluation of the safety and clinical utility of the active, separated system\r\n\r\n      with enhanced controller (SSEC) fentanyl 40 mcg for the management of acute postoperative\r\n\r\n      pain in pediatric patients 12 to less than 18",
            "OverallStatus": "Completed",
            "StartDate": "June 2015",
            "CompletionDate": "September 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "The Medicines Company",
            "StudyCondition": "Pain, Postoperative",
            "studyLocation": "Packard Children's Hospital at Stanford",
            "Enrollment": "62",
            "NctKeyword": "Pediatric, Postoperative, Pain Management,",
            "MeshKeyword": "Pain, Postoperative,",
            "InterventionKeyword": "Fentanyl,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients whose parent(s) or guardian(s) have/has signed and dated an informed consent\r\n\r\n             form for the patient to participate in the study, or patients who have provided\r\n\r\n             writt",
            "EligibleGender": "All",
            "MinAge": "12 Years",
            "MaxAge": "18 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Palo Alto",
            "State": "California",
            "Zip": "94304",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 15, 2016",
            "FirstReceived": "March 10, 2015",
            "OverallOfficial": "Elliot J Krane, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Stanford Children's Health",
            "LocationName": "Packard Children's Hospital at Stanford",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02395653",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150494 - Incline Therapeutics/ Inc. - Missair",
            "FileProcessContentId": "440",
            "Division": "Anesthesiology",
            "StdyDivision": "10236",
            "EprostNbr": "20150494",
            "StudyNumber": "20150494 - Incline Therapeutics/ Inc. - Missair",
            "StudyTitle": "An open label evaluation of the safety and clinical utility of the active, separated system with enhanced controller (SSEC) fentanyl 40 mcg for the management of acute postoperative pain in pediatric patients 12 to less than 18 years of age.",
            "PIID": "1774",
            "PicNum": "C06025033",
            "PILastName": "Missair",
            "PIFirstName": "Andres",
            "CoodCNbr": "C10565278",
            "CoordLastName": "Gutierrez",
            "CoordFirstName": "Juan",
            "CoordEmail": "JGutierrez4@med.miami.edu",
            "EnteredByCNbr": "C06025033",
            "EnteredByLastName": "Missair",
            "EnteredByFirstName": "Andres",
            "ActiveEnrollingDate": "07/13/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/13/2016",
            "IRBApprovedFrom": "10/06/2015",
            "IRBApprovedTo": "08/01/2017",
            "Expr1": "Phase III",
            "Tarea": "Pain Management",
            "TareaCode": "16648",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Incline Therapeutics/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "4",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "2",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Juan Gutierrez,Lilibet Fernandez Valdes",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02395653",
            "StudyKeywords": "Pain, Post operative pain, fentanyl, Ionsys, opioids, pediatric pain",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02396732",
            "BriefTitle": "Aspirin and Enoxaparin for VTE in Trauma",
            "OfficialTitle": "The Role Of Combined Therapy With Aspirin and Enoxaparin In Prevention Of Venous Thromboembolism In Trauma Patients: A Randomized-Controlled Trial",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine if the addition of antiplatelet therapy (i.e.\r\n\r\n      aspirin) to low-molecular-weight-heparin (i.e. enoxaparin) will decrease the incidence of\r\n\r\n      venous thromboembolism (VTE) in high-risk critica",
            "Description": "This is a prospective, randomized, controlled, open-label clinical trial evaluating the\r\n\r\n      effect of dual thromboprophylaxis with enoxaparin and aspirin versus enoxaparin alone on the\r\n\r\n      incidence of VTE in trauma patients. Once a tr",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "February 2016",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "University of Miami",
            "StudyCondition": "Venous Thromboembolism",
            "Enrollment": "800",
            "NctKeyword": "Aspirin, Enoxaparin, Thromboprophylaxis, Trauma, Venous thromboembolism,",
            "MeshKeyword": "Wounds and Injuries, Venous Thromboembolism, Thromboembolism,",
            "InterventionKeyword": "Aspirin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Age 18 years or older\r\n\r\n\r\n\r\n          -  Blunt or penetrating trauma\r\n\r\n\r\n\r\n          -  Requires VTE thromboprophylaxis\r\n\r\n\r\n\r\n          -  High-risk for VTE\r\n\r\n\r\n\r\n        Exclusion Criteria:",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "VerificationDate": "April 2016",
            "LastChanged": "April 11, 2016",
            "FirstReceived": "March 12, 2015",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02396732",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140937 - Intramural - Proctor",
            "FileProcessContentId": "440",
            "Division": "Emergency Medicine",
            "StdyDivision": "10240",
            "EprostNbr": "20140937",
            "StudyNumber": "20140937 - Intramural - Proctor",
            "StudyTitle": "The Role Of Combined Therapy with Aspirin and Enoxaparin In Prevention Of Venous Thromboembolism In Trauma Patients: A Randomized-Controlled Trial",
            "PIID": "913",
            "PicNum": "C01985801",
            "PILastName": "Proctor",
            "PIFirstName": "Kenneth",
            "CoodCNbr": "C00610103",
            "CoordLastName": "Manning",
            "CoordFirstName": "Ronald",
            "CoordEmail": "rmanning@med.miami.edu",
            "CoordPhone": "3053554972",
            "EnteredByCNbr": "C01985801",
            "EnteredByLastName": "Proctor",
            "EnteredByFirstName": "Kenneth",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "06/01/2015",
            "IRBApprovedFrom": "06/01/2015",
            "IRBApprovedTo": "08/14/2017",
            "Expr1": "Phase IV",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Ronald Manning",
            "NationalSampleSize": "2000",
            "NCTNbr": "NCT02396732",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT02398604",
            "BriefTitle": "Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome",
            "OfficialTitle": "Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.",
            "LeadSponsorClass": "Joshua M Hare",
            "SponsorAgency": "Other",
            "LeadSponsor": "Joshua M Hare",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study is intended to evaluate the safety and feasibility of intramyocardial injection\r\n\r\n      of allogeneic mesenchymal cells during the Bi-Directional Cavopulmonary Anastomosis (BDCPA)\r\n\r\n      surgery for hypoplastic left heart syndrome",
            "Description": "This is an open label study, intended as a safety and efficacy assessment prior to a full\r\n\r\n      comparator study. In this Phase I study, cells administered will be delivered in 6\r\n\r\n      intramyocardial injections that will be tested in 15 p",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2015",
            "CompletionDate": "October 2022",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Hypoplastic Left Heart Syndrome",
            "studyLocation": "University of Maryland Medical Center",
            "Enrollment": "30",
            "NctKeyword": "Pediatrics, HLHS,",
            "MeshKeyword": "Syndrome, Hypoplastic Left Heart Syndrome,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subjects with hypoplastic left heart syndrome (all types) requiring BDCPA surgery.\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -  Have HLHS and restrictive or intact atrial septum.",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "28 Days",
            "Volunteers": "No",
            "City": "Baltimore",
            "State": "Maryland",
            "Zip": "21201",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 14, 2016",
            "FirstReceived": "December 24, 2014",
            "OverallOfficial": "Sunjay Kaushal, MD, Ph.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Maryland",
            "ContactName": "Joshua M Hare, MD",
            "ContactPhone": "305-243-5579",
            "ContactEmail": "jhare@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Maryland Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02398604",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140718 - Intramural - Hare",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20140718",
            "StudyNumber": "20140718 - Intramural - Hare",
            "StudyTitle": "ELPIS: Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients with Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.",
            "PIID": "896",
            "PicNum": "C05065867",
            "PILastName": "Hare",
            "PIFirstName": "Joshua",
            "CoodCNbr": "C00194136",
            "CoordLastName": "Pujol",
            "CoordFirstName": "Marietsy",
            "CoordEmail": "mpujol@med.miami.edu",
            "CoordPhone": "3052437273",
            "EnteredByCNbr": "C05065867",
            "EnteredByLastName": "Hare",
            "EnteredByFirstName": "Joshua",
            "ActiveEnrollingDate": "01/29/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/29/2016",
            "IRBApprovedFrom": "04/21/2015",
            "IRBApprovedTo": "04/18/2017",
            "Expr1": "Pilot/Feasibility",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Darcy Difede,Lina Caceres Cardenas,Mayra Vidro Casiano,Russell Saltzman,Jairo Tovar,Cindy Delgado",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02398604",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02400242",
            "BriefTitle": "Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma",
            "OfficialTitle": "A Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Antitumor Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma",
            "LeadSponsorClass": "Acetylon Pharmaceuticals Incorporated",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Acetylon Pharmaceuticals Incorporated",
            "OversightAuthority": "No",
            "BriefSummary": "This is a phase 1a/1b, multicenter, single-arm, open-label, dose escalation study to\r\n\r\n      determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary antitumor\r\n\r\n      activity of ACY-241 for oral administration as mo",
            "Description": "During phase 1a, patients will receive 1 cycle of ACY-241 monotherapy. Patients who complete\r\n\r\n      the ACY-241 monotherapy cycle without a dose limiting toxicity (DLT) and are clinically\r\n\r\n      stable may continue to phase 1b combination th",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2015",
            "CompletionDate": "April 2017",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Acetylon Pharmaceuticals Incorporated",
            "StudyCondition": "Multiple Myeloma",
            "studyLocation": "University of Arizona",
            "Enrollment": "115",
            "MeshKeyword": "Multiple Myeloma, Neoplasms, Plasma Cell,",
            "InterventionKeyword": "Dexamethasone acetate, Dexamethasone, Dexamethasone 21-phosphate, Pomalidomide, Thalidomide, BB 1101, Histone Deacetylase Inhibitors,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Must have a documented diagnosis of MM and have relapsed or relapsed-and-refractory\r\n\r\n             disease. All patients must have relapsed after having achieved at least stable\r\n\r\n             dise",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Tucson",
            "State": "Arizona",
            "Zip": "8719",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 12, 2016",
            "FirstReceived": "March 3, 2015",
            "OverallOfficial": "Ruben Niesvizky, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Weill Medical College of Cornell University",
            "ContactName": "Lisa M Smith",
            "ContactPhone": "617-245-1332",
            "ContactEmail": "lsmith@acetylon.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Arizona",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02400242",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150654 - Acetylon Pharmaceuticals - Hoffman",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150654",
            "StudyNumber": "20150654 - Acetylon Pharmaceuticals - Hoffman",
            "StudyTitle": "A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma",
            "PIID": "4418",
            "PicNum": "C11465246",
            "PILastName": "Hoffman",
            "PIFirstName": "James",
            "CoodCNbr": "C11954409",
            "CoordLastName": "Ogden",
            "CoordFirstName": "Jillian",
            "CoordEmail": "jbo25@miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "03/11/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/11/2016",
            "IRBApprovedFrom": "11/02/2015",
            "IRBApprovedTo": "10/16/2017",
            "AccountNbr": "666309",
            "DiseaseSiteListDesc": "Multiple Myeloma",
            "Expr1": "Phase I",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "5",
            "Totalaccrued": "3",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "5",
            "FirstNinety": "2",
            "SiteSampleSize": "UMHC:4,UMMG:N/A",
            "AccrualPercentageMet": "75",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "4",
            "EprostState": "Approved",
            "StudyCoordinator": "Yvonne Dinh,Randy Astaiza,Tamara Leon Aliz",
            "NationalSampleSize": "4",
            "NCTNbr": "NCT02400242",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02401048",
            "BriefTitle": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas",
            "OfficialTitle": "A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Lymphomas",
            "LeadSponsorClass": "Pharmacyclics LLC.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Pharmacyclics LLC.",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to evaluate the efficacy, safety and tolerability of the\r\n\r\n      combination treatment of ibrutinib and MEDI4736 in patients with relapsed or refractory\r\n\r\n      lymphomas.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "May 2015",
            "CompletionDate": "July 2018",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Pharmacyclics LLC.",
            "StudyCondition": "Diffuse Large B-Cell Lymphoma",
            "studyLocation": "Site-0397",
            "Enrollment": "109",
            "MeshKeyword": "Lymphoma, Follicular, Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse,",
            "InterventionKeyword": "Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Pathologically documented relapsed or refractory diffuse large B-cell lymphoma\r\n\r\n             (DLBCL) or follicular lymphoma (FL)\r\n\r\n\r\n\r\n          -  Measurable disease sites on CT scan (>1.5 cm in long",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 10, 2016",
            "FirstReceived": "March 4, 2015",
            "LocationName": "Site-0397",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02401048",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150903 - Pharmacyclics - Rosenblatt",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150903",
            "StudyNumber": "20150903 - Pharmacyclics - Rosenblatt",
            "StudyTitle": "A Multi-Center Open-Label Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Lymphomas",
            "PIID": "442",
            "PicNum": "C02006947",
            "PILastName": "Rosenblatt",
            "PIFirstName": "Joseph",
            "CoodCNbr": "C11964599",
            "CoordLastName": "Martinez",
            "CoordFirstName": "Micaela",
            "CoordEmail": "mem334@miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "08/16/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/16/2016",
            "IRBApprovedFrom": "04/05/2016",
            "IRBApprovedTo": "04/04/2017",
            "AccountNbr": "667368",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma",
            "Expr1": "Phase I/II",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Pharmacyclics",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "3",
            "FirstNinety": "3",
            "SiteSampleSize": "Plantation:N/A,UMMG:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Rachel Pallapati,Nathalie Luis",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02401048",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02401815",
            "BriefTitle": "PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors",
            "OfficialTitle": "A Phase 1b Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors and Patients With Locally Advanced, Unresectable, or Metast",
            "LeadSponsorClass": "Plexxikon",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Plexxikon",
            "OversightAuthority": "No",
            "BriefSummary": "The goal of this clinical research study is to learn how PLX9486 may affect cancer cells\r\n\r\n      with certain mutations in the KIT gene, specifically in patients with types of advanced\r\n\r\n      solid tumors including Gastrointestinal Stromal Tu",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2015",
            "CompletionDate": "September 2018",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Plexxikon",
            "StudyCondition": "Gastrointestinal Stromal Tumors",
            "studyLocation": "Plexxikon Investigative Site",
            "Enrollment": "92",
            "NctKeyword": "Gastrointestinal Stromal Tumors, KIT, Biomarkers, PLX9486, PLX3397,",
            "MeshKeyword": "Gastrointestinal Stromal Tumors,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male or female ≥ 18 years old\r\n\r\n\r\n\r\n          -  Part 1 and Part 2b: Patients with advanced solid tumors who have tumor progression\r\n\r\n             following standard therapy, have treatment-refractory",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90095",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 21, 2016",
            "FirstReceived": "March 19, 2015",
            "ContactName": "Oscar Alcantar",
            "ContactEmail": "oalcantar@plexxikon.com",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "Plexxikon Investigative Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02401815",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150108 - Plexxikon - Trent",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150108",
            "StudyNumber": "20150108 - Plexxikon - Trent",
            "StudyTitle": "A Phase 1b Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX9486 as a Single Agent and in Combination with PLX3397 in Patients with Advanced Solid Tumors and Patients with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) Who Have Been Previously Treated with Imatinib Mesylate, Sunitinib Malate, and Regorafanib",
            "PIID": "3651",
            "PicNum": "C10602427",
            "PILastName": "Trent",
            "PIFirstName": "Jonathan",
            "CoodCNbr": "C11968022",
            "CoordLastName": "Leon Aliz",
            "CoordFirstName": "Tamara",
            "CoordEmail": "txl351@med.miami.edu",
            "EnteredByCNbr": "C11917328",
            "EnteredByLastName": "Englund",
            "EnteredByFirstName": "Kristen",
            "ActiveEnrollingDate": "04/03/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/03/2015",
            "IRBApprovedFrom": "03/20/2015",
            "IRBApprovedTo": "09/06/2016",
            "AccountNbr": "664835",
            "InfoEdNbr": "74863",
            "DiseaseSiteListDesc": "Soft Tissue",
            "Expr1": "Phase I",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Plexxikon, Inc.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "3",
            "Totalpatients": "4",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Karen Blackburn,Daniel Sumarriva,Sandra Pineda,Yvonne Dinh",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02401815",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02402660",
            "SecondaryId": "R01FD004098",
            "BriefTitle": "Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease",
            "OfficialTitle": "A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease",
            "LeadSponsorClass": "Alkeus Pharmaceuticals, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Alkeus Pharmaceuticals, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine the long term safety and tolerability of ALK-001\r\n\r\n      (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of\r\n\r\n      Stargardt disease in patients between the ages of",
            "Description": "This is a multicenter, randomized, double-masked, parallel group, placebo-controlled study\r\n\r\n      evaluating the effects of ALK-001 administered daily by mouth in subjects with Stargardt\r\n\r\n      disease (ABCA4-related).\r\n\r\n\r\n\r\n      Stargardt",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "CompletionDate": "March 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Alkeus Pharmaceuticals, Inc.",
            "StudyCondition": "Stargardt Disease",
            "studyLocation": "University of California Los Angeles - Jules Stein Eye Institute",
            "Enrollment": "50",
            "MeshKeyword": "Macular Degeneration,",
            "Eligibility": "Simplified Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male or female between 12 and 60 years old (inclusive), with any visual acuity\r\n\r\n\r\n\r\n          -  Has a clinical diagnosis of typical autosomal recessive Stargardt macular dystrophy",
            "EligibleGender": "All",
            "MinAge": "12 Years",
            "MaxAge": "60 Years",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90095",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 5, 2016",
            "FirstReceived": "March 9, 2015",
            "OverallOfficial": "Hendrik Scholl, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "University of Basel",
            "ContactName": "Leonide Saad, PhD",
            "ContactPhone": "800-287-2755",
            "ContactEmail": "trials@alkeus.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of California Los Angeles - Jules Stein Eye Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02402660",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150709 - Intramural - Lam",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20150709",
            "StudyNumber": "20150709 - Intramural - Lam",
            "StudyTitle": "A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease",
            "PIID": "1115",
            "PicNum": "C00679155",
            "PILastName": "Lam",
            "PIFirstName": "Byron",
            "CoodCNbr": "C07458455",
            "CoordLastName": "Morante",
            "CoordFirstName": "Alexis",
            "CoordEmail": "amorante@med.miami.edu",
            "EnteredByCNbr": "C00679155",
            "EnteredByLastName": "Lam",
            "EnteredByFirstName": "Byron",
            "ActiveEnrollingDate": "04/19/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/19/2016",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Alexis Morante,Jennifer Verriotto,Potyra Rosa",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02402660",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02403674",
            "SecondaryId": "2014-003382-17",
            "BriefTitle": "Comparison of MK-1439A and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus (HIV)-Infected Participants (MK-1439A-021)",
            "OfficialTitle": "A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects",
            "LeadSponsorClass": "Merck Sharp & Dohme Corp.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Merck Sharp & Dohme Corp.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to compare the antiretroviral activity of MK-1439A, a\r\n\r\n      single-tablet, once-daily (q.d.) fixed-dose combination (FDC) containing MK-1439 100 mg +\r\n\r\n      lamivudine 300 mg + tenofovir disoproxil fumarate 300",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "June 2015",
            "CompletionDate": "February 2020",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Merck Sharp & Dohme Corp.",
            "StudyCondition": "Human Immunodeficiency Virus (HIV)",
            "Enrollment": "680",
            "MeshKeyword": "Immunologic Deficiency Syndromes, Acquired Immunodeficiency Syndrome, HIV Infections,",
            "InterventionKeyword": "Tenofovir, Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Is HIV-1 positive as determined by a positive result on an enzyme-immunoassay, has\r\n\r\n             screening plasma HIV-1 RNA (determined by the central laboratory) ≥1000 copies/mL\r\n\r\n             within",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "VerificationDate": "January 2017",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "March 26, 2015",
            "OverallOfficial": "Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Merck Sharp & Dohme Corp.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02403674",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150363 - Merck & Co. - Campo",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20150363",
            "StudyNumber": "20150363 - Merck & Co. - Campo",
            "StudyTitle": "A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)",
            "PIID": "233",
            "PicNum": "C00432804",
            "PILastName": "Castro",
            "PIFirstName": "Jose",
            "CoodCNbr": "C00548607",
            "CoordLastName": "Salvarrey",
            "CoordFirstName": "Annie",
            "CoordEmail": "als215@miami.edu",
            "CoordPhone": "+1 (305) 243-4668",
            "EnteredByCNbr": "C00552940",
            "EnteredByLastName": "Campo",
            "EnteredByFirstName": "Rafael E.",
            "ActiveEnrollingDate": "03/29/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/29/2016",
            "IRBApprovedFrom": "07/21/2015",
            "IRBApprovedTo": "07/04/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Merck & Co.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Kenia Moreno,Tom Tanner",
            "NationalSampleSize": "14",
            "NCTNbr": "NCT02403674",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02403674",
            "SecondaryId": "2014-003382-17",
            "BriefTitle": "Comparison of MK-1439A and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus (HIV)-Infected Participants (MK-1439A-021)",
            "OfficialTitle": "A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects",
            "LeadSponsorClass": "Merck Sharp & Dohme Corp.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Merck Sharp & Dohme Corp.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to compare the antiretroviral activity of MK-1439A, a\r\n\r\n      single-tablet, once-daily (q.d.) fixed-dose combination (FDC) containing MK-1439 100 mg +\r\n\r\n      lamivudine 300 mg + tenofovir disoproxil fumarate 300",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "June 2015",
            "CompletionDate": "February 2020",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Merck Sharp & Dohme Corp.",
            "StudyCondition": "Human Immunodeficiency Virus (HIV)",
            "Enrollment": "680",
            "MeshKeyword": "Immunologic Deficiency Syndromes, Acquired Immunodeficiency Syndrome, HIV Infections,",
            "InterventionKeyword": "Tenofovir, Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Is HIV-1 positive as determined by a positive result on an enzyme-immunoassay, has\r\n\r\n             screening plasma HIV-1 RNA (determined by the central laboratory) ≥1000 copies/mL\r\n\r\n             within",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "VerificationDate": "January 2017",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "March 26, 2015",
            "OverallOfficial": "Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Merck Sharp & Dohme Corp.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02403674",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150335 - Merck & Co. - Campo",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20150335",
            "StudyNumber": "20150335 - Merck & Co. - Campo",
            "StudyTitle": "A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once Daily Versus Atripla Once daily in Treatment Naïve HIV-1 Infected Subjects",
            "PIID": "233",
            "PicNum": "C00432804",
            "PILastName": "Castro",
            "PIFirstName": "Jose",
            "CoodCNbr": "C00548607",
            "CoordLastName": "Salvarrey",
            "CoordFirstName": "Annie",
            "CoordEmail": "als215@miami.edu",
            "CoordPhone": "+1 (305) 243-4668",
            "EnteredByCNbr": "C00552940",
            "EnteredByLastName": "Campo",
            "EnteredByFirstName": "Rafael E.",
            "ActiveEnrollingDate": "10/01/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/01/2015",
            "IRBApprovedFrom": "07/21/2015",
            "IRBApprovedTo": "07/18/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Merck & Co.",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "15",
            "Totalaccrued": "10",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "10",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "15",
            "FirstNinety": "6",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Kenia Moreno,Tom Tanner",
            "NationalSampleSize": "16",
            "NCTNbr": "NCT02403674",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02404545",
            "BriefTitle": "Prevention of Parastomal Hernia by Mesh Placement",
            "OfficialTitle": "A Randomized Study of the Utility of Composite Mesh Placement to Prevent Parastomal Hernia in Patients Undergoing Urinary Diversion With Ileal Conduit",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "Total cystectomy (surgical removal of the bladder) is performed in a number of settings,\r\n\r\n      including invasive bladder cancer and radiation cystitis. This requires a urinary diversion\r\n\r\n      to be performed. The most common type of urina",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "CompletionDate": "April 2021",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Parastomal Hernia",
            "studyLocation": "University Of Miami Hospital",
            "Enrollment": "60",
            "NctKeyword": "Hernia, Mesh, Ileal conduit,",
            "MeshKeyword": "Hernia,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Patients eligible to undergo urinary diversion with ileal conduit.\r\n\r\n\r\n\r\n          2. Patients with the ability to understand and willingness to sign a written informed\r\n\r\n             consent document.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 17, 2016",
            "FirstReceived": "March 26, 2015",
            "OverallOfficial": "Murugesan Manoharan, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Fanchette Auguste, RN",
            "ContactPhone": "3052437207",
            "ContactEmail": "f.auguste@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University Of Miami Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02404545",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140277 - Intramural - Manoharan",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140277",
            "StudyNumber": "20140277 - Intramural - Manoharan",
            "StudyTitle": "A randomized study of the utility of composite mesh placement to prevent parastomal hernia in patients undergoing urinary diversion with ileal conduit",
            "PIID": "401",
            "PicNum": "C03158387",
            "PILastName": "Manoharan",
            "PIFirstName": "Murugesan",
            "CoodCNbr": "C11969658",
            "CoordLastName": "Barakat",
            "CoordFirstName": "Rody",
            "CoordEmail": "rxb773@med.miami.edu",
            "EnteredByCNbr": "C11904602",
            "EnteredByLastName": "Harb De La Rosa",
            "EnteredByFirstName": "Alfredo",
            "ActiveEnrollingDate": "04/07/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/07/2015",
            "IRBApprovedFrom": "04/07/2015",
            "IRBApprovedTo": "04/04/2017",
            "DiseaseSiteListDesc": "Other Urinary",
            "Expr1": "Phase II/III",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Randomization": "Randomized",
            "Expr2": "Prevention",
            "StudyType_Code": "6163",
            "ResearchType": "Device",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "12",
            "Totalaccrued": "12",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "12",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,Plantation:N/A,UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Fanchette Auguste,Marinellie Vega,Alfredo Harb De La Rosa",
            "NationalSampleSize": "60",
            "NCTNbr": "NCT02404545",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02408861",
            "SecondaryId": "NCI-2015-00461",
            "BriefTitle": "Nivolumab and Ipilimumab in Treating Patients With HIV Associated Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
            "OfficialTitle": "A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "No",
            "BriefSummary": "This phase I trial studies the side effects and best dose of nivolumab when given with\r\n\r\n      ipilimumab in treating patients with human immunodeficiency virus (HIV) associated solid\r\n\r\n      tumors have spread to other places in the body or c",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To demonstrate safety and feasibility of ipilimumab and nivolumab at the standard doses\r\n\r\n      of drug in solid tumor participants with human immunodeficiency virus (HIV) infection given\r\n\r\n      the possibi",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Advanced Solid Neoplasm",
            "studyLocation": "UCLA Center for Clinical AIDS Research and Education",
            "Enrollment": "42",
            "MeshKeyword": "Neoplasms, Carcinoma, HIV Infections, Lung Neoplasms, Sarcoma, Kaposi, Anus Neoplasms,",
            "InterventionKeyword": "Nivolumab, Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Participants must have histologically confirmed solid tumor malignancy that is\r\n\r\n             metastatic or unresectable and for which standard curative or palliative measures do\r\n\r\n             not exi",
            "EligibleGender": "All",
            "MinAge": "19 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90035",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "April 3, 2015",
            "OverallOfficial": "Lakshmi Rajdev",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "AIDS Malignancy Consortium",
            "LocationStatus": "Recruiting",
            "LocationName": "UCLA Center for Clinical AIDS Research and Education",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02408861",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160656 - AMC - Ramos",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160656",
            "StudyNumber": "20160656 - AMC - Ramos",
            "StudyTitle": "A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors",
            "PIID": "433",
            "PicNum": "C03978871",
            "PILastName": "Ramos",
            "PIFirstName": "Juan Carlos",
            "CoodCNbr": "C11923689",
            "CoordLastName": "Mohan",
            "CoordFirstName": "Vivin",
            "CoordEmail": "vxm153@miami.edu",
            "EnteredByCNbr": "C11964150",
            "EnteredByLastName": "Smith",
            "EnteredByFirstName": "Nyesha",
            "ActiveEnrollingDate": "01/06/2017",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/06/2017",
            "IRBApprovedFrom": "08/15/2016",
            "IRBApprovedTo": "08/14/2017",
            "DiseaseSiteListDesc": "Lip, Oral Cavity and Pharynx,Other Hematopoietic,Anus,Lung",
            "Expr1": "Phase I",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Sandra O'Mellan,Nathalie Luis",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT02408861",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02420756",
            "BriefTitle": "Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study",
            "OfficialTitle": "Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study",
            "LeadSponsorClass": "American College of Radiology Imaging Network",
            "SponsorAgency": "Other",
            "LeadSponsor": "American College of Radiology Imaging Network",
            "OversightAuthority": "No",
            "BriefSummary": "The Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study will establish an\r\n\r\n      open-label, longitudinal cohort study to assess the impact of amyloid PET on patient\r\n\r\n      outcomes. The study will be performed in accordance with th",
            "Description": "The IDEAS Study is an observational, open-label, longitudinal cohort study designed to\r\n\r\n      assess the impact of amyloid PET on patient-oriented outcomes in Medicare beneficiaries with\r\n\r\n      mild cognitive impairment (MCI) or dementia of",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "CompletionDate": "February 2019",
            "Phase": "N/A",
            "StudyType": "Observational [Patient Registry]",
            "StudyPhase": "N/A",
            "StudySource": "American College of Radiology Imaging Network",
            "StudyCondition": "Alzheimer's Disease",
            "studyLocation": "See website for sites: http://www.ideas-study.org/list-of-active-sites/",
            "Enrollment": "18488",
            "MeshKeyword": "Alzheimer Disease, Cognition Disorders, Dementia, Mild Cognitive Impairment,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  65 and older;\r\n\r\n\r\n\r\n          -  Medicare beneficiary;\r\n\r\n\r\n\r\n          -  Diagnosis of MCI or dementia, according to DSM-IV and/or National Institutes of\r\n\r\n             Aging-Alzheimer's Association c",
            "EligibleGender": "All",
            "MinAge": "65 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Http://www.ideas-study.org/list-of-active-sites/",
            "State": "Pennsylvania",
            "Zip": "19103",
            "Country": "United States",
            "VerificationDate": "February 2016",
            "LastChanged": "February 8, 2016",
            "FirstReceived": "April 15, 2015",
            "OverallOfficial": "Gil D Rabinovici, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "University of California, San Francisco",
            "ContactName": "Cynthia Olson",
            "ContactEmail": "IDEAS-Study@acr.org",
            "LocationStatus": "Recruiting",
            "LocationName": "See website for sites: http://www.ideas-study.org/list-of-active-sites/",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02420756",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151051 - American College of Radiology (ACR) - Crocco",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20151051",
            "StudyNumber": "20151051 - American College of Radiology (ACR) - Crocco",
            "StudyTitle": "Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study:\nA Coverage with Evidence Development Longitudinal Cohort Study",
            "PIID": "3693",
            "PicNum": "C00802143",
            "PILastName": "Crocco",
            "PIFirstName": "Elizabeth",
            "CoodCNbr": "C11874787",
            "CoordLastName": "Kaplan",
            "CoordFirstName": "Sara",
            "CoordEmail": "skaplan1@med.miami.edu",
            "CoordPhone": "305-243-6489",
            "EnteredByCNbr": "C00802143",
            "EnteredByLastName": "Crocco",
            "EnteredByFirstName": "Elizabeth",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "07/18/2016",
            "IRBApprovedFrom": "07/18/2016",
            "IRBApprovedTo": "07/17/2017",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "SponsorGroup": "Foundation",
            "Sponsor": "American College of Radiology (ACR)",
            "SiteSampleSize": "UMMG:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nicole Brenson,Belinda Robertson",
            "NationalSampleSize": "50",
            "NCTNbr": "NCT02420756",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02425111",
            "SecondaryId": "U1111-1159-5806",
            "BriefTitle": "Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease",
            "OfficialTitle": "An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV",
            "LeadSponsorClass": "Takeda",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Takeda",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by\r\n\r\n      ileocolonoscopy.",
            "Description": "The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to\r\n\r\n      treat people who have Crohn's disease. This study will look at mucosal healing in people who\r\n\r\n      take vedolizumab.\r\n\r\n\r\n\r\n      The study wil",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "April 2015",
            "CompletionDate": "December 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Takeda",
            "StudyCondition": "Crohn's Disease",
            "Enrollment": "100",
            "NctKeyword": "Drug therapy,",
            "MeshKeyword": "Crohn Disease,",
            "InterventionKeyword": "Vedolizumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. In the opinion of the investigator, the participant is capable of understanding and\r\n\r\n             complying with protocol requirements.\r\n\r\n\r\n\r\n          2. Signs and dates a written, informed consent f",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "La Jolla",
            "State": "California",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 13, 2016",
            "FirstReceived": "March 26, 2015",
            "OverallOfficial": "Medical Director Clinical Science",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Takeda",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02425111",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150183 - Takeda - Abreu",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20150183",
            "StudyNumber": "20150183 - Takeda - Abreu",
            "StudyTitle": "An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn’s Disease Treated With Vedolizumab IV",
            "PIID": "651",
            "PicNum": "C00510000",
            "PILastName": "Abreu",
            "PIFirstName": "Maria",
            "CoodCNbr": "C09950089",
            "CoordLastName": "Morillo",
            "CoordFirstName": "Diana",
            "CoordEmail": "dmorillo@med.miami.edu",
            "CoordPhone": "3052436405",
            "EnteredByCNbr": "C00510000",
            "EnteredByLastName": "Abreu",
            "EnteredByFirstName": "Maria",
            "ActiveEnrollingDate": "03/17/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/17/2016",
            "IRBApprovedFrom": "06/16/2015",
            "IRBApprovedTo": "06/06/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Takeda",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diana Morillo,Marianela Carvajal,Francia Carabali",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02425111",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02426125",
            "SecondaryId": "I4T-MC-JVDC",
            "BriefTitle": "A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer",
            "OfficialTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therap",
            "LeadSponsorClass": "Eli Lilly and Company",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Eli Lilly and Company",
            "OversightAuthority": "Yes",
            "BriefSummary": "The main purpose of this study is to evaluate the safety and efficacy of the study drug\r\n\r\n      ramucirumab in combination with docetaxel in participants with urothelial cancer who failed\r\n\r\n      prior platinum-based therapy.",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2015",
            "CompletionDate": "March 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Eli Lilly and Company",
            "StudyCondition": "Urothelial Carcinoma",
            "studyLocation": "Highlands Oncology Group",
            "Enrollment": "524",
            "NctKeyword": "carcinoma of the bladder, carcinoma of the urethra, carcinoma the of ureter, carcinoma of the renal pelvis, transitional cell carcinoma, transitional cell tumor, RANGE, bladder cancer,",
            "MeshKeyword": "Carcinoma, Carcinoma, Transitional Cell,",
            "InterventionKeyword": "Docetaxel, Ramucirumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Have histologically or cytologically confirmed, locally advanced or unresectable or\r\n\r\n             metastatic urothelial (transitional cell) carcinoma of the bladder, urethra, ureter,\r\n\r\n             or",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Fayetteville",
            "State": "Arkansas",
            "Zip": "72703",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "April 21, 2015",
            "OverallOfficial": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Eli Lilly and Company",
            "ContactName": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or",
            "ContactPhone": "1-317-615-4559",
            "LocationStatus": "Recruiting",
            "LocationName": "Highlands Oncology Group",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02426125",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150428 - Eli Lilly - Singal",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150428",
            "StudyNumber": "20150428 - Eli Lilly - Singal",
            "StudyTitle": "“A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic  Urothelial Carcinoma  Who Progressed on or After Platinum Based Therapy”.",
            "PIID": "459",
            "PicNum": "C03089847",
            "PILastName": "Singal",
            "PIFirstName": "Rakesh",
            "CoodCNbr": "C12026538",
            "CoordLastName": "Grez",
            "CoordFirstName": "Nester",
            "CoordEmail": "Nester.Grez@med.miami.edu",
            "CoordPhone": "305-243-4033",
            "EnteredByCNbr": "C12021320",
            "EnteredByLastName": "Sample",
            "EnteredByFirstName": "Paul",
            "ActiveEnrollingDate": "05/19/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/19/2016",
            "IRBApprovedFrom": "10/06/2015",
            "IRBApprovedTo": "09/13/2017",
            "AccountNbr": "666797",
            "DiseaseSiteListDesc": "Other Urinary",
            "Expr1": "Phase III",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Eli Lilly",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Luis,Katherine Hauck Perez,Vivianne Velez-Bravo,Penny Eyer",
            "NationalSampleSize": "24",
            "NCTNbr": "NCT02426125",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02429752",
            "BriefTitle": "Low Back Pain and Breathing Pattern Dysfunction",
            "OfficialTitle": "The Association of Breathing Pattern Dysfunction and Low Back Pain Presentation and Outcomes Following Physical Therapy",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The goal of this study is to identify if there is a significant prevalence of abnormal\r\n\r\n      respiratory patterns in a sample of patients with low back pain (LBP), and if the presence\r\n\r\n      of abnormal respiratory patterns are predictive o",
            "Description": "The purpose of the first stage of this study is to assess the association and prognostic\r\n\r\n      value of respiratory variables to low back pain presentation and outcomes with standard\r\n\r\n      physical therapy care. Thus, a prospective longitu",
            "OverallStatus": "Completed",
            "StartDate": "October 2015",
            "CompletionDate": "August 2016",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Low Back Pain",
            "studyLocation": "University of Miami",
            "Enrollment": "31",
            "NctKeyword": "inspiratory muscle training, low back pain, respiration, breathing,",
            "MeshKeyword": "Back Pain, Low Back Pain, Respiratory Aspiration,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Adults aged 18-65,\r\n\r\n\r\n\r\n          -  seeking physical therapy services for lumbar or pelvic pain will be recruited for\r\n\r\n             this study.\r\n\r\n\r\n\r\n          -  Subjects must intend to complete t",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33176",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 30, 2016",
            "FirstReceived": "April 20, 2015",
            "OverallOfficial": "Marlon L Wong, DPT",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02429752",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140764 - Intramural - Wong",
            "FileProcessContentId": "440",
            "Division": "Physical Therapy",
            "StdyDivision": "10255",
            "EprostNbr": "20140764",
            "StudyNumber": "20140764 - Intramural - Wong",
            "StudyTitle": "The Association of Breathing Pattern Dysfunction and Low Back Pain Presentation and Outcomes Following Physical Therapy",
            "PIID": "22668",
            "PicNum": "C0985179",
            "PILastName": "Wong",
            "PIFirstName": "Marlon",
            "CoodCNbr": "C0985179",
            "CoordLastName": "Wong",
            "CoordFirstName": "Marlon",
            "CoordEmail": "mwong2@miami.edu",
            "EnteredByCNbr": "C0985179",
            "EnteredByLastName": "Wong",
            "EnteredByFirstName": "Marlon",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "07/08/2015",
            "IRBApprovedFrom": "07/08/2015",
            "IRBApprovedTo": "07/07/2016",
            "Expr1": "N/A",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Post-Review",
            "NationalSampleSize": "75",
            "NCTNbr": "NCT02429752",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT02431247",
            "SecondaryId": "TMC114FD2HTX3001",
            "BriefTitle": "A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Tr",
            "OfficialTitle": "A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicis",
            "LeadSponsorClass": "Janssen Sciences Ireland UC",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Janssen Sciences Ireland UC",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to demonstrate non-inferiority in efficacy of a\r\n\r\n      darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination\r\n\r\n      (FDC) tablet versus Darunavir/Cobicistat (DRV/COBI) FDC co",
            "Description": "This is a Phase 3, multicenter (when more than one hospital or medical school team work on a\r\n\r\n      medical research study), randomized (study drug assigned by chance), double-blind (a medical\r\n\r\n      research study in which neither the resea",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "July 2015",
            "CompletionDate": "April 2020",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Janssen Sciences Ireland UC",
            "StudyCondition": "Immunodeficiency Virus Type 1, Human",
            "Enrollment": "749",
            "NctKeyword": "Immunodeficiency Virus Type 1, Human, Darunavir, Cobicistat, Tenofovir Alafenamide, Emtricitabine, Tenofovir Disoproxil Fumarate,",
            "MeshKeyword": "Immunologic Deficiency Syndromes,",
            "InterventionKeyword": "Tenofovir, Emtricitabine, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Cobicistat, Darunavir,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject must be antiretroviral (ARV) treatment-naive (never treated with an ARV\r\n\r\n             including post-exposure prophylaxis and pre-exposure prophylaxis); no prior use of\r\n\r\n             any appr",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 21, 2016",
            "FirstReceived": "April 27, 2015",
            "OverallOfficial": "Janssen Sciences Ireland UC Clinical Trial",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Janssen Sciences Ireland UC",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02431247",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150513 - Janssen Research & Development/ LLC - Jayaweera",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20150513",
            "StudyNumber": "20150513 - Janssen Research & Development/ LLC - Jayaweera",
            "StudyTitle": "A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed  dose combination regimen versus a regimen consisting of darunavir/cobicistat fixed dose combination  coadministered with emtricitabine/tenofovir disoproxil fumarate fixed dose combination in antiretroviral treatment-naïve human immunodeficiency virus type infected subjects.",
            "PIID": "234",
            "PicNum": "C00043390",
            "PILastName": "Jayaweera",
            "PIFirstName": "Dushyantha T.",
            "CoodCNbr": "C00548607",
            "CoordLastName": "Salvarrey",
            "CoordFirstName": "Annie",
            "CoordEmail": "als215@miami.edu",
            "CoordPhone": "+1 (305) 243-4668",
            "EnteredByCNbr": "C00043390",
            "EnteredByLastName": "Jayaweera",
            "EnteredByFirstName": "Dushyantha T.",
            "ActiveEnrollingDate": "08/20/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/20/2015",
            "IRBApprovedFrom": "07/20/2015",
            "IRBApprovedTo": "07/17/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Janssen Research & Development/ LLC",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "8",
            "Totalaccrued": "5",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "5",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "8",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Kenia Moreno,Tom Tanner",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02431247",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02431312",
            "BriefTitle": "Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects",
            "OfficialTitle": "Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic",
            "LeadSponsorClass": "Inovio Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Inovio Pharmaceuticals",
            "OversightAuthority": "No",
            "BriefSummary": "This is an open-label study to evaluate the safety, tolerability, and immunogenicity of dose\r\n\r\n      combinations of INO-1800 (DNA plasmids encoding HBsAg and HBcAg) and INO-9112 (DNA plasmid\r\n\r\n      encoding human interleukin 12) delivered by",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2015",
            "CompletionDate": "August 2018",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Inovio Pharmaceuticals",
            "StudyCondition": "Hepatitis B",
            "studyLocation": "Research and Education, Inc.",
            "Enrollment": "90",
            "NctKeyword": "Chronic HBV, immunotherapy, DNA vaccine, electroporation,",
            "MeshKeyword": "Hepatitis, Hepatitis A, Hepatitis, Chronic, Hepatitis B, Hepatitis B, Chronic,",
            "Eligibility": "INCLUSION CRITERIA:\r\n\r\n\r\n\r\n          -  Chronic Hepatitis B virus infection\r\n\r\n\r\n\r\n          -  Negative for Hepatitis A IgM, C, D and HIV\r\n\r\n\r\n\r\n          -  Liver biopsy, Fibroscan® or equivalent elastography-based test obtained within the",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "San Diego",
            "State": "California",
            "Zip": "92105",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 8, 2016",
            "FirstReceived": "April 21, 2015",
            "OverallOfficial": "Scott White, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Inovio Pharmaceuticals",
            "ContactName": "Mandeep Kaushal",
            "ContactPhone": "+ 61 (0) 3 8401 3797",
            "ContactEmail": "mandeep.kaushal@quintiles.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Research and Education, Inc.",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02431312",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150831 - Inovio Pharmaceuticals/ Inc. - Schiff",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20150831",
            "StudyNumber": "20150831 - Inovio Pharmaceuticals/ Inc. - Schiff",
            "StudyTitle": "HBV-001-PHASE I, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF INO-1800 ALONE OR IN COMBINATION WITH INO-9112 DELIVERED IM FOLLOWED BY ELECTROPORATION IN SELECT NUCLEOS(T)IDE ANALOGUE-TREATED, CHRONIC HEPATITIS B PATIENTS",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C00758491",
            "EnteredByLastName": "Schiff",
            "EnteredByFirstName": "Eugene",
            "ActiveEnrollingDate": "03/16/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/16/2016",
            "IRBApprovedFrom": "02/08/2016",
            "IRBApprovedTo": "02/07/2017",
            "Expr1": "Phase I",
            "ResearchType": "Drug/Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Inovio Pharmaceuticals/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "10",
            "Totalaccrued": "9",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "10",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02431312",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02431702",
            "SecondaryId": "R092670SCH3013",
            "BriefTitle": "A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform",
            "OfficialTitle": "A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate L",
            "LeadSponsorClass": "Janssen Scientific Affairs, LLC",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Janssen Scientific Affairs, LLC",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of the study is to compare effectiveness of paliperidone palmitate (PP:\r\n\r\n      paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP)\r\n\r\n      on delaying time to treatment failure. The study wi",
            "Description": "A Prospective, matched-control, Randomized (assignment of study drug by chance), open-label,\r\n\r\n      flexible-dose, study in participants with recent-onset schizophrenia or schizophreniform\r\n\r\n      disorder to compare disease progression and d",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2015",
            "CompletionDate": "May 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Janssen Scientific Affairs, LLC",
            "StudyCondition": "Schizophrenia",
            "Enrollment": "275",
            "NctKeyword": "Paliperidone Palmitate, Oral Antipsychotics, Schizophrenia, Psychotic Disorders, Cognition in Schizophrenia, Brain intracortical myelin volume, Personal and Social Performance, Disease Modification,",
            "MeshKeyword": "Schizophrenia, Mental Disorders, Psychotic Disorders, Disease Progression,",
            "InterventionKeyword": "Polystyrene sulfonic acid, Risperidone, Paliperidone Palmitate, Antipsychotic Agents, Aripiprazole, Quetiapine Fumarate, Olanzapine, Haloperidol, Haloperidol decanoate, Perphenazine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Participant must have a current diagnosis of schizophrenia (295.90) or\r\n\r\n             schizophreniform disorder (295.40) as defined by Diagnostic and Statistical Manual of\r\n\r\n             Mental Disorde",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "35 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Little Rock",
            "State": "Arkansas",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 18, 2017",
            "FirstReceived": "April 28, 2015",
            "OverallOfficial": "Janssen Scientific Affairs, LLC Clinical Trial",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Janssen Scientific Affairs, LLC",
            "ContactName": "Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:",
            "ContactEmail": "JNJ.CT@sylogent.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02431702",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150362 - Johnson & Johnson - Strassnig",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20150362",
            "StudyNumber": "20150362 - Johnson & Johnson - Strassnig",
            "StudyTitle": "DREAM - A Prospective, Randomized, Matched Control, Open-Label, Rater-Blinded, Flexible-Dose Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Interception Following Treatment with Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics",
            "PIID": "4295",
            "PicNum": "C10560217",
            "PILastName": "Strassnig",
            "PIFirstName": "Martin",
            "CoodCNbr": "C04892431",
            "CoordLastName": "Brenson",
            "CoordFirstName": "Nicole",
            "CoordEmail": "nbrenson@med.miami.edu",
            "CoordPhone": "3053558186",
            "EnteredByCNbr": "C10560217",
            "EnteredByLastName": "Strassnig",
            "EnteredByFirstName": "Martin",
            "ActiveEnrollingDate": "02/09/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/09/2016",
            "IRBApprovedFrom": "10/26/2015",
            "IRBApprovedTo": "10/31/2017",
            "Expr1": "Phase III",
            "Tarea": "Urologic",
            "TareaCode": "229",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Johnson & Johnson",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nicole Brenson,Tania Guardia,Belinda Robertson",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT02431702",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02433158",
            "BriefTitle": "Safety Of Rivipansel (GMI-1070) In The Treatment Of One or More Vaso-occlusive Crises In Hospitalized Subjects With Sickle Cell Disease",
            "OfficialTitle": "An Open-label Extension Study To Evaluate The Safety Of Rivipansel (Gmi-1070) In The Treatment Of One Or More Vaso-occlusive Crises In Hospitalized Subjects With Sickle Cell Disease",
            "LeadSponsorClass": "Pfizer",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Pfizer",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is an open label extension study in subjects with Sickle Cell Disease (SCD) who have\r\n\r\n      completed the double blind Phase 3 study (B5201002).",
            "Description": "This is an open label extension study in subjects who are 6 years of age or older with\r\n\r\n      Sickle Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002). This\r\n\r\n      study is designed to evaluate the safety and de",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2015",
            "CompletionDate": "January 2020",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Pfizer",
            "StudyCondition": "Sickle Cell Anemia",
            "studyLocation": "University of South Alabama Women's and Children's Hospital",
            "Enrollment": "250",
            "NctKeyword": "Rivipansel, GMI-1070, Selectin Inhibitor, SCD, VOC,",
            "MeshKeyword": "Anemia, Sickle Cell,",
            "Eligibility": "Inclusion Criteria: Completion of Study B5201002. Documented diagnosis of SCD. At least 6\r\n\r\n        years of age. Male and female subjects of childbearing potential and at risk for pregnancy\r\n\r\n        must agree to use a highly effective met",
            "EligibleGender": "All",
            "MinAge": "6 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Mobile",
            "State": "Alabama",
            "Zip": "36604",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 17, 2017",
            "FirstReceived": "April 29, 2015",
            "OverallOfficial": "Pfizer CT.gov Call Center",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Pfizer",
            "ContactName": "Pfizer CT.gov Call Center",
            "ContactPhone": "1-800-718-1021",
            "LocationStatus": "Recruiting",
            "LocationName": "University of South Alabama Women's and Children's Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02433158",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160304 - Pfizer - Alvarez",
            "FileProcessContentId": "440",
            "Division": "Pediatrics Oncology",
            "StdyDivision": "10646",
            "EprostNbr": "20160304",
            "StudyNumber": "20160304 - Pfizer - Alvarez",
            "StudyTitle": "AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL (GMI-1070) IN THE TREATMENT OF ONE OR MORE VASO-OCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE",
            "PIID": "299",
            "PicNum": "C01335657",
            "PILastName": "Alvarez",
            "PIFirstName": "Ofelia",
            "CoodCNbr": "C11875174",
            "CoordLastName": "Cumming",
            "CoordFirstName": "Vanessa",
            "CoordEmail": "v.cumming@med.miami.edu",
            "CoordPhone": "9542947473",
            "EnteredByCNbr": "C01335657",
            "EnteredByLastName": "Alvarez",
            "EnteredByFirstName": "Ofelia",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "09/19/2016",
            "IRBApprovedFrom": "09/19/2016",
            "IRBApprovedTo": "09/18/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Pfizer",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Vanessa Cumming",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT02433158",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02435992",
            "BriefTitle": "Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis",
            "OfficialTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis",
            "LeadSponsorClass": "Celgene",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Celgene",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine whether RPC1063 is effective in the treatment of\r\n\r\n      Ulcerative Colitis (UC).",
            "Description": "The trial is composed of 2 periods: Induction and Maintenance. Patients will be entered into\r\n\r\n      the trial in 2 separate cohorts through the Induction Period (10 weeks) and those patients\r\n\r\n      in clinical response at the end of the Indu",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Celgene",
            "StudyCondition": "Ulcerative Colitis",
            "studyLocation": "Receptos Study Site 144",
            "Enrollment": "900",
            "MeshKeyword": "Ulcer, Colitis, Ulcerative, Colitis,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Ulcerative Colitis (UC) confirmed on endoscopy\r\n\r\n\r\n\r\n          -  Moderately to severely active UC (Mayo score 6-12)\r\n\r\n\r\n\r\n          -  Currently receiving treatment with aminosalisylate, prednison",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Tucson",
            "State": "Arizona",
            "Zip": "85712",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 9, 2017",
            "FirstReceived": "April 24, 2015",
            "ContactName": "Receptos True North Study",
            "ContactPhone": "1-844-266-9299",
            "ContactEmail": "truenorth@quintiles.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Receptos Study Site 144",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02435992",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150370 - Receptos/ Inc. - Abreu",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20150370",
            "StudyNumber": "20150370 - Receptos/ Inc. - Abreu",
            "StudyTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe\nUlcerative Colitis",
            "PIID": "651",
            "PicNum": "C00510000",
            "PILastName": "Abreu",
            "PIFirstName": "Maria",
            "CoodCNbr": "C11914779",
            "CoordLastName": "Carabali",
            "CoordFirstName": "Francia",
            "CoordEmail": "fxc123@miami.edu",
            "EnteredByCNbr": "C00510000",
            "EnteredByLastName": "Abreu",
            "EnteredByFirstName": "Maria",
            "ActiveEnrollingDate": "07/21/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/21/2016",
            "IRBApprovedFrom": "08/17/2015",
            "IRBApprovedTo": "07/04/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Receptos/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "3",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diana Morillo,Francia Carabali",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02435992",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02440789",
            "SecondaryId": "2UM1AI068636",
            "BriefTitle": "Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive ART",
            "OfficialTitle": "Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy",
            "LeadSponsorClass": "AIDS Clinical Trials Group",
            "SponsorAgency": "Other",
            "LeadSponsor": "AIDS Clinical Trials Group",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to find out about the safety of sirolimus in individuals with\r\n\r\n      HIV infection who are also being treated with ART. The investigators want to learn whether\r\n\r\n      sirolimus will decrease inflammation and immu",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "CompletionDate": "August 2017",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "AIDS Clinical Trials Group",
            "StudyCondition": "HIV-1 Infection",
            "studyLocation": "Ucsd, Avrc Crs (701)",
            "Enrollment": "30",
            "InterventionKeyword": "Sirolimus, Everolimus,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or\r\n\r\n             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and\r\n\r\n             confirmed b",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "San Diego",
            "State": "California",
            "Zip": "92103",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 23, 2016",
            "FirstReceived": "April 6, 2015",
            "OverallOfficial": "Timothy Henrich, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Brigham and Women's Hospital",
            "LocationStatus": "Recruiting",
            "LocationName": "Ucsd, Avrc Crs (701)",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02440789",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151137 - National Institute of Allergy and Infectious Disea - Fischl",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20151137",
            "StudyNumber": "20151137 - National Institute of Allergy and Infectious Disea - Fischl",
            "StudyTitle": "A5337:  Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy Version 2.0",
            "PIID": "825",
            "PicNum": "C00454409",
            "PILastName": "Fischl",
            "PIFirstName": "Margaret",
            "CoodCNbr": "C00454409",
            "CoordLastName": "Fischl",
            "CoordFirstName": "Margaret",
            "CoordEmail": "mfischl@med.miami.edu",
            "CoordPhone": "3052433847",
            "EnteredByCNbr": "C00454409",
            "EnteredByLastName": "Fischl",
            "EnteredByFirstName": "Margaret",
            "ActiveEnrollingDate": "08/17/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/17/2016",
            "IRBApprovedFrom": "01/19/2016",
            "IRBApprovedTo": "01/18/2017",
            "Expr1": "Phase I/II",
            "ResearchType": "Drug",
            "SponsorGroup": "Other",
            "Sponsor": "National Institute of Allergy and Infectious Diseases",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "4",
            "NCTNbr": "NCT02440789",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02442765",
            "BriefTitle": "Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",
            "OfficialTitle": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients",
            "LeadSponsorClass": "Avanir Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Avanir Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "Patients with agitation secondary to dementia of the Alzheimer's type. The diagnosis of\r\n\r\n      probable Alzheimer's disease (AD) will be based on the '2011 Diagnostic Guidelines for\r\n\r\n      Alzheimer's Disease' issued by the National Institut",
            "Description": "Eligible participants for this study must have a diagnosis of probable AD and must have\r\n\r\n      clinically meaningful agitation secondary to AD.\r\n\r\n\r\n\r\n      This is a multicenter, randomized, placebo-controlled study, consisting of 12 weeks of",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2015",
            "CompletionDate": "July 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Avanir Pharmaceuticals",
            "StudyCondition": "Agitation in Patients With Dementia of the Alzheimer's Type",
            "Enrollment": "380",
            "MeshKeyword": "Dementia, Psychomotor Agitation, Alzheimer Disease,",
            "InterventionKeyword": "Dextromethorphan, Quinidine, Quinidine gluconate,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of probable Alzheimer's Disease (AD)\r\n\r\n\r\n\r\n          -  The participant has clinically significant, moderate/severe agitation at the time of\r\n\r\n             screening and for at least 2 weeks",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "90 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85032",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 19, 2016",
            "FirstReceived": "May 11, 2015",
            "ContactName": "Uyen Nguyen",
            "ContactEmail": "unguyen@avanir.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02442765",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150712 - Avanir Pharmaceuticals/ Inc. - Crocco",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20150712",
            "StudyNumber": "20150712 - Avanir Pharmaceuticals/ Inc. - Crocco",
            "StudyTitle": "A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type.",
            "PIID": "3693",
            "PicNum": "C00802143",
            "PILastName": "Crocco",
            "PIFirstName": "Elizabeth",
            "CoodCNbr": "C06046616",
            "CoordLastName": "Robertson",
            "CoordFirstName": "Belinda",
            "CoordEmail": "BRobertson@med.miami.edu",
            "EnteredByCNbr": "C00802143",
            "EnteredByLastName": "Crocco",
            "EnteredByFirstName": "Elizabeth",
            "ActiveEnrollingDate": "07/29/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/29/2016",
            "IRBApprovedFrom": "10/06/2015",
            "IRBApprovedTo": "10/03/2017",
            "AccountNbr": "brobertson",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Avanir Pharmaceuticals/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "2",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nicole Brenson,Belinda Robertson",
            "AgentDevices": "AVP-786",
            "StudyObjective": "The objectives of the study are to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type.",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02442765",
            "StudyKeywords": "Alzheimers, dementia, Triad, dextromethorphan, quinidine, agitation, AVP-786, Avanir",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02443155",
            "SecondaryId": "2014-001215-39",
            "BriefTitle": "A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function",
            "OfficialTitle": "A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preserv",
            "LeadSponsorClass": "Novo Nordisk A/S",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novo Nordisk A/S",
            "OversightAuthority": "No",
            "BriefSummary": "This trial is conducted globally. The aim of this trial is to assess the clinical\r\n\r\n      proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in\r\n\r\n      adult subjects with newly diagnosed type 1 diabetes m",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2015",
            "CompletionDate": "April 2019",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Novo Nordisk A/S",
            "StudyCondition": "Diabetes",
            "studyLocation": "Novo Nordisk Investigational Site",
            "Enrollment": "304",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1,",
            "InterventionKeyword": "Liraglutide,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Informed consent obtained before any trial-related activities. Trial-related\r\n\r\n             activities are any procedures that are carried out as part of the trial, including\r\n\r\n             activities",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "45 Years",
            "Volunteers": "No",
            "City": "Northridge",
            "State": "California",
            "Zip": "91325",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "May 11, 2015",
            "OverallOfficial": "Global Clinical Registry (GCR, 1452)",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Novo Nordisk A/S",
            "ContactName": "Novo Nordisk",
            "ContactEmail": "clinicaltrials@novonordisk.com",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "Novo Nordisk Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02443155",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150820 - Novo Nordisk - Marks",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20150820",
            "StudyNumber": "20150820 - Novo Nordisk - Marks",
            "StudyTitle": "A randomised, double-blind, double-dummy, placebo-controlled, parallel-group\nmulti-centre clinical proof-of-principle trial in adult subjects with newly\ndiagnosed type 1 diabetes mellitus investigating the effect of NNC0114-0006 and liraglutide on preservation of beta-cell function",
            "PIID": "877",
            "PicNum": "C00763957",
            "PILastName": "Marks",
            "PIFirstName": "Jennifer",
            "CoodCNbr": "C00694387",
            "CoordLastName": "Matheson",
            "CoordFirstName": "Della",
            "CoordEmail": "dmatheso@miami.edu",
            "CoordPhone": "3052433781",
            "EnteredByCNbr": "C00763957",
            "EnteredByLastName": "Marks",
            "EnteredByFirstName": "Jennifer",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "11/02/2015",
            "IRBApprovedFrom": "11/02/2015",
            "IRBApprovedTo": "11/01/2016",
            "Expr1": "Phase II",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Novo Nordisk",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Natalia Sanders,Carlos Blaschke,Della Matheson",
            "NationalSampleSize": "4",
            "NCTNbr": "NCT02443155",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02446132",
            "BriefTitle": "Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",
            "OfficialTitle": "A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",
            "LeadSponsorClass": "Avanir Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Avanir Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is an extension study of the Phase 3 Studies 15-AVP-786-301 and 15-AVP-786-302, which\r\n\r\n      also allows participants from the Phase 2 Study 12-AVR-131 to be included.",
            "Description": "Participant has successfully completed Studies 15-AVP-786-301, 15-AVP-786-302, or\r\n\r\n      12-AVR-131.\r\n\r\n\r\n\r\n      Participants will be enrolled in the study for approximately 52 weeks.\r\n\r\n\r\n\r\n      Approximately 550 participants will be enroll",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2015",
            "CompletionDate": "July 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Avanir Pharmaceuticals",
            "StudyCondition": "Agitation in Alzheimer's Disease",
            "Enrollment": "550",
            "MeshKeyword": "Alzheimer Disease, Dementia, Psychomotor Agitation,",
            "InterventionKeyword": "Dextromethorphan, Quinidine, Quinidine gluconate,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Participant has successfully completed Studies 15-AVP-786-301, 15-AVP-786-302, or\r\n\r\n             12-AVR-131\r\n\r\n\r\n\r\n          -  Participants from Study 12-AVR-131 with a diagnosis of probable AD accordi",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "90 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "92591",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 21, 2016",
            "FirstReceived": "May 11, 2015",
            "ContactName": "Uyen Nguyen",
            "ContactEmail": "unguyen@avanir.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02446132",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150934 - Avanir Pharmaceuticals/ Inc. - Crocco",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20150934",
            "StudyNumber": "20150934 - Avanir Pharmaceuticals/ Inc. - Crocco",
            "StudyTitle": "A Phase 3, Multicenter, Long-term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type",
            "PIID": "3693",
            "PicNum": "C00802143",
            "PILastName": "Crocco",
            "PIFirstName": "Elizabeth",
            "CoodCNbr": "C06046616",
            "CoordLastName": "Robertson",
            "CoordFirstName": "Belinda",
            "CoordEmail": "BRobertson@med.miami.edu",
            "EnteredByCNbr": "C00802143",
            "EnteredByLastName": "Crocco",
            "EnteredByFirstName": "Elizabeth",
            "ActiveEnrollingDate": "07/29/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/29/2016",
            "IRBApprovedFrom": "01/05/2016",
            "IRBApprovedTo": "11/17/2017",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Avanir Pharmaceuticals/ Inc.",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Tania Guardia,Belinda Robertson,Nicole Brenson",
            "AgentDevices": "AVP-786",
            "StudyObjective": "The objectives of the study are to evaluate the long-term safety and maintenance of efficacy of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer’s type.",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02446132",
            "StudyKeywords": "Alzheimers, dementia, Triad, dextromethorphan, quinidine, agitation, AVP-786, Avanir",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02446210",
            "SecondaryId": "R01NS076589-01",
            "BriefTitle": "Neural Control of Bilateral Movements After SCI",
            "OfficialTitle": "Neural Control of Bilateral Hand, Arm, and Leg Movements After Spinal Cord Injury",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The long‐term goal is to acquire scientific knowledge that can be used to develop\r\n\r\n      mechanistic-driven intervention strategies aiming at restoring upper and lower-limb motor\r\n\r\n      function in individuals with cervical or thoracic spina",
            "Description": "If the participant qualifies to take part in this research study, they will be asked to\r\n\r\n      participate in 15-190 study visits,to complete the experimental procedures. These procedures\r\n\r\n      have been broken up into \"Phases\" and will be",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2015",
            "CompletionDate": "March 2019",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Spinal Cord Injury",
            "studyLocation": "University of Miami The Miami Project to Cure Paralysis",
            "Enrollment": "514",
            "NctKeyword": "SCI, Neural Control, Bilateral Movement, TMS,",
            "MeshKeyword": "Spinal Cord Injuries,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Inclusion criteria for individuals with SCI:\r\n\r\n\r\n\r\n               -  Male and females between ages 18-85 years\r\n\r\n\r\n\r\n               -  SCI (≥1 month after injury)\r\n\r\n\r\n\r\n               -  Cervical, tho",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "85 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 1, 2016",
            "FirstReceived": "May 11, 2015",
            "OverallOfficial": "Monica A Perez, PhD, PT",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Univeraity of Miami",
            "ContactName": "Monica A Perez, PhD, PT",
            "ContactPhone": "305-243-7119",
            "ContactEmail": "perezmo@miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami The Miami Project to Cure Paralysis",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02446210",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140997 - National Institute of Neurological Disorders and S - Perez",
            "FileProcessContentId": "440",
            "Division": "Neurosurgery",
            "StdyDivision": "9636",
            "EprostNbr": "20140997",
            "StudyNumber": "20140997 - National Institute of Neurological Disorders and S - Perez",
            "StudyTitle": "Neural Control of Bilateral Hand, Arm, and Leg Movements after Spinal Cord Injury",
            "PIID": "23805",
            "PicNum": "C00544663",
            "PILastName": "Perez",
            "PIFirstName": "Monica",
            "CoodCNbr": "C00544663",
            "CoordLastName": "Perez",
            "CoordFirstName": "Monica",
            "EnteredByCNbr": "C00544663",
            "EnteredByLastName": "Perez",
            "EnteredByFirstName": "Monica",
            "ActiveEnrollingDate": "04/07/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/07/2015",
            "IRBApprovedFrom": "02/25/2015",
            "IRBApprovedTo": "01/05/2018",
            "Expr1": "Approved Drug/Off-Label use",
            "Tarea": "Spine",
            "TareaCode": "9641",
            "ResearchType": "Drug/Device",
            "SponsorGroup": "Other",
            "Sponsor": "National Institute of Neurological Disorders and Stroke/Craig H. Neilsen Foundation",
            "Prescreened": "6",
            "Screenedfailed": "2",
            "SignedICF": "68",
            "Totalaccrued": "65",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "59",
            "CurrentlyActiveTreatment": "6",
            "Totalpatients": "68",
            "FirstNinety": "7",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Toshiki Tazoe,Sarah Lehmann",
            "NationalSampleSize": "514",
            "NCTNbr": "NCT02446210",
            "StudyKeywords": "Miami Project",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02446912",
            "BriefTitle": "Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus",
            "OfficialTitle": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus",
            "LeadSponsorClass": "AstraZeneca",
            "SponsorAgency": "Industry",
            "LeadSponsor": "AstraZeneca",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment\r\n\r\n      regimen of two doses of anifrolumab versus placebo in adult subjects with moderately to\r\n\r\n      severely active, autoantibody-positive systemi",
            "Description": "This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled\r\n\r\n      study to evaluate the efficacy and safety of an intravenous treatment regimen of two doses\r\n\r\n      of anifrolumab versus placebo in subjects wi",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2015",
            "CompletionDate": "May 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "AstraZeneca",
            "StudyCondition": "Active Systemic Lupus Erythematosus",
            "studyLocation": "Research Site",
            "Enrollment": "450",
            "NctKeyword": "Active Systemic Lupus Erythematosus,",
            "MeshKeyword": "Lupus Erythematosus, Systemic,",
            "InterventionKeyword": "Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Aged 18 through 70 years at the time of screening\r\n\r\n\r\n\r\n          2. Diagnosis of paediatric or adult SLE with a diagnosis of SLE according to the ACR\r\n\r\n             1982 revised criteria ≥24 weeks pri",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "70 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 22, 2016",
            "FirstReceived": "May 14, 2015",
            "OverallOfficial": "Herbert Hutman, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Medical Science Director",
            "ContactName": "AstraZeneca Clinical Study Information Center",
            "ContactPhone": "1-877-240-9479",
            "ContactEmail": "information.center@astrazeneca.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Research Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02446912",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150915 - AstraZeneca - Carpintero",
            "FileProcessContentId": "440",
            "Division": "Rheumatology and Immunology",
            "StdyDivision": "10260",
            "EprostNbr": "20150915",
            "StudyNumber": "20150915 - AstraZeneca - Carpintero",
            "StudyTitle": "A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus",
            "PIID": "3095",
            "PicNum": "C09933446",
            "PILastName": "Carpintero",
            "PIFirstName": "Maria",
            "CoodCNbr": "C02440329",
            "CoordLastName": "Pignac-Kobinger",
            "CoordFirstName": "Judith",
            "CoordEmail": "jpignac@med.miami.edu",
            "CoordPhone": "3052438567",
            "EnteredByCNbr": "C09933446",
            "EnteredByLastName": "Carpintero",
            "EnteredByFirstName": "Maria",
            "ActiveEnrollingDate": "03/16/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/16/2016",
            "IRBApprovedFrom": "12/15/2015",
            "IRBApprovedTo": "12/05/2017",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "AstraZeneca",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Judith Pignac-Kobinger,Bethly Aubourg,Lisa Harlow",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02446912",
            "StudyKeywords": "SLE",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02448641",
            "BriefTitle": "Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke",
            "OfficialTitle": "A Double-Blind, Controlled Phase 2B Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke",
            "LeadSponsorClass": "SanBio, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "SanBio, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "Controlled study of stereotactic, intracranial injection of SB623 cells in patients with\r\n\r\n      fixed motor deficits from ischemic stroke",
            "Description": "This is a double-blind, sham-surgery controlled study of stereotactic, intracranial\r\n\r\n      injection of SB623 cells in patients with fixed motor deficits from ischemic stroke. The\r\n\r\n      study will be conducted at approximately 60 sites in t",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2016",
            "CompletionDate": "September 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "SanBio, Inc.",
            "StudyCondition": "Chronic Ischemic Stroke",
            "studyLocation": "The Research Center of Southern California (Assessment)",
            "Enrollment": "156",
            "NctKeyword": "ischemic stroke, chronic stroke, fixed motor deficits,",
            "MeshKeyword": "Stroke, Ischemia, Cerebral Infarction,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age 18-75 years, inclusive\r\n\r\n\r\n\r\n          2. Documented history of completed ischemic stroke in subcortical region of MCA or\r\n\r\n             lenticulostriate artery with or without cortical involvement",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Carlsbad",
            "State": "California",
            "Zip": "92011",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 23, 2016",
            "FirstReceived": "May 15, 2015",
            "OverallOfficial": "Gary Steinberg, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Stanford Hospital and Clinics, School of Medicine",
            "ContactName": "Damien Bates, MD, PhD",
            "ContactPhone": "650-625-8965",
            "ContactEmail": "mirella.machuca@san-bio.com",
            "LocationStatus": "Recruiting",
            "LocationName": "The Research Center of Southern California (Assessment)",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02448641",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150896 - Sunovion Pharmaceuticals - Yavagal",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20150896",
            "StudyNumber": "20150896 - Sunovion Pharmaceuticals - Yavagal",
            "StudyTitle": "A Double-Blind, Controlled Phase 2B Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients with Chronic Motor Deficit from Ischemic Stroke",
            "PIID": "252",
            "PicNum": "C06459010",
            "PILastName": "Yavagal",
            "PIFirstName": "Dileep",
            "CoodCNbr": "C11877018",
            "CoordLastName": "Ramdas",
            "CoordFirstName": "Kevin",
            "CoordEmail": "k.ramdas@med.miami.edu",
            "CoordPhone": "305-243-1132",
            "EnteredByCNbr": "C06459010",
            "EnteredByLastName": "Yavagal",
            "EnteredByFirstName": "Dileep",
            "ActiveEnrollingDate": "12/16/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/16/2016",
            "IRBApprovedFrom": "03/28/2016",
            "IRBApprovedTo": "03/27/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Sunovion Pharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Letitia Fisher,Karen Bates",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02448641",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02449291",
            "BriefTitle": "Study of APD421 as PONV Treatment (no Prior Prophylaxis)",
            "OfficialTitle": "Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had no Prior Prophylaxis",
            "LeadSponsorClass": "Acacia Pharma Ltd",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Acacia Pharma Ltd",
            "OversightAuthority": "Yes",
            "BriefSummary": "Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless,\r\n\r\n      dose-selecting study to compare the efficacy of APD421 to placebo as treatment of\r\n\r\n      established PONV, in patients who have not had prior PONV proph",
            "OverallStatus": "Completed",
            "StartDate": "September 2015",
            "CompletionDate": "July 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Acacia Pharma Ltd",
            "StudyCondition": "Postoperative Nausea and Vomiting",
            "studyLocation": "Jackson Memorial Hospital",
            "Enrollment": "568",
            "MeshKeyword": "Nausea, Vomiting, Postoperative Nausea and Vomiting,",
            "Eligibility": "Inclusion criteria:\r\n\r\n\r\n\r\n          -  Male or female patients ≥ 18 years of age\r\n\r\n\r\n\r\n          -  Provision of written informed consent\r\n\r\n\r\n\r\n          -  Patients scheduled to undergo elective surgery (open or laparoscopic technique) und",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 3, 2016",
            "FirstReceived": "May 18, 2015",
            "OverallOfficial": "Keith Candiotti, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationName": "Jackson Memorial Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02449291",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150579 - Acacia Pharma - Rodriguez",
            "FileProcessContentId": "440",
            "Division": "Anesthesiology",
            "StdyDivision": "10236",
            "EprostNbr": "20150579",
            "StudyNumber": "20150579 - Acacia Pharma - Rodriguez",
            "StudyTitle": "Randomised, double-blind, placebo-controlled study\nof APD421 (amisulpride for IV injection) as treatment\nof established post-operative nausea and vomiting,\nin patients who have had no prior prophylaxis",
            "PIID": "1070",
            "PicNum": "C03849637",
            "PILastName": "Rodriguez",
            "PIFirstName": "Yiliam",
            "CoodCNbr": "C10588120",
            "CoordLastName": "Antor",
            "CoordFirstName": "Maria",
            "CoordEmail": "mantor@med.miami.edu",
            "CoordPhone": "3055857677",
            "EnteredByCNbr": "C03849637",
            "EnteredByLastName": "Rodriguez",
            "EnteredByFirstName": "Yiliam",
            "ActiveEnrollingDate": "10/26/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/26/2015",
            "IRBApprovedFrom": "08/04/2015",
            "IRBApprovedTo": "08/01/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Acacia Pharma",
            "Prescreened": "0",
            "Screenedfailed": "67",
            "SignedICF": "107",
            "Totalaccrued": "34",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "107",
            "FirstNinety": "16",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Isabel Jaraba,Angelica Jaramillo Virgen,Maria Antor",
            "NationalSampleSize": "150",
            "NCTNbr": "NCT02449291",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02451137",
            "SecondaryId": "U1111-1168-0354",
            "BriefTitle": "A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)",
            "OfficialTitle": "A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in Insulin-naive Patients With Uncontrolled Type 2 Diabete",
            "LeadSponsorClass": "Sanofi",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Sanofi",
            "OversightAuthority": "No",
            "BriefSummary": "Primary Objective:\r\n\r\n\r\n\r\n      Demonstrate clinical benefit of Toujeo in achieving individualized HEDIS HbA1c targets (<8%\r\n\r\n      if age 65 years or with defined comorbidities (as listed in Appendix G) or otherwise <7%) at\r\n\r\n      6 months w",
            "Description": "The total study duration per patient will be up to 53 weeks, consisting of a 1-week\r\n\r\n      screening period at the site, a 26-week treatment period, and a 26-week extension period.",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2015",
            "CompletionDate": "May 2018",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "Sanofi",
            "StudyCondition": "Diabetes Mellitus, Type 2",
            "studyLocation": "Investigational Site Number 840731",
            "Enrollment": "3270",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 2,",
            "InterventionKeyword": "Insulin, Globin Zinc, Insulin, Insulin Glargine, Insulin Detemir,",
            "Eligibility": "Inclusion criteria :\r\n\r\n\r\n\r\n          -  Patients with T2DM, as defined by the American Diabetes Association/World Health\r\n\r\n             Organization, diagnosed for at least 1 year at the time of the screening visit,\r\n\r\n             insuffici",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35205",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 18, 2017",
            "FirstReceived": "May 19, 2015",
            "OverallOfficial": "Clinical Sciences & Operations",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Sanofi",
            "ContactName": "For site information, send an email with site number to",
            "ContactEmail": "Contact-Us@sanofi.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Investigational Site Number 840731",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02451137",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150340 - Sanofi - Miranda-Palma",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20150340",
            "StudyNumber": "20150340 - Sanofi - Miranda-Palma",
            "StudyTitle": "A randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of Toujeo® compared to commercially available basal insulins for initiation of therapy in insulin naïve patients with uncontrolled type 2 diabetes mellitus\nSTUDY NUMBER: LPS14347\nSTUDY NAME: Achieve Control Real Life Study Program",
            "PIID": "1111",
            "PicNum": "C02129536",
            "PILastName": "Miranda-Palma",
            "PIFirstName": "Bresta",
            "CoodCNbr": "C00121533",
            "CoordLastName": "Masters",
            "CoordFirstName": "Burlett",
            "CoordEmail": "bmasters2@med.miami.edu",
            "CoordPhone": "305-243-5354",
            "EnteredByCNbr": "C02129536",
            "EnteredByLastName": "Miranda-Palma",
            "EnteredByFirstName": "Bresta",
            "ActiveEnrollingDate": "02/11/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/11/2016",
            "IRBApprovedFrom": "09/01/2015",
            "IRBApprovedTo": "08/15/2017",
            "Expr1": "Phase IV",
            "Tarea": "Diabetes (Type II)",
            "TareaCode": "12544",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Sanofi",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Burlett Masters,Ada Konwai",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02451137",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02452047",
            "SecondaryId": "2015-000066-62",
            "BriefTitle": "Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)",
            "OfficialTitle": "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Estimate the Efficacy and Safety of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem/Cilastatin in Subjects With Imipenem-Resistant Bact",
            "LeadSponsorClass": "Merck Sharp & Dohme Corp.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Merck Sharp & Dohme Corp.",
            "OversightAuthority": "No",
            "BriefSummary": "The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (MK-7655A)\r\n\r\n      versus colistimethate sodium + imipenem+cilastatin in the treatment of imipenem-resistant\r\n\r\n      bacterial infections. Infections evaluated i",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "CompletionDate": "June 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Merck Sharp & Dohme Corp.",
            "StudyCondition": "Bacterial Infections",
            "studyLocation": "Call for Information (Investigational Site 1320)",
            "Enrollment": "64",
            "MeshKeyword": "Infection, Communicable Diseases, Bacterial Infections,",
            "InterventionKeyword": "Colistin, Imipenem, MK-7655, Cilastatin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Hospitalization that requires treatment with IV antibiotic therapy for a new,\r\n\r\n             persistent or progressing bacterial infection involving at least 1 of 3 primary\r\n\r\n             infection typ",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90095",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 15, 2016",
            "FirstReceived": "May 20, 2015",
            "OverallOfficial": "Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Merck Sharp & Dohme Corp.",
            "ContactName": "Toll Free Number",
            "ContactPhone": "1-888-577-8839",
            "LocationStatus": "Recruiting",
            "LocationName": "Call for Information (Investigational Site 1320)",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02452047",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150226 - Merck & Co. - Gebhard",
            "FileProcessContentId": "440",
            "Division": "Anesthesiology",
            "StdyDivision": "10236",
            "EprostNbr": "20150226",
            "StudyNumber": "20150226 - Merck & Co. - Gebhard",
            "StudyTitle": "A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Estimate the Efficacy and Safety of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem/Cilastatin in Subjects with Imipenem-Resistant Bacterial Infection",
            "PIID": "706",
            "PicNum": "C04976318",
            "PILastName": "Gebhard",
            "PIFirstName": "Ralf",
            "CoodCNbr": "C10565278",
            "CoordLastName": "Gutierrez",
            "CoordFirstName": "Juan",
            "CoordEmail": "JGutierrez4@med.miami.edu",
            "EnteredByCNbr": "C04976318",
            "EnteredByLastName": "Gebhard",
            "EnteredByFirstName": "Ralf",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "08/03/2015",
            "IRBApprovedFrom": "08/03/2015",
            "IRBApprovedTo": "08/02/2016",
            "Expr1": "Phase III",
            "Tarea": "Critical Care Medicine",
            "TareaCode": "16645",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Merck & Co.",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Juan Gutierrez,Maria Antor",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT02452047",
            "StudyKeywords": "imipenem resistance, CRE, infectious disease, Beta lactamase, antibiotics, ICU, bacterial infection, pneumonia, urinary tract infection, UTI, intra abdominal infection, infection",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02452528",
            "BriefTitle": "Study of ARC-520 in Patients With HBeAg (Hepatitis B e Antigen) Positive Chronic Hepatitis B Virus",
            "OfficialTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive,",
            "LeadSponsorClass": "Arrowhead Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Arrowhead Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "Patients with chronic Hepatitis B Virus (HBV) infection will receive multiple doses of\r\n\r\n      ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.",
            "Description": "This is a multi-center, randomized, double-blind, placebo-controlled, multi-dose study of\r\n\r\n      ARC-520 in combination with entecavir or tenofovir administered to patients with HBeAg\r\n\r\n      positive and immune active chronic HBV infection,",
            "OverallStatus": "Terminated",
            "StartDate": "August 2015",
            "CompletionDate": "February 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Arrowhead Pharmaceuticals",
            "StudyCondition": "Chronic Hepatitis B",
            "studyLocation": "Kaiser Permanente",
            "Enrollment": "4",
            "NctKeyword": "Hepatitis B Virus, Chronic Hepatitis B, HBV,",
            "MeshKeyword": "Hepatitis, Hepatitis A, Hepatitis, Chronic, Hepatitis B, Hepatitis B, Chronic,",
            "InterventionKeyword": "Tenofovir, Entecavir,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male or female, 18 to 75 years of age\r\n\r\n\r\n\r\n          -  Written informed consent\r\n\r\n\r\n\r\n          -  Body mass index (BMI) between 17.5 and 30.0 kg/m2\r\n\r\n\r\n\r\n          -  No clinically significant abno",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "San Francisco",
            "State": "California",
            "Zip": "94118",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 2, 2016",
            "FirstReceived": "May 15, 2015",
            "LocationName": "Kaiser Permanente",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02452528",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150969 - Arrowhead Research Corporation - Hernandez",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20150969",
            "StudyNumber": "20150969 - Arrowhead Research Corporation - Hernandez",
            "StudyTitle": "Heparc 2004 - A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection",
            "PIID": "22138",
            "PicNum": "C11868323",
            "PILastName": "Hernandez",
            "PIFirstName": "Maria Del Pilar",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C11868323",
            "EnteredByLastName": "Hernandez",
            "EnteredByFirstName": "Maria Del Pilar",
            "ActiveEnrollingDate": "04/22/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/22/2016",
            "IRBApprovedFrom": "11/23/2015",
            "IRBApprovedTo": "10/09/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Arrowhead Research Corporation",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diane Sabogal",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT02452528",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02456103",
            "BriefTitle": "Extension Study of Ataluren for Nonsense Mutation Cystic Fibrosis",
            "OfficialTitle": "A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis",
            "LeadSponsorClass": "PTC Therapeutics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "PTC Therapeutics",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is an open-label extension study for patients who complete a Phase 3,\r\n\r\n      placebo-controlled study of ataluren in patients with nonsense mutation cystic fibrosis\r\n\r\n      (nmCF) not receiving chronic inhaled aminoglycosides.",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "July 2015",
            "CompletionDate": "October 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "PTC Therapeutics",
            "StudyCondition": "Cystic Fibrosis",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "200",
            "MeshKeyword": "Fibrosis, Cystic Fibrosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Completion of study treatment (placebo or active) in the previous Phase 3,\r\n\r\n             double-blind study protocol (Protocol PTC124-GD-021-CF)\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -  O",
            "EligibleGender": "All",
            "MinAge": "6 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "May 2015",
            "LastChanged": "May 26, 2015",
            "FirstReceived": "May 26, 2015",
            "OverallOfficial": "Joseph McIntosh, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "PTC Therapeutics",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02456103",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150851 - PTC Therapeutics/ Inc. - Salathe",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20150851",
            "StudyNumber": "20150851 - PTC Therapeutics/ Inc. - Salathe",
            "StudyTitle": "A PHASE 3 EXTENSION STUDY OF ATALUREN (PTC124) IN\nPATIENTS WITH NONSENSE MUTATION CYSTIC FIBROSIS",
            "PIID": "528",
            "PicNum": "C00319179",
            "PILastName": "Salathe",
            "PIFirstName": "Matthias",
            "CoodCNbr": "C09943370",
            "CoordLastName": "Aguiar",
            "CoordFirstName": "Carolina",
            "CoordEmail": "caguiar2@med.miami.edu",
            "CoordPhone": "3052435545",
            "EnteredByCNbr": "C00319179",
            "EnteredByLastName": "Salathe",
            "EnteredByFirstName": "Matthias",
            "ActiveEnrollingDate": "12/09/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/09/2015",
            "IRBApprovedFrom": "11/16/2015",
            "IRBApprovedTo": "11/06/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "PTC Therapeutics/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "7",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "6",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "4",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Patricia Rebolledo,Carolina Aguiar,Patricia Graham-Borras,Johana Arana",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02456103",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02463032",
            "BriefTitle": "Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer",
            "OfficialTitle": "A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women",
            "LeadSponsorClass": "GTx",
            "SponsorAgency": "Industry",
            "LeadSponsor": "GTx",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine if GTx-024 at different dosages (9 mg or 18 mg) is\r\n\r\n      effective and safe in the treatment of patients with metastatic or locally advanced ER+ and\r\n\r\n      AR+ breast cancer in postmenopausal women.",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "CompletionDate": "August 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "GTx",
            "StudyCondition": "ER+ and AR+ Breast Cancer",
            "studyLocation": "Holy Cross Hospital",
            "Enrollment": "88",
            "MeshKeyword": "Breast Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Adult women (≥ 18 years of age) with metastatic or recurrent locally advanced BC, not\r\n\r\n             amenable to curative treatment by surgery or radiotherapy, with objective evidence of",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Fort Lauderdale",
            "State": "Florida",
            "Zip": "33308",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 31, 2016",
            "FirstReceived": "June 2, 2015",
            "OverallOfficial": "Beth A Overmoyer, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Susan Smith Center for Women's Cancers, Dana-Farber Cancer Institute",
            "ContactName": "Mayzie Johnston, PharmD",
            "ContactPhone": "901-523-9700",
            "ContactEmail": "mjohnston@gtxinc.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Holy Cross Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02463032",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150869 - GTx - Vogel",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150869",
            "StudyNumber": "20150869 - GTx - Vogel",
            "StudyTitle": "A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating the Efficacy and Safety of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women",
            "PIID": "2271",
            "PicNum": "C00189505",
            "PILastName": "Vogel",
            "PIFirstName": "Charles",
            "CoodCNbr": "C11967166",
            "CoordLastName": "Eyer",
            "CoordFirstName": "Penny",
            "CoordEmail": "ple19@med.miami.edu",
            "CoordPhone": "954-698-3673",
            "EnteredByCNbr": "C12001301",
            "EnteredByLastName": "Delgado",
            "EnteredByFirstName": "Yisenny",
            "ActiveEnrollingDate": "04/21/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/21/2016",
            "IRBApprovedFrom": "12/21/2015",
            "IRBApprovedTo": "06/05/2017",
            "AccountNbr": "666410",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase II",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "7",
            "Totalaccrued": "5",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "2",
            "SiteSampleSize": "SCCC Deerfield:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A,UM Kendall:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Onaidy Torres,Carla Munevar,Deborah Conte,Sarah Raybin,Michelle Mikhail,Halyna Hailes,Anthony Minichiello,Cristina Rojas-Mejia,Pascale Timothee,Karen Henry",
            "NationalSampleSize": "4",
            "NCTNbr": "NCT02463032",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02465060",
            "SecondaryId": "NCI-2015-00054",
            "BriefTitle": "NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma",
            "OfficialTitle": "Molecular Analysis for Therapy Choice (MATCH)",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "No",
            "BriefSummary": "This phase II trial studies how well treatment that is directed by genetic testing works in\r\n\r\n      patients with solid tumors or lymphomas that have progressed following at least one line of\r\n\r\n      standard treatment or for which no agreed u",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To evaluate the proportion of patients with objective response (OR) to targeted study\r\n\r\n      agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.\r\n\r\n\r\n\r\n      SECONDARY OBJECTIVE",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Advanced Malignant Neoplasm",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "3000",
            "MeshKeyword": "Neoplasms, Multiple Myeloma, Neoplasms, Plasma Cell, Lymphoma,",
            "InterventionKeyword": "Sunitinib, Nivolumab, Trametinib, Palbociclib, Ado-trastuzumab emtansine, Dabrafenib, Osimertinib, Trastuzumab, Dasatinib, Maytansine, Crizotinib, Immunoconjugates,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Women of childbearing potential must have a negative serum pregnancy test within 2\r\n\r\n             weeks prior to registration; patients that are pregnant or breast feeding are\r\n\r\n             excluded;",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "June 3, 2015",
            "OverallOfficial": "Keith Flaherty",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "ECOG-ACRIN Cancer Research Group",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02465060",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150671 - ECOG - Slomovitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150671",
            "StudyNumber": "20150671 - ECOG - Slomovitz",
            "StudyTitle": "Molecular Analysis for Therapy Choice (MATCH)",
            "PIID": "22712",
            "PicNum": "C11916703",
            "PILastName": "Slomovitz",
            "PIFirstName": "Brian",
            "CoodCNbr": "C12029661",
            "CoordLastName": "Baun",
            "CoordFirstName": "Katrina",
            "CoordEmail": "kxb604@med.miami.edu",
            "CoordPhone": "305-243-1481",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "08/05/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/05/2016",
            "IRBApprovedFrom": "07/14/2015",
            "IRBApprovedTo": "01/18/2017",
            "AccountNbr": "665895",
            "DiseaseSiteListDesc": "Cervix,Corpus Uteri,Ovary,Other Female Genital,Non-Hodgkins Lymphoma",
            "Expr1": "Phase II",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Sponsor": "ECOG",
            "Prescreened": "0",
            "Screenedfailed": "20",
            "SignedICF": "71",
            "Totalaccrued": "43",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "5",
            "CurrentlyActiveTreatment": "5",
            "Totalpatients": "71",
            "FirstNinety": "23",
            "SiteSampleSize": "UM Coral Springs:N/A,UMMG:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Michelle Mikhail,Carla Munevar,Sarah Raybin,Sharon Khadaran,Onaidy Torres,Halyna Hailes,Anthony Minichiello,Maydelis Escalona,Deborah Conte,Evan Dadas,Claudia Grandas Moreno,Cristina Rojas-Mejia,Penny Eyer,Isabel Moya",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02465060",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02468778",
            "BriefTitle": "Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)",
            "OfficialTitle": "Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)",
            "LeadSponsorClass": "St. Jude Medical",
            "SponsorAgency": "Industry",
            "LeadSponsor": "St. Jude Medical",
            "OversightAuthority": "Yes",
            "BriefSummary": "The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for\r\n\r\n      use during high risk percutaneous coronary interventions (PCI) performed in elective or\r\n\r\n      urgent, hemodynamically stable patients with sev",
            "Description": "Prospective, randomized, multi-center, open-label trial of the HeartMate PHP at up to 100\r\n\r\n      sites in the US. Control device will be any Abiomed Impella device approved for use in\r\n\r\n      high-risk PCI.\r\n\r\n\r\n\r\n      Nonrandomized roll-in",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "CompletionDate": "January 2018",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "St. Jude Medical",
            "StudyCondition": "Coronary Artery Disease",
            "studyLocation": "Arizona Heart Hospital",
            "Enrollment": "425",
            "NctKeyword": "HeartMate PHP, High Risk PCI, Left Ventricular Dysfunction, Thoratec Corporation,",
            "MeshKeyword": "Coronary Artery Disease, Myocardial Ischemia, Coronary Disease,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  At least 18 years of age\r\n\r\n\r\n\r\n          -  Patient is undergoing elective or urgent high risk PCI procedure and is\r\n\r\n             hemodynamically stable\r\n\r\n\r\n\r\n          -  Patient is indicated for a",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "100 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85018",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 14, 2016",
            "FirstReceived": "May 29, 2015",
            "OverallOfficial": "Poornima Sood, MD, MBA",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Thoratec LLC, St. Jude Medical",
            "ContactName": "Kausar Qidwai, MSc",
            "ContactPhone": "781-852-8201",
            "ContactEmail": "kqidwai@sjm.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Arizona Heart Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02468778",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150621 - Thoratec Corporation - Cohen",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20150621",
            "StudyNumber": "20150621 - Thoratec Corporation - Cohen",
            "StudyTitle": "Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left ventricular Support device (SHIELD ll)",
            "PIID": "1752",
            "PicNum": "C07441231",
            "PILastName": "Cohen",
            "PIFirstName": "Mauricio",
            "CoodCNbr": "C06968089",
            "CoordLastName": "Lang",
            "CoordFirstName": "Barbara",
            "CoordEmail": "blang@med.miami.edu",
            "CoordPhone": "3052434950",
            "EnteredByCNbr": "C07441231",
            "EnteredByLastName": "Cohen",
            "EnteredByFirstName": "Mauricio",
            "ActiveEnrollingDate": "04/20/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/20/2016",
            "IRBApprovedFrom": "11/23/2015",
            "IRBApprovedTo": "10/23/2017",
            "Expr1": "N/A",
            "ResearchType": "Device/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Thoratec Corporation",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carmen Baez-Garcia,Barbara Lang",
            "NationalSampleSize": "60",
            "NCTNbr": "NCT02468778",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02469090",
            "BriefTitle": "Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease",
            "OfficialTitle": "Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes)",
            "LeadSponsorClass": "Sunovion",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Sunovion",
            "OversightAuthority": "Yes",
            "BriefSummary": "A 12-week, prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3\r\n\r\n      study in L-Dopa responsive PD patients with motor fluctuations (\"OFF\" episodes), designed to\r\n\r\n      determine the efficacy, safety and tolerab",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2015",
            "CompletionDate": "July 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Sunovion",
            "StudyCondition": "Parkinson Disease",
            "studyLocation": "University of Alabama, Birmingham",
            "Enrollment": "126",
            "MeshKeyword": "Parkinson Disease,",
            "InterventionKeyword": "Apomorphine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male or female ≥ 18 years of age.\r\n\r\n\r\n\r\n          -  Clinical diagnosis of Idiopathic PD, consistent with UK Brain Bank Criteria.\r\n\r\n\r\n\r\n          -  Clinically meaningful response to L-Dopa with well-d",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 6, 2017",
            "FirstReceived": "June 9, 2015",
            "OverallOfficial": "CNS Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Sunovion",
            "ContactName": "CNS Medical Director",
            "ContactPhone": "1-866-503-6351",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama, Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02469090",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150604 - Cynapsus Therapeutics Inc - Singer",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20150604",
            "StudyNumber": "20150604 - Cynapsus Therapeutics Inc - Singer",
            "StudyTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes)",
            "PIID": "143",
            "PicNum": "C00407776",
            "PILastName": "Singer",
            "PIFirstName": "Carlos",
            "CoodCNbr": "C11907212",
            "CoordLastName": "Vargas",
            "CoordFirstName": "Silvia",
            "CoordEmail": "s.vargasparra@med.miami.edu",
            "EnteredByCNbr": "C00407776",
            "EnteredByLastName": "Singer",
            "EnteredByFirstName": "Carlos",
            "ActiveEnrollingDate": "01/19/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/19/2016",
            "IRBApprovedFrom": "09/14/2015",
            "IRBApprovedTo": "08/07/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Cynapsus Therapeutics Inc",
            "Prescreened": "1",
            "Screenedfailed": "3",
            "SignedICF": "6",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Padron,Silvia Vargas",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT02469090",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02469857",
            "BriefTitle": "Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections",
            "OfficialTitle": "Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study of AB103 as Compared to Placebo in Patients With Necrotizing Soft Tissue Infections. ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)",
            "LeadSponsorClass": "Atox Bio Ltd",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Atox Bio Ltd",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine whether AB103 is safe and effective in the\r\n\r\n      treatment of patients with necrotizing soft tissue infections receiving standard of care\r\n\r\n      therapy.",
            "Description": "The primary hypothesis of this study is that in addition to standard of care treatment\r\n\r\n      (which includes surgical intervention, antimicrobial therapy and critical care support for\r\n\r\n      organ dysfunction or failure), AB103 will demonst",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2015",
            "CompletionDate": "March 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Atox Bio Ltd",
            "StudyCondition": "Necrotizing Soft Tissue Infections",
            "studyLocation": "Maricopa Medical Center",
            "Enrollment": "290",
            "NctKeyword": "AB103, Necrotizing fasciitis,",
            "MeshKeyword": "Infection, Communicable Diseases, Fasciitis, Soft Tissue Infections, Gangrene, Fasciitis, Necrotizing, Fournier Gangrene,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Surgical confirmation of NSTI by attending surgeon;\r\n\r\n\r\n\r\n          2. mSOFA score ≥3 (in any one or combination of the 5 major components of SOFA score\r\n\r\n             with one organ component having a",
            "EligibleGender": "All",
            "MinAge": "12 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85008",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 21, 2016",
            "FirstReceived": "June 6, 2015",
            "OverallOfficial": "Wayne M Dankner, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Atox Bio Ltd",
            "ContactName": "Wayne M Dankner, MD",
            "ContactPhone": "919-219-6377",
            "ContactEmail": "wayned@atoxbio.com",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "Maricopa Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02469857",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150585 - DHHS/NIH/NIAID - Namias",
            "FileProcessContentId": "440",
            "Division": "Surgery",
            "StdyDivision": "7805",
            "EprostNbr": "20150585",
            "StudyNumber": "20150585 - DHHS/NIH/NIAID - Namias",
            "StudyTitle": "PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, STUDY OF AB103 AS COMPARED TO PLACEBO IN PATIENTS WITH NECROTIZING SOFT TISSUE INFECTIONS (NSTI)",
            "PIID": "677",
            "PicNum": "C00552485",
            "PILastName": "Namias",
            "PIFirstName": "Nicholas",
            "CoodCNbr": "C00610103",
            "CoordLastName": "Manning",
            "CoordFirstName": "Ronald",
            "CoordEmail": "rmanning@med.miami.edu",
            "CoordPhone": "3053554972",
            "EnteredByCNbr": "C00552485",
            "EnteredByLastName": "Namias",
            "EnteredByFirstName": "Nicholas",
            "ActiveEnrollingDate": "10/06/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/06/2016",
            "IRBApprovedFrom": "10/06/2015",
            "IRBApprovedTo": "08/29/2017",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Other",
            "Sponsor": "DHHS/NIH/NIAID",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Ronald Manning,Olga Orozco",
            "AgentDevices": "AB103",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02469857",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02470806",
            "BriefTitle": "Single-Use Negative Pressure Wound Therapy System vs. Traditional Negative Pressure Wound Therapy System (tNPWT)",
            "OfficialTitle": "A Prospective, Randomized, Comparative Effectiveness Study of a Single-Use, Negative Pressure Wound Therapy System (PICO) Versus a Traditional Negative Pressure Wound Therapy System (tNPWT) in the Treatment of Lower Extremity Ulcers",
            "LeadSponsorClass": "Healthpoint",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Healthpoint",
            "OversightAuthority": "No",
            "BriefSummary": "The aim of this study is to compare the clinical efficacy of two types of NPWT systems;\r\n\r\n\r\n\r\n        -  tNPWT systems that has successfully completed a coding verification request with CMS\r\n\r\n           and has the following capabilities (e.g.",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2015",
            "CompletionDate": "August 2017",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "Healthpoint",
            "StudyCondition": "Venous Leg Ulcers",
            "Enrollment": "160",
            "NctKeyword": "Venous leg ulcer, ulcer, venous stasis, compression, diabetic foot ulcers, dfu, vlu,",
            "MeshKeyword": "Ulcer, Diabetic Foot, Foot Ulcer, Leg Ulcer, Varicose Ulcer,",
            "Eligibility": "INCLUSION CRITERIA:\r\n\r\n\r\n\r\n          -  Provide informed consent\r\n\r\n\r\n\r\n          -  Age ≥ 18 years and of either sex\r\n\r\n\r\n\r\n          -  Willing to comply with protocol instructions, including allowing all study\r\n\r\n             assessments",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Carlsbad",
            "State": "California",
            "Zip": "92009",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 18, 2017",
            "FirstReceived": "June 10, 2015",
            "OverallOfficial": "Jamie E Dickerson, PhD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Smith & Nephew, Inc.",
            "ContactName": "John Cockwill, MS",
            "ContactPhone": "727-643-2323",
            "ContactEmail": "john.cockwill@smith-nephew.com",
            "LocationStatus": "Not yet recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02470806",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150465 - Smith & Nephew plc - Kirsner",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20150465",
            "StudyNumber": "20150465 - Smith & Nephew plc - Kirsner",
            "StudyTitle": "A Prospective, Randomized, Comparative Effectiveness Study of a Single-Use, Negative Pressure Wound Therapy System (PICO) versus a Traditional Negative Pressure Wound Therapy System (tNPWT) in the Treatment of Lower Extremity Ulcers",
            "PIID": "717",
            "PicNum": "C00519753",
            "PILastName": "Kirsner",
            "PIFirstName": "Robert",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C00519753",
            "EnteredByLastName": "Kirsner",
            "EnteredByFirstName": "Robert",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "08/17/2015",
            "IRBApprovedFrom": "08/17/2015",
            "IRBApprovedTo": "07/25/2017",
            "Expr1": "N/A",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "Smith & Nephew plc",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Aliette Espinosa,Carol Kittles",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT02470806",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02472769",
            "BriefTitle": "IBP-9414 for the Prevention of Necrotizing Enterocolitis",
            "OfficialTitle": "A Randomized, Double Blind, Parallel-group, Dose Escalation Placebo-controlled Multicenter Study to Investigate the Safety and Tolerability of IBP-9414 Administered in Preterm Infants.",
            "LeadSponsorClass": "Infant Bacterial Therapeutics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Infant Bacterial Therapeutics",
            "BriefSummary": "Two different dose levels will be evaluated in two different birth weight categories,\r\n\r\n      compared to placebo with regards to safety and tolerability.",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2016",
            "CompletionDate": "October 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Infant Bacterial Therapeutics",
            "StudyCondition": "Necrotizing Enterocolitis",
            "studyLocation": "Univ. Arkansas Medical Sciences",
            "Enrollment": "120",
            "MeshKeyword": "Enterocolitis, Enterocolitis, Necrotizing,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Gestational age ≤32 weeks\r\n\r\n\r\n\r\n          2. Birth weight: a) ≤ 2,000 g and b) ≤ 1,000 g.\r\n\r\n\r\n\r\n          3. < 48 hours of age.\r\n\r\n\r\n\r\n          4. Written informed consent from the patient's legally a",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "48 Hours",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Zip": "72202",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 3, 2016",
            "FirstReceived": "June 2, 2015",
            "OverallOfficial": "Josef Neu, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Florida College of Medicine, Gainsville, FL",
            "ContactName": "Eamonn Connolly, Ph.D.",
            "ContactPhone": "+46733461154",
            "ContactEmail": "eamonn.connolly@ibtherapeutics.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Univ. Arkansas Medical Sciences",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02472769",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160157 - Infant Bacterial Therapeutics (IBT) - Delmoral",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20160157",
            "StudyNumber": "20160157 - Infant Bacterial Therapeutics (IBT) - Delmoral",
            "StudyTitle": "A randomized, double blind, parallel-group, dose escalation placebo-controlled multicenter study to investigate the safety and tolerability of IBP-9414 administered in preterm infants",
            "PIID": "503",
            "PicNum": "C00071160",
            "PILastName": "DelMoral",
            "PIFirstName": "Teresa",
            "CoodCNbr": "C00071160",
            "CoordLastName": "DelMoral",
            "CoordFirstName": "Teresa",
            "CoordEmail": "Tdelmoral@med.miami.edu",
            "CoordPhone": "3055856408",
            "EnteredByCNbr": "C00071160",
            "EnteredByLastName": "DelMoral",
            "EnteredByFirstName": "Teresa",
            "ActiveEnrollingDate": "07/17/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/17/2016",
            "IRBApprovedFrom": "05/16/2016",
            "IRBApprovedTo": "05/15/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "9",
            "Totalaccrued": "9",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "9",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "9",
            "FirstNinety": "5",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Silvia Vanbuskirk",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02472769",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02475655",
            "SecondaryId": "11977",
            "BriefTitle": "Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults",
            "OfficialTitle": "A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults",
            "LeadSponsorClass": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate the safety and tolerability of ruxolitinib in\r\n\r\n      HIV-infected adults who are virologically suppressed and who are on antiretroviral therapy\r\n\r\n      (ART).",
            "Description": "Ruxolitinib is a medication approved by the U.S. Food and Drug Administration (FDA) to treat\r\n\r\n      myelofibrosis, a disorder in which bone marrow is replaced by scar (fibrosis) tissue. Many\r\n\r\n      of the cytokines affected by myelofibrosis",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "National Institute of Allergy and Infectious Diseases (NIAID)",
            "StudyCondition": "HIV Infections",
            "studyLocation": "Alabama CRS",
            "Enrollment": "60",
            "MeshKeyword": "HIV Infections,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or\r\n\r\n             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and\r\n\r\n             confirmed b",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 12, 2016",
            "FirstReceived": "June 16, 2015",
            "OverallOfficial": "Vincent Marconi, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Emory University",
            "LocationStatus": "Recruiting",
            "LocationName": "Alabama CRS",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02475655",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160695 - NATL INST OF ALLERGY & INFECTIOUS DISEASES - Fischl",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20160695",
            "StudyNumber": "20160695 - NATL INST OF ALLERGY & INFECTIOUS DISEASES - Fischl",
            "StudyTitle": "A5336:  A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults Version 2.0\n\nLetter of Amendment #1 for Protocol A5336, Version 2.0",
            "PIID": "825",
            "PicNum": "C00454409",
            "PILastName": "Fischl",
            "PIFirstName": "Margaret",
            "CoodCNbr": "C00454409",
            "CoordLastName": "Fischl",
            "CoordFirstName": "Margaret",
            "CoordEmail": "mfischl@med.miami.edu",
            "CoordPhone": "3052433847",
            "EnteredByCNbr": "C00454409",
            "EnteredByLastName": "Fischl",
            "EnteredByFirstName": "Margaret",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "09/06/2016",
            "IRBApprovedFrom": "09/06/2016",
            "IRBApprovedTo": "09/05/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug",
            "SponsorGroup": "Other",
            "Sponsor": "NATL INST OF ALLERGY & INFECTIOUS DISEASES",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Post-Review",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02475655",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02477800",
            "SecondaryId": "2015-000966-72",
            "BriefTitle": "221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease",
            "OfficialTitle": "A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease",
            "LeadSponsorClass": "Biogen",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Biogen",
            "OversightAuthority": "Yes",
            "BriefSummary": "The primary objective of the study is to evaluate the efficacy of monthly doses of\r\n\r\n      aducanumab in slowing cognitive and functional impairment as measured by changes in the\r\n\r\n      Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "CompletionDate": "March 2022",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Biogen",
            "StudyCondition": "Alzheimer's Disease",
            "studyLocation": "St. Joseph's Hospital and Medical Center",
            "Enrollment": "1350",
            "NctKeyword": "BIIB037, Aducanumab,",
            "MeshKeyword": "Alzheimer Disease,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Must meet all of the following clinical criteria for MCI due to AD or mild AD and\r\n\r\n             must have:\r\n\r\n\r\n\r\n          -  A Clinical Dementia Rating (CDR)-Global Score of 0.5.",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85013",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "June 18, 2015",
            "OverallOfficial": "Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Biogen",
            "ContactName": "Aducanumab Global Clinical Trial Center",
            "ContactEmail": "clinicaltrials@biogen.com",
            "LocationStatus": "Recruiting",
            "LocationName": "St. Joseph's Hospital and Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02477800",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150453 - Biogen Idec - Baumel",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20150453",
            "StudyNumber": "20150453 - Biogen Idec - Baumel",
            "StudyTitle": "A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease",
            "PIID": "22263",
            "PicNum": "C00471281",
            "PILastName": "Baumel",
            "PIFirstName": "Bernard",
            "CoodCNbr": "C03834528",
            "CoordLastName": "Perez",
            "CoordFirstName": "Carmen",
            "CoordEmail": "c.perez71@med.miami.edu",
            "CoordPhone": "3052435610",
            "EnteredByCNbr": "C00471281",
            "EnteredByLastName": "Baumel",
            "EnteredByFirstName": "Bernard",
            "ActiveEnrollingDate": "05/06/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/06/2016",
            "IRBApprovedFrom": "11/16/2015",
            "IRBApprovedTo": "11/06/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Biogen Idec",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "5",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carmen Perez,Jonathan Landman",
            "NationalSampleSize": "7",
            "NCTNbr": "NCT02477800",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02481154",
            "BriefTitle": "Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation",
            "OfficialTitle": "A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Muta",
            "LeadSponsorClass": "Agios Pharmaceuticals, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Agios Pharmaceuticals, Inc.",
            "BriefSummary": "This study evaluates the safety, pharmacokinetics, pharmacodynamics and clinical activity of\r\n\r\n      AG-881 in advanced solid tumors, including gliomas, that harbor an IDH1 and/or IDH2\r\n\r\n      mutation.",
            "Description": "The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics,\r\n\r\n      pharmacodynamics and clinical activity of AG-881 in advanced solid tumors, including\r\n\r\n      gliomas, that harbor an IDH1and/or IDH2 mutation.",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2015",
            "CompletionDate": "October 2018",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Agios Pharmaceuticals, Inc.",
            "StudyCondition": "Cholangiocarcinoma",
            "Enrollment": "150",
            "NctKeyword": "Chondrosarcoma, Cholangiocarcinoma, Advanced Solid Tumors, Glioma, IDH1, IDH2, Dual Mutation, AG-881,",
            "MeshKeyword": "Glioma, Cholangiocarcinoma, Chondrosarcoma,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patient must be ≥18 years of age\r\n\r\n\r\n\r\n          -  Patient must have histologically or cytologically confirmed solid tumor, including\r\n\r\n             glioma, with documented IDH1 and/or IDH2 gene-mutat",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90024",
            "Country": "United States",
            "VerificationDate": "May 2016",
            "LastChanged": "August 24, 2016",
            "FirstReceived": "June 16, 2015",
            "ContactName": "Susan Pandya, M.D.",
            "ContactPhone": "617-844-6430",
            "ContactEmail": "susan.pandya@agios.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02481154",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160380 - Agios Pharmaceuticals - De La Fuente",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160380",
            "StudyNumber": "20160380 - Agios Pharmaceuticals - De La Fuente",
            "StudyTitle": "A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Solid Tumors, Including Gliomas, with an IDH1 and/or IDH2 Mutation",
            "PIID": "22734",
            "PicNum": "C11916526",
            "PILastName": "De La Fuente",
            "PIFirstName": "Macarena",
            "CoodCNbr": "C12030188",
            "CoordLastName": "Salvador",
            "CoordFirstName": "Juan",
            "CoordEmail": "juan.salvador@miami.edu",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "09/01/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/01/2016",
            "IRBApprovedFrom": "07/14/2016",
            "IRBApprovedTo": "01/14/2017",
            "DiseaseSiteListDesc": "Bones and Joints",
            "Expr1": "Phase I",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "3",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "3",
            "FirstNinety": "3",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Dalissa Tejera,Daniel Sumarriva,Sandra Pineda,Nadia Myrthil,Karen Blackburn,Yvonne Dinh,Tamara Leon Aliz",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02481154",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02481609",
            "BriefTitle": "NAC Trial for Anosmia",
            "OfficialTitle": "Pilot Study of Topical Intranasal N-acetyl Cysteine Administration for the Treatment of Anosmia",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this research study is to evaluate the use of NAC in the treatment of anosmia\r\n\r\n      (a loss of the sense of smell). This drug is already approved by the Food and Drug\r\n\r\n      Administration (FDA) for oral or pulmonary (lung) i",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2014",
            "CompletionDate": "December 2016",
            "Phase": "Phase 0",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 0",
            "StudySource": "University of Miami",
            "StudyCondition": "Anosmia",
            "studyLocation": "University of Miami, Miller School of Medicine, Clinical Research Building",
            "Enrollment": "30",
            "NctKeyword": "Loss of Smell, Olfaction, Hyposmia,",
            "MeshKeyword": "Olfaction Disorders,",
            "InterventionKeyword": "Acetylcysteine, N-monoacetylcystine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  adults at least 18 years of age with documented microsmia or anosmia by University of\r\n\r\n             Pennsylvania Smell Identification Test.\r\n\r\n\r\n\r\n          -  patients must have no evidence of active",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 10, 2016",
            "FirstReceived": "June 22, 2015",
            "OverallOfficial": "Bradley J Goldstein, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Constanza H Pelusso, MD",
            "ContactPhone": "305-243-7102",
            "ContactEmail": "cpelusso@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami, Miller School of Medicine, Clinical Research Building",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02481609",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20130996 - Intramural - Goldstein",
            "FileProcessContentId": "440",
            "Division": "Otolaryngology",
            "StdyDivision": "10136",
            "EprostNbr": "20130996",
            "StudyNumber": "20130996 - Intramural - Goldstein",
            "StudyTitle": "Pilot study of topical intranasal N-acetyl cysteine administration for the treatment of anosmia",
            "PIID": "4184",
            "PicNum": "C11271990",
            "PILastName": "Goldstein",
            "PIFirstName": "Bradley",
            "CoodCNbr": "C11271990",
            "CoordLastName": "Goldstein",
            "CoordFirstName": "Bradley",
            "EnteredByCNbr": "C11271990",
            "EnteredByLastName": "Goldstein",
            "EnteredByFirstName": "Bradley",
            "ActiveEnrollingDate": "07/21/2014",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/21/2014",
            "IRBApprovedFrom": "06/23/2014",
            "IRBApprovedTo": "05/10/2016",
            "Expr1": "Approved Drug/Off-Label use",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "25",
            "Totalaccrued": "24",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "23",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "25",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Constanza Pelusso",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02481609",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02482298",
            "BriefTitle": "A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease",
            "OfficialTitle": "A Randomised, Double-blind, Double-dummy, Parallel-group, Multicenter, Phase IIb Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing the Number of Days With Pain in Young Adults With Sickle Cell Disease",
            "LeadSponsorClass": "AstraZeneca",
            "SponsorAgency": "Industry",
            "LeadSponsor": "AstraZeneca",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to determine whether ticagrelor is effective in reducing the\r\n\r\n      number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle\r\n\r\n      cell disease",
            "Description": "This is a randomised, double-blind, double-dummy, parallel-group, placebo-controlled, study\r\n\r\n      evaluating 2 doses of ticagrelor in 90 patients aged 18 to 30 years, with sickle cell\r\n\r\n      disease (SCD). Patients will be randomised to dou",
            "OverallStatus": "Completed",
            "StartDate": "July 2015",
            "CompletionDate": "November 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "AstraZeneca",
            "StudyCondition": "Sickle Cell Disease",
            "studyLocation": "Research Site",
            "Enrollment": "194",
            "NctKeyword": "Sickle cell disease, Young adults, Hestia2, Ticagrelor,",
            "MeshKeyword": "Anemia, Sickle Cell,",
            "InterventionKeyword": "Ticagrelor,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Confirmed medical history or diagnosis of homozygous sickle cell (HbSS) or sickle\r\n\r\n             beta-zero-thalassaemia (HbS/β0) by HPLC\r\n\r\n\r\n\r\n          -  If treated with hydroxyurea, the dose must ha",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "30 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 12, 2016",
            "FirstReceived": "June 17, 2015",
            "OverallOfficial": "Maria Ignacia -Berraondo, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Quintiles, Inc.",
            "LocationName": "Research Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02482298",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150577 - AstraZeneca - Harrington",
            "FileProcessContentId": "440",
            "Division": "Hematology Oncology",
            "StdyDivision": "10245",
            "EprostNbr": "20150577",
            "StudyNumber": "20150577 - AstraZeneca - Harrington",
            "StudyTitle": "A randomised, double-blind, double-dummy, parallel-group, multicenter, phase IIb study to evaluate the effect of ticagrelor 10 mg and 45 mg bid versus placebo in reducing the number of days with pain in young adults with sickle cell disease",
            "PIID": "363",
            "PicNum": "C00768138",
            "PILastName": "Harrington",
            "PIFirstName": "Thomas",
            "CoodCNbr": "C00768138",
            "CoordLastName": "Harrington",
            "CoordFirstName": "Thomas",
            "CoordEmail": "tharring@med.miami.edu",
            "CoordPhone": "3052436626",
            "EnteredByCNbr": "C00768138",
            "EnteredByLastName": "Harrington",
            "EnteredByFirstName": "Thomas",
            "ActiveEnrollingDate": "03/04/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/04/2016",
            "IRBApprovedFrom": "10/05/2015",
            "IRBApprovedTo": "10/04/2016",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "2",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Vanessa Cumming",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02482298",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02486003",
            "BriefTitle": "Testing mTBI in Athletes",
            "OfficialTitle": "The Use of a Portable 3D Head Mounted Display (HMD) With Integrated Eye Capture Technology for the Diagnosis of Dizziness Associated With Mild Traumatic Brain Injury (mTBI)",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "This study will assess the effectiveness of a portable goggle system in the diagnosis of\r\n\r\n      mild traumatic brain injury (mTBI) in athletes.",
            "Description": "The purpose of this research study is to assess oculomotor, vestibular and reaction time\r\n\r\n      responses in mild traumatic brain injury (mTBI) athletes, as well as healthy individuals.\r\n\r\n      These measurements will be recorded using a port",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2015",
            "CompletionDate": "January 2019",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Mild Traumatic Brain Injury",
            "studyLocation": "University of Miami Miller School of Medicine",
            "Enrollment": "300",
            "MeshKeyword": "Brain Injuries, Brain Concussion,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Males and females from 18 - 40 years of age who participate in intercollegiate\r\n\r\n             athletics at the University of Miami to include all levels of sports whether NCAA or\r\n\r\n             club. I",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "40 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 22, 2016",
            "FirstReceived": "June 26, 2015",
            "ContactName": "Michael E Hoffer, M.D.",
            "ContactPhone": "(305) 243-1484",
            "ContactEmail": "michael.hoffer@miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Miller School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02486003",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150361 - National Football League (NFL) - Hoffer",
            "FileProcessContentId": "440",
            "Division": "Otolaryngology",
            "StdyDivision": "10136",
            "EprostNbr": "20150361",
            "StudyNumber": "20150361 - National Football League (NFL) - Hoffer",
            "StudyTitle": "The use of a Portable 3D Head mounted display (HMD) with integrated eye capture technology for the diagnosis of dizziness associated with mild traumatic brain injury (mTBI)",
            "PIID": "23064",
            "PicNum": "C11915566",
            "PILastName": "Hoffer",
            "PIFirstName": "Michael",
            "CoodCNbr": "C06931201",
            "CoordLastName": "Pelusso",
            "CoordFirstName": "Constanza",
            "CoordEmail": "cpelusso@med.miami.edu",
            "CoordPhone": "3052431653",
            "EnteredByCNbr": "C11915566",
            "EnteredByLastName": "Hoffer",
            "EnteredByFirstName": "Michael",
            "ActiveEnrollingDate": "07/08/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/08/2015",
            "IRBApprovedFrom": "05/19/2015",
            "IRBApprovedTo": "04/27/2017",
            "Expr1": "Other",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "National Football League (NFL)",
            "Prescreened": "0",
            "Screenedfailed": "21",
            "SignedICF": "251",
            "Totalaccrued": "229",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "165",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "251",
            "FirstNinety": "137",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Sara Murphy,Thomas Iglesias,James Buskirk,Constanza Pelusso",
            "NationalSampleSize": "600",
            "NCTNbr": "NCT02486003",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT02486718",
            "BriefTitle": "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]",
            "OfficialTitle": "A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stag",
            "LeadSponsorClass": "Hoffmann-La Roche",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Hoffmann-La Roche",
            "BriefSummary": "The primary efficacy objective of the study is to evaluate the efficacy of 16 cycles of\r\n\r\n      Atezolizumab (MPDL3280A) treatment compared with best supportive care as measured by\r\n\r\n      disease-free survival (DFS) as assessed by the investi",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "CompletionDate": "February 2026",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Hoffmann-La Roche",
            "StudyCondition": "Non-Small Cell Lung Cancer",
            "Enrollment": "1127",
            "MeshKeyword": "Lung Neoplasms, Carcinoma, Non-Small-Cell Lung,",
            "InterventionKeyword": "Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        Inclusion Criteria for Enrollment Phase\r\n\r\n\r\n\r\n          -  Age >/= 18 years\r\n\r\n\r\n\r\n          -  Ability to comply with protocol\r\n\r\n\r\n\r\n          -  ECOG performance status of 0 or 1\r\n\r\n\r\n\r\n          -  Histo",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Mesa",
            "State": "Arizona",
            "Zip": "85206",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 3, 2016",
            "FirstReceived": "June 4, 2015",
            "OverallOfficial": "Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Hoffmann-La Roche",
            "ContactName": "Reference Study ID Number: GO29527 www.roche.com/about_roche/roche_worldwide.htm",
            "ContactPhone": "888-662-6728 (U.S. and Canada)",
            "ContactEmail": "global.rochegenentechtrials@roche.com",
            "LocationStatus": "Not yet recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02486718",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150598 - F Hoffman LaRoche - Ikpeazu",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150598",
            "StudyNumber": "20150598 - F Hoffman LaRoche - Ikpeazu",
            "StudyTitle": "A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY)\nCOMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PD-L1-SELECTED PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER",
            "PIID": "373",
            "PicNum": "C06163680",
            "PILastName": "Ikpeazu",
            "PIFirstName": "Chukwuemeka",
            "CoodCNbr": "C11967166",
            "CoordLastName": "Eyer",
            "CoordFirstName": "Penny",
            "CoordEmail": "ple19@med.miami.edu",
            "CoordPhone": "954-698-3673",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "08/25/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/25/2016",
            "IRBApprovedFrom": "11/23/2015",
            "IRBApprovedTo": "11/06/2017",
            "AccountNbr": "667179",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase III",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "F Hoffman LaRoche",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UM Kendall:N/A,SCCC Hollywood:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Michelle Mikhail,Carla Munevar,Halyna Hailes,Deborah Conte,Evan Dadas,Cristina Rojas-Mejia,Pascale Timothee,Karen Henry,Claudia Grandas Moreno,Anthony Minichiello",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02486718",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02488915",
            "BriefTitle": "Analysis of Revascularization in Ischemic Stroke With EmboTrap",
            "OfficialTitle": "ARISE II (Analysis of Revascularization in Ischemic Stroke With EmboTrap) Study",
            "LeadSponsorClass": "Neuravi Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Neuravi Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The study objective is to examine the recanalization efficacy of the EmboTrap device and its\r\n\r\n      associated performance characteristics and to record associated clinical outcomes in a\r\n\r\n      manner that facilitates relevant comparison of",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2015",
            "CompletionDate": "July 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Neuravi Inc.",
            "StudyCondition": "Stroke",
            "studyLocation": "UCLA",
            "Enrollment": "228",
            "NctKeyword": "Brain, Brain Clot, Brain Diseases, Brain Infarction, Cerebral Ischemia, Cerebrovascular Disorders, EmboTrap® Revascularization Device, EmboTrap, Ischemia, Ischemic, Ischemic Stroke, Mechanical Thrombectomy, Neurovascular Intervention, Revascularization, S",
            "MeshKeyword": "Stroke, Ischemia,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. The patient or the patient's legally authorized representative has signed and dated\r\n\r\n             an Informed Consent Form.\r\n\r\n\r\n\r\n          2. Aged between 18 years and 85 years (inclusive).",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90095",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 26, 2016",
            "FirstReceived": "June 30, 2015",
            "OverallOfficial": "Prof. Sam Zaidat, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "St. Vincent Mercy Mercy Hospital, Toledo,Ohio, USA",
            "ContactName": "Mairsíl Claffey",
            "ContactEmail": "mclaffey@neuravi.com",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "UCLA",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02488915",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160088 - Neuravi Ltd. - Yavagal",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20160088",
            "StudyNumber": "20160088 - Neuravi Ltd. - Yavagal",
            "StudyTitle": "ARISE II (Analysis of Revascularization in Ischemic Stroke with EmboTrap®) Study",
            "PIID": "252",
            "PicNum": "C06459010",
            "PILastName": "Yavagal",
            "PIFirstName": "Dileep",
            "CoodCNbr": "C11877018",
            "CoordLastName": "Ramdas",
            "CoordFirstName": "Kevin",
            "CoordEmail": "k.ramdas@med.miami.edu",
            "CoordPhone": "305-243-1132",
            "EnteredByCNbr": "C06459010",
            "EnteredByLastName": "Yavagal",
            "EnteredByFirstName": "Dileep",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "06/07/2016",
            "IRBApprovedFrom": "06/07/2016",
            "IRBApprovedTo": "06/06/2017",
            "Expr1": "Phase III",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "Neuravi Ltd.",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Luis Guada,Silvia Balladares-Huete,Karen Bates",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02488915",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02488967",
            "SecondaryId": "NCI-2015-00128",
            "BriefTitle": "Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer",
            "OfficialTitle": "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer",
            "LeadSponsorClass": "NRG Oncology",
            "SponsorAgency": "Other",
            "LeadSponsor": "NRG Oncology",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase III trial studies how well doxorubicin hydrochloride and\r\n\r\n      cyclophosphamide followed by paclitaxel with or without carboplatin work in treating\r\n\r\n      patients with triple-negative breast cancer. Drugs used in chem",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To determine whether the addition of carboplatin to an adjuvant chemotherapy regimen of\r\n\r\n      doxorubicin (doxorubicin hydrochloride)/cyclophosphamide followed by paclitaxel will improve\r\n\r\n      the invasi",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "NRG Oncology",
            "StudyCondition": "Breast Adenocarcinoma",
            "studyLocation": "Southern Cancer Center PC-Providence",
            "Enrollment": "990",
            "MeshKeyword": "Adenocarcinoma, Breast Neoplasms,",
            "InterventionKeyword": "Paclitaxel, Liposomal doxorubicin, Albumin-Bound Paclitaxel, Doxorubicin, Cyclophosphamide, Carboplatin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  The patient must have signed and dated an institutional review board (IRB)-approved\r\n\r\n             consent form that conforms to federal and institutional guidelines\r\n\r\n\r\n\r\n          -  Eastern Cooperat",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Mobile",
            "State": "Alabama",
            "Zip": "36608",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 4, 2016",
            "FirstReceived": "June 30, 2015",
            "OverallOfficial": "Vicente Valero",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "NRG Oncology",
            "LocationStatus": "Suspended",
            "LocationName": "Southern Cancer Center PC-Providence",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02488967",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160188 - NRG Oncology - Perez",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160188",
            "StudyNumber": "20160188 - NRG Oncology - Perez",
            "StudyTitle": "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer",
            "PIID": "25232",
            "PicNum": "C11967904",
            "PILastName": "Perez",
            "PIFirstName": "Alejandra",
            "CoodCNbr": "C12024030",
            "CoordLastName": "Conte",
            "CoordFirstName": "Deborah",
            "CoordEmail": "dmc238@med.miami.edu",
            "CoordPhone": "954-830-2360",
            "EnteredByCNbr": "C11835659",
            "EnteredByLastName": "Rivera",
            "EnteredByFirstName": "Diana",
            "ActiveEnrollingDate": "11/17/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/17/2016",
            "IRBApprovedFrom": "04/30/2015",
            "IRBApprovedTo": "02/17/2017",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase III",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A,UM Kendall:N/A,Plantation:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Cristina Rojas-Mejia,Sarah Raybin,Evan Dadas,Penny Eyer,Onaidy Torres,Halyna Hailes,Anthony Minichiello",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02488967",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02492711",
            "BriefTitle": "Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer",
            "OfficialTitle": "A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment",
            "LeadSponsorClass": "MacroGenics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "MacroGenics",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine whether patients treated with margetuximab plus\r\n\r\n      chemotherapy have longer progression free survival and overall survival than patients\r\n\r\n      treated with trastuzumab plus chemotherapy.",
            "Description": "An evaluation of efficacy, as measured by progression-free survival (PFS) assessed by\r\n\r\n      independent review and overall survival (OS), of margetuximab plus chemotherapy compared to\r\n\r\n      trastuzumab plus chemotherapy in patients with ad",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2015",
            "CompletionDate": "May 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "MacroGenics",
            "StudyCondition": "HER-2 Positive Breast Cancer",
            "studyLocation": "Southern Cancer Center",
            "Enrollment": "530",
            "MeshKeyword": "Breast Neoplasms, Neoplasm Metastasis,",
            "InterventionKeyword": "Gemcitabine, Capecitabine, Vinorelbine, Trastuzumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Histologically-proven metastatic or locally-advanced relapsed/refractory HER2+ breast\r\n\r\n             cancer based on the most recently available tumor biopsy collected from the patient.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Mobile",
            "State": "Alabama",
            "Zip": "36608",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "July 6, 2015",
            "OverallOfficial": "Naimish Pandya, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "MacroGenics",
            "ContactName": "Sutton Edlich",
            "ContactPhone": "(240) 552-8082",
            "LocationStatus": "Recruiting",
            "LocationName": "Southern Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02492711",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160020 - MacroGenics Inc - Perez",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160020",
            "StudyNumber": "20160020 - MacroGenics Inc - Perez",
            "StudyTitle": "A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment",
            "PIID": "25232",
            "PicNum": "C11967904",
            "PILastName": "Perez",
            "PIFirstName": "Alejandra",
            "CoodCNbr": "C12024030",
            "CoordLastName": "Conte",
            "CoordFirstName": "Deborah",
            "CoordEmail": "dmc238@med.miami.edu",
            "CoordPhone": "954-830-2360",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "08/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/08/2016",
            "IRBApprovedFrom": "06/06/2016",
            "IRBApprovedTo": "09/20/2016",
            "AccountNbr": "667376",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase III",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "SiteSampleSize": "UMMG:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Michelle Liendo,Penny Eyer,Sarah Raybin,Cristina Rojas-Mejia,Mohammad El-Sorady,Evan Dadas,Onaidy Torres,Anthony Minichiello",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02492711",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02496767",
            "SecondaryId": "2014-005413-23",
            "BriefTitle": "Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year",
            "OfficialTitle": "A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)",
            "LeadSponsorClass": "Cytokinetics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Cytokinetics",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study is to assess the effect of tirasemtiv versus placebo on respiratory function in\r\n\r\n      patients with ALS.",
            "Description": "CY 4031 is a multi-national, double-blind, randomized, placebo-controlled, stratified,\r\n\r\n      parallel group study in patients with ALS with the selective fast skeletal muscle troponin\r\n\r\n      activator, tirasemtiv. The study includes three p",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "August 2015",
            "CompletionDate": "July 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Cytokinetics",
            "StudyCondition": "Amyotrophic Lateral Sclerosis",
            "studyLocation": "St. Joseph's Hospital & Medical Center - Barrow Neurology Clinics",
            "Enrollment": "743",
            "NctKeyword": "fast skeletal troponin activator, tirasemtiv, CK-2017357, double-blind, randomized, placebo-controlled,",
            "MeshKeyword": "Sclerosis, Motor Neuron Disease, Amyotrophic Lateral Sclerosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  A diagnosis of familial or sporadic ALS (defined as meeting the possible,\r\n\r\n             laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS\r\n\r\n             according to",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85013",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 6, 2017",
            "FirstReceived": "July 10, 2015",
            "OverallOfficial": "MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Cytokinetics",
            "LocationName": "St. Joseph's Hospital & Medical Center - Barrow Neurology Clinics",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02496767",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150619 - Cytokinetics/ Inc.  - Benatar",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20150619",
            "StudyNumber": "20150619 - Cytokinetics/ Inc.  - Benatar",
            "StudyTitle": "CY 4031: A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS)",
            "PIID": "3255",
            "PicNum": "C09944978",
            "PILastName": "Benatar",
            "PIFirstName": "Michael",
            "CoodCNbr": "C00565231",
            "CoordLastName": "Steele",
            "CoordFirstName": "Julie",
            "CoordEmail": "j.steele@med.miami.edu",
            "CoordPhone": "3052437336",
            "EnteredByCNbr": "C09944978",
            "EnteredByLastName": "Benatar",
            "EnteredByFirstName": "Michael",
            "ActiveEnrollingDate": "12/22/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/22/2015",
            "IRBApprovedFrom": "11/09/2015",
            "IRBApprovedTo": "11/08/2016",
            "Expr1": "Phase III",
            "Tarea": "Neuro-Muscular Disorders",
            "TareaCode": "8938",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Cytokinetics/ Inc.",
            "Prescreened": "10",
            "Screenedfailed": "4",
            "SignedICF": "17",
            "Totalaccrued": "13",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "6",
            "Totalpatients": "17",
            "FirstNinety": "8",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Wendy Levy,Danielle Sheldon,Julie Steele",
            "NationalSampleSize": "35",
            "NCTNbr": "NCT02496767",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02501811",
            "SecondaryId": "5UM1HL087318",
            "BriefTitle": "Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure",
            "OfficialTitle": "A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, and Efficacy of Autologous Mesenchymal Stem Cells and C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic Heart Failure",
            "LeadSponsorClass": "The University of Texas Health Science Center, Houston",
            "SponsorAgency": "Other",
            "LeadSponsor": "The University of Texas Health Science Center, Houston",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a phase II, randomized, placebo-controlled clinical trial designed to assess\r\n\r\n      feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells\r\n\r\n      (MSCs) and c-kit+ cardiac stem cells (CSCs) both alon",
            "Description": "This is a randomized, placebo-controlled clinical trial designed to evaluate the\r\n\r\n      feasibility, safety, and effect of Combo, MSCs alone, and CSCs alone compared with placebo\r\n\r\n      as well as each other in subjects with heart failure of",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "CompletionDate": "February 2019",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "The University of Texas Health Science Center, Houston",
            "StudyCondition": "Ischemic Cardiomyopathy",
            "studyLocation": "Stanford University School of Medicine (Falk Cardiovascular Research Center)",
            "Enrollment": "144",
            "NctKeyword": "Heart Failure, Ischemia, Autologous Stem Cells, LV dysfunction, Mesenchymal Stem Cells, ckit Cardiac Stem Cells, Combination Cell Therapy, LV function, Functional status,",
            "MeshKeyword": "Heart Failure, Ischemia, Cardiomyopathies,",
            "InterventionKeyword": "Plasma-lyte 148,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Be ≥ 21 and <80 years of age\r\n\r\n\r\n\r\n          2. Have documented coronary artery disease (CAD) with evidence of myocardial injury, LV\r\n\r\n             dysfunction, and clinical evidence of HF",
            "EligibleGender": "All",
            "MinAge": "21 Years",
            "MaxAge": "79 Years",
            "Volunteers": "No",
            "City": "Stanford",
            "State": "California",
            "Zip": "94305",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 19, 2016",
            "FirstReceived": "July 15, 2015",
            "OverallOfficial": "Robert Simari, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "CCTRN Steering Committee Chair",
            "ContactName": "Rachel Vojvodic, MPH",
            "ContactPhone": "713-500-9528",
            "ContactEmail": "Rachel.W.Vojvodic@uth.tmc.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Stanford University School of Medicine (Falk Cardiovascular Research Center)",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02501811",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150670 - National Heart/ Lung/ and Blood Institute - Mitrani",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20150670",
            "StudyNumber": "20150670 - National Heart/ Lung/ and Blood Institute - Mitrani",
            "StudyTitle": "A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility,\nand Efficacy of Autologous Mesenchymal Stem Cells and c-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects with Ischemic Heart Failure",
            "PIID": "3795",
            "PicNum": "C00295064",
            "PILastName": "Mitrani",
            "PIFirstName": "Raul",
            "CoodCNbr": "C00130574",
            "CoordLastName": "Difede",
            "CoordFirstName": "Darcy",
            "CoordEmail": "ddifede@med.miami.edu",
            "CoordPhone": "3052439106",
            "EnteredByCNbr": "C00295064",
            "EnteredByLastName": "Mitrani",
            "EnteredByFirstName": "Raul",
            "ActiveEnrollingDate": "10/30/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/30/2015",
            "IRBApprovedFrom": "06/12/2015",
            "IRBApprovedTo": "05/31/2016",
            "Expr1": "Phase II",
            "Tarea": "Myocardial infarction",
            "TareaCode": "16642",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "National Heart/ Lung/ and Blood Institute",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "11",
            "Totalaccrued": "6",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "11",
            "FirstNinety": "2",
            "SiteSampleSize": "UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "2",
            "PaymentRcvd": "15660",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Clarification Requested (Pre-Review)",
            "StudyCoordinator": "Darcy Difede,Jairo Tovar,Lina Caceres Cardenas,Mayra Vidro Casiano,Cindy Delgado,Russell Saltzman",
            "NationalSampleSize": "160",
            "NCTNbr": "NCT02501811",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02503332",
            "BriefTitle": "Study of of APL-2 Therapy in Patients Geographic Atrophy",
            "OfficialTitle": "A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients Geographic Atrophy (GA)",
            "LeadSponsorClass": "Apellis Pharmaceuticals, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Apellis Pharmaceuticals, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The primary objectives of the study are to assess the safety, tolerability and evidence of\r\n\r\n      activity of multiple intravitreal (IVT) injections of APL-2 in subjects with Geographic\r\n\r\n      Atrophy associated with Age-Related Macular Dege",
            "Description": "This is a Phase II, prospective, multicenter, randomized, single-masked, sham-controlled\r\n\r\n      study to assess the safety, tolerability and evidence of activity of multiple IVT injections\r\n\r\n      of APL-2 in subjects with GA associated with",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "September 2015",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Apellis Pharmaceuticals, Inc.",
            "StudyCondition": "Geographic Atrophy",
            "studyLocation": "Retinal Research Institute",
            "Enrollment": "240",
            "MeshKeyword": "Atrophy, Geographic Atrophy,",
            "Eligibility": "Inclusion Criteria: Unless specified otherwise, ocular specific inclusion criteria apply\r\n\r\n        to the study eye only.\r\n\r\n\r\n\r\n          1. Male or Female.\r\n\r\n\r\n\r\n          2. Age greater than of equal to 50 years.\r\n\r\n\r\n\r\n          3. BCVA",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85014",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 20, 2016",
            "FirstReceived": "July 14, 2015",
            "OverallOfficial": "Federico Grossi, MD PhD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Apellis Pharmaceuticals, Inc.",
            "LocationName": "Retinal Research Institute",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02503332",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150455 - Apellis Pharmaceuticals - Yehoshua",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20150455",
            "StudyNumber": "20150455 - Apellis Pharmaceuticals - Yehoshua",
            "StudyTitle": "A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled\nStudy of Safety, Tolerability and Evidence of Activity of Intravitreal\nAPL-2 Therapy in Patients with Geographic Atrophy (GA) - FILLY -",
            "PIID": "1823",
            "PicNum": "C06958118",
            "PILastName": "Yehoshua",
            "PIFirstName": "Zohar",
            "CoodCNbr": "C00293224",
            "CoordLastName": "Arango",
            "CoordFirstName": "Monica",
            "CoordEmail": "mrarango@med.miami.edu",
            "CoordPhone": "3053266351",
            "EnteredByCNbr": "C06958118",
            "EnteredByLastName": "Yehoshua",
            "EnteredByFirstName": "Zohar",
            "ActiveEnrollingDate": "01/27/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/27/2016",
            "IRBApprovedFrom": "10/26/2015",
            "IRBApprovedTo": "10/09/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Apellis Pharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "7",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "2",
            "SiteSampleSize": "ABLEH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Cristina Lage-Rodriguez,Chantey Roberts,Fabiola Salvador,Ailen Gutierrez,Maria Esquiabro,Belen Rodriguez,Monica Arango",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02503332",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02506153",
            "SecondaryId": "NCI-2014-02676",
            "BriefTitle": "High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery",
            "OfficialTitle": "A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "No",
            "BriefSummary": "This randomized phase III trial studies how well high-dose recombinant interferon alfa-2B or\r\n\r\n      ipilimumab works compared with pembrolizumab in treating patients with stage III-IV melanoma\r\n\r\n      that has been removed by surgery but is l",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To compare overall survival (OS) of patients with resected stage III and IV melanoma\r\n\r\n      treated with physician/patient choice of either high dose interferon alfa-2b (recombinant\r\n\r\n      interferon alfa-",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Metastatic Non-Cutaneous Melanoma",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "1378",
            "MeshKeyword": "Melanoma,",
            "InterventionKeyword": "Pembrolizumab, Interferons, Interferon-alpha, Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  STEP 1 REGISTRATION:\r\n\r\n\r\n\r\n          -  Patients must have completely resected melanoma of cutaneous origin or of unknown\r\n\r\n             primary in order to be eligible for this study; patients must be",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "July 22, 2015",
            "OverallOfficial": "Kenneth Grossmann",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Southwest Oncology Group",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02506153",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151123 - SWOG - Acquavella",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151123",
            "StudyNumber": "20151123 - SWOG - Acquavella",
            "StudyTitle": "A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma",
            "PIID": "23755",
            "PicNum": "C11919904",
            "PILastName": "Acquavella",
            "PIFirstName": "Nicolas",
            "CoodCNbr": "C05004058",
            "CoordLastName": "Wang",
            "CoordFirstName": "Weiwen",
            "CoordEmail": "wwang1@med.miami.edu",
            "CoordPhone": "305-243-2122",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "05/24/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/24/2016",
            "IRBApprovedFrom": "05/27/2015",
            "IRBApprovedTo": "01/04/2018",
            "DiseaseSiteListDesc": "Melanoma, skin",
            "Expr1": "Phase III",
            "Tarea": "Melanoma and Related Skin Cancers",
            "TareaCode": "12441",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "5",
            "Totalaccrued": "2",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "5",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,Plantation:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Vanessa Paredes,Penny Eyer,Vivianne Velez-Bravo,Eduardo Cianferra",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02506153",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02507284",
            "SecondaryId": "1U44NS090616-01A1",
            "BriefTitle": "Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease",
            "OfficialTitle": "An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)",
            "LeadSponsorClass": "Azevan Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Azevan Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study evaluates the tolerability, safety and activity of SRX246 in the treatment of\r\n\r\n      irritability in patients with Huntington's disease. Two-thirds of all participants will\r\n\r\n      receive SRX246, while the other third will receive",
            "Description": "SRX246 is a first-in-class vasopressin 1a (V1a) receptor antagonist that crosses the\r\n\r\n      blood-brain barrier following oral administration. The molecule exhibits high affinity and\r\n\r\n      high selectivity for its target receptor. Preclinic",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2016",
            "CompletionDate": "June 2018",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Azevan Pharmaceuticals",
            "StudyCondition": "Irritable Mood",
            "studyLocation": "University of Alabama",
            "Enrollment": "108",
            "MeshKeyword": "Huntington Disease,",
            "InterventionKeyword": "SRX246,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Male and female Subjects aged 18 years or older\r\n\r\n\r\n\r\n          2. Subjects must have clinical features of HD, which can include motor, cognitive, or\r\n\r\n             behavioral symptoms",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "June 2016",
            "LastChanged": "June 21, 2016",
            "FirstReceived": "July 22, 2015",
            "ContactName": "Neal G Simon, PhD",
            "ContactPhone": "610-419-1057",
            "ContactEmail": "ngsimon@azevan.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02507284",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160180 - National Institute of Neurological Disorders and S - Drazinic",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20160180",
            "StudyNumber": "20160180 - National Institute of Neurological Disorders and S - Drazinic",
            "StudyTitle": "An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects with Huntington's Disease (HD)",
            "PIID": "25864",
            "PicNum": "C11953721",
            "PILastName": "Drazinic",
            "PIFirstName": "Carolyn",
            "CoodCNbr": "C00578829",
            "CoordLastName": "Waltz",
            "CoordFirstName": "Alexandra",
            "CoordEmail": "awaltz@med.miami.edu",
            "CoordPhone": "3052433329",
            "EnteredByCNbr": "C11953721",
            "EnteredByLastName": "Drazinic",
            "EnteredByFirstName": "Carolyn",
            "ActiveEnrollingDate": "06/17/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/17/2016",
            "IRBApprovedFrom": "02/09/2016",
            "IRBApprovedTo": "02/09/2017",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "National Institute of Neurological Disorders and Stroke/Azevan Pharmaceuticals/ Inc.",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Julie Steele,Danielle Sheldon,Silvia Vargas,Nathalie Padron",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02507284",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02508467",
            "SecondaryId": "2015-001662-26",
            "BriefTitle": "A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma",
            "OfficialTitle": "A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients With Hepatocellular Carcinoma",
            "LeadSponsorClass": "Blueprint Medicines Corporation",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Blueprint Medicines Corporation",
            "OversightAuthority": "No",
            "BriefSummary": "This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety,\r\n\r\n      tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic\r\n\r\n      activity of BLU- 554 administered orally in p",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2015",
            "CompletionDate": "May 2019",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Blueprint Medicines Corporation",
            "StudyCondition": "Hepatocellular Carcinoma (HCC)",
            "Enrollment": "70",
            "NctKeyword": "Liver cancer, FGF19 gene amplification, FGF19 overexpression, FGF19 upregulation, Cyclin D1 (CCND1) gene amplification, Cyclin D1 (CCND1) copy number gain, BLU-554, FGFR4, Hepatocellular carcinoma, Liver Disease, Liver Neoplasms,",
            "MeshKeyword": "Carcinoma, Carcinoma, Hepatocellular,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Confirmed diagnosis of HCC by histological examination or by non-invasive criteria\r\n\r\n             according to European Association for the Study of the Liver (EASL) or American\r\n\r\n             Asso",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Rialto",
            "State": "California",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "July 9, 2015",
            "ContactName": "Blueprint Medicines",
            "ContactPhone": "617-714-6707",
            "ContactEmail": "studydirector@blueprintmedicines.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02508467",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160630 - Blueprint Medicines - Feun",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160630",
            "StudyNumber": "20160630 - Blueprint Medicines - Feun",
            "StudyTitle": "A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma",
            "PIID": "343",
            "PicNum": "C00770064",
            "PILastName": "Feun",
            "PIFirstName": "Lynn",
            "CoodCNbr": "C00349551",
            "CoordLastName": "Blackburn",
            "CoordFirstName": "Karen",
            "CoordEmail": "k.blackburn@med.miami.edu",
            "CoordPhone": "3052430863",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "12/07/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/07/2016",
            "IRBApprovedFrom": "06/16/2016",
            "IRBApprovedTo": "01/02/2017",
            "AccountNbr": "667904",
            "DiseaseSiteListDesc": "Liver",
            "Expr1": "Phase I",
            "Tarea": "Pancreatic, Liver, and Related Cancers",
            "TareaCode": "12443",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Juan Salvador,Daniel Sumarriva,Tamara Leon Aliz,Yvonne Dinh,Sandra Pineda",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02508467",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02509585",
            "BriefTitle": "A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Di",
            "OfficialTitle": "A Prospective, Open-Label Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are",
            "LeadSponsorClass": "Navidea Biopharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Navidea Biopharmaceuticals",
            "OversightAuthority": "No",
            "BriefSummary": "Prospective, open-label, within-patient, multi-center study of Lymphoseek in the detection\r\n\r\n      of lymph nodes in subjects with known cancer of the cervix. All subjects will receive a\r\n\r\n      single dose of 50 µg Lymphoseek radiolabeled wit",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2016",
            "CompletionDate": "March 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Navidea Biopharmaceuticals",
            "StudyCondition": "Uterine Cervical Neoplasms",
            "studyLocation": "University of California, San Diego",
            "Enrollment": "40",
            "MeshKeyword": "Uterine Cervical Neoplasms,",
            "InterventionKeyword": "Dextrans, Technetium Tc 99m Pentetate,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject has provided written informed consent with HIPAA authorization\r\n\r\n\r\n\r\n          -  Has cervical cancer and is a candidate for surgical intervention, with lymph node\r\n\r\n             dissection bei",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "La Jolla",
            "State": "California",
            "Zip": "92093",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 20, 2016",
            "FirstReceived": "July 24, 2015",
            "OverallOfficial": "Michael Blue, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Navidea Biopharmaceuticals",
            "ContactName": "Joanna Shuping, BS",
            "ContactPhone": "614 822-2388",
            "ContactEmail": "jshuping@navidea.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of California, San Diego",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02509585",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150563 - Navidea Biopharmaceuticals - Pearson",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150563",
            "StudyNumber": "20150563 - Navidea Biopharmaceuticals - Pearson",
            "StudyTitle": "A Prospective, Open-Label Trial of Comparing the Pathology Status of Lymphoseek- Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection",
            "PIID": "558",
            "PicNum": "C03855244",
            "PILastName": "Pearson",
            "PIFirstName": "Matt",
            "CoodCNbr": "C11920201",
            "CoordLastName": "Moya",
            "CoordFirstName": "Isabel",
            "CoordEmail": "iam18@miami.edu",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "07/07/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/07/2016",
            "IRBApprovedFrom": "03/01/2016",
            "IRBApprovedTo": "02/28/2017",
            "AccountNbr": "666477",
            "DiseaseSiteListDesc": "Cervix",
            "Expr1": "Phase II",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Diagnostic",
            "StudyType_Code": "6179",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Navidea Biopharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "2",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,UMD:N/A,Plantation:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Michelle Mikhail,Negin Habibi Khameneh,Mae Lyssa Bauduy-Roy,Evan Dadas,Claudia Grandas Moreno,Halyna Hailes",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02509585",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02510079",
            "BriefTitle": "Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.",
            "OfficialTitle": "Emergent Expanded Access to Use Autologous Human Schwann Cell Augmentation of Nerve Autograft Repair in a Single Patient With Severe Peripheral Nerve Injury",
            "LeadSponsorClass": "W. Dalton Dietrich",
            "SponsorAgency": "Other",
            "LeadSponsor": "W. Dalton Dietrich",
            "BriefSummary": "The primary purpose of this research study is to determine the safety of injecting ones own\r\n\r\n      Schwann cells to augment sural nerve autografts after a severe, non-lacerating injury to the\r\n\r\n      sciatic nerve has occurred.",
            "Description": "The secondary purpose of this research project is to evaluate whether transplanted Schwann\r\n\r\n      cells can enhance recovery of sensory and motor function. Emergency expanded access for a\r\n\r\n      single patient was granted, as the patient was",
            "OverallStatus": "Temporarily not available",
            "Phase": "N/A",
            "StudyType": "Expanded Access",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Sciatic Nerve Injury",
            "studyLocation": "University of Miami",
            "MeshKeyword": "Wounds and Injuries, Peripheral Nerve Injuries,",
            "Eligibility": "Single patient with severe sciatic nerve injury enrolled under emergency request",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 10, 2017",
            "FirstReceived": "July 15, 2015",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02510079",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150501 - Intramural - Levi",
            "FileProcessContentId": "440",
            "Division": "Neurosurgery",
            "StdyDivision": "9636",
            "EprostNbr": "20150501",
            "StudyNumber": "20150501 - Intramural - Levi",
            "StudyTitle": "The safety and efficacy of autologous human Schwann cell\n(ahSC) augmentation of nerve autografts after severe peripheral\nnerve injury.",
            "PIID": "167",
            "PicNum": "C00155778",
            "PILastName": "Levi",
            "PIFirstName": "Allan",
            "CoodCNbr": "C08177251",
            "CoordLastName": "Anderson",
            "CoordFirstName": "Kimberly",
            "CoordEmail": "kanderson3@med.miami.edu",
            "CoordPhone": "305-243-5569",
            "EnteredByCNbr": "C00155778",
            "EnteredByLastName": "Levi",
            "EnteredByFirstName": "Allan",
            "ActiveEnrollingDate": "06/22/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/22/2015",
            "IRBApprovedFrom": "06/16/2015",
            "IRBApprovedTo": "06/12/2017",
            "Expr1": "Phase I",
            "Tarea": "Spine",
            "TareaCode": "9641",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "George Jimsheleishvili",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02510079",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02510794",
            "BriefTitle": "Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (LADDER)",
            "OfficialTitle": "A Phase II Multicenter, Randomized, Active Treatment-Controlled Study of The Efficacy and Safety of The Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration",
            "LeadSponsorClass": "Genentech, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Genentech, Inc.",
            "BriefSummary": "This is a Phase II clinical study to evaluate the efficacy, safety and pharmacokinetics of\r\n\r\n      three different formulations of ranibizumab delivered via the Ranibizumab Port Delivery\r\n\r\n      System (RPDS) implant compared with the standard",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2015",
            "CompletionDate": "May 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Genentech, Inc.",
            "StudyCondition": "Macular Degeneration",
            "Enrollment": "220",
            "MeshKeyword": "Macular Degeneration, Wet Macular Degeneration,",
            "InterventionKeyword": "Ranibizumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Age over 50 years\r\n\r\n\r\n\r\n          -  Newly diagnosed with wet AMD within 6 months of screening visit\r\n\r\n\r\n\r\n          -  Participant must have received at least 2 prior anti-VEGF injections. The most re",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85014",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 3, 2016",
            "FirstReceived": "July 17, 2015",
            "OverallOfficial": "Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Hoffmann-La Roche",
            "ContactName": "Reference Study ID Number: GX28228 www.roche.com/about_roche/roche_worldwide.htm",
            "ContactPhone": "888-662-6728 (U.S. and Canada)",
            "ContactEmail": "global.rochegenentechtrials@roche.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02510794",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150570 - Genentech - Berrocal",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20150570",
            "StudyNumber": "20150570 - Genentech - Berrocal",
            "StudyTitle": "A PHASE II, MULTICENTER, RANDOMIZED, ACTIVE TREATMENT-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THE RANIBIZUMAB PORT DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF RANIBIZUMAB IN PATIENTS WITH\nSUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION",
            "PIID": "514",
            "PicNum": "C00260650",
            "PILastName": "Berrocal",
            "PIFirstName": "Audina",
            "CoodCNbr": "C05008647",
            "CoordLastName": "Negron",
            "CoordFirstName": "Catherin",
            "CoordEmail": "CNegron@med.miami.edu",
            "EnteredByCNbr": "C00260650",
            "EnteredByLastName": "Berrocal",
            "EnteredByFirstName": "Audina",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "12/28/2015",
            "IRBApprovedFrom": "12/28/2015",
            "IRBApprovedTo": "12/27/2016",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Genentech",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Maria Esquiabro,Catherin Negron",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02510794",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02514174",
            "BriefTitle": "Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older",
            "OfficialTitle": "A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations",
            "LeadSponsorClass": "Boehringer Ingelheim",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Boehringer Ingelheim",
            "BriefSummary": "Continuos treatment until progression or occurence of intolerable Adverse Event (AE) or end\r\n\r\n      of trial. The end of trial is one year after the last patient has entered the study.",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "CompletionDate": "March 2018",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "Boehringer Ingelheim",
            "StudyCondition": "Carcinoma, Non-Small-Cell Lung",
            "studyLocation": "Boehringer Ingelheim Investigational Site",
            "Enrollment": "50",
            "MeshKeyword": "Carcinoma, Non-Small-Cell Lung,",
            "Eligibility": "Inclusion criteria:\r\n\r\n\r\n\r\n          1. Pathologically or cytologically confirmed NSCLC\r\n\r\n\r\n\r\n          2. Stage IV Cancer (includes cytologically proven pleural effusion or pericardial\r\n\r\n             effusion) or recurrent disease. The stag",
            "EligibleGender": "All",
            "MinAge": "70 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 4, 2017",
            "FirstReceived": "July 17, 2015",
            "OverallOfficial": "Boehringer Ingelheim",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Boehringer Ingelheim",
            "ContactName": "Boehringer Ingelheim Call Center",
            "ContactPhone": "1-800-243-0127",
            "ContactEmail": "clintriage.rdg@boehringer-ingelheim.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Boehringer Ingelheim Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02514174",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150594 - Boehringer Ingelheim - Jahanzeb",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150594",
            "StudyNumber": "20150594 - Boehringer Ingelheim - Jahanzeb",
            "StudyTitle": "BI 1200.209: A Single Arm Phase IV Study of Afatinib in Elderly Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer  (NSCLC) Whose Tumors Have Common Epidernal Growth Factor Receptor (EGFR) Mutations (Exon 19 Deletions or Exon 21 L858R Substitution Mutations)",
            "PIID": "2421",
            "PicNum": "C09904097",
            "PILastName": "Jahanzeb",
            "PIFirstName": "Mohammad",
            "CoodCNbr": "C11975723",
            "CoordLastName": "Minichiello",
            "CoordFirstName": "Anthony",
            "CoordEmail": "agm112@miami.edu",
            "EnteredByCNbr": "C12001301",
            "EnteredByLastName": "Delgado",
            "EnteredByFirstName": "Yisenny",
            "ActiveEnrollingDate": "08/24/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/24/2016",
            "IRBApprovedFrom": "02/08/2016",
            "IRBApprovedTo": "02/07/2017",
            "AccountNbr": "666906",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase IV",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Boehringer Ingelheim",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Penny Eyer,Deborah Conte,Evan Dadas,Halyna Hailes,Claudia Grandas Moreno,Michelle Mikhail",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02514174",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02516605",
            "SecondaryId": "2015-001590-41",
            "BriefTitle": "A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of LJN452 in PBC Patients",
            "OfficialTitle": "A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Biliary Cirrhosis",
            "LeadSponsorClass": "Novartis Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novartis Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "A multi-part study to assess safety, tolerability and efficacy of LJN452 in patients with\r\n\r\n      primary biliary cirrhosis",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2015",
            "CompletionDate": "December 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Novartis",
            "StudyCondition": "Primary Biliary Cirrhosis",
            "studyLocation": "Novartis Investigative Site",
            "Enrollment": "95",
            "NctKeyword": "Primary Biliary Cirrhosis, PBC,",
            "MeshKeyword": "Fibrosis, Liver Cirrhosis, Liver Cirrhosis, Biliary,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of PBC as demonstrated by the presence of ≥ 2 of the following 3 diagnostic\r\n\r\n             criteria:\r\n\r\n\r\n\r\n          -  History of Alkaline Phosphatase elevated above upper limit of normal fo",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Rialto",
            "State": "California",
            "Zip": "CA",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 5, 2016",
            "FirstReceived": "August 4, 2015",
            "ContactName": "Novartis Pharmaceuticals",
            "ContactPhone": "1-888-669-6682",
            "LocationStatus": "Recruiting",
            "LocationName": "Novartis Investigative Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02516605",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150642 - Novartis - Levy",
            "FileProcessContentId": "440",
            "Division": "Hepatology",
            "StdyDivision": "10246",
            "EprostNbr": "20150642",
            "StudyNumber": "20150642 - Novartis - Levy",
            "StudyTitle": "Novartis/CLJN452X2201- A multi-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and efficacy of LJN452 in patients with Primary Biliary Cholangitis",
            "PIID": "2230",
            "PicNum": "C09420731",
            "PILastName": "Levy",
            "PIFirstName": "Cynthia",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C09420731",
            "EnteredByLastName": "Levy",
            "EnteredByFirstName": "Cynthia",
            "ActiveEnrollingDate": "03/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/08/2016",
            "IRBApprovedFrom": "09/21/2015",
            "IRBApprovedTo": "08/28/2017",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Novartis",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diane Sabogal,Sonia Carvalho",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02516605",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02516813",
            "SecondaryId": "2015-000673-12",
            "BriefTitle": "Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy",
            "OfficialTitle": "An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors",
            "LeadSponsorClass": "EMD Serono Research & Development Institute, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "EMD Serono Research & Development Institute, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is an open label Phase 1a/1b, dose escalation, and dose expansion trial designed to\r\n\r\n      explore the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics (PD) profile,\r\n\r\n      and clinical activity of MSC2490484A in combinat",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2015",
            "CompletionDate": "July 2021",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "EMD Serono",
            "StudyCondition": "Solid Tumors",
            "studyLocation": "Please Contact U.S. Medical Information",
            "Enrollment": "59",
            "NctKeyword": "M3814, Solid Tumors,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  All subjects in Phase 1a and cPoP must agree to have tumor biopsies collected\r\n\r\n\r\n\r\n          -  For subjects in Phase 1b, archival tumor material must be available, either as a\r\n\r\n             block or",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Rockland",
            "State": "Massachusetts",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 22, 2016",
            "FirstReceived": "August 4, 2015",
            "OverallOfficial": "Medical Responsible",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Merck KGaA",
            "ContactName": "US Medical Information",
            "ContactPhone": "888-275-7376",
            "LocationStatus": "Recruiting",
            "LocationName": "Please Contact U.S. Medical Information",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02516813",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160382 - EMD Serono - Samuels",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160382",
            "StudyNumber": "20160382 - EMD Serono - Samuels",
            "StudyTitle": "An Open Label, Phase Ia/Ib Trial of the DNA-PK\nInhibitor MSC2490484A in Combination with\nRadiotherapy in Patients with Advanced Solid Tumors",
            "PIID": "3262",
            "PicNum": "C10007990",
            "PILastName": "Samuels",
            "PIFirstName": "Michael",
            "CoodCNbr": "C11997004",
            "CoordLastName": "Pickens",
            "CoordFirstName": "Brandon",
            "CoordEmail": "bpickens@med.miami.edu",
            "EnteredByCNbr": "C00349551",
            "EnteredByLastName": "Blackburn",
            "EnteredByFirstName": "Karen",
            "ActiveEnrollingDate": "10/10/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/10/2016",
            "IRBApprovedFrom": "06/28/2016",
            "IRBApprovedTo": "04/04/2017",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma,Lung",
            "Expr1": "Phase I",
            "Tarea": "Head and Neck Cancer",
            "TareaCode": "12440",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "2",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Yvonne Dinh,Juan Salvador,Daniel Sumarriva,Sandra Pineda,Tamara Leon Aliz",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02516813",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02517398",
            "BriefTitle": "MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors",
            "OfficialTitle": "A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indicatio",
            "LeadSponsorClass": "EMD Serono Research & Development Institute, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "EMD Serono Research & Development Institute, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The main purpose of this Phase I study is to test MSB0011359C (M7824) at different dose\r\n\r\n      levels to see if it is safe and well tolerated when given once every 2 weeks. Phase I means\r\n\r\n      the study drug has not previously been given to",
            "Description": "This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group\r\n\r\n      expansion in selected solid tumor indications. The current trial is composed of a standard\r\n\r\n      dose escalation \"3 + 3\" cohort design, for which 3",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "CompletionDate": "November 2018",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "EMD Serono",
            "StudyCondition": "Solid Tumors",
            "studyLocation": "Arizona Clinical Research Center",
            "Enrollment": "638",
            "NctKeyword": "Solid tumor, MSB0011359C (M7824), Metastatic or Locally Advanced Solid Tumors,",
            "MeshKeyword": "Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Ability to understand the purpose of the study, provide signed and dated informed\r\n\r\n             consent, and able to comply with all procedures\r\n\r\n\r\n\r\n          -  Male or female subjects aged greater",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Tucson",
            "State": "Arizona",
            "Zip": "85715",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 28, 2016",
            "FirstReceived": "July 30, 2015",
            "OverallOfficial": "Medical Responsible",
            "OverallRole": "Study Director",
            "OverallAffilitation": "EMD Serono Research & Development Institute, Inc, an affiliate of MerckKGaA, Darmstadt, Germany",
            "ContactName": "US Medical Information",
            "ContactPhone": "888-275-7376",
            "LocationStatus": "Recruiting",
            "LocationName": "Arizona Clinical Research Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02517398",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160121 - EMD Serono - Feun",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160121",
            "StudyNumber": "20160121 - EMD Serono - Feun",
            "StudyTitle": "A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications",
            "PIID": "343",
            "PicNum": "C00770064",
            "PILastName": "Feun",
            "PIFirstName": "Lynn",
            "CoodCNbr": "C12030188",
            "CoordLastName": "Salvador",
            "CoordFirstName": "Juan",
            "CoordEmail": "juan.salvador@miami.edu",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "11/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/08/2016",
            "IRBApprovedFrom": "05/10/2016",
            "IRBApprovedTo": "12/01/2016",
            "AccountNbr": "667200",
            "DiseaseSiteListDesc": "Liver,Lung,Bones and Joints,Melanoma, skin",
            "Expr1": "Phase I",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "3",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Yvonne Dinh,Tamara Leon Aliz,Daniel Sumarriva,Sandra Pineda,Karen Blackburn",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT02517398",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02517619",
            "BriefTitle": "Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis",
            "OfficialTitle": "A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspe",
            "LeadSponsorClass": "Eyegate Pharmaceuticals, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Eyegate Pharmaceuticals, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis\r\n\r\n      with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery\r\n\r\n      System (EGDS) compared to prednisolone acetat",
            "Description": "This will be a Phase 3, randomized, double-masked, parallel arm, positive-controlled\r\n\r\n      non-inferiority study, in which up to 250 subjects (approximately 125 subjects per treatment\r\n\r\n      arm) will be enrolled at up to 60 clinical sites.",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2016",
            "CompletionDate": "October 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Eyegate Pharmaceuticals, Inc.",
            "StudyCondition": "Anterior Uveitis",
            "studyLocation": "Virginia Eye Consultants",
            "Enrollment": "250",
            "NctKeyword": "Iontophoresis, Ophthalmology, Non-Infectious Anterior Segment Uveitis,",
            "MeshKeyword": "Uveitis, Uveitis, Anterior, Iridocyclitis,",
            "InterventionKeyword": "Pharmaceutical Solutions, Dexamethasone acetate, Prednisolone acetate, Methylprednisolone acetate, Dexamethasone, Prednisolone, Methylprednisolone, Methylprednisolone Hemisuccinate, Dexamethasone 21-phosphate, Prednisolone hemisuccinate, Prednisolone phos",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age 12 to 85 years with a diagnosis of non-infectious anterior segment uveitis\r\n\r\n             defined as an AC cell count of ≥ 11 cells\r\n\r\n\r\n\r\n          2. Receive, understand, and sign a copy of the wr",
            "EligibleGender": "All",
            "MinAge": "12 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Norfolk",
            "State": "Virginia",
            "Zip": "23502",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 1, 2016",
            "FirstReceived": "August 5, 2015",
            "OverallOfficial": "John D. Sheppard, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Study Principal Investigator",
            "ContactName": "Lisa Brandano",
            "ContactEmail": "lbrandano@eyegatepharma.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Virginia Eye Consultants",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02517619",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160058 - EyeGate Pharma - Perez",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20160058",
            "StudyNumber": "20160058 - EyeGate Pharma - Perez",
            "StudyTitle": "A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients with Non-Infectious Anterior Segment Uveitis",
            "PIID": "946",
            "PicNum": "C05063045",
            "PILastName": "Perez quinones",
            "PIFirstName": "Victor",
            "CoodCNbr": "C11996439",
            "CoordLastName": "Braun",
            "CoordFirstName": "Marisa",
            "CoordEmail": "mxb1423@med.miami.edu",
            "EnteredByCNbr": "C05063045",
            "EnteredByLastName": "Perez quinones",
            "EnteredByFirstName": "Victor",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "05/23/2016",
            "IRBApprovedFrom": "05/23/2016",
            "IRBApprovedTo": "05/22/2017",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Device",
            "SponsorGroup": "Industry",
            "Sponsor": "EyeGate Pharma",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Esdras  Arrieta Quintero,Marisa Braun",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02517619",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02518685",
            "BriefTitle": "ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss",
            "OfficialTitle": "Endoscopic Treatment for Weight Reduction in Patients With Obesity Using the TransPyloric Shuttle® System: A Multicenter, Prospective, Randomized, Double-Blind, Sham-Controlled, Parallel-Design Study",
            "LeadSponsorClass": "BaroNova, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "BaroNova, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this clinical research trial is to study safety and effectiveness of the\r\n\r\n      TransPyloric Shuttle System (TPSS) for weight reduction in patients who are considered\r\n\r\n      medically obese.",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2015",
            "CompletionDate": "December 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "BaroNova, Inc.",
            "StudyCondition": "Obesity",
            "studyLocation": "HonorHealth Bariatric Center",
            "Enrollment": "270",
            "NctKeyword": "Obesity, Weight loss, Device, Non-surgical, Endoscopic, TransPyloric Shuttle, TPS,",
            "MeshKeyword": "Obesity,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male and female subjects between the ages of 22 to 60\r\n\r\n\r\n\r\n          -  A BMI between 30.0 to 40.0 kg/m2, inclusive. Subjects with a BMI of 30.0 kg/m2 to\r\n\r\n             34.9 kg/m2 are required to have",
            "EligibleGender": "All",
            "MinAge": "22 Years",
            "MaxAge": "60 Years",
            "Volunteers": "No",
            "City": "Scottsdale",
            "State": "Arizona",
            "Zip": "85258",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 7, 2016",
            "FirstReceived": "August 6, 2015",
            "LocationStatus": "Active, not recruiting",
            "LocationName": "HonorHealth Bariatric Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02518685",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150549 - BAROnova/ Inc. - de la Cruz-Munoz",
            "FileProcessContentId": "440",
            "Division": "Surgery",
            "StdyDivision": "7805",
            "EprostNbr": "20150549",
            "StudyNumber": "20150549 - BAROnova/ Inc. - de la Cruz-Munoz",
            "StudyTitle": "Endoscopic Treatment for Weight Reduction in Patients with Obesity Using the TransPyloric Shuttle® System: A Multicenter, Prospective, Randomized, Double-Blind, Sham-Controlled, Parallel-Design Study (ENDObesity® II Study)",
            "PIID": "3329",
            "PicNum": "C00597789",
            "PILastName": "de la Cruz-Munoz",
            "PIFirstName": "Nestor",
            "CoodCNbr": "C03528213",
            "CoordLastName": "Cuesta",
            "CoordFirstName": "Melissa",
            "CoordEmail": "mcuesta@med.miami.edu",
            "CoordPhone": "305-689-1910",
            "EnteredByCNbr": "C00597789",
            "EnteredByLastName": "de la Cruz-Munoz",
            "EnteredByFirstName": "Nestor",
            "ActiveEnrollingDate": "11/19/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/16/2015",
            "IRBApprovedFrom": "09/14/2015",
            "IRBApprovedTo": "08/15/2017",
            "Expr1": "N/A",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "ResearchType": "Drug/Device",
            "SponsorGroup": "Industry",
            "Sponsor": "BAROnova/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "28",
            "SignedICF": "62",
            "Totalaccrued": "29",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "26",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "62",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Melissa Cuesta,Meredith Young",
            "NationalSampleSize": "67",
            "NCTNbr": "NCT02518685",
            "StudyKeywords": "Obesity, Weight loss, overweight, endoscopic",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02520284",
            "SecondaryId": "2014-005217-24",
            "BriefTitle": "Safety and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative Colitis",
            "OfficialTitle": "A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Ulcerative Colitis",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will evaluate the efficacy, safety, and tolerability of GS-5745. It will consist\r\n\r\n      of 3 parts: Induction Study (Cohort 1), and Maintenance Study (Cohort 2), and an Extended\r\n\r\n      Treatment Phase.",
            "OverallStatus": "Terminated",
            "StartDate": "September 2015",
            "CompletionDate": "November 2016",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "Ulcerative Colitis",
            "Enrollment": "165",
            "MeshKeyword": "Ulcer, Colitis, Ulcerative, Colitis,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Ulcerative Colitis (UC) confirmed on endoscopy\r\n\r\n\r\n\r\n          -  Moderately to severely active UC (Mayo Score 6-12)\r\n\r\n\r\n\r\n          -  May be receiving oral 5-aminosalicylate (ASA), oral corticost",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Dothan",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 12, 2016",
            "FirstReceived": "August 7, 2015",
            "OverallOfficial": "Gilead Study Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02520284",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150686 - Gilead - Kerman",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20150686",
            "StudyNumber": "20150686 - Gilead - Kerman",
            "StudyTitle": "A Combined Phase 2/3, Double-Blind, Randomized,\nPlacebo-Controlled, Induction and Maintenance Study\nEvaluating the Safety and Efficacy of GS-5745 in Subjects\nwith Moderately to Severely Active Ulcerative Colitis",
            "PIID": "652",
            "PicNum": "C04244223",
            "PILastName": "Kerman",
            "PIFirstName": "David",
            "CoodCNbr": "C11914779",
            "CoordLastName": "Carabali",
            "CoordFirstName": "Francia",
            "CoordEmail": "fxc123@miami.edu",
            "EnteredByCNbr": "C04244223",
            "EnteredByLastName": "Kerman",
            "EnteredByFirstName": "David",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "03/14/2016",
            "IRBApprovedFrom": "03/14/2016",
            "IRBApprovedTo": "03/13/2017",
            "Expr1": "Phase II/III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Gilead",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diana Morillo,Francia Carabali",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02520284",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02523014",
            "SecondaryId": "NCI-2015-00546",
            "BriefTitle": "A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas",
            "OfficialTitle": "Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations",
            "LeadSponsorClass": "Alliance for Clinical Trials in Oncology",
            "SponsorAgency": "Other",
            "LeadSponsor": "Alliance for Clinical Trials in Oncology",
            "OversightAuthority": "Yes",
            "BriefSummary": "This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor\r\n\r\n      GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grew\r\n\r\n      back after treatment. Vismodegib and FAK inhibi",
            "Description": "Each arm is a prospective, one-stage phase 2 study evaluating the efficacy of smoothened\r\n\r\n      receptor SMO or FAK inhibitors in patients with SMO-mutated or neurofibromin 2 (NF2)-mutated\r\n\r\n      meningiomas, respectively. There will be a se",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Alliance for Clinical Trials in Oncology",
            "StudyCondition": "Intracranial Meningioma",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "56",
            "MeshKeyword": "Meningioma,",
            "Eligibility": "Pre-Registration Eligibility Criteria\r\n\r\n\r\n\r\n        1. Central Pathology Review Submission: This review is mandatory prior to registration to\r\n\r\n        confirm eligibility.\r\n\r\n\r\n\r\n          -  Patients must have local diagnosis of meningioma",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 16, 2016",
            "FirstReceived": "August 11, 2015",
            "OverallOfficial": "Priscilla Brastianos, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Massachusetts General Hospital",
            "ContactName": "Priscilla Brastianos, MD",
            "ContactPhone": "617-643-1939",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02523014",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151026 - Alliance - De La Fuente",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151026",
            "StudyNumber": "20151026 - Alliance - De La Fuente",
            "StudyTitle": "PHASE II TRIAL OF SMO/AKT/NF2 INHIBITORS IN PROGRESSIVE MENINGIOMAS WITH SMO/AKT/NF2 MUTATIONS",
            "PIID": "22734",
            "PicNum": "C11916526",
            "PILastName": "De La Fuente",
            "PIFirstName": "Macarena",
            "CoodCNbr": "C04228283",
            "CoordLastName": "Garcia",
            "CoordFirstName": "Helen",
            "CoordEmail": "heg32@med.miami.edu",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "03/21/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/21/2016",
            "IRBApprovedFrom": "06/15/2015",
            "IRBApprovedTo": "04/04/2017",
            "AccountNbr": "666525",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "Phase II",
            "Tarea": "Neurological Cancer",
            "TareaCode": "12442",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UM Kendall:N/A,UMMG:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Cristina Rojas-Mejia",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT02523014",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02523599",
            "BriefTitle": "Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty",
            "OfficialTitle": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the XaraColl® Bupivacaine Implant (300 mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty",
            "LeadSponsorClass": "Innocoll",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Innocoll",
            "OversightAuthority": "No",
            "BriefSummary": "This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled\r\n\r\n      efficacy and safety study of postoperative pain in adults who are scheduled for unilateral\r\n\r\n      inguinal hernioplasty via open laparotomy (",
            "Description": "This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled\r\n\r\n      study in adults who are scheduled for unilateral inguinal hernioplasty via open laparotomy\r\n\r\n      (tension-free technique). Patients will rec",
            "OverallStatus": "Completed",
            "StartDate": "August 2015",
            "CompletionDate": "April 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Innocoll",
            "StudyCondition": "Pain, Postoperative",
            "Enrollment": "305",
            "NctKeyword": "post operative pain, hernioplasty, bupivacaine,",
            "MeshKeyword": "Pain, Postoperative,",
            "InterventionKeyword": "Bupivacaine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Has a planned (non-emergent) unilateral inguinal hernioplasty (open laparotomy,\r\n\r\n             tension-free technique) to be performed according to standard surgical technique\r\n\r\n             under gene",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Mobile",
            "State": "Alabama",
            "Zip": "36617",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 28, 2016",
            "FirstReceived": "August 12, 2015",
            "OverallOfficial": "Nigel Jones",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Vice President, Global Clinical Operations, Innocoll Pharmaceutical",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02523599",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150668 - Innocoll Pharmaceuticals - Candiotti",
            "FileProcessContentId": "440",
            "Division": "Anesthesiology",
            "StdyDivision": "10236",
            "EprostNbr": "20150668",
            "StudyNumber": "20150668 - Innocoll Pharmaceuticals - Candiotti",
            "StudyTitle": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study to\nInvestigate the Efficacy and Safety of the XaraColl® Bupivacaine\nImplant (300 mg Bupivacaine Hydrochloride) After Open\nLaparotomy Hernioplasty",
            "PIID": "912",
            "PicNum": "C00745788",
            "PILastName": "Candiotti",
            "PIFirstName": "Keith",
            "CoodCNbr": "C10588120",
            "CoordLastName": "Antor",
            "CoordFirstName": "Maria",
            "CoordEmail": "mantor@med.miami.edu",
            "CoordPhone": "3055857677",
            "EnteredByCNbr": "C00745788",
            "EnteredByLastName": "Candiotti",
            "EnteredByFirstName": "Keith",
            "ActiveEnrollingDate": "02/24/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/24/2016",
            "IRBApprovedFrom": "09/15/2015",
            "IRBApprovedTo": "09/14/2016",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Innocoll Pharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Isabel Jaraba,Angelica Jaramillo Virgen,Maria Antor",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02523599",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02528318",
            "BriefTitle": "Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA",
            "OfficialTitle": "A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA",
            "LeadSponsorClass": "Windtree Therapeutics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Windtree Therapeutics",
            "OversightAuthority": "Yes",
            "BriefSummary": "The primary objective of this study is to evaluate the safety and tolerability of\r\n\r\n      lucinactant for inhalation, administered as an aerosolized dose in up to four escalating\r\n\r\n      doses to preterm neonates 26 to 28 weeks gestational age",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "CompletionDate": "November 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Windtree Therapeutics",
            "StudyCondition": "Respiratory Distress Syndrome",
            "studyLocation": "Loma Linda University Medical Center",
            "Enrollment": "64",
            "MeshKeyword": "Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome, Adult,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Informed consent from a legally authorized representative.\r\n\r\n\r\n\r\n          2. Gestational age 26 to 28 completed weeks post menstrual age (PMA).\r\n\r\n\r\n\r\n          3. Successful implementation of controll",
            "EligibleGender": "All",
            "MinAge": "26 Weeks",
            "MaxAge": "28 Weeks",
            "Volunteers": "No",
            "City": "Loma Linda",
            "State": "California",
            "Zip": "92354",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 1, 2016",
            "FirstReceived": "August 17, 2015",
            "OverallOfficial": "Steve Simonson, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Windtree Therapeutics",
            "ContactName": "Robert Segal, MD, FACP",
            "ContactPhone": "215-488-9450",
            "ContactEmail": "rsegal@windtreetx.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Loma Linda University Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02528318",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150827 - Discovery Laboratories/ Inc. - Navarrete",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20150827",
            "StudyNumber": "20150827 - Discovery Laboratories/ Inc. - Navarrete",
            "StudyTitle": "A Multicenter, Randomized, Open-label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 26 to 28 Weeks PMA",
            "PIID": "1148",
            "PicNum": "C04008942",
            "PILastName": "Navarrete",
            "PIFirstName": "Cristina",
            "CoodCNbr": "C04008942",
            "CoordLastName": "Navarrete",
            "CoordFirstName": "Cristina",
            "CoordEmail": "cnavarrete@med.miami.edu",
            "CoordPhone": "3055856408",
            "EnteredByCNbr": "C04008942",
            "EnteredByLastName": "Navarrete",
            "EnteredByFirstName": "Cristina",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "12/07/2015",
            "IRBApprovedFrom": "12/07/2015",
            "IRBApprovedTo": "10/09/2017",
            "AccountNbr": "666605",
            "Expr1": "Phase II",
            "Tarea": "Neonatology",
            "TareaCode": "10436",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Discovery Laboratories/ Inc.",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carmen D'Ugard,Silvia Vanbuskirk",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT02528318",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02530619",
            "SecondaryId": "NCI-2015-01219",
            "BriefTitle": "Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia",
            "OfficialTitle": "A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase A, in Adult Patients With Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post-Polycythemic Myelof",
            "LeadSponsorClass": "Northwestern University",
            "SponsorAgency": "Other",
            "LeadSponsor": "Northwestern University",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate the safety of alisertib and its effect, bad and/or\r\n\r\n      good, on acute megakaryoblastic leukemia (AMKL) or myelofibrosis (MF). The study drug,\r\n\r\n      alisertib, is an investigational drug. An invest",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. Determine the safety profile of alisertib in patients with acute megakaryoblastic\r\n\r\n      leukemia (AMKL) and in patients with myelofibrosis (MF).\r\n\r\n\r\n\r\n      SECONDARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. Determine",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Northwestern University",
            "StudyCondition": "Acute Megakaryoblastic Leukemia",
            "studyLocation": "University of Miami Miller School of Medicine-Sylvester Cancer Center",
            "Enrollment": "24",
            "MeshKeyword": "Leukemia, Primary Myelofibrosis, Leukemia, Megakaryoblastic, Acute,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  AMKL PATIENTS: Patients must have a confirmed diagnosis of relapsed/refractory acute\r\n\r\n             megakaryoblastic leukemia (AMKL), as defined by World Health Organization (WHO)\r\n\r\n             criter",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 10, 2016",
            "FirstReceived": "August 18, 2015",
            "OverallOfficial": "Brady Stein, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Northwestern University",
            "ContactName": "Study Coordinator",
            "ContactPhone": "(312)695-1301",
            "ContactEmail": "cancertrials@northwestern.edu",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "University of Miami Miller School of Medicine-Sylvester Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02530619",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151074 - NW Uni Feinberg - Swords",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151074",
            "StudyNumber": "20151074 - NW Uni Feinberg - Swords",
            "StudyTitle": "1138131\nA Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), A Novel Inhibitor of Aurora Kinase A, in Adult Patients with Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post- Polycythemic Myelofibrosis)",
            "PIID": "4223",
            "PicNum": "C11249826",
            "PILastName": "Swords",
            "PIFirstName": "Ronan",
            "CoodCNbr": "C11954409",
            "CoordLastName": "Ogden",
            "CoordFirstName": "Jillian",
            "CoordEmail": "jbo25@miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "06/24/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/24/2016",
            "IRBApprovedFrom": "02/16/2016",
            "IRBApprovedTo": "02/15/2017",
            "AccountNbr": "667181",
            "DiseaseSiteListDesc": "Myeloid and Monocytic Leukemia",
            "Expr1": "Phase I",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "2",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Tamara Leon Aliz,Yvonne Dinh,Daniel Sumarriva",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT02530619",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02531113",
            "BriefTitle": "Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease",
            "OfficialTitle": "A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Th",
            "LeadSponsorClass": "Celgene",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Celgene",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose is to determine whether RPC1063 is effective in the treatment of Crohn's\r\n\r\n      disease.",
            "Description": "This open-label trial is composed of two periods: Induction and Extension. All eligible\r\n\r\n      patients will be enrolled into the 12-Week Induction period and receive study medication.\r\n\r\n      Patients who complete the Induction period may th",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "September 2015",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Celgene",
            "StudyCondition": "Crohn's Disease",
            "studyLocation": "Receptos Study Site 165",
            "Enrollment": "60",
            "MeshKeyword": "Crohn Disease,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Crohn's disease (CD) confirmed by endoscopy and histology\r\n\r\n\r\n\r\n          -  Active disease as evaluated by Crohn's Disease Activity Index Score and Simple\r\n\r\n             Endoscopic Score for CD",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Tucson",
            "State": "Arizona",
            "Zip": "85741",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "August 26, 2016",
            "FirstReceived": "August 20, 2015",
            "LocationName": "Receptos Study Site 165",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02531113",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150865 - Receptos/ Inc. - Abreu",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20150865",
            "StudyNumber": "20150865 - Receptos/ Inc. - Abreu",
            "StudyTitle": "A Phase 2, Multi-Center, Open-Label Induction Trial with Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients with Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy",
            "PIID": "651",
            "PicNum": "C00510000",
            "PILastName": "Abreu",
            "PIFirstName": "Maria",
            "CoodCNbr": "C11914779",
            "CoordLastName": "Carabali",
            "CoordFirstName": "Francia",
            "CoordEmail": "fxc123@miami.edu",
            "EnteredByCNbr": "C00510000",
            "EnteredByLastName": "Abreu",
            "EnteredByFirstName": "Maria",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "01/04/2016",
            "IRBApprovedFrom": "01/04/2016",
            "IRBApprovedTo": "01/03/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Receptos/ Inc.",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diana Morillo,Marianela Carvajal,Francia Carabali",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02531113",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02531126",
            "BriefTitle": "Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis",
            "OfficialTitle": "A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis",
            "LeadSponsorClass": "Celgene",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Celgene",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients\r\n\r\n      diagnosed with moderate to severe ulcerative colitis.",
            "Description": "The trial is an open label extension study. Eligible patients from the RPC01-3101 trial\r\n\r\n      diagnosed with moderate to severe ulcerative colitis will be enrolled to receive study\r\n\r\n      medication for up to 5 years or until marketed appro",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Celgene",
            "StudyCondition": "Ulcerative Colitis",
            "studyLocation": "Receptos Study Site 144",
            "Enrollment": "1200",
            "MeshKeyword": "Ulcer, Colitis, Ulcerative, Colitis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Previous participation on a trial of RPC1063 for ulcerative colitis (UC) and may\r\n\r\n             benefit from continued treatment\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -  Require initiation",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Tucson",
            "State": "Arizona",
            "Zip": "85712",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 2, 2016",
            "FirstReceived": "August 20, 2015",
            "ContactName": "Receptos True North Study",
            "ContactPhone": "1-844-266-9299",
            "ContactEmail": "truenorth@quintiles.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Receptos Study Site 144",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02531126",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150537 - Receptos/ Inc. - Abreu",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20150537",
            "StudyNumber": "20150537 - Receptos/ Inc. - Abreu",
            "StudyTitle": "A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis",
            "PIID": "651",
            "PicNum": "C00510000",
            "PILastName": "Abreu",
            "PIFirstName": "Maria",
            "CoodCNbr": "C11914779",
            "CoordLastName": "Carabali",
            "CoordFirstName": "Francia",
            "CoordEmail": "fxc123@miami.edu",
            "EnteredByCNbr": "C00510000",
            "EnteredByLastName": "Abreu",
            "EnteredByFirstName": "Maria",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "03/07/2016",
            "IRBApprovedFrom": "03/07/2016",
            "IRBApprovedTo": "03/06/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Receptos/ Inc.",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diana Morillo,Marianela Carvajal,Francia Carabali",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02531126",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02535364",
            "BriefTitle": "Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)",
            "OfficialTitle": "A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia",
            "LeadSponsorClass": "Juno Therapeutics, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Juno Therapeutics, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "This single-arm, multicenter Phase 2 trial will treat adult patients who have relapsed or\r\n\r\n      refractory B-ALL with an infusion of the patient's own T cells that have been genetically\r\n\r\n      modified to express a chimeric antigen receptor",
            "Description": "This is a single-arm, multicenter Phase 2 study to determine the efficacy and safety of\r\n\r\n      JCAR015 in adult patients with relapsed or refractory B-ALL. The study will have the\r\n\r\n      following sequential phases: Part A (screening, leukap",
            "OverallStatus": "Suspended",
            "StartDate": "August 2015",
            "CompletionDate": "May 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Juno Therapeutics, Inc.",
            "StudyCondition": "Acute Lymphoblastic Leukemia",
            "studyLocation": "University of Alabama Birmingham Comprehensive Cancer Center",
            "Enrollment": "110",
            "NctKeyword": "acute lymphoblastic leukemia, ALL, chimeric antigen receptor, CAR, CAR T cells, JCAR015, autologous T cell therapy, cell therapy,",
            "MeshKeyword": "Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, Burkitt Lymphoma,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age ≥ 18 years at the time of consent\r\n\r\n\r\n\r\n          2. Relapsed or refractory B-ALL, defined as:\r\n\r\n\r\n\r\n               -  First or greater bone marrow relapse from CR, or\r\n\r\n\r\n\r\n               -  Any",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35295",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "November 29, 2016",
            "FirstReceived": "August 24, 2015",
            "OverallOfficial": "Nikolaus Trede, MD, PhD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Juno Therapeutics, Inc.",
            "LocationName": "University of Alabama Birmingham Comprehensive Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02535364",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150406 - Juno Therapeutics - Komanduri",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150406",
            "StudyNumber": "20150406 - Juno Therapeutics - Komanduri",
            "StudyTitle": "The ROCKET Study: A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia",
            "PIID": "1930",
            "PicNum": "C06948118",
            "PILastName": "Komanduri",
            "PIFirstName": "Krishna",
            "CoodCNbr": "C11923689",
            "CoordLastName": "Mohan",
            "CoordFirstName": "Vivin",
            "CoordEmail": "vxm153@miami.edu",
            "EnteredByCNbr": "C11964150",
            "EnteredByLastName": "Smith",
            "EnteredByFirstName": "Nyesha",
            "ActiveEnrollingDate": "02/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/08/2016",
            "IRBApprovedFrom": "10/05/2015",
            "IRBApprovedTo": "04/03/2017",
            "AccountNbr": "666243",
            "DiseaseSiteListDesc": "Lymphoid Leukemia",
            "Expr1": "Phase II",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Juno Therapeutics",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "2",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nohelia Gonzalez,Nathalie Luis",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02535364",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02536339",
            "BriefTitle": "Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy",
            "OfficialTitle": "An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)",
            "LeadSponsorClass": "Genentech, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Genentech, Inc.",
            "BriefSummary": "This study will examine the safety and efficacy of pertuzumab in combination with high-dose\r\n\r\n      trastuzumab in adult participants with HER2-positive MBC with CNS metastases and disease\r\n\r\n      progression in the brain following radiotherap",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2015",
            "CompletionDate": "December 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Genentech, Inc.",
            "StudyCondition": "Metastatic Breast Cancer",
            "Enrollment": "40",
            "MeshKeyword": "Breast Neoplasms,",
            "InterventionKeyword": "Pertuzumab, Trastuzumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Adults at least 18 years of age\r\n\r\n\r\n\r\n          -  Pathologically confirmed HER2-positive MBC\r\n\r\n\r\n\r\n          -  Progression of or new brain metastases after completion of whole-brain radiotherapy",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Tucson",
            "State": "Arizona",
            "Zip": "85719",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 1, 2016",
            "FirstReceived": "August 10, 2015",
            "OverallOfficial": "Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Hoffmann-La Roche",
            "ContactName": "Reference Study ID Number: ML29366 www.roche.com/about_roche/roche_worldwide.htm",
            "ContactPhone": "888-662-6728 (U.S. and Canada)",
            "ContactEmail": "global.rochegenentechtrials@roche.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02536339",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150973 - Genentech - Perez",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150973",
            "StudyNumber": "20150973 - Genentech - Perez",
            "StudyTitle": "An Open-Label, Single-Arm, Phase II Study of Pertuzumab with High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients with HER2-Positive Metastatic Breast Cancer (PATRICIA)",
            "PIID": "25232",
            "PicNum": "C11967904",
            "PILastName": "Perez",
            "PIFirstName": "Alejandra",
            "CoodCNbr": "C12024030",
            "CoordLastName": "Conte",
            "CoordFirstName": "Deborah",
            "CoordEmail": "dmc238@med.miami.edu",
            "CoordPhone": "954-830-2360",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "08/16/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/16/2016",
            "IRBApprovedFrom": "07/14/2016",
            "IRBApprovedTo": "05/25/2017",
            "AccountNbr": "667306",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase II",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Genentech",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,Plantation:N/A,UMMG:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Michelle Liendo,Cristina Rojas-Mejia,Sarah Raybin,Mohammad El-Sorady,Penny Eyer,Evan Dadas,Halyna Hailes,Anthony Minichiello,Onaidy Torres",
            "NationalSampleSize": "3",
            "NCTNbr": "NCT02536339",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02542384",
            "BriefTitle": "A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery",
            "OfficialTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study Evaluating the Analgesic Efficacy and Safety of Intravenous CR845 in Patients Undergoing Abdominal Surgery",
            "LeadSponsorClass": "Cara Therapeutics, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Cara Therapeutics, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The study schedule is comprised of a 14-day Screening Period, a treatment period and an\r\n\r\n      observation period. All eligible subjects will be randomized into one of 3 treatment groups\r\n\r\n      (1 of 2 dose levels or matched placebo). Study",
            "Description": "Patients will be admitted to the surgical center on the day of their abdominal surgery (Day\r\n\r\n      1, unless admission the night before is required). All patients will be seen by the study\r\n\r\n      staff to confirm eligibility, review study pr",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2015",
            "CompletionDate": "June 2017",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "Cara Therapeutics, Inc.",
            "StudyCondition": "Post Abdominal Surgery Pain",
            "studyLocation": "Cara Therapeutics Study Site",
            "Enrollment": "450",
            "NctKeyword": "abdominal surgery, laparoscopy, Hysterectomy, Prostatectomy, Hemi-colectomy, Ventral Hernia repair, CR845, analgesic, kappa opioid, partial bowel resection,",
            "InterventionKeyword": "Analgesics,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        - A patient will be eligible for study participation if the subject meets the following\r\n\r\n        criteria:\r\n\r\n\r\n\r\n          1. Voluntarily provide written informed consent to participate in the study prior",
            "EligibleGender": "All",
            "MinAge": "21 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Sheffield",
            "State": "Alabama",
            "Zip": "34209",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "December 8, 2016",
            "FirstReceived": "September 3, 2015",
            "OverallOfficial": "Joseph Stauffer, DO, MBA",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Cara Therapeutics",
            "ContactName": "Paul Windt, PharmD, MBA",
            "ContactPhone": "203.406.3723",
            "ContactEmail": "clinicaltrials.gov@caratherapeutics.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Cara Therapeutics Study Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02542384",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150510 - Cara Therapeutics/ Inc. - Candiotti",
            "FileProcessContentId": "440",
            "Division": "Anesthesiology",
            "StdyDivision": "10236",
            "EprostNbr": "20150510",
            "StudyNumber": "20150510 - Cara Therapeutics/ Inc. - Candiotti",
            "StudyTitle": "A multicenter, randomized, double-blind, placebo-controlled, adaptive design study evaluating the analgesic efficacy and safety of intravenous cr845 in patients undergoing abdominal surgery",
            "PIID": "912",
            "PicNum": "C00745788",
            "PILastName": "Candiotti",
            "PIFirstName": "Keith",
            "CoodCNbr": "C10588120",
            "CoordLastName": "Antor",
            "CoordFirstName": "Maria",
            "CoordEmail": "mantor@med.miami.edu",
            "CoordPhone": "3055857677",
            "EnteredByCNbr": "C00745788",
            "EnteredByLastName": "Candiotti",
            "EnteredByFirstName": "Keith",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "10/06/2015",
            "IRBApprovedFrom": "10/06/2015",
            "IRBApprovedTo": "10/17/2017",
            "Expr1": "Phase II/III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Cara Therapeutics/ Inc.",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Isabel Jaraba,Angelica Jaramillo Virgen,Maria Antor,Juan Gutierrez",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT02542384",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02542696",
            "SecondaryId": "2016-000637-43",
            "BriefTitle": "An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of \"OFF\" Episodes in Patients With Parkinson's Disease",
            "OfficialTitle": "An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes)",
            "LeadSponsorClass": "Sunovion",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Sunovion",
            "OversightAuthority": "Yes",
            "BriefSummary": "A 24-week, prospective, multi-center, open-label, Phase 3 study in L-Dopa responsive PD\r\n\r\n      patients with motor fluctuations (\"OFF\" episodes), designed to evaluate the long-term\r\n\r\n      safety, tolerability and efficacy of APL-130277.",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2015",
            "CompletionDate": "March 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Sunovion",
            "StudyCondition": "Parkinson Disease",
            "studyLocation": "University of Alabama Birmingham",
            "Enrollment": "226",
            "MeshKeyword": "Parkinson Disease,",
            "InterventionKeyword": "Apomorphine,",
            "Eligibility": "De Novo Patients:\r\n\r\n\r\n\r\n        Inclusion Criteria\r\n\r\n\r\n\r\n          -  Male or female ≥ 18 years of age.\r\n\r\n\r\n\r\n          -  Clinical diagnosis of Idiopathic PD, consistent with UK Brain Bank Criteria\r\n\r\n\r\n\r\n          -  Clinically meaningful",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 6, 2017",
            "FirstReceived": "September 3, 2015",
            "OverallOfficial": "CNS Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Sunovion",
            "ContactName": "CNS Medical Director",
            "ContactPhone": "1-866-503-6351",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02542696",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151075 - Cynapsus Therapeutics Inc - Singer",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20151075",
            "StudyNumber": "20151075 - Cynapsus Therapeutics Inc - Singer",
            "StudyTitle": "An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (“OFF” Episodes)",
            "PIID": "143",
            "PicNum": "C00407776",
            "PILastName": "Singer",
            "PIFirstName": "Carlos",
            "CoodCNbr": "C11907212",
            "CoordLastName": "Vargas",
            "CoordFirstName": "Silvia",
            "CoordEmail": "s.vargasparra@med.miami.edu",
            "EnteredByCNbr": "C00407776",
            "EnteredByLastName": "Singer",
            "EnteredByFirstName": "Carlos",
            "ActiveEnrollingDate": "09/22/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/22/2016",
            "IRBApprovedFrom": "07/27/2015",
            "IRBApprovedTo": "07/20/2016",
            "Expr1": "Phase III",
            "Tarea": "Movement Disorders",
            "TareaCode": "8937",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Cynapsus Therapeutics Inc",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "5",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Nathalie Padron,Silvia Vargas",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT02542696",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02544880",
            "BriefTitle": "PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC",
            "OfficialTitle": "PDE5 Inhibition Via Tadalafil (Cialis®) to Enhance Anti-Tumor MUC1 Vaccine Efficacy in Patients With Resectable, and Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase I/II Clinical Trial",
            "LeadSponsorClass": "Donald T. Weed",
            "SponsorAgency": "Other",
            "LeadSponsor": "Donald T. Weed",
            "OversightAuthority": "Yes",
            "BriefSummary": "The investigators hypothesize that Tadalafil treatment, by lowering Myeloid Derived\r\n\r\n      Suppressor Cells (MDSCs) and regulatory T cells (Tregs), can prime an antitumor immune\r\n\r\n      response and promote a permissive environment that shoul",
            "Description": "The investigators will perform a phase I/II placebo-controlled clinical trial in patients\r\n\r\n      with HNSCC whose tumor has recurred, or secondary primary tumor is detected, post\r\n\r\n      conventional radiotherapy with or without prior surgery",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2016",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Head and Neck Squamous Cell Carcinoma",
            "studyLocation": "University of Miami",
            "Enrollment": "104",
            "NctKeyword": "HNSCC, Head and Neck Squamous Cell Carcinoma, Tadalafil, PDE5 Inhibition, Anti-MUC1 Vaccine, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent HNSCC, Second primary site disease stage III, Second primary site disease stage IV, Anti-Influenza Vacc",
            "MeshKeyword": "Carcinoma, Squamous Cell, Carcinoma, Head and Neck Neoplasms,",
            "InterventionKeyword": "Vaccines, Tadalafil,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Biopsy-proven recurrent or second primary HNSCC of the oral cavity, oropharynx,\r\n\r\n             hypopharynx or larynx (second primary includes unknown primary)\r\n\r\n\r\n\r\n          2. Stage III or IV (AJCC,",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 21, 2016",
            "FirstReceived": "September 4, 2015",
            "OverallOfficial": "Donald T Weed, MD, FACS",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Donald T Weed, MD, FACS",
            "ContactPhone": "305-243-9095",
            "ContactEmail": "dweed@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02544880",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140960 - Intramural - Weed",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140960",
            "StudyNumber": "20140960 - Intramural - Weed",
            "StudyTitle": "PDE5 Inhibition via Tadalafil (Cialis®) to Enhance Anti-Tumor MUC1 Vaccine Efficacy in Patients with Resectable, and Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase I/II Clinical Trial",
            "PIID": "288",
            "PicNum": "C00524870",
            "PILastName": "Weed",
            "PIFirstName": "Donald",
            "CoodCNbr": "C12003895",
            "CoordLastName": "Vazquez Pascual",
            "CoordFirstName": "Fernando",
            "CoordEmail": "fxv109@miami.edu",
            "CoordPhone": "305-243-5620",
            "EnteredByCNbr": "C11972191",
            "EnteredByLastName": "Harris",
            "EnteredByFirstName": "Bretinsa",
            "ActiveEnrollingDate": "04/07/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/07/2016",
            "IRBApprovedFrom": "11/23/2015",
            "IRBApprovedTo": "10/23/2017",
            "DiseaseSiteListDesc": "Lip, Oral Cavity and Pharynx",
            "Expr1": "Phase I/II",
            "Tarea": "Head and Neck Cancer",
            "TareaCode": "12440",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "6",
            "Totalaccrued": "5",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "3",
            "Totalpatients": "6",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A,Plantation:N/A,UMD:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "4",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Maggie Chislom,Pavel Noa Hechavarria,Jerri Halgowich,Marinellie Vega,Lilibet Zamora Cabezas,Lilly Sanchez,Greeyt Hernandez,Doris Martin",
            "NationalSampleSize": "48",
            "NCTNbr": "NCT02544880",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02547220",
            "BriefTitle": "A Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Patients With Kidney Transplant",
            "OfficialTitle": "A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients",
            "LeadSponsorClass": "Shire",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Shire",
            "OversightAuthority": "Yes",
            "BriefSummary": "To evaluate the efficacy of Cinryze® given for the treatment of acute antibody-mediated\r\n\r\n      rejection (of renal allograft) (AMR) in kidney transplant recipients as measured by the\r\n\r\n      proportion of subjects with new or worsening transp",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "CompletionDate": "February 2022",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Shire",
            "StudyCondition": "Acute Antibody-Mediated Rejection (AMR)",
            "studyLocation": "MedStar Georgetown University Hospital",
            "Enrollment": "112",
            "InterventionKeyword": "Antibodies, Complement C1 Inhibitor Protein, Complement C1 Inactivator Proteins,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Be at least 18 years of age.\r\n\r\n\r\n\r\n          2. Weigh at least 40 kg.\r\n\r\n\r\n\r\n          3. Have had human leukocyte antigen (HLA) DSA identified at the time of diagnosis of\r\n\r\n             AMR.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Washington",
            "State": "District of Columbia",
            "Zip": "20057",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 13, 2017",
            "FirstReceived": "September 2, 2015",
            "OverallOfficial": "Shire Study Physician",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Shire",
            "ContactName": "Shire Contact",
            "ContactEmail": "clinicaltransparency@shire.com",
            "LocationStatus": "Recruiting",
            "LocationName": "MedStar Georgetown University Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02547220",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150688 - Shire - Mattiazzi",
            "FileProcessContentId": "440",
            "Division": "Nephrology",
            "StdyDivision": "10250",
            "EprostNbr": "20150688",
            "StudyNumber": "20150688 - Shire - Mattiazzi",
            "StudyTitle": "A randomized double-blind placebo-controlled study to evaluate the efficacy and safety of Cinryze® (C1 esterase inhibitor [human]) for the treatment of acute antibody-mediated rejection in kidney transplant patients",
            "PIID": "2552",
            "PicNum": "C02369857",
            "PILastName": "Mattiazzi",
            "PIFirstName": "Adela",
            "CoodCNbr": "C03064784",
            "CoordLastName": "Tueros",
            "CoordFirstName": "Lissett",
            "CoordEmail": "ltueros@med.miami.edu",
            "CoordPhone": "3053555315",
            "EnteredByCNbr": "C02369857",
            "EnteredByLastName": "Mattiazzi",
            "EnteredByFirstName": "Adela",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "10/26/2015",
            "IRBApprovedFrom": "10/26/2015",
            "IRBApprovedTo": "09/01/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Shire",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Isabel Fernandez,Lissett Tueros,Sandra Flores",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02547220",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02548351",
            "BriefTitle": "Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment",
            "OfficialTitle": "A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis",
            "LeadSponsorClass": "Intercept Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Intercept Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "The primary objectives of this study are to evaluate the effect of Obeticholic Acid\r\n\r\n      treatment compared to placebo on 1) histological improvement and 2) liver-related clinical\r\n\r\n      outcomes in patients with non-cirrhotic nonalcoholic",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2015",
            "CompletionDate": "October 2021",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Intercept Pharmaceuticals",
            "StudyCondition": "Non Alcoholic Steatohepatitis (NASH)",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "2000",
            "NctKeyword": "Non Alcoholic Steatohepatitis, fatty liver disease, NASH,",
            "MeshKeyword": "Fatty Liver, Non-alcoholic Fatty Liver Disease,",
            "InterventionKeyword": "Chenodeoxycholic Acid,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Histologic evidence of NASH upon central read of a liver biopsy obtained no more than\r\n\r\n             6 months before Day 1 defined by presence of all 3 key histological features of NASH",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 10, 2017",
            "FirstReceived": "September 1, 2015",
            "OverallOfficial": "Cathi Sciacca",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Vice President Clinical Operations, Intercept Pharmaceuticals Inc.",
            "ContactName": "Szecho Lin, B.S.",
            "ContactPhone": "858 832 4509",
            "ContactEmail": "szecho.lin@interceptpharma.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02548351",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150713 - Intercept Pharmaceuticals - Schiff",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20150713",
            "StudyNumber": "20150713 - Intercept Pharmaceuticals - Schiff",
            "StudyTitle": "Intercept 747-303-A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled,Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C00758491",
            "EnteredByLastName": "Schiff",
            "EnteredByFirstName": "Eugene",
            "ActiveEnrollingDate": "10/28/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/28/2015",
            "IRBApprovedFrom": "09/21/2015",
            "IRBApprovedTo": "08/28/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Intercept Pharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "6",
            "SignedICF": "9",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "9",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Andrea Elibero",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02548351",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02548455",
            "BriefTitle": "St Jude Medical LV Lead - Quartet 1457Q IDE",
            "OfficialTitle": "A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an Investigational Device Exemption (IDE) Study",
            "LeadSponsorClass": "St. Jude Medical",
            "SponsorAgency": "Industry",
            "LeadSponsor": "St. Jude Medical",
            "OversightAuthority": "No",
            "BriefSummary": "The primary intent of this study is to assess the safety of the model 1457Q Quartet Left\r\n\r\n      Ventricular (LV) lead at 3 months in a patient population indicated for cardiac\r\n\r\n      resynchronization therapy.",
            "Description": "This is a prospective, multi-center, IDE clinical study designed to evaluate the safety of\r\n\r\n      the Model 1457Q Quartet LV lead.\r\n\r\n\r\n\r\n      A minimum of 94 and a maximum of 430 subjects will be enrolled in this study at up to 40\r\n\r\n      c",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "CompletionDate": "April 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "St. Jude Medical",
            "StudyCondition": "Heart Failure",
            "studyLocation": "Heart Center Research",
            "Enrollment": "430",
            "MeshKeyword": "Heart Failure,",
            "InterventionKeyword": "Ethinyl estradiol, levonorgestrel drug combination,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Meets current SJM clinical indication for implantation of a CRT system:\r\n\r\n\r\n\r\n             \" to provide a reduction of the symptoms of moderate to severe heart failure (New\r\n\r\n             York Heart As",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Huntsville",
            "State": "Alabama",
            "Zip": "35801",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 12, 2016",
            "FirstReceived": "September 10, 2015",
            "OverallOfficial": "David Delurgio, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Emory University",
            "ContactName": "Jemymah C. Morley",
            "ContactPhone": "972-309-8503",
            "ContactEmail": "jmorley@sjm.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Heart Center Research",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02548455",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151091 - St. Jude Medical - Carrillo",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20151091",
            "StudyNumber": "20151091 - St. Jude Medical - Carrillo",
            "StudyTitle": "CRD616: A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an Investigational Device Exemption (IDE) Study.",
            "PIID": "1975",
            "PicNum": "C00394135",
            "PILastName": "Carrillo",
            "PIFirstName": "Roger",
            "CoodCNbr": "C06989384",
            "CoordLastName": "Khan",
            "CoordFirstName": "Rosa",
            "CoordEmail": "ekhan@med.miami.edu",
            "CoordPhone": "3056892780",
            "EnteredByCNbr": "C00394135",
            "EnteredByLastName": "Carrillo",
            "EnteredByFirstName": "Roger",
            "ActiveEnrollingDate": "01/05/2017",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/05/2017",
            "IRBApprovedFrom": "01/19/2016",
            "IRBApprovedTo": "11/06/2017",
            "Expr1": "Phase I",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "St. Jude Medical",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Raiza Salceda,Rosa Khan",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02548455",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02551159",
            "BriefTitle": "Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer",
            "OfficialTitle": "A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients",
            "LeadSponsorClass": "AstraZeneca",
            "SponsorAgency": "Industry",
            "LeadSponsor": "AstraZeneca",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine\r\n\r\n      the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy\r\n\r\n      versus SoC (EXTREME regimen) in the treatment of",
            "Description": "Patients will be randomized in a 2:1:1 ratio to MEDI4736 + tremelimumab combination therapy,\r\n\r\n      MEDI4736 monotherapy, or SoC. Patients in all arms will continue therapy until progression.\r\n\r\n      Tumor assessments will be performed on com",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "CompletionDate": "July 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "AstraZeneca",
            "StudyCondition": "Squamous Cell Carcinoma of the Head and Neck",
            "studyLocation": "Research Site",
            "Enrollment": "760",
            "NctKeyword": "programmed cell death ligand 1 (PD-L1), MEDI4736, Cytotoxic T-lymphocyte-associated antigen 4 {CTLA-4}, PFS, SCCHN,",
            "MeshKeyword": "Carcinoma, Squamous Cell, Head and Neck Neoplasms,",
            "InterventionKeyword": "Tremelimumab, Cetuximab, Fluorouracil, Carboplatin, Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age ≥18 years at the time of screening\r\n\r\n\r\n\r\n          2. Documented evidence of recurrent or metastatic SCCHN (oral cavity, oropharynx,\r\n\r\n             hypopharynx, or larynx).\r\n\r\n\r\n\r\n          3. A fr",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 23, 2016",
            "FirstReceived": "September 9, 2015",
            "OverallOfficial": "Michael McDevitt",
            "OverallRole": "Study Director",
            "OverallAffilitation": "200 Orchard Ridge Drive 1208F, Gaithersburg, MD",
            "ContactName": "AstraZeneca Clinical Study Information Center",
            "ContactPhone": "1-877-240-9479",
            "ContactEmail": "information.center@astrazeneca.com",
            "LocationStatus": "Withdrawn",
            "LocationName": "Research Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02551159",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151030 - AstraZeneca - Ikpeazu",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151030",
            "StudyNumber": "20151030 - AstraZeneca - Ikpeazu",
            "StudyTitle": "A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients",
            "PIID": "373",
            "PicNum": "C06163680",
            "PILastName": "Ikpeazu",
            "PIFirstName": "Chukwuemeka",
            "CoodCNbr": "C11971258",
            "CoordLastName": "El-Sorady",
            "CoordFirstName": "Mohammad",
            "CoordEmail": "mie25@med.miami.edu",
            "CoordPhone": "954-371-3203",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "09/15/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/15/2016",
            "IRBApprovedFrom": "02/22/2016",
            "IRBApprovedTo": "02/21/2017",
            "AccountNbr": "667496",
            "DiseaseSiteListDesc": "Lip, Oral Cavity and Pharynx",
            "Expr1": "Phase III",
            "Tarea": "Head and Neck Cancer",
            "TareaCode": "12440",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "SiteSampleSize": "UMD:N/A,UMMG:N/A,UMHC:N/A,Plantation:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Penny Eyer,Carla Munevar,Marinellie Vega,Greeyt Hernandez,Doris Martin,Lilly Sanchez",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02551159",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02553135",
            "BriefTitle": "Choroideremia Gene Therapy Clinical Trial",
            "OfficialTitle": "An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)",
            "LeadSponsorClass": "Byron Lam",
            "SponsorAgency": "Other",
            "LeadSponsor": "Byron Lam",
            "OversightAuthority": "Yes",
            "BriefSummary": "Phase II gene therapy study, involving a total of 6 male patients with choroideremia. The\r\n\r\n      study will be conducted at the Bascom Palmer Eye Institute, University of Miami. Patients\r\n\r\n      will be required to attend a total of 11 study",
            "Description": "This is a Phase II, open label study involving patients with a clinical phenotype of\r\n\r\n      choroideremia and a confirmed CHM genotype. Following consent, patients will be required to\r\n\r\n      attend an initial screening visit (Visit 1). Withi",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "September 2015",
            "CompletionDate": "February 2021",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Choroideremia",
            "studyLocation": "Bascom Palmer Eye Institute, University of Miami",
            "Enrollment": "6",
            "NctKeyword": "choroideremia, gene therapy,",
            "MeshKeyword": "Choroideremia,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  18 Years and older\r\n\r\n\r\n\r\n          -  Male\r\n\r\n\r\n\r\n          -  Able to give informed consent\r\n\r\n\r\n\r\n          -  Genetically confirmed diagnosis of choroideremia\r\n\r\n\r\n\r\n          -  Active disease visib",
            "EligibleGender": "Male",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 6, 2016",
            "FirstReceived": "June 17, 2015",
            "OverallOfficial": "BYRON LAM, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "UNIVERSITY OF MIAMI, BASCOM PALMER EYE INSTITUTE",
            "LocationName": "Bascom Palmer Eye Institute, University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02553135",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150371 - Intramural - Lam",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20150371",
            "StudyNumber": "20150371 - Intramural - Lam",
            "StudyTitle": "An open label Phase 2 clinical trial of retinal gene therapy for choroideremia using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1)",
            "PIID": "1115",
            "PicNum": "C00679155",
            "PILastName": "Lam",
            "PIFirstName": "Byron",
            "CoodCNbr": "C07458455",
            "CoordLastName": "Morante",
            "CoordFirstName": "Alexis",
            "CoordEmail": "amorante@med.miami.edu",
            "EnteredByCNbr": "C00679155",
            "EnteredByLastName": "Lam",
            "EnteredByFirstName": "Byron",
            "ActiveEnrollingDate": "10/20/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/20/2015",
            "IRBApprovedFrom": "08/24/2015",
            "IRBApprovedTo": "07/24/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "7",
            "Screenedfailed": "1",
            "SignedICF": "7",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Alexis Morante,Jennifer Verriotto,Potyra Rosa",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT02553135",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02553330",
            "BriefTitle": "A Study With INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)",
            "OfficialTitle": "An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata",
            "LeadSponsorClass": "Incyte Corporation",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Incyte Corporation",
            "OversightAuthority": "No",
            "BriefSummary": "A phase 2 study to find out if the drug INCB018424 Phosphate Cream is safe and has\r\n\r\n      beneficial effects in people who have alopecia areata (partial or complete hair loss) when\r\n\r\n      applied to the skin.",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "October 2015",
            "CompletionDate": "January 2019",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Incyte Corporation",
            "StudyCondition": "Alopecia Areata",
            "Enrollment": "90",
            "NctKeyword": "Hair loss, alopecia areata, alopecia totalis, alopecia universalis, JAK inhibitors, topical hair growth,",
            "MeshKeyword": "Alopecia, Alopecia Areata,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of AA\r\n\r\n\r\n\r\n          -  Duration and extent of current episode of AA\r\n\r\n\r\n\r\n          -  Evidence of active hair loss\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -  Evidence of diffus",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "70 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 10, 2016",
            "FirstReceived": "September 16, 2015",
            "OverallOfficial": "Kathleen Butler, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Incyte Corporation",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02553330",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150727 - Incyte Corporation - Tosti",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20150727",
            "StudyNumber": "20150727 - Incyte Corporation - Tosti",
            "StudyTitle": "INCB 18424-204: An Open-Label (Part A) and a Double-Blind, Randomized, Placebo-Controlled (Part B) Study, With an Open-Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata",
            "PIID": "2884",
            "PicNum": "C09884823",
            "PILastName": "Tosti",
            "PIFirstName": "Antonella",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C09884823",
            "EnteredByLastName": "Tosti",
            "EnteredByFirstName": "Antonella",
            "ActiveEnrollingDate": "03/29/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/29/2016",
            "IRBApprovedFrom": "11/03/2015",
            "IRBApprovedTo": "10/17/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Incyte Corporation",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "9",
            "Totalaccrued": "8",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "5",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "9",
            "FirstNinety": "7",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Carol Kittles,Aliette Espinosa",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT02553330",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02556203",
            "SecondaryId": "2015-001975-30",
            "BriefTitle": "Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes",
            "OfficialTitle": "Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes",
            "LeadSponsorClass": "Bayer",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Bayer",
            "OversightAuthority": "Yes",
            "BriefSummary": "To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR,\r\n\r\n      compared to an antiplatelet-based strategy, is superior in reducing death or first\r\n\r\n      thromboembolic events (DTE).\r\n\r\n\r\n\r\n      To assess t",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2015",
            "CompletionDate": "July 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Bayer",
            "StudyCondition": "Transcatheter Aortic Valve Replacement",
            "studyLocation": "Universitätsklinikum Heidelberg",
            "Enrollment": "1520",
            "NctKeyword": "TAVR, TAVI, Transfemoral aortic valve implantation,",
            "InterventionKeyword": "Clopidogrel, Aspirin, Rivaroxaban,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Successful TAVR (Transcatheter Aortic Valve Replacement) of an aortic valve stenosis\r\n\r\n             (either native or valve-in-valve)\r\n\r\n\r\n\r\n               -  By iliofemoral or subclavian access",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 3, 2017",
            "FirstReceived": "September 5, 2015",
            "OverallOfficial": "Bayer Study Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Bayer",
            "ContactName": "Bayer Clinical Trials Contact",
            "ContactEmail": "clinical-trials-contact@bayerhealthcare.com",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "Universitätsklinikum Heidelberg",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02556203",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151165 - Bayer HealthCare Pharmaceuticals/ Inc. - Cohen",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20151165",
            "StudyNumber": "20151165 - Bayer HealthCare Pharmaceuticals/ Inc. - Cohen",
            "StudyTitle": "GALILEO - Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an anti-pLatelet-based strategy after transcatheter aortIc vaLve\nrEplacement (TAVR) to Optimize clinical outcomes.",
            "PIID": "1752",
            "PicNum": "C07441231",
            "PILastName": "Cohen",
            "PIFirstName": "Mauricio",
            "CoodCNbr": "C06968089",
            "CoordLastName": "Lang",
            "CoordFirstName": "Barbara",
            "CoordEmail": "blang@med.miami.edu",
            "CoordPhone": "3052434950",
            "EnteredByCNbr": "C07441231",
            "EnteredByLastName": "Cohen",
            "EnteredByFirstName": "Mauricio",
            "ActiveEnrollingDate": "11/22/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/22/2016",
            "IRBApprovedFrom": "07/11/2016",
            "IRBApprovedTo": "07/10/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Bayer HealthCare Pharmaceuticals/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Laura Hudson,Barbara Lang,Carmen Baez-Garcia",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT02556203",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02565511",
            "SecondaryId": "2015-002715-15",
            "BriefTitle": "A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease",
            "OfficialTitle": "A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.",
            "LeadSponsorClass": "Novartis Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novartis Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to test whether two investigational drugs called CAD106 and\r\n\r\n      CNP520, administered separately, can slow down the onset and progression of clinical\r\n\r\n      symptoms associated with Alzheimer's disease (AD) in",
            "Description": "This study will assess the effects of each of the two therapies given separately, both\r\n\r\n      targeting amyloid, on cognition, global clinical status, and underlying pathology in\r\n\r\n      participants at risk for the onset of clinical symptoms",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2015",
            "CompletionDate": "August 2023",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Novartis",
            "StudyCondition": "Alzheimer's Disease",
            "studyLocation": "Novartis Investigative Site",
            "Enrollment": "1340",
            "NctKeyword": "Randomization, Placebo controlled, Parallel-group, APOE4 Homozygotes, Preclinical Alzheimer's Disease (AD), Aβ lowering,",
            "MeshKeyword": "Alzheimer Disease,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male or female, age 60 to 75 years inclusive. Females must be considered\r\n\r\n             post-menopausal and not of child bearing potential.\r\n\r\n\r\n\r\n          -  Mini-Mental State Examination (MMSE) total",
            "EligibleGender": "All",
            "MinAge": "60 Years",
            "MaxAge": "75 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85006",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 10, 2016",
            "FirstReceived": "September 28, 2015",
            "ContactName": "Novartis Pharmaceuticals",
            "ContactPhone": "1-888-669-6682",
            "LocationStatus": "Recruiting",
            "LocationName": "Novartis Investigative Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02565511",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150891 - Novartis - Loewenstein",
            "FileProcessContentId": "440",
            "Division": "Geriatrics",
            "StdyDivision": "9436",
            "EprostNbr": "20150891",
            "StudyNumber": "20150891 - Novartis - Loewenstein",
            "StudyTitle": "CAPI015A2201J: A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s disease",
            "PIID": "3693",
            "PicNum": "C00802143",
            "PILastName": "Crocco",
            "PIFirstName": "Elizabeth",
            "CoodCNbr": "C04892431",
            "CoordLastName": "Brenson",
            "CoordFirstName": "Nicole",
            "CoordEmail": "nbrenson@med.miami.edu",
            "CoordPhone": "3053558186",
            "EnteredByCNbr": "C00471770",
            "EnteredByLastName": "Loewenstein",
            "EnteredByFirstName": "David",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "04/25/2016",
            "IRBApprovedFrom": "04/25/2016",
            "IRBApprovedTo": "04/24/2017",
            "Expr1": "Phase II/III",
            "Tarea": "Prevention",
            "TareaCode": "8951",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Novartis",
            "SiteSampleSize": "Mount Sinai Hospital:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nicole Brenson,Nicolette gomez,Tania Guardia,Belinda Robertson",
            "NationalSampleSize": "300",
            "NCTNbr": "NCT02565511",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02565914",
            "SecondaryId": "2014-004827-29",
            "BriefTitle": "A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation",
            "OfficialTitle": "A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation",
            "LeadSponsorClass": "Vertex Pharmaceuticals Incorporated",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Vertex Pharmaceuticals Incorporated",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a Phase 3, multicenter, open-label, rollover study in subjects with CF who are\r\n\r\n      homozygous or heterozygous for the F508del-CFTR mutation and who participated in Studies 103\r\n\r\n      (NCT02070744), 106 (NCT02347657), 107 (NCT02516",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "August 2015",
            "CompletionDate": "July 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Vertex Pharmaceuticals Incorporated",
            "StudyCondition": "Cystic Fibrosis",
            "Enrollment": "1292",
            "MeshKeyword": "Fibrosis, Cystic Fibrosis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subjects entering the Treatment Cohort must meet all of the following criteria:\r\n\r\n\r\n\r\n          -  Elect to enroll in the Treatment Cohort\r\n\r\n\r\n\r\n          -  Completed study drug Treatment Period in a",
            "EligibleGender": "All",
            "MinAge": "12 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "March 2016",
            "LastChanged": "April 27, 2016",
            "FirstReceived": "September 18, 2015",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02565914",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150700 - Vertex Pharmaceuticals - Salathe",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20150700",
            "StudyNumber": "20150700 - Vertex Pharmaceuticals - Salathe",
            "StudyTitle": "A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With VX-661 in Combination With Ivacaftor in Subjects\nAged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR\nMutation",
            "PIID": "528",
            "PicNum": "C00319179",
            "PILastName": "Salathe",
            "PIFirstName": "Matthias",
            "CoodCNbr": "C09943370",
            "CoordLastName": "Aguiar",
            "CoordFirstName": "Carolina",
            "CoordEmail": "caguiar2@med.miami.edu",
            "CoordPhone": "3052435545",
            "EnteredByCNbr": "C00319179",
            "EnteredByLastName": "Salathe",
            "EnteredByFirstName": "Matthias",
            "ActiveEnrollingDate": "02/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/08/2016",
            "IRBApprovedFrom": "11/03/2015",
            "IRBApprovedTo": "10/31/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Vertex Pharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "5",
            "Totalaccrued": "5",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "5",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Patricia Rebolledo,Carolina Aguiar,Patricia Graham-Borras,Johana Arana,Eliana Mendes",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02565914",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02574520",
            "BriefTitle": "Trial of Extended Release Bupivacaine for Pain Relief After Surgery",
            "OfficialTitle": "A Placebo-controlled Trial (Part 1) or Active-controlled (Part 2) of SABER® Bupivacaine for the Management of Postoperative Pain Following Laparoscopic Cholecystectomy",
            "LeadSponsorClass": "Durect",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Durect",
            "OversightAuthority": "No",
            "BriefSummary": "This is a research study of SABER® -Bupivacaine, an experimental medication designed to\r\n\r\n      relieve pain for up to 3 days after surgery. Given once by the surgeon at the end of\r\n\r\n      surgery, SABER® - Bupivacaine delivers a locally-actin",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Durect",
            "StudyCondition": "Post Operative Pain",
            "studyLocation": "Durect Study Site 04",
            "Enrollment": "264",
            "NctKeyword": "Post-operative pain, opioid, opioid reduction, laparoscopic cholecystectomy, laparoscopic surgery, bupivacaine, extended release, locally acting analgesic,",
            "MeshKeyword": "Pain, Postoperative,",
            "InterventionKeyword": "Bupivacaine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients scheduled for elective outpatient laparoscopic cholecystectomy using a\r\n\r\n             conventional 4-port laparoscopic procedure.\r\n\r\n\r\n\r\n          -  Must be able and willing to provide written",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Florence",
            "State": "Alabama",
            "Zip": "35360",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 3, 2017",
            "FirstReceived": "October 9, 2015",
            "OverallOfficial": "Dave Ellis, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Durect",
            "ContactName": "Deborah Scott, Masters",
            "ContactPhone": "408-777-1417",
            "ContactEmail": "Deborah.scott@durect.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Durect Study Site 04",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02574520",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150985 - DURECT Corporation - Candiotti",
            "FileProcessContentId": "440",
            "Division": "Anesthesiology",
            "StdyDivision": "10236",
            "EprostNbr": "20150985",
            "StudyNumber": "20150985 - DURECT Corporation - Candiotti",
            "StudyTitle": "A Placebo-controlled trial of SABER®-Bupivacaine for the management of poStoperative pain following laparoScopic cholecysTectomy (PERSIST)",
            "PIID": "912",
            "PicNum": "C00745788",
            "PILastName": "Candiotti",
            "PIFirstName": "Keith",
            "CoodCNbr": "C06076027",
            "CoordLastName": "Nieto",
            "CoordFirstName": "Margarita",
            "CoordEmail": "m.nieto@med.miami.edu",
            "EnteredByCNbr": "C00745788",
            "EnteredByLastName": "Candiotti",
            "EnteredByFirstName": "Keith",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "04/18/2016",
            "IRBApprovedFrom": "04/18/2016",
            "IRBApprovedTo": "04/17/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Adriana Martini,Angelica Jaramillo Virgen",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02574520",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02576665",
            "BriefTitle": "A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors",
            "OfficialTitle": "A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors",
            "LeadSponsorClass": "Tocagen Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Tocagen Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "This is a multicenter, open label, single arm study of Toca 511 and Toca FC. Based on their\r\n\r\n      cancer diagnosis (brain metastases from non small cell lung cancer or breast cancer;\r\n\r\n      colorectal cancer with liver metastases; metastati",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2016",
            "CompletionDate": "November 2019",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Tocagen Inc.",
            "StudyCondition": "Metastatic Colorectal Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "26",
            "MeshKeyword": "Colorectal Neoplasms, Pancreatic Neoplasms, Carcinoma, Renal Cell,",
            "InterventionKeyword": "Flucytosine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Metastatic solid tumor, including:\r\n\r\n\r\n\r\n               -  Subjects with brain metastases with a primary tumor of non small cell lung\r\n\r\n                  cancer (NSCLC) or breast cancer, suitable for p",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "90 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 9, 2016",
            "FirstReceived": "October 12, 2015",
            "OverallOfficial": "Jaime R Merchan, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Jolene Shorr",
            "ContactPhone": "(858) 412-8467",
            "ContactEmail": "jshorr@tocagen.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02576665",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160019 - Tocagen Inc - Merchan",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160019",
            "StudyNumber": "20160019 - Tocagen Inc - Merchan",
            "StudyTitle": "The Toca 6 Study: A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects with Solid Tumors",
            "PIID": "407",
            "PicNum": "C00251535",
            "PILastName": "Merchan",
            "PIFirstName": "Jaime",
            "CoodCNbr": "C11968022",
            "CoordLastName": "Leon Aliz",
            "CoordFirstName": "Tamara",
            "CoordEmail": "txl351@med.miami.edu",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "07/26/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/26/2016",
            "IRBApprovedFrom": "05/02/2016",
            "IRBApprovedTo": "05/01/2017",
            "AccountNbr": "667425",
            "DiseaseSiteListDesc": "Lip, Oral Cavity and Pharynx,Prostate,Brain and Nervous System,Colon,Breast-Female,Rectum,Melanoma, skin",
            "Expr1": "Phase I",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "4",
            "Totalaccrued": "3",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "4",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Daniel Sumarriva,Juan Salvador,Karen Blackburn,Sandra Pineda,Yvonne Dinh",
            "NationalSampleSize": "7",
            "NCTNbr": "NCT02576665",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02577406",
            "BriefTitle": "An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation",
            "OfficialTitle": "A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation",
            "LeadSponsorClass": "Celgene Corporation",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Celgene Corporation",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is an international, multicenter, open-label, randomized, Phase 3 study comparing the\r\n\r\n      efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years\r\n\r\n      or older with acute myeloid leukemia (AML) r",
            "Description": "Acute myeloid leukaemia (AML) is a form of cancer that is common in older patients.\r\n\r\n      Mutations in the isocitrate dehydrogenase enzyme 2 (IDH2) have been found in approximately\r\n\r\n      15% of patients with AML.\r\n\r\n\r\n\r\n      The outcome o",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2015",
            "CompletionDate": "February 2020",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Celgene Corporation",
            "StudyCondition": "Leukemia, Myeloid",
            "studyLocation": "University of Southern California Norris Cancer Center",
            "Enrollment": "280",
            "NctKeyword": "AG-221, CC-90007, Efficacy, Safety, Leukemia, Acute myloid meukemia, Isocitrate dehydrogenase 2 mutation, Enasidenib,",
            "MeshKeyword": "Leukemia, Myeloid, Leukemia, Myeloid, Acute, Leukemia,",
            "InterventionKeyword": "Cytarabine, Azacitidine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        Subjects must satisfy the following criteria to be enrolled in the study:\r\n\r\n\r\n\r\n          1. Subject is ≥ 60 years of age at the time of signing the ICF\r\n\r\n\r\n\r\n          2. Subject has primary (ie, de novo)",
            "EligibleGender": "All",
            "MinAge": "60 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90033",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 28, 2016",
            "FirstReceived": "October 14, 2015",
            "OverallOfficial": "Ira Gupta, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Celgene Corporation",
            "ContactName": "Associate Director Clinical Trial Disclosure",
            "ContactPhone": "1-888-260-1599",
            "ContactEmail": "clinicaltrialdisclosure@celgene.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Southern California Norris Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02577406",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150826 - Celgene - Watts",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150826",
            "StudyNumber": "20150826 - Celgene - Watts",
            "StudyTitle": "A Phase 3, Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regiments in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation",
            "PIID": "22711",
            "PicNum": "C11915545",
            "PILastName": "Watts",
            "PIFirstName": "Justin",
            "CoodCNbr": "C11908603",
            "CoordLastName": "Pallapati",
            "CoordFirstName": "Rachel",
            "CoordEmail": "rpallapati@med.miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "07/25/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/25/2016",
            "IRBApprovedFrom": "02/01/2016",
            "IRBApprovedTo": "01/05/2018",
            "AccountNbr": "665327",
            "DiseaseSiteListDesc": "Myeloid and Monocytic Leukemia",
            "Expr1": "Phase III",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "5",
            "Totalaccrued": "3",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Teresa Kamar,Micaela Martinez,Penny Eyer",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02577406",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02580591",
            "SecondaryId": "2014-005256-26",
            "BriefTitle": "Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)",
            "OfficialTitle": "A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-3)",
            "LeadSponsorClass": "Boehringer Ingelheim",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Boehringer Ingelheim",
            "BriefSummary": "The study will investigate the efficacy, safety, tolerability and PK of 3 doses of\r\n\r\n      empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes\r\n\r\n      mellitus as adjunctive therapy to insulin",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "CompletionDate": "September 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Boehringer Ingelheim",
            "StudyCondition": "Diabetes Mellitus, Type 1",
            "studyLocation": "Boehringer Ingelheim Investigational Site",
            "Enrollment": "960",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1,",
            "InterventionKeyword": "Empagliflozin,",
            "Eligibility": "Inclusion criteria:\r\n\r\n\r\n\r\n          -  Signed and dated written informed consent\r\n\r\n\r\n\r\n          -  Male or female patient receiving insulin for the treatment of documented diagnosis of\r\n\r\n             type 1 diabetes mellitus (T1DM) > 1 yea",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Montgomery",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 17, 2017",
            "FirstReceived": "October 19, 2015",
            "OverallOfficial": "Boehringer Ingelheim",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Boehringer Ingelheim",
            "ContactName": "Boehringer Ingelheim Call Center",
            "ContactPhone": "1-800-243-0127",
            "ContactEmail": "clintriage.rdg@boehringer-ingelheim.com",
            "LocationStatus": "Completed",
            "LocationName": "Boehringer Ingelheim Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02580591",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150862 - Boehringer Ingelheim - Miranda-Palma",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20150862",
            "StudyNumber": "20150862 - Boehringer Ingelheim - Miranda-Palma",
            "StudyTitle": "A Phase III, randomised, double blind, placebo-controlled,\nparallel group, efficacy, safety and tolerability trial of once\ndaily, oral doses of Empagliflozin as Adjunctive to inSulin\nthErapy over 26 weeks in patients with Type 1 Diabetes\nMellitus (EASE-3)",
            "PIID": "1111",
            "PicNum": "C02129536",
            "PILastName": "Miranda-Palma",
            "PIFirstName": "Bresta",
            "CoodCNbr": "C00121533",
            "CoordLastName": "Masters",
            "CoordFirstName": "Burlett",
            "CoordEmail": "bmasters2@med.miami.edu",
            "CoordPhone": "305-243-5354",
            "EnteredByCNbr": "C02129536",
            "EnteredByLastName": "Miranda-Palma",
            "EnteredByFirstName": "Bresta",
            "ActiveEnrollingDate": "04/06/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/06/2016",
            "IRBApprovedFrom": "12/28/2015",
            "IRBApprovedTo": "11/27/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Boehringer Ingelheim",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "6",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Burlett Masters,Ada Konwai",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02580591",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02580877",
            "BriefTitle": "Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)",
            "OfficialTitle": "Exploring Immunologic Effects of Oral Insulin in Relatives at Risk for Type 1",
            "LeadSponsorClass": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
            "OversightAuthority": "Yes",
            "BriefSummary": "The study is a 2 arm, multi-center, randomized, open-labeled clinical trial designed to\r\n\r\n      assess the effects of varying doses and schedules of oral insulin on immunological and\r\n\r\n      metabolic markers in relatives at risk for type 1 di",
            "Description": "A minimum of 40 eligible participants will be identified for study participation from the\r\n\r\n      TrialNet Pathway to Prevention study. Participants must have a relative with type 1 diabetes\r\n\r\n      and be positive for insulin autoantibodies a",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2016",
            "CompletionDate": "December 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
            "StudyCondition": "Type 1 Diabetes",
            "studyLocation": "University of California - San Francisco",
            "Enrollment": "40",
            "NctKeyword": "oral insulin,",
            "MeshKeyword": "Diabetes Mellitus, Type 1,",
            "InterventionKeyword": "Insulin, Globin Zinc, Insulin, Methamphetamine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Participants in TrialNet Natural History/Pathway to Prevention Study (TN01); is\r\n\r\n             relative of proband with type 1 diabetes\r\n\r\n\r\n\r\n          -  Between ages 3-45 with normal Oral Glucose Tol",
            "EligibleGender": "All",
            "MinAge": "3 Years",
            "MaxAge": "45 Years",
            "Volunteers": "No",
            "City": "San Francisco",
            "State": "California",
            "Zip": "94158-2549",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 17, 2017",
            "FirstReceived": "September 30, 2015",
            "OverallOfficial": "Carla Greenbaum, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Type 1 Diabetes TrialNet",
            "ContactName": "Lisa E Rafkin, MS",
            "ContactPhone": "305-243-6146",
            "ContactEmail": "lrafkin@miami.edu",
            "LocationStatus": "Active, not recruiting",
            "LocationName": "University of California - San Francisco",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02580877",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151097 - National Institutes of Health (NIH) - Marks",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20151097",
            "StudyNumber": "20151097 - National Institutes of Health (NIH) - Marks",
            "StudyTitle": "Exploring Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus",
            "PIID": "877",
            "PicNum": "C00763957",
            "PILastName": "Marks",
            "PIFirstName": "Jennifer",
            "CoodCNbr": "C00694387",
            "CoordLastName": "Matheson",
            "CoordFirstName": "Della",
            "CoordEmail": "dmatheso@miami.edu",
            "CoordPhone": "3052433781",
            "EnteredByCNbr": "C00763957",
            "EnteredByLastName": "Marks",
            "EnteredByFirstName": "Jennifer",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "01/04/2016",
            "IRBApprovedFrom": "01/04/2016",
            "IRBApprovedTo": "01/03/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug",
            "SponsorGroup": "Other",
            "Sponsor": "National Institutes of Health (NIH)",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Natalia Sanders,Carlos Blaschke,Della Matheson",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02580877",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02582905",
            "BriefTitle": "Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders",
            "OfficialTitle": "Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders",
            "LeadSponsorClass": "University of Texas Southwestern Medical Center",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Texas Southwestern Medical Center",
            "OversightAuthority": "Yes",
            "BriefSummary": "Preclinical and clinical data as well as mechanistic justification have been presented\r\n\r\n      suggesting citicoline and pregnenolone are each promising treatments for alcohol use in BPD.\r\n\r\n      Both appear to have favorable side effect profi",
            "Description": "A 12-week, randomized, double-blind, parallel-group, placebo-controlled adaptive, Drop The\r\n\r\n      Loser (DTL) design clinical trial of citicoline and pregnenolone will be conducted in 199\r\n\r\n      outpatients with bipolar I or II disorder, dep",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2016",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "University of Texas Southwestern Medical Center",
            "StudyCondition": "Alcohol Use Disorder",
            "studyLocation": "University of Miami",
            "Enrollment": "199",
            "NctKeyword": "Alcohol Use Disorder, Bipolar Disorder, Mood, Alcohol craving, Pregnenolone, Citicoline,",
            "MeshKeyword": "Disease, Bipolar Disorder, Alcohol Drinking,",
            "InterventionKeyword": "Ethanol, Choline, Cytidine Diphosphate Choline,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Outpatient men and women age 18-65 years old with bipolar I or II disorder (currently\r\n\r\n             depressed)\r\n\r\n\r\n\r\n          -  English or Spanish speaking\r\n\r\n\r\n\r\n          -  Current diagnosis of a",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 29, 2016",
            "FirstReceived": "October 20, 2015",
            "ContactName": "Collette B. Bice, MS",
            "ContactPhone": "214-645-6954",
            "ContactEmail": "collette.bice@utsouthwestern.edu",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02582905",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150701 - National Institute on Alcohol Abuse and Alcoholism - Salloum",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20150701",
            "StudyNumber": "20150701 - National Institute on Alcohol Abuse and Alcoholism - Salloum",
            "StudyTitle": "Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders",
            "PIID": "1254",
            "PicNum": "C05555269",
            "PILastName": "Salloum",
            "PIFirstName": "Ihsan",
            "CoodCNbr": "C00155937",
            "CoordLastName": "Carmona",
            "CoordFirstName": "Yamila",
            "CoordEmail": "yic3@med.miami.edu",
            "CoordPhone": "(305) 243-2686",
            "EnteredByCNbr": "C05555269",
            "EnteredByLastName": "Salloum",
            "EnteredByFirstName": "Ihsan",
            "ActiveEnrollingDate": "03/26/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/26/2016",
            "IRBApprovedFrom": "01/04/2016",
            "IRBApprovedTo": "06/19/2017",
            "Expr1": "Phase I/II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "National Institute on Alcohol Abuse and Alcoholism",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "12",
            "Totalaccrued": "12",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "7",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "12",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "2",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yamila Carmona,Anam Shariq,Akriti Sinha,Feng Miao,Gabriela Vargas",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT02582905",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02586831",
            "BriefTitle": "Diabetes Islet Preservation Immune Treatment",
            "OfficialTitle": "A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Pegylated Granulocyte Colony Stimulating Factor (GCSF), Low Dose Interleukin-2 (IL-2), Etanercept and Exenatide in the Treatment of New Onset Type 1 Diabetes",
            "LeadSponsorClass": "Camillo Ricordi and Jay Skyler",
            "SponsorAgency": "Other",
            "LeadSponsor": "Camillo Ricordi and Jay Skyler",
            "OversightAuthority": "Yes",
            "BriefSummary": "To assess whether there is a difference in endogenous insulin secretion, measured as\r\n\r\n      stimulated C-peptide secretion (area under the curve during a 4-hour mixed meal tolerance\r\n\r\n      test), at the 1 year visit, for study subjects recei",
            "Description": "There is a critical need to test therapies that afford long-lasting immunomodulation through\r\n\r\n      the combined use of short courses of depleting agents, more chronic use of drugs that\r\n\r\n      promote immunoregulation and critically control",
            "OverallStatus": "Not yet recruiting",
            "StartDate": "June 2017",
            "CompletionDate": "January 2021",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Diabetes Mellitus, Type 1",
            "studyLocation": "Diabetes Research Institute, University of Miami Miller School of Medicine",
            "Enrollment": "42",
            "NctKeyword": "Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases, Diabetes Mellitus,",
            "MeshKeyword": "Diabetes Mellitus, Hypoglycemia, Diabetes Mellitus, Type 1, Autoimmune Diseases,",
            "InterventionKeyword": "Etanercept, Antilymphocyte Serum, Interleukin-2, Lenograstim, Exenatide, Aldesleukin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must meet all of the following criteria to be eligible to participate in\r\n\r\n             this study:\r\n\r\n\r\n\r\n               1. Subject must be able to understand and provide informed consent.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "35 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 28, 2016",
            "FirstReceived": "October 23, 2015",
            "OverallOfficial": "Rodolfo Alejandro, M.D.",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Diabetes Research Institute, University of Miami",
            "ContactName": "Rodolfo Alejandro, M.D.",
            "ContactPhone": "(305) 243-5324",
            "ContactEmail": "ralejand@med.miami.edu",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "Diabetes Research Institute, University of Miami Miller School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02586831",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150856 - Intramural - Alejandro",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20150856",
            "StudyNumber": "20150856 - Intramural - Alejandro",
            "StudyTitle": "A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Pegylated Granulocyte Colony Stimulating Factor (GCSF), Low Dose Interleukin-2 (IL-2), Etanercept and Exenatide in the Treatment of New Onset Type 1 Diabetes. \n\nDIPIT study: Diabetes Islet Preservation Immune Treatment",
            "PIID": "473",
            "PicNum": "C00309269",
            "PILastName": "Alejandro",
            "PIFirstName": "Rodolfo",
            "CoodCNbr": "C07209050",
            "CoordLastName": "Hirani",
            "CoordFirstName": "Khemraj",
            "CoordEmail": "khirani@med.miami.edu",
            "EnteredByCNbr": "C00309269",
            "EnteredByLastName": "Alejandro",
            "EnteredByFirstName": "Rodolfo",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "10/06/2015",
            "IRBApprovedFrom": "10/06/2015",
            "IRBApprovedTo": "10/05/2016",
            "Expr1": "Phase I/II",
            "Tarea": "Diabetes (Type I)",
            "TareaCode": "12541",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Natalia Sanders,Carlos Blaschke,Della Matheson",
            "NationalSampleSize": "42",
            "NCTNbr": "NCT02586831",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02587728",
            "BriefTitle": "Carpal Tunnel/Amyloidosis Blood Sample Study",
            "OfficialTitle": "Collection of Peripheral Blood Samples From Patients With Carpal Tunnel Syndrome for Laboratory Screening of Amyloidosis",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "Carpal tunnel is an early manifestation of amyloidosis in a significant minority of\r\n\r\n      patients. This specimen collection protocol will allow the investigators to screen patients\r\n\r\n      with carpal tunnel syndrome for amyloidosis.",
            "Description": "The investigators propose to assess a high risk population of patients, those with carpal\r\n\r\n      tunnel syndrome, and systematically assess them for Amyloid Light-chain (AL) amyloidosis and\r\n\r\n      Transthyretin-Related Amyloidosis (ATTR) wit",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Carpal Tunnel Syndrome",
            "studyLocation": "University of Miami",
            "Enrollment": "500",
            "NctKeyword": "Carpal Tunnel Syndrome, Amyloidosis,",
            "MeshKeyword": "Syndrome, Amyloidosis, Carpal Tunnel Syndrome,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  1. Patients with symptoms and signs \"highly suggestive of\" or consistent with\r\n\r\n             \"possible\" carpal tunnel syndrome.\r\n\r\n\r\n\r\n          -  2. Patients with electrographic confirmation of median",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 13, 2017",
            "FirstReceived": "October 23, 2015",
            "OverallOfficial": "James Hoffman, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02587728",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140503 - Intramural - Hoffman",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20140503",
            "StudyNumber": "20140503 - Intramural - Hoffman",
            "StudyTitle": "Collection of Peripheral Blood Samples From Patients with Carpal Tunnel Syndrome for Laboratory Screening of Amyloidosis.",
            "PIID": "4418",
            "PicNum": "C11465246",
            "PILastName": "Hoffman",
            "PIFirstName": "James",
            "CoodCNbr": "C11908603",
            "CoordLastName": "Pallapati",
            "CoordFirstName": "Rachel",
            "CoordEmail": "rpallapati@med.miami.edu",
            "EnteredByCNbr": "C04092184",
            "EnteredByLastName": "Rajakumar",
            "EnteredByFirstName": "Gopal",
            "ActiveEnrollingDate": "10/19/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/19/2015",
            "IRBApprovedFrom": "07/24/2015",
            "IRBApprovedTo": "07/10/2017",
            "DiseaseSiteListDesc": "Other Hematopoietic",
            "Expr1": "N/A",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Correlative",
            "StudyType_Code": "140",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "6",
            "Totalaccrued": "5",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Vivin Mohan,Micaela Martinez",
            "NationalSampleSize": "500",
            "NCTNbr": "NCT02587728",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02588612",
            "BriefTitle": "NY-ESO-1ᶜ²⁵⁹T for Advanced NSCLC",
            "OfficialTitle": "A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)",
            "LeadSponsorClass": "Adaptimmune",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Adaptimmune",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study is intended for men and women at least 18 years of age who have advanced lung\r\n\r\n      cancer which has grown or returned after being treated. In particular, it is a study for\r\n\r\n      subjects who have a blood test positive for HLA-A",
            "Description": "This is a single-arm study of genetically engineered NY-ESO-1ᶜ²⁵⁹T cells in HLA-A*0201,\r\n\r\n      HLA-A*0205 and/or HLA-A*0206 positive subjects with advanced (Stage IIIb or V) NSCLC.\r\n\r\n      Subjects with measurable disease will be screened for",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2015",
            "CompletionDate": "November 2017",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Adaptimmune",
            "StudyCondition": "Carcinoma, Non-Small-Cell Lung",
            "studyLocation": "City of Hope",
            "Enrollment": "10",
            "NctKeyword": "Previously Treated, Cell Therapy, T Cell Therapy, NY-ESO-1, Immuno-oncology, T Cell Receptor,",
            "MeshKeyword": "Carcinoma, Non-Small-Cell Lung,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Subject has voluntarily agreed to participate by giving written informed consent\r\n\r\n\r\n\r\n          2. Subject is ≥18 years of age\r\n\r\n\r\n\r\n          3. Histologically or cytologically confirmed diagnosis of",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Duarte",
            "State": "California",
            "Zip": "91010",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 4, 2016",
            "FirstReceived": "October 26, 2015",
            "OverallOfficial": "John Heymach, MD, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "M.D. Anderson Cancer Center",
            "ContactName": "John Heymach, MD, PhD",
            "ContactEmail": "jheymach@mdanderson.org",
            "LocationStatus": "Recruiting",
            "LocationName": "City of Hope",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02588612",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150769 - Adaptimmune - Mudad",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150769",
            "StudyNumber": "20150769 - Adaptimmune - Mudad",
            "StudyTitle": "A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)",
            "PIID": "22226",
            "PicNum": "C11878042",
            "PILastName": "Mudad",
            "PIFirstName": "Raja",
            "CoodCNbr": "C11982423",
            "CoordLastName": "Grandas Moreno",
            "CoordFirstName": "Claudia",
            "CoordEmail": "c.grandas@miami.edu",
            "CoordPhone": "305-243-7530",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "05/19/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/19/2016",
            "IRBApprovedFrom": "02/02/2016",
            "IRBApprovedTo": "02/01/2017",
            "AccountNbr": "666908",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase I/II",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,Plantation:N/A,UMD:N/A,SCCC Hollywood:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Anthony Minichiello,Mohammad El-Sorady,Penny Eyer,Vivin Mohan,Teresa Kamar,Michelle Mikhail,Nohelia Gonzalez",
            "NationalSampleSize": "2",
            "NCTNbr": "NCT02588612",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02592577",
            "BriefTitle": "MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC",
            "OfficialTitle": "A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)",
            "LeadSponsorClass": "Adaptimmune",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Adaptimmune",
            "OversightAuthority": "No",
            "BriefSummary": "This first time in human study is intended for men and women at least 18 years of age who\r\n\r\n      have advanced lung cancer which has grown or returned after being treated. In particular, it\r\n\r\n      is a study for subjects who have a blood tes",
            "Description": "This is first time in human study is a single-arm study of genetically engineered MAGE\r\n\r\n      A10ᶜ⁷⁹⁶T cells in HLA-A*0201 and/or HLA-A*0206 positive subjects with advanced (Stage IIIb\r\n\r\n      or V) NSCLC. Subjects with measurable disease wil",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2015",
            "CompletionDate": "November 2017",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Adaptimmune",
            "StudyCondition": "Non-Small Cell Lung Cancer",
            "studyLocation": "City of Hope",
            "Enrollment": "32",
            "NctKeyword": "Previously Treated, Cell Therapy, T Cell Therapy, MAGE-A10, Immuno-oncology, T Cell Receptor, Metastatic,",
            "MeshKeyword": "Lung Neoplasms, Carcinoma, Non-Small-Cell Lung,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Subject has voluntarily agreed to participate by giving written informed consent\r\n\r\n\r\n\r\n          2. Subject is ≥18 years of age\r\n\r\n\r\n\r\n          3. Histologically or cytologically confirmed diagnosis of",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Duarte",
            "State": "California",
            "Zip": "91010",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 4, 2016",
            "FirstReceived": "October 20, 2015",
            "OverallOfficial": "Ben Creelan, MD, MS",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "H. Lee Moffitt Cancer Center",
            "ContactName": "Ben Creelan, MD, MS",
            "ContactPhone": "813-745-3050",
            "LocationStatus": "Recruiting",
            "LocationName": "City of Hope",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02592577",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150768 - Adaptimmune - Mudad",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150768",
            "StudyNumber": "20150768 - Adaptimmune - Mudad",
            "StudyTitle": "A Phase I/II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10 c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)",
            "PIID": "22226",
            "PicNum": "C11878042",
            "PILastName": "Mudad",
            "PIFirstName": "Raja",
            "CoodCNbr": "C11982423",
            "CoordLastName": "Grandas Moreno",
            "CoordFirstName": "Claudia",
            "CoordEmail": "c.grandas@miami.edu",
            "CoordPhone": "305-243-7530",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "05/19/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/19/2016",
            "IRBApprovedFrom": "12/15/2015",
            "IRBApprovedTo": "12/05/2017",
            "AccountNbr": "666828",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase I/II",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SiteSampleSize": "UMD:N/A,UMMG:N/A,UMHC:N/A,Plantation:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Anthony Minichiello,Mohammad El-Sorady,Penny Eyer,Vivin Mohan,Teresa Kamar,Michelle Mikhail,Nohelia Gonzalez",
            "NationalSampleSize": "2",
            "NCTNbr": "NCT02592577",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02592798",
            "BriefTitle": "Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)",
            "OfficialTitle": "A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms With Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change)",
            "LeadSponsorClass": "Bristol-Myers Squibb",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Bristol-Myers Squibb",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is evaluate if abatacept is effective and safe in decreasing the\r\n\r\n      level of protein loss in the urine in patients with excessive loss of protein in the urine\r\n\r\n      (nephrotic syndrome) due to either focal segm",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2016",
            "CompletionDate": "April 2019",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Bristol-Myers Squibb",
            "StudyCondition": "Nephrotic Syndrome",
            "studyLocation": "The Childrens Hospital Of Alabama",
            "Enrollment": "90",
            "MeshKeyword": "Syndrome, Nephrotic Syndrome, Nephrosis, Glomerulosclerosis, Focal Segmental,",
            "InterventionKeyword": "Abatacept,",
            "Eligibility": "For more information regarding BMS clinical trial participation, please visit\r\n\r\n        www.BMSStudyConnect.com\r\n\r\n\r\n\r\n        Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male and female subjects ages ≥ 6 years\r\n\r\n\r\n\r\n          -  Subjects resist",
            "EligibleGender": "All",
            "MinAge": "6 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "January 5, 2017",
            "FirstReceived": "October 29, 2015",
            "OverallOfficial": "Bristol Myers Squibb",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Bristol-Myers Squibb",
            "ContactName": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:",
            "ContactEmail": "Clinical.Trials@bms.com",
            "LocationStatus": "Recruiting",
            "LocationName": "The Childrens Hospital Of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02592798",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160375 - Bristol-Myers Squibb - Chandar",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20160375",
            "StudyNumber": "20160375 - Bristol-Myers Squibb - Chandar",
            "StudyTitle": "A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms with Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change)",
            "PIID": "871",
            "PicNum": "C00779838",
            "PILastName": "Chandar",
            "PIFirstName": "Jayanthi",
            "CoodCNbr": "C12006449",
            "CoordLastName": "Alexander",
            "CoordFirstName": "Theresa",
            "CoordEmail": "Toa11@med.miami.edu",
            "CoordPhone": "305-243-4304",
            "EnteredByCNbr": "C00779838",
            "EnteredByLastName": "Chandar",
            "EnteredByFirstName": "Jayanthi",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "11/21/2016",
            "IRBApprovedFrom": "11/21/2016",
            "IRBApprovedTo": "11/20/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Bristol-Myers Squibb",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Deferred",
            "StudyCoordinator": "Theresa Alexander",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02592798",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02595437",
            "BriefTitle": "Triferic Pediatric Pharmacokinetic Protocol",
            "OfficialTitle": "Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Via Dialysate and IV to Pediatric Patients on Chronic Hemodialysis",
            "LeadSponsorClass": "Rockwell Medical Technologies, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Rockwell Medical Technologies, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered\r\n\r\n      intravenously in pediatric patients with chronic kidney disease on chronic hemodialysis\r\n\r\n      (CKD-5HD). It is an open-label, two-period sequent",
            "Description": "This is a Phase 1/2, open-label, 2-period, single-dose study assessing the safety and\r\n\r\n      pharmacokinetics (PK) of Triferic (ferric pyrophosphate citrate, or FPC) administered via\r\n\r\n      dialysate and IV to pediatric patients (< 18 years",
            "OverallStatus": "Completed",
            "StartDate": "November 1, 2015",
            "CompletionDate": "January 2017",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Rockwell Medical Technologies, Inc.",
            "StudyCondition": "End Stage Renal Disease",
            "studyLocation": "Children's Hospital of Alabama",
            "Enrollment": "22",
            "NctKeyword": "dialysis, pediatric, chronic kidney disease,",
            "MeshKeyword": "Kidney Failure, Chronic,",
            "InterventionKeyword": "Citric Acid, Iron, Hemodialysis Solutions,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n        A patient will be eligible for inclusion in the study only if all of the following\r\n\r\n        criteria are met:\r\n\r\n\r\n\r\n          1. Parents/legal guardians of the patient have the ability to understand the",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "17 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 18, 2017",
            "FirstReceived": "October 30, 2015",
            "OverallOfficial": "Raymond D Pratt, MD FACP",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Rockwell Medical, Inc",
            "LocationName": "Children's Hospital of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02595437",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150808 - Rockwell Medical/ Inc. - Katsoufis",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20150808",
            "StudyNumber": "20150808 - Rockwell Medical/ Inc. - Katsoufis",
            "StudyTitle": "Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered via Dialysate and IV to Pediatric Patients on Chronic Hemodialysis",
            "PIID": "3437",
            "PicNum": "C02493825",
            "PILastName": "Katsoufis",
            "PIFirstName": "Chryso",
            "CoodCNbr": "C02493825",
            "CoordLastName": "Katsoufis",
            "CoordFirstName": "Chryso",
            "CoordEmail": "ckatsoufis@med.miami.edu",
            "EnteredByCNbr": "C02493825",
            "EnteredByLastName": "Katsoufis",
            "EnteredByFirstName": "Chryso",
            "ActiveEnrollingDate": "04/21/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/21/2016",
            "IRBApprovedFrom": "12/07/2015",
            "IRBApprovedTo": "12/06/2016",
            "Expr1": "Phase I/II",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Karla Gonzalez,Theresa Alexander",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02595437",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02595944",
            "SecondaryId": "NCI-2015-01916",
            "BriefTitle": "Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer",
            "OfficialTitle": "Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers",
            "LeadSponsorClass": "National Cancer Institute (NCI)",
            "SponsorAgency": "NIH",
            "LeadSponsor": "National Cancer Institute (NCI)",
            "OversightAuthority": "Yes",
            "BriefSummary": "This randomized phase III trial studies how well nivolumab after surgery and chemotherapy\r\n\r\n      work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal\r\n\r\n      antibodies, such as nivolumab, may stimulate the immu",
            "Description": "PRIMARY OBJECTIVES:\r\n\r\n\r\n\r\n      I. To evaluate whether adjuvant therapy with nivolumab will result in improved overall\r\n\r\n      survival (OS) and/or disease-free survival (DFS) over standard observation in patients with\r\n\r\n      stage IB >= 4 c",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "National Cancer Institute (NCI)",
            "StudyCondition": "Stage IB Non-Small Cell Lung Carcinoma",
            "studyLocation": "University of Alabama at Birmingham Cancer Center",
            "Enrollment": "714",
            "MeshKeyword": "Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma,",
            "InterventionKeyword": "Nivolumab, Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must have undergone complete surgical resection of their stage IB (>= 4 cm),\r\n\r\n             II or IIIA NSCLC according to the American Joint Committee on Cancer (AJCC) 7th\r\n\r\n             editi",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "January 20, 2017",
            "FirstReceived": "November 3, 2015",
            "OverallOfficial": "Jamie Chaft",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "ECOG-ACRIN Cancer Research Group",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02595944",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160778 - ECOG - Mudad",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160778",
            "StudyNumber": "20160778 - ECOG - Mudad",
            "StudyTitle": "Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers",
            "PIID": "22226",
            "PicNum": "C11878042",
            "PILastName": "Mudad",
            "PIFirstName": "Raja",
            "CoodCNbr": "C11982423",
            "CoordLastName": "Grandas Moreno",
            "CoordFirstName": "Claudia",
            "CoordEmail": "c.grandas@miami.edu",
            "CoordPhone": "305-243-7530",
            "EnteredByCNbr": "C00673977",
            "EnteredByLastName": "McIntosh",
            "EnteredByFirstName": "Janet",
            "ActiveEnrollingDate": "01/23/2017",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/23/2017",
            "IRBApprovedFrom": "12/23/2015",
            "IRBApprovedTo": "10/05/2017",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase III",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Cooperative Group",
            "SiteSampleSize": "UMMG:N/A,UMHC:4,Plantation:N/A,UM Hollywood:N/A,UM Kendall:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "4",
            "EprostState": "External IRB",
            "StudyCoordinator": "Michelle Mikhail,Anthony Minichiello,Halyna Hailes,Frances Valdes,Cristina Rojas-Mejia,Penny Eyer",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02595944",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02596971",
            "SecondaryId": "2015-001364-19",
            "BriefTitle": "A Phase 1b Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma",
            "OfficialTitle": "A Phase IB/II Study Evaluating the Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma",
            "LeadSponsorClass": "Hoffmann-La Roche",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Hoffmann-La Roche",
            "BriefSummary": "This study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment\r\n\r\n      consisting of atezolizumab in combination with either obinutuzumab plus bendamustine\r\n\r\n      (MPDL-G-benda) in participants with follicular lymp",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2015",
            "CompletionDate": "January 2020",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Hoffmann-La Roche",
            "StudyCondition": "Diffuse Large B-Cell Lymphoma, Lymphoma, Follicular",
            "Enrollment": "92",
            "MeshKeyword": "Lymphoma, Follicular, Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse,",
            "InterventionKeyword": "Doxorubicin, Liposomal doxorubicin, Obinutuzumab, Prednisone, Cyclophosphamide, Vincristine, Bendamustine Hydrochloride, Antibodies, Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2\r\n\r\n\r\n\r\n          -  For participants enrolled in the safety run-in phase: lymphoma classified as either\r\n\r\n             relapsed",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90033",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 1, 2016",
            "FirstReceived": "November 3, 2015",
            "OverallOfficial": "Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Hoffmann-La Roche",
            "ContactName": "Reference Study ID Number: BO29563 www.roche.com/about_roche/roche_worldwide.htm",
            "ContactPhone": "888-662-6728 (U.S. and Canada)",
            "ContactEmail": "global.rochegenentechtrials@roche.com",
            "LocationStatus": "Not yet recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02596971",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150848 - F Hoffman - Lossos",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150848",
            "StudyNumber": "20150848 - F Hoffman - Lossos",
            "StudyTitle": "A Phase IB/II Study Evaluating the Safety and Efficacy of MPDL3280A in Combination with Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients with Follicular Lymphoma or Diffuse Large B-Cell Lymphoma",
            "PIID": "396",
            "PicNum": "C02540370",
            "PILastName": "Lossos",
            "PIFirstName": "Izidore",
            "CoodCNbr": "C11954409",
            "CoordLastName": "Ogden",
            "CoordFirstName": "Jillian",
            "CoordEmail": "jbo25@miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "08/18/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/18/2016",
            "IRBApprovedFrom": "04/11/2016",
            "IRBApprovedTo": "04/10/2017",
            "AccountNbr": "666677",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma",
            "Expr1": "Phase I/II",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SiteSampleSize": "UM Kendall:N/A,UMHC:N/A,Plantation:N/A,UMD:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yvonne Dinh,Randy Astaiza,Tamara Leon Aliz",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT02596971",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02597933",
            "SecondaryId": "2015-000392-28",
            "BriefTitle": "A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis",
            "OfficialTitle": "A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)",
            "LeadSponsorClass": "Boehringer Ingelheim",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Boehringer Ingelheim",
            "BriefSummary": "Systemic Sclerosis (SSc) is a devastating disease of unknown etiology. Patients suffer from\r\n\r\n      multiple organ fibrosis whereas lung fibrosis (interstitial lung disease, ILD) is one of the\r\n\r\n      main driver for mortality. There is precli",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2015",
            "CompletionDate": "December 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Boehringer Ingelheim",
            "StudyCondition": "Scleroderma, Systemic",
            "studyLocation": "Boehringer Ingelheim Investigational Site",
            "Enrollment": "520",
            "MeshKeyword": "Scleroderma, Systemic, Scleroderma, Diffuse,",
            "InterventionKeyword": "Nintedanib,",
            "Eligibility": "Inclusion criteria:\r\n\r\n\r\n\r\n          -  Age >= 18 years\r\n\r\n\r\n\r\n          -  2013 ACR / EULAR classification criteria for SSc fulfilled\r\n\r\n\r\n\r\n          -  SSc disease onset (defined by first non-Raynaud symptom) within 5 years",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 3, 2017",
            "FirstReceived": "October 8, 2015",
            "OverallOfficial": "Boehringer Ingelheim",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Boehringer Ingelheim",
            "ContactName": "Boehringer Ingelheim Call Center",
            "ContactPhone": "1-800-243-0127",
            "ContactEmail": "clintriage.rdg@boehringer-ingelheim.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Boehringer Ingelheim Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02597933",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150852 - Boehringer Ingelheim - Glassberg",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20150852",
            "StudyNumber": "20150852 - Boehringer Ingelheim - Glassberg",
            "StudyTitle": "A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD)",
            "PIID": "839",
            "PicNum": "C00393339",
            "PILastName": "Glassberg Csete",
            "PIFirstName": "Marilyn",
            "CoodCNbr": "C00047281",
            "CoordLastName": "Simonet",
            "CoordFirstName": "Emmanuelle",
            "CoordEmail": "esimonet@med.miami.edu",
            "CoordPhone": "3052433728",
            "EnteredByCNbr": "C00393339",
            "EnteredByLastName": "Glassberg Csete",
            "EnteredByFirstName": "Marilyn",
            "ActiveEnrollingDate": "08/10/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/10/2016",
            "IRBApprovedFrom": "12/01/2015",
            "IRBApprovedTo": "10/31/2017",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Boehringer Ingelheim",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "3",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Emmanuelle Simonet,Johana Arana,Eliana Mendes,Patricia Rebolledo,Esther Diaz",
            "AgentDevices": "NINTEDANIB (BIBF1120)",
            "StudyObjective": "To investigate the efficacy and safety of 150 mg bid nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease.",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02597933",
            "StudyKeywords": "ILD, Interstitial Lung Disease, Fibrosis, scleroderma, skin, dermatology, systemic sclerosis",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02600130",
            "BriefTitle": "Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer's Disease",
            "OfficialTitle": "A Phase, I Prospective, Randomized, Double-Blinded, Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Longeveron Allogeneic Human Mesenchymal Stem Cell (LMSCs) Infusion Versus Placebo in Patients With Alzheimer's Disease",
            "LeadSponsorClass": "Longeveron LLC",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Longeveron LLC",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a Phase I, prospective, randomized, placebo-controlled, double-blinded study\r\n\r\n      designed to test the safety and efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) for\r\n\r\n      the treatment of subjects with clinically diagnosed",
            "Description": "This is a randomized, placebo-controlled clinical trial designed to evaluate the safety and\r\n\r\n      efficacy of LMSCs (Longeveron Mesenchymal Stem Cells) or placebo in subjects with\r\n\r\n      Alzheimer's Disease. Following a successful Safety Ru",
            "OverallStatus": "Recruiting",
            "StartDate": "August 2016",
            "CompletionDate": "October 2019",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Longeveron LLC",
            "StudyCondition": "Alzheimer's Disease",
            "studyLocation": "University of Miami Miller School of Medicine",
            "Enrollment": "30",
            "MeshKeyword": "Alzheimer Disease,",
            "Eligibility": "Inclusion Criteria: - All subjects enrolled in this trial must:\r\n\r\n\r\n\r\n          -  provide written informed consent;\r\n\r\n\r\n\r\n          -  be 50 - 80 years of age at the time of signing the Informed Consent form;\r\n\r\n\r\n\r\n          -  have a body",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 5, 2016",
            "FirstReceived": "November 2, 2015",
            "OverallOfficial": "Bernard S. Baumel, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Principal Investigator",
            "ContactName": "Darcy L. DiFede, RN,BSN",
            "ContactPhone": "305-632-2294",
            "ContactEmail": "ddifede@longeveron.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Miller School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02600130",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150898 - Longeveron - Baumel",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20150898",
            "StudyNumber": "20150898 - Longeveron - Baumel",
            "StudyTitle": "A Phase I, Prospective, Randomized, Double-Blinded, Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients with Alzheimer’s Disease.",
            "PIID": "22263",
            "PicNum": "C00471281",
            "PILastName": "Baumel",
            "PIFirstName": "Bernard",
            "CoodCNbr": "C03834528",
            "CoordLastName": "Perez",
            "CoordFirstName": "Carmen",
            "CoordEmail": "c.perez71@med.miami.edu",
            "CoordPhone": "3052435610",
            "EnteredByCNbr": "C00471281",
            "EnteredByLastName": "Baumel",
            "EnteredByFirstName": "Bernard",
            "ActiveEnrollingDate": "06/21/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/21/2016",
            "IRBApprovedFrom": "10/07/2015",
            "IRBApprovedTo": "10/06/2016",
            "Expr1": "Phase I",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "8",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "8",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Carmen Perez,Jonathan Landman",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02600130",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02603107",
            "SecondaryId": "2015-004011-20",
            "BriefTitle": "Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults",
            "OfficialTitle": "A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will evaluate the safety and efficacy of switching to a fixed dose combination\r\n\r\n      (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing on a\r\n\r\n      regimen consisting of boosted atazanavir (ATV)",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "November 2015",
            "CompletionDate": "May 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "HIV-1 Infection",
            "Enrollment": "520",
            "InterventionKeyword": "Lamivudine, Tenofovir, Abacavir, Emtricitabine, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Darunavir, Atazanavir Sulfate,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Currently receiving a once daily antiretroviral regimen consisting of ritonavir or\r\n\r\n             cobicistat boosted ATV or DRV plus either FTC/TDF or ABC/3TC for ≥ 6 months preceding",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85012",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 23, 2016",
            "FirstReceived": "November 10, 2015",
            "OverallOfficial": "Gilead Study Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02603107",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160233 - Gilead - Campo",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20160233",
            "StudyNumber": "20160233 - Gilead - Campo",
            "StudyTitle": "A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and\nEfficacy of Switching from Regimens Consisting of Boosted Atazanavir or\nDarunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to\nGS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed\nHIV-1 Infected Adults",
            "PIID": "234",
            "PicNum": "C00043390",
            "PILastName": "Jayaweera",
            "PIFirstName": "Dushyantha T.",
            "CoodCNbr": "C00548607",
            "CoordLastName": "Salvarrey",
            "CoordFirstName": "Annie",
            "CoordEmail": "als215@miami.edu",
            "CoordPhone": "+1 (305) 243-4668",
            "EnteredByCNbr": "C00552940",
            "EnteredByLastName": "Campo",
            "EnteredByFirstName": "Rafael E.",
            "ActiveEnrollingDate": "06/01/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/01/2016",
            "IRBApprovedFrom": "04/26/2016",
            "IRBApprovedTo": "04/25/2017",
            "Expr1": "Phase II/III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Gilead",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Kenia Moreno,Sam-mosley Ayuk,Tom Tanner",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02603107",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02607735",
            "SecondaryId": "2015-003455-21",
            "BriefTitle": "Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy",
            "OfficialTitle": "A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects With Chronic HC",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will evaluate the safety and efficacy of treatment with\r\n\r\n      sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic HCV infection who\r\n\r\n      have previously received treatment with direct-acting antiviral thera",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "November 2015",
            "CompletionDate": "June 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "Hepatitis C",
            "Enrollment": "416",
            "NctKeyword": "Chronic Hepatitis C Infection,",
            "MeshKeyword": "Infection, Hepatitis, Hepatitis C,",
            "InterventionKeyword": "Antiviral Agents, Sofosbuvir,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Willing and able to provide written informed consent\r\n\r\n\r\n\r\n          -  HCV RNA ≥ 10^4 IU/mL at screening\r\n\r\n\r\n\r\n          -  Chronic HCV infection (≥ 6 months)\r\n\r\n\r\n\r\n          -  Treatment experie",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Long Beach",
            "State": "California",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 26, 2016",
            "FirstReceived": "November 16, 2015",
            "OverallOfficial": "Robert H. Hyland, DPhil",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02607735",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151036 - Gilead - Schiff",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20151036",
            "StudyNumber": "20151036 - Gilead - Schiff",
            "StudyTitle": "GS-US-367-1171-A Phase 3, Global, Multicenter, Randomized, Double-Blind,\nPlacebo-Controlled Study to Investigate the Safety and Efficacy of\nSofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C00758491",
            "EnteredByLastName": "Schiff",
            "EnteredByFirstName": "Eugene",
            "ActiveEnrollingDate": "01/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/08/2016",
            "IRBApprovedFrom": "12/28/2015",
            "IRBApprovedTo": "11/17/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Gilead",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "12",
            "Totalaccrued": "12",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "7",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "12",
            "FirstNinety": "12",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Maria Onate-Silva",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02607735",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02607956",
            "SecondaryId": "2015-003988-10",
            "BriefTitle": "Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",
            "OfficialTitle": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will evaluate the efficacy of a fixed dose combination (FDC) containing\r\n\r\n      bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + a FDC\r\n\r\n      containing emtricitabine/tenofovir alafenamide (F/TA",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "November 2015",
            "CompletionDate": "April 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "HIV-1 Infection",
            "Enrollment": "645",
            "NctKeyword": "HIV,",
            "InterventionKeyword": "Tenofovir, Emtricitabine, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Dolutegravir,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Antiretroviral treatment naive (≤ 10 days of prior therapy with any antiretroviral\r\n\r\n             agent following a diagnosis of HIV-1 infection) except the use for PrEP (pre-exposure",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85012",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 23, 2016",
            "FirstReceived": "November 10, 2015",
            "OverallOfficial": "Gilead Study Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02607956",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160200 - Gilead - Campo",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20160200",
            "StudyNumber": "20160200 - Gilead - Campo",
            "StudyTitle": "A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naïve Adults",
            "PIID": "235",
            "PicNum": "C00552940",
            "PILastName": "Campo",
            "PIFirstName": "Rafael E.",
            "CoodCNbr": "C00548607",
            "CoordLastName": "Salvarrey",
            "CoordFirstName": "Annie",
            "CoordEmail": "als215@miami.edu",
            "CoordPhone": "+1 (305) 243-4668",
            "EnteredByCNbr": "C00552940",
            "EnteredByLastName": "Campo",
            "EnteredByFirstName": "Rafael E.",
            "ActiveEnrollingDate": "05/24/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/24/2016",
            "IRBApprovedFrom": "04/05/2016",
            "IRBApprovedTo": "04/04/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Gilead",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "4",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Kenia Moreno,Sam-mosley Ayuk,Tom Tanner",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02607956",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02610777",
            "SecondaryId": "U1111-1169-6540",
            "BriefTitle": "An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)",
            "OfficialTitle": "A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast",
            "LeadSponsorClass": "Millennium Pharmaceuticals, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Millennium Pharmaceuticals, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to evaluate the efficacy and safety of pevonedistat plus\r\n\r\n      azacitidine versus single-agent azacitidine in participants with higher-risk myelodysplastic\r\n\r\n      syndromes, chronic myelomonocytic leukemia and l",
            "Description": "The drug being tested in this study is called pevonedistat. Pevonedistat is being tested to\r\n\r\n      treat people with myelodysplastic syndromes, chronic myelomonocytic leukemia and low-blast\r\n\r\n      acute myelogenous leukemia as a combination",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2016",
            "CompletionDate": "March 2019",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Takeda",
            "StudyCondition": "Myelodysplastic Syndromes",
            "Enrollment": "117",
            "NctKeyword": "Drug Therapy,",
            "MeshKeyword": "Leukemia, Syndrome, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myelomonocytic, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute,",
            "InterventionKeyword": "Azacitidine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Male or female participants 18 years or older.\r\n\r\n\r\n\r\n          2. Morphologically confirmed diagnosis of MDS or nonproliferative CMML (that is, with\r\n\r\n             white blood cells [WBC] <20,000 per m",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 12, 2017",
            "FirstReceived": "November 18, 2015",
            "OverallOfficial": "Medical Director Clinical Science",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Millennium Pharmaceuticals, Inc.",
            "ContactName": "Takeda Study Registration Call Center",
            "ContactPhone": "+1-877-674-3784",
            "ContactEmail": "GlobalOncologyMedinfo@takeda.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02610777",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151147 - Millennium Pharma - Swords",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151147",
            "StudyNumber": "20151147 - Millennium Pharma - Swords",
            "StudyTitle": "Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia",
            "PIID": "4223",
            "PicNum": "C11249826",
            "PILastName": "Swords",
            "PIFirstName": "Ronan",
            "CoodCNbr": "C10180073",
            "CoordLastName": "Gonzalez",
            "CoordFirstName": "Nohelia",
            "CoordEmail": "ngonzalez5@med.miami.edu",
            "CoordPhone": "3052434903",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "07/11/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/11/2016",
            "IRBApprovedFrom": "06/01/2016",
            "IRBApprovedTo": "11/30/2016",
            "AccountNbr": "667222",
            "DiseaseSiteListDesc": "Myeloid and Monocytic Leukemia",
            "Expr1": "Phase II",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "9",
            "Totalaccrued": "8",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "6",
            "Totalpatients": "9",
            "FirstNinety": "5",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Rachel Pallapati,Micaela Martinez,Sandra O'Mellan",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT02610777",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02614547",
            "BriefTitle": "A Study to Evaluate SAGE-547 in Patients With Severe Postpartum Depression",
            "OfficialTitle": "A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating The Efficacy, Safety, And Pharmacokinetics Of SAGE-547 Injection In The Treatment Of Adult Female Subjects With Severe Postpartum Depression",
            "LeadSponsorClass": "Sage Therapeutics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Sage Therapeutics",
            "OversightAuthority": "No",
            "BriefSummary": "This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of\r\n\r\n      the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female subjects\r\n\r\n      diagnosed with severe postpartum depression",
            "OverallStatus": "Completed",
            "StartDate": "November 2015",
            "CompletionDate": "July 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Sage Therapeutics",
            "StudyCondition": "Severe Postpartum Depression",
            "studyLocation": "University of Arkansas",
            "Enrollment": "21",
            "MeshKeyword": "Depression, Depressive Disorder, Depression, Postpartum,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject either must have ceased lactating at Screening; or if still lactating at\r\n\r\n             Screening, must have already fully and permanently weaned their infant(s) from\r\n\r\n             breastm",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "45 Years",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Zip": "72205",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 20, 2016",
            "FirstReceived": "November 2, 2015",
            "OverallOfficial": "Stephen J Kanes, MD, PhD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Sage Therapeutics",
            "LocationName": "University of Arkansas",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02614547",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151010 - SAGE Therapeutics - Newport",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20151010",
            "StudyNumber": "20151010 - SAGE Therapeutics - Newport",
            "StudyTitle": "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLELGROUP,\nPLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SAGE-547 INJECTION IN THE TREATMENT OF ADULT FEMALE SUBJECTS WITH SEVERE POSTPARTUM DEPRESSION",
            "PIID": "23152",
            "PicNum": "C11918102",
            "PILastName": "Newport",
            "PIFirstName": "Donald",
            "CoodCNbr": "C02793694",
            "CoordLastName": "Vargas",
            "CoordFirstName": "Gabriela",
            "CoordEmail": "gvargas3@med.miami.edu",
            "CoordPhone": "3052434782",
            "EnteredByCNbr": "C11918102",
            "EnteredByLastName": "Newport",
            "EnteredByFirstName": "Donald",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "05/17/2016",
            "IRBApprovedFrom": "05/17/2016",
            "IRBApprovedTo": "05/16/2017",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "SAGE Therapeutics",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Post-Review",
            "StudyCoordinator": "Gabriela Vargas",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02614547",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02614794",
            "BriefTitle": "Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",
            "OfficialTitle": "Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)",
            "LeadSponsorClass": "Cascadian Therapeutics Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Cascadian Therapeutics Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to assess the effect of tucatinib vs. placebo in combination\r\n\r\n      with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on\r\n\r\n      independent central review.",
            "Description": "This is a Phase 2 randomized, international, multi-center, double-blinded study of tucatinib\r\n\r\n      or placebo in combination with capecitabine and trastuzumab in patients with pretreated\r\n\r\n      unresectable locally advanced or metastatic HE",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2015",
            "CompletionDate": "January 2021",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Cascadian Therapeutics Inc.",
            "StudyCondition": "HER2 Positive Breast Cancer",
            "studyLocation": "University of Alabama",
            "Enrollment": "480",
            "NctKeyword": "Tucatinib, Capecitabine, Trastuzumab, Xeloda, Herceptin, Breast Cancer, ARRY-380, ONT-380,",
            "MeshKeyword": "Breast Neoplasms,",
            "InterventionKeyword": "Trastuzumab, Capecitabine,",
            "Eligibility": "Inclusion Criteria\r\n\r\n\r\n\r\n        Patients must meet the following criteria to be eligible for the study:\r\n\r\n\r\n\r\n          1. Have histologically confirmed HER2+ breast carcinoma, with HER2+ defined by\r\n\r\n             fluorescence in situ hybr",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 23, 2016",
            "FirstReceived": "November 20, 2015",
            "OverallOfficial": "Luke Walker, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Cascadian Therapeutics Inc.",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02614794",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160056 - Oncothyreon Inc - Mani",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160056",
            "StudyNumber": "20160056 - Oncothyreon Inc - Mani",
            "StudyTitle": "Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma",
            "PIID": "25266",
            "PicNum": "C11971128",
            "PILastName": "Mani",
            "PIFirstName": "Aruna",
            "CoodCNbr": "C12024030",
            "CoordLastName": "Conte",
            "CoordFirstName": "Deborah",
            "CoordEmail": "dmc238@med.miami.edu",
            "CoordPhone": "954-830-2360",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "08/16/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/16/2016",
            "IRBApprovedFrom": "07/01/2016",
            "IRBApprovedTo": "01/01/2017",
            "AccountNbr": "667255",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase II",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Oncothyreon Inc",
            "Prescreened": "2",
            "Screenedfailed": "3",
            "SignedICF": "4",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "4",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMD:N/A,Plantation:N/A,UM Kendall:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Anthony Minichiello,Halyna Hailes,Mohammad El-Sorady,Cristina Rojas-Mejia,Sarah Raybin,Evan Dadas,Penny Eyer,Onaidy Torres,Michelle Liendo",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT02614794",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02615002",
            "BriefTitle": "Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)",
            "OfficialTitle": "Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease",
            "LeadSponsorClass": "Neurim Pharmaceuticals Ltd.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Neurim Pharmaceuticals Ltd.",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine\r\n\r\n      (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on\r\n\r\n      efficacy (cognitive performance), safety a",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2015",
            "CompletionDate": "March 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Neurim Pharmaceuticals Ltd.",
            "StudyCondition": "Alzheimer's Disease",
            "studyLocation": "Xenoscience, Inc",
            "Enrollment": "500",
            "NctKeyword": "Cognition, mild Alzheimer's disease, Sleep,",
            "MeshKeyword": "Alzheimer Disease,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patient and caregiver are willing to take part in the entire study\r\n\r\n\r\n\r\n          -  Signed informed consent from the patient and the caregiver\r\n\r\n\r\n\r\n          -  Patient has a clearly documented hist",
            "EligibleGender": "All",
            "MinAge": "60 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85004",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 21, 2016",
            "FirstReceived": "November 18, 2015",
            "OverallOfficial": "Lon Schneider, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Keck School of Medicine of USC, Los Angeles, CA",
            "ContactName": "Neurim Pharmaceuticals, Ltd.",
            "ContactPhone": "972-3-7684965",
            "ContactEmail": "recognition@neurim.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Xenoscience, Inc",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02615002",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150961 - Neurim Pharmaceuticals AG - Crocco",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20150961",
            "StudyNumber": "20150961 - Neurim Pharmaceuticals AG - Crocco",
            "StudyTitle": "NEUP11-AD2: RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP,\r\nPLACEBO-CONTROLLED, DOSE-RANGING STUDY OF\r\nPIROMELATINE IN PATIENTS WITH MILD DEMENTIA DUE TO\r\nALZHEIMER’S DISEASE",
            "PIID": "3693",
            "PicNum": "C00802143",
            "PILastName": "Crocco",
            "PIFirstName": "Elizabeth",
            "CoodCNbr": "C06046616",
            "CoordLastName": "Robertson",
            "CoordFirstName": "Belinda",
            "CoordEmail": "BRobertson@med.miami.edu",
            "EnteredByCNbr": "C00802143",
            "EnteredByLastName": "Crocco",
            "EnteredByFirstName": "Elizabeth",
            "ActiveEnrollingDate": "11/04/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/04/2016",
            "IRBApprovedFrom": "07/05/2016",
            "IRBApprovedTo": "07/04/2017",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Neurim Pharmaceuticals AG",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nicole Brenson,Belinda Robertson",
            "AgentDevices": "Piromelatine",
            "StudyObjective": "To compare the effect of piromelatine (5, 20, and 50 mg) to that of placebo on cognitive function primarily assessed by the change from baseline in global composite score of the computerized Neuropsychological Test.",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02615002",
            "StudyKeywords": "MCI, mild cognitive impairment, Alzheimer’s Disease, piromelatine, Mild Dementia, Neurim",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02617589",
            "SecondaryId": "2015-003739-37",
            "BriefTitle": "Study of Nivolumab Compared to Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",
            "OfficialTitle": "A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint",
            "LeadSponsorClass": "Bristol-Myers Squibb",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Bristol-Myers Squibb",
            "OversightAuthority": "Yes",
            "BriefSummary": "The main purpose of this study is to compare how long patients with glioblastoma (GBM, a\r\n\r\n      malignant brain cancer) live after receiving nivolumab every two weeks in addition to\r\n\r\n      radiation therapy (RT), and then every four weeks, c",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "CompletionDate": "October 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Bristol-Myers Squibb",
            "StudyCondition": "Brain Cancer",
            "studyLocation": "University Of Alabama At Birmingham",
            "Enrollment": "550",
            "MeshKeyword": "Glioblastoma, Brain Neoplasms,",
            "InterventionKeyword": "Temozolomide, Dacarbazine, Nivolumab, Antibodies, Monoclonal,",
            "Eligibility": "For more information regarding BMS clinical trial participation, please visit\r\n\r\n        www.BMSStudyConnect.com\r\n\r\n\r\n\r\n        Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Males and Females, age ≥ 18 years old\r\n\r\n\r\n\r\n          -  Newly-diagnosed b",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 17, 2017",
            "FirstReceived": "November 26, 2015",
            "OverallOfficial": "Bristol-Myers Squibb",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Bristol-Myers Squibb",
            "ContactName": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:",
            "ContactEmail": "Clinical.Trials@bms.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University Of Alabama At Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02617589",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160108 - Bristol Myers Squibb - De La Fuente",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160108",
            "StudyNumber": "20160108 - Bristol Myers Squibb - De La Fuente",
            "StudyTitle": "A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma",
            "PIID": "22734",
            "PicNum": "C11916526",
            "PILastName": "De La Fuente",
            "PIFirstName": "Macarena",
            "CoodCNbr": "C04228283",
            "CoordLastName": "Garcia",
            "CoordFirstName": "Helen",
            "CoordEmail": "heg32@med.miami.edu",
            "EnteredByCNbr": "C07181703",
            "EnteredByLastName": "Zhang",
            "EnteredByFirstName": "Lei",
            "ActiveEnrollingDate": "09/22/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/22/2016",
            "IRBApprovedFrom": "05/04/2016",
            "IRBApprovedTo": "02/17/2017",
            "AccountNbr": "667047",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "Phase III",
            "Tarea": "Neurological Cancer",
            "TareaCode": "12442",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Bristol-Myers Squibb",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "5",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Nathalie Luis,Doris Caldwell",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02617589",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02618187",
            "BriefTitle": "A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Ulcerative Colitis",
            "OfficialTitle": "A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis",
            "LeadSponsorClass": "Seres Therapeutics, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Seres Therapeutics, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "A Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of\r\n\r\n      SER-287 in Subjects with Mild-to-Moderate Ulcerative Colitis.",
            "Description": "This is a Phase 1b multicenter, randomized, double-blind, placebo-controlled multiple dose\r\n\r\n      study designed to evaluate the safety and tolerability of SER-287, and to evaluate the\r\n\r\n      microbiome alterations and pharmacodynamics assoc",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2015",
            "CompletionDate": "June 2017",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Seres Therapeutics, Inc.",
            "StudyCondition": "Ulcerative Colitis",
            "studyLocation": "Inland Empire Liver Foundation",
            "Enrollment": "55",
            "MeshKeyword": "Ulcer, Colitis, Ulcerative, Colitis,",
            "InterventionKeyword": "Vancomycin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Ulcerative colitis diagnosed by routine clinical, radiographic, endoscopic and\r\n\r\n             pathologic criteria (preferably confirmed by colonoscopy and pathology records within\r\n\r\n             last 2",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Rialto",
            "State": "California",
            "Zip": "92377",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 2, 2016",
            "FirstReceived": "November 20, 2015",
            "ContactName": "Michele Trucksis, PhD, MD",
            "ContactEmail": "clinicalstudies@serestherapeutics.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Inland Empire Liver Foundation",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02618187",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151157 - Seres Therapeutics/ Inc. - Kerman",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20151157",
            "StudyNumber": "20151157 - Seres Therapeutics/ Inc. - Kerman",
            "StudyTitle": "A Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects with Mild-to- Moderate Ulcerative Colitis",
            "PIID": "652",
            "PicNum": "C04244223",
            "PILastName": "Kerman",
            "PIFirstName": "David",
            "CoodCNbr": "C09950089",
            "CoordLastName": "Morillo",
            "CoordFirstName": "Diana",
            "CoordEmail": "dmorillo@med.miami.edu",
            "CoordPhone": "3052436405",
            "EnteredByCNbr": "C04244223",
            "EnteredByLastName": "Kerman",
            "EnteredByFirstName": "David",
            "ActiveEnrollingDate": "10/20/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/20/2016",
            "IRBApprovedFrom": "11/04/2015",
            "IRBApprovedTo": "11/03/2017",
            "Expr1": "Phase I",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Seres Therapeutics/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Diana Morillo,Marianela Carvajal,Francia Carabali",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02618187",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02625246",
            "BriefTitle": "Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non‐Cystic Fibrosis Bronchiectasis",
            "OfficialTitle": "A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell (hMSC) Infusion in Patients With Non-Cystic Fibrosis Bronchiectasis",
            "LeadSponsorClass": "Marilyn Glassberg",
            "SponsorAgency": "Other",
            "LeadSponsor": "Marilyn Glassberg",
            "OversightAuthority": "Yes",
            "BriefSummary": "To demonstrate the safety of bone marrow-derived allogeneic human Mesenchymal Stem Cells\r\n\r\n      (hMSCs) in patients with bronchiectasis receiving standard of care therapy, and to explore\r\n\r\n      treatment efficacy",
            "Description": "A Phase 1 investigation will be performed to test the safety of two doses of bone-marrow\r\n\r\n      derived hMSCs (20,000,000 and 100,000,000) administered via peripheral intravenous infusion.\r\n\r\n\r\n\r\n      Group 1: 3 subjects will receive a single",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2015",
            "CompletionDate": "December 2020",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Bronchiectasis",
            "studyLocation": "University of Miami Hospital",
            "Enrollment": "6",
            "NctKeyword": "bronchiectasis, mesenchymal stem cell, lung, pulmonary, interstitial lung disease,",
            "MeshKeyword": "Bronchiectasis,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Provide written informed consent,\r\n\r\n\r\n\r\n          -  be between 30 and 87 years old at the time of signing the Informed Consent,\r\n\r\n\r\n\r\n          -  weight over 45 and under 150 kg,\r\n\r\n\r\n\r\n          -",
            "EligibleGender": "All",
            "MinAge": "30 Years",
            "MaxAge": "87 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 15, 2016",
            "FirstReceived": "December 4, 2015",
            "OverallOfficial": "Glassberg K Marilyn, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Emmanuelle Simonet, MA",
            "ContactPhone": "305-243-3728",
            "ContactEmail": "esimonet@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02625246",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150627 - Marcus Foundation - Glassberg",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20150627",
            "StudyNumber": "20150627 - Marcus Foundation - Glassberg",
            "StudyTitle": "A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients with Non-Cystic Fibrosis Bronchiectasis",
            "PIID": "839",
            "PicNum": "C00393339",
            "PILastName": "Glassberg Csete",
            "PIFirstName": "Marilyn",
            "CoodCNbr": "C00047281",
            "CoordLastName": "Simonet",
            "CoordFirstName": "Emmanuelle",
            "CoordEmail": "esimonet@med.miami.edu",
            "CoordPhone": "3052433728",
            "EnteredByCNbr": "C00393339",
            "EnteredByLastName": "Glassberg Csete",
            "EnteredByFirstName": "Marilyn",
            "ActiveEnrollingDate": "02/01/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/01/2016",
            "IRBApprovedFrom": "10/06/2015",
            "IRBApprovedTo": "10/03/2017",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase I",
            "Tarea": "Other",
            "TareaCode": "9437",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "6",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "6",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Emmanuelle Simonet,Johana Arana,Patricia Rebolledo,Eliana Mendes,Esther Diaz,Elisa Basora,Gustavo Rubio",
            "AgentDevices": "human Mesenchymal Stem Cells",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02625246",
            "StudyKeywords": "lung, non-CF bronchiectasis, pulmonary fibrosis, stem cell, mesenchymal",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02628600",
            "SecondaryId": "2015-003170-33",
            "BriefTitle": "Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212",
            "LeadSponsorClass": "Insmed Incorporated",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Insmed Incorporated",
            "BriefSummary": "This open-label safety extension study will assess the safety and tolerability of once daily\r\n\r\n      dosing of 590 mg Liposomal Amikacin for Inhalation (LAI) added to a multi-drug regimen in\r\n\r\n      subjects with non-tuberculous mycobacterium",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "December 2015",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Insmed Incorporated",
            "StudyCondition": "NTM Lung Infection Due to MAC",
            "Enrollment": "200",
            "InterventionKeyword": "Amikacin,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          1. have successfully completed the Month 6 and End of Treatment visits in Study INS-212\r\n\r\n\r\n\r\n          2. have not achieved the INS-212 protocol definition of culture conversion by Month 6 in",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "San Diego",
            "State": "California",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 27, 2016",
            "FirstReceived": "December 8, 2015",
            "OverallOfficial": "Gina Eagle, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Insmed Incorporated",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02628600",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151078 - Insmed - Schmid",
            "FileProcessContentId": "440",
            "Division": "Pulmonary  and Critical Care",
            "StdyDivision": "10257",
            "EprostNbr": "20151078",
            "StudyNumber": "20151078 - Insmed - Schmid",
            "StudyTitle": "An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment",
            "PIID": "1956",
            "PicNum": "C06974957",
            "PILastName": "Schmid",
            "PIFirstName": "Andreas",
            "CoodCNbr": "C09943370",
            "CoordLastName": "Aguiar",
            "CoordFirstName": "Carolina",
            "CoordEmail": "caguiar2@med.miami.edu",
            "CoordPhone": "3052435545",
            "EnteredByCNbr": "C06974957",
            "EnteredByLastName": "Schmid",
            "EnteredByFirstName": "Andreas",
            "ActiveEnrollingDate": "06/13/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/13/2016",
            "IRBApprovedFrom": "04/11/2016",
            "IRBApprovedTo": "04/10/2017",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Insmed",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Patricia Rebolledo,Lilian Cadet,Carolina Aguiar,Patricia Graham-Borras,Johana Arana",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02628600",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02631577",
            "SecondaryId": "2015-002467-42",
            "BriefTitle": "A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma",
            "OfficialTitle": "A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH OBINUTUZUMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA",
            "LeadSponsorClass": "Hoffmann-La Roche",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Hoffmann-La Roche",
            "BriefSummary": "This study will evaluate the safety, efficacy, pharmacokinetics and immunogenicity of\r\n\r\n      induction treatment consisting of atezolizumab in combination with obinutuzumab plus\r\n\r\n      lenalidomide in patients with relapsed or refractory fol",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2015",
            "CompletionDate": "January 2020",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Hoffmann-La Roche",
            "StudyCondition": "Lymphoma, Follicular",
            "Enrollment": "46",
            "MeshKeyword": "Lymphoma, Follicular, Lymphoma,",
            "InterventionKeyword": "Lenalidomide, Thalidomide, Antibodies, Monoclonal, Obinutuzumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2\r\n\r\n\r\n\r\n          -  Relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy\r\n\r\n             regimen",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294-0017",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 1, 2016",
            "FirstReceived": "December 14, 2015",
            "OverallOfficial": "Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Hoffmann-La Roche",
            "ContactName": "Reference Study ID Number: BO29562 www.roche.com/about_roche/roche_worldwide.htm",
            "ContactPhone": "888-662-6728 (U.S. and Canada)",
            "ContactEmail": "global.rochegenentechtrials@roche.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02631577",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151006 - F Hoffmann - Lossos",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151006",
            "StudyNumber": "20151006 - F Hoffmann - Lossos",
            "StudyTitle": "A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH OBINUTUZUMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR\nLYMPHOMA",
            "PIID": "396",
            "PicNum": "C02540370",
            "PILastName": "Lossos",
            "PIFirstName": "Izidore",
            "CoodCNbr": "C11954409",
            "CoordLastName": "Ogden",
            "CoordFirstName": "Jillian",
            "CoordEmail": "jbo25@miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "02/02/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/02/2016",
            "IRBApprovedFrom": "12/15/2015",
            "IRBApprovedTo": "12/05/2017",
            "AccountNbr": "666470",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma",
            "Expr1": "Phase I",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "F. Hoffman-La Roche",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Tamara Leon Aliz,Randy Astaiza,Juan Salvador,Yvonne Dinh",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT02631577",
            "StudyKeywords": "Leukemia, Lymphoma, and Myeloma",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02633111",
            "BriefTitle": "DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas",
            "OfficialTitle": "DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas",
            "LeadSponsorClass": "Memorial Sloan Kettering Cancer Center",
            "SponsorAgency": "Other",
            "LeadSponsor": "Memorial Sloan Kettering Cancer Center",
            "BriefSummary": "The purpose of this study is to determine whether a blood test can accurately detect whether\r\n\r\n      if the participant's lymphoma has come back after completion of initial chemotherapy\r\n\r\n      treatment for their aggressive B-cell Non-Hodgkin",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Memorial Sloan Kettering Cancer Center",
            "StudyCondition": "B-cell Non-Hodgkin Lymphoma",
            "studyLocation": "University of Miami",
            "Enrollment": "500",
            "NctKeyword": "DNA Sequencing, 15-180,",
            "MeshKeyword": "Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Aggression, Neoplasm, Residual,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  18 years of age at time of signing informed consent\r\n\r\n\r\n\r\n          -  Histology-confirmed aggressive B-cell Non-Hodgkin lymphoma\r\n\r\n\r\n\r\n               -  De novo diffuse large B-cell lymphoma (includin",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "55902",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 10, 2017",
            "FirstReceived": "December 15, 2015",
            "OverallOfficial": "Anita Kumar, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Memorial Sloan Kettering Cancer Center",
            "ContactName": "Anita Kumar, MD",
            "ContactPhone": "212-639-2668",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02633111",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160422 - Intramural - Lossos",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160422",
            "StudyNumber": "20160422 - Intramural - Lossos",
            "StudyTitle": "DNA SEQUENCING-BASED MONITORING OF MINIMAL RESIDUAL DISEASE TO\r\nPREDICT CLINICAL RELAPSE IN AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMAS",
            "PIID": "396",
            "PicNum": "C02540370",
            "PILastName": "Lossos",
            "PIFirstName": "Izidore",
            "CoodCNbr": "C11923689",
            "CoordLastName": "Mohan",
            "CoordFirstName": "Vivin",
            "CoordEmail": "vxm153@miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "12/29/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/29/2016",
            "IRBApprovedFrom": "07/29/2016",
            "IRBApprovedTo": "07/28/2017",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma",
            "Expr1": "N/A",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Epidemiological",
            "StudyType_Code": "6146",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Luis,Micaela Martinez",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT02633111",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02633956",
            "BriefTitle": "Combination OCA and Statins for Monitoring of Lipids (CONTROL)",
            "OfficialTitle": "A Phase 2, Randomized, Double Blind, Placebo Controlled Clinical Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Subjects With Nonalcoholic Steatohepatitis",
            "LeadSponsorClass": "Intercept Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Intercept Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "This Phase 2, double-blind, randomized, placebo-controlled, multicenter study, with an\r\n\r\n      open-label LTSE, will evaluate the effect of Obeticholic Acid, and the subsequent addition\r\n\r\n      of statin therapy, on lipoprotein metabolism in s",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "December 2015",
            "CompletionDate": "August 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Intercept Pharmaceuticals",
            "StudyCondition": "Nonalcoholic Steatohepatitis",
            "studyLocation": "St. Joseph's Hospital and Medical Center",
            "Enrollment": "80",
            "NctKeyword": "Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver Disease, NASH,",
            "MeshKeyword": "Fatty Liver, Non-alcoholic Fatty Liver Disease,",
            "InterventionKeyword": "Atorvastatin Calcium, Chenodeoxycholic Acid,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age ≥18 years\r\n\r\n\r\n\r\n          2. Histologic evidence of NASH, as assessed by central reading of a liver biopsy\r\n\r\n             obtained no more than 1 year prior to randomization, defined by the presenc",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85013",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 9, 2017",
            "FirstReceived": "November 18, 2015",
            "OverallOfficial": "Cathi Sciacca",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Vice President Clinical Operations Intercept Pharmaceuticals Inc",
            "LocationName": "St. Joseph's Hospital and Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02633956",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150916 - Intercept Pharmaceuticals - Schiff",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20150916",
            "StudyNumber": "20150916 - Intercept Pharmaceuticals - Schiff",
            "StudyTitle": "Intercept-747-209-A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Subjects with Nonalcoholic Steatohepatitis",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C00758491",
            "EnteredByLastName": "Schiff",
            "EnteredByFirstName": "Eugene",
            "ActiveEnrollingDate": "03/23/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/23/2016",
            "IRBApprovedFrom": "11/23/2015",
            "IRBApprovedTo": "11/13/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Intercept Pharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "4",
            "SignedICF": "11",
            "Totalaccrued": "7",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "7",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "11",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Andrea Elibero",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02633956",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02633969",
            "BriefTitle": "Study of Indomethacin Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age",
            "OfficialTitle": "A Phase IIA, Open-label, Safety and Pharmacokinetic Study of Indomethacin Capsules in Pediatric Subjects 6 to <17 Years of Age With Mild to Moderate Acute Postoperative Pain Following Elective Surgery",
            "LeadSponsorClass": "Iroko Pharmaceuticals, LLC",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Iroko Pharmaceuticals, LLC",
            "OversightAuthority": "No",
            "BriefSummary": "The purposes of this study are to evaluate the safety and tolerability and to model the\r\n\r\n      single-dose pharmacokinetic profile of indomethacin capsules low dose and high dose in\r\n\r\n      children ages 6 to <17 years experiencing mild to mo",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2015",
            "CompletionDate": "February 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Iroko Pharmaceuticals, LLC",
            "StudyCondition": "Pain, Postoperative",
            "Enrollment": "30",
            "MeshKeyword": "Pain, Postoperative,",
            "InterventionKeyword": "Indomethacin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Body weight ≥20 kilograms\r\n\r\n\r\n\r\n          -  Mild to moderate acute pain requiring treatment with analgesic medication\r\n\r\n\r\n\r\n          -  Willing to have blood samples taken for PK sampling using an in",
            "EligibleGender": "All",
            "MinAge": "6 Years",
            "MaxAge": "16 Years",
            "Volunteers": "No",
            "City": "Sheffield",
            "State": "Alabama",
            "Zip": "35660",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 18, 2016",
            "FirstReceived": "December 15, 2015",
            "ContactName": "Claire Sheridan",
            "ContactPhone": "267-546-3061",
            "ContactEmail": "csheridan@iroko.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02633969",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151099 - Iroko Pharmaceuticals/ LLC  - Gebhard",
            "FileProcessContentId": "440",
            "Division": "Anesthesiology",
            "StdyDivision": "10236",
            "EprostNbr": "20151099",
            "StudyNumber": "20151099 - Iroko Pharmaceuticals/ LLC  - Gebhard",
            "StudyTitle": "A Phase IIA, Open-label, Safety and Pharmacokinetic Study of Tivorbex® Capsules in Pediatric Subjects 6 to <17 Years of Age with Mild to Moderate Acute Postoperative Pain Following Elective Surgery",
            "PIID": "706",
            "PicNum": "C04976318",
            "PILastName": "Gebhard",
            "PIFirstName": "Ralf",
            "CoodCNbr": "C10565278",
            "CoordLastName": "Gutierrez",
            "CoordFirstName": "Juan",
            "CoordEmail": "JGutierrez4@med.miami.edu",
            "EnteredByCNbr": "C04976318",
            "EnteredByLastName": "Gebhard",
            "EnteredByFirstName": "Ralf",
            "ActiveEnrollingDate": "08/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/08/2016",
            "IRBApprovedFrom": "05/09/2016",
            "IRBApprovedTo": "05/08/2017",
            "Expr1": "Phase II",
            "Tarea": "Acute Perioperative Pain Management",
            "TareaCode": "16650",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Iroko Pharmaceuticals/ LLC",
            "Prescreened": "1",
            "Screenedfailed": "4",
            "SignedICF": "8",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "8",
            "FirstNinety": "2",
            "SiteSampleSize": "ABLEH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Juan Gutierrez,Lilibet Fernandez Valdes",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02633969",
            "StudyKeywords": "Pediatric pain, post op pain, surgical pain, NSAID, mild to moderate pain",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02634333",
            "SecondaryId": "EY14231",
            "BriefTitle": "Anti-VEGF Treatment for Prevention of PDR/DME",
            "OfficialTitle": "Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk",
            "LeadSponsorClass": "Jaeb Center for Health Research",
            "SponsorAgency": "Other",
            "LeadSponsor": "Jaeb Center for Health Research",
            "OversightAuthority": "Yes",
            "BriefSummary": "Multiple studies have implicated vascular endothelial growth factor VEGF as a major\r\n\r\n      causative factor in human eye diseases characterized by neovascularization including\r\n\r\n      proliferative diabetic retinopathy (PDR) and vascular perm",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2016",
            "CompletionDate": "January 2022",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Jaeb Center for Health Research",
            "StudyCondition": "Diabetic Retinopathy",
            "studyLocation": "Arizona Retina and Vitreous Consultants",
            "Enrollment": "322",
            "NctKeyword": "anti-vascular endothelial growth factor, nonproliferative diabetic retinopathy,",
            "MeshKeyword": "Macular Edema, Diabetic Retinopathy, Retinal Diseases,",
            "InterventionKeyword": "Mitogens, Endothelial Growth Factors,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Age >= 18 years\r\n\r\n\r\n\r\n          2. Diagnosis of diabetes mellitus (type 1 or type 2)\r\n\r\n\r\n\r\n             • Any one of the following will be considered to be sufficient evidence that diabetes",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85021",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "December 11, 2015",
            "OverallOfficial": "Jennifer K. Sun, MD, MPH",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Joslin Diabetes Center",
            "LocationStatus": "Recruiting",
            "LocationName": "Arizona Retina and Vitreous Consultants",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02634333",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151072 - National Eye Institute - Townsend",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20151072",
            "StudyNumber": "20151072 - National Eye Institute - Townsend",
            "StudyTitle": "Intravitreous Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk (Protocol W)",
            "PIID": "2251",
            "PicNum": "C09879746",
            "PILastName": "Townsend",
            "PIFirstName": "Justin",
            "CoodCNbr": "C00479172",
            "CoordLastName": "Rodriguez",
            "CoordFirstName": "Belen",
            "CoordEmail": "brodrig1@med.miami.edu",
            "CoordPhone": "3053266349",
            "EnteredByCNbr": "C09879746",
            "EnteredByLastName": "Townsend",
            "EnteredByFirstName": "Justin",
            "ActiveEnrollingDate": "10/20/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/20/2016",
            "IRBApprovedFrom": "05/23/2016",
            "IRBApprovedTo": "05/22/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Other",
            "Sponsor": "National Eye Institute",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,ABLEH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Belen Rodriguez,Monica Arango,Cristina Lage-Rodriguez",
            "NationalSampleSize": "8",
            "NCTNbr": "NCT02634333",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02635893",
            "BriefTitle": "Lower Limb Function After Spinal Cord Injury",
            "OfficialTitle": "Corticospinal Excitability of Leg Muscles After Spinal Cord Injury",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "This is a randomized, experimental study that examines the physiology of central nervous\r\n\r\n      system pathways contributing to the control of bilateral movements in individuals with\r\n\r\n      spinal cord injuries and promotes the recovery of l",
            "Description": "This study plans to examine plasticity in corticospinal synapses of lower-limb muscles. it\r\n\r\n      has been demonstrated that plasticity elicited at corticospinal synapses in the spinal cord\r\n\r\n      result in enhancements in electromyographic",
            "OverallStatus": "Recruiting",
            "StartDate": "October 2015",
            "CompletionDate": "October 2020",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "University of Miami",
            "StudyCondition": "Spinal Cord Injury",
            "studyLocation": "The Miami Project to Cure Paralysis",
            "Enrollment": "257",
            "NctKeyword": "SCI,",
            "MeshKeyword": "Wounds and Injuries, Spinal Cord Injuries,",
            "InterventionKeyword": "Cycloserine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  4. Inclusion criteria for individuals with SCI:\r\n\r\n\r\n\r\n               -  Male and females between ages 18-85 years of age\r\n\r\n\r\n\r\n               -  SCI ( ≥1 month of injury)\r\n\r\n\r\n\r\n               -  ASIA",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "85 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Miami,",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 1, 2016",
            "FirstReceived": "December 11, 2015",
            "OverallOfficial": "Monica A Perez, PT, Phd",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Monica Perez, PT PhD",
            "ContactPhone": "305-243-7119",
            "ContactEmail": "perezmo@miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "The Miami Project to Cure Paralysis",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02635893",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150605 - Craig H. Neilsen Foundation - Perez",
            "FileProcessContentId": "440",
            "Division": "Neurosurgery",
            "StdyDivision": "9636",
            "EprostNbr": "20150605",
            "StudyNumber": "20150605 - Craig H. Neilsen Foundation - Perez",
            "StudyTitle": "Corticospinal excitability of leg muscles after Spinal Cord Injury",
            "PIID": "23805",
            "PicNum": "C00544663",
            "PILastName": "Perez",
            "PIFirstName": "Monica",
            "CoodCNbr": "C03082005",
            "CoordLastName": "Lehmann",
            "CoordFirstName": "Sarah",
            "CoordEmail": "SXL938@miami.edu",
            "EnteredByCNbr": "C00544663",
            "EnteredByLastName": "Perez",
            "EnteredByFirstName": "Monica",
            "ActiveEnrollingDate": "10/22/2015",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/22/2015",
            "IRBApprovedFrom": "09/15/2015",
            "IRBApprovedTo": "01/16/2018",
            "Expr1": "Approved Drug/Off-Label use",
            "ResearchType": "Drug/Device",
            "SponsorGroup": "Foundation",
            "Sponsor": "Craig H. Neilsen Foundation",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Sarah Lehmann",
            "NationalSampleSize": "257",
            "NCTNbr": "NCT02635893",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT02636725",
            "BriefTitle": "Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas",
            "OfficialTitle": "A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)",
            "LeadSponsorClass": "Breelyn Wilky",
            "SponsorAgency": "Other",
            "LeadSponsor": "Breelyn Wilky",
            "OversightAuthority": "Yes",
            "BriefSummary": "The investigators hypothesize that combination axitinib with pembrolizumab will improve\r\n\r\n      progression-free survival relative to historical controls.",
            "Description": "The study will be a single-institution, open-label, single-arm phase II study. Since the\r\n\r\n      primary endpoint is survival outcome, progression-free survival (PFS) sample size\r\n\r\n      calculation is based on a single-arm survival design. Th",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Alveolar Soft Part Sarcoma",
            "studyLocation": "University of Miami",
            "Enrollment": "30",
            "NctKeyword": "Advanced Alveolar Soft Part Sarcoma, ASPS, Soft Tissue Sarcomas, STS, Alveolar Soft Part Sarcoma,",
            "MeshKeyword": "Sarcoma, Sarcoma, Alveolar Soft Part,",
            "InterventionKeyword": "Pembrolizumab, Axitinib,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Patients must have histologically confirmed sarcoma with pathology review required\r\n\r\n             for any outside samples.\r\n\r\n\r\n\r\n          2. The following histologies may be enrolled without prior tre",
            "EligibleGender": "All",
            "MinAge": "16 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 1, 2016",
            "FirstReceived": "December 14, 2015",
            "OverallOfficial": "Breelyn Wilky, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Breelyn Wilky, MD",
            "ContactPhone": "305-243-1287",
            "ContactEmail": "b.wilky@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02636725",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150932 - Institutional - Wilky",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150932",
            "StudyNumber": "20150932 - Institutional - Wilky",
            "StudyTitle": "A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects with Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)",
            "PIID": "4630",
            "PicNum": "C11848802",
            "PILastName": "Wilky",
            "PIFirstName": "Breelyn",
            "CoodCNbr": "C12022610",
            "CoordLastName": "Solomon",
            "CoordFirstName": "Thankam",
            "CoordEmail": "thankam.solomon@med.miami.edu",
            "EnteredByCNbr": "C11972191",
            "EnteredByLastName": "Harris",
            "EnteredByFirstName": "Bretinsa",
            "ActiveEnrollingDate": "03/29/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/29/2016",
            "IRBApprovedFrom": "02/08/2016",
            "IRBApprovedTo": "02/07/2017",
            "AccountNbr": "666615",
            "DiseaseSiteListDesc": "Soft Tissue",
            "Expr1": "Phase II",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "19",
            "Totalaccrued": "17",
            "InFollowUp": "4",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "11",
            "Totalpatients": "19",
            "FirstNinety": "7",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "5",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nathalie Luis,Magdolna Pakocs",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02636725",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02636855",
            "BriefTitle": "Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination",
            "OfficialTitle": "A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid or Hematological Maligna",
            "LeadSponsorClass": "Adaptimmune",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Adaptimmune",
            "OversightAuthority": "No",
            "BriefSummary": "This screening study is intended for men and women at least 18 years of age who have\r\n\r\n      advanced solid or hematologic malignancy. The study will assess a subject's tumor antigen\r\n\r\n      expression profile and HLA subtype. Based on the res",
            "Description": "This multicenter screening study will be conducted in order to determine a subject's tumor\r\n\r\n      antigen expression profile and HLA subtype, and subsequent eligibility for Adaptimmune\r\n\r\n      sponsored clinical treatment trials studying the",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2015",
            "CompletionDate": "November 2025",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "Adaptimmune",
            "StudyCondition": "Solid and Hematological Malignancies",
            "studyLocation": "City of Hope",
            "Enrollment": "300",
            "NctKeyword": "Solid and Hematological Malignancies, Screening, Metastatic, Previously Treated, NY-ESO-1, MAGE A10,",
            "MeshKeyword": "Neoplasms,",
            "Eligibility": "Inclusion Criteria\r\n\r\n\r\n\r\n          1. Signed written informed consent;\r\n\r\n\r\n\r\n          2. Histologically or cytologically confirmed diagnosis of advanced solid or hematologic\r\n\r\n             malignancy or recurrent disease, as described in t",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Duarte",
            "State": "California",
            "Zip": "91101",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 14, 2016",
            "FirstReceived": "November 23, 2015",
            "OverallOfficial": "Ramaswamy Govindan, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Washington University School of Medicine",
            "ContactName": "Ramaswamy Govindan, MD",
            "ContactPhone": "314-747-7405",
            "ContactEmail": "rgovinda@DOM.wustl.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "City of Hope",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02636855",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150874 - Adaptimmune - Ikpeazu",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150874",
            "StudyNumber": "20150874 - Adaptimmune - Ikpeazu",
            "StudyTitle": "A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)",
            "PIID": "373",
            "PicNum": "C06163680",
            "PILastName": "Ikpeazu",
            "PIFirstName": "Chukwuemeka",
            "CoodCNbr": "C11982423",
            "CoordLastName": "Grandas Moreno",
            "CoordFirstName": "Claudia",
            "CoordEmail": "c.grandas@miami.edu",
            "CoordPhone": "305-243-7530",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "04/26/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/26/2016",
            "IRBApprovedFrom": "02/16/2016",
            "IRBApprovedTo": "02/15/2017",
            "AccountNbr": "666829",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "N/A",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Expr2": "Screening",
            "StudyType_Code": "6181",
            "ResearchType": "Specimen",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "16",
            "Totalaccrued": "16",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "5",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "16",
            "FirstNinety": "2",
            "SiteSampleSize": "UM Hollywood:N/A,UMHC:N/A,UMMG:N/A,UMD:N/A,UMH:N/A,Plantation:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Penny Eyer,Anthony Minichiello,Carla Munevar,Halyna Hailes,Nohelia Gonzalez",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02636855",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02637856",
            "BriefTitle": "A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)",
            "OfficialTitle": "AN OPEN-LABEL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO HAVE HAD A SUBOPTIMAL RESPONSE TO AN ADEQUATE COURSE OF DISEASE MODIFYING TREATMENT",
            "LeadSponsorClass": "Genentech, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Genentech, Inc.",
            "BriefSummary": "This study will evaluate the efficacy and safety of ocrelizumab in participants with RRMS\r\n\r\n      who have had a suboptimal response to an adequate course of DMT. Participants will receive\r\n\r\n      ocrelizumab as an initial dose of two 300-mill",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "CompletionDate": "December 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Genentech, Inc.",
            "StudyCondition": "Multiple Sclerosis, Relapsing-Remitting",
            "Enrollment": "600",
            "MeshKeyword": "Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Diagnosis of multiple sclerosis (specifically RRMS), in accordance with the revised\r\n\r\n             2010 McDonald criteria\r\n\r\n\r\n\r\n          -  Disease duration from first symptom of less than or equal to",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "55 Years",
            "Volunteers": "No",
            "City": "Cullman",
            "State": "Alabama",
            "Zip": "35058",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 1, 2016",
            "FirstReceived": "December 18, 2015",
            "OverallOfficial": "Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Hoffmann-La Roche",
            "ContactName": "Reference Study ID Number: MN30035 www.roche.com/about_roche/roche_worldwide.htm",
            "ContactPhone": "888-662-6728 (U.S. and Canada)",
            "ContactEmail": "global.rochegenentechtrials@roche.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02637856",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160577 - Genentech - Sheremata",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20160577",
            "StudyNumber": "20160577 - Genentech - Sheremata",
            "StudyTitle": "AN OPEN-LABEL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF\nOCRELIZUMAB IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO HAVE HAD A SUBOPTIMAL RESPONSE TO AN ADEQUATE COURSE OF DISEASE-MODIFYING TREATMENT",
            "PIID": "121",
            "PicNum": "C00457629",
            "PILastName": "Sheremata",
            "PIFirstName": "William",
            "CoodCNbr": "C00457629",
            "CoordLastName": "Sheremata",
            "CoordFirstName": "William",
            "CoordEmail": "wsherema@med.miami.edu",
            "CoordPhone": "3052436658",
            "EnteredByCNbr": "C00457629",
            "EnteredByLastName": "Sheremata",
            "EnteredByFirstName": "William",
            "ActiveEnrollingDate": "09/19/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/19/2016",
            "IRBApprovedFrom": "07/19/2016",
            "IRBApprovedTo": "07/18/2017",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "Prescreened": "1",
            "Screenedfailed": "2",
            "SignedICF": "8",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "9",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yanet Babcock,Gloria Rodriguez (Neurology)",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02637856",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02637895",
            "BriefTitle": "Vortioxetine for Posttraumatic Stress Disorder",
            "OfficialTitle": "Evaluation of the Efficacy of Vortioxetine for Posttraumatic Stress Disorder",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "Post-traumatic stress disorder (PTSD) can result from having experienced or witnessed a\r\n\r\n      traumatic event. Patients with PTSD symptoms can sometimes experience symptom relief after\r\n\r\n      treatment with antidepressants; however, few pat",
            "Description": "Patients included in the study will either take the study medication or will take a placebo,\r\n\r\n      a pill without the active medication. This will be determined by chance like a flip of a\r\n\r\n      coin.\r\n\r\n\r\n\r\n      Study procedures will incl",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2016",
            "CompletionDate": "July 2019",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "University of Miami",
            "StudyCondition": "Post-Traumatic Stress Disorder",
            "studyLocation": "University of Miami",
            "Enrollment": "80",
            "NctKeyword": "PTSD,, trauma, stress disorder, post-traumatic stress disorder, anxiety disorder,",
            "MeshKeyword": "Disease, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic,",
            "InterventionKeyword": "Vortioxetine,",
            "Eligibility": "Inclusion\r\n\r\n\r\n\r\n          1. Males and Females between the ages of 18 and 65\r\n\r\n\r\n\r\n          2. Fulfills DSM-5 criteria for primary diagnosis of PTSD.\r\n\r\n\r\n\r\n          3. Able to give consent\r\n\r\n\r\n\r\n          4. Willingness to sign the treat",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "65 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 10, 2017",
            "FirstReceived": "December 15, 2015",
            "OverallOfficial": "Philip Harvey, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Gabriela Vargas, B.S",
            "ContactPhone": "305-243-2708",
            "ContactEmail": "gvargas3@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02637895",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150534 - Takeda - Harvey",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20150534",
            "StudyNumber": "20150534 - Takeda - Harvey",
            "StudyTitle": "Evaluation of the Efficacy of Vortioxetine for Posttraumatic Stress Disorder",
            "PIID": "3581",
            "PicNum": "C09911652",
            "PILastName": "Harvey",
            "PIFirstName": "Philip",
            "CoodCNbr": "C12013764",
            "CoordLastName": "Montgomery",
            "CoordFirstName": "Jennifer",
            "CoordEmail": "jjm297@med.miami.edu",
            "EnteredByCNbr": "C09911652",
            "EnteredByLastName": "Harvey",
            "EnteredByFirstName": "Philip",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "11/17/2015",
            "IRBApprovedFrom": "11/17/2015",
            "IRBApprovedTo": "10/31/2017",
            "Expr1": "Approved Drug/Off-Label use",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Takeda",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Gabriela Vargas,Sterling Pilsbury ,Nicole Brenson",
            "NationalSampleSize": "40",
            "NCTNbr": "NCT02637895",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02641639",
            "BriefTitle": "FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer",
            "OfficialTitle": "FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo",
            "LeadSponsorClass": "Mateon Therapeutics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Mateon Therapeutics",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a multicenter, multinational, randomized, double-blind, 2-arm, parallel-group, Phase\r\n\r\n      2/3 study to evaluate the efficacy and safety of PCC plus bevacizumab and CA4P versus PCC\r\n\r\n      plus bevacizumab and placebo in subjects wit",
            "Description": "This is a multicenter, multinational, randomized, double-blind, 2-arm, parallel-group, Phase\r\n\r\n      2/3 study to evaluate the efficacy and safety of PCC plus bevacizumab and CA4P versus PCC\r\n\r\n      plus bevacizumab and placebo in subjects wit",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2016",
            "CompletionDate": "July 2018",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "Mateon Therapeutics",
            "StudyCondition": "Platinum Resistant Ovarian Cancer",
            "studyLocation": "University of Alabama at Birmingham Comprehensive Cancer Center",
            "Enrollment": "436",
            "MeshKeyword": "Ovarian Neoplasms,",
            "InterventionKeyword": "Paclitaxel, Fosbretabulin, Combretastatin, Liposomal doxorubicin, Bevacizumab, Doxorubicin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Signed informed consent form (ICF)\r\n\r\n\r\n\r\n          2. Age ≥ 18 years (Age ≥ 19 years if required by local regulatory authorities)\r\n\r\n\r\n\r\n          3. ECOG PS of 0-1\r\n\r\n\r\n\r\n          4. Histologically or",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35249",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 4, 2017",
            "FirstReceived": "December 21, 2015",
            "OverallOfficial": "Mark Gelder, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Backup Medical Monitor",
            "ContactName": "Charles Cram, BS",
            "ContactPhone": "650-635-7018",
            "ContactEmail": "ccram@mateon.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham Comprehensive Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02641639",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160550 - OXiGENE - Slomovitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160550",
            "StudyNumber": "20160550 - OXiGENE - Slomovitz",
            "StudyTitle": "FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer",
            "PIID": "22712",
            "PicNum": "C11916703",
            "PILastName": "Slomovitz",
            "PIFirstName": "Brian",
            "CoodCNbr": "C11920201",
            "CoordLastName": "Moya",
            "CoordFirstName": "Isabel",
            "CoordEmail": "iam18@miami.edu",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "09/27/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/27/2016",
            "IRBApprovedFrom": "08/01/2016",
            "IRBApprovedTo": "03/14/2017",
            "DiseaseSiteListDesc": "Ovary,Other Female Genital",
            "Expr1": "Phase II/III",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A,UMD:N/A,Plantation:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Negin Habibi Khameneh,Claudia Grandas Moreno,Mohammad El-Sorady,Michelle Mikhail,Evan Dadas,Halyna Hailes",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02641639",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02646566",
            "BriefTitle": "Study of APD421 as PONV Treatment (Prior Prophylaxis)",
            "OfficialTitle": "Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had Prior Prophylaxis",
            "LeadSponsorClass": "Acacia Pharma Ltd",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Acacia Pharma Ltd",
            "OversightAuthority": "Yes",
            "BriefSummary": "Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless,\r\n\r\n      dose-selecting study to compare the efficacy of APD421 to placebo as treatment of\r\n\r\n      established PONV, in patients who have had prior PONV prophylax",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2016",
            "CompletionDate": "October 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Acacia Pharma Ltd",
            "StudyCondition": "Postoperative Nausea and Vomiting",
            "studyLocation": "Jackson Memorial Hospital",
            "Enrollment": "580",
            "MeshKeyword": "Nausea, Vomiting, Postoperative Nausea and Vomiting,",
            "Eligibility": "Inclusion criteria:\r\n\r\n\r\n\r\n          -  Male or female patients ≥ 18 years of age\r\n\r\n\r\n\r\n          -  Provision of written informed consent\r\n\r\n\r\n\r\n          -  Patients scheduled to undergo elective surgery (open or laparoscopic technique) und",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 3, 2016",
            "FirstReceived": "January 4, 2016",
            "OverallOfficial": "Gabriel Fox, MB BChir",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Acacia Pharma Ltd",
            "ContactName": "Gabriel Fox, MB BChir",
            "ContactEmail": "gabrielfox@acaciapharma.com",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "Jackson Memorial Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02646566",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160054 - Acacia Pharma - Candiotti",
            "FileProcessContentId": "440",
            "Division": "Anesthesiology",
            "StdyDivision": "10236",
            "EprostNbr": "20160054",
            "StudyNumber": "20160054 - Acacia Pharma - Candiotti",
            "StudyTitle": "Randomised,'doubleGblind,'placeboGcontrolled'study'\nof'APD421'(amisulpride'for'IV'injection)'as'treatment'\nof'established'postGoperative'nausea'and'vomiting,'\nin'patients'who'have'had'prior'prophylaxis'",
            "PIID": "912",
            "PicNum": "C00745788",
            "PILastName": "Candiotti",
            "PIFirstName": "Keith",
            "CoodCNbr": "C10588120",
            "CoordLastName": "Antor",
            "CoordFirstName": "Maria",
            "CoordEmail": "mantor@med.miami.edu",
            "CoordPhone": "3055857677",
            "EnteredByCNbr": "C00745788",
            "EnteredByLastName": "Candiotti",
            "EnteredByFirstName": "Keith",
            "ActiveEnrollingDate": "06/27/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/27/2016",
            "IRBApprovedFrom": "02/16/2016",
            "IRBApprovedTo": "02/15/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Acacia Pharma",
            "Prescreened": "0",
            "Screenedfailed": "74",
            "SignedICF": "110",
            "Totalaccrued": "36",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "110",
            "FirstNinety": "21",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Isabel Jaraba,Adriana Martini,Angelica Jaramillo Virgen,Maria Antor",
            "NationalSampleSize": "100",
            "NCTNbr": "NCT02646566",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02649075",
            "BriefTitle": "To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease",
            "OfficialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Pilot Study Evaluating Serum-Derived Bovine Immunoglobulin / Protein Isolate in the Dietary Management of Mild to Moderate Crohn's Disease",
            "LeadSponsorClass": "Entera Health, Inc",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Entera Health, Inc",
            "OversightAuthority": "No",
            "BriefSummary": "The objective of this study is to evaluate the nutritional therapy with SBI (a medical food)\r\n\r\n      as compared to placebo in the clinical dietary management of mild to moderate Crohn's\r\n\r\n      disease.",
            "Description": "This is a randomized, double-blind, placebo-controlled, multi-center, pilot study evaluating\r\n\r\n      SBI 10 g BID compared to matching placebo for 12 weeks followed by a 12 week open-label\r\n\r\n      extension SBI 10 g BID (EnteraGam) in the diet",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "CompletionDate": "January 2018",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Entera Health, Inc",
            "StudyCondition": "Crohn's Disease",
            "studyLocation": "North Little Rock",
            "Enrollment": "24",
            "NctKeyword": "IBD, Inflammatory Bowel Disease, Crohn's, Crohns, SBI, Serum-derived bovine immunoglobulin / protein isolate, EnteraGam,",
            "MeshKeyword": "Crohn Disease,",
            "InterventionKeyword": "Immunoglobulins, Antibodies,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Confirmed diagnosis of mild to moderate Crohn's disease for at least 3 months.\r\n\r\n\r\n\r\n          -  Screening CDAI between >150 and ≤ 250 based on subject recall.\r\n\r\n\r\n\r\n          -  Average of greater th",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "North Little Rock",
            "State": "Arkansas",
            "Zip": "72117",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 16, 2016",
            "FirstReceived": "October 12, 2015",
            "OverallOfficial": "Audrey L Shaw, PhD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Entera Health, Inc",
            "ContactName": "Audrey L Shaw, PhD",
            "ContactPhone": "515-963-7565",
            "ContactEmail": "Audrey.Shaw@enterahealth.com",
            "LocationStatus": "Recruiting",
            "LocationName": "North Little Rock",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02649075",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150946 - Entera Health/ Inc. - Kerman",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20150946",
            "StudyNumber": "20150946 - Entera Health/ Inc. - Kerman",
            "StudyTitle": "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of Serum-derived Bovine Immunoglobulin/Protein Isolate (SBI) on Clostridium Difficile (C. difficile) Infection (CDI) in Hospitalized Ulcerative Colitis (UC) Patients",
            "PIID": "652",
            "PicNum": "C04244223",
            "PILastName": "Kerman",
            "PIFirstName": "David",
            "CoodCNbr": "C11914779",
            "CoordLastName": "Carabali",
            "CoordFirstName": "Francia",
            "CoordEmail": "fxc123@miami.edu",
            "EnteredByCNbr": "C04244223",
            "EnteredByLastName": "Kerman",
            "EnteredByFirstName": "David",
            "ActiveEnrollingDate": "07/19/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/19/2016",
            "IRBApprovedFrom": "02/16/2016",
            "IRBApprovedTo": "12/19/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Entera Health/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diana Morillo,Marianela Carvajal,Francia Carabali",
            "NationalSampleSize": "30",
            "NCTNbr": "NCT02649075",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02652624",
            "BriefTitle": "Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women",
            "OfficialTitle": "A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) From Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study will evaluate the efficacy of switching to a fixed-dose combination (FDC) of\r\n\r\n      bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing on a regimen\r\n\r\n      consisting of elvitegravir/cobicistat/emtricitabin",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "CompletionDate": "August 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "HIV-1 Infection",
            "Enrollment": "470",
            "InterventionKeyword": "Tenofovir, Emtricitabine,",
            "Eligibility": "Key Inclusion Criteria\r\n\r\n\r\n\r\n        Medically stable HIV-1 infected women who meet the following criteria:\r\n\r\n\r\n\r\n          -  Completion of the Week 48 open-label extension (OLE) visit or any post Week 48 OLE\r\n\r\n             visits in Gilea",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Sacramento",
            "State": "California",
            "Zip": "95817",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 22, 2016",
            "FirstReceived": "January 8, 2016",
            "OverallOfficial": "Gilead Study Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "ContactName": "Gilead Study Team",
            "ContactEmail": "GS-US-380-1961@gilead.com",
            "LocationStatus": "Withdrawn",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02652624",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160144 - Gilead - Jayaweera",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20160144",
            "StudyNumber": "20160144 - Gilead - Jayaweera",
            "StudyTitle": "GS-US-380-1961 A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) from Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistate/Emtricitabine/Tenofovir disoproxil fumarate (E/C/F/TDF) or Atazanavir + Ritonavir+Embtricitabine/Tenofovir disoproxil fumarate (ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women",
            "PIID": "234",
            "PicNum": "C00043390",
            "PILastName": "Jayaweera",
            "PIFirstName": "Dushyantha T.",
            "CoodCNbr": "C00548607",
            "CoordLastName": "Salvarrey",
            "CoordFirstName": "Annie",
            "CoordEmail": "als215@miami.edu",
            "CoordPhone": "+1 (305) 243-4668",
            "EnteredByCNbr": "C00043390",
            "EnteredByLastName": "Jayaweera",
            "EnteredByFirstName": "Dushyantha T.",
            "ActiveEnrollingDate": "08/02/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/02/2016",
            "IRBApprovedFrom": "06/08/2016",
            "IRBApprovedTo": "04/08/2017",
            "Expr1": "Phase II/III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Gilead",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "2",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Pre-Review",
            "StudyCoordinator": "Kenia Moreno,Tom Tanner",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02652624",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02653625",
            "BriefTitle": "PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis",
            "OfficialTitle": "PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis",
            "LeadSponsorClass": "Tobira Therapeutics, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Tobira Therapeutics, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "This is a single-arm, open label, proof of concept (PoC) study of Cenicriviroc (CVC) in\r\n\r\n      adult subjects with Primary Sclerosing Cholangitis (PSC). The main objective of this PoC\r\n\r\n      study is to assess changes in alkaline phosphatase",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "CompletionDate": "June 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Tobira Therapeutics, Inc.",
            "StudyCondition": "Primary Sclerosing Cholangitis",
            "Enrollment": "25",
            "NctKeyword": "Primary Sclerosing Cholangitis,",
            "MeshKeyword": "Cholangitis, Cholangitis, Sclerosing,",
            "InterventionKeyword": "TAK-652,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subjects with chronic cholestatic liver disease for at least 6 months\r\n\r\n\r\n\r\n          -  Clinical diagnosis of PSC as evident by chronic cholestasis of more than six months\r\n\r\n             duration with",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Sacramento",
            "State": "California",
            "Country": "United States",
            "VerificationDate": "April 2016",
            "LastChanged": "April 18, 2016",
            "FirstReceived": "January 8, 2016",
            "OverallOfficial": "Pamela Vig, PhD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Tobira Therapeutics, Inc.",
            "ContactName": "William Chang, JD",
            "ContactEmail": "wchang@tobiratherapeutics.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02653625",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151149 - Tobira Therapeutics/ Inc. - Levy",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20151149",
            "StudyNumber": "20151149 - Tobira Therapeutics/ Inc. - Levy",
            "StudyTitle": "Tobira 652-205 - PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects with Primary Sclerosing Cholangitis (PSC)",
            "PIID": "2230",
            "PicNum": "C09420731",
            "PILastName": "Levy",
            "PIFirstName": "Cynthia",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C09420731",
            "EnteredByLastName": "Levy",
            "EnteredByFirstName": "Cynthia",
            "ActiveEnrollingDate": "03/30/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/30/2016",
            "IRBApprovedFrom": "02/22/2016",
            "IRBApprovedTo": "02/21/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Tobira Therapeutics/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "4",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Diane Sabogal",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02653625",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02658019",
            "BriefTitle": "Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma",
            "OfficialTitle": "Phase II Study of Pembrolizumab (Keytruda®) in Advanced Hepatocellular Carcinoma (HCC)",
            "LeadSponsorClass": "Lynn Feun",
            "SponsorAgency": "Other",
            "LeadSponsor": "Lynn Feun",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a single-arm phase II trial of Pembrolizumab (Keytruda) in patients with advanced,\r\n\r\n      unresectable hepatocellular carcinoma. The primary objective is to assess its therapeutic\r\n\r\n      efficacy in patients with unresectable hepatoc",
            "Description": "The study will be an open-label, single-institution, non-randomized, single-arm, Phase II\r\n\r\n      study of pembrolizumab therapy in patients with advanced HCC. Patients will be treated in\r\n\r\n      three-week cycles, with intravenous (IV) admini",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Hepatocellular Carcinoma",
            "studyLocation": "University of Miami",
            "Enrollment": "28",
            "NctKeyword": "Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma,",
            "MeshKeyword": "Carcinoma, Carcinoma, Hepatocellular,",
            "InterventionKeyword": "Pembrolizumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Patients must have diagnosis of advanced hepatocellular cancer (HCC) by one of the\r\n\r\n             following:\r\n\r\n\r\n\r\n               -  Histopathology\r\n\r\n\r\n\r\n               -  Elevated serum alpha-fetopro",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 16, 2016",
            "FirstReceived": "January 14, 2016",
            "OverallOfficial": "Lynn Feun, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Lynn Feun, MD",
            "ContactPhone": "305-243-6606",
            "ContactEmail": "lfeun@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02658019",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151049 - Intramural - Feun",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151049",
            "StudyNumber": "20151049 - Intramural - Feun",
            "StudyTitle": "Phase II Study of Pembrolizumab (Keytruda®) in Advanced, Unresectable Hepatocellular Carcinoma (HCC)",
            "PIID": "343",
            "PicNum": "C00770064",
            "PILastName": "Feun",
            "PIFirstName": "Lynn",
            "CoodCNbr": "C11979873",
            "CoordLastName": "Cianferra",
            "CoordFirstName": "Eduardo",
            "CoordEmail": "exc642@miami.edu",
            "CoordPhone": "305-243-1139",
            "EnteredByCNbr": "C11972191",
            "EnteredByLastName": "Harris",
            "EnteredByFirstName": "Bretinsa",
            "ActiveEnrollingDate": "04/27/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/27/2016",
            "IRBApprovedFrom": "03/28/2016",
            "IRBApprovedTo": "03/27/2017",
            "AccountNbr": "666674",
            "DiseaseSiteListDesc": "Liver",
            "Expr1": "Phase II",
            "Tarea": "Pancreatic, Liver, and Related Cancers",
            "TareaCode": "12443",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "16",
            "Totalaccrued": "14",
            "InFollowUp": "4",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "5",
            "Totalpatients": "16",
            "FirstNinety": "7",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "3",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Miriam Isma,Nester Grez",
            "NationalSampleSize": "28",
            "NCTNbr": "NCT02658019",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02659020",
            "SecondaryId": "I5B-MC-JGDL",
            "BriefTitle": "A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma",
            "OfficialTitle": "A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma",
            "LeadSponsorClass": "Eli Lilly and Company",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Eli Lilly and Company",
            "OversightAuthority": "Yes",
            "BriefSummary": "The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer\r\n\r\n      drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in\r\n\r\n      participants with advanced soft tissue sarcoma (S",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2016",
            "CompletionDate": "August 2020",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Eli Lilly and Company",
            "StudyCondition": "Soft Tissue Sarcoma",
            "studyLocation": "Univ of California San Francisco",
            "Enrollment": "196",
            "MeshKeyword": "Sarcoma,",
            "InterventionKeyword": "Gemcitabine, Docetaxel,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  The participant may have no more than 2 prior lines of systemic therapies\r\n\r\n             (neoadjuvant and adjuvant therapies will not be considered as a prior line of\r\n\r\n             therapy) for advanc",
            "EligibleGender": "All",
            "MinAge": "16 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "San Francisco",
            "State": "California",
            "Zip": "94115",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 13, 2017",
            "FirstReceived": "January 15, 2016",
            "OverallOfficial": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Eli Lilly and Company",
            "ContactName": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or",
            "ContactPhone": "1-317-615-4559",
            "LocationStatus": "Recruiting",
            "LocationName": "Univ of California San Francisco",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02659020",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151057 - Eli Lilly - Trent",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151057",
            "StudyNumber": "20151057 - Eli Lilly - Trent",
            "StudyTitle": "A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma",
            "PIID": "3651",
            "PicNum": "C10602427",
            "PILastName": "Trent",
            "PIFirstName": "Jonathan",
            "CoodCNbr": "C11968022",
            "CoordLastName": "Leon Aliz",
            "CoordFirstName": "Tamara",
            "CoordEmail": "txl351@med.miami.edu",
            "EnteredByCNbr": "C07181703",
            "EnteredByLastName": "Zhang",
            "EnteredByFirstName": "Lei",
            "ActiveEnrollingDate": "05/13/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/13/2016",
            "IRBApprovedFrom": "03/01/2016",
            "IRBApprovedTo": "02/28/2017",
            "AccountNbr": "666621",
            "DiseaseSiteListDesc": "Soft Tissue",
            "Expr1": "Phase I",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Eli Lilly",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Yvonne Dinh,Juan Salvador,Daniel Sumarriva,Sandra Pineda,Thankam Solomon,Karen Blackburn",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02659020",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02663817",
            "SecondaryId": "R01CA163370",
            "BriefTitle": "DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy",
            "OfficialTitle": "DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "The hypotheses of the study are as follows:\r\n\r\n\r\n\r\n        -  Mass-based inverse optimization in radiotherapy treatment planning will result in a\r\n\r\n           reduction of normal tissue and organs at risk (OAR) doses for desired prescription",
            "Description": "Cancer patients continue to represent a challenging disease population, which faces rather\r\n\r\n      poor prognosis with current treatment planning and delivery practices. Venues for a\r\n\r\n      potential dose escalation and/or increased healthy t",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2013",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Head and Neck Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "200",
            "MeshKeyword": "Head and Neck Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patients must have histologically confirmed head-and-neck, lung, or prostate tumors.\r\n\r\n\r\n\r\n          -  Patients who will be treated with radiation therapy or concurrent chemoradiation\r\n\r\n             t",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 10, 2017",
            "FirstReceived": "January 19, 2016",
            "OverallOfficial": "Ivaylo Mihaylov, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Ivaylo Mihaylov, PhD",
            "ContactPhone": "305-243-8223",
            "ContactEmail": "i.mihaylov@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02663817",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20130751 - Intramural - Mihaylov",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20130751",
            "StudyNumber": "20130751 - Intramural - Mihaylov",
            "StudyTitle": "DMHBASED PLAN EVALUATION AND INVERSE OPTIMIZATION IN RADIOTHERAPY",
            "PIID": "4687",
            "PicNum": "C11829713",
            "PILastName": "Mihaylov",
            "PIFirstName": "Ivaylo",
            "CoodCNbr": "C11829713",
            "CoordLastName": "Mihaylov",
            "CoordFirstName": "Ivaylo",
            "EnteredByCNbr": "C11829713",
            "EnteredByLastName": "Mihaylov",
            "EnteredByFirstName": "Ivaylo",
            "ActiveEnrollingDate": "11/03/2013",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "02/13/2015",
            "IRBApprovedFrom": "11/03/2013",
            "IRBApprovedTo": "08/22/2017",
            "DiseaseSiteListDesc": "Lip, Oral Cavity and Pharynx,Prostate,Lung",
            "Expr1": "N/A",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Expr2": "Diagnostic",
            "StudyType_Code": "6179",
            "ResearchType": "Other",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "31",
            "Totalaccrued": "29",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "5",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "31",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A,UMD:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Nicole McCullough,Hesley Solano,Hesley Solano",
            "NationalSampleSize": "200",
            "NCTNbr": "NCT02663817",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02667587",
            "SecondaryId": "2015-004722-34",
            "BriefTitle": "Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer).",
            "OfficialTitle": "A Randomized Phase 2 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma - CheckMate 548: CHECKpoin",
            "LeadSponsorClass": "Bristol-Myers Squibb",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Bristol-Myers Squibb",
            "OversightAuthority": "Yes",
            "BriefSummary": "The main purpose of this study is to compare how long patients with glioblastoma (GBM, a\r\n\r\n      malignant brain cancer) live after receiving temozolomide plus radiation therapy compared\r\n\r\n      with patients receiving nivolumab in addition to",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2016",
            "CompletionDate": "November 2020",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Bristol-Myers Squibb",
            "StudyCondition": "Brain Neoplasms",
            "studyLocation": "Local Institution",
            "Enrollment": "320",
            "MeshKeyword": "Glioblastoma, Brain Neoplasms,",
            "InterventionKeyword": "Temozolomide, Dacarbazine, Nivolumab, Antibodies, Monoclonal,",
            "Eligibility": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please\r\n\r\n        visit www.BMSStudyConnect.com\r\n\r\n\r\n\r\n        Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Males and Females, age ≥ 18 years old\r\n\r\n\r\n\r\n          -",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "January 26, 2016",
            "OverallOfficial": "Bristol-Myers Squibb",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Bristol-Myers Squibb",
            "ContactName": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:",
            "ContactEmail": "Clinical.Trials@bms.com",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "Local Institution",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02667587",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160112 - Bristol Myers Squibb - De La Fuente",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160112",
            "StudyNumber": "20160112 - Bristol Myers Squibb - De La Fuente",
            "StudyTitle": "A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma",
            "PIID": "22734",
            "PicNum": "C11916526",
            "PILastName": "De La Fuente",
            "PIFirstName": "Macarena",
            "CoodCNbr": "C04228283",
            "CoordLastName": "Garcia",
            "CoordFirstName": "Helen",
            "CoordEmail": "heg32@med.miami.edu",
            "EnteredByCNbr": "C07181703",
            "EnteredByLastName": "Zhang",
            "EnteredByFirstName": "Lei",
            "ActiveEnrollingDate": "10/03/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/03/2016",
            "IRBApprovedFrom": "04/20/2016",
            "IRBApprovedTo": "04/23/2017",
            "AccountNbr": "667052",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "Phase II",
            "Tarea": "Neurological Cancer",
            "TareaCode": "12442",
            "Blinding": "Single",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Bristol Myers Squibb",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Nathalie Luis",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02667587",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02670330",
            "SecondaryId": "2014-005679-96",
            "BriefTitle": "Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa",
            "OfficialTitle": "An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa",
            "LeadSponsorClass": "Scioderm, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Scioderm, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "The aim is to assess the long-term safety of topical use of ZORBLISA in patients with\r\n\r\n      Epidemolysis Bullosa.",
            "Description": "Epidermolysis Bullosa (EB) is a rare group of inherited disorders that typically manifest at\r\n\r\n      birth as blistering and lesion formation on the skin and, in some cases, the epithelial\r\n\r\n      lining of other organs, in response to little",
            "OverallStatus": "Active, not recruiting",
            "StartDate": "May 2015",
            "CompletionDate": "September 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Scioderm, Inc.",
            "StudyCondition": "Epidermolysis Bullosa",
            "studyLocation": "Stanford University-Dept of Dermatology",
            "Enrollment": "130",
            "NctKeyword": "Epidermolysis Bullosa, Simplex, Recessive Dystrophic, Junctional non-Herlitz,",
            "MeshKeyword": "Epidermolysis Bullosa,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Informed Consent form signed by the subject or subject's legal representative; if the\r\n\r\n             subject is under the age of 18 but capable of providing assent, signed assent from\r\n\r\n             th",
            "EligibleGender": "All",
            "MinAge": "1 Month",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Redwood City",
            "State": "California",
            "Zip": "94063",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 31, 2016",
            "FirstReceived": "July 28, 2015",
            "LocationName": "Stanford University-Dept of Dermatology",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02670330",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160623 - Scioderm/ Inc - Schachner",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20160623",
            "StudyNumber": "20160623 - Scioderm/ Inc - Schachner",
            "StudyTitle": "An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of ZorblisaTM (SD-101-6.0) in Patients with Epidermolysis Bullosa",
            "PIID": "793",
            "PicNum": "C00433811",
            "PILastName": "Schachner",
            "PIFirstName": "Lawrence",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C00433811",
            "EnteredByLastName": "Schachner",
            "EnteredByFirstName": "Lawrence",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "09/20/2016",
            "IRBApprovedFrom": "09/20/2016",
            "IRBApprovedTo": "09/19/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Scioderm/ Inc",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Aliette Espinosa,Carol Kittles",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02670330",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02670577",
            "BriefTitle": "Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry",
            "OfficialTitle": "Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry",
            "LeadSponsorClass": "Agendia",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Agendia",
            "OversightAuthority": "No",
            "BriefSummary": "The scope of this study is to measure the impact of MammaPrint on treatment in Hormone\r\n\r\n      Receptor (HR)-positive HER2-negative breast cancer patients.\r\n\r\n\r\n\r\n      In addition, the impact of MammaPrint on treatment in patients with T1a/T1b",
            "Description": "Eligible patients will have their tumor sample analyzed for MammaPrint, BluePrint and\r\n\r\n      TargetPrint. Patients cannot start treatment before the MammaPrint and BluePrint result is\r\n\r\n      received and taken into consideration for the trea",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2015",
            "CompletionDate": "May 2017",
            "Phase": "N/A",
            "StudyType": "Observational [Patient Registry]",
            "StudyPhase": "N/A",
            "StudySource": "Agendia",
            "StudyCondition": "Breast Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "481",
            "NctKeyword": "stage I, stage II, HER2 positive, Triple Negative,",
            "MeshKeyword": "Breast Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Eligible to receive chemotherapy and endocrine therapy as defined by a good Karnofsky\r\n\r\n             index (≥80) and no hematologic, cardiologic or hepatic contraindications, nor any\r\n\r\n             imp",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33442",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 1, 2016",
            "FirstReceived": "January 27, 2016",
            "ContactName": "Sarah Untch, M.S.",
            "ContactPhone": "(412) 770-6906",
            "ContactEmail": "sarah.untch@agendia.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02670577",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160552 - Agendia Inc - Mahtani",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160552",
            "StudyNumber": "20160552 - Agendia Inc - Mahtani",
            "StudyTitle": "Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry (IMPACt)",
            "PIID": "2603",
            "PicNum": "C09937436",
            "PILastName": "Mahtani",
            "PIFirstName": "Reshma",
            "CoodCNbr": "C11967166",
            "CoordLastName": "Eyer",
            "CoordFirstName": "Penny",
            "CoordEmail": "ple19@med.miami.edu",
            "CoordPhone": "954-698-3673",
            "EnteredByCNbr": "C12001301",
            "EnteredByLastName": "Delgado",
            "EnteredByFirstName": "Yisenny",
            "ActiveEnrollingDate": "08/17/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/17/2016",
            "IRBApprovedFrom": "07/15/2016",
            "IRBApprovedTo": "09/21/2016",
            "AccountNbr": "667525",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "N/A",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Expr2": "Observational",
            "StudyType_Code": "6182",
            "ResearchType": "Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Agendia Inc",
            "Prescreened": "1",
            "Screenedfailed": "2",
            "SignedICF": "29",
            "Totalaccrued": "23",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "29",
            "FirstNinety": "15",
            "SiteSampleSize": "UM Coral Springs:N/A,UMHC:N/A,Plantation:N/A,UM Hollywood:N/A,UMD:N/A,UM Kendall:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Evan Dadas,Halyna Hailes,Onaidy Torres,Michelle Liendo,Deborah Conte,Cristina Rojas-Mejia,Sarah Raybin,Anthony Minichiello,Michelle Mikhail",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02670577",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT02677350",
            "BriefTitle": "AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PEri-fistula iNjEctions (GALENE)",
            "OfficialTitle": "A Phase I, Pilot Trial to Evaluate the Safety and Efficacy of Injection of Allogeneic Mesenchymal Bone-Marrow Derived Human Stem Cells in Patients With Fistulizing Crohn's Disease.",
            "LeadSponsorClass": "Joshua M Hare",
            "SponsorAgency": "Other",
            "LeadSponsor": "Joshua M Hare",
            "OversightAuthority": "Yes",
            "BriefSummary": "To evaluate the role of allogeneic mesenchymal stem cells for treatment of perianal\r\n\r\n      fistulizing Crohn disease.\r\n\r\n\r\n\r\n      Twenty (20) Crohn's disease patients with complex or multiple perianal or rectovaginal\r\n\r\n      fistulas will be",
            "Description": "Twenty (20) subjects will be treated with 20 million (2 x 10^7) allogeneic MSC's total\r\n\r\n      divided into 10 injections of 2 million cells/cm of tract in 0.5 ml volume (for total volume\r\n\r\n      of 5 ml per visit) at 4 week intervals for a ma",
            "OverallStatus": "Not yet recruiting",
            "StartDate": "November 2016",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Crohn's Disease",
            "studyLocation": "Univeristy of Miami Miller School of Medicine",
            "Enrollment": "20",
            "MeshKeyword": "Crohn Disease,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Provide written informed consent.\r\n\r\n\r\n\r\n          2. Male and Female subjects ≥ 18 years of age at the time of signing the Informed\r\n\r\n             Consent Form.\r\n\r\n\r\n\r\n          3. Subjects with Fistul",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 3, 2016",
            "FirstReceived": "February 1, 2016",
            "OverallOfficial": "David Kerman, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "ISCI / University of Miami",
            "ContactName": "David Kerman, MD",
            "ContactPhone": "305-243-8644",
            "ContactEmail": "dkerman@med.miami.edu",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "Univeristy of Miami Miller School of Medicine",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02677350",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150965 - Intramural - Kerman",
            "FileProcessContentId": "440",
            "Division": "Gastroenterology",
            "StdyDivision": "10243",
            "EprostNbr": "20150965",
            "StudyNumber": "20150965 - Intramural - Kerman",
            "StudyTitle": "A Phase I, Pilot Trial to evaluate the Safety and Efficacy of Injection of Allogeneic Mesenchymal Bone-Marrow Derived Human Stem Cells in Patients with Fistulizing Crohn’s Disease.\n\nAllogeneic Human Mesenchymal Stem Cells (hMSC) in Patients with Fistulizing Crohn’s Disease via Peri-fistula injections. (The GALENE Study)",
            "PIID": "652",
            "PicNum": "C04244223",
            "PILastName": "Kerman",
            "PIFirstName": "David",
            "CoodCNbr": "C00194136",
            "CoordLastName": "Pujol",
            "CoordFirstName": "Marietsy",
            "CoordEmail": "mpujol@med.miami.edu",
            "CoordPhone": "3052437273",
            "EnteredByCNbr": "C04244223",
            "EnteredByLastName": "Kerman",
            "EnteredByFirstName": "David",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "11/21/2016",
            "IRBApprovedFrom": "11/21/2016",
            "IRBApprovedTo": "08/28/2017",
            "Expr1": "Phase I",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Modifications Submitted",
            "StudyCoordinator": "Darcy Difede,Lina Caceres Cardenas,Jairo Tovar,Mayra Vidro Casiano,Francia Carabali,Diana Morillo,Cindy Delgado,Russell Saltzman",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02677350",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02680834",
            "BriefTitle": "VLU Non-inferiority Study Comparing a Dual Action Pneumatic Compression Device to Multi-layer Bandaging",
            "OfficialTitle": "Randomized Trial Comparing a Dual Action Pneumatic Compression System Against Multi-Layer Bandaging Systems: A Non-inferiority Study",
            "LeadSponsorClass": "Tactile Medical",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Tactile Medical",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of the study is to test non-inferiority of chronic Venous Leg Ulcer (VLU) area\r\n\r\n      closure at 16 weeks with a dual action pneumatic compression device compared to multi-layer\r\n\r\n      bandaging.",
            "Description": "Participants with a chronic venous leg ulcer will participate in a 2 week run in phase using\r\n\r\n      standard of care multi-layer bandaging before being randomly assigned to either treatment\r\n\r\n      using a dual action pneumatic compression de",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "CompletionDate": "March 2019",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Tactile Medical",
            "StudyCondition": "Venous Leg Ulcer",
            "studyLocation": "Phoenix VA Health Care System",
            "Enrollment": "204",
            "NctKeyword": "venous stasis ulcer, wound, chronic venous insufficiency,",
            "MeshKeyword": "Leg Ulcer, Varicose Ulcer,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject must be ≥ 18 years of age or legal age at the time of enrollment.\r\n\r\n\r\n\r\n          -  Chronic venous insufficiency confirmed by ultrasound within previous 12 months or\r\n\r\n             prior to ra",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85012",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 17, 2016",
            "FirstReceived": "February 9, 2016",
            "OverallOfficial": "William Marston, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of North Carolina, Chapel Hill",
            "ContactName": "Missy Broich",
            "ContactEmail": "mbroich@tactilemedical.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Phoenix VA Health Care System",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02680834",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160087 - Tactile Medical - Kirsner",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20160087",
            "StudyNumber": "20160087 - Tactile Medical - Kirsner",
            "StudyTitle": "Randomized Trial Comparing a Dual Action Pneumatic Compression System against Multi-Layer Bandaging Systems: A non-inferiority study",
            "PIID": "717",
            "PicNum": "C00519753",
            "PILastName": "Kirsner",
            "PIFirstName": "Robert",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C00519753",
            "EnteredByLastName": "Kirsner",
            "EnteredByFirstName": "Robert",
            "ActiveEnrollingDate": "04/04/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "04/04/2016",
            "IRBApprovedFrom": "03/06/2016",
            "IRBApprovedTo": "03/05/2017",
            "Expr1": "N/A",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "Tactile Medical",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "7",
            "Totalaccrued": "5",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "7",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Aliette Espinosa,Carol Kittles",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT02680834",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02683941",
            "SecondaryId": "2015-004992-62",
            "BriefTitle": "Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors",
            "OfficialTitle": "A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumor Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typica",
            "LeadSponsorClass": "Ipsen",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Ipsen",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a Phase 3, prospective, multi-center, randomized, double-blind, study evaluating the\r\n\r\n      efficacy and safety of LAN plus BSC versus placebo plus BSC for the treatment of\r\n\r\n      well-differentiated, metastatic and/or unresectable,",
            "Description": "The DB Phase will include a Screening Visit to establish protocol eligibility and disease\r\n\r\n      characteristics. The Baseline Visit will confirm eligibility prior to randomization and\r\n\r\n      treatment. The DB Phase of the study will end on",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "CompletionDate": "August 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Ipsen",
            "StudyCondition": "Neuroendocrine Tumors",
            "studyLocation": "Cedars Sinai Medical Center",
            "Enrollment": "216",
            "MeshKeyword": "Neuroendocrine Tumors, Carcinoid Tumor,",
            "InterventionKeyword": "Lanreotide, Angiopeptin, Somatostatin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Have metastatic and/or unresectable pathologically confirmed well-differentiated,\r\n\r\n             typical or atypical neuroendocrine tumor of the lung\r\n\r\n\r\n\r\n          -  Histologic evidence of Well diff",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Los Angeles",
            "State": "California",
            "Zip": "90048",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 28, 2016",
            "FirstReceived": "September 21, 2015",
            "OverallOfficial": "Beloo Mirakhur, M.D.",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Ipsen",
            "ContactName": "Ipsen Recruitment Enquiries",
            "ContactEmail": "Clinical.trials@ipsen.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Cedars Sinai Medical Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02683941",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150721 - Ipsen Biopharmaceuticals - Jahanzeb",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150721",
            "StudyNumber": "20150721 - Ipsen Biopharmaceuticals - Jahanzeb",
            "StudyTitle": "A Phase 3,Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 mg plus BSC vs. Placebo plus BSC for Tumor Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumors",
            "PIID": "2421",
            "PicNum": "C09904097",
            "PILastName": "Jahanzeb",
            "PIFirstName": "Mohammad",
            "CoodCNbr": "C11975723",
            "CoordLastName": "Minichiello",
            "CoordFirstName": "Anthony",
            "CoordEmail": "agm112@miami.edu",
            "EnteredByCNbr": "C12001301",
            "EnteredByLastName": "Delgado",
            "EnteredByFirstName": "Yisenny",
            "ActiveEnrollingDate": "08/25/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/25/2016",
            "IRBApprovedFrom": "11/09/2015",
            "IRBApprovedTo": "09/21/2017",
            "AccountNbr": "666609",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase II",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Ipsen Biopharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A,UM Hollywood:N/A,Plantation:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Claudia Grandas Moreno,Carla Munevar,Halyna Hailes,Penny Eyer",
            "NationalSampleSize": "4",
            "NCTNbr": "NCT02683941",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02686762",
            "BriefTitle": "Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis",
            "OfficialTitle": "A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis",
            "LeadSponsorClass": "Conatus Pharmaceuticals Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Conatus Pharmaceuticals Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a multicenter, double-blind, randomized, placebo-controlled trial involving subjects\r\n\r\n      with a diagnosis of \"definite NASH\" with fibrosis (excluding cirrhosis) as determined by the\r\n\r\n      central histopathologist. Upon successful",
            "OverallStatus": "Recruiting",
            "StartDate": "January 2016",
            "CompletionDate": "October 2018",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Conatus Pharmaceuticals Inc.",
            "StudyCondition": "Non-alcoholic Steatohepatitis",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "330",
            "NctKeyword": "NASH,",
            "MeshKeyword": "Fibrosis, Liver Diseases, Fatty Liver, Non-alcoholic Fatty Liver Disease,",
            "InterventionKeyword": "Caspase Inhibitors,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Male or female subjects 18 years or older, able to provide written informed consent,\r\n\r\n             and able to understand and willing to comply with the requirements of the study\r\n\r\n\r\n\r\n          2. Hi",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35233",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 16, 2017",
            "FirstReceived": "February 10, 2016",
            "OverallOfficial": "David Hagerty, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Conatus Pharmaceuticals Inc.",
            "ContactName": "Lisa Grubbs",
            "ContactPhone": "(858) 376-2627",
            "ContactEmail": "lgrubbs@conatuspharma.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02686762",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160162 - Conatus Pharmaceuticals/ Inc. - Schiff",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20160162",
            "StudyNumber": "20160162 - Conatus Pharmaceuticals/ Inc. - Schiff",
            "StudyTitle": "IDN-6556-12 - A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial of Emricasan (IDN-6556), an Oral Caspase Inhibitor, in Subjects with Nonalcoholic  Steatohepatit s (NASH) Fibrosis",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C00758491",
            "EnteredByLastName": "Schiff",
            "EnteredByFirstName": "Eugene",
            "ActiveEnrollingDate": "06/01/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/01/2016",
            "IRBApprovedFrom": "03/28/2016",
            "IRBApprovedTo": "03/27/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Conatus Pharmaceuticals/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "4",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Andrea Elibero",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT02686762",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02688933",
            "SecondaryId": "U1111-1176-0936",
            "BriefTitle": "A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus",
            "OfficialTitle": "Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus",
            "LeadSponsorClass": "Sanofi",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Sanofi",
            "OversightAuthority": "No",
            "BriefSummary": "Primary Objective:\r\n\r\n\r\n\r\n      To demonstrate that morning injection of Toujeo compared to Lantus will provide better\r\n\r\n      glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult patients with\r\n\r\n      type 1 diabetes mel",
            "Description": "The maximum study duration per patient will be approximately 20 weeks that will consist of a\r\n\r\n      4-week screening and training period including a 1-2 week CGM performance (allow for\r\n\r\n      re-training), a 14-week open-label, comparative t",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2016",
            "CompletionDate": "June 2017",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "Sanofi",
            "StudyCondition": "Type 1 Diabetes Mellitus",
            "studyLocation": "Investigational Site Number 840-151",
            "Enrollment": "616",
            "MeshKeyword": "Diabetes Mellitus, Diabetes Mellitus, Type 1,",
            "InterventionKeyword": "Insulin, Globin Zinc, Insulin glulisine, Insulin, Insulin Glargine, Insulin Lispro, Insulin Aspart,",
            "Eligibility": "Inclusion criteria:\r\n\r\n\r\n\r\n          -  Adult patients (male and female) with type 1 diabetes mellitus (T1DM).\r\n\r\n\r\n\r\n          -  Signed written informed consent.\r\n\r\n\r\n\r\n        Exclusion criteria:\r\n\r\n\r\n\r\n          -  Age <18 years or >70 yea",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "70 Years",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Zip": "72205",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 14, 2016",
            "FirstReceived": "February 18, 2016",
            "OverallOfficial": "Clinical Sciences & Operations",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Sanofi",
            "ContactName": "For site information, send an email with site number to",
            "ContactEmail": "Contact-Us@sanofi.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Investigational Site Number 840-151",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02688933",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160206 - Sanofi - Miranda-Palma",
            "FileProcessContentId": "440",
            "Division": "Diabetes Research Institute",
            "StdyDivision": "10239",
            "EprostNbr": "20160206",
            "StudyNumber": "20160206 - Sanofi - Miranda-Palma",
            "StudyTitle": "A Randomized, Active-Controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients with Type 1 Diabetes Mellitus",
            "PIID": "1111",
            "PicNum": "C02129536",
            "PILastName": "Miranda-Palma",
            "PIFirstName": "Bresta",
            "CoodCNbr": "C00121533",
            "CoordLastName": "Masters",
            "CoordFirstName": "Burlett",
            "CoordEmail": "bmasters2@med.miami.edu",
            "CoordPhone": "305-243-5354",
            "EnteredByCNbr": "C02129536",
            "EnteredByLastName": "Miranda-Palma",
            "EnteredByFirstName": "Bresta",
            "ActiveEnrollingDate": "09/12/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/12/2016",
            "IRBApprovedFrom": "05/02/2016",
            "IRBApprovedTo": "01/17/2017",
            "Expr1": "Phase IV",
            "Tarea": "Diabetes (Type I)",
            "TareaCode": "12541",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Sanofi",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "5",
            "Totalaccrued": "5",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "4",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Burlett Masters,Ada Konwai",
            "NationalSampleSize": "50",
            "NCTNbr": "NCT02688933",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02691455",
            "BriefTitle": "The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS)",
            "OfficialTitle": "The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study",
            "LeadSponsorClass": "Robert Feldman",
            "SponsorAgency": "Other",
            "LeadSponsor": "Robert Feldman",
            "OversightAuthority": "Yes",
            "BriefSummary": "Outcomes of subjects with uncontrolled glaucoma with a single existing aqueous tube shunt\r\n\r\n      implant undergoing a second aqueous shunt to transscleral diode laser cyclophotocoagulation.",
            "Description": "This is a study comparing short- (1 year), mid- (3 years), and long-term (5 years)\r\n\r\n      cumulative incidences of failures in participants who undergo a second aqueous shunt (SAS)\r\n\r\n      to those cumulative incidences of failures in partici",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "February 2016",
            "CompletionDate": "January 2023",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "The University of Texas Health Science Center, Houston",
            "StudyCondition": "Glaucoma",
            "studyLocation": "Little Rock Eye Clinic",
            "Enrollment": "280",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Women and men 40 to 85 years of age\r\n\r\n\r\n\r\n          -  Glaucoma not adequately controlled (IOP >18 mmHg on maximum tolerated topical\r\n\r\n             therapy) with a single aqueous shunt (AS).",
            "EligibleGender": "All",
            "MinAge": "40 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Zip": "72205",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 13, 2017",
            "FirstReceived": "February 15, 2016",
            "OverallOfficial": "Robert Feldman, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Robert Cizik Eye Clinic",
            "LocationName": "Little Rock Eye Clinic",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02691455",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160239 - Intramural - Kishor",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20160239",
            "StudyNumber": "20160239 - Intramural - Kishor",
            "StudyTitle": "The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study",
            "PIID": "22495",
            "PicNum": "C05023525",
            "PILastName": "Kishor",
            "PIFirstName": "Krishna",
            "CoodCNbr": "C11892911",
            "CoordLastName": "Roberts",
            "CoordFirstName": "Chantey",
            "CoordEmail": "c.roberts3@med.miami.edu",
            "CoordPhone": "561-515-1534",
            "EnteredByCNbr": "C05023525",
            "EnteredByLastName": "Kishor",
            "EnteredByFirstName": "Krishna",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "07/11/2016",
            "IRBApprovedFrom": "07/11/2016",
            "IRBApprovedTo": "07/10/2017",
            "Expr1": "N/A",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Chantey Roberts",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02691455",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02691455",
            "BriefTitle": "The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS)",
            "OfficialTitle": "The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study",
            "LeadSponsorClass": "Robert Feldman",
            "SponsorAgency": "Other",
            "LeadSponsor": "Robert Feldman",
            "OversightAuthority": "Yes",
            "BriefSummary": "Outcomes of subjects with uncontrolled glaucoma with a single existing aqueous tube shunt\r\n\r\n      implant undergoing a second aqueous shunt to transscleral diode laser cyclophotocoagulation.",
            "Description": "This is a study comparing short- (1 year), mid- (3 years), and long-term (5 years)\r\n\r\n      cumulative incidences of failures in participants who undergo a second aqueous shunt (SAS)\r\n\r\n      to those cumulative incidences of failures in partici",
            "OverallStatus": "Enrolling by invitation",
            "StartDate": "February 2016",
            "CompletionDate": "January 2023",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "The University of Texas Health Science Center, Houston",
            "StudyCondition": "Glaucoma",
            "studyLocation": "Little Rock Eye Clinic",
            "Enrollment": "280",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Women and men 40 to 85 years of age\r\n\r\n\r\n\r\n          -  Glaucoma not adequately controlled (IOP >18 mmHg on maximum tolerated topical\r\n\r\n             therapy) with a single aqueous shunt (AS).",
            "EligibleGender": "All",
            "MinAge": "40 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Zip": "72205",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 13, 2017",
            "FirstReceived": "February 15, 2016",
            "OverallOfficial": "Robert Feldman, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "Robert Cizik Eye Clinic",
            "LocationName": "Little Rock Eye Clinic",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02691455",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160555 - Intramural - Vazquez",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20160555",
            "StudyNumber": "20160555 - Intramural - Vazquez",
            "StudyTitle": "The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation \nTreatment Study (ASSISTS)",
            "PIID": "22797",
            "PicNum": "C11855053",
            "PILastName": "Vazquez",
            "PIFirstName": "Luis",
            "CoodCNbr": "C04107119",
            "CoordLastName": "Waren",
            "CoordFirstName": "Daniel",
            "CoordEmail": "d.waren@med.miami.edu",
            "CoordPhone": "305-243-2158",
            "EnteredByCNbr": "C11855053",
            "EnteredByLastName": "Vazquez",
            "EnteredByFirstName": "Luis",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "09/12/2016",
            "IRBApprovedFrom": "09/12/2016",
            "IRBApprovedTo": "09/11/2017",
            "Expr1": "N/A",
            "Tarea": "Glaucoma",
            "TareaCode": "12037",
            "ResearchType": "Device",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02691455",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02694328",
            "BriefTitle": "A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)",
            "OfficialTitle": "A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia",
            "LeadSponsorClass": "Alkermes, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Alkermes, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects\r\n\r\n      with schizophrenia.",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "CompletionDate": "March 2018",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Alkermes, Inc.",
            "StudyCondition": "Schizophrenia",
            "studyLocation": "Alkermes Investigational Site",
            "Enrollment": "540",
            "NctKeyword": "Alkermes, ALKS 3831, Samidorphan, Schizophrenia, Olanzapine, Weight,",
            "MeshKeyword": "Schizophrenia,",
            "InterventionKeyword": "Olanzapine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject has a body mass index (BMI) of 18.0-30.0 kg/m^2, inclusive, at Visit 1 and\r\n\r\n             Visit 2\r\n\r\n\r\n\r\n          -  Subject meets the DSM-5 criteria for a primary diagnosis of schizophrenia",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "55 Years",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Zip": "72211",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 16, 2016",
            "FirstReceived": "February 24, 2016",
            "OverallOfficial": "David McDonnell, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Alkermes, Inc.",
            "ContactName": "Premier Research",
            "ContactPhone": "866-921-3155",
            "ContactEmail": "ALKE3813CT@premier-research.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Alkermes Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02694328",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151107 - Alkermes - Strassnig",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20151107",
            "StudyNumber": "20151107 - Alkermes - Strassnig",
            "StudyTitle": "A Phase 3 Study to Evaluate Weight Gain of ALKS 3831\nCompared to Olanzapine in Adults with Schizophrenia",
            "PIID": "4295",
            "PicNum": "C10560217",
            "PILastName": "Strassnig",
            "PIFirstName": "Martin",
            "CoodCNbr": "C00145327",
            "CoordLastName": "Guardia",
            "CoordFirstName": "Tania",
            "CoordEmail": "tguardia@med.miami.edu",
            "EnteredByCNbr": "C10560217",
            "EnteredByLastName": "Strassnig",
            "EnteredByFirstName": "Martin",
            "ActiveEnrollingDate": "09/26/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/26/2016",
            "IRBApprovedFrom": "06/28/2016",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Alkermes",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "3",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Pre-Review",
            "StudyCoordinator": "Tania Guardia,Nicole Brenson",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT02694328",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02694822",
            "BriefTitle": "AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers",
            "OfficialTitle": "A Phase 1, Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer",
            "LeadSponsorClass": "Agenus Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Agenus Inc.",
            "BriefSummary": "This is an open-label, Phase 1, multicenter study to evaluate the safety, PK, and PD of an\r\n\r\n      anti-CTLA-4 human monoclonal antibody (AGEN1884) and to estimate the MTD in subjects with\r\n\r\n      advanced or refractory cancer. The study will",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2016",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Agenus Inc.",
            "StudyCondition": "Advanced Solid Cancers",
            "studyLocation": "School of Medicine at the University of Miami",
            "Enrollment": "48",
            "InterventionKeyword": "Antibodies, Immunoglobulins,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Sign informed consent.\r\n\r\n\r\n\r\n          2. ≥18 years of age.\r\n\r\n\r\n\r\n          3. Histological or cytological diagnosis of solid cancer or lymphoma that is considered\r\n\r\n             incurable and without",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 2, 2016",
            "FirstReceived": "February 12, 2016",
            "ContactName": "Agenus Medical Monitor, MD",
            "ContactPhone": "781-674-4508",
            "LocationStatus": "Recruiting",
            "LocationName": "School of Medicine at the University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02694822",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160238 - Agenus - Wilky",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160238",
            "StudyNumber": "20160238 - Agenus - Wilky",
            "StudyTitle": "A Phase 1 Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer",
            "PIID": "4630",
            "PicNum": "C11848802",
            "PILastName": "Wilky",
            "PIFirstName": "Breelyn",
            "CoodCNbr": "C11968022",
            "CoordLastName": "Leon Aliz",
            "CoordFirstName": "Tamara",
            "CoordEmail": "txl351@med.miami.edu",
            "EnteredByCNbr": "C11917328",
            "EnteredByLastName": "Englund",
            "EnteredByFirstName": "Kristen",
            "ActiveEnrollingDate": "06/23/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/23/2016",
            "IRBApprovedFrom": "04/23/2016",
            "IRBApprovedTo": "08/05/2016",
            "AccountNbr": "667207",
            "DiseaseSiteListDesc": "Brain and Nervous System,Leukemia, Other,Bones and Joints,Melanoma, skin",
            "Expr1": "Phase I",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "5",
            "Totalaccrued": "5",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "2",
            "Totalpatients": "5",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Yvonne Dinh,Juan Salvador,Daniel Sumarriva,Sandra Pineda,Karen Blackburn",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02694822",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02700945",
            "BriefTitle": "Stroke AF - Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin",
            "OfficialTitle": "Stroke AF - Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin",
            "LeadSponsorClass": "Medtronic Cardiac Rhythm and Heart Failure",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Medtronic Cardiac Rhythm and Heart Failure",
            "OversightAuthority": "No",
            "BriefSummary": "The purpose of the Stroke AF study is to compare the incidence of atrial fibrillation (AF)\r\n\r\n      through 12 months between continuous cardiac rhythm monitoring with the Reveal LINQ™\r\n\r\n      Insertable Cardiac Monitor (ICM) (continuous monito",
            "Description": "Stroke AF is a prospective, multi-site, randomized, controlled, non-blinded, post-market\r\n\r\n      study. The Stroke AF study will compare the incidence rate of atrial fibrillation through 12\r\n\r\n      months between the continuous monitoring arm",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2016",
            "CompletionDate": "February 2021",
            "Phase": "Phase 4",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 4",
            "StudySource": "Medtronic Cardiac Rhythm and Heart Failure",
            "StudyCondition": "Stroke, Acute",
            "studyLocation": "Innovative Medical Research",
            "Enrollment": "496",
            "MeshKeyword": "Stroke, Atrial Fibrillation,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject has had an ischemic stroke believed to be due to small vessel disease, large\r\n\r\n             vessel cervical or intracranial atherosclerosis within the past 10 days\r\n\r\n\r\n\r\n          -  Subject is",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Aventura",
            "State": "Florida",
            "Zip": "33180",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 8, 2016",
            "FirstReceived": "March 2, 2016",
            "LocationStatus": "Recruiting",
            "LocationName": "Innovative Medical Research",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02700945",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160309 - Medtronic - Koch",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20160309",
            "StudyNumber": "20160309 - Medtronic - Koch",
            "StudyTitle": "Stroke AF",
            "PIID": "171",
            "PicNum": "C00123749",
            "PILastName": "Koch",
            "PIFirstName": "Sebastian",
            "CoodCNbr": "C00460088",
            "CoordLastName": "Campo-Bustillo",
            "CoordFirstName": "Iszet",
            "CoordEmail": "icampo@med.miami.edu",
            "CoordPhone": "3052438018",
            "EnteredByCNbr": "C00123749",
            "EnteredByLastName": "Koch",
            "EnteredByFirstName": "Sebastian",
            "ActiveEnrollingDate": "01/04/2017",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/04/2017",
            "IRBApprovedFrom": "06/02/2016",
            "IRBApprovedTo": "06/02/2017",
            "InfoEdNbr": "80701",
            "WIrb": "UMiami-Stroke AF 1251799",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "N/A",
            "Tarea": "Stroke",
            "TareaCode": "8943",
            "Blinding": "None",
            "Randomization": "Randomized",
            "Expr2": "Diagnostic",
            "StudyType_Code": "6179",
            "ResearchType": "Other",
            "SponsorGroup": "Industry",
            "Sponsor": "Medtronic, Inc",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Andrea Escobar,Avi Landman,Mario Perez",
            "AgentDevices": "Reveal LINQ™ Insertable Cardiac Monitor (ICM)  (Market-released)",
            "StudyObjective": "Primary objective: To compare the incidence rate of AF through 12 months between the continuous monitoring arm vs control arm in subjects with a recent ischemic stroke of presumed known origin.\r\n\r\nSecondary objective: To compare the incidence rates of AF through the duration of study follow-up between study arms.",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT02700945",
            "StudyKeywords": "Ischemic stroke, Atrial Fibrillation",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02701764",
            "BriefTitle": "Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?",
            "OfficialTitle": "Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "Dry eye symptoms can occur after LASIK surgery. They generally get better with time but in\r\n\r\n      some patients, they can persist. The investigators believe that in some individuals, dry eye\r\n\r\n      symptoms after LASIK persist because the ne",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2016",
            "CompletionDate": "July 2017",
            "Phase": "Phase 2/Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2/Phase 3",
            "StudySource": "University of Miami",
            "StudyCondition": "Dry Eye",
            "studyLocation": "Anat Galor",
            "Enrollment": "100",
            "NctKeyword": "laser-assisted in situ keratomileusis, dry eye symptoms, LASIK, prevention,",
            "MeshKeyword": "Keratoconjunctivitis Sicca, Dry Eye Syndromes,",
            "InterventionKeyword": "Pregabalin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  21 and 65 years of age\r\n\r\n\r\n\r\n          -  undergoing LASIK (unilateral or bilateral procedure).\r\n\r\n\r\n\r\n          -  Females of child-bearing age will need a negative urine or serum pregnancy test at",
            "EligibleGender": "All",
            "MinAge": "21 Years",
            "MaxAge": "65 Years",
            "Volunteers": "Accepts Healthy Volunteers",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33133",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 5, 2016",
            "FirstReceived": "February 26, 2016",
            "OverallOfficial": "Anat Galor, MD, MSPH",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Anat Galor, MD, MSPH",
            "ContactPhone": "3054506050",
            "ContactEmail": "agalor@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Anat Galor",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02701764",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160095 - Intramural - Galor",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20160095",
            "StudyNumber": "20160095 - Intramural - Galor",
            "StudyTitle": "Can pregabalin reduce the frequency and severity of dry eye symptoms after laser-assisted in situ keratomileusis?",
            "PIID": "1817",
            "PicNum": "C06036267",
            "PILastName": "Galor",
            "PIFirstName": "Anat",
            "CoodCNbr": "C06036267",
            "CoordLastName": "Galor",
            "CoordFirstName": "Anat",
            "EnteredByCNbr": "C06036267",
            "EnteredByLastName": "Galor",
            "EnteredByFirstName": "Anat",
            "ActiveEnrollingDate": "05/17/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/17/2016",
            "IRBApprovedFrom": "04/25/2016",
            "IRBApprovedTo": "04/24/2017",
            "Expr1": "Approved Drug/Off-Label use",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "26",
            "Totalaccrued": "25",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "25",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "26",
            "FirstNinety": "5",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Ailen Gutierrez,Marlene P. Perez,Belen Rodriguez",
            "NationalSampleSize": "60",
            "NCTNbr": "NCT02701764",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02703571",
            "SecondaryId": "2015-005019-34",
            "BriefTitle": "Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors",
            "OfficialTitle": "A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors",
            "LeadSponsorClass": "Novartis Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Novartis Pharmaceuticals",
            "OversightAuthority": "No",
            "BriefSummary": "Phase Ib dose escalation in advanced solid tumors to identify dose for Phase II dose\r\n\r\n      expansion in advanced or metastatic pancreatic cancer and KRAS-mutant colorectal cancer.\r\n\r\n      Open-label, nonrandomized.",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2016",
            "CompletionDate": "October 2018",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Novartis",
            "StudyCondition": "Solid Tumors",
            "studyLocation": "Highlands Oncology Group",
            "Enrollment": "84",
            "NctKeyword": "Trametinib, Ribociclib, LEE011, TMT212, advanced solid tumors, pancreatic cancer, KRAS-mutant colorectal cancer, colorectal cancer, advanced pancreatic cancer, metastatic pancreatic cancer,",
            "MeshKeyword": "Colorectal Neoplasms, Pancreatic Neoplasms,",
            "InterventionKeyword": "Trametinib,",
            "Eligibility": "Inclusion Criteria (All):\r\n\r\n\r\n\r\n          -  Written informed consent must\r\n\r\n\r\n\r\n          -  Patient has histologically and/or cytologically confirmed malignancies:\r\n\r\n\r\n\r\n        Phase I:\r\n\r\n\r\n\r\n        • Patients with advanced or metastat",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Fayetteville",
            "State": "Arkansas",
            "Zip": "72703",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 18, 2017",
            "FirstReceived": "March 4, 2016",
            "OverallOfficial": "Novartis Pharmaceuticals",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Novartis Pharmaceuticals",
            "ContactName": "Novartis Pharmaceuticals",
            "ContactPhone": "1-888-669-6682",
            "LocationStatus": "Recruiting",
            "LocationName": "Highlands Oncology Group",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02703571",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160381 - Novartis - Merchan",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160381",
            "StudyNumber": "20160381 - Novartis - Merchan",
            "StudyTitle": "A phase I/II study of safety and efficacy of ribociclib\n(LEE011) in combination with trametinib (TMT212) in\npatients with metastatic or advanced solid tumors",
            "PIID": "407",
            "PicNum": "C00251535",
            "PILastName": "Merchan",
            "PIFirstName": "Jaime",
            "CoodCNbr": "C12016748",
            "CoordLastName": "Sumarriva",
            "CoordFirstName": "Daniel",
            "CoordEmail": "dss173@med.miami.edu",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "06/28/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/28/2016",
            "IRBApprovedFrom": "06/09/2016",
            "IRBApprovedTo": "12/09/2016",
            "AccountNbr": "667206",
            "DiseaseSiteListDesc": "Bones and Joints",
            "Expr1": "Phase I",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Karen Blackburn,Juan Salvador,Sandra Pineda,Tamara Leon Aliz,Yvonne Dinh",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02703571",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02704364",
            "BriefTitle": "Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis",
            "OfficialTitle": "A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis",
            "LeadSponsorClass": "NGM Biopharmaceuticals, Inc",
            "SponsorAgency": "Industry",
            "LeadSponsor": "NGM Biopharmaceuticals, Inc",
            "OversightAuthority": "Yes",
            "BriefSummary": "The purpose of this study is to determine the safety, tolerability, and activity of NGM282\r\n\r\n      in patients with Primary Sclerosing Cholangitis.",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "CompletionDate": "June 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "NGM Biopharmaceuticals, Inc",
            "StudyCondition": "Primary Sclerosing Cholangitis",
            "studyLocation": "NGM Clinical Study Site 118",
            "Enrollment": "60",
            "MeshKeyword": "Cholangitis, Cholangitis, Sclerosing,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Confirmed diagnosis of PSC\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -  Clinically significant acute or chronic liver disease of an etiology other than PSC\r\n\r\n\r\n\r\n          -  Secondary or IgG4",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Sacramento",
            "State": "California",
            "Country": "United States",
            "VerificationDate": "September 2016",
            "LastChanged": "September 20, 2016",
            "FirstReceived": "February 29, 2016",
            "OverallOfficial": "Stephen J Rossi, PharmD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "NGM Biopharmaceuticals, Inc",
            "ContactName": "Kathy Kim",
            "ContactPhone": "6502435572",
            "ContactEmail": "kkim@ngmbio.com",
            "LocationStatus": "Recruiting",
            "LocationName": "NGM Clinical Study Site 118",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02704364",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151159 - NGM Biopharmaceuticals/ Inc. - Levy",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20151159",
            "StudyNumber": "20151159 - NGM Biopharmaceuticals/ Inc. - Levy",
            "StudyTitle": "NGM 15-0106-A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER STUDY TO EVALUATE THE\nSAFETY, TOLERABILITY, AND EFFICACY OF NGM282 ADMINISTERED FOR\n12 WEEKS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC)",
            "PIID": "2230",
            "PicNum": "C09420731",
            "PILastName": "Levy",
            "PIFirstName": "Cynthia",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C09420731",
            "EnteredByLastName": "Levy",
            "EnteredByFirstName": "Cynthia",
            "ActiveEnrollingDate": "03/31/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "03/31/2016",
            "IRBApprovedFrom": "02/22/2016",
            "IRBApprovedTo": "02/21/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "NGM Biopharmaceuticals/ Inc.",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "4",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Odalys Rodriguez-Bravo",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02704364",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02704403",
            "SecondaryId": "2015-005385-38",
            "BriefTitle": "Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)",
            "OfficialTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis",
            "LeadSponsorClass": "Genfit",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Genfit",
            "OversightAuthority": "Yes",
            "BriefSummary": "The primary objectives of this study are to evaluate the effect of Elafibranor treatment\r\n\r\n      compared to placebo on 1) histological improvement and 2) all-cause mortality and\r\n\r\n      liver-related outcomes in patients with nonalcoholic ste",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Genfit",
            "StudyCondition": "Nonalcoholic Steatohepatitis (NASH) With Fibrosis",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "2000",
            "NctKeyword": "Elafibranor, NASH, Nonalcoholic steatohepatitis, Fatty liver disease, Fibrosis,",
            "MeshKeyword": "Fibrosis, Fatty Liver, Non-alcoholic Fatty Liver Disease,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Males or females aged from 18 to 75 years inclusive at first screening visit.\r\n\r\n\r\n\r\n          2. Must provide signed written informed consent and agree to comply with the study\r\n\r\n             protocol.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 18, 2017",
            "FirstReceived": "February 16, 2016",
            "OverallOfficial": "Sophie Megnien, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Chief Medical Officer, Genfit",
            "ContactName": "Alice Roudot, PharmD",
            "ContactEmail": "alice.roudot@genfit.com",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02704403",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160560 - GENFIT - Schiff",
            "FileProcessContentId": "440",
            "Division": "Hepatology",
            "StdyDivision": "10246",
            "EprostNbr": "20160560",
            "StudyNumber": "20160560 - GENFIT - Schiff",
            "StudyTitle": "GFT505-315-1-A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis",
            "PIID": "1208",
            "PicNum": "C00758491",
            "PILastName": "Schiff",
            "PIFirstName": "Eugene",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C00758491",
            "EnteredByLastName": "Schiff",
            "EnteredByFirstName": "Eugene",
            "ActiveEnrollingDate": "08/18/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/18/2016",
            "IRBApprovedFrom": "06/24/2016",
            "IRBApprovedTo": "02/10/2017",
            "Expr1": "Phase III",
            "Tarea": "Liver Disease",
            "TareaCode": "12638",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "GENFIT",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Andrea Elibero",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT02704403",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02704403",
            "SecondaryId": "2015-005385-38",
            "BriefTitle": "Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)",
            "OfficialTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis",
            "LeadSponsorClass": "Genfit",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Genfit",
            "OversightAuthority": "Yes",
            "BriefSummary": "The primary objectives of this study are to evaluate the effect of Elafibranor treatment\r\n\r\n      compared to placebo on 1) histological improvement and 2) all-cause mortality and\r\n\r\n      liver-related outcomes in patients with nonalcoholic ste",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Genfit",
            "StudyCondition": "Nonalcoholic Steatohepatitis (NASH) With Fibrosis",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "2000",
            "NctKeyword": "Elafibranor, NASH, Nonalcoholic steatohepatitis, Fatty liver disease, Fibrosis,",
            "MeshKeyword": "Fibrosis, Fatty Liver, Non-alcoholic Fatty Liver Disease,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Males or females aged from 18 to 75 years inclusive at first screening visit.\r\n\r\n\r\n\r\n          2. Must provide signed written informed consent and agree to comply with the study\r\n\r\n             protocol.",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Zip": "35294",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 18, 2017",
            "FirstReceived": "February 16, 2016",
            "OverallOfficial": "Sophie Megnien, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Chief Medical Officer, Genfit",
            "ContactName": "Alice Roudot, PharmD",
            "ContactEmail": "alice.roudot@genfit.com",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02704403",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160544 - GENFIT S.A. - Martin",
            "FileProcessContentId": "440",
            "Division": "Hepatology",
            "StdyDivision": "10246",
            "EprostNbr": "20160544",
            "StudyNumber": "20160544 - GENFIT S.A. - Martin",
            "StudyTitle": "Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis.",
            "PIID": "697",
            "PicNum": "C06441920",
            "PILastName": "Martin",
            "PIFirstName": "Paul",
            "CoodCNbr": "C11973174",
            "CoordLastName": "Carvajal",
            "CoordFirstName": "Marianela",
            "CoordEmail": "mxc1535@miami.edu",
            "EnteredByCNbr": "C06441920",
            "EnteredByLastName": "Martin",
            "EnteredByFirstName": "Paul",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "08/05/2016",
            "IRBApprovedFrom": "08/05/2016",
            "IRBApprovedTo": "02/10/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "GENFIT S.A.",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "1",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Diana Morillo,Marianela Carvajal",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02704403",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02707406",
            "BriefTitle": "Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K",
            "OfficialTitle": "A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)",
            "LeadSponsorClass": "Tissue Tech Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Tissue Tech Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "The study is evaluating NEOX®CORD 1K, a cryopreserved human umbilical cord allograft.\r\n\r\n\r\n\r\n      The purpose of the study is to evaluate the safety, incidence and rate of wound closure\r\n\r\n      following application of the product compared to",
            "Description": "A total of 114 patients presenting with a non-healing diabetic foot ulcer (DFU) that is\r\n\r\n      located below the malleoli (plantar only) of at least 4 weeks in duration and a size of at\r\n\r\n      least 0.5 cm2 up to 5.0 cm2 for plantar wounds m",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "CompletionDate": "April 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Tissue Tech Inc.",
            "StudyCondition": "Diabetic Foot Ulcers",
            "Enrollment": "114",
            "MeshKeyword": "Ulcer, Diabetic Foot, Foot Ulcer,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Patient has signed the informed consent form\r\n\r\n\r\n\r\n          -  Male or female patient at least 18 years of age or older, as of the date of the\r\n\r\n             screening visit\r\n\r\n\r\n\r\n          -  Confir",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Carlsbad",
            "State": "California",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 12, 2016",
            "FirstReceived": "February 25, 2016",
            "ContactName": "Tommy Lee",
            "ContactEmail": "tLee@tissuetechinc.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02707406",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160080 - TissueTech/ Inc - Kirsner",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20160080",
            "StudyNumber": "20160080 - TissueTech/ Inc - Kirsner",
            "StudyTitle": "A Multi-center, Randomized, Controlled Trial of Non-healing Diabetic Foot Ulcers (DFU) Treated with Standard of Care with or without Cryopreserved Umbilical Cord Allograft (NEOX® CORD  1K)",
            "PIID": "717",
            "PicNum": "C00519753",
            "PILastName": "Kirsner",
            "PIFirstName": "Robert",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C00519753",
            "EnteredByLastName": "Kirsner",
            "EnteredByFirstName": "Robert",
            "ActiveEnrollingDate": "06/06/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/06/2016",
            "IRBApprovedFrom": "05/17/2016",
            "IRBApprovedTo": "05/16/2017",
            "Expr1": "Phase III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "TissueTech/ Inc",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "3",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Aliette Espinosa,Carol Kittles",
            "NationalSampleSize": "25",
            "NCTNbr": "NCT02707406",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02707601",
            "SecondaryId": "2014-004545-27",
            "BriefTitle": "Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (",
            "OfficialTitle": "A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamid",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "No",
            "BriefSummary": "This study will evaluate efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) as measured by the\r\n\r\n      proportion of participants achieving hepatitis C virus (HCV) RNA below the lower limit of\r\n\r\n      quantification (LLOQ) 12 weeks after the last dos",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2016",
            "CompletionDate": "September 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "HIV-1 Infection",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "240",
            "NctKeyword": "HIV, HCV, Antiretroviral therapy, HCV direct acting antiviral(s) (DAA),",
            "MeshKeyword": "Infection, Communicable Diseases,",
            "InterventionKeyword": "Tenofovir, Emtricitabine, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Ledipasvir, sofosbuvir drug combination, Cobicistat, Ledipasvir, Rilpivirine, Sofosbuvir,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Chronic genotype (GT) 1, HCV infected, male and non-pregnant/ non-lactating female\r\n\r\n             individuals, without cirrhosis, treatment-naive or treatment-experienced with\r\n\r\n             interferon",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 22, 2016",
            "FirstReceived": "March 9, 2016",
            "OverallOfficial": "Gilead Study Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "ContactName": "Gilead Study Team",
            "ContactEmail": "GS-US-366-1992@gilead.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02707601",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160231 - Gilead - Jayaweera",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20160231",
            "StudyNumber": "20160231 - Gilead - Jayaweera",
            "StudyTitle": "GS-US-366-1992 A Phase 3 Be Randomized Open-label, Controlled Study of Efficacy, Safety and Tolerability of 12 weeks of Ledipasvir/Sofasbuvir(LDV/SOF) treatment for HIV/HCV Co-Infected Subjects who Switch to Elvitegravir/Cobicistat/Emtricitabein/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/F/TAF) prior to LDV/SOF HCF Treatment, the HIV/HCV Co STARs study (Co-Infection Treatment with Single Tablet Antiviral Regiments)",
            "PIID": "234",
            "PicNum": "C00043390",
            "PILastName": "Jayaweera",
            "PIFirstName": "Dushyantha T.",
            "CoodCNbr": "C00548607",
            "CoordLastName": "Salvarrey",
            "CoordFirstName": "Annie",
            "CoordEmail": "als215@miami.edu",
            "CoordPhone": "+1 (305) 243-4668",
            "EnteredByCNbr": "C00043390",
            "EnteredByLastName": "Jayaweera",
            "EnteredByFirstName": "Dushyantha T.",
            "ActiveEnrollingDate": "09/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "09/08/2016",
            "IRBApprovedFrom": "07/18/2016",
            "IRBApprovedTo": "07/17/2017",
            "Expr1": "Phase II",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Gilead",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "3",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "3",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "3",
            "FirstNinety": "3",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Kenia Moreno,Sam-mosley Ayuk,Tom Tanner",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02707601",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02707601",
            "SecondaryId": "2014-004545-27",
            "BriefTitle": "Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (",
            "OfficialTitle": "A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamid",
            "LeadSponsorClass": "Gilead Sciences",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Gilead Sciences",
            "OversightAuthority": "No",
            "BriefSummary": "This study will evaluate efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) as measured by the\r\n\r\n      proportion of participants achieving hepatitis C virus (HCV) RNA below the lower limit of\r\n\r\n      quantification (LLOQ) 12 weeks after the last dos",
            "OverallStatus": "Recruiting",
            "StartDate": "March 2016",
            "CompletionDate": "September 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Gilead Sciences",
            "StudyCondition": "HIV-1 Infection",
            "studyLocation": "University of Alabama at Birmingham",
            "Enrollment": "240",
            "NctKeyword": "HIV, HCV, Antiretroviral therapy, HCV direct acting antiviral(s) (DAA),",
            "MeshKeyword": "Infection, Communicable Diseases,",
            "InterventionKeyword": "Tenofovir, Emtricitabine, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Ledipasvir, sofosbuvir drug combination, Cobicistat, Ledipasvir, Rilpivirine, Sofosbuvir,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Chronic genotype (GT) 1, HCV infected, male and non-pregnant/ non-lactating female\r\n\r\n             individuals, without cirrhosis, treatment-naive or treatment-experienced with\r\n\r\n             interferon",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 22, 2016",
            "FirstReceived": "March 9, 2016",
            "OverallOfficial": "Gilead Study Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Gilead Sciences",
            "ContactName": "Gilead Study Team",
            "ContactEmail": "GS-US-366-1992@gilead.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Alabama at Birmingham",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02707601",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160283 - Gilead - Campo",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20160283",
            "StudyNumber": "20160283 - Gilead - Campo",
            "StudyTitle": "A Phase 3b Randomized, Open-label, Controlled Study of the\nEfficacy, Safety and Tolerability of 12 Weeks of\nLedipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV\nCo-infected Subjects who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide\n(E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide\n(F/R/TAF) prior to LDV/SOF HCV Treatment, the HIV/HCV\nCo-STARs study (Co-infection treatment with Single Tablet Antiviral\nRegimens)",
            "PIID": "235",
            "PicNum": "C00552940",
            "PILastName": "Campo",
            "PIFirstName": "Rafael E.",
            "CoodCNbr": "C00548607",
            "CoordLastName": "Salvarrey",
            "CoordFirstName": "Annie",
            "CoordEmail": "als215@miami.edu",
            "CoordPhone": "+1 (305) 243-4668",
            "EnteredByCNbr": "C00552940",
            "EnteredByLastName": "Campo",
            "EnteredByFirstName": "Rafael E.",
            "ActiveEnrollingDate": "08/17/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/17/2016",
            "IRBApprovedFrom": "05/26/2016",
            "IRBApprovedTo": "03/30/2017",
            "Expr1": "Phase II/III",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Gilead",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "2",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "2",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Pre-Review",
            "StudyCoordinator": "Maria Pieiga,Sam-mosley Ayuk,Tom Tanner,Kenia Moreno",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02707601",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02710422",
            "BriefTitle": "Miami Membrane for Potency (MMEP) Trial",
            "OfficialTitle": "Miami Membrane for Potency (MMeP) Trial to Assess the Impact of Dehydrated Human Amnion Membrane Allograft Placement During Robotic Radical Prostatectomy on Early Return of Erectile Function",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "The use of dehydrated human amnionic membrane allograft improves erectile function recovery\r\n\r\n      (as measured by (Sexual History Inventory for Men (SHIM) score) at 12 months after robotic\r\n\r\n      assisted radical prostatectomy (RARP) compar",
            "Description": "This is a phase 2 prospective randomized trial investigating the impact of amniotic membrane\r\n\r\n      placement over the neurovascular bundles after bilateral nerve sparing robot assisted\r\n\r\n      radical prostatectomy on potency. The study will",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Prostate Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "280",
            "NctKeyword": "Prostate Cancer, Amniotic Membrane Placement, Robotic Assisted Radical Prostatectomy, RARP, Human Amniotic Membrane Allograft,",
            "MeshKeyword": "Prostatic Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Men age 40-80 with localized prostate cancer who are undergoing bilateral nerve\r\n\r\n             sparing RARP at the University of Miami\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n          -  Men with poo",
            "EligibleGender": "Male",
            "MinAge": "40 Years",
            "MaxAge": "80 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 17, 2016",
            "FirstReceived": "March 11, 2016",
            "OverallOfficial": "Sanoj Punnen, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02710422",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150952 - Vivex - Punnen",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150952",
            "StudyNumber": "20150952 - Vivex - Punnen",
            "StudyTitle": "Miami Membrane for Potency (MMEP) Trial to Assess the Impact of Dehydrated Human Amnion Membrane Allograft Placement during Robotic Radical Prostatectomy on Early Return of Erectile Function",
            "PIID": "4718",
            "PicNum": "C11876129",
            "PILastName": "Punnen",
            "PIFirstName": "Sanoj",
            "CoodCNbr": "C11969658",
            "CoordLastName": "Barakat",
            "CoordFirstName": "Rody",
            "CoordEmail": "rxb773@med.miami.edu",
            "EnteredByCNbr": "C11965476",
            "EnteredByLastName": "Gonzalez",
            "EnteredByFirstName": "Liz",
            "ActiveEnrollingDate": "05/02/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/02/2016",
            "IRBApprovedFrom": "03/01/2016",
            "IRBApprovedTo": "02/28/2017",
            "DiseaseSiteListDesc": "Prostate",
            "Expr1": "Phase II",
            "Tarea": "Prostate, Bladder, and Kidney Cancers",
            "TareaCode": "12537",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "9",
            "Totalaccrued": "7",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "6",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "9",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Marinellie Vega,Greeyt Hernandez",
            "NationalSampleSize": "280",
            "NCTNbr": "NCT02710422",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02711137",
            "BriefTitle": "A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",
            "OfficialTitle": "A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",
            "LeadSponsorClass": "Incyte Corporation",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Incyte Corporation",
            "OversightAuthority": "No",
            "BriefSummary": "This is an open-label, dose-escalation/dose-expansion study of INCB057643 in subjects with\r\n\r\n      advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or\r\n\r\n      a tolerated dose that demonstrates sufficie",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2016",
            "CompletionDate": "July 2018",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Incyte Corporation",
            "StudyCondition": "Advanced Cancer",
            "Enrollment": "155",
            "NctKeyword": "Solid tumor, lymphoma, leukemia, AML, myelodysplastic syndrome (MDS), multiple myeloma, myeloproliferative neoplasm (MPN), MDS/MPN, myelofibrosis (MF), pancreatic cancer, colorectal cancer, non-small cell lung cancer, prostate cancer, breast cancer, ovari",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Histologically or cytologically confirmed diagnosis of advanced malignancy:\r\n\r\n\r\n\r\n               -  Part 1: advanced solid tumor or hematologic malignancy\r\n\r\n\r\n\r\n               -  Part 2: histologically",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Birmingham",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 3, 2016",
            "FirstReceived": "March 9, 2016",
            "OverallOfficial": "Fred Zheng, MD, PhD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Incyte Corporation",
            "ContactName": "Incyte Corporation Call Center",
            "ContactPhone": "1.855.463.3463",
            "LocationStatus": "Not yet recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02711137",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160292 - Incyte Corporation - Watts",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160292",
            "StudyNumber": "20160292 - Incyte Corporation - Watts",
            "StudyTitle": "A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies",
            "PIID": "22711",
            "PicNum": "C11915545",
            "PILastName": "Watts",
            "PIFirstName": "Justin",
            "CoodCNbr": "C11954409",
            "CoordLastName": "Ogden",
            "CoordFirstName": "Jillian",
            "CoordEmail": "jbo25@miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "07/26/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/26/2016",
            "IRBApprovedFrom": "05/12/2016",
            "IRBApprovedTo": "09/02/2016",
            "AccountNbr": "667282",
            "DiseaseSiteListDesc": "Ovary,Non-Hodgkins Lymphoma,Multiple Myeloma,Myeloid and Monocytic Leukemia,Leukemia, Other,Leukemia, not otherwise specified,Colon,Breast-Female,Rectum,Bones and Joints",
            "Expr1": "Phase I",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "3",
            "FirstNinety": "1",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Yvonne Dinh,Juan Salvador,Tamara Leon Aliz,Karen Blackburn,Daniel Sumarriva,Sandra Pineda",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02711137",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02713204",
            "BriefTitle": "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection",
            "OfficialTitle": "A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration",
            "LeadSponsorClass": "Regeneron Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Regeneron Pharmaceuticals",
            "BriefSummary": "The primary objective of the study is to compare the efficacy of intravitreal\r\n\r\n      (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "CompletionDate": "November 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Regeneron Pharmaceuticals",
            "StudyCondition": "Neovascular Age-Related Macular Degeneration",
            "studyLocation": "Regeneron Investigational Site",
            "Enrollment": "360",
            "MeshKeyword": "Macular Degeneration, Wet Macular Degeneration,",
            "InterventionKeyword": "Endothelial Growth Factors,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Men or women ≥50 years of age with active subfoveal CNV secondary to AMD, including\r\n\r\n             juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye as\r\n\r\n             as",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Mobile",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 10, 2017",
            "FirstReceived": "March 14, 2016",
            "OverallOfficial": "Clinical Trial Management",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Regeneron Pharmaceuticals",
            "ContactName": "Clinical Trials Administrator",
            "ContactEmail": "clinicaltrials@regeneron.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Regeneron Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02713204",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160702 - REGENERON PHARM INC - Kovach",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20160702",
            "StudyNumber": "20160702 - REGENERON PHARM INC - Kovach",
            "StudyTitle": "A Randomized, Double-masked Active-Controlled Phase 2 Study of the Efficacy, Safety, and tolerability of repeated doses of Intravitreal REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration",
            "PIID": "1262",
            "PicNum": "C05023433",
            "PILastName": "Kovach",
            "PIFirstName": "Jaclyn",
            "CoodCNbr": "C12016733",
            "CoordLastName": "Dear",
            "CoordFirstName": "Paula",
            "CoordEmail": "pmd74@med.miami.edu",
            "EnteredByCNbr": "C05023433",
            "EnteredByLastName": "Kovach",
            "EnteredByFirstName": "Jaclyn",
            "ActiveEnrollingDate": "11/21/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/21/2016",
            "IRBApprovedFrom": "09/15/2016",
            "IRBApprovedTo": "02/09/2017",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "REGENERON PHARM INC",
            "Prescreened": "0",
            "Screenedfailed": "3",
            "SignedICF": "4",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "4",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,BPPB:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Paula Dear,Ailen Gutierrez,Maria Esquiabro,Jacob Welch",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02713204",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02713204",
            "BriefTitle": "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection",
            "OfficialTitle": "A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration",
            "LeadSponsorClass": "Regeneron Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Regeneron Pharmaceuticals",
            "BriefSummary": "The primary objective of the study is to compare the efficacy of intravitreal\r\n\r\n      (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).",
            "OverallStatus": "Recruiting",
            "StartDate": "February 2016",
            "CompletionDate": "November 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Regeneron Pharmaceuticals",
            "StudyCondition": "Neovascular Age-Related Macular Degeneration",
            "studyLocation": "Regeneron Investigational Site",
            "Enrollment": "360",
            "MeshKeyword": "Macular Degeneration, Wet Macular Degeneration,",
            "InterventionKeyword": "Endothelial Growth Factors,",
            "Eligibility": "Key Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Men or women ≥50 years of age with active subfoveal CNV secondary to AMD, including\r\n\r\n             juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye as\r\n\r\n             as",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Mobile",
            "State": "Alabama",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 10, 2017",
            "FirstReceived": "March 14, 2016",
            "OverallOfficial": "Clinical Trial Management",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Regeneron Pharmaceuticals",
            "ContactName": "Clinical Trials Administrator",
            "ContactEmail": "clinicaltrials@regeneron.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Regeneron Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02713204",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160430 - Regeneron Pharmaceuticals/ Inc. - Haddock",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20160430",
            "StudyNumber": "20160430 - Regeneron Pharmaceuticals/ Inc. - Haddock",
            "StudyTitle": "A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF REPEATED DOSES OF INTRAVITREAL REGN910-3 IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION",
            "PIID": "23592",
            "PicNum": "C10569047",
            "PILastName": "Haddock",
            "PIFirstName": "Luis",
            "CoodCNbr": "C11963475",
            "CoordLastName": "Larez",
            "CoordFirstName": "Lorena",
            "CoordEmail": "llarez@med.miami.edu",
            "EnteredByCNbr": "C10569047",
            "EnteredByLastName": "Haddock",
            "EnteredByFirstName": "Luis",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "02/11/2016",
            "IRBApprovedFrom": "02/11/2016",
            "IRBApprovedTo": "02/09/2017",
            "Expr1": "Phase II",
            "Tarea": "Retina",
            "TareaCode": "12038",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Regeneron Pharmaceuticals/ Inc.",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Pre-Review",
            "StudyCoordinator": "Lorena Larez,Chantey Roberts",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02713204",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02713828",
            "SecondaryId": "CDX011-54",
            "BriefTitle": "Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung",
            "OfficialTitle": "A Phase I/II Study of Glembatumumab Vedotin in Patients With gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung",
            "LeadSponsorClass": "PrECOG, LLC.",
            "SponsorAgency": "Other",
            "LeadSponsor": "PrECOG, LLC.",
            "OversightAuthority": "Yes",
            "BriefSummary": "Patients with advanced or metastatic, gpNMB-expressing Squamous Cell Carcinoma (SCC) of the\r\n\r\n      lung who have failed a prior platinum-based chemotherapy regimen will receive glembatumumab\r\n\r\n      vedotin.\r\n\r\n\r\n\r\n      Glembatumumab vedotin",
            "Description": "Lung cancer is the most frequent cancer in the world, with annual cases worldwide currently\r\n\r\n      estimated at one million and increasing to 10 million by the year 2025. In the United\r\n\r\n      States, despite the declining incidence in white",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2016",
            "CompletionDate": "August 2020",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "PrECOG, LLC.",
            "StudyCondition": "Squamous Cell Carcinoma of the Lung",
            "studyLocation": "University of Miami Hospital",
            "Enrollment": "49",
            "NctKeyword": "gpNMB-Expressing Squamous Cell Carcinoma of the Lung, Stage IIIb, Stage IV, Advanced Squamous Cell Cancer of the Lung, Metastatic Squamous Cell Cancer of the Lung, gpNMB-Expressing, Glembatumumab Vedotin,",
            "MeshKeyword": "Carcinoma, Squamous Cell, Carcinoma, Lung Neoplasms,",
            "InterventionKeyword": "Antibodies, Monoclonal,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Read, understood, and provided written informed consent and Health Insurance\r\n\r\n             Portability and Accountability Act (HIPAA) authorization after the nature of the\r\n\r\n             study has bee",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 7, 2016",
            "FirstReceived": "March 8, 2016",
            "OverallOfficial": "Rathi Pillai, MD",
            "OverallRole": "Study Chair",
            "OverallAffilitation": "PrECOG, LLC.",
            "ContactName": "Carolyn Andrews, RN",
            "ContactPhone": "215-789-7001",
            "ContactEmail": "candrews@precogllc.org",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02713828",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160326 - PrECOG - Ikpeazu",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160326",
            "StudyNumber": "20160326 - PrECOG - Ikpeazu",
            "StudyTitle": "A Phase I/II Study of Glembatumumab Vedotin in Patients with gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung",
            "PIID": "373",
            "PicNum": "C06163680",
            "PILastName": "Ikpeazu",
            "PIFirstName": "Chukwuemeka",
            "CoodCNbr": "C11967166",
            "CoordLastName": "Eyer",
            "CoordFirstName": "Penny",
            "CoordEmail": "ple19@med.miami.edu",
            "CoordPhone": "954-698-3673",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "11/07/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/07/2016",
            "IRBApprovedFrom": "05/27/2016",
            "IRBApprovedTo": "11/26/2016",
            "AccountNbr": "668095",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase I/II",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,Plantation:N/A,UM Kendall:N/A,UMMG:N/A,UMD:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Michelle Mikhail,Carla Munevar,Evan Dadas,Cristina Rojas-Mejia,Claudia Grandas Moreno,Anthony Minichiello",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02713828",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02714153",
            "BriefTitle": "Bridge Occlusion Balloon in Lead Extraction Procedure",
            "OfficialTitle": "Bridge Occlusion Balloon Initial Use in Humans Study",
            "LeadSponsorClass": "Yale University",
            "SponsorAgency": "Other",
            "LeadSponsor": "Yale University",
            "OversightAuthority": "Yes",
            "BriefSummary": "To evaluate the use of an occlusion balloon (Bridge™ Occlusion Balloon, Spectranetics)\r\n\r\n      within the Superior Vena Cava in lead extraction patients.",
            "Description": "This study will evaluate the use of an occlusion balloon (Bridge™ Occlusion Balloon,\r\n\r\n      Spectranetics) within the Superior Vena Cava in lead extraction patients. This will be\r\n\r\n      performed in a non-emergent setting to allow for evalua",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2016",
            "CompletionDate": "May 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Yale University",
            "StudyCondition": "C.Surgical Procedure; Cardiac",
            "studyLocation": "University of Miami Hospital",
            "Enrollment": "25",
            "NctKeyword": "Lead extraction, Superior Vena Cava Tear, Pacemaker/Defibrillator lead extraction,",
            "MeshKeyword": "Arrhythmias, Cardiac,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subject age more than 18 years\r\n\r\n\r\n\r\n          -  Lead extraction patients\r\n\r\n\r\n\r\n        Exclusion Criteria:\r\n\r\n\r\n\r\n        Lead extraction patients with:\r\n\r\n\r\n\r\n          -  Superior Vena Cava occlusi",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33125",
            "Country": "United States",
            "VerificationDate": "October 2016",
            "LastChanged": "October 14, 2016",
            "FirstReceived": "March 4, 2016",
            "OverallOfficial": "Jude Clancy, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Yale University",
            "ContactName": "Medhat Abdelmessih, MD",
            "ContactPhone": "(203)737-1330",
            "ContactEmail": "medhat.abdelmessih@yale.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Hospital",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02714153",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160201 - Spectranetics - Carrillo",
            "FileProcessContentId": "440",
            "Division": "Cardiology",
            "StdyDivision": "7802",
            "EprostNbr": "20160201",
            "StudyNumber": "20160201 - Spectranetics - Carrillo",
            "StudyTitle": "Bridge Occlusion Balloon Initial Use in Humans Study.",
            "PIID": "1975",
            "PicNum": "C00394135",
            "PILastName": "Carrillo",
            "PIFirstName": "Roger",
            "CoodCNbr": "C06989384",
            "CoordLastName": "Khan",
            "CoordFirstName": "Rosa",
            "CoordEmail": "ekhan@med.miami.edu",
            "CoordPhone": "3056892780",
            "EnteredByCNbr": "C00394135",
            "EnteredByLastName": "Carrillo",
            "EnteredByFirstName": "Roger",
            "ActiveEnrollingDate": "05/12/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "05/12/2016",
            "IRBApprovedFrom": "03/28/2016",
            "IRBApprovedTo": "03/27/2017",
            "Expr1": "N/A",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "Spectranetics",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "5",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "5",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,UMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Raiza Salceda,Rosa Khan",
            "NationalSampleSize": "5",
            "NCTNbr": "NCT02714153",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02716155",
            "BriefTitle": "[Trial of device that is not approved or cleared by the U.S. FDA]",
            "OfficialTitle": "[Trial of device that is not approved or cleared by the U.S. FDA]",
            "LeadSponsorClass": "[Redacted]",
            "SponsorAgency": "Industry",
            "LeadSponsor": "[Redacted]",
            "OverallStatus": "Withheld",
            "StartDate": "September 2016",
            "Phase": "N/A",
            "StudyType": "N/A",
            "StudyPhase": "N/A",
            "StudySource": "[Redacted]",
            "LastChanged": "October 20, 2016",
            "FirstReceived": "March 15, 2016",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02716155",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160478 - CareFusion Corporation - Bancalari",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20160478",
            "StudyNumber": "20160478 - CareFusion Corporation - Bancalari",
            "StudyTitle": "Multicenter Study of Saturation Targeting by Automated vs. Manual Adjustment of Inspired Oxygen in Neonates and Infants",
            "PIID": "1186",
            "PicNum": "C00161505",
            "PILastName": "Bancalari",
            "PIFirstName": "Eduardo",
            "CoodCNbr": "C00405474",
            "CoordLastName": "Claure",
            "CoordFirstName": "Nelson",
            "CoordEmail": "nclaure@med.miami.edu",
            "CoordPhone": "305-585-6408",
            "EnteredByCNbr": "C00161505",
            "EnteredByLastName": "Bancalari",
            "EnteredByFirstName": "Eduardo",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "08/15/2016",
            "IRBApprovedFrom": "08/15/2016",
            "IRBApprovedTo": "08/14/2017",
            "Expr1": "N/A",
            "Tarea": "Neonatology",
            "TareaCode": "10436",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "CareFusion Corporation",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Modifications Required",
            "StudyCoordinator": "Carmen D'Ugard",
            "NationalSampleSize": "24",
            "NCTNbr": "NCT02716155",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02717195",
            "SecondaryId": "2014-003569-12",
            "BriefTitle": "Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia",
            "OfficialTitle": "Interventional, Randomised, Double-blind, Active-controlled, Fixed-dose Study of Lu AF35700 in Patients With Treatment-resistant Schizophrenia",
            "LeadSponsorClass": "H. Lundbeck A/S",
            "SponsorAgency": "Industry",
            "LeadSponsor": "H. Lundbeck A/S",
            "OversightAuthority": "No",
            "BriefSummary": "To evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in\r\n\r\n      patients with treatment-resistant schizophrenia (TRS)",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2016",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "H. Lundbeck A/S",
            "StudyCondition": "Schizophrenia",
            "studyLocation": "US1041",
            "Enrollment": "964",
            "MeshKeyword": "Schizophrenia,",
            "InterventionKeyword": "Risperidone, Olanzapine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  The patient has schizophrenia, diagnosed according to DSM-5(TM) (Diagnostic and\r\n\r\n             Statistical Manual of Mental Disorders) and confirmed by the Mini International\r\n\r\n             Neuropsychi",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Cerritos",
            "State": "California",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 21, 2016",
            "FirstReceived": "March 11, 2016",
            "OverallOfficial": "Email contact via H. Lundbeck A/S",
            "OverallRole": "Study Director",
            "OverallAffilitation": "LundbeckClinicalTrials@Lundbeck.com",
            "ContactName": "Email contact via H. Lundbeck A/S",
            "ContactEmail": "LundbeckClinicalTrials@Lundbeck.com",
            "LocationStatus": "Recruiting",
            "LocationName": "US1041",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02717195",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160192 - Lundbeck Na Ltd. - Strassnig",
            "FileProcessContentId": "440",
            "Division": "Psychiatry",
            "StdyDivision": "10256",
            "EprostNbr": "20160192",
            "StudyNumber": "20160192 - Lundbeck Na Ltd. - Strassnig",
            "StudyTitle": "Interventional, randomized, double-blind, active-controlled, fixed-dose study of Lu AF35700 in patients with Treatment-resistant Schizophrenia",
            "PIID": "4295",
            "PicNum": "C10560217",
            "PILastName": "Strassnig",
            "PIFirstName": "Martin",
            "CoodCNbr": "C04892431",
            "CoordLastName": "Brenson",
            "CoordFirstName": "Nicole",
            "CoordEmail": "nbrenson@med.miami.edu",
            "CoordPhone": "3053558186",
            "EnteredByCNbr": "C10560217",
            "EnteredByLastName": "Strassnig",
            "EnteredByFirstName": "Martin",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "06/20/2016",
            "IRBApprovedFrom": "06/20/2016",
            "IRBApprovedTo": "01/27/2017",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Lundbeck Na Ltd.",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Pre-Review",
            "StudyCoordinator": "Tania Guardia,Nicole Brenson",
            "NationalSampleSize": "15",
            "NCTNbr": "NCT02717195",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02719574",
            "BriefTitle": "Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation",
            "OfficialTitle": "A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation",
            "LeadSponsorClass": "Forma Therapeutics, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Forma Therapeutics, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "This Phase 1/1b study will utilize a multicenter, open-label dose-escalation design to\r\n\r\n      evaluate the safety, PK, and PD of FT-2102 (single agent) and FT-2102 + azacitidine\r\n\r\n      (combination agent) administered via one or more intermi",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2016",
            "CompletionDate": "July 2018",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Forma Therapeutics, Inc.",
            "StudyCondition": "Acute Myeloid Leukemia",
            "studyLocation": "University of Miami, Sylvester Comprehensive Cancer Center",
            "Enrollment": "76",
            "NctKeyword": "AML, MDS, IDH1, IDH,",
            "MeshKeyword": "Leukemia, Myeloid, Leukemia, Myeloid, Acute, Leukemia, Syndrome, Myelodysplastic Syndromes, Preleukemia,",
            "InterventionKeyword": "Azacitidine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Pathologically proven acute myeloid leukemia or high risk or very high risk MDS as\r\n\r\n             defined by the World Health Organization (WHO) criteria or Revised International\r\n\r\n             Prognos",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 8, 2016",
            "FirstReceived": "March 21, 2016",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami, Sylvester Comprehensive Cancer Center",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02719574",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160327 - FORMA Therapeutics - Watts",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160327",
            "StudyNumber": "20160327 - FORMA Therapeutics - Watts",
            "StudyTitle": "A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation",
            "PIID": "22711",
            "PicNum": "C11915545",
            "PILastName": "Watts",
            "PIFirstName": "Justin",
            "CoodCNbr": "C11954409",
            "CoordLastName": "Ogden",
            "CoordFirstName": "Jillian",
            "CoordEmail": "jbo25@miami.edu",
            "EnteredByCNbr": "C07181703",
            "EnteredByLastName": "Zhang",
            "EnteredByFirstName": "Lei",
            "ActiveEnrollingDate": "08/04/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/04/2016",
            "IRBApprovedFrom": "05/06/2016",
            "IRBApprovedTo": "02/11/2017",
            "AccountNbr": "667281",
            "DiseaseSiteListDesc": "Myeloid and Monocytic Leukemia",
            "Expr1": "Phase I",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "2",
            "SignedICF": "6",
            "Totalaccrued": "4",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "4",
            "Totalpatients": "6",
            "FirstNinety": "3",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Tamara Leon Aliz,Randy Astaiza",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02719574",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02727881",
            "BriefTitle": "Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD",
            "OfficialTitle": "OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD)",
            "LeadSponsorClass": "Ohr Pharmaceutical Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Ohr Pharmaceutical Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2%\r\n\r\n      Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Patients will\r\n\r\n      receive injections of ranibizumab. In addition,",
            "Description": "Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2%\r\n\r\n      Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration Methodology: Phase\r\n\r\n      III, multicenter, randomized, double-masked, p",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2016",
            "CompletionDate": "April 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Ohr Pharmaceutical Inc.",
            "StudyCondition": "Age-related Macular Degeneration",
            "studyLocation": "Investigational Site",
            "Enrollment": "650",
            "NctKeyword": "AMD, CNV, choroidal neovascularization, retinal eye disease,",
            "MeshKeyword": "Macular Degeneration,",
            "InterventionKeyword": "Pharmaceutical Solutions, Ophthalmic Solutions, Ranibizumab, Squalamine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Age ≥ 50 years\r\n\r\n\r\n\r\n          -  A diagnosis of choroid neovascularization (CNV) secondary to AMD with CNV comprising\r\n\r\n             at least 50% of the total lesion area on fluorescein angiography (F",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "110 Years",
            "Volunteers": "No",
            "City": "Mobile",
            "State": "Alabama",
            "Zip": "36608",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 5, 2016",
            "FirstReceived": "March 28, 2016",
            "OverallOfficial": "Avner Ingerman, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Ohr Pharmaceutical",
            "ContactName": "Avner Ingerman, MD",
            "ContactPhone": "2126828452",
            "ContactEmail": "aingerman@ohrpharmaceutical.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02727881",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160704 - Ohr Pharmaceutical Inc - Kovach",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20160704",
            "StudyNumber": "20160704 - Ohr Pharmaceutical Inc - Kovach",
            "StudyTitle": "OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice daily in Subjects with Neovascular Age-Related Macular Degeneration",
            "PIID": "1262",
            "PicNum": "C05023433",
            "PILastName": "Kovach",
            "PIFirstName": "Jaclyn",
            "CoodCNbr": "C12016733",
            "CoordLastName": "Dear",
            "CoordFirstName": "Paula",
            "CoordEmail": "pmd74@med.miami.edu",
            "EnteredByCNbr": "C05023433",
            "EnteredByLastName": "Kovach",
            "EnteredByFirstName": "Jaclyn",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "10/05/2016",
            "IRBApprovedFrom": "10/05/2016",
            "IRBApprovedTo": "01/19/2017",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "Ohr Pharmaceutical Inc",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Paula Dear,Jacob Welch,Maria Esquiabro",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02727881",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02727881",
            "BriefTitle": "Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD",
            "OfficialTitle": "OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD)",
            "LeadSponsorClass": "Ohr Pharmaceutical Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Ohr Pharmaceutical Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2%\r\n\r\n      Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Patients will\r\n\r\n      receive injections of ranibizumab. In addition,",
            "Description": "Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2%\r\n\r\n      Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration Methodology: Phase\r\n\r\n      III, multicenter, randomized, double-masked, p",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2016",
            "CompletionDate": "April 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Ohr Pharmaceutical Inc.",
            "StudyCondition": "Age-related Macular Degeneration",
            "studyLocation": "Investigational Site",
            "Enrollment": "650",
            "NctKeyword": "AMD, CNV, choroidal neovascularization, retinal eye disease,",
            "MeshKeyword": "Macular Degeneration,",
            "InterventionKeyword": "Pharmaceutical Solutions, Ophthalmic Solutions, Ranibizumab, Squalamine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Age ≥ 50 years\r\n\r\n\r\n\r\n          -  A diagnosis of choroid neovascularization (CNV) secondary to AMD with CNV comprising\r\n\r\n             at least 50% of the total lesion area on fluorescein angiography (F",
            "EligibleGender": "All",
            "MinAge": "50 Years",
            "MaxAge": "110 Years",
            "Volunteers": "No",
            "City": "Mobile",
            "State": "Alabama",
            "Zip": "36608",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 5, 2016",
            "FirstReceived": "March 28, 2016",
            "OverallOfficial": "Avner Ingerman, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Ohr Pharmaceutical",
            "ContactName": "Avner Ingerman, MD",
            "ContactPhone": "2126828452",
            "ContactEmail": "aingerman@ohrpharmaceutical.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Investigational Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02727881",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160512 - CHILTERN INTNL INC - Yehoshua",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20160512",
            "StudyNumber": "20160512 - CHILTERN INTNL INC - Yehoshua",
            "StudyTitle": "OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration in combination with intravitreal (IVT) injections of ranibizumab (lucentis)",
            "PIID": "1823",
            "PicNum": "C06958118",
            "PILastName": "Yehoshua",
            "PIFirstName": "Zohar",
            "CoodCNbr": "C09867862",
            "CoordLastName": "Gutierrez",
            "CoordFirstName": "Ailen",
            "CoordEmail": "aeg155@miami.edu",
            "EnteredByCNbr": "C06958118",
            "EnteredByLastName": "Yehoshua",
            "EnteredByFirstName": "Zohar",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "01/20/2016",
            "IRBApprovedFrom": "01/20/2016",
            "IRBApprovedTo": "01/19/2017",
            "ResearchType": "Drug",
            "SponsorGroup": "Intramural",
            "Sponsor": "Intramural",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Monica Arango,Ailen Gutierrez,Maria Esquiabro",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02727881",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "N"
         },
         {
            "NCTdataId": "NCT02729896",
            "SecondaryId": "2015-004845-25",
            "BriefTitle": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
            "OfficialTitle": "A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS POLATUZUMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND OR RITUXIMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS POLATUZUMAB",
            "LeadSponsorClass": "Hoffmann-La Roche",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Hoffmann-La Roche",
            "BriefSummary": "This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of\r\n\r\n      obinutuzumab (G) + atezolizumab (Atezo) + polatuzumab vedotin (Pola) in participants with\r\n\r\n      relapsed or refractory FL or DLBCL. The study will",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2016",
            "CompletionDate": "July 2020",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Hoffmann-La Roche",
            "StudyCondition": "Lymphoma",
            "studyLocation": "University Miami",
            "Enrollment": "73",
            "MeshKeyword": "Lymphoma, Follicular, Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse,",
            "InterventionKeyword": "Antibodies, Monoclonal, Immunoconjugates, Obinutuzumab,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Eastern Cooperative Oncology Group (ECOG) A21 Status of 0, 1, or 2\r\n\r\n\r\n\r\n          -  For participants enrolled in the dose-escalation phase: relapsed or refractory FL\r\n\r\n             after treatment wi",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 21, 2016",
            "FirstReceived": "April 1, 2016",
            "OverallOfficial": "Clinical Trials",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Hoffmann-La Roche",
            "ContactName": "Reference Study ID Number: BO29561 www.roche.com/about_roche/roche_worldwide.htm",
            "ContactPhone": "888-662-6728 (U.S. and Canada)",
            "ContactEmail": "global.rochegenentechtrials@roche.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02729896",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160244 - F Hoffmann La Roche - Lossos",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160244",
            "StudyNumber": "20160244 - F Hoffmann La Roche - Lossos",
            "StudyTitle": "A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS POLATUZUMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA",
            "PIID": "396",
            "PicNum": "C02540370",
            "PILastName": "Lossos",
            "PIFirstName": "Izidore",
            "CoodCNbr": "C11954409",
            "CoordLastName": "Ogden",
            "CoordFirstName": "Jillian",
            "CoordEmail": "jbo25@miami.edu",
            "EnteredByCNbr": "C11956581",
            "EnteredByLastName": "Warren",
            "EnteredByFirstName": "Tricia",
            "ActiveEnrollingDate": "07/05/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/05/2016",
            "IRBApprovedFrom": "04/27/2016",
            "IRBApprovedTo": "02/28/2017",
            "AccountNbr": "667079",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma",
            "Expr1": "Phase I/II",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "2",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Yvonne Dinh,Randy Astaiza,Juan Salvador,Tamara Leon Aliz",
            "NationalSampleSize": "12",
            "NCTNbr": "NCT02729896",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02734810",
            "BriefTitle": "SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis",
            "OfficialTitle": "A Phase 3, Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency",
            "LeadSponsorClass": "Anthera Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Anthera Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "Liprotamase consists of 3 soluble, non-porcine digestive enzymes, lipase, protease, and\r\n\r\n      amylase, combined in a fixed ratio. Liprotamase is stable in the stomach and can be\r\n\r\n      formulated without enteric coating for administration e",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2016",
            "CompletionDate": "June 2017",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Anthera Pharmaceuticals",
            "StudyCondition": "Exocrine Pancreatic Insufficiency",
            "studyLocation": "Investigator Site 139",
            "Enrollment": "46",
            "NctKeyword": "Exocrine Pancreatic Insufficiency, Cystic Fibrosis, Liprotamase, Pancreatic Enzyme Replacement Therapy (PERT),",
            "MeshKeyword": "Fibrosis, Cystic Fibrosis, Exocrine Pancreatic Insufficiency,",
            "InterventionKeyword": "Pharmaceutical Solutions,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  For Part A: males or females ≥7 years of age\r\n\r\n\r\n\r\n          -  For Part B: males or females 28 days to <7 years\r\n\r\n\r\n\r\n          -  Diagnosis of cystic fibrosis based on presentation, genotype and/or s",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Little Rock",
            "State": "Arkansas",
            "Zip": "72202",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 21, 2016",
            "FirstReceived": "April 6, 2016",
            "ContactName": "Monica Gangal",
            "ContactEmail": "mgangal@anthera.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Investigator Site 139",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02734810",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160488 - Anthera Pharmaceuticals Inc. - Colin",
            "FileProcessContentId": "440",
            "Division": "Pediatrics",
            "StdyDivision": "9736",
            "EprostNbr": "20160488",
            "StudyNumber": "20160488 - Anthera Pharmaceuticals Inc. - Colin",
            "StudyTitle": "Anthera Simplicity Studying Impacts on Malabsorption with Liprotamase in Cystic Fibrosis",
            "PIID": "2292",
            "PicNum": "C04265141",
            "PILastName": "Colin",
            "PIFirstName": "Andrew",
            "CoodCNbr": "C01984185",
            "CoordLastName": "Boza",
            "CoordFirstName": "Henry",
            "EnteredByCNbr": "C04265141",
            "EnteredByLastName": "Colin",
            "EnteredByFirstName": "Andrew",
            "ActiveEnrollingDate": "08/01/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "08/01/2016",
            "IRBApprovedFrom": "05/20/2016",
            "IRBApprovedTo": "04/21/2017",
            "SponsorGroup": "Industry",
            "Sponsor": "Anthera Pharmaceuticals Inc.",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Patricia Graham-Borras,Henry Boza",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02734810",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02737046",
            "BriefTitle": "Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma",
            "OfficialTitle": "A Phase II Trial of Belinostat as Consolidation Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "The investigators propose to use Belinostat in combination with AZT as consolidation therapy\r\n\r\n      for the treatment of ATLL.",
            "Description": "ATLL is an aggressive malignancy caused by HTLV-1. ATLL cannot be cured by conventional\r\n\r\n      chemotherapy thus urging the development of new therapeutic strategies. HDAC inhibitors are\r\n\r\n      broadly active anti-neoplastic agents that can",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Adult T-cell Leukemia-Lymphoma",
            "studyLocation": "University of Miami",
            "Enrollment": "20",
            "NctKeyword": "Adult T-cell Leukemia-Lymphoma, ATLL,",
            "MeshKeyword": "Lymphoma, Leukemia, Leukemia, T-Cell, Leukemia-Lymphoma, Adult T-Cell,",
            "InterventionKeyword": "Belinostat, Interferons, Interferon-alpha, Zidovudine, Peginterferon alfa-2b,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Histologically or cytologically documented adult T-cell leukemia/lymphoma (ATLL) with\r\n\r\n             the following characteristics:\r\n\r\n\r\n\r\n               -  any stage of disease,\r\n\r\n\r\n\r\n               -",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 14, 2016",
            "FirstReceived": "April 10, 2016",
            "OverallOfficial": "Juan C Ramos, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02737046",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20150567 - Intramural - Ramos",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20150567",
            "StudyNumber": "20150567 - Intramural - Ramos",
            "StudyTitle": "A Phase II Trial of Belinostat as Consolidation Therapy with Zidovudine for Adult T-Cell Leukemia-Lymphoma",
            "PIID": "433",
            "PicNum": "C03978871",
            "PILastName": "Ramos",
            "PIFirstName": "Juan Carlos",
            "CoodCNbr": "C11923689",
            "CoordLastName": "Mohan",
            "CoordFirstName": "Vivin",
            "CoordEmail": "vxm153@miami.edu",
            "EnteredByCNbr": "C11972191",
            "EnteredByLastName": "Harris",
            "EnteredByFirstName": "Bretinsa",
            "ActiveEnrollingDate": "11/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/08/2016",
            "IRBApprovedFrom": "01/20/2016",
            "IRBApprovedTo": "01/04/2017",
            "AccountNbr": "307344",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma,Leukemia, Other",
            "Expr1": "Phase II",
            "Tarea": "Leukemia, Lymphoma, and Myeloma",
            "TareaCode": "10938",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "1",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A,UMHC:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Lapsed",
            "StudyCoordinator": "Sandra O'Mellan",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02737046",
            "StudyKeywords": "Per protocol Dr. Ramos sponsor the IND.(page3. Per Jennifer Munoz email 7/16/2015 Hi Vivi,\r\nDr. Ramos will be submitting an IND application to the FDA and he will hold the IND as Sponsor-Investigator.  He will cross reference Spectrum Pharmaceuticals, Inc. IND (#070789) in his submission for the Investigational Agent.If you need anything else, please feel free to ask. Thank you. Jen",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02737501",
            "BriefTitle": "ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients",
            "OfficialTitle": "A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer",
            "LeadSponsorClass": "Ariad Pharmaceuticals",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Ariad Pharmaceuticals",
            "OversightAuthority": "Yes",
            "BriefSummary": "A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in\r\n\r\n      ALK-positive Advanced Lung Cancer Patients",
            "Description": "The purpose of this phase III, randomized, open-label, comparative, multicenter,\r\n\r\n      international study is to compare the efficacy and safety of brigatinib to that of\r\n\r\n      crizotinib in anaplastic lymphoma kinase (ALK)-positive locally",
            "OverallStatus": "Recruiting",
            "StartDate": "April 2016",
            "CompletionDate": "April 2021",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Ariad Pharmaceuticals",
            "StudyCondition": "Non-small Cell Lung Cancer",
            "studyLocation": "Kaiser Permanente Southern California, Site #208",
            "Enrollment": "270",
            "NctKeyword": "Non-small cell lung cancer, Non-small cell lung carcinoma, Epithelial lung cancer, Squamous cell carcinoma, Large cell carcinoma, Adenocarcinoma, Carcinoma, Anaplastic Lymphoma Kinase (ALK), Advanced Cancers, Brigatinib, AP26113,",
            "MeshKeyword": "Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma,",
            "InterventionKeyword": "Crizotinib,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Have histologically or cytologically confirmed stage IIIB (and not a candidate for\r\n\r\n             definitive multimodality therapy) or stage IV NSCLC.\r\n\r\n\r\n\r\n          2. Must have documented ALK rearra",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "San Diego",
            "State": "California",
            "Zip": "92120",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "December 21, 2016",
            "FirstReceived": "March 30, 2016",
            "ContactName": "David Kerstein, MD",
            "ContactPhone": "(617) 494-0400",
            "ContactEmail": "David.Kerstein@ARIAD.com",
            "LocationStatus": "Recruiting",
            "LocationName": "Kaiser Permanente Southern California, Site #208",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02737501",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160601 - Ariad Pharmaceuticals - Jahanzeb",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160601",
            "StudyNumber": "20160601 - Ariad Pharmaceuticals - Jahanzeb",
            "StudyTitle": "A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer",
            "PIID": "2421",
            "PicNum": "C09904097",
            "PILastName": "Jahanzeb",
            "PIFirstName": "Mohammad",
            "CoodCNbr": "C11975723",
            "CoordLastName": "Minichiello",
            "CoordFirstName": "Anthony",
            "CoordEmail": "agm112@miami.edu",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "11/07/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/07/2016",
            "IRBApprovedFrom": "08/25/2016",
            "IRBApprovedTo": "03/09/2017",
            "AccountNbr": "667953",
            "DiseaseSiteListDesc": "Lung",
            "Expr1": "Phase III",
            "Tarea": "Thoracic Oncology",
            "TareaCode": "12539",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMD:N/A,UMHC:N/A,UMMG:N/A,UM Hollywood:N/A,Plantation:N/A,UM Kendall:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Penny Eyer,Claudia Grandas Moreno,Michelle Mikhail,Carla Munevar",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02737501",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02770716",
            "BriefTitle": "A Study To Confirm Efficacy and Safety of Terlipressin in HRS Type 1",
            "OfficialTitle": "A Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects With Hepatorenal Syndrome Type 1 (The CONFIRM Study)",
            "LeadSponsorClass": "Mallinckrodt",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Mallinckrodt",
            "OversightAuthority": "Yes",
            "BriefSummary": "This study is to confirm the efficacy and safety of intravenous terlipressin versus placebo\r\n\r\n      in the treatment of adult subjects with hepatorenal syndrome (HRS) Type 1.",
            "Description": "This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter pivotal trial\r\n\r\n      of terlipressin in subjects with HRS type 1. HRS is a rare syndrome of marked renal\r\n\r\n      dysfunction in patients with cirrhosis, decompensate",
            "OverallStatus": "Recruiting",
            "StartDate": "May 2016",
            "CompletionDate": "January 2020",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Mallinckrodt",
            "StudyCondition": "Hepatorenal Syndrome",
            "studyLocation": "University of Arizona",
            "Enrollment": "300",
            "MeshKeyword": "Syndrome, Hepatorenal Syndrome,",
            "InterventionKeyword": "Terlipressin, Lypressin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Adults with cirrhosis and ascites\r\n\r\n\r\n\r\n          -  Rapidly progressive worsening in renal function to a serum creatinine (SCr) ≥2.25\r\n\r\n             mg/dL\r\n\r\n\r\n\r\n          -  No sustained improvement",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Tucson",
            "State": "Arizona",
            "Zip": "85724",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 3, 2016",
            "FirstReceived": "May 10, 2016",
            "OverallOfficial": "Khurram Jamil, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Mallinckrodt",
            "ContactName": "Kelly R Williams, BS",
            "ContactPhone": "3146543277",
            "ContactEmail": "kelly.williams2@mallinckrodt.com",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "University of Arizona",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02770716",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160328 - Mallinckrodt Pharmaceuticals - Bhamidimarri",
            "FileProcessContentId": "440",
            "Division": "Hepatology",
            "StdyDivision": "10246",
            "EprostNbr": "20160328",
            "StudyNumber": "20160328 - Mallinckrodt Pharmaceuticals - Bhamidimarri",
            "StudyTitle": "MNK19013058-A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM EFFICACY AND SAFETY OF TERLIPRESSIN IN SUBJECTS WITH HEPATORENAL SYNDROME TYPE 1",
            "PIID": "3536",
            "PicNum": "C10581001",
            "PILastName": "Bhamidimari",
            "PIFirstName": "Kalyan",
            "CoodCNbr": "C09262846",
            "CoordLastName": "Carvalho",
            "CoordFirstName": "Sonia",
            "EnteredByCNbr": "C10581001",
            "EnteredByLastName": "Bhamidimari",
            "EnteredByFirstName": "Kalyan",
            "ActiveEnrollingDate": "12/08/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/08/2016",
            "IRBApprovedFrom": "05/18/2016",
            "IRBApprovedTo": "03/31/2017",
            "Expr1": "Phase III",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Mallinckrodt Pharmaceuticals",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02770716",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02783573",
            "SecondaryId": "I8D-MC-AZET",
            "BriefTitle": "A Study of LY3314814 in Participants With Mild Alzheimer's Disease Dementia",
            "OfficialTitle": "A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia",
            "LeadSponsorClass": "Eli Lilly and Company",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Eli Lilly and Company",
            "OversightAuthority": "Yes",
            "BriefSummary": "The main purpose of this study is to evaluate the efficacy of the study drug known as\r\n\r\n      LY3314814 in participants with mild Alzheimer's disease (AD) dementia.",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2016",
            "CompletionDate": "April 2021",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Eli Lilly and Company",
            "StudyCondition": "Alzheimer's Disease",
            "studyLocation": "Xenoscience",
            "Enrollment": "1899",
            "NctKeyword": "dementia, brain diseases, neurodegenerative diseases, central nervous system diseases, nervous system diseases, mental disorders, delirium, dementia, amnestic, cognitive, tauopathies, memory, amyloid,",
            "MeshKeyword": "Alzheimer Disease, Dementia,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Participant must meet the National Institute on Aging (NIA) and the Alzheimer's\r\n\r\n             Association (AA) (NIA-AA) criteria for probable AD dementia.\r\n\r\n\r\n\r\n          -  MMSE score of 20 to 26 inc",
            "EligibleGender": "All",
            "MinAge": "55 Years",
            "MaxAge": "85 Years",
            "Volunteers": "No",
            "City": "Phoenix",
            "State": "Arizona",
            "Zip": "85004",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 19, 2017",
            "FirstReceived": "May 24, 2016",
            "OverallOfficial": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Eli Lilly and Company",
            "ContactName": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or",
            "ContactPhone": "1-317-615-4559",
            "LocationStatus": "Recruiting",
            "LocationName": "Xenoscience",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02783573",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160687 - Eli Lilly - Baumel",
            "FileProcessContentId": "440",
            "Division": "Neurology",
            "StdyDivision": "7804",
            "EprostNbr": "20160687",
            "StudyNumber": "20160687 - Eli Lilly - Baumel",
            "StudyTitle": "A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s Disease Dementia (The DAYBREAK Study)",
            "PIID": "22263",
            "PicNum": "C00471281",
            "PILastName": "Baumel",
            "PIFirstName": "Bernard",
            "CoodCNbr": "C03834528",
            "CoordLastName": "Perez",
            "CoordFirstName": "Carmen",
            "CoordEmail": "c.perez71@med.miami.edu",
            "CoordPhone": "3052435610",
            "EnteredByCNbr": "C00471281",
            "EnteredByLastName": "Baumel",
            "EnteredByFirstName": "Bernard",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "09/24/2016",
            "IRBApprovedFrom": "09/24/2016",
            "IRBApprovedTo": "08/31/2017",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Eli Lilly",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Carmen Perez,Jonathan Landman",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02783573",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02784795",
            "SecondaryId": "I6F-MC-JJCD",
            "BriefTitle": "A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors",
            "OfficialTitle": "A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors",
            "LeadSponsorClass": "Eli Lilly and Company",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Eli Lilly and Company",
            "OversightAuthority": "No",
            "BriefSummary": "The main purpose of this study is to evaluate the safety of the study drug known as\r\n\r\n      LY3039478 in combination with other anticancer agents in participants with advanced or\r\n\r\n      metastatic solid tumors.",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2016",
            "CompletionDate": "August 2018",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "Eli Lilly and Company",
            "StudyCondition": "Solid Tumor",
            "studyLocation": "University of California - San Diego",
            "Enrollment": "163",
            "NctKeyword": "Notch Inhibitor,",
            "MeshKeyword": "Sarcoma, Cholangiocarcinoma,",
            "InterventionKeyword": "Gemcitabine, Cisplatin, Carboplatin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  For all parts: The participant must be, in the judgment of the investigator, an\r\n\r\n             appropriate candidate for experimental therapy after available standard therapies\r\n\r\n             have fail",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "La Jolla",
            "State": "California",
            "Zip": "92037-0845",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 13, 2017",
            "FirstReceived": "May 25, 2016",
            "OverallOfficial": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Eli Lilly and Company",
            "ContactName": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or",
            "ContactPhone": "1-317-615-4559",
            "LocationStatus": "Not yet recruiting",
            "LocationName": "University of California - San Diego",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02784795",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160333 - Eli Lilly - Merchan",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160333",
            "StudyNumber": "20160333 - Eli Lilly - Merchan",
            "StudyTitle": "A Phase 1b Study of LY3039478 in Combination with Other Anticancer Agents in Patients with Advanced or Metastatic Solid Tumors",
            "PIID": "407",
            "PicNum": "C00251535",
            "PILastName": "Merchan",
            "PIFirstName": "Jaime",
            "CoodCNbr": "C11968022",
            "CoordLastName": "Leon Aliz",
            "CoordFirstName": "Tamara",
            "CoordEmail": "txl351@med.miami.edu",
            "EnteredByCNbr": "C11917328",
            "EnteredByLastName": "Englund",
            "EnteredByFirstName": "Kristen",
            "ActiveEnrollingDate": "10/18/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "10/18/2016",
            "IRBApprovedFrom": "06/09/2016",
            "IRBApprovedTo": "12/08/2016",
            "AccountNbr": "667362",
            "DiseaseSiteListDesc": "Non-Hodgkins Lymphoma,Hodgkins Lymphoma,Colon,Breast-Female,Liver,Bones and Joints",
            "Expr1": "Phase I",
            "Tarea": "Bone and Soft Tissue Cancers",
            "TareaCode": "10936",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "3",
            "FirstNinety": "2",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Karen Blackburn,Juan Salvador,Daniel Sumarriva,Sandra Pineda,Yvonne Dinh",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02784795",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02793960",
            "BriefTitle": "Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa",
            "OfficialTitle": "A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Therapeutic Effect of Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "This is a single-center study to investigate the effects of a topical cream on patients 12\r\n\r\n      years of age and older that have been diagnosed with epidermolysis bullosa.",
            "Description": "The trial will be conducted in patients with any form of Epidermolysis Bullosa (EB) with at\r\n\r\n      least 1 active EB wound between 2.5 and 50 cm2 in size or up to 10% of the Body Surface\r\n\r\n      Area. The investigators will identify an \"index",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2016",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Epidermolysis Bullosa",
            "studyLocation": "University of Miami Department of Dermatology",
            "Enrollment": "10",
            "MeshKeyword": "Epidermolysis Bullosa,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Male or female at least 12 years of age at the time of screening.\r\n\r\n\r\n\r\n          2. Have primary, histologically confirmed EB verified by immunofluorescent antigenic\r\n\r\n             mapping (EM) prior",
            "EligibleGender": "All",
            "MinAge": "12 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "July 2016",
            "LastChanged": "July 25, 2016",
            "FirstReceived": "May 18, 2016",
            "ContactName": "Shasa Hu, M.D.",
            "ContactPhone": "305-243-6045",
            "ContactEmail": "shu@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami Department of Dermatology",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02793960",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151103 - BERG - Hu",
            "FileProcessContentId": "440",
            "Division": "Dermatology",
            "StdyDivision": "10238",
            "EprostNbr": "20151103",
            "StudyNumber": "20151103 - BERG - Hu",
            "StudyTitle": "A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Therapeutic Effect of Topical BPM31510 3.0% Cream in Patients with Epidermolysis Bullosa",
            "PIID": "2366",
            "PicNum": "C03923266",
            "PILastName": "Hu",
            "PIFirstName": "Shasa",
            "CoodCNbr": "C03413356",
            "CoordLastName": "Kittles",
            "CoordFirstName": "Carol",
            "CoordEmail": "ckittles@med.miami.edu",
            "CoordPhone": "3052438485",
            "EnteredByCNbr": "C03923266",
            "EnteredByLastName": "Hu",
            "EnteredByFirstName": "Shasa",
            "ActiveEnrollingDate": "01/05/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "01/05/2016",
            "IRBApprovedFrom": "01/05/2016",
            "IRBApprovedTo": "01/04/2017",
            "Expr1": "Pilot/Feasibility",
            "ResearchType": "Drug",
            "SponsorGroup": "Industry",
            "Sponsor": "BERG",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "2",
            "Totalaccrued": "2",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "2",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Aliette Espinosa,Carol Kittles",
            "NationalSampleSize": "10",
            "NCTNbr": "NCT02793960",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02804750",
            "BriefTitle": "Study to Evaluate CORT125134 in Patients With Cushing's Syndrome",
            "OfficialTitle": "Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome",
            "LeadSponsorClass": "Corcept Therapeutics",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Corcept Therapeutics",
            "OversightAuthority": "Yes",
            "BriefSummary": "Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels\r\n\r\n      of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated\r\n\r\n      endogenous or exogenous sources of cortisol. Endog",
            "Description": "This is a Phase 2, open-label study with two dose groups, each with a two-step dose\r\n\r\n      escalation, designed to evaluate the safety and efficacy of CORT125134 for the treatment of\r\n\r\n      endogenous Cushing's syndrome. CORT125134 will be a",
            "OverallStatus": "Recruiting",
            "StartDate": "June 2016",
            "CompletionDate": "December 2017",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "Corcept Therapeutics",
            "StudyCondition": "Cushing's Syndrome",
            "Enrollment": "30",
            "NctKeyword": "Cushing's Syndrome, Cushing's Disease, Cushings, Hypercortisolemia, Cushingoid, Type 2 Diabetes, Impaired Glucose Intolerance, Hypertension, Adrenal Corticotrophic Hormone (ACTH), Adrenocortical Carcinoma, Primary Pigmented Nodular Adrenal Disease (PPNAD)",
            "MeshKeyword": "Syndrome, Cushing Syndrome,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. Has a confirmed diagnosis of endogenous Cushing's syndrome.\r\n\r\n\r\n\r\n          2. Requires medical treatment of hypercortisolemia.\r\n\r\n\r\n\r\n          3. Meets at least one of the following criteria:",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "75 Years",
            "Volunteers": "No",
            "City": "Ft. Lauderdale",
            "State": "Florida",
            "Zip": "33312",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 13, 2016",
            "FirstReceived": "June 15, 2016",
            "OverallOfficial": "Andreas G Moraitis, MD",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Corcept Therapeutics",
            "ContactName": "Kristi Balacy",
            "ContactEmail": "CorceptStudy451@corcept.com",
            "LocationStatus": "Recruiting",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02804750",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160628 - Corcept Therapeutics Inc. - Kargi",
            "FileProcessContentId": "440",
            "Division": "Endocrinology",
            "StdyDivision": "10241",
            "EprostNbr": "20160628",
            "StudyNumber": "20160628 - Corcept Therapeutics Inc. - Kargi",
            "StudyTitle": "Phase 2 Study of the Safety and Efficacy of CORT125134 in\nthe Treatment of Endogenous Cushing’s Syndrome",
            "PIID": "3249",
            "PicNum": "C06983051",
            "PILastName": "Kargi",
            "PIFirstName": "Atil",
            "CoodCNbr": "C00121533",
            "CoordLastName": "Masters",
            "CoordFirstName": "Burlett",
            "CoordEmail": "bmasters2@med.miami.edu",
            "CoordPhone": "305-243-5354",
            "EnteredByCNbr": "C06983051",
            "EnteredByLastName": "Kargi",
            "EnteredByFirstName": "Atil",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "08/03/2016",
            "IRBApprovedFrom": "08/03/2016",
            "IRBApprovedTo": "08/02/2017",
            "Expr1": "Phase II",
            "Tarea": "Other",
            "TareaCode": "9437",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Corcept Therapeutics Inc.",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Pre-Review",
            "StudyCoordinator": "Burlett Masters,Ada Konwai",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02804750",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02807753",
            "BriefTitle": "The Hemophilia Ultrasound Project",
            "OfficialTitle": "Evaluation of Joint Arthropathy Using Ultrasound Technique in Children With Severe Hemophilia Undergoing Prophylaxis Regimen",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "BriefSummary": "To evaluate the prevalence of subclinical arthropathy in children with severe hemophilia\r\n\r\n      undergoing a prophylaxis regimen and without evidence of target joints, using a validated\r\n\r\n      ultrasound scoring method.",
            "Description": "Persons with Hemophilia (A or B) often experience recurrent joint bleeds, most commonly\r\n\r\n      affecting the ankles, knees and elbows. These bleeds can lead to significant pain and\r\n\r\n      disability over time. If recurrent joint bleeds are n",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2016",
            "CompletionDate": "July 2021",
            "Phase": "N/A",
            "StudyType": "Observational",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Hemophilia A",
            "studyLocation": "The University of Miami - Department of Pediatrics",
            "Enrollment": "60",
            "NctKeyword": "Hemophilia, Arthropathy, Pediatric,",
            "MeshKeyword": "Hemophilia A, Hemophilia B,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Severe Hemophilia Cohort:Patients from 0 up to 30 months of age with diagnosis of\r\n\r\n             severe hemophilia A or B defined as a factor VIII:C/IX:C of <1% undergoing\r\n\r\n             prophylaxis re",
            "EligibleGender": "All",
            "MinAge": "N/A",
            "MaxAge": "30 Months",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 2, 2016",
            "FirstReceived": "June 1, 2016",
            "OverallOfficial": "Fernando F. Corrales-Medina, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Fernando F Corrales-Medina, MD",
            "ContactPhone": "305-243-8652",
            "ContactEmail": "ffc5@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "The University of Miami - Department of Pediatrics",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02807753",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151156 - Baxter - Corrales-Medina",
            "FileProcessContentId": "440",
            "Division": "Pediatrics Oncology",
            "StdyDivision": "10646",
            "EprostNbr": "20151156",
            "StudyNumber": "20151156 - Baxter - Corrales-Medina",
            "StudyTitle": "Evaluation of Joint Arthropathy Using Ultrasound Technique in Children with Severe Hemophilia Undergoing Prophylaxis Regimen: The Hemophilia Ultrasound Project (H.U.P. Study)",
            "PIID": "23193",
            "PicNum": "C11918839",
            "PILastName": "Corrales Medina",
            "PIFirstName": "Fernando",
            "CoodCNbr": "C11956115",
            "CoordLastName": "Pisani",
            "CoordFirstName": "Leandro",
            "CoordEmail": "LFP34@miami.edu",
            "CoordPhone": "305-243-6925",
            "EnteredByCNbr": "C11918839",
            "EnteredByLastName": "Corrales Medina",
            "EnteredByFirstName": "Fernando",
            "ActiveEnrollingDate": "06/24/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "06/24/2016",
            "IRBApprovedFrom": "05/02/2016",
            "IRBApprovedTo": "05/01/2017",
            "Expr1": "N/A",
            "ResearchType": "Specimen",
            "SponsorGroup": "Industry",
            "Sponsor": "Baxter",
            "Prescreened": "1",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Maria Santaella,Leandro Pisani",
            "NationalSampleSize": "6",
            "NCTNbr": "NCT02807753",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02816437",
            "BriefTitle": "FMT for MDRO Colonization in Solid Organ Transplant",
            "OfficialTitle": "Fecal Microbiota Transplantation for the Treatment of Multidrug-Resistant Organism Colonization in Solid Organ Transplant Recipients",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "This is a pilot feasibility study to determine whether fecal microbiota transplantation\r\n\r\n      (FMT) can suppress or reverse gastrointestinal carriage of MDROs in hospitalized solid organ\r\n\r\n      transplant recipients with a history of one or",
            "Description": "This is a pilot feasibility study to determine whether fecal microbiota transplantation\r\n\r\n      (FMT) can suppress or reverse gastrointestinal carriage of MDROs in hospitalized solid organ\r\n\r\n      transplant recipients with a history of one or",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2016",
            "CompletionDate": "June 2017",
            "Phase": "Phase 1",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 1",
            "StudySource": "University of Miami",
            "StudyCondition": "Infection Due to Resistant Organism",
            "studyLocation": "Jackson Health System",
            "Enrollment": "20",
            "Eligibility": "Inclusion Criteria\r\n\r\n\r\n\r\n          -  Age ≥18 years old\r\n\r\n\r\n\r\n          -  Solid organ transplant recipients: liver, intestinal, multivisceral transplants,\r\n\r\n             heart, lung, pancreas or kidney transplant recipients",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 19, 2016",
            "FirstReceived": "June 10, 2016",
            "OverallOfficial": "Lilian Abbo, M.D",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Olga Orozco, CCRC",
            "ContactPhone": "305-585-8160",
            "ContactEmail": "oorozco@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "Jackson Health System",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02816437",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160351 - Clinical and Translational Science Institute (CTSI - Abbo",
            "FileProcessContentId": "440",
            "Division": "Infectious Diseases",
            "StdyDivision": "9936",
            "EprostNbr": "20160351",
            "StudyNumber": "20160351 - Clinical and Translational Science Institute (CTSI - Abbo",
            "StudyTitle": "Fecal Microbiota Transplantation for the Treatment of Multidrug-Resistant Organism Colonization in Solid Organ Transplant Recipients",
            "PIID": "2166",
            "PicNum": "C06970688",
            "PILastName": "Abbo",
            "PIFirstName": "Lilian",
            "CoodCNbr": "C11878871",
            "CoordLastName": "Orozco",
            "CoordFirstName": "Olga",
            "CoordEmail": "oorozco@med.miami.edu",
            "CoordPhone": "305-585-8160",
            "EnteredByCNbr": "C06970688",
            "EnteredByLastName": "Abbo",
            "EnteredByFirstName": "Lilian",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "04/26/2016",
            "IRBApprovedFrom": "04/26/2016",
            "IRBApprovedTo": "04/25/2017",
            "DiseaseSiteListDesc": "Colon",
            "Expr1": "Phase I",
            "Tarea": "Infectious Diseases",
            "TareaCode": "9937",
            "Blinding": "None",
            "ResearchType": "Drug",
            "SponsorGroup": "Other",
            "Sponsor": "Clinical and Translational Science Institute (CTSI)",
            "SiteSampleSize": "JMH:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Olga Orozco",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02816437",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02819518",
            "SecondaryId": "2016-001432-35",
            "BriefTitle": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)",
            "OfficialTitle": "A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)",
            "LeadSponsorClass": "Merck Sharp & Dohme Corp.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Merck Sharp & Dohme Corp.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The study will consist of two parts. In Part 1, the safety of pembrolizumab (MK-3475) in\r\n\r\n      combination with one of three different chemotherapies will be assessed in the treatment of\r\n\r\n      locally recurrent inoperable or metastatic tri",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2016",
            "CompletionDate": "December 2019",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Merck Sharp & Dohme Corp.",
            "StudyCondition": "Triple Negative Breast Cancer (TNBC)",
            "studyLocation": "Call for Information (Investigational Site 0027)",
            "Enrollment": "858",
            "NctKeyword": "PD1, PD-1, PDL1, PD-L1,",
            "MeshKeyword": "Breast Neoplasms, Triple Negative Breast Neoplasms,",
            "InterventionKeyword": "Paclitaxel, Gemcitabine, Pembrolizumab, Albumin-Bound Paclitaxel, Carboplatin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Has locally recurrent inoperable breast cancer not previously treated with\r\n\r\n             chemotherapy and which cannot be treated with curative intent OR has metastatic\r\n\r\n             breast cancer no",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Monterey",
            "State": "California",
            "Zip": "93940",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 14, 2016",
            "FirstReceived": "June 28, 2016",
            "OverallOfficial": "Medical Director",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Merck Sharp & Dohme Corp.",
            "ContactName": "Toll Free Number",
            "ContactPhone": "1-888-577-8839",
            "LocationStatus": "Recruiting",
            "LocationName": "Call for Information (Investigational Site 0027)",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02819518",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160724 - Merck Sharp - Valdes",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160724",
            "StudyNumber": "20160724 - Merck Sharp - Valdes",
            "StudyTitle": "A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer – (KEYNOTE-355)",
            "PIID": "25499",
            "PicNum": "C00486358",
            "PILastName": "Valdes",
            "PIFirstName": "Frances",
            "CoodCNbr": "C03391642",
            "CoordLastName": "Rojas-Mejia",
            "CoordFirstName": "Cristina",
            "CoordEmail": "cmr190@miami.edu",
            "CoordPhone": "305-270-3467",
            "EnteredByCNbr": "C05567650",
            "EnteredByLastName": "Barnaby",
            "EnteredByFirstName": "Dino",
            "ActiveEnrollingDate": "12/20/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/20/2016",
            "IRBApprovedFrom": "09/23/2016",
            "IRBApprovedTo": "05/24/2017",
            "AccountNbr": "668090",
            "DiseaseSiteListDesc": "Breast-Female",
            "Expr1": "Phase III",
            "Tarea": "Breast Cancer",
            "TareaCode": "12436",
            "Blinding": "Double",
            "Randomization": "Randomized",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "0",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "0",
            "SiteSampleSize": "UMMG:N/A,Plantation:N/A,UM Kendall:N/A,UMD:N/A,UMHC:7",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "7",
            "EprostState": "External IRB",
            "StudyCoordinator": "Penny Eyer,Onaidy Torres,Deborah Conte,Sarah Raybin,Evan Dadas,Halyna Hailes,Anthony Minichiello",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02819518",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02834975",
            "BriefTitle": "Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).",
            "OfficialTitle": "Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy",
            "LeadSponsorClass": "Marilyn Huang",
            "SponsorAgency": "Other",
            "LeadSponsor": "Marilyn Huang",
            "OversightAuthority": "Yes",
            "BriefSummary": "The investigators hypothesize that tumor cell killing by cytotoxic chemotherapy exposes the\r\n\r\n      immune system to high levels of tumor antigens.The combination of Paclitaxel/Carboplatin and\r\n\r\n      Pembrolizumab will invigorate tumor-specif",
            "Description": "This is a single arm, open-label, phase II study to assess pathologic objective response\r\n\r\n      rate (complete response + partial response) in patients treated with pembrolizumab,\r\n\r\n      paclitaxel and carboplatin for advanced stage III or I",
            "OverallStatus": "Recruiting",
            "StartDate": "December 2016",
            "Phase": "Phase 2",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 2",
            "StudySource": "University of Miami",
            "StudyCondition": "Fallopian Tube Carcinoma",
            "studyLocation": "University of Miami",
            "Enrollment": "40",
            "NctKeyword": "Fallopian Tube Carcinoma, Peritoneal Carcinoma, Epithelial Ovarian Cancer,",
            "MeshKeyword": "Carcinoma, Ovarian Neoplasms, Neoplasms, Glandular and Epithelial, Fallopian Tube Neoplasms,",
            "InterventionKeyword": "Paclitaxel, Pembrolizumab, Albumin-Bound Paclitaxel, Carboplatin,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          1. No prior treatment for primary advanced (Stage III or IV) high grade epithelial\r\n\r\n             ovarian, primary peritoneal, or fallopian tube carcinoma such as irradiation,\r\n\r\n             chemotherapy,",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "December 2016",
            "LastChanged": "December 15, 2016",
            "FirstReceived": "July 13, 2016",
            "OverallOfficial": "Marilyn Huang, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02834975",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160477 - Institutional- Huang",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160477",
            "StudyNumber": "20160477 - Institutional- Huang",
            "StudyTitle": "Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients with Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy",
            "PIID": "25456",
            "PicNum": "C11974849",
            "PILastName": "Huang",
            "PIFirstName": "Marilyn",
            "CoodCNbr": "C12022809",
            "CoordLastName": "Habibi Khameneh",
            "CoordFirstName": "Negin",
            "CoordEmail": "negin.khameneh@med.miami.edu",
            "EnteredByCNbr": "C11972191",
            "EnteredByLastName": "Harris",
            "EnteredByFirstName": "Bretinsa",
            "ActiveEnrollingDate": "12/09/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "12/09/2016",
            "IRBApprovedFrom": "11/07/2016",
            "IRBApprovedTo": "12/04/2017",
            "AccountNbr": "668220",
            "DiseaseSiteListDesc": "Ovary,Other Female Genital",
            "Expr1": "Phase II",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "3",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "0",
            "CurrentlyActiveTreatment": "1",
            "Totalpatients": "3",
            "FirstNinety": "1",
            "SiteSampleSize": "Plantation:N/A,UMHC:N/A,UMD:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Isabel Moya,Mae Lyssa Bauduy-Roy,Halyna Hailes,Evan Dadas,Michelle Mikhail",
            "NationalSampleSize": "40",
            "NCTNbr": "NCT02834975",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02834988",
            "BriefTitle": "Sentinel Lymph Node Dissection (SLND) in Patients With Apparent Early Stage Endometrial Cancer",
            "OfficialTitle": "The Validity of Sentinel Lymph Node Dissection (SLND) in Patients With Apparent Early Stage Endometrial Cancer (EC)",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "Yes",
            "BriefSummary": "The investigators hypothesize that performing SLND (instead of complete lymphadenectomy)\r\n\r\n      will decrease complications such as hemorrhage, lower extremity lymphedema and lymphocyst\r\n\r\n      formation while enhancing quality of life in EC",
            "Description": "This is an interventional, prospective, and non-therapeutic study evaluating the clinical\r\n\r\n      utility of SLND for detecting nodal metastasis of early stage endometrial cancer.\r\n\r\n\r\n\r\n      Patients will undergo surgical staging for EC (sent",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2016",
            "CompletionDate": "June 2020",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Endometrial Cancer",
            "studyLocation": "University of Miami",
            "Enrollment": "1700",
            "NctKeyword": "Endometrial Cancer, Sentinel Lymph Node Dissection, SLND,",
            "MeshKeyword": "Endometrial Neoplasms,",
            "InterventionKeyword": "Fluorophosphate,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  1. Patients must have histologically and/or cytologically confirmed endometrial\r\n\r\n             cancer.\r\n\r\n\r\n\r\n          -  2. Clinically apparent early stage endometrial cancer (i.e. disease confined to",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "November 2016",
            "LastChanged": "November 6, 2016",
            "FirstReceived": "July 13, 2016",
            "OverallOfficial": "Brian Slomovitz, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Brian Slomovitz, MD",
            "ContactPhone": "305-243-2233",
            "ContactEmail": "bslomovitz@med.miami.edu",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02834988",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20151012 - Intramural - Slomovitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20151012",
            "StudyNumber": "20151012 - Intramural - Slomovitz",
            "StudyTitle": "The Validity of Sentinel Lymph Node Dissection (SLND) in Patients with Apparent Early Stage Endometrial Cancer (EC)",
            "PIID": "22712",
            "PicNum": "C11916703",
            "PILastName": "Slomovitz",
            "PIFirstName": "Brian",
            "CoodCNbr": "C10541408",
            "CoordLastName": "Morales",
            "CoordFirstName": "Guillermo",
            "CoordEmail": "g.morales4@umiami.edu",
            "EnteredByCNbr": "C04092184",
            "EnteredByLastName": "Rajakumar",
            "EnteredByFirstName": "Gopal",
            "ActiveEnrollingDate": "07/28/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "07/28/2016",
            "IRBApprovedFrom": "07/01/2016",
            "IRBApprovedTo": "06/20/2017",
            "DiseaseSiteListDesc": "Corpus Uteri",
            "Expr1": "N/A",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Diagnostic",
            "StudyType_Code": "6179",
            "ResearchType": "Specimen",
            "SponsorGroup": "Intramural",
            "Prescreened": "0",
            "Screenedfailed": "1",
            "SignedICF": "21",
            "Totalaccrued": "21",
            "InFollowUp": "2",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "21",
            "FirstNinety": "16",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A,JMH:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Madeline Krause,Michelle Mikhail,Lidia Sanchez Ortiz",
            "NationalSampleSize": "1700",
            "NCTNbr": "NCT02834988",
            "StudyInvIND": "0",
            "ClinicalTrial": "No",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02844465",
            "BriefTitle": "Stereotactic Laser Ablation for Temporal Lobe Epilepsy",
            "OfficialTitle": "Stereotactic Laser Ablation for Temporal Lobe Epilepsy",
            "LeadSponsorClass": "Medtronic Navigation, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Medtronic Navigation, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "The study is designed to evaluate the safety and efficacy of the Visualase MRI-guided laser\r\n\r\n      ablation system for mesial temporal epilepsy (MTLE).",
            "Description": "The purpose of the study is to evaluate the safety and efficacy of the Visualase MRI-guided\r\n\r\n      laser ablation system for necrotization or coagulation of epileptogenic foci in patients\r\n\r\n      with intractable mesial temporal lobe epilepsy",
            "OverallStatus": "Recruiting",
            "StartDate": "November 2016",
            "CompletionDate": "October 2020",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "Medtronic Surgical Technologies",
            "StudyCondition": "Temporal Lobe Epilepsy",
            "studyLocation": "University of Miami",
            "Enrollment": "120",
            "NctKeyword": "epilepsy, laser ablation, Visualase, laser interstitial thermal therapy,",
            "MeshKeyword": "Epilepsy, Epilepsy, Temporal Lobe,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  History of drug-resistant mesial temporal lobe epilepsy (MTLE)\r\n\r\n\r\n\r\n          -  If the subject has a vagus nerve stimulator (VNS), must have failed to achieve\r\n\r\n             sustained seizure freedom",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Zip": "33136",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 13, 2017",
            "FirstReceived": "July 15, 2016",
            "OverallOfficial": "Robert Gross, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "Emory University",
            "ContactName": "Guy Alvarez, PhD",
            "ContactEmail": "rs.slatestudy@medtronic.com",
            "LocationStatus": "Recruiting",
            "LocationName": "University of Miami",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02844465",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160746 - MEDTRONIC INC - Jagid",
            "FileProcessContentId": "440",
            "Division": "Neurosurgery",
            "StdyDivision": "9636",
            "EprostNbr": "20160746",
            "StudyNumber": "20160746 - MEDTRONIC INC - Jagid",
            "StudyTitle": "Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE)",
            "PIID": "526",
            "PicNum": "C02000304",
            "PILastName": "Jagid",
            "PIFirstName": "Jonathan",
            "CoodCNbr": "C00161858",
            "CoordLastName": "Fisher",
            "CoordFirstName": "Letitia",
            "CoordEmail": "lfisher@med.miami.edu",
            "EnteredByCNbr": "C02000304",
            "EnteredByLastName": "Jagid",
            "EnteredByFirstName": "Jonathan",
            "ActiveEnrollingDate": "11/21/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/21/2016",
            "IRBApprovedFrom": "09/19/2016",
            "IRBApprovedTo": "10/02/2017",
            "WIrb": "20161547",
            "DiseaseSiteListDesc": "Brain and Nervous System",
            "Expr1": "N/A",
            "Tarea": "Cranial",
            "TareaCode": "9639",
            "Blinding": "None",
            "Randomization": "Non - Randomized",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "MEDTRONIC INC",
            "Prescreened": "0",
            "Screenedfailed": "0",
            "SignedICF": "1",
            "Totalaccrued": "1",
            "InFollowUp": "0",
            "CurrentlyEnrolled": "1",
            "CurrentlyActiveTreatment": "0",
            "Totalpatients": "1",
            "FirstNinety": "1",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Letitia Fisher,Carlos Millan,Pedro Figueredo",
            "AgentDevices": "Visualase System",
            "StudyObjective": "To evaluate the safety and efficacy of the Visualase System for necrotization or coagulation of epileptogenic foci in patients with intractable mesial temporal lobe epilepsy (MTLE)",
            "NationalSampleSize": "20",
            "NCTNbr": "NCT02844465",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02853604",
            "BriefTitle": "Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer",
            "OfficialTitle": "Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV",
            "LeadSponsorClass": "Advaxis, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Advaxis, Inc.",
            "OversightAuthority": "Yes",
            "BriefSummary": "High-risk locally advanced carcinoma of the cervix (HRLACC) following concurrent\r\n\r\n      chemotherapy and radiation therapy. This is a group of patients with a significant unmet\r\n\r\n      need. The estimated probability of disease recurrence or",
            "Description": "This is a double-blind, placebo-controlled randomized study of ADXS11 001 administered in\r\n\r\n      the adjuvant setting after completion of cisplatin-based CCRT in subjects with locally\r\n\r\n      advanced cervical cancer at higher risk for recurr",
            "OverallStatus": "Recruiting",
            "StartDate": "September 2016",
            "CompletionDate": "June 2021",
            "Phase": "Phase 3",
            "StudyType": "Interventional",
            "StudyPhase": "Phase 3",
            "StudySource": "Advaxis, Inc.",
            "StudyCondition": "High Risk Cervical Cancer",
            "studyLocation": "Site",
            "Enrollment": "450",
            "MeshKeyword": "Uterine Cervical Neoplasms,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Subjects must have a biopsy confirmed diagnosis of squamous cell, adenocarcinoma, or\r\n\r\n             adenosquamous carcinoma of the cervix. Histologic confirmation of the original\r\n\r\n             primary",
            "EligibleGender": "Female",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Miami",
            "State": "Florida",
            "Country": "United States",
            "VerificationDate": "January 2017",
            "LastChanged": "January 18, 2017",
            "FirstReceived": "July 28, 2016",
            "OverallOfficial": "Thomas J Herzog, MD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Cincinnati",
            "ContactName": "ADVAXIS HOTLINE",
            "ContactPhone": "844-783-1529",
            "LocationStatus": "Recruiting",
            "LocationName": "Site",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02853604",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160749 - Advaxis - Slomovitz",
            "FileProcessContentId": "440",
            "Division": "Cancer Center",
            "StdyDivision": "7801",
            "EprostNbr": "20160749",
            "StudyNumber": "20160749 - Advaxis - Slomovitz",
            "StudyTitle": "Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV",
            "PIID": "22712",
            "PicNum": "C11916703",
            "PILastName": "Slomovitz",
            "PIFirstName": "Brian",
            "CoodCNbr": "C11920201",
            "CoordLastName": "Moya",
            "CoordFirstName": "Isabel",
            "CoordEmail": "iam18@miami.edu",
            "EnteredByCNbr": "C11997004",
            "EnteredByLastName": "Pickens",
            "EnteredByFirstName": "Brandon",
            "ActiveEnrollingDate": "11/22/2016",
            "CurrentStudyStatus": "Active/Enrolling",
            "StudyStatus_Code": "205",
            "CurrentStartDate": "11/22/2016",
            "IRBApprovedFrom": "09/28/2016",
            "IRBApprovedTo": "03/02/2017",
            "AccountNbr": "668249",
            "DiseaseSiteListDesc": "Cervix",
            "Expr1": "Phase III",
            "Tarea": "Gynecologic Cancer",
            "TareaCode": "12439",
            "Expr2": "Therapeutic",
            "StudyType_Code": "6167",
            "ResearchType": "Drug/Specimen",
            "SponsorGroup": "Industry",
            "SiteSampleSize": "UMHC:N/A,UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Michelle Mikhail,Mae Lyssa Bauduy-Roy,Negin Habibi Khameneh,Evan Dadas,Claudia Grandas Moreno,Halyna Hailes",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02853604",
            "StudyInvIND": "0",
            "ClinicalTrial": "Yes",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02871817",
            "BriefTitle": "A Comparison of the Paxos Mobile App to Standard Vision Assessment Tools",
            "OfficialTitle": "The Correlation of Paxos Checkup Mobile App to Standard in Office Visual Assessement",
            "LeadSponsorClass": "Digisight Technologies, Inc.",
            "SponsorAgency": "Industry",
            "LeadSponsor": "Digisight Technologies, Inc.",
            "OversightAuthority": "No",
            "BriefSummary": "The CLEAR study is testing the level of agreement between in office visual acuity and Amsler\r\n\r\n      grid testing using a mobile vision testing application, Paxos Checkup Study and standard in\r\n\r\n      office methods. In addition the percent of",
            "Description": "BACKGROUND AND INTRODUCTION Neovascular Age - related Macular Degeneration (AMD) is the most\r\n\r\n      common cause of vision loss in subjects over the age of 60. Today in the US over 15 million\r\n\r\n      people live with some form of AMD, and app",
            "OverallStatus": "Recruiting",
            "StartDate": "July 2016",
            "CompletionDate": "December 2016",
            "Phase": "Phase 1/Phase 2",
            "StudyType": "Observational",
            "StudyPhase": "Phase 1/Phase 2",
            "StudySource": "Digisight Technologies, Inc.",
            "StudyCondition": "Age - Related Macular Degeneration",
            "studyLocation": "Retinal Associates of Cleveland",
            "Enrollment": "154",
            "NctKeyword": "Near Corrected Visual Acuity, Early Treatment Diabetes Retinopathy Study, Amsler Grid, Home Monitoring,",
            "MeshKeyword": "Macular Degeneration, Diabetic Retinopathy, Retinal Diseases, Vision Disorders,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Male or female 18 years of age and older\r\n\r\n\r\n\r\n          -  Best Corrected Near Visual acuity 20/200 or better in study eye(s)\r\n\r\n\r\n\r\n          -  Able and willing to make the required study visits",
            "EligibleGender": "All",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "No",
            "City": "Cleveland",
            "State": "Ohio",
            "Zip": "44122",
            "Country": "United States",
            "VerificationDate": "August 2016",
            "LastChanged": "August 15, 2016",
            "FirstReceived": "July 18, 2016",
            "OverallOfficial": "Russell J Ivanhoe, MD MBA",
            "OverallRole": "Study Director",
            "OverallAffilitation": "Digisight Technologies, Inc.",
            "ContactName": "Russell J Ivanhoe, MD MBA",
            "ContactPhone": "6502832402",
            "ContactEmail": "Russell.ivanhoe@digisight.net",
            "LocationStatus": "Recruiting",
            "LocationName": "Retinal Associates of Cleveland",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02871817",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20160494 - INDUSTRY-SUPPORTED - remove if no funding provided - Yehoshua",
            "FileProcessContentId": "440",
            "Division": "Ophthalmology",
            "StdyDivision": "10252",
            "EprostNbr": "20160494",
            "StudyNumber": "20160494 - INDUSTRY-SUPPORTED - remove if no funding provided - Yehoshua",
            "StudyTitle": "THE CORRELATION OF PAXOS CHECKUP MOBILE APP TO STANDARD\nIN OFFICE VISUAL ASSESSMENT",
            "PIID": "1823",
            "PicNum": "C06958118",
            "PILastName": "Yehoshua",
            "PIFirstName": "Zohar",
            "CoodCNbr": "C00293224",
            "CoordLastName": "Arango",
            "CoordFirstName": "Monica",
            "CoordEmail": "mrarango@med.miami.edu",
            "CoordPhone": "3053266351",
            "EnteredByCNbr": "C06958118",
            "EnteredByLastName": "Yehoshua",
            "EnteredByFirstName": "Zohar",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "08/25/2016",
            "IRBApprovedFrom": "08/25/2016",
            "IRBApprovedTo": "08/25/2017",
            "InfoEdNbr": "81576",
            "ResearchType": "Device",
            "SponsorGroup": "Industry",
            "Sponsor": "INDUSTRY-SUPPORTED - remove if no funding provided",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "External IRB",
            "StudyCoordinator": "Cristina Lage-Rodriguez,Monica Arango,Maria Esquiabro,Belen Rodriguez",
            "NationalSampleSize": "0",
            "NCTNbr": "NCT02871817",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         },
         {
            "NCTdataId": "NCT02873377",
            "SecondaryId": "1R21CA202993-01A1",
            "BriefTitle": "Smoking Cessation in Hispanic Construction Workers",
            "OfficialTitle": "A Novel Worksite Smoking Cessation Intervention for Hispanic Construction Workers",
            "LeadSponsorClass": "University of Miami",
            "SponsorAgency": "Other",
            "LeadSponsor": "University of Miami",
            "OversightAuthority": "No",
            "BriefSummary": "Construction workers have the highest rate of smoking among all occupations, and are\r\n\r\n      frequently exposed to a wide range of workplace hazards (e.g. toxins), which interact with\r\n\r\n      smoking to increase their health risks. Minority co",
            "Description": "A two-arm, cluster-randomized controlled trial will be conducted with 14 construction sites,\r\n\r\n      selected from one Construction Company in south Florida. Cluster randomization is used with\r\n\r\n      construction site chosen as the unit of al",
            "OverallStatus": "Not yet recruiting",
            "StartDate": "August 2016",
            "CompletionDate": "August 2017",
            "Phase": "N/A",
            "StudyType": "Interventional",
            "StudyPhase": "N/A",
            "StudySource": "University of Miami",
            "StudyCondition": "Smoking Cessation",
            "Enrollment": "126",
            "NctKeyword": "Hispanics, Construction workers, Tobacco Quitline, Nicotine replacement therapy,",
            "InterventionKeyword": "Nicotine,",
            "Eligibility": "Inclusion Criteria:\r\n\r\n\r\n\r\n          -  Hispanic\r\n\r\n\r\n\r\n          -  Construction worker\r\n\r\n\r\n\r\n          -  Have smoked ≥ 5 cigarettes/day in the past year.\r\n\r\n\r\n\r\n          -  Have access to telephone\r\n\r\n\r\n\r\n          -  Have no plans to mov",
            "EligibleGender": "Male",
            "MinAge": "18 Years",
            "MaxAge": "N/A",
            "Volunteers": "Accepts Healthy Volunteers",
            "VerificationDate": "August 2016",
            "LastChanged": "August 16, 2016",
            "FirstReceived": "July 28, 2016",
            "OverallOfficial": "David J Lee, PhD",
            "OverallRole": "Principal Investigator",
            "OverallAffilitation": "University of Miami",
            "ContactName": "Taghrid Asfar, MD",
            "ContactPhone": "305-243-3826",
            "ContactEmail": "tasfar@med.miami.edu",
            "LinkUrl": "https://clinicaltrials.gov/show/NCT02873377",
            "InvalidRowFlag": "N",
            "CreateUser": "CGCENT\\s.shetty",
            "CreateTimeStamp": "2017-01-23T23:01:25.2370000",
            "UpdateUser": "CGCENT\\s.shetty",
            "UpdateTimeStamp": "2017-01-23T23:01:25.2370000",
            "StudyId": "20140019 - National Institutes of Health (NIH) - Lee",
            "FileProcessContentId": "440",
            "Division": "Unknown",
            "StdyDivision": "16136",
            "EprostNbr": "20140019",
            "StudyNumber": "20140019 - National Institutes of Health (NIH) - Lee",
            "StudyTitle": "A Novel Worksite Smoking Cessation Intervention for Hispanic Construction Workers",
            "PIID": "2727",
            "PicNum": "C00202592",
            "PILastName": "Lee",
            "PIFirstName": "David",
            "CoodCNbr": "C10868794",
            "CoordLastName": "Asfar",
            "CoordFirstName": "Taghrid",
            "EnteredByCNbr": "C00202592",
            "EnteredByLastName": "Lee",
            "EnteredByFirstName": "David",
            "CurrentStudyStatus": "IRB - Approved",
            "StudyStatus_Code": "6255",
            "CurrentStartDate": "03/07/2014",
            "IRBApprovedFrom": "03/07/2014",
            "IRBApprovedTo": "06/28/2017",
            "ResearchType": "Drug",
            "SponsorGroup": "Other",
            "Sponsor": "National Institutes of Health (NIH)",
            "SiteSampleSize": "UMMG:N/A",
            "AccrualPercentageMet": "0",
            "ActiveCal": "0",
            "PaymentRcvd": "0",
            "PaymentMade": "0",
            "TotalLocalSampleSize": "0",
            "EprostState": "Approved",
            "StudyCoordinator": "Laura McClure,Katerina Santiago",
            "NationalSampleSize": "201",
            "NCTNbr": "NCT02873377",
            "StudyInvIND": "0",
            "ClinicalTrial": "Auto/Blank",
            "CrrcTrack": "Y"
         }
      ]
   }
}